CN100451004C - Novel quinoline,Tetrahydroquinazoline,And pyrimidine derivatives and methods of treatment related to the use thereof - Google Patents

Abstract

The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Description

Pyrimidine derivatives

Invention field

The present invention relates to compound, and relate to the purposes of these compounds in medicinal compositions as the MCH receptor antagonist.

Background of invention

Melanin-concentrating hormone (Melanin Concentrating Hormone) (MCH), a kind of cyclic peptide has been accredited as the endogenic ligand of orphan G-protein linked receptor SLC-1.Referring to, for example, Shimomura etc., Biochem.Biophys.Res.Commun.261,622-26 (1999).Studies show that MCH replys to change many behaviors, for example food habits as neurotransmitter/neuroregulator.For example, reported that injecting MCH to rat can increase their consumption to food.Report points out that the genetically engineered mouse that lacks MCH shows as weight increase and metabolism increase.See Saito etc., TEM, vol.11,299 (2000).Equally, the document proposes, and the discovery of the MCH antagonist of the cell interaction of expressing with SCL-1 will have purposes in the agent of exploitation obesity treatment.See Shimomura etc., Biochem.Biophys.Res.Commun.261,622-26 (1999).

The motif of the total common structure of g protein coupled receptor (GPCRs).All these acceptors have 7 sequences between 22-24 the hydrophobic amino acid, and these amino acid form 7 α spirochetes, and wherein each all strides film.The 4th and the 5th transbilayer helix body are connected on the cell outside of film by one amino acid that forms bigger ring texture.Transbilayer helix body 5 and 6 on the cell inboard of another bigger ring texture (mainly constituting) junctional membrane by hydrophilic amino acid.The acceptor C-terminal is positioned at cell, and N-terminal is positioned at extracellular space.Think that now described ring texture connects spirochete 5 and 6, and C-terminal, with the G protein-interacting.At present, Gq, Gs, Gi and Go are for being accredited as and the synergistic reasonable proteic G albumen of acceptor.

Under physiological conditions, GPCRs is present in the cytolemma with 2 kinds of different states or the equilibrated state between the conformation: i.e. " inactive " state and " activatory " state.The acceptor of disactivation state can not be connected in the endocellular transduction approach that produces biological answer-reply.But receptor conformation is changed into active state joint transduction approach and produced biological answer-reply.

By endogenic ligand or exogenous agonist ligand, acceptor that can the stable activation state.Nearest discovery comprises (but being not limited only to) modification to described receptor amino acid sequence, and the another kind of mechanism that is different from part stable activation state conformation is provided.These approach are incorporated into the effect of the part of acceptor, the acceptor of stable activation state effectively by simulation.Stabilization by such part-independence approach is called as " effect of composition receptor activation ".On the contrary, antagonist can be incorporated into described acceptor in identical site competitiveness as agonist, does not reply but do not activate in the cell that is started by the activated form of acceptor, thereby suppresses because of replying in the cell due to the agonist.

Reported that some 2-amido quinazoline derivatives is the NPY antagonist, it is believed that these antagonists can effectively treat illness and the disease relevant with npy receptor hypotype Y5.See PCT patent application 97/20823.Found that also quinazoline derivant can be used for strengthening anti-tumor activity.See PCT patent application 92/07844.The quinoline that the MCH acceptor is had antagonistic activity also is found in the following patent: WO03/070244, WO03/105850, WO03/45313, WO03/045920 and WO04/04726.

Recently, the current understanding of relevant people's obesity has had noticeable progress.In the past, obesity was considered to be in a kind of Addictive Behaviors of unsuitable feed under the environment of tempting food.The biological chemistry of obesity The Animal Model Study, humans and animals changes, and make the mental community that the people is liable to obesity and the complex interactions of cultural factor show that human this disease is multifaceted (multifaceted) problem and takes root in biosystem dearly.Therefore, can affirm that almost obesity has Different types of etiopathogenises, thereby have dissimilar obesity.Not only the MCHR1 antagonist has effective and persistent resisting-the obesity effect in rodent, and it also has surprising antidepressant and anxiolytic properties (Borowsky etc., NatureMedicine, 8,825-830,2002).Reported that the MCHR1 antagonist demonstrates antidepressant and anxiety activity in rodent model, for example in social activity, forced swimming test and the ultrasonic pronunciation model.These results show that the MCHR1 antagonist can be used for treating the obesity patient who is caused by Different types of etiopathogenises.In addition, the MCHR1 antagonist not only can be used for treating the patient who suffers from obesity, and can be used for treating those patients that suffer from dysthymia disorders and anxiety disorder.These advantages make it be different from the npy receptor antagonist, and it is the same that measurable thus and NPY itself have anxiety-sample effect, and it has anxiety-sample activity.

Obesity also is considered to a kind of chronic disease, and the possibility of this long-term treatment is a kind of more attention notion that is subjected to.In this article, it should be noted that exhausting of MCH causes hypophagia and thin and weak (Shimada etc., Nature, 396,670-674,1998).As a comparison, NPY (Erickson etc., Nature, 381,415-418,1996) and Y1 (Pedrazzini etc., Nature Medicine, 4,722-726,1998) and Y5 acceptor (Marsh etc., Nature Medicine, 4,718-721,1998) mouse of rejecting keeps stable body weight or becomes fat a little.Consider above report, aspect obesity patient's long-term treatment, MCHR ₁Antagonist may be more attractive than Y1 or Y5 receptor antagonist.

The insulin resistance and the diabetes height correlation of obesity (it is unbalanced result between calorie intake and the energy expenditure) and experimental animal and philtrum.Yet the molecule mechanism that relates to obesity-diabetic syndrome it be unclear that.In the early-stage development of obesity, increase insulin secretion and can offset the insulin resistant effect and protect the patient to avoid hyperglycemia (Le Stunff, etc. diabetes 43,696-702 (1989)).Yet after decades, the β cell function is degenerated and about 20% obese people develops into non--insulin-dependent diabetes (Pederson, P.Diab.Metab.Rev.5,505-509 (1989)) and (Brancati, F.L., Deng, Arch.Intern.Med.159,957-963 (1999)).Because obesity high prevalence rate in modern society, thus it become NIDDM primary Hazard Factor (Hill, J.O., etc., Science 280,1371-1374 (1998)).Yet, in advance the part patient is handled and changes insulin secretion and still do not know with the factor that influences fat generation.

Whether someone is categorized as overweight or obesity depends on its weight index (BMI) usually, this index is by with square (m of body weight (kg) divided by height ²) calculate.Therefore, the unit of BMI is kg/m ², it is possible calculating the BMI scope relevant with each minimum mortality in 10 years of life.Overweight is defined as BMI at 25-30kg/m ²In the scope, and obesity is defined as BMI greater than 30kg/m ²(seeing the following form).The problem that this definition exists is that it does not consider that muscle is with respect to the ratio of fat (fatty tissue) in the body weight.In order to consider this point, obesity also can define according to the content of body fat: masculinity and femininity should be respectively greater than 25% and 30%.

(BMI) classifies to body weight with weight index

BMI	Classification
		＜18.5	Underweight
18.5-24.9	Normally
		25.0-29.9	Overweight
30.0-34.9	Fat (I level)
		35.0-39.9	Fat (II level)
＞40	Extremely fat (III level)

Along with the increase of BMI, because of the various former thereby dead danger that are independent of other Hazard Factor increase.Modal disease with obesity is cardiovascular disorder (particularly hypertension), diabetes (obesity increases the weight of the development of diabetes), gallbladder disease (particularly carcinoma of gallbladder) and genital diseases.Suitably alleviating of body weight studies show that, even also can correspondingly make the pathogenetic danger of coronary disease significantly reduce.

Compound as anti--obesity drug listing comprises orlistat (XENICAL ^TM) and sibutramine.Orlistat (a kind of lipase inhibitor) directly suppresses fat absorbing, is easy to produce the side effect that makes people's unhappiness (though harmless relatively) of high rate, for example diarrhoea.Sibutramine (a kind of blended 5-HT/ NRI) can increase some patient's blood pressure and the rhythm of the heart is accelerated.Reported serotonin releasing agent/reuptake inhibitor Phenfluoramine (Pondimin ^TM) and dexfenfluramine (Redux ^TM) reduce food intake and in long-time (greater than 6 months) lose weight.Yet, after these two kinds of drug deactivated, there is report to think, preliminary sign shows that heart valve is unusual relevant with their use.Therefore, exist the demand of the safer anti--obesity drug of exploitation.

Obesity also increases the danger that cardiovascular disorder takes place significantly.Coronary insufficiency, atheromatous disease and cardiac insufficiency are the cardiovascular complication diseases the earliest that is caused by obesity.Can infer that if all the crowd has the ideal body weight, the danger of coronary insufficiency will reduce 25%, and the danger of cardiac insufficiency and cerebrovascular accident will reduce 35%.Body weight surpasses among the patient of the right side of fifty of 30%, and the incidence of coronary disease increases by 1 times.The diabetic subject faces the danger of life-span (lifespan) minimizing 30%.After 45 years old, the crowd who suffers from diabetes suffers to suffer from a sharp attack of heart failure may Duo 3 times than the crowd who does not suffer from diabetes, and the patient who suffers from apoplexy then may be up to more than 5 times.These results highlight, in the Hazard Factor of NIDDM and coronary heart disease and prevent based on obesity prevention to exist between the potential value of the comprehensive approach of these diseases interrelated (Perry, I.J., etc., BMJ 310,560-564 (1995)).

The number of children and teen-age overweight constantly increases.Though the children that are not all overweight must grow into the adult of overweight, the Childhood the growth that takes place of obesity reflected the increase of obesity when adult probably.The possibility that the high prevalence rate of the obesity in the crowd of growing up and following its people will become fat more need be checked (re-examination) to health affected to this disease.Referring to, Health Implications ofObesity (the healthy implication of obesity).NIH?Consens.Statement?Online?1985?Feb11-13；5(9)：1-7。

" clinical obesity " for a kind of excessive body fat with respect to the measuring of fat-free mass, and be defined as body weight and surpass more than 20% of ideal body weight.Nearest assessment prompting has 1 people to be obesity by clinical diagnosis in per 2 adults of the U.S., increases more than 25% in the past few decades.Flegal M.D etc., 22 Int.J.Obes.Relat.Metab.Disor.39 (1998).Overweight situation and clinical obesity are worldwide main health problem, particularly because clinical obesity often with a lot of complication, as hypertension and type ii diabetes, these diseases can cause the late complication and the neonatal death of coronary artery disease, apoplexy, diabetes again.(see, for example, Nishina P.M etc., 43 Metab.554 (1994)).

Though the basic nosetiology mechanism of obesity needs also further to understand fully that the independent effect of this kind mechanism has caused the imbalance between energy intake and the consumption.The h and E factor all may be relevant with the pathogeny of obesity.These comprise excessive calorie intake, sports minimizing and metabolism and cryptorrhea.

Not only significant by pharmacological agent overweight situation and clinical obesity to illness itself, and to prevent other with (for example, clinical obesity) possibility of diseases associated, and the patient that overweight or clinical obesity and experience body weight are obviously alleviated often with " oneself " sensation strengthens its forward and feels significant.According to discussion above, apparent, the compound that helps to treat this type of disease will be useful and the progress of research and clinical medicine two aspects will be provided.The present invention relates to these and other important goal.

Summary of the invention

The invention describes and be incorporated into GPCR and regulate the active compound of GPCR (being called MCH herein), with and uses thereof.Term MCH used herein is included in the directed homologous gene (orthologs) of human sequence (registration number NM 005297), naturally occurring allelic variation, Mammals, biological active fragment and the recombinant mutant thereof that GeneBank (gene pool) finds.

One aspect of the present invention relates to some heterogeneous ring compound or its pharmacy acceptable salt, hydrate or solvate by the replacement of formula (I) expression:

Wherein Q is:

R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Halogen,

Hydroxyl,

Oxo,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Isocyclic aryl,

Heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces,

C _1-5The alkyl-carbonyl oxygen base,

Carbocylic radical oxygen base,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Oxo,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-C by halogenated isocyclic aryl replacement _1-5Alkylamino,

Two-C by halogenated isocyclic aryl replacement _1-5Alkylamino,

The isocyclic aryl carbonylamino and

By the isocyclic aryl carbonylamino of halogen replacement,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl and

Carboxyl,

Heterocyclic radical-ethyleneimino oxygen the base that replaces,

C _1-5Alkoxy carbonyl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

By independently being selected from one-C that following substituting group replaces _1-5Alkylamino:

Cyano group,

Isocyclic aryl and

Heterocyclic radical,

Two-C _1-5Alkylamino,

By independently being selected from two-C that following substituting group replaces _1-5Alkylamino:

Cyano group,

Isocyclic aryl and

Heterocyclic radical,

One-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl and

Carboxyl,

Two-isocyclic aryl amino,

By independently being selected from two-isocyclic aryl amino that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl and

Carboxyl,

One-heterocyclic radical amino,

By independently being selected from one-heterocyclic radical amino that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl and

Carboxyl,

Two-heterocyclic radical amino,

By independently being selected from two-heterocyclic radical amino that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Nitro,

Cyano group,

Amino,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkoxyl group replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl and

Carboxyl,

C _1-5Alkyl-carbonyl-amino,

By independently being selected from the C that following substituting group replaces _1-5Alkyl-carbonyl-amino:

C _1-5Alkyl-carbonyl-amino,

The isocyclic aryl carbonylamino and

Heterocyclic radical,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl carbonylamino,

The heterocyclic radical carbonylamino,

The isocyclic aryl sulfuryl amino,

By independently being selected from the isocyclic aryl sulfuryl amino that following substituting group replaces:

Nitro,

C _1-5Alkyl,

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

Two-isocyclic aryl amino,

By two-isocyclic aryl amino of halogen replacement,

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

By independently being selected from the carbocyclic ring arylthio that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The isocyclic aryl sulfinyl,

By independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The heterocycle sulfenyl,

By independently being selected from the heterocycle sulfenyl that following substituting group replaces:

Nitro and

C _1-5Alkyl,

C _3-6Cycloalkyl,

By C _1-5The C that alkyl replaces _3-6Cycloalkyl,

C by the isocyclic aryl replacement _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Nitro,

Amino,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Oxo,

Isocyclic aryl,

Heterocyclic radical,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

By independently being selected from two-isocyclic aryl amino that following substituting group replaces:

Halogen

Nitro,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

C _2-5Alkenyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

C _1-5Alkoxy carbonyl,

C _1-5The alkyl-carbonyl oxygen base,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

Two-isocyclic aryl amino,

By two-isocyclic aryl amino of halogen replacement,

One-isocyclic aryl aminocarboxyl,

By independently being selected from one-isocyclic aryl aminocarboxyl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

Two-isocyclic aryl aminocarboxyl,

By independently being selected from two-isocyclic aryl aminocarboxyl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

Sulfydryl,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

C _1-5Alkyl sulphonyl,

C _3-6Cycloalkyl,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Nitro,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl and

Formamyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-8Alkenyl and

By independently being selected from the C that following substituting group replaces _2-8Alkenyl:

Halogen,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Hydroxyl,

Nitro,

C _1-5Alkyl and

C _1-5Alkoxyl group,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Hydroxyl,

Oxo and

Isocyclic aryl,

One-C _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

The isocyclic aryl carbonylamino,

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(v) C _3-6Cycloalkenyl group and

By C _1-5The C that alkyl replaces _3-6Cycloalkenyl group,

(vi) carbocylic radical and

By independently being selected from the carbocylic radical that following substituting group replaces:

Hydroxyl and

Nitro,

(vii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Oxo,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-C _1-5Alkylamino-N-oxygen base,

Two-C _1-5Alkylamino-N-oxygen base,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

The carbocylic radical imino-,

By the carbocylic radical imino-of isocyclic aryl replacement,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkoxyl group replaces,

By C _1-5Two-isocyclic aryl amino that alkoxyl group replaces,

One-isocyclic aryl aminocarboxyl,

Two-isocyclic aryl aminocarboxyl,

By C _1-5One-isocyclic aryl aminocarboxyl that alkoxyl group replaces,

By C _1-5Two-isocyclic aryl aminocarboxyl that alkoxyl group replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces,

C _2-5Alkenyl,

C by the isocyclic aryl replacement _2-5Alkenyl,

C _1-9Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-9Alkoxyl group:

Hydroxyl,

Halogen,

Carboxyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

Isocyclic aryl,

Halogenated isocyclic aryl,

Heterocyclic radical,

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

C _2-5Alkenyl oxy,

C _3-6Cycloalkyloxy,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Nitro,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl and

Formamyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Nitro,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl and

Formamyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(isocyclic aryl) S (O) ₂O,

Carboxyl,

Formamyl,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

One-isocyclic aryl aminocarboxyl,

Two-isocyclic aryl aminocarboxyl,

By C _1-5One-isocyclic aryl aminocarboxyl that alkyl replaces,

By C _1-5Two-isocyclic aryl aminocarboxyl that alkyl replaces,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl sulfuryl amino,

By C _1-5The isocyclic aryl sulfuryl amino that alkyl replaces,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

The isocyclic aryl azo-group,

By one-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

By two-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By independently being selected from the carbocyclic ring arylthio that following substituting group replaces:

Halogen,

Nitro,

Cyano group and

C _1-5Alkyl,

Amino-sulfonyl,

The heterocycle sulfenyl,

C _1-5Alkyl sulphonyl,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl,

The heterocyclic radical alkylsulfonyl,

C _3-6Cycloalkyl,

By C _1-5The C that alkyl replaces _3-6Cycloalkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

C _1-7Alkyl and

C by the halogen replacement _1-7Alkyl,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl and

(viii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Nitro,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

Oxo,

C _1-5The alkyl-carbonyl oxygen base,

The isocyclic aryl carbonylamino,

By the isocyclic aryl carbonylamino of halogen replacement,

C _1-5Alkoxy carbonyl,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

Nitro,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

Nitro,

Cyano group,

Hydroxyl,

Carboxyl,

Formamyl,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl and

Formamyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C _3-6Cycloalkyl,

C _2-5Alkenyl,

C _2-5Alkynyl,

Carboxyl,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _3-6The cycloalkyl amino carbonyl,

Two-C _3-6The cycloalkyl amino carbonyl,

One-C _1-5Alkyl amino-carbonyl amino,

Two-C _1-5Alkyl amino-carbonyl amino,

One-C _3-6The cycloalkyl amino carbonylamino,

Two-C _3-6The cycloalkyl amino carbonylamino,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

C _1-5Alkyl sulphinyl,

C by the halogen replacement _1-5Alkyl sulphinyl,

C _1-5Alkyl sulphonyl and

C by the halogen replacement _1-5Alkyl sulphonyl,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

Nitro,

Hydroxyl,

Carboxyl,

Formamyl,

Cyano group,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl and

Formamyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

C _1-5Alkyl-carbonyl-amino,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of halogen replacement,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _1-5Alkyl sulphinyl,

C _1-5Alkyl sulphonyl,

The isocyclic aryl sulfinyl,

By the isocyclic aryl sulfinyl of halogen replacement,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C _1-5Alkoxy carbonyl;

R ₂Be selected from:

Hydrogen, halogen, hydroxyl, carboxyl, formamyl, amino, C _1-5Alkyl, the C that replaces by halogen _1-5Alkyl, the C that replaces by hydroxyl _1-5Alkyl, by the C of carboxyl substituted _1-5Alkyl, the C that replaces by formamyl _1-5Alkyl, C _1-5Alkoxyl group, the C that replaces by halogen _1-5Alkoxyl group ,-NHNH ₂,-NHNHBoc ,-N (R _2a) (R _2b), morpholino, 4-ethanoyl-piperazinyl or 4-phenyl-Piperazine base,

R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl, C _3-6Cycloalkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

C _1-5Alkoxyl group,

Amino,

·-NHBoc，

C _3-6Cycloalkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

··-SO ₂NH ₂，

Heterocyclic radical and

C _3-6Cycloalkyl, isocyclic aryl, by independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

The group of formula V:

Wherein Boc is a carboxylamine tertiary butyl ester and G is C _1-5Alkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl,

Halogenated isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces;

Or when Q be formula (II) and Y be singly-bound or-CH ₂-time, R ₂Be methylamino or dimethylamino; Each T independently is selected from halogen, hydroxyl, carboxyl, formamyl, amino, cyano group, nitro, C _1-5Alkyl, the C that replaces by halogen _1-5Alkyl, the C that replaces by hydroxyl _1-5Alkyl, by the C of carboxyl substituted _1-5Alkyl, the C that replaces by formamyl _1-5Alkyl, C _2-5Alkenyl, C _2-5Alkynyl, C _3-6Cycloalkyl, C _1-5Alkoxyl group, the C that replaces by halogen _1-5Alkoxyl group, isocyclic aryl, heterocyclic radical and-N (R _2a) (R _2b);

P is 0,1,2,3,4 or 5;

L is selected from formula (VI) to (XXI):

R wherein ₃And R ₄Independent is hydrogen or C _1-5Alkyl; And A and B independently be singly-bound ,-CH ₂-or-(CH ₂) ₂-;

With

Y represents:

(i)-C (O) NR ₅-,-C (S) NR ₅-,-C (O) O-,-S (O) ₂-,-C (O)-,-C (S)-, singly-bound or-CH ₂(when L is selected from formula (VI) to (XIII)); Or

(ii)-C (O) NR ₅-,-C (S) NR ₅-,-C (O) O-or-OC (O)-(when L is selected from formula (XIV) to (XXI));

R wherein ₅Be hydrogen or C _1-5Alkyl perhaps as Y is-C (O) NR ₅-time, then R ₅And R ₁The nitrogen-atoms that connects with them forms heterocyclic radical;

Wherein isocyclic aryl is phenyl, naphthyl, anthryl (anthranyl), phenanthryl or xenyl;

Carbocylic radical is 10,11-dihydro-5-oxo-dibenzo [a, d] suberyl, 1-oxo-indanyl, 7,7-dimethyl-2-oxo-two ring [2.2.1] heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthenyl (acenaphthyl), anthraquinonyl, C-fluorenes-9-subunit, indanyl, indenyl, 1,2,3,4-tetrahydrochysene-naphthyl or two ring [2.2.1] heptenyls;

Heterocyclic radical is 1,2,3,4-tetrahydrochysene-isoquinolyl, 1,2, the 3-thiadiazolyl group, 1,2, the 3-triazolyl, 1,2-dihydro-3-oxo-pyrazolyl, 1,3, the 4-thiadiazolyl group, 1,3-dioxo-pseudoindoyl, 1, the 3-dioxolanyl, the 1H-indyl, 1H-pyrrolo-[2,3-c] pyridyl, the 1H-pyrryl, 1-oxo-3H-isobenzofuran-base, 2,2 ', 5 '; 2 "-terthienyl base (terthiophenyl), 2,2 '-bithiophene base, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzo [1,4] dioxine base, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidyl, 3,4-dihydro-2H-benzo [1,4] oxazinyl, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases (dioxepinyl), 4H-benzo [1,3] dioxine base, the 4H-benzopyranyl, 4-oxo-1,5,6,7-tetrahydrochysene-indyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxy--thioxanthene base, the 9H-carbazyl, the 9H-xanthenyl, azetidinyl, benzimidazolyl-, benzo [1,3] dioxa cyclopentenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, cinnolinyl, furyl, imidazo [2,1-b] thiazolyl, imidazolyl isoxazolyl, morpholino, morpholinyl oxazolyl, oxa-penta cyclic group (oxolanyl), piperazinyl, piperidyl, pyridyl, pyrazolo [5,1-b] thiazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalinyl, thiazolidyl, thiazolyl, thienyl, thia penta cyclic group (thiolanyl), 2,3-dihydro-benzofuryl, tetrahydrochysene-thienyl or benzofuryl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

One aspect of the present invention relates to medicinal compositions, and it comprises at least a as described compound in this article with pharmaceutically acceptable carrier blended.

One aspect of the present invention relates to prevention or treats the method for following disease: improve memory function, sleep and excited, anxiety disorder, dysthymia disorders, emotional handicap, epileptic seizures, obesity, diabetes, appetite and eating disorder, cardiovascular disorder, hypertension, hyperlipemia, myocardial infarction, mad food disease (comprising Bulimia nerovsa), anorexia, comprise manic depression of sex, schizophrenia, psychiatric disorder, dull-witted, nervous, cognitive disorder, attention deficit syndrome, the psychological disorders of substance abuse disease out of control and dyskinesia (comprising Parkinson's disease), epilepsy and addiction, this method comprise the individual treatment significant quantity of suffering from described illness as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to prevention or treats the method for following disease: eating disorder, obesity or the disease relevant, this method with obesity comprise the individual treatment significant quantity of suffering from described illness as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to prevention or treats the method for following disease: anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy, this method comprise the individual treatment significant quantity of suffering from described illness as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to as described compound or its medicinal compositions in this article, and it is used for the methods of treatment of human body or animal body by treatment.

One aspect of the present invention relates to as described compound or its medicinal compositions in this article, and it is used for the eating disorder, obesity of human body or animal body or the prevention or the methods of treatment of the disease relevant with obesity by treatment.

One aspect of the present invention relates to as described compound or its medicinal compositions in this article, and it is used for the prevention or the methods of treatment of anxiety disorder, dysthymia disorders, schizophrenia, addiction or the epilepsy of human body or animal body by treatment.

One aspect of the present invention relates to the purposes that is used for preventing or treat the medicine of eating disorder, obesity or the disease relevant with obesity as described The compounds of this invention in this article in preparation.

One aspect of the present invention relates to the purposes that is used for preventing or treat the medicine of anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy as described The compounds of this invention in this article in preparation.

One aspect of the present invention relates to the method that reduces individual food intake, this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to the method for inducing individual satietion (satiety), this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to control or reduces the method that whose body weight increases, this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates in individuality the method for regulating the MCH acceptor, and this method comprises to be made described acceptor and contact as described compound in this article.In some embodiments, described compound is an antagonist.In some embodiments, the regulating effect of MCH acceptor is used to prevent or treat eating disorder, disease that obesity is relevant with obesity.In some embodiments, the regulating effect of MCH acceptor reduces individual food intake.In some embodiments, the regulating effect of MCH acceptor is induced individual satietion.In some embodiments, control of the regulating effect of MCH acceptor or minimizing whose body weight increase.In some embodiments, the regulating effect of MCH acceptor is used for prevention or treatment anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy.

In some embodiments, described individuality is a Mammals.

In some embodiments, described Mammals is behaved.

In some embodiments, described people's weight index is about 18.5-about 45.In some embodiments, described people's weight index is about 25-about 45.In some embodiments, described people's weight index is about 30-about 45.In some embodiments, described people's weight index is about 35-about 45.

One aspect of the present invention relates to the method for preparing medicinal compositions, this method comprise with as in this article described compound mix with pharmaceutically acceptable carrier.

The application requires US temporary patent application series number 60/458,530 (submission on March 31st, 2003); Series number 60/495,911 (submission on August 19th, 2003); Series number 60/510,186 (submission on October 9th, 2003); Right of priority with series number 60/530,360 (submission on December 16th, 2003); All these patent documentations are attached to herein by reference in full.

Detailed Description Of The Invention

One aspect of the present invention relates to some heterogeneous ring compound by the replacement of formula (I) expression:

Or its pharmacy acceptable salt, hydrate or solvate, wherein Q, L, Y and R ₁Such as in this article definition.

Should be appreciated that existing clear some feature of the present invention of describing also can be provided with array configuration in the content of each embodiment in the discrete embodiment.On the contrary, the of the present invention various features of Short Description also can separately provide or close form (subcombination) with any suitable subgroup and provide in the content of discrete embodiment.

In some embodiments of the present invention, R ₂Be selected from: hydrogen, halogen, hydroxyl, carboxyl, formamyl, amino, the C that replaces by hydroxyl _1-5Alkyl, by the C of carboxyl substituted _1-5Alkyl, the C that replaces by formamyl _1-5Alkyl, C _1-5Alkoxyl group, the C that replaces by halogen _1-5Alkoxyl group ,-NHNH ₂,-NHNHBoc ,-N (R _2a) (R _2b), morpholino, 4-ethanoyl-piperazinyl or 4-phenyl-Piperazine base,

R wherein _2aBe hydrogen or C _1-5Alkyl, and R _2bBe C _1-5Alkyl, C _3-6Cycloalkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

C _1-5Alkoxyl group,

Amino,

·-NHBoc，

C _3-6Cycloalkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

··-SO ₂NH ₂，

Heterocyclic radical and

C _3-6Cycloalkyl, isocyclic aryl, by independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

The group of formula V:

Wherein Boc is a carboxylamine tertiary butyl ester and G is C _1-5Alkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl,

Halogenated isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces.

In some embodiments of the present invention, R ₂For-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl, C _3-6Cycloalkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

C _1-5Alkoxyl group,

Amino,

·-NHBoc，

C _3-6Cycloalkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

··-SO ₂NH ₂，

Heterocyclic radical and

C _3-6Cycloalkyl, isocyclic aryl, by independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group and

The group of formula V:

Wherein Boc is a carboxylamine tertiary butyl ester and G is C _1-5Alkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl,

Halogenated isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces.

In some embodiments of the present invention, R ₂For-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl or C _3-6Cycloalkyl.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

Two-isocyclic aryl amino,

By two-isocyclic aryl amino of halogen replacement,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl carbonylamino,

The isocyclic aryl sulfuryl amino,

The C that the isocyclic aryl sulfuryl amino replaces _1-5Alkyl,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By the heterocycle sulfenyl of nitro replacement,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _2-5Alkenyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

C _1-5Alkyl,

C by the replacement of oxo base _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl and

Isocyclic aryl,

(v) carbocylic radical,

(vi) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

Carboxyl,

Formamyl,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen,

Hydroxyl,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-7Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-7Alkoxyl group:

Halogen,

Isocyclic aryl and

Halogenated isocyclic aryl,

C _2-5Alkenyl oxy,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of nitro replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

C _1-5Alkoxycarbonyl amino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

The isocyclic aryl azo-group,

By one-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

By two-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of nitro replacement,

By the carbocyclic ring arylthio of cyano group replacement,

Amino-sulfonyl,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl,

The heterocyclic radical alkylsulfonyl,

C _3-6Cycloalkyl,

By C _1-5The C that alkyl replaces _3-6Cycloalkyl,

Isocyclic aryl,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

(vii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

Amino,

Hydroxyl,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

C _1-5Alkoxy carbonyl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Heterocyclic radical;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantyl, two ring [2.2.1] heptenyls, two ring [2.2.1] heptyl, indanyl, indenyl or

Base;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzo [1,4] dioxine base, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases, 4,5,6,7-tetrahydrochysene-benzo [b] thienyl, 4H-benzo [1,3] dioxine base, 4-oxo-1,5,6,7-tetrahydrochysene-indyl, 4-oxo-benzopyranyl, the 9H-carbazyl, the 9H-xanthenyl, azetidinyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [2,1,3] thiadiazolyl group, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazo [2,1-b] thiazolyl, imidazolyl isoxazolyl, morpholino, morpholinyl oxazolyl, phenanthro-[9,10-d] oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, tetrahydrofuran base, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, Q is formula (II) compound or its pharmacy acceptable salt, hydrate or solvate;

R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By the isocyclic aryl oxygen base of nitro replacement,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl carbonylamino,

The isocyclic aryl sulfuryl amino,

The C that the isocyclic aryl sulfuryl amino replaces _1-5Alkyl,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _2-5Alkenyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl,

C by the replacement of oxo base _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl and

Isocyclic aryl,

(v) carbocylic radical,

(vi) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Isocyclic aryl and

Halogenated isocyclic aryl,

C _2-5Alkenyl oxy,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of cyano group replacement,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl and

Isocyclic aryl,

(vii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Heterocyclic radical;

When Y be singly-bound or-CH ₂-time, R ₂Be methylamino or dimethylamino;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, two ring [2.2.1] heptyl, indenyl or

Base;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzo [1,4] dioxine base, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases, 4-oxo-benzopyranyl, the 9H-carbazyl, the 9H-xanthenyl, azetidinyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazo [2,1-b] thiazolyl, imidazolyl isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-7Alkyl and

By independently being selected from the C that following substituting group replaces _1-7Alkyl:

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

One-C _1-5Alkylamino,

By independently being selected from one-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

Two-C _1-5Alkylamino,

By independently being selected from two-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

The isocyclic aryl sulfuryl amino,

By C _1-5The isocyclic aryl sulfuryl amino that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Isocyclic aryl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

Heterocyclic radical,

The heterocyclic radical that replaces by isocyclic aryl and

By the heterocyclic radical of halogen replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl and

By the isocyclic aryl of C1-5 alkoxyl group replacement,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl and

C by the isocyclic aryl replacement _1-5Alkyl,

(v) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

C _2-5Alkenyl oxy,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _1-5Alkylthio and

C by the halogen replacement _1-5Alkylthio,

(vi) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Hydroxyl and

Isocyclic aryl,

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

L is formula (VII);

Y be singly-bound or-CH ₂-;

R ₂Be methylamino or dimethylamino;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzo [1,4] dioxine base, 4-oxo-benzopyranyl, 9H-carbazyl, azetidinyl, benzo [1,3] dioxolyl, benzo [b] thienyl, furyl, imidazo [2,1-b] thiazolyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p is 0; R ₃And R ₄Be hydrogen; A be singly-bound or-CH ₂-; With B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

Heterocyclic radical and

By the heterocyclic radical of isocyclic aryl replacement,

(ii) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group and

C _2-5Alkenyl oxy,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C _1-5Alkoxy carbonyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, azetidinyl or benzo [1, a 3] dioxa cyclopentenyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) amino] methyl }-the 1H-Ethyl indole-2-carboxylate;

2) 3-[{2-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-amino] ethyl } (phenyl)-amino] propionitrile;

3) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[2-(2-phenyl-1H-indol-3-yl) ethyl] amino }-cyclohexyl) quinoline-2, the 4-diamines;

4) N ²-[cis-4-({ [1-(diphenyl methyl) azetidine-3-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

5) N ²-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

6) N ²-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

7) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

8) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] amino }-methyl)-the 6-methoxyphenol;

9) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

10) N ²-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

11) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

12) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl) quinoline-2, the 4-diamines;

13) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

14) N ²-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

15) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

16) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl) quinoline-2, the 4-diamines;

17) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl) quinoline-2, the 4-diamines;

18) N ²-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

19) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl quinoline-2, the 4-diamines;

20) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines;

21) N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl) amino-cyclohexyl]-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines;

22) N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl) amino-cyclohexyl]-N ⁴-methyl-quinoline-2, the 4-diamines;

23) N ²-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-quinoline-2, the 4-diamines;

24) N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-quinoline-2, the 4-diamines;

25) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-quinoline-2, the 4-diamines;

26) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines;

27) N ⁴, N ⁴-dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-quinoline-2, the 4-diamines;

28) cis-N-(3, the 5-dimethoxy-benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines; With

29) cis-N-(3, the 5-dichloro benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ¹Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Hydroxyl,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

The isocyclic aryl carbonylamino,

C _1-5Alkoxycarbonyl amino,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl,

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl

Isocyclic aryl,

By the isocyclic aryl that independently is selected from following substituting group replacement,

Halogen and

Nitro,

(iii) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Isocyclic aryl and

Isocyclic aryl,

(iv) carbocylic radical,

(v) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

Carboxyl,

Formamyl,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl,

Halogen,

Hydroxyl,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of cyano group replacement,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl and

Isocyclic aryl,

(vi) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

Hydroxyl,

Amino,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl,

Halogen,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkyl,

Heterocyclic radical;

L is formula (VII);

Y is-C (O)-;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl or indenyl;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, the 9H-xanthenyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be hydrogen, halogen, methyl, trifluoromethyl, methoxyl group, formamyl, amino, methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

C _3-6Cycloalkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxyl group and

Isocyclic aryl,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

Nitro,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

Formamyl,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C by the hydroxyl replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base and

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces

Halogen,

Nitro,

Amino,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

The isocyclic aryl that replaces by nitro and

Heterocyclic radical;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is 1,2,3-triazoles base, 1H-indyl, 1H-pyrryl, 9H-xanthenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, furyl, isoxazolyl, pyridyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _1-5Alkoxyl group and

Heterocyclic radical,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

Hydroxyl,

Cyano group,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base and

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

The isocyclic aryl that replaces by nitro and

Heterocyclic radical;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is 1H-indyl, 1H-pyrryl, 9H-xanthenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, furyl, isoxazolyl, pyridyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

2) 3-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

3) 4-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

4) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

5) 3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

6) 4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

7) 4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

8) 3-cyano group-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

9) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) benzamide;

10) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) benzamide;

11) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

12) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

13) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide;

14) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

15) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

16) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-methyl-3-nitro benzamide;

17) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

18) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group butyramide;

19) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group propionic acid amide;

20) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl benzamide;

21) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy)-benzamide;

22) 4-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl benzamide;

23) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-phenyl-iodide methane amide;

24) 3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,4 difluorobenzene methane amide;

25) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,5-dimethyl-3-furoamide;

26) 3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

27) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

28) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

29) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl)-benzamide;

30) (2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(4-nitrophenyl)-acrylamide;

31) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

32) 2,5-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiophene-3-methane amide;

33) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-ethanamide;

34) 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-5-methyl-isoxazole-4-methane amide;

35) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-cyclopentane formamide;

36) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

37) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

38) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

39) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

40) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

41) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitro-2-furoamide;

42) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy-acetamide;

43) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) quinoxaline-2-methane amide;

44) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-ethanamide;

45) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-5-methyl-isoxazole-4-methane amide;

46) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group niacinamide;

47) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methylphenoxy)-niacinamide;

48) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

49) 5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-thiophene-2-carboxamide derivatives;

50) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2,3, the 6-trichlorophenyl)-ethanamide;

51) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-furoamide;

52) 5-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-thiophene-2-carboxamide derivatives;

53) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-iodo-2-furoamide;

54) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-iodine substituted phenyl) ethanamide;

55) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide;

56) (2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(3-nitrophenyl)-acrylamide;

57) 2, two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-ethanamide;

58) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-2-methane amide;

59) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl-4-nitrobenzamide;

60) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

61) 5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-furoamide;

62) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

63) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

64) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide;

65) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

66) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

67) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2,4, the 6-Trichlorophenoxy)-ethanamide;

68) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-the 4-methoxy benzamide;

69) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy benzamide;

70) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenylquinoline-4-methane amide;

71) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide;

72) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

73) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

74) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-nitrobenzamide;

75) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-methoxyl group-4-nitrobenzamide;

76) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

77) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-dimethyl-4-nitrobenzamide;

78) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-

Base-2-oxo ethanamide;

79) 5-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-hydroxybenzamide;

80) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methoxy benzamide;

81) 3-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

82) 4-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

83) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,1,3-Ben Bing oxadiazole-5-methane amide;

84) 3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

85) 4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

86) 4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 3-nitrobenzamide;

87) 3-cyano group-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] benzamide;

88) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

89) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

90) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide;

91) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

92) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 5-difluorobenzamide;

93) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide;

94) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-fluoro-5-(trifluoromethyl) benzamide;

95) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-methyl-3-nitro benzamide;

96) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide;

97) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group butyramide;

98) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group propionic acid amide;

99) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide;

100) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide;

101) 4-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

102) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-phenyl-iodide methane amide;

103) 3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 2,4 difluorobenzene methane amide;

104) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,5-dimethyl-3-furoamide;

105) 3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 4-fluoro benzamide;

106) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide;

107) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

108) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

109) (2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

110) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide;

111) 2,5-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-thiophene-3-methane amide;

112) 2,6-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

113) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide;

114) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

115) (2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] acrylamide;

116) 5-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] thiophene-2-carboxamide derivatives;

117) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

118) 5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl]-the 2-furoamide;

119) 5-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] thiophene-2-carboxamide derivatives;

120) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-iodo-2-furoamide;

121) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2-iodine substituted phenyl)-ethanamide;

122) (2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide;

123) 2,2-two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] ethanamide;

124) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-nitrothiophene-2-methane amide;

125) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

126) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

127) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide;

128) 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

129) 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

130) 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

131) 3-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

132) N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide;

133) 3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

134) 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

135) 3-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

136) 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

137) 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

138) 3-chloro-4-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

139) 3,5-dimethoxy-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

140) 3,4-two chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

141) benzo [2,3,1] oxadiazole-5-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

142) 3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

143) 3-methoxyl group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

144) 4-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

145) 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

146) 9H-xanthene-9-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

147) 5-(4-chloro-phenyl)-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

148) 3-nitro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

149) 4-fluoro-3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

150) 3-bromo-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

151) 2-(2-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

152) 3-cyano group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

153) N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-trifluoromethyl-benzamide;

154) N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide;

155) 3,4-two chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

156) 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

157) 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

158) 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

159) 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

160) 5-bromo-furans-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

161) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-ethanamide;

162) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-ethanamide;

163) 2,2-phenylbenzene-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

164) 5-bromo-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

165) benzo [2,3,1] oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

166) 3-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

167) 3-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

168) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide;

169) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2,2-phenylbenzene-ethanamide;

170) 2-(4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

171) 2-(4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

172) 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

173) 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

174) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide;

175) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide;

176) 2-(4-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

177) 2-(4-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

178) 2-(4-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

179) 2-(4-bromo-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

180) 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

181) 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

182) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

183) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

184) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide;

185) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide;

186) 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

187) 2-(3-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

188) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

189) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

190) C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

191) 2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

192) 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

193) 2-(3-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

194) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

195) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

196) C-(methyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

197) 2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

198) 3-hydroxy-n-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

199) N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the isophthalamic acid methyl ester;

200) N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide;

201) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-di-trifluoromethyl-benzamide;

202) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide;

203) N-[cis-4-(4-amino-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide;

204) C-(ethyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

205) C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

206) 3-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

207) 2-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

208) 2,3-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

209) 2,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

210) 2,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

211) 2,6-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

212) 3,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

213) C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

214) 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

215) 4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

216) 3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

217) 2-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

218) 4-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

219) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the isophthalamic acid methyl ester;

220) 3,5-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

221) 4-chloro-3-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

222) C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

223) 6-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

224) 6-dimethylamino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

225) 3-hydroxymethyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

226) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-different benzene diamide (isophthalamide);

227) 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

228) 3,4,5-three fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

229) pyridine-2-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

230) 4-chloro-pyridine-2-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

231) 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

232) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-6-trifluoromethyl-niacinamide;

233) 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-benzamide;

234) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide;

235) N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide;

236) 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-benzamide;

237) 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-niacinamide;

238) amino 4-methyl-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } benzamide;

239) amino 2-(4-chloro phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } ethanamide;

240) 3,4,5-trimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide;

241) amino 2-(3, the 4-difluorophenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } ethanamide;

242) amino 2-(2-bromo-4,5-Dimethoxyphenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-ethanamide;

243) 2,6-dimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } niacinamide;

244) amino N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-4-(trifluoromethoxy) benzamide;

245) 5-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide; With

246) 5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) 3-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

2) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

3) 3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

4) 4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-benzamide;

5) 4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

6) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) benzamide;

7) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

8) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

9) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

10) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group butyramide;

11) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group propionic acid amide;

12) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl benzamide;

13) 4-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl benzamide;

14) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,5-dimethyl-3-furoamide;

15) 3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

16) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

17) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

18) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-ethanamide;

19) 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-5-methyl-isoxazole-4-methane amide;

20) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

21) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

22) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

23) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitro-2-furoamide;

24) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy-acetamide;

25) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-ethanamide;

26) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-5-methyl-isoxazole-4-methane amide;

27) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group niacinamide;

28) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methylphenoxy)-niacinamide;

29) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

30) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2,3, the 6-trichlorophenyl)-ethanamide;

31) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-iodo-2-furoamide;

32) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-2-methane amide;

33) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl-4-nitrobenzamide;

34) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

35) 5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-furoamide;

36) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

37) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide;

38) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide;

39) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

40) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

41) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-nitrobenzamide;

42) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

43) 3-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

44) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,1,3-Ben Bing oxadiazole-5-methane amide;

45) 3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

46) 4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-benzamide;

47) 4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 3-nitrobenzamide;

48) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

49) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

50) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide;

51) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide;

52) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group butyramide;

53) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group propionic acid amide;

54) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide;

55) 4-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

56) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,5-dimethyl-3-furoamide;

57) 3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-the 4-fluoro benzamide;

58) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

59) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide;

60) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide;

61) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino }-cyclohexyl) methyl]-benzamide;

62) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

63) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-iodo-2-furoamide;

64) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-nitrothiophene-2-methane amide;

65) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

66) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

67) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide;

68) 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

69) 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

70) 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

71) 3-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

72) 3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

73) 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

74) 3-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

75) 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

76) 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

77) 3-chloro-4-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

78) 3,5-dimethoxy-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

79) 3,4-two chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

80) benzo [2,3,1] oxadiazole-5-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

81) 3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

82) 3-methoxyl group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

83) 4-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

84) 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

85) 9H-xanthene-9-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

86) 3-nitro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

87) 4-fluoro-3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

88) 3-bromo-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

89) 2-(2-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

90) 3-cyano group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

91) N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-trifluoromethyl-benzamide;

92) N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide;

93) 3,4-two chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

94) 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

95) 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

96) 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

97) 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

98) 5-bromo-furans-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

99) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-ethanamide;

100) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-ethanamide;

101) 2,2-phenylbenzene-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

102) 5-bromo-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-acid amides;

103) benzo [2,3,1] oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acid amides;

104) 3-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

105) 3-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

106) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide;

107) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2,2-phenylbenzene-ethanamide;

108) 2-(4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

109) 2-(4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

110) 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

111) 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

112) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide;

113) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide;

114) 2-(4-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

115) 2-(4-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

116) 2-(4-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

117) 2-(4-bromo-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

118) 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide;

119) 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

120) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

121) N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide;

122) N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide;

123) 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

124) 2-(3-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

125) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

126) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

127) C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

128) 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

129) 2-(3-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

130) 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

131) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

132) C-(methyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

133) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide;

134) N-[cis-4-(4-amino-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide;

135) C-(ethyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

136) C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

137) 3-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

138) 2,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

139) 3,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

140) C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-ethanamide;

141) 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

142) 4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

143) 3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

144) 4-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

145) N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the isophthalamic acid methyl ester;

146) 3,5-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

147) 4-chloro-3-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide;

148) C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-ethanamide;

149) 6-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

150) 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

151) 3,4,5-three fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide;

152) 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

153) amino 4-methyl-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } benzamide;

154) amino 2-(4-chloro phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-ethanamide;

155) 3,4,5-trimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide;

156) amino 2-(3, the 4-difluorophenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-ethanamide;

157) amino 2-(2-bromo-4,5-Dimethoxyphenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)]-cyclohexyl }-ethanamide;

158) 2,6-dimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } niacinamide;

159) amino N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-4-(trifluoromethoxy)-benzamide;

160) 5-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide; With

161) 5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

L is formula (XV);

Y is-C (O) NR ₅-;

Wherein isocyclic aryl is a phenyl; With

Halogen is fluoro base, chloro base or bromo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Wherein isocyclic aryl is a phenyl; With

Halogen is fluoro base, chloro base or bromo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methyl; P is 0; R ₃And R ₄Be hydrogen; A and B are singly-bound; And R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

Cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-N-[(1R)-1-(2-fluoro phenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-N-[(1S)-1-(2-fluoro phenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl }-cyclohexane carboxamide;

Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl }-cyclohexane carboxamide;

Cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide; With

Cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

Cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-N-[(1S)-1-(2-fluoro phenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino]-cyclohexane carboxamide;

Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl }-cyclohexane carboxamide; With

Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl }-cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkoxy carbonyl,

C _1-5Alkylthio,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _2-5Alkenyl,

(ii) C _3-6Cycloalkyl and

C by the isocyclic aryl replacement _3-6Cycloalkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces

Halogen,

Cyano group,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

C _1-5Alkylthio and

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

Isocyclic aryl;

L is formula (VII);

Y is-C (O) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, 3,4-dihydro-2H-benzo [b] [1,4]-two oxa-English in heptan base (dioxepinyl), benzo [1,3] dioxolyl, furyl or isoxazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be hydrogen, methyl, methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkoxy carbonyl,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

(iii) heterocyclic radical,

By C _1-5The heterocyclic radical that alkyl replaces and

Heterocyclic radical by the isocyclic aryl replacement;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is an isoxazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

2) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethyl-6-aminomethyl phenyl) urea;

3) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-

The base urea;

4) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl)-urea;

5) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl)-urea;

6) N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

7) N-(2,6-diethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

8) N-(2-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

9) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) urea;

10) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

11) N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

12) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(diphenyl methyl) urea;

13) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

14) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea;

15) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-1-naphthyl urea;

16) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl]-urea;

17) N-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-amino] carbonyl }-phenylalanine (phenylalaninate) methyl esters;

18) N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea;

19) N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

20) N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) urea;

21) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-aminomethyl phenyl) urea;

22) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '- The base urea;

23) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2,4, the 6-trichlorophenyl) urea;

24) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2,4,6-tribromo phenyl) urea;

25) N-(2,4-two bromo-6-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl] urea;

26) N-(2,6-diethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-methyl] urea;

27) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-quinoline-2-yl] amino } cyclohexyl) methyl] urea;

28) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-isopropyl phenyl) urea;

29) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

30) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea;

31) N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl] urea;

32) N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] urea;

33) N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(diphenyl methyl) urea;

34) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl] urea;

35) N-(2, the 3-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] urea;

36) N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl] urea;

37) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-urea; With

38) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

(ii) carbocylic radical,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino and

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxy carbonyl and

Isocyclic aryl;

L is formula (VII);

Y is-C (S) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is two ring [2.2.1] heptyl;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, benzo [1,3] dioxolyl, isoxazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl

C _1-5Alkoxyl group,

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino,

(ii) heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces and

By C _1-5The heterocyclic radical that alkoxy carbonyl replaces;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is a thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-thiocarbamide;

N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide;

N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl)-thiocarbamide;

N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl)-thiocarbamide;

N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-

The base thiocarbamide;

N-(2,6-diethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl)-thiocarbamide;

N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide;

N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide;

N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-quinoline-2-yl] amino } cyclohexyl) thiocarbamide;

N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide;

N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide;

N-(2,4-two chloro-6-aminomethyl phenyls) N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) thiocarbamide; With

3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-amino]-thioformyl (carbonothioyl) } amino)-4-thiotolene-2-carboxylic acid methyl ester;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Carbocylic radical,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(ii) C _2-5Alkenyl,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group;

L is formula (VII);

Y is-C (O) O-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical be the 9H-fluorenyl or

Base; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, Q is formula (III);

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By the isocyclic aryl oxygen base of nitro replacement,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

Two-isocyclic aryl amino,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

The isocyclic aryl sulfuryl amino,

The C that the isocyclic aryl sulfuryl amino replaces _1-5Alkyl,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _2-5Alkenyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(iii) C _2-5Alkynyl,

(iv) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

C _1-5Alkyl,

C by the replacement of oxo base _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl and

Isocyclic aryl,

(v) carbocylic radical,

(vi) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-10Alkyl

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-7Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-7Alkoxyl group:

Halogen,

Isocyclic aryl and

Halogenated isocyclic aryl,

C _2-5Alkenyl oxy,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of nitro replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

Carboxyl,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

C _1-5Alkoxycarbonyl amino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

The isocyclic aryl azo-group,

By one-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

By two-C _1-5The isocyclic aryl azo-group that alkylamino replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of nitro replacement,

By the carbocyclic ring arylthio of cyano group replacement,

Amino-sulfonyl,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl,

The heterocyclic radical alkylsulfonyl,

C _3-6Cycloalkyl,

By C _1-5The C that alkyl replaces _3-6Cycloalkyl,

Isocyclic aryl,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

(vii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkyl sulphonyl

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

C _1-5Alkoxy carbonyl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Heterocyclic radical;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantyl, two ring [2.2.1] heptenyls, two ring [2.2.1] heptyl, indanyl, indenyl or

Base;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzo [1,4] dioxine base, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases, 4,5,6,7-tetrahydrochysene-benzo [b] thienyl, 4H-benzo [1,3] dioxine base, 4-oxo-1,5,6,7-tetrahydrochysene-indyl, 4-oxo-benzopyranyl, the 9H-carbazyl, the 9H-xanthenyl, azetidinyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [2,1,3] thiadiazolyl group, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazo [2,1-b] thiazolyl isoxazolyl, morpholino, morpholinyl oxazolyl, phenanthro-[9,10-d] oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, tetrahydrofuran base, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-7Alkyl and

By independently being selected from the C that following substituting group replaces _1-7Alkyl:

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-C _1-5Alkylamino,

By independently being selected from one-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

Two-C _1-5Alkylamino

By independently being selected from two-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

The isocyclic aryl sulfuryl amino,

By C _1-5The isocyclic aryl sulfuryl amino that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Isocyclic aryl,

C _1-5Alkoxyl group,

Heterocyclic radical and

By the heterocyclic radical of isocyclic aryl replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

(iii) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl

C _1-5Alkyl and

C by the isocyclic aryl replacement _1-5Alkyl,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

C _2-5Alkenyl oxy,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _1-5Alkylthio and

C by the halogen replacement _1-5Alkylthio,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Hydroxyl and

Isocyclic aryl,

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl;

L is formula (VII);

Y be singly-bound or-CH ₂-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzo [1,4] dioxine base, 4-oxo-benzopyranyl, 9H-carbazyl, azetidinyl, benzo [1,3] dioxolyl, benzo [b] thienyl, furyl, imidazo [2,1-b] thiazolyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

The isocyclic aryl sulfuryl amino,

By C _1-5The isocyclic aryl sulfuryl amino that alkyl replaces,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

(ii) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 4-oxo-benzopyranyl, azetidinyl, benzo [1,3] dioxolyl or pyrazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

The isocyclic aryl sulfuryl amino,

By C _1-5The isocyclic aryl sulfuryl amino that alkyl replaces and

Isocyclic aryl,

(ii) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C _1-5Alkoxy carbonyl,

Isocyclic aryl and

Isocyclic aryl by the halogen replacement;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is 1H-indyl, azetidinyl or pyrazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N ²-cis-4-[(2,6-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

2) N ²-cis-4-[(2-ethoxy benzyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

3) N ²-cis-4-[(1H-indol-3-yl methyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

4) N ²-cis-4-[(2,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

5) N ²-(cis-4-{[(4-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

6) N ²-(cis-4-{[(5-methoxyl group-1H-indol-3-yl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

7) 4-bromo-2-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) amino] methyl }-the 6-methoxyphenol;

8) N ²-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

9) 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino] methyl }-2, the 6-syringol;

10) N ²-cis-4-[(3-oxyethyl group-4-methoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

11) N ⁴, N ⁴-dimethyl-N ²-cis-4-[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl }-methyl)-amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

12) N ⁴, N ⁴-dimethyl-N ²-cis-4-[(3,4,5-trimethoxy benzyl) and amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

13) N ⁴, N ⁴-dimethyl-N ²-cis-4-[(pentamethyl-benzyl) and amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

14) N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

15) 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino] methyl }-2-iodo-6-methoxyphenol;

16) 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino] methyl }-2, the 6-xylenol;

17) 3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino] methyl }-6,8-dimethyl-4H-chromene-4-ketone;

18) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

19) N ²-[cis-4-({ [3-(4-fluoro phenyl)-1H-pyrazoles-4-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

20) N ⁴, N ⁴-dimethyl-N ²-[4-(pentamethylbenzene ylmethyl-amino)-cyclohexyl]-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

21) 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-amino] ethyl } (3-aminomethyl phenyl) amino] propionitrile;

22) 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-amino] ethyl } (phenyl) amino] propionitrile;

23) N-{ (1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) amino] ethyl }-the 4-methyl benzenesulfonamide;

24) N ²-(cis-4-{[2-(3, the 5-Dimethoxyphenyl) ethyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

25) N ²-[cis-4-({ [1-(diphenyl methyl) azetidine-3-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

26) N ²-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

27) N ²-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

28) N ²-(cis-4-{[(1H-indol-3-yl methyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

29) N ²-(cis-4-{[(2,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

30) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

31) N ²-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

32) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol;

33) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

34) N ²-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

35) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl)-amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

36) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(3,4,5-trimethoxy benzyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

37) N ²-(cis-4-{[(3,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

38) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2-iodo-6-methoxyphenol;

39) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2, the 6-xylenol;

40) 3-chloro-4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] amino } methyl) phenol;

41) N ²-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

42) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

43) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-the 2-thanatol;

44) N ²-cis-4-[({[4-(dimethylamino)-1-naphthyl] and methyl } amino) methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

45) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

46) 2-bromo-4-chloro-6-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenol;

47) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

48) N ²-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

49) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

50) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

51) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

52) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl)-methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

53) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-the 2-methylphenol;

54) N ²-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

55) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2-fluoro-6-methoxyphenol;

56) N ⁴, N ⁴-dimethyl-N ²-[cis-4-({ [(1-phenyl-5-propyl group-1H-pyrazoles-4-yl) methyl] amino } methyl)-cyclohexyl]-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

57) N ²-cis-4-[({[1-(4-chlorophenyl)-5-propyl group-1H-pyrazoles-4-yl] methyl }-amino) methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

58) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino] cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

59) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

60) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

61) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

62) N ⁴, N ⁴-dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines; With

63) N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N ²-(cis-4-{[(5-methoxyl group-1H-indol-3-yl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

2) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

3) N ²-[cis-4-({ [3-(4-fluoro phenyl)-1H-pyrazoles-4-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

4) 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-amino] ethyl } (phenyl) amino] propionitrile;

5) N-{ (1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) amino] ethyl }-the 4-methyl benzenesulfonamide;

6) N ²-[cis-4-({ [1-(diphenyl methyl) azetidine-3-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

7) N ²-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

8) N ²-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

9) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

10) N ²-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

11) 4-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2-iodo-6-methoxyphenol;

12) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

13) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

14) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

15) N ²-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

16) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

17) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

18) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

19) N ⁴, N ⁴-dimethyl-N ²-[cis-4-({ [(1-phenyl-5-propyl group-1H-pyrazoles-4-yl) methyl] amino } methyl)-cyclohexyl]-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

20) N ²-cis-4-[({[1-(4-chlorophenyl)-5-propyl group-1H-pyrazoles-4-yl] methyl }-amino) methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines;

21) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

22) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

23) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines; With

24) N ⁴, N ⁴-dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

C _1-5Alkoxyl group

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By the isocyclic aryl oxygen base of nitro replacement,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

The isocyclic aryl carbonylamino

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces

C _3-6Cycloalkyl

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

One-isocyclic aryl aminocarboxyl,

By one-isocyclic aryl aminocarboxyl of halogen replacement,

Two-isocyclic aryl aminocarboxyl,

By two-isocyclic aryl aminocarboxyl of halogen replacement,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

Nitro,

(iii) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Isocyclic aryl,

Isocyclic aryl,

(iv) carbocylic radical,

(v) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-5Alkoxyl group

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of cyano group replacement,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl,

Isocyclic aryl,

Heterocyclic radical,

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

(vi) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl

Halogen,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkyl,

Heterocyclic radical;

L is formula (VII);

Y is-C (O)-;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl or indenyl;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydrochysene-indyl, the 9H-xanthenyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

The isocyclic aryl carbonylamino

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

The heterocycle sulfenyl

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Heterocyclic radical

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxyl group and

Isocyclic aryl,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By the isocyclic aryl of nitro replacement,

(iii) C _3-6Cycloalkyl and

C by the isocyclic aryl replacement _3-6Cycloalkyl,

(iv) carbocylic radical,

(v) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo and

Isocyclic aryl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces and

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

(vi) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl and

Heterocyclic radical,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkyl,

Heterocyclic radical;

Wherein isocyclic aryl is a phenyl;

Carbocylic radical is 1-oxo-indanyl or indenyl;

Heterocyclic radical is 1,2,3-triazolyl, 1H-indyl, 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2-oxo-benzopyranyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl;

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

The isocyclic aryl carbonylamino,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl and

C _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxyl group and

Isocyclic aryl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen and

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces and

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C by the heterocyclic radical replacement _1-5Alkyl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Isocyclic aryl by the nitro replacement;

Wherein isocyclic aryl is a phenyl;

Carbocylic radical is an indenyl;

Heterocyclic radical is 1H-indyl, 1H-pyrryl, 2-oxo-benzopyranyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, furyl, isoxazolyl, morpholino, pyridyl, quinoxalinyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-methoxy benzamide;

2) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

3) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

4) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

5) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

6) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

7) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-nitrobenzamide;

8) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

9) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

10) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

11) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

12) N-(cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,2-phenylbenzene ethanamide;

13) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3, the 4-difluorobenzamide;

14) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3, the 5-difluorobenzamide;

15) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-fluoro benzamide;

16) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

17) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-hexanamide;

18) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-methyl-3-nitro benzamide;

19) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-nitrobenzamide;

20) (2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenyl cyclopropane carboxamide;

21) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenoxy group butyramide;

22) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenoxy group propionic acid amide;

23) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-methyl benzamide;

24) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-methyl benzamide;

25) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-(trifluoromethoxy) benzamide;

26) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-methyl benzamide;

27) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-phenyl-iodide methane amide;

28) 2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-fluoro benzamide;

29) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(3-p-methoxy-phenyl) ethanamide;

30) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-fluoro phenyl) ethanamide;

31) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-p-methoxy-phenyl) ethanamide;

32) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furoamide;

33) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,5-dimethyl-3-furoamide;

34) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-fluoro benzamide;

35) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-fluoro-4-methyl benzamide;

36) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-dimethoxy benzamide;

37) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

38) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-fluoro-3-methyl benzamide;

39) 2,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-3-methane amide;

40) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(rosickyite base) niacinamide;

41) the 1-benzyl-3-tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide;

42) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) niacinamide;

43) acetate 2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino]-2-oxo-1-phenylethylester;

44) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-benzamide;

45) 2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) ethanamide;

46) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

47) 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

48) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) cyclopentane formamide;

49) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

50) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-1,3-dimethyl-1H-pyrazoles-5-methane amide;

51) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-fluoro benzamide;

52) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

53) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

54) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

55) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitro-2-furoamide;

56) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-phenoxy-acetamide;

57) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-quinoxaline-2-methane amide;

58) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-(trifluoromethyl) benzamide;

59) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

60) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

61) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenoxy group niacinamide;

62) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-methylphenoxy) niacinamide;

63) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

64) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

65) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2,3, the 6-trichlorophenyl) ethanamide;

66) 2-(2-chloro-4-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

67) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-furoamide;

68) 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

69) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,3-diphenylprop acid amides;

70) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-(2-hydroxy phenyl) propionic acid amide;

71) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-iodo-2-furoamide;

72) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2-iodine substituted phenyl) ethanamide;

73) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide;

74) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-oxo indane-1-methane amide;

75) 2-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

76) 2, and two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

77) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide;

78) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitrothiophene-2-methane amide;

79) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-methyl-4-nitrobenzamide;

80) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

81) 3-ethanoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

82) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

83) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-[(4-methylpyrimidine-2-yl) sulfo-] ethanamide;

84) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-furoamide;

85) 2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

86) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-hydroxyl-3,5-Dimethoxyphenyl) ethanamide;

87) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

88) N ², N ⁶-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) lysyl amine (lysinamide);

89) 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide;

90) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

91) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-(4-fluoro phenyl)-4-oxo butyramide;

92) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide;

93) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl) phenyl] propionic acid amide;

94) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(1H-indol-3-yl) ethanamide;

95) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(7-methoxyl group-2-oxo-2H-chromene-4-yl) ethanamide;

96) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

97) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy) phenyl] amino carbonyl) amino]-benzamide;

98) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group (prop-2-ynoyl)) amino] benzamide;

99) 4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxo butyramide;

100) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

101) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide;

102) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-(4-nitrophenyl) butyramide;

103) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(3-Phenoxyphenyl) ethanamide;

104) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-Phenoxyphenyl) ethanamide;

105) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

106) N ²-benzoyl-N ⁵-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N ¹, N ¹-dipropyl glutamine (glutamamide);

107) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-phenoxy benzamide;

108) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide;

109) N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N, N-two [(1S)-1-phenylethyl] phthalamide;

110) (2S)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide;

111) sulfo-2-[(4-benzyl chloride base)]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

112) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl ethanamide;

113) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide;

114) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-methoxy benzamide;

115) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide;

116) sulfo-1-{2-[(2-chloro-6-fluoro benzyl)] ethyl }-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

117) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-phenoxy benzamide;

118) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenylquinoline-4-methane amide;

119) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-(3-nitrophenyl)-2-furoamide;

120) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitrothiophene-3-methane amide;

121) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

122) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-methoxyl group-4-nitrobenzamide;

123) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-methoxyl group-2-phenyl-acetamides;

124) 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-hydroxybenzamide;

125) 3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] benzamide;

126) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(ethylmercapto group) niacinamide;

127) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(4-p-methoxy-phenyl) ethanamide;

128) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furoamide;

129) (2E)-and N-[(cis-4-{[4-(dimethylamino)-5.6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

130) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-4-fluoro-3-methyl benzamide;

131) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(rosickyite base) niacinamide;

132) 2,6-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] benzamide;

133) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2,4,6-Three methyl Benzene methane amide;

134) 2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl]-the 6-fluoro benzamide;

135) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] benzamide;

136) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

137) (2E)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide; With

138) N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-methoxy benzamide;

2) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

3) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

4) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

5) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

6) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-nitrobenzamide;

7) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

8) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

9) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

10) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

11) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,2-phenylbenzene ethanamide;

12) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3, the 4-difluorobenzamide;

13) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3, the 5-difluorobenzamide;

14) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-fluoro benzamide;

15) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

16) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-methyl-3-nitro benzamide;

17) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-nitrobenzamide;

18) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenoxy group butyramide;

19) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-phenoxy group propionic acid amide;

20) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-methyl benzamide;

21) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-phenyl-iodide methane amide;

22) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-fluoro phenyl) ethanamide;

23) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2,5-dimethyl-3-furoamide;

24) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-fluoro benzamide;

25) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-dimethoxy benzamide;

26) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

27) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-fluoro-3-methyl benzamide;

28) 2,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-3-methane amide;

29) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) niacinamide;

30) acetate 2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-amino]-2-oxo-1-phenylethylester;

31) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

32) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-fluoro benzamide;

33) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

34) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

35) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitro-2-furoamide;

36) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-phenoxy-acetamide;

37) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-quinoxaline-2-methane amide;

38) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-(trifluoromethyl) benzamide;

39) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

40) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

41) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-methylphenoxy) niacinamide;

42) 2-(2-chloro-4-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

43) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-furoamide;

44) 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

45) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-iodo-2-furoamide;

46) 2, and two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

47) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitrothiophene-2-methane amide;

48) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-methyl-4-nitrobenzamide;

49) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

50) 3-ethanoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) benzamide;

51) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

52) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-furoamide;

53) 2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide;

54) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(4-hydroxyl-3,5-Dimethoxyphenyl) ethanamide;

55) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-furoamide;

56) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(1H-indol-3-yl) ethanamide;

57) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(7-methoxyl group-2-oxo-2H-chromene-4-yl) ethanamide;

58) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy) phenyl] amino carbonyl) amino]-benzamide;

59) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group) amino] benzamide;

60) 4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxo butyramide;

61) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide;

62) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-4-(4-nitrophenyl) butyramide;

63) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

64) N ²-benzoyl-N ⁵-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N ¹, N ¹-dipropyl glutamine;

65) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 3-phenoxy benzamide;

66) N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N, N-two [(1S)-1-phenylethyl] phthalamide;

67) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl ethanamide;

68) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 4-methoxy benzamide;

69) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-phenoxy benzamide;

70) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-5-nitrothiophene-3-methane amide;

71) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

72) 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-the 2-hydroxybenzamide;

73) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(ethylmercapto group) niacinamide;

74) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(4-p-methoxy-phenyl) ethanamide;

75) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furoamide;

76) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-2-(rosickyite base) niacinamide; With

77) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] benzamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _2-5Alkenyl and

C _1-5Alkoxyl group,

C _1-5Alkylthio and

Heterocyclic radical,

(ii) C _3-6Cycloalkyl and

C by the isocyclic aryl replacement _3-6Cycloalkyl,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo and

Isocyclic aryl,

C _1-5Alkoxy carbonyl,

C _1-7Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-7Alkoxyl group:

Halogen and

Isocyclic aryl,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio and

Isocyclic aryl,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C by the isocyclic aryl replacement _1-5Alkoxy carbonyl and

Isocyclic aryl;

L is formula (VII);

Y is-C (O) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is indanyl, adamantyl or 9H-fluorenyl;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases, 4H-benzo [1,3] dioxine base, benzo [1,3] dioxolyl, furyl, isoxazolyl, piperidyl, pyridyl or thienyl;

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkoxy carbonyl,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(iii) heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces and

Heterocyclic radical by the isocyclic aryl replacement;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is an isoxazolyl;

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-ethyl-6-aminomethyl phenyl) urea;

2) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-fluoro phenyl) urea;

3) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-

The base urea;

4) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

5) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2,4,6-tribromo phenyl) urea;

6) N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

7) N-(2,6-diethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

8) N-(2-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

9) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) urea;

10) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-ethylphenyl) urea;

11) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

12) N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

13) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(diphenyl methyl) urea;

14) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

15) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea;

16) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-1-naphthyl urea;

17) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-[1-(1-naphthyl) ethyl] urea;

18) N-(2, the 4-dibromo phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

19) N-(2, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

20) N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

21) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-ethoxyl phenenyl) urea;

22) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-fluoro benzyl) urea;

23) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea;

24) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

25) N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

26) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-fluoro benzyl) urea;

27) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) urea;

28) N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

29) N-[1-(4-bromophenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

30) N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

31) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) urea;

32) N-(2, the 3-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

33) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-aminomethyl phenyl) urea;

34) N-(2, the 6-diisopropyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

35) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2,4, the 5-trichlorophenyl) urea;

36) N-(2, the 5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

37) N-(4-bromo-2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea;

38) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethoxy) phenyl] urea;

39) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2, the 6-3,5-dimethylphenyl) urea;

40) N-(2,4 difluorobenzene base)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

41) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2-ethyl-6-aminomethyl phenyl) urea;

42) N-({ [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) methyl] amino } carbonyl) the leucine ethyl ester;

43) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(4-fluoro phenyl) urea;

44) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-

The base urea;

45) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2,4, the 6-trichlorophenyl) urea;

46) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2,4,6-tribromo phenyl) urea;

47) N-(2,6-diethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

48) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

49) N-(2-chloro-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

50) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2-ethyl-6-isopropyl phenyl) urea;

51) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

52) N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

53) N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

54) N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

55) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

56) N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

57) N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-methyl]-N '-(2,3-dimethyl-6-nitrophenyl) urea;

58) N-(2,6-two bromo-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea;

59) N-(2, the 6-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea; With

60) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from.

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _1-5Alkoxyl group,

Heterocyclic radical,

(ii) C _2-5Alkynyl,

(iii) C _2-5Alkenyl,

(iv) C _3-12Cycloalkyl,

(v) carbocylic radical,

(vi) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen and

Oxo,

Carboxyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of nitro replacement,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl azo-group,

By independently being selected from the isocyclic aryl azo-group that following substituting group replaces:

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of nitro replacement,

Amino-sulfonyl,

The heterocyclic radical alkylsulfonyl,

C _3-6Cycloalkyl,

By C _1-5The C that alkyl replaces _3-6Cycloalkyl,

Isocyclic aryl and

Heterocyclic radical,

(vii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxy carbonyl,

Isocyclic aryl oxygen base,

Isocyclic aryl and

Heterocyclic radical;

L is formula (VII);

Y is-C (S) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is indanyl, two ring [2.2.1] heptyl, two ring [2.2.1] heptenyl or adamantyls;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, 4,5,6,7-tetrahydrochysene-benzo [b] thienyl, benzo [1,3] dioxolyl, benzo [2,1,3] thiadiazolyl group, furyl, isoxazolyl, morpholinyl, oxazolyl, phenanthro-[9,10-d] oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuran base or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

C by the isocyclic aryl replacement _1-5Alkyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino;

Wherein isocyclic aryl is a phenyl or naphthyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

2) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide;

3) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

4) N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

5) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-methoxyl group-5-aminomethyl phenyl) thiocarbamide;

6) N-(4-bromo-2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

7) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-iodine substituted phenyl) thiocarbamide;

8) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2,4,6-tribromo phenyl) thiocarbamide;

9) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) thiocarbamide;

10) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-

The base thiocarbamide;

11) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2, the 4-3,5-dimethylphenyl) thiocarbamide;

12) N-(2,6-diethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

13) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

14) N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

15) N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

16) N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

17) N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

18) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-fluoro-2-aminomethyl phenyl) thiocarbamide;

19) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) thiocarbamide;

20) N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

21) N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

22) N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

23) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2-ethoxyl phenenyl) thiocarbamide;

24) N-[4-bromo-2-(trifluoromethoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide;

25) N-(4-chloro-2,5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide; With

26) N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-N '-(2, the 2-diphenyl-ethyl) thiocarbamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Carbocylic radical,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(ii) C _2-5Alkenyl,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group;

L is formula (VII);

Y is-C (O) O-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical be the 9H-fluorenyl or

Base; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, Q is formula (IV); P is 0; R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By the isocyclic aryl oxygen base of nitro replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

One-C by the isocyclic aryl replacement _1-5Alkylamino,

Two-C _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

Two-C by the isocyclic aryl replacement _1-5Alkylamino,

One-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

Two-isocyclic aryl amino,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

C _1-5Alkoxycarbonyl amino,

The isocyclic aryl carbonylamino,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By the heterocycle sulfenyl of nitro replacement,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _2-5Alkenyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl,

C by the replacement of oxo base _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl and

Isocyclic aryl,

(v) carbocylic radical,

(vi) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Isocyclic aryl and

Halogenated isocyclic aryl,

C _2-5Alkenyl oxy,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

C _1-5Alkoxy carbonyl,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of cyano group replacement,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl,

Isocyclic aryl,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

(vii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Heterocyclic radical;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, two ring [2.2.1] heptyl, indenyl or

Base;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzo [1,4] dioxine base, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo [b] [1,4] dioxepin thiazolinyl (dioxepinyl), 4-oxo-1,5,6,7-tetrahydrochysene-indyl, 4-oxo-benzopyranyl, the 9H-carbazyl, the 9H-xanthenyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazo [2,1-b] thiazolyl, imidazolyl isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-7Alkyl and

By independently being selected from the C that following substituting group replaces _1-7Alkyl:

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

One-C _1-5Alkylamino,

By independently being selected from one-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

Two-C _1-5Alkylamino,

By independently being selected from two-C that following substituting group replaces _1-5Alkylamino:

Cyano group and

Isocyclic aryl,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By C _1-5One-isocyclic aryl amino that alkyl replaces,

By C _1-5Two-isocyclic aryl amino that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _1-5Alkoxyl group,

(ii) C _2-7Alkenyl and

By independently being selected from the C that following substituting group replaces _2-7Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkoxyl group replaces,

(iii) C _2-5Alkynyl and

C by the isocyclic aryl replacement _2-5Alkynyl,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

C _2-5Alkenyl oxy,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino,

Two-C by the cyano group replacement _1-5Alkylamino,

C _1-5Alkylthio and

C by the halogen replacement _1-5Alkylthio,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the hydroxyl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

By C _1-5The carbocyclic ring arylthio that alkoxy carbonyl replaces,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl;

L is formula (VII);

Y be singly-bound or-CH ₂-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzo [1,4] dioxine base, 4-oxo-benzopyranyl, 9H-carbazyl, benzo [1,3] dioxolyl, benzo [b] thienyl, furyl, imidazo [2,1-b] thiazolyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkyl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

C _2-5Alkenyl oxy,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-C by the cyano group replacement _1-5Alkylamino and

Two-C by the cyano group replacement _1-5Alkylamino,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 9H-carbazyl, benzo [1,3] dioxolyl, pyrazolyl or pyridyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkyl

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C _2-5Alkenyl oxy,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _1-5Alkoxy carbonyl,

Isocyclic aryl,

By C _1-5The isocyclic aryl that alkyl replaces and

By halogenated C _1-5The isocyclic aryl that alkyl replaces;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 9H-carbazyl, benzo [1,3] dioxolyl or pyrazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (1), and wherein said compound is selected from:

1) N ²-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

2) N ²-[cis-4-({ [5-(4-fluoro phenyl) pyridin-3-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

3) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl)-amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

4) N ²-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

5) N ²-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

6) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

7) N ²-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

8) N ²-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

9) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol;

10) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

11) N ²-(cis-4-{[(2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴N ⁴-dimethyl pyrimidine-2, the 4-diamines;

12) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,3,4-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

13) N ²(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

14) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl)-amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines;

15) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(3,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

16) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] amino } methyl)-2-iodo-6-methoxyphenol;

17) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol;

18) N ²-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

19) N ²-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

20) N ²-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

21) N ²-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

22) N ²-(cis-4-{[(4-isopropoxide benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

23) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

24) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 2-thanatol;

25) N ²-cis-4-[({[4-(dimethylamino)-1-naphthyl] and methyl } amino) methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

26) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

27) N ²-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

28) N ²-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

29) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

30) N ²-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

31) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

32) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

33) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

34) N ²-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

35) N ⁴, N ⁴-dimethyl-N ²-[cis-4-({ [(1-Methyl-1H-indole-3-yl) methyl] amino }-methyl) cyclohexyl]-pyrimidine-2, the 4-diamines;

36) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

37) N ²-(cis-4-{[(3-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

38) N ²-(cis-4-{[(4-methoxyl group-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

39) N ²-(cis-4-{[(2-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

40) N ²-(cis-4-{[(3,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

41) N ²-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

42) 3-[[4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] amino }-methyl) phenyl] (methyl) amino] propionitrile (propanenitrile);

43) N ²-cis-4-[({4-[(4-bromobenzyl) and the oxygen base] benzyl } amino) methyl] cyclohexyl }-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

44) N ²-(cis-4-{[(3,5-two bromo-2-ethoxy benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

45) N ²-[4-(4-bromo-2-trifluoromethoxy-benzyl) amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

46) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines; With

47) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl)-amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

2) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

3) N ²-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

4) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol;

5) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

6) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,3,4-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

7) N ²-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

8) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl)-amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines;

9) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2-iodo-6-methoxyphenol;

10) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol;

11) N ²-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

12) N ²-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

13) N ²-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

14) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

15) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

16) N ²-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

17) N ²-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

18) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

19) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

20) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

21) N ²-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

22) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

23) N ²-(cis-4-{[(3-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

24) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines; With

25) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

C _1-5The alkyl-carbonyl oxygen base,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By the isocyclic aryl oxygen base of nitro replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

The heterocyclyloxy base,

By C _1-5The heterocyclyloxy base that alkyl replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

The isocyclic aryl carbonylamino,

C _1-5Alkoxycarbonyl amino,

C _1-5Alkylthio,

By independently being selected from the C that following substituting group replaces _1-5Alkylthio:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

The carbocyclic ring arylthio,

The heterocycle sulfenyl,

By C _1-5The heterocycle sulfenyl that alkyl replaces,

By the heterocycle sulfenyl of nitro replacement,

C _3-6Cycloalkyl,

C _3-6Cycloalkenyl group,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _1-5Alkoxyl group,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

Isocyclic aryl and

Heterocyclic radical,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the isocyclic aryl replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

Nitro,

(iii) C _3-6Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-6Cycloalkyl:

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo and

Isocyclic aryl and

Isocyclic aryl,

(iv) carbocylic radical,

(v) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Cyano group,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo,

Isocyclic aryl oxygen base,

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl replaces,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Amino,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

(isocyclic aryl) NHC (O) NH,

By C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

By halogenated C _1-5(isocyclic aryl) NHC (O) NH that alkoxyl group replaces,

C _1-5Alkylthio,

C by the halogen replacement _1-5Alkylthio,

The carbocyclic ring arylthio,

By the carbocyclic ring arylthio of cyano group replacement,

One-C _1-5Alkyl amino sulfonyl,

Two-C _1-5Alkyl amino sulfonyl and

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

Halogenated isocyclic aryl,

(vi) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _2-5Alkenyl thio,

The carbocyclic ring arylthio,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkyl,

Heterocyclic radical;

L is formula (VII);

Y is-C (O)-;

Wherein isocyclic aryl is phenyl, naphthyl or anthryl;

Carbocylic radical is 1,2,3,4-tetralyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl or indenyl;

Heterocyclic radical is 1,2, the 3-triazolyl, the 1H-indyl, the 1H-pyrryl, 2,3-dihydro-1-oxo-pseudoindoyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, the 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydrochysene-indyl, the 9H-xanthenyl, benzo [1,3] dioxolyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be hydrogen, trifluoromethyl, methoxyl group, methylamino, dimethylamino, ethylamino, ethylmethylamino or hydroxyethyl methylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

The isocyclic aryl carbonylamino,

C _1-5Alkylthio,

C _3-6Cycloalkyl,

Carbocylic radical,

By independently being selected from the carbocylic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl and

By C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl and

Heterocyclic radical

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

Nitro,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Oxo and

Isocyclic aryl,

C _1-5Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

Halogen and

Isocyclic aryl,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

C _2-5The alkynyl carbonylamino,

C by the isocyclic aryl replacement _2-5The alkynyl carbonylamino,

One-C _1-5Alkyl amino sulfonyl and

Two-C _1-5Alkyl amino sulfonyl,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio,

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl,

The isocyclic aryl that replaces by halogen and

Heterocyclic radical,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

C _1-5Alkylthio,

C _1-5Alkyl sulphonyl,

The isocyclic aryl alkylsulfonyl,

By C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkyl,

Heterocyclic radical;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is 1-oxo-indanyl, 9-oxo-9H-fluorenyl or indenyl;

Heterocyclic radical is 1,2,3-triazolyl, 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 9H-xanthenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Oxo,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino,

One-isocyclic aryl amino,

Two-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

By two-isocyclic aryl amino of halogen replacement,

C _1-5Alkylthio,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

C _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

Isocyclic aryl,

By the isocyclic aryl of nitro replacement,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Hydroxyl,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

One-C _1-5Alkyl amino-carbonyl,

Two-C _1-5Alkyl amino-carbonyl,

One-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

Two-C by the isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

One-C _1-5Alkyl amino sulfonyl and

Two-C _1-5Alkyl amino sulfonyl,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkylthio,

C by the isocyclic aryl replacement _1-5Alkylthio and

C by halogenated isocyclic aryl replacement _1-5Alkylthio,

Isocyclic aryl oxygen base,

By the isocyclic aryl oxygen base of halogen replacement,

By C _1-5The isocyclic aryl oxygen base that alkyl replaces,

Isocyclic aryl,

By the isocyclic aryl of halogen replacement,

The isocyclic aryl that replaces by nitro and

Heterocyclic radical;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is 1-oxo-indanyl;

Heterocyclic radical is 1,2,3-triazolyl, 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzofuryl, 9H-xanthenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, furyl, isoxazolyl, pyridyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxy benzamide;

2) 3-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

3) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

4) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

5) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

6) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

7) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

8) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

9) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

10) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide;

11) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 5-difluorobenzamide;

12) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

13) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-methyl-3-nitro benzamide;

14) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

15) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group butyramide;

16) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

17) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethoxy)-benzamide;

18) 4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

19) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenyl-iodide methane amide;

20) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,5-dimethyl-3-furoamide;

21) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro benzamide;

22) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethoxy benzamide;

23) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl)-benzamide;

24) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

25) 2,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiophene-3-methane amide;

26) the 1-benzyl-3-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-1H-pyrazoles-5-methane amide;

27) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-naphthyl) ethanamide;

28) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-ethanamide;

29) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-cyclopentane formamide;

30) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-5-methyl-isoxazole-4-methane amide;

31) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

32) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

33) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

34) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy-acetamide;

35) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-quinoxaline-2-methane amide;

36) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethyl)-benzamide;

37) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(penta fluoro benzene oxygen base)-ethanamide;

38) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-ethanamide;

39) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

40) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group niacinamide;

41) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methylphenoxy)-niacinamide;

42) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-[(dipropyl amino)-and alkylsulfonyl] benzamide;

43) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl propanamide;

44) 2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-1,3-thiazoles-4-methane amide;

45) the 3-tertiary butyl-1-(2, the 4-dichloro benzyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-1H-pyrazoles-5-methane amide;

46) 6-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2H-chromene-3-methane amide;

47) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

48) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

49) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-iodo-2-furoamide;

50) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide;

51) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-2-methane amide;

52) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl-4-nitrobenzamide;

53) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

54) 1-benzyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1H-indoles-3-methane amide;

55) 3-ethanoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

56) 5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

57) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

58) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

59) 2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) ethanamide;

60) N ², N ⁶-dibenzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-lysyl amine;

61) 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-benzamide;

62) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

63) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-ethanamide;

64) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazoles-4-yl) ethanamide;

65) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

66) 4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-(1H-indol-3-yl)-4-oxo butyramide;

67) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group) amino] benzamide;

68) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

69) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide;

70) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(4-nitrophenyl)-butyramide;

71) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

72) N ²-benzoyl-N ⁵-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-N ¹, N ¹-dipropyl glutamine;

73) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenoxy benzamide;

74) the 3-benzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

75) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide;

76) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(1R)-1-(1-naphthyl) ethyl] phthalamide;

77) (2S)-2-(3-benzoyl phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-propionic acid amide;

78) N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N, N-two [(1S)-and the 1-phenylethyl] phthalamide;

79) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl } ethanamide;

80) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide;

81) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-methoxy benzamide;

82) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide;

83) sulfo-1-{2-[(2-chloro-6-fluoro benzyl)] ethyl }-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

84) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy benzamide;

85) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenylquinoline-4-methane amide;

86) 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

87) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-[(4-aminomethyl phenyl)-alkylsulfonyl]-the 1H-pyrrole-3-carboxamide;

88) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide,

89) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives;

90) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-iodo-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives;

91) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

92) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

93) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-nitrobenzamide;

94) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethyl-4-nitrobenzamide;

95) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2- Base-2-oxo ethanamide;

96) 3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-hydroxybenzamide;

97) 4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-benzamide;

98) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-the 3-Phenyl Acrylamide;

99) 4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-the 3-nitrobenzamide;

100) 2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-methyl] ethanamide;

101) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-benzamide;

102) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-benzamide;

103) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide;

104) 2,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-the 5-fluoro benzamide;

105) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenoxy group butyramide;

106) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenylbutanamides;

107) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(3-p-methoxy-phenyl) ethanamide;

108) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(4-p-methoxy-phenyl) ethanamide;

109) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

110) (2E)-N-{ (cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

111) 2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-methyl] ethanamide;

112) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(rosickyite base)-niacinamide;

113) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(1-naphthyl)-ethanamide;

114) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9-oxo-9H-fluorenes-4-methane amide;

115) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide;

116) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-benzamide;

117) (2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] acrylamide;

118) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

119) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,3-diphenylprop acid amides;

120) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-5-iodo-2-furoamide;

121) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide;

122) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide;

123) 2-benzyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-benzamide;

124) 2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases of 2-] amino } cyclohexyl)-methyl] ethanamide;

125) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

126) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

127) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl] ethanamide;

128) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide;

129) 2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] ethanamide;

130) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide;

131) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

132) C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

133) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

134) 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

135) 5-bromo-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-niacinamide;

136) 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

137) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

138) 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

139) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

140) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide;

141) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

142) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-ethanamide; With

143) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) 3-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

2) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

3) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

4) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

5) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide,

6) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

7) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide;

8) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

9) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethoxy)-benzamide;

10) 4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

11) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenyl-iodide methane amide;

12) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro benzamide;

13) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethoxy benzamide;

14) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl)-benzamide;

15) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

16) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-ethanamide;

17) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

18) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

19) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

20) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-quinoxaline-2-methane amide;

21) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-ethanamide;

22) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

23) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methylphenoxy)-niacinamide;

24) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-[(dipropyl amino)-and alkylsulfonyl] benzamide;

25) 2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-1,3-thiazoles-4-methane amide;

26) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

27) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

28) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

29) 5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

30) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

31) 2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) ethanamide;

32) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

33) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

34) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

35) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

36) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide;

37) N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N, N-two [(1S)-and the 1-phenylethyl] phthalamide;

38) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-methoxy benzamide;

39) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide;

40) sulfo-1-{2-[(2-chloro-6-fluoro benzyl)] ethyl }-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

41) 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

42) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

43) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

44) 3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-hydroxybenzamide;

45) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide;

46) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenylbutanamides;

47) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

48) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(1-naphthyl)-ethanamide;

49) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

50) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide;

51) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide;

52) 2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases of 2-] amino } cyclohexyl)-methyl] ethanamide;

53) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

54) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

55) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl] ethanamide;

56) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide;

57) 2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] ethanamide;

58) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide;

59) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

60) C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

61) 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

62) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

63) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

64) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-ethanamide; With

65) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

C _1-5Alkoxy carbonyl,

C _1-5Alkylthio,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C _2-5Alkenyl,

(ii) C _3-6Cycloalkyl,

C by the isocyclic aryl replacement _3-6Cycloalkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

C _3-6Cycloalkyloxy,

Isocyclic aryl oxygen base,

C _1-5Alkylthio and

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

Isocyclic aryl;

L is formula (VII);

Y is-C (O) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, 3,4-dihydro-2H-benzo [b] [1,4] two oxa-English in heptan bases, benzo [1,3] dioxolyl, furyl or isoxazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from

(i) C _1-5Alkyl and

C by the isocyclic aryl replacement _1-5Alkyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C _3-6Cycloalkyloxy,

(iii) heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces and

Heterocyclic radical by the isocyclic aryl replacement;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is an isoxazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-

The base urea;

2) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl)-urea;

3) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl)-urea;

4) N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) urea;

5) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(diphenyl methyl) urea;

6) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) urea;

7) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl]-urea;

8) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea;

9) N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) urea;

10) N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) urea;

11) N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) urea;

12) N-(2,6-two bromo-4-isopropyl phenyls)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) urea;

13) N-[3-(cyclopentyloxy)-4-p-methoxy-phenyl]-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) urea;

14) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2, the 6-3,5-dimethylphenyl) urea;

15) N-(2,4 difluorobenzene base)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

16) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-aminomethyl phenyl) urea;

17) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(4-fluoro phenyl) urea;

18) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-

The base urea;

19) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,4, the 6-trichlorophenyl) urea;

20) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,4,6-tribromo phenyl) urea;

21) N-(2,4-two bromo-6-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino)-hexamethylene raises) methyl] urea;

22) N-(2,6-diethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

23) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

24) N-(2-chloro-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

25) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-isopropyl phenyl) urea;

26) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

27) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea;

28) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-propyl group phenyl) urea;

29) methyl N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-{ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)] urea;

30) N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

31) N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

32) N-(4-bromo-2,6-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

33) N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

34) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(diphenyl methyl) urea;

35) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

36) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea;

37) N-(3, the 5-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

38) N-(2, the 3-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

39) N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

40) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,3-dimethyl-6-nitrophenyl) urea;

41) N-(2,6-two bromo-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

42) N-(2, the 6-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

43) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methoxyl group-5-aminomethyl phenyl) urea;

44) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methyl-6-nitrophenyl) urea;

45) N-(3, the 4-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

46) N-(3, the 5-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea; With

47) N-(3-chloro-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] urea;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

(ii) carbocylic radical,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxy carbonyl,

C _1-5Alkoxyl group,

C by the halogen replacement _1-5Alkoxyl group,

One-C _1-5Alkylamino,

Two-C _1-5Alkylamino and

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

C _1-5Alkyl,

C _1-5Alkoxy carbonyl and

Isocyclic aryl;

L is formula (VII);

Y is-C (S) NR ₅-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is two ring [2.2.1] heptyl;

Heterocyclic radical is 2,3-dihydro-benzo [1,4] dioxine base, benzo [1,3] dioxolyl, isoxazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

C _1-5Alkyl,

C _1-5Alkoxyl group,

One-C _1-5Alkylamino and

Two-C _1-5Alkylamino;

Wherein isocyclic aryl is a phenyl or naphthyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-thiocarbamide;

N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide;

N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl)-thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '- The base thiocarbamide;

N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide; With

N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

Halogen,

C _1-5Alkoxyl group,

C by the isocyclic aryl replacement _1-5Alkoxyl group,

Carbocylic radical,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro and

C _1-5Alkoxyl group,

(ii) C _2-5Alkenyl,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group;

L is formula (VII);

Y is-C (O) O-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical be the 9H-fluorenyl or

Base; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₂Be methylamino or dimethylamino; P is 0; R ₃And R ₄Be hydrogen; A is a singly-bound; B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, Q is formula (IV); P is 1 or 2;

R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Hydroxyl,

Oxo,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

One-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group and

C _1-5Alkyl,

The isocyclic aryl sulfinyl,

By independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group and

Heterocyclic radical,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

C _1-5Alkoxyl group,

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen and

Hydroxyl,

C _1-9Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-9Alkoxyl group:

Halogen and

Isocyclic aryl,

Carboxyl,

C _1-5Alkoxy carbonyl,

Two-C _1-5Alkylamino,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkylthio,

C _1-5Alkyl sulphinyl,

C _1-5Alkyl sulphonyl,

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Hydroxyl,

Amino,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By the heterocyclyloxy base of halogen replacement,

The heterocyclic radical alkylsulfonyl,

By C _1-5The heterocyclic radical alkylsulfonyl that alkyl replaces,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

C _1-5Alkylthio,

C _1-5Alkyl sulphinyl,

The isocyclic aryl sulfinyl,

By the isocyclic aryl sulfinyl of halogen replacement,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

R ₂Be selected from:

Amino, C _1-5Alkyl, C _1-5Alkoxyl group ,-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl or C _3-6Cycloalkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 3,4-dihydro-1H-isoquinolyl, benzo [1,3] dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Oxo,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(ii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

The isocyclic aryl sulfinyl and

By the isocyclic aryl sulfinyl of halogen replacement,

L is formula (VII);

Y be singly-bound or-CH ₂-;

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Isocyclic aryl is a phenyl;

Heterocyclic radical is a pyrazinyl; With

Halogen is fluoro base, chloro base or bromo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

(ii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

The isocyclic aryl sulfinyl and

By the isocyclic aryl sulfinyl of halogen replacement,

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Isocyclic aryl is a phenyl;

Heterocyclic radical is a pyrazinyl; With

Halogen is fluoro base or bromo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ¹Be selected from:

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

The isocyclic aryl sulfinyl and

By the isocyclic aryl sulfinyl of halogen replacement,

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Isocyclic aryl is a phenyl;

Heterocyclic radical is a pyrazinyl; With

Halogen is the fluoro base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 and T be C _1-5Alkyl; R ₃And R ₄Be hydrogen; A and B are singly-bound; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

N ²-cis-4-[(3-bromobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2,4-diamines;

N ²-cis-4-[(3,4-difluorobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2,4-diamines; With

N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is:

N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Hydroxyl,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

One-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group and

C _1-5Alkyl,

The isocyclic aryl sulfinyl,

By independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

C _1-5Alkoxyl group,

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen and

Hydroxyl,

C _1-9Alkoxyl group,

C by the halogen replacement _1-9Alkoxyl group,

Carboxyl,

C _1-5Alkoxy carbonyl,

Two-C _1-5Alkylamino,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkyl sulphonyl and

Isocyclic aryl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

Hydroxyl,

Amino,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By the heterocyclyloxy base of halogen replacement,

The heterocyclic radical alkylsulfonyl,

By C _1-5The heterocyclic radical alkylsulfonyl that alkyl replaces,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

C _1-5Alkylthio,

C _1-5Alkyl sulphinyl,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

L is formula (VII);

Y is-C (O)-;

R ₂Be selected from:

Amino, C _1-5Alkyl, C _1-5Alkoxyl group ,-N (R _2a) (R _2b),

R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl or C _3-6Cycloalkyl;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is benzo [1,3] dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Hydroxyl,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By the heterocyclyloxy base of halogen replacement,

One-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group and

C _1-5Alkyl,

The isocyclic aryl sulfinyl,

By independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

C _1-5Alkoxyl group,

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-10Alkyl,

By independently being selected from the C that following substituting group replaces _1-10Alkyl:

Halogen and

Hydroxyl,

C _1-9Alkoxyl group,

C by the halogen replacement _1-9Alkoxyl group,

Carboxyl,

C _1-5Alkoxy carbonyl and

C _1-5Alkyl sulphonyl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By the heterocyclyloxy base of halogen replacement,

The heterocyclic radical alkylsulfonyl,

By C _1-5The heterocyclic radical alkylsulfonyl that alkyl replaces,

One-isocyclic aryl amino,

By one-isocyclic aryl amino of halogen replacement,

C _1-5Alkylthio,

The isocyclic aryl alkylsulfonyl,

By independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

R ₂Be selected from:

C _1-5Alkoxyl group ,-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is benzo [1,3] dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Hydroxyl,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

The heterocyclyloxy base,

By independently being selected from the heterocyclyloxy base that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

One-isocyclic aryl amino,

By independently being selected from one-isocyclic aryl amino that following substituting group replaces:

Halogen,

C _1-5Alkoxyl group and

C _1-5Alkyl,

The isocyclic aryl sulfinyl,

By independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

C _1-5Alkoxyl group,

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Cyano group,

Nitro,

C _1-10Alkyl,

C by the halogen replacement _1-10Alkyl,

C _1-9Alkoxyl group and

C by the halogen replacement _1-9Alkoxyl group,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group,

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl and

C _1-5Alkoxyl group,

C _1-5Alkylthio,

The isocyclic aryl alkylsulfonyl,

By the isocyclic aryl alkylsulfonyl of halogen replacement,

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is benzo [1,3] dioxolyl, furyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 and T be C _1-5Alkyl; R ₃And R ₄Be hydrogen; A be singly-bound and B be singly-bound or-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

2) N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

3) N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

4) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

5) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

6) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

7) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide;

8) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;

9) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide;

10) 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

11) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-(trifluoromethyl) benzamide;

12) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

13) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

14) 4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

15) 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

16) N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-dimethoxy benzamide;

17) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl] benzamide;

18) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl]-the 3-methyl benzamide;

19) 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl] benzamide;

20) 3,4-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl] benzamide;

21) N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide;

22) N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3, the 4-difluorobenzamide;

23) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl] benzamide;

24) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl]-the 3-methyl benzamide;

25) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-fluorinated phenoxy) niacinamide;

26) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide;

27) N-(4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

28) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

29) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

30) 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

31) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

32) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

33) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

34) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

35) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

36) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

37) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

38) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

39) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

40) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

41) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methylphenoxy) niacinamide;

42) 2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

43) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

44) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide;

45) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) niacinamide;

46) 2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

47) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) niacinamide;

48) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group) niacinamide;

49) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-iodo phenoxy group) niacinamide;

50) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

51) 2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-(and methyl-4-(methylamino) pyrimidine-2-base] amino-cyclohexyl) ethanamide;

52) 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

53) N-(cis-4-{[4-(dimethylamino)-5-ethyl-pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

54) N-[cis-4-({ 4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3, the 4-difluorobenzamide;

55) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

56) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-methoxyl group phenoxy group) niacinamide;

57) 2-(2-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

58) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

59) 2-(3-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

60) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] niacinamide;

61) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide;

62) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) ethanamide;

63) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] ethanamide;

64) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

65) oxygen base 2-[(5-chloropyridine-3-yl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

66) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

67) 2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

68) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide;

69) 2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

70) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide;

71) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[2-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

72) sulfinyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

73) sulfinyl 2-[(3-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

74) 2-[(3, the 4-difluorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

75) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

76) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

77) 1-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

78) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

79) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

80) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

81) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

82) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

83) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,4 difluorobenzene methane amide;

84) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2, the 5-difluorobenzamide;

85) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate;

86) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

87) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

88) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

89) 2-[(3, the 4-dichlorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

90) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

91) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl } ethanamide;

92) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(iprotiazem base) niacinamide;

93) 2-(uncle's butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

94) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base)-niacinamide;

95) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(methyl sulphonyl) benzamide;

96) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

97) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

98) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

99) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

100) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

101) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

102) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

103) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

104) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

105) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

106) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

107) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

108) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

109) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

110) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

111) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

112) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

113) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

114) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-methoxy benzamide;

115) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

116) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

117) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

118) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

119) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-3-methane amide;

120) 2-(3, the 5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

121) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-methyl isophthalic acid, 3-oxazole-4-methane amide;

122) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2,6-dimethoxy niacinamide;

123) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

124) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

125) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

126) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

127) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

128) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

129) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

130) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

131) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-thiotolene-2-methane amide;

132) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-6-(trifluoromethyl) niacinamide;

133) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

134) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

135) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

136) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

137) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

138) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethoxy benzamide;

139) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

140) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

141) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

142) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

143) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

144) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

145) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

146) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

147) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

148) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

149) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

150) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide;

151) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

152) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

153) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

154) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

155) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethyl benzamide;

156) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

157) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

158) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

159) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

160) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

161) 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

162) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

163) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-two fluoro-1,3-benzo dioxole-5-methane amide;

164) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

165) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

166) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

167) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

168) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

169) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

170) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

171) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

172) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

173) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

174) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-methyl propanamide;

175) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

176) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) the tetramethylene methane amide;

177) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

178) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-methyl propanamide;

179) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

180) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) the tetramethylene methane amide;

181) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

182) 2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

183) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-[2,2,2-three fluoro-1-hydroxyl-1-(trifluoromethyl) ethyls] benzamide;

184) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

185) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-aminomethyl phenyl) cyclopropane carboxamide;

186) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) propionic acid amide;

187) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

188) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-p-methoxy-phenyl) cyclopropane carboxamide;

189) N ²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

190) N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

191) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl-N ²-(3-aminomethyl phenyl) G-NH2;

192) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-fluoro phenyl)-N ²-methyl G-NH2;

193) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-fluoro phenyl)-N ²-methyl G-NH2;

194) N ²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

195) N ²-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

196) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-p-methoxy-phenyl)-N ²-methyl G-NH2;

197) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-p-methoxy-phenyl)-N ²-methyl G-NH2;

198) 2-[(3, the 4-difluorophenyl) amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

199) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

200) trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

201) trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

202) trans-2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

203) trans-2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

204) trans-2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

205) alkylsulfonyl 2-[(4-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

206) alkylsulfonyl 2-[(3-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

207) alkylsulfonyl 2-[(4-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

208) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[4-(trifluoromethyl) phenyl] alkylsulfonyl } niacinamide;

209) N-(cis-4-[[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide;

210) alkylsulfonyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

211) alkylsulfonyl 2-[(3-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

212) 3,4-two chloro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl }-benzamide;

213) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

214) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

215) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

216) 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

217) 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

218) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

219) 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

220) 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

221) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

222) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

223) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide; With

224) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

2) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

3) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;

4) 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

5) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

6) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

7) 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl)-cyclohexyl] benzamide;

8) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-fluorinated phenoxy) niacinamide;

9) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide;

10) N-(4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

11) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

12) 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

13) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

14) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

15) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

16) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

17) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

19) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

20) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

21) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

22) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

23) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methylphenoxy) niacinamide;

24) 2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

25) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

26) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide;

27) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) niacinamide;

28) 2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

29) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) niacinamide;

30) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group) niacinamide;

31) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-iodo phenoxy group) niacinamide;

32) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

33) 2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

34) 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

35) N-[cis-4-({ 4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3, the 4-difluorobenzamide;

36) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

37) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-methoxyl group phenoxy group) niacinamide;

38) 2-(2-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

39) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

40) 2-(3-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

41) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] niacinamide;

42) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide;

43) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) ethanamide;

44) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] ethanamide;

45) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

46) oxygen base 2-[(5-chloropyridine-3-yl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

47) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

48) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide;

49) 2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

50) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide;

51) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[2-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

52) sulfinyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

53) sulfinyl 2-[(3-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

54) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

55) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

56) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

57) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

58) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

59) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

60) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

61) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

62) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,4 difluorobenzene methane amide;

63) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2, the 5-difluorobenzamide;

64) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate;

65) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

66) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

67) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

68) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(iprotiazem base) niacinamide;

69) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide;

70) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

71) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

72) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

73) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

74) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

75) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

76) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

77) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

78) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

79) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

80) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

81) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

82) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

83) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

84) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

85) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

86) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

87) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

88) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

89) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2,6-dimethoxy niacinamide;

90) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

91) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

92) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

93) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

94) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

95) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

96) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

97) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-thiotolene-2-methane amide;

98) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

99) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

100) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

101) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

102) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

103) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

104) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

105) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

106) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

107) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

108) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

109) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

110) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

111) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

112) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

113) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

114) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide;

115) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

116) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

117) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

118) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethyl benzamide;

119) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

120) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

121) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

122) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

123) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

124) 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

125) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

126) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-two fluoro-1,3-benzo dioxole-5-methane amide;

127) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

128) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

129) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

130) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

131) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-niacinamide;

132) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

133) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

134) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

135) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

136) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-methyl propanamide

137) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

138) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) the tetramethylene methane amide;

139) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

140) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-methyl propanamide;

141) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

142) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) the tetramethylene methane amide;

143) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

144) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

145) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-aminomethyl phenyl) cyclopropane carboxamide;

146) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) propionic acid amide;

147) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

148) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-p-methoxy-phenyl) cyclopropane carboxamide;

149) N ²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

150) N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

151) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl-N ²-(3-aminomethyl phenyl) G-NH2;

152) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-fluoro phenyl)-N ²-methyl G-NH2;

135) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-fluoro phenyl)-N ²-methyl G-NH2;

154) N ²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

155) N ²-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

156) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-p-methoxy-phenyl)-N ²-methyl G-NH2;

157) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

158) trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

159) trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

160) trans-2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) cyclopropane carboxamide;

161) trans-2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

162) trans-2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

163) alkylsulfonyl 2-[(4-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

164) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide;

165) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

166) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

167) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

168) 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

169) 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

170) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

171) 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

172) 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

173) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

174) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

175) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide; With

176) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ¹Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl-carbonyl-amino,

C _3-6Cycloalkyl amino carbonyl,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(ii) C _3-12Cycloalkyl and

C by the isocyclic aryl replacement _3-12Cycloalkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-10Alkyl,

C by the halogen replacement _1-10Alkyl,

C _1-9Alkoxyl group and

C _1-5Alkylthio,

(iv) heterocyclic radical,

L is formula (XV);

Y is-C (O) NR ₅-;

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 3,4-dihydro-1H-isoquinolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

Nitro,

C _1-5Alkyl,

C by the halogen replacement _1-5Alkyl,

C _1-5Alkoxyl group and

C by the halogen replacement _1-5Alkoxyl group,

(ii) C _3-12Cycloalkyl and

C by the isocyclic aryl replacement _3-12Cycloalkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-10Alkyl,

C by the halogen replacement _1-10Alkyl and

C _1-9Alkoxyl group,

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 3,4-dihydro-1H-isoquinolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 and T be C _1-5Alkyl; R ₃And R ₄Be hydrogen; And A and B are singly-bound; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide)-cyclohexane carboxamide;

2) cis-N-(2, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

3) cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

4) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl)-cyclohexane carboxamide;

5) cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

6) cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

7) cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

8) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl]-cyclohexane carboxamide;

9) cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

10) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methoxy-benzyl)-cyclohexane carboxamide;

11) cis-N-(4-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

12) cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

13) cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

14) cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

15) cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

16) cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

17) cis-4-{ (dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl)-cyclohexane carboxamide;

18) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl]-cyclohexane carboxamide;

19) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-the 1-phenylethyl]-cyclohexane carboxamide;

20) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide;

21) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

22) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

23) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

24) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

25) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

26) cis-N-[(R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

27) cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

28) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide;

29) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-1-(4-nitrophenyl) ethyl]-cyclohexane carboxamide;

30) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-fluoro phenyl)-cyclohexane carboxamide;

31) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-p-methoxy-phenyl)-cyclohexane carboxamide;

32) cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

33) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S, 2R)-the 2-phenycyclopropyl] cyclohexane carboxamide;

34) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[4-(trifluoromethyl) phenyl]-cyclohexane carboxamide;

35) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

36) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

37) cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

38) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-fluoro benzyl)-cyclohexane carboxamide;

39) cis-N-(3, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

40) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

41) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

42) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

43) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

44) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-1-(1-naphthyl) ethyl]-cyclohexane carboxamide;

45) cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

46) cis-N-[(1S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

47) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

48) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide;

49) cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

50) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

51) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

52) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1R)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

53) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

54) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

55) cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide; With

56) cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide)-cyclohexane carboxamide;

2) cis-N-(2, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

3) cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

4) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl)-cyclohexane carboxamide;

5) cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

6) cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

7) cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

8) cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

9) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methoxy-benzyl)-cyclohexane carboxamide;

10) cis-N-(4-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

11) cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

12) cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

13) cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

14) cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

15) cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

16) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl)-cyclohexane carboxamide;

17) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl]-cyclohexane carboxamide;

18) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide;

19) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

20) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

21) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

22) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

23) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

24) cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

25) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide;

26) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-p-methoxy-phenyl)-cyclohexane carboxamide;

27) cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

28) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S, 2R)-the 2-phenycyclopropyl] cyclohexane carboxamide;

29) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[4-(trifluoromethyl) phenyl]-cyclohexane carboxamide;

30) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

31) cis-N-(3, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

32) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

33) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

34) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

35) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-1-(1-naphthyl) ethyl]-cyclohexane carboxamide;

36) cis-N-[(S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

37) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

38) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide;

39) cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

40) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

41) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide; With

42) cis-N-[(R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) C _1-16Alkyl and

By independently being selected from the C that following substituting group replaces _1-16Alkyl:

Isocyclic aryl,

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-5Alkyl and

C by the halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

Isocyclic aryl and

By the isocyclic aryl of halogen replacement,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-10Alkyl,

C by the halogen replacement _1-10Alkyl,

C _1-9Alkoxyl group,

By independently being selected from the C that following substituting group replaces _1-9Alkoxyl group:

Halogen and

Isocyclic aryl,

L is formula (VII);

Y is-C (O) NR ₅-;

R ₂For-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 or 2 and each T independently for C _1-5Alkyl; R ₃Be hydrogen; R ₄Be hydrogen or C _1-5Alkyl; A and B are singly-bound; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has formula (I), and wherein said compound is selected from:

1) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea;

2) N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

3) N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

4) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(3-aminomethyl phenyl) urea;

5) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(4-aminomethyl phenyl) urea;

6) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-fluoro phenyl)-N-methyl urea;

7) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-fluoro phenyl)-N-methyl urea;

8) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

9) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

10) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-p-methoxy-phenyl)-N-methyl urea;

11) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-p-methoxy-phenyl)-N-methyl urea;

12) N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

13) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

14) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

15) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

16) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

17) N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino cyclohexyl]-N '-(2-p-methoxy-phenyl) urea;

19) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea;

20) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) urea;

21) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea;

22) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) urea;

23) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino cyclohexyl]-N '-[2-(trifluoromethoxy) phenyl] urea;

24) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) urea;

25) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

26) N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) urea;

27) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) urea;

28) N-benzyl-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

29) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

30) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

31) N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

32) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy) phenyl] urea;

33) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the N-ethyl carbamide;

34) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide;

35) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(2-fluoro phenyl)-N-methyl urea;

36) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy) phenyl] urea;

37) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-phenylurea;

38) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-(3-aminomethyl phenyl) urea; With

39) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention has the wherein said compound of formula (1) and is selected from:

1) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea;

2) N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

3) N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

4) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(3-aminomethyl phenyl) urea;

5) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(4-aminomethyl phenyl) urea;

6) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-fluoro phenyl)-N-methyl urea;

7) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-fluoro phenyl)-N-methyl urea;

8) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

9) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

10) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-p-methoxy-phenyl)-N-methyl urea;

11) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-p-methoxy-phenyl)-N-methyl urea;

12) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

13) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

14) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

15) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea;

16) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethoxy) phenyl] urea;

17) N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) urea;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) urea;

19) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

20) N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N-methyl urea;

21) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy) phenyl] urea;

22) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the N-ethyl carbamide;

23) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide;

24) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-phenylurea;

25) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-(3-aminomethyl phenyl) urea; With

26) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

Isocyclic aryl oxygen base,

By independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

Halogen and

C _1-5Alkoxyl group,

L is a formula (X) or (XI);

Y is-C (O)-;

R ₂For-N (R _2a) (R _2b) R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl; Heterocyclic radical is a pyridyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 and T be C _1-5Alkyl; R ₃And R ₄Be hydrogen; A is that singly-bound and B are-CH ₂-; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R ₁Be selected from:

(i) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

Halogen,

C _1-10Alkyl and

C by the halogen replacement _1-10Alkyl,

(ii) heterocyclic radical,

L is formula (VII); With

Y is-S (O) ₂-;

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is a furyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, p be 1 and T be C _1-5Alkyl; R ₃And R ₄Be hydrogen and A and B and be singly-bound; Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments, compound of the present invention is:

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzsulfamide;

Or its pharmacy acceptable salt, hydrate or solvate.

In some embodiments of the present invention, R wherein ₁Be selected from hydrogen ,-CO ₂TBu or-CO ₂Bn (Bn is a benzyl);

R ₂Be selected from:

Hydrogen, halogen, hydroxyl, carboxyl, formamyl, amino, C _1-5Alkyl, the C that replaces by halogen _1-5Alkyl, the C that replaces by hydroxyl _1-5Alkyl, by the C of carboxyl substituted _1-5Alkyl, the C that replaces by formamyl _1-5Alkyl, C _1-5Alkoxyl group, the C that replaces by halogen _1-5Alkoxyl group ,-N (R _2a) (R _2b);

R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl, C _3-6Cycloalkyl or by independently being selected from the C that following substituting group replaces _1-5Alkyl:

Halogen,

Hydroxyl,

Carboxyl,

Formamyl,

C _1-5Alkoxyl group,

Amino,

C _3-6Cycloalkyl

Perhaps when Q is formula (II), R ₂Be methylamino or dimethylamino;

Each T independently is selected from halogen, hydroxyl, carboxyl, formamyl, amino, cyano group, nitro, C _1-5Alkyl, the C that replaces by halogen _1-5Alkyl, the C that replaces by hydroxyl _1-5Alkyl, by the C of carboxyl substituted _1-5Alkyl, the C that replaces by formamyl _1-5Alkyl, C _2-5Alkenyl, C _2-5Alkynyl, C _3-6Cycloalkyl, C _1-5Alkoxyl group, the C that replaces by halogen _1-5Alkoxyl group, isocyclic aryl, heterocyclic radical and-N (R _2a) (R _2b);

P is 0,1,2,3,4 or 5;

L is selected from formula (VII), (X), (XI), (XV), (XVIII) or (XIX): R wherein ₃And R ₄Independent is hydrogen or C _1-5Alkyl; And A and B independently be singly-bound or-CH ₂-; With

Y is a singly-bound;

Or its pharmacy acceptable salt, hydrate or solvate.

One aspect of the present invention relates to medicinal compositions, and it comprises at least a as described compound in this article with pharmaceutically acceptable carrier blended.

One aspect of the present invention relates to prevention or treats the method for following disease: improve memory function, sleep and excited, anxiety disorder, dysthymia disorders, emotional handicap, epileptic seizures, obesity, diabetes, appetite and eating disorder, cardiovascular disorder, hypertension, hyperlipemia, myocardial infarction, mad food disease (comprising Bulimia nerovsa), anorexia, psychological disorders comprises manic depression of sex, schizophrenia, psychiatric disorder, dull-witted, nervous, cognitive disorder, attention deficit syndrome, substance abuse disease out of control and dyskinesia (comprising Parkinson's disease), epilepsy and addiction, this method comprise compound as described herein or its medicinal compositions of the individual treatment significant quantity of suffering from described illness.

One aspect of the present invention relates to prevention or treats the method for following disease: eating disorder, obesity or the disease relevant, this method with obesity comprise the individual treatment significant quantity of suffering from described illness as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to prevention or treats the method for following disease: anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy, this method comprise the individual treatment significant quantity of suffering from described illness as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to as described compound or its medicinal compositions in this article, and it is used for the methods of treatment of human body or animal body by treatment.

One aspect of the present invention relates to that it is used for the eating disorder, obesity of human body or animal body or the prevention or the methods of treatment of the disease relevant with obesity by treatment as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to as described compound or its medicinal compositions in this article, and it is used for the prevention or the methods of treatment of anxiety disorder, dysthymia disorders, schizophrenia, addiction or the epilepsy of human body or animal body by treatment.

One aspect of the present invention relates to the purposes that is used for preventing or treat the medicine of eating disorder, obesity or the disease relevant with obesity as described The compounds of this invention in this article in preparation.

One aspect of the present invention relates to the purposes that is used for preventing or treat the medicine of anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy as described The compounds of this invention in this article in preparation.

One aspect of the present invention relates to the method that reduces individual food intake, this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to the method for inducing individual satietion, this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates to control or reduces the method that whose body weight increases, this method comprise give described individual treatment significant quantity as described compound or its medicinal compositions in this article.

One aspect of the present invention relates in individuality the method for regulating the MCH acceptor, and this method comprises to be made described acceptor and contact as described compound in this article.In some embodiments, described compound is an antagonist.In some embodiments, the regulating effect of MCH acceptor is used to prevent or treat eating disorder, disease that obesity is relevant with obesity.In some embodiments, the regulating effect of MCH acceptor reduces individual food intake.In some embodiments, the regulating effect of MCH acceptor is induced individual satietion.In some embodiments, control of the regulating effect of MCH acceptor or minimizing whose body weight increase.

In some embodiments, the regulating effect of MCH acceptor is used for prevention or treatment anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy.

In some embodiments, described individuality is a Mammals.

In some embodiments, described Mammals is behaved.

In some embodiments, described people's weight index is about 18.5-about 45.In some embodiments, described people's weight index is about 25-about 45.In some embodiments, described people's weight index is about 30-about 45.In some embodiments, described people's weight index is about 35-about 45.

One aspect of the present invention relates to the method for preparing medicinal compositions, this method comprise with as in this article described compound mix with pharmaceutically acceptable carrier.

One aspect of the present invention relates to the method for preventing or treating following disease in the Mammals of this treatment of needs: improve memory function, sleep and excited, anxiety disorder, dysthymia disorders, emotional handicap, epileptic seizures, obesity, diabetes, appetite and eating disorder, cardiovascular disorder, hypertension, hyperlipemia, myocardial infarction, mad food disease (comprising Bulimia nerovsa), anorexia, psychological disorders, comprise manic depression of sex, schizophrenia, psychiatric disorder, dull-witted, nervous, cognitive disorder, attention deficit syndrome, substance abuse disease out of control and dyskinesia (comprising Parkinson's disease), epilepsy and addiction, this method comprise compound as described herein or its medicinal compositions that gives described Mammals treatment significant quantity.

One embodiment of the invention comprise that optionally in conjunction with any The compounds of this invention of MCH acceptor, such selective binding preferably shows: the Ki that the Ki of one or more other GPCR (s) (preferred NPY) is compared any discrete MCH acceptor (preferred MCHR1) is big at least 10 times.

Term used herein " alkyl " means the hydrocarbon compound that comprises straight or branched, and it for example comprises (but being not limited to) methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, sec-butyl, the tertiary butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl etc.

Term " alkoxyl group " means the substituting group of formula-O-alkyl.

In the application's full text, the substituting group of The compounds of this invention is open as group.The present invention plans especially to comprise that each of this type of group member and all independently subgroups close (subcombination).

G-protein linked receptor (GPCRs) is represented a big class cell surface receptor, and many neurotransmitters and these acceptor interactions are to regulate their effect.Inferring now that GPCRs has 7 kinds of membrane spaning domains and connects the receptor activation effect by the G-albumen with biological chemistry result in the cell (for example activate adenylyl cyclase stimulate) is coupled on their effector (effectors).Melanin-concentrating hormone (MCH), a kind of cyclic peptide has been accredited as the endogenic ligand of orphan G-protein linked receptor SLC-1.Referring to, for example, Shimomura etc., Biochem.Biophys.Res.Commun.261,622-26 (1999).Studies show that MCH is as neurotransmitter/modulator/conditioning agent, to change many behavior reactions.

Between rat, mouse and people, Mammals MCH (19 amino acid) is a high conservative, demonstrates 100% amino acid identity, but its physiological role is but very unclear.Reported that MCH participates in various processes, comprised balance, energy metabolism, whole body excitement/state of attention, memory and the cognitive function of pickuping food, water, and psychiatric disorders.Relevant summary is seen 1.Baker, Int.Rev.Cytol.126:1-47 (1991); 2.Baker, TEM 5:120-126 (1994); 3.Nahon, Critical Rev.in Neurobiol 221:221-262, (1994); 4.Knigge etc., Peptides 18 (7): 1095-1097, (1996).MCH on the feed or the effect of body weight in regulating obtain Qu etc., Nature 380:243-247, (1996) support, show the hypothalamus overexpression (with ob/+ mouse compare) of MCH the ob/ob mouse, and show that during fasting fasting further increases the MCHmRNA of fat and normal mouse.At Endocrinology 138:351-355, reported in (1997) that as Rossi etc. during tricorn, MCH also stimulates the feed of normal rat outside MCH is injected into.Report the behavior effect of MCH antagonism α-MSH on function in addition; See: Miller etc., Peptides 14:1-10, (1993); Gonzalez et al, Peptides 17:171-177, (1996); With Sanchez etc., Peptides 18:3933-396, (1997).In addition, shown that Stress also increases POMC mRNA level, reduced MCH precursor preproMCH (ppMCH) mRNA level simultaneously; Presse etc., Endocrinology 131:1241-1250, (1992).Therefore, MCH can be used as and Stress reaction and relevant with the regulating effect of sexuality on the feed comprehensive neuropeptide; Baker, Int.Rev.Cytol.126:1-47, (1991); Knigge etc., Peptides 17:1063-1073, (1996).

The location of MCH peptide and biologic activity prompting, the adjusting of MCH receptor active can be used in many therapeutic application.MCH expresses at outside hypothalamus, and hypothalamus is and thirsty sense and the hungry relevant brain region of adjusting: Grillon etc., Neuropeptides 31:131-136, (1997); Shown that recently phenzoline (orexins) A and B (they are effective appetizers) have the extremely similar positioning action with MCH at outside hypothalamus; Sakurai etc., Cell 92:573-585 (1998).Deprived food after 24 hours rat, the MCH mRNA level in brain region increases; Herve and Fellmann, Neurpeptides 31:237-242 (1997); Behind the insulin injection, enrichment and the staining power of observing MCH immunoreactivity perikarya and fiber obviously increase, and correspondingly the level of MCHmRNA obviously increases; Bahjaoui-Bouhaddi etc., Neuropeptides 24:251-258, (1994).Consistent with the ability of MCH stimulation in rats feed; Rossi etc., Endocrinology 138:351-355, (1997); Observe that MCH mRNA level raises in the hypothalamus of fat ob/ob mouse; Qu etc., Nature 380:243-247, (1996); And the MCH mRNA level in the hypothalamus of the rat of handling with leptin reduces, and food intake and the body weight of rat also reduce; Sahu, Endocrinology 139:795-798, (1998).As if in HPA (hypothalamus hypophysis/hypothalamic pituitary adrenal axis), MCH is as the functional antagonist in the casting skin matter hormone system that plays a role to food intake with to hormone secretion; Ludwig etc., Am.J.Physiol.Endocrinol.Metab.274:E627-E633, (1998).These data point out endogenous MCH regulating energy balance and to the effect in the reaction of Stress jointly, and provide developmental function in the ultimate principle of MCH acceptor with the special compound that is used for the treatment of obesity and Stress-diseases associated.

Therefore, the MCH receptor antagonist presses for for prevention or treatment of obesity or the disease relevant with obesity.The disease relevant with obesity is a kind of and the direct or indirect diseases associated of obesity, as, type ii diabetes, X syndrome, glucose tolerance is impaired, unusual lipidemia, hypertension, coronary heart disease and other cardiovascular disorder (comprising atherosclerosis), insulin resistant relevant with obesity and psoriasis are used for the treatment of for example polycystic ovary syndrome (PCOS) of diabetic complication and other disease, some kidney disease comprises diabetic nephropathy, glomerulonephritis, the glomerulus sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, late period, kidney disease and tubulin were urinated (microalbuminuria) and some eating disorder.

In various researchs up to now, the neuronic major part of MCH cell mass occupies suitable constant site in outside hypothalamus and those zones of subthalamus, they are positioned on these sites and can be used as that some is so-called " extrapyramidal " part of transmission circuit.These comprise suitable striatum-and pallidofugal path, and these approach relate to thalamus and pallium, hypothalamic area, and with corpus hypothalamicum, black substance and in-the interactive contact point of mesencephalic centre; Bittencourt etc., J.Comp.Neurol.319:218-245, (1992).In their location, the MCH cell mass can provide the bridging or the mechanism of the motor activity of expressing hypothalamus visceral motility and suitable and coordination.Consider that clinically the MCH system relates to dyskinesia, for example Parkinson's disease and Huntington (wherein known pyramidal tract external loop is relevant with it), it can have some value.

People heredity is being found out reliable hMCH position and finding out the hMCH position (Pedeutour etc., 1994) of variation on karyomit(e) 5 (5q12-13) in conjunction with research on the karyomit(e) 12 (12q23-24).Now provided consistent 12q23-24 position, position with the II type cerebellar ataxia (SCA2) of autosome dominance; Auburger etc., Cytogenet.Cell.Genet.61:252-256, (1992); Twells etc., Cytogenet.Cell.Genet.61:262-265, (1992).This disease comprises neurodegenerative disease, comprises olivopontocerebellar atrophy.In addition, the gene map of darier's disease is position 12q23-24; Craddock etc., Hum.Mol.Genet.2:1941-1943, (1993).Darier's disease is characterised in that the unusual keratinocyte I in some family adheres to and psychosis.From rat and neural function of human brain MCH and neuroanatomy model, the MCH gene can be represented SCA2 or various diseases. good drug candidate.What is interesting is, to this position mapping with the social sex disease of height.Really, use hereditary binding analysis, the gene of having assert the chronic or acute form that causes spinal muscular atrophy is karyomit(e) 5q12-13; Melki etc., Nature (London) 344:767-768, (1990); Westbrook etc., Cytogenet.Cell.Genet.61:225-231, (1992).In addition, the serious schizoid position of various independently evidence support is karyomit(e) 5q11.2-13.3; Sherrington etc., Nature (London) 336:164-167, (1988); Bassett etc., Lancet 1:799-801, (1988); Gilliam etc., Genomics 5:940-944, (1989).More than research prompting, MCH can work in neurodegenerative disease and affective disorder.

In other biology system, the other treatment application of MCH-related compound has been proposed by the effect of observed MCH.For example, MCH can regulate male and reproductive function female rats.Find MCH transcript and MCH peptide in the sexual cell of adult rat testis, this prompting MCH can participate in stem cell and upgrade and/or early stage spermatocytal differentiation; Hervieu etc., Biology of Reduction 54:1161-1172, (1996).Direct injection enters the MCH pungency activity of inboard optic lobe proparea (MPOA) of female rat or ventromedial nucleus (VMN); Gonzalez etc., Peptides 17:171-177, (1996).In the ovariectomized rat of contacted estradiol, MCH stimulates lutropin (LH) to discharge, and anti--MCH antiserum(antisera) suppresses LH release simultaneously; Gonzalez etc., Neuroendocrinology 66:254-262, (1997).The zona incerta that contains a large amount of MCH cell paste before had been accredited as the preceding-LH of ovulation and had discharged the regulatory site at peak; MacKenzie etc., Neuroendocrinology39:289-295, (1984).Reported that MCH influences the pituitary hormone release of (comprising ACTH and pitocin).The MCH analogue also can be used for treating epilepsy.In the PTZ epilepsy model, injection MCH can prevent that neurone that seizure activity in rat and the cavy, this prompting contain MCH from can participate in the neuron circuit based on the epileptic seizures of PTZ-inductive before the sign of epileptic seizures is arranged; Knigge and Wagner, Peptides 18:1095-1097, (1997).Also having observed MCH influences the behavior dependency of behavior cognitive function.The disappearance of the passive avoidance response of rat is accelerated in the MCH treatment; McBride etc., Peptides 15:757-759, (1994); This point has increased the possibility that the MCH receptor antagonist can be of value to memory storage and/or maintenance.By MCH-positivity fiber, MCH the adjusting of pain or the possible effect in the consciousness obtain managing all grey matters (periaqueductal grey) (PAG) in the intensive neural support that distributes.At last, MCH can participate in the adjusting of fluid intake.In clear-headed sheep through ICV infusion MCH produce because of plasma volume increase cause diuresis, urine sodium and urine potassium change; Parkes, J.Neuroendocrinol.8:57-63, (1996).Anatomical data in the presence of the MCH in the fluid regulation zone of brain, these results show that MCH may be a kind of important peptide that participates in the homeostatic maincenter control of liquid in the Mammals.

In nearest quoting as proof, the MCHR1 antagonist shows its effect as anti--depressant drug and/or anti--anxiety medicine surprisingly.Reported the MCHR1 antagonist at rodent model, as demonstrating antidepressant and anxiety activity in social activity, forced swimming test and the ultrasonic articulation test.Therefore, the MCHR1 antagonist can be used for the treatment of the patient who suffers from dysthymia disorders and/or anxiety disorder independently.And the MCHR1 antagonist can be used for treating the patient who suffers from dysthymia disorders and/or anxiety disorder and obesity.

The invention provides a kind of method of in the patient, treating abnormality disease, wherein said abnormality disease can improve by the activity that reduces Mammals MCH1 acceptor, and this method comprises the compound as Mammals MCH1 receptor antagonist that gives the amount that described patient effectively treats abnormality disease.In other embodiments, described abnormality disease is a kind of adjusting to following disease: steroid or pituitrin disorder, suprarenin discharges disorderly, anxiety disorder, the genta gastrointestinal dysfunction, cardiovascular disorder, the electrolyte balance disorder, hypertension, diabetes, respiratory tract disease, asthma, the reproductive function obstacle, Immunological diseases, endocrine regulation, musculoskeletal disease, neuroendocrine disturbance, cognitive disorder, dysmnesia, consciousness is regulated and conductive impairment, the motor coordination obstacle, the sensation asynchronism, the behavior disorder of motion and environmental harmony, the dopaminergic dysfunction, the conductive impairment of sensation, olfactory disorder, sympathetic nerve movement perception obstacle, affective disorder, with Stress-diseases associated, liquid-disequilibrium, the epileptic seizures disease, pain, psychotic behavior, the morphine tolerance, opiate addiction or migraine.

Composition of the present invention can give with unit dosage easily, and can prepare by any method that pharmacy field is known, for example at Remington ' s Pharmaceutical Sciences (Mack Pub.Co., Easton, PA, 1980) method described in the method for describing.

Compound of the present invention can be used as independent promoting agent or can unite use with other activeconstituents in medicine, these other activeconstituentss can promote the therapeutic action of described compound.

Compound of the present invention or its solvate or its physiological functional deriv can be as the activeconstituentss in the medicinal compositions, particularly as the MCH receptor antagonist.With it is generally acknowledged medicinal benefit is not provided " non-active ingredient " opposite, term " activeconstituents " is limited in this article " medicinal compositions " in, and the composition of the medicinal compositions of the medicinal benefit that refers to provide main.Term " medicinal compositions " should refer to comprise at least a activeconstituents and at least a non-active ingredient (such as but not limited to, the material that weighting agent, dyestuff or be used for slowly discharges) composition, therefore described composition is used for producing special, effective result of treatment in Mammals (for example, but be not limited to the people).

Medicinal compositions, (for example include, but is not limited to comprise as at least a The compounds of this invention of activeconstituents and/or its acceptable salt or solvate, pharmacy acceptable salt or solvate) and at least a carrier of blended or vehicle be (for example with it, pharmaceutical carrier or vehicle) medicinal compositions, can be used for treating clinical disease into the indication of MCH receptor antagonist.The carrier of at least a The compounds of this invention with solid or liquid form can be mixed in unit dose formulations.Described pharmaceutical carrier is necessary can be suitable with other composition in the composition, and must be tolerated by individual recipient.If desired, and if other composition in such composition and the described composition suitable, other physiologically active composition can be joined in the medicinal compositions of the present invention.Described preparation can be by any suitable method, is generally active compound and liquid or finely divided solid carrier (or both) are mixed equably with required ratio, then, if desired, the mixture that obtains is made required shape prepare.

Conventional excipients, for example tackiness agent, weighting agent, acceptable wetting agent, compressing tablet lubricant and disintegrating agent can be used for the tablet and the capsule of orally give.The liquid preparation that is used for orally give can be the form of solution, emulsion, water-based or oily suspensions and syrup.Perhaps, oral preparations can be the form of dried powder, and this powder can be prepared with water or another kind of suitable liquid medium before use again.Other additive, for example suspension agent or emulsifying agent, non--aqueous medium (comprising edible oil), sanitas and sweetener and tinting material also can join in the liquid preparation.Parenteral dosage forms can be by being dissolved in described The compounds of this invention in the suitable liquid medium, and through this solution of sterile filtration, is filled in suitable bottle or the ampoule then and sealing prepares.These only are the several examples that are used for preparing the many suitable method of formulation well known in the art.

Should be noted that when using the MCH receptor antagonist as the activeconstituents in the medicinal compositions, these antagonists should only not be used for the people, are used for other non--people Mammals yet.Really, the latest developments of animal health-nursing field require (for example to consider to use MCH receptor antagonist treatment domestic animal, cat and dog) obesity, with (for example the MCH receptor antagonist is used for described disease or illness and unconspicuous other domestic animal, feeding animals (food-orientedanimals), for example ox, chicken, fish etc.).Be easy to believe that those of ordinary skill in the art can understand the purposes of compound in such design.

Free bronsted lowry acids and bases bronsted lowry form that the pharmacy acceptable salt of compound of the present invention can be by making these compounds and suitable alkali or acid are reacted in water, in organic solvent or the mixture at the two and are prepared; In general, preferred non-aqueous media is as ether, ethyl acetate, ethanol, Virahol, dioxane or acetonitrile.For example, when described compound (I) when having acidic functionality, it can form inorganic salt, an alkali metal salt (for example, sodium salt, sylvite etc.) for example, alkaline earth salt (for example calcium salt, magnesium salts, barium salt etc.) and ammonium salt.When described compound (I) when having basic functionality, it (for example can form inorganic salt, hydrochloride, vitriol, phosphoric acid salt, hydrobromate etc.) or organic salt (for example, acetate, maleate, fumarate, succinate, mesylate, right-tosylate, Citrate trianion, tartrate etc.).

Other purposes

Another object of the present invention relates to radiolabeled formula (1a) compound, it not only is used for radiation-imaging, and be used for test (external and body in), with the location of the MCH that is used for tissue sample (comprising the people) and quantitatively and the combination by suppressing radiolabeled compound with identification of M CH part.Another purpose of the present invention is the new MCH test that exploitation comprises this radiolabeled compound.

Can include but not limited to the suitable radionuclide of compound bonded of the present invention ³H (also writing T), ¹¹C, ¹⁴C, ¹⁸F, ¹²⁵I, ⁸²Br, ¹²³I, ¹²⁴I, ¹²⁵I, ¹³¹I, ⁷⁵Br, ⁷⁶Br, ¹⁵O, ¹³N, ³⁵S and ⁷⁷Br.The application-specific that can will depend on radiolabeled compound with radiolabeled compound bonded radionuclide of the present invention.Therefore, for external MCH mark and competition experiments, can with ³H, ¹⁴C, ¹²⁵I, ¹³¹I, ³⁵S and ⁸²Br bonded compound is normally the most useful.For radiation-imaging applications, ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br and ⁷⁷Br is normally the most useful.

Should be appreciated that " radiation-mark " and " compound of mark " be formula (Ia) compound in conjunction with at least a radionuclide; In some embodiments, described radionuclide is selected from ³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br; In some embodiments, described radionuclide is selected from ³H and ¹⁴C.In addition, should be appreciated that all atoms of representing in the The compounds of this invention can be isotropic substance or the more rare radiation-isotropic substances or the non-radioactive-active isotropic substances of normal appearance of this type of atom.

Radiation-isotropic substance is attached to the synthetic method of organic compound, comprise those synthetic methods that are applied to those compounds of the present invention, be well known to those skilled in the art, it comprises that the tritium with activity level is attached in the target molecule: A. tritium gas catalytic reduction-this method obtains the active product of high specific usually, and needs halogenated or undersaturated precursor.B. use sodium borohydride [ ³H] reduction-this method is quite cheap, but need contains the precursor of functional group's (for example aldehyde, ketone, lactone, ester etc.) of vattability.C. lithium aluminum hydride [ ³H] reduction-this method provides the almost product of theoretic activity specific.This method also needs to contain the precursor of functional group's (for example aldehyde, ketone, lactone, ester etc.) of vattability.D. tritium gas contact mark method-this method is included in the appropriate catalyst existence down, and the precursor that contains exchangeable protons is contacted with tritium gas.E. use methyl-iodide [ ³H] carry out N-methylate-this method be commonly used to by with high specific active methyl iodine ( ³H) handle suitable precursor prepare O-methyl or N-methyl ( ³H) product.This method has the high specific activity usually, for example about 80-87Ci/mmol.

With activity level ¹²⁵The synthetic method that I is attached to target molecule comprises: reaction-these methods such as A. mountain moral enzyme are converted into diazonium salt with aryl or heteroaryl amine, and for example a tetrafluoro borate is used Na subsequently ¹²⁵I is converted into ¹²⁵The compound of I mark.A kind of representational method is by Zhu, and D.-G and colleague thereof be at J.Org.Chem.2002, and 67, report among the 943-948.B. the ortho position of phenol ¹²⁵Iodization-this method makes ¹²⁵I is attached to the ortho position of phenol, as Collier, T.L and colleague at J.Labelled Compd Radiopharm.1999,42, report among the S264-S266.C. aryl and heteroaryl bromine with ¹²⁵I exchange-this method is generally two-step approach.The first step is at three-alkyl tin halide or six alkyl, two tin [for example, (CH ₃) ₃SnSn (CH ₃) ₃] exist down, for example to use, the Pd catalyzed reaction [is Pd (Ph ₃P) ₄] or by aryl or heteroaryl lithium, aryl or heteroaryl bromine are converted into corresponding three-tin alkyl intermediate.A kind of representational method is by Bas, and M.-D and colleague thereof be at J.Labelled Compd Radiopharm.2001, and 44, report among the S280-S282.

The radiolabeled MCH compound of formula (I) can be used for shaker test, with evaluation/assessing compound.In general can estimate new synthetic or compounds identified (that is test compound) and reduce the ability that " radiolabeled formula (Ia) compound " is incorporated into the MCH acceptor.Therefore, test compound is directly related with its binding affinity with the ability that " radiolabeled formula (Ia) compound " competitiveness is incorporated into the MCH acceptor.

Tagged compound of the present invention is incorporated into the MCH acceptor.In one embodiment, the compound of described mark has the IC that is lower than about 500 μ M ₅₀, in another embodiment, the compound of described mark has the IC that is lower than about 100 μ M ₅₀, in another embodiment, the compound of described mark has the IC that is lower than about 10 μ M ₅₀, in another embodiment, the compound of described mark has the IC that is lower than about 1 μ M ₅₀, and in another embodiment, the compound of described mark has the IC that is lower than about 0.1 μ M ₅₀

Preparation-the universal synthesis method of formula (I) compound

The quinoline of the replacement that the present invention is new, tetrahydro quinazoline and pyrimidine can easily prepare according to various synthetic methods, and all these methods all are that those skilled in the art are familiar with.Be used for preparing those that compound preferable methods of the present invention includes, but are not limited to describe at flow process 1-24.

The intermediate (F) commonly used of the quinoline of described new replacement can prepare as shown in Scheme 1.Have or alkali-free under, by halogenating agent, can be with 2 of commercially available acquisition, 4-dihydroxyl quinoline (A), wherein T and p are converted into 2 as defined above, 4-dihalo-quinoline (B) (wherein X is a halogen, for example chloro base, bromo base or iodo base).Described halogenating agent comprises phosphoryl chloride (POCl ₃), phosphoryl bromide (POBr ₃) or phosphorus pentachloride (PCl ₅).Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine etc.) or aromatic amine (preferred N, accelerine etc.).Range of reaction temperature is at about 100 ℃-200 ℃, preferred about 140 ℃-180 ℃.

In inert solvent, have or alkali-free under, 2, the halogen on 4 of 4-dihalo-quinoline (B) can be by primary amine or secondary amine (HNR _2aR _2b, R wherein _2aAnd R _2bOptionally replace as defined above), to obtain the amino adducts (C) that corresponding 4-replaces.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.) or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 0 ℃-200 ℃, preferred about 10 ℃-150 ℃.

In inert solvent, have or alkali-free under, described amino adducts successively again can be by one-diamines (D) of protection (R wherein ₃, R ₄, A and B as defined above and P be blocking group) replaced, to provide 2, the dibasic quinolylamine of 4-(E).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.) or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-150 ℃.This reaction also can be carried out under microwave condition.

The representational blocking group that is suitable for various synthetic conversions is disclosed in Greene and Wuts, Protective Groups in Organic Synthesis (blocking group in the organic synthesis), second edition, John Wiley ﹠amp; Sohs, New York, 1991, its disclosure is attached to herein by reference in full.The common intermediate (F) that removes to protect the quinoline that obtains new replacement of blocking group.

Flow process 1

Common intermediate (F) is summarized in the flow process 2 to the conversion of the quinoline (G-K) of new replacement of the present invention.

In inert solvent, have or alkali-free under, make described amine (F) and carboxylic acid (R ₁CO ₂H) and dehydrating condensation agent reaction, obtain new acid amides of the present invention (G).

Described dehydrating condensation agent comprises dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCHCl), bromo-three-pyrrolidyl (pyrrolidino)-phosphorus hexafluorophosphate (PyBroP), O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea hexafluorophosphate (HATU) or 1-cyclohexyl-3-methylated polystyrene-carbodiimide.Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine or triethylamine etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), nitrile solvent (preferred acetonitrile etc.) or amide solvent (preferred N, dinethylformamide etc.).Under the situation of needs, I-hydroxybenzotriazole (HOBT), HOBT-6-formamido-(carboxaamido) methylated polystyrene or 1-hydroxyl-7-azepine benzotriazole (HOAT) can be used as reagent.Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

Perhaps, new acid amides of the present invention (G) can be by using acyl chlorides (R ₁COCl) and alkali in inert solvent, carry out amidate action and obtain.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles, poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), amide solvent (preferred N, dinethylformamide etc.) or aromatic solvent (preferred toluene or pyridine etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

In inert solvent, make new acid amides of the present invention (G) and reductive agent reaction, obtain new amine of the present invention (H).Described reductive agent comprises alkali metal aluminum hydride (preferred lithium aluminum hydride), alkali metal borohydride (preferred lithium borohydride), basic metal tri-alkoxy aluminum hydride (preferred lithium tri-t-butoxyaluminium hydride), dialkyl aluminum hydride (preferred two-hydrogenation aluminium isobutyl), borine, Dialkylborane (preferred two-isopentyl borine), basic metal trialkylboron hydride (preferred lithium triethylborohydride).Described inert solvent comprises ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Range of reaction temperature is being made an appointment with-78 ℃ to 200 ℃, preferred about 50 ℃-120 ℃.

Perhaps, in inert solvent, having under acid or the anacidity, new amine of the present invention (H) can be by using aldehyde (R ₁CHO) and reductive agent carry out reductive amination process and obtain.Described reductive agent comprises sodium triacetoxy borohydride, sodium cyanoborohydride, sodium borohydride or borine-pyridine mixture, preferred sodium triacetoxy borohydride or sodium cyanoborohydride.Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol or ethanol etc.), rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Described acid comprises mineral acid (preferred hydrochloric acid or sulfuric acid) or organic acid (preferred acetate).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.This reaction also can be carried out under microwave condition.

New urea of the present invention (1) can have under alkali or the alkali-free by in inert solvent, uses isocyanic ester (R ₁NCO) carry out urea reaction and obtaining.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free under, make described amine (F) and lsothiocyanates (R ₁NCS) reaction obtains new thiocarbamide of the present invention (J).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or amide solvent (preferred N, dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, having under alkali or the alkali-free, new urethane of the present invention (K) can be by using R ₁OCOX (wherein X is for example chloro base, bromo base or an iodo base of halogen) carries out urethane reaction and obtains.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles or poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

Flow process 2

Formula (N) compound can be as preparing as shown in the flow process 3.[4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester (L) is by synthetic in method described in the WO 01/72710.The protection of going of Boc-group realizes by acid, to obtain amine (M).The coupling of described amine and quinoline nuclei (C) (as synthetic described in the flow process 1) obtains 2, the dibasic quinolylamine of 4-.The protection of going of Z-group realizes by hydrogen reduction, to obtain formula (N) compound.

Flow process 3

Formula (P) compound can be as preparing as shown in the flow process 4.By curtius' rearrangement, can be with the cis-hexanaphthene-1 of commercially available acquisition, the dicarboxylic acid of 4-dicarboxylic acid is converted into carboxylamine dibenzyl ester.The protection of going of Z-group realizes by hydrogen reduction, to obtain diamines.One of described diamines-protection can be passed through at Synthetic communications, and 20, method described in the 2559-2564 (1990) realizes, obtains described compound (O).The coupling of described amine and quinoline nuclei (C) (synthetic shown in flow process 1) obtains 2, the dibasic quinolylamine of 4-.The protection of going of Boc-group realizes by acid, obtains amine (P).

Flow process 4

The intermediate commonly used (V) of the tetrahydro quinazoline of new replacement can be as preparing as shown in the flow process 5.According to the method for describing among the EP 0604920, can be with the 2-cyclohexanone carboxylic acid ethyl ester (Q) of commercially available acquisition, wherein T and p are converted into 2 as defined above, 4-dihydroxyl tetrahydro quinazoline (R).By have or alkali-free under use halogenating agent, with 2,4-dihydroxyl tetrahydro quinazoline (R) is converted into 2,4-dihalo-tetrahydro quinazoline (S) (wherein X is a halogen, for example chloro base, bromo base or iodo base).Described halogenating agent comprises phosphoryl chloride (POCl ₃), phosphoryl bromide (POBr ₃) or phosphorus pentachloride (PCl ₅).Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine etc.) or aromatic amine (preferred N, accelerine etc.).Range of reaction temperature is at about 100 ℃-200 ℃, preferred about 140 ℃-180 ℃.

In inert solvent, have or alkali-free exists down, 2, the halogen on the 4-position of 4-dihalo-tetrahydro quinazoline (S) is by primary amine or secondary amine (HNR _2aR _2b, R wherein _2aAnd R _2bOptionally replace as defined above), to obtain the amino adducts (T) that corresponding 4-replaces.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.) or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 0 ℃-200 ℃, preferred about 10 ℃-150 ℃.

Successively, in inert solvent, have or alkali-free exists down, this can be by the diamines (D) of one-protection (R wherein ₃, R ₄, A and B as defined above and P be blocking group) replace, to provide 2, the dibasic amino tetrahydro quinazoline of 4-(U).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.) or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-150 ℃.This reaction also can be carried out under microwave condition.

The intermediate commonly used (V) that removes to protect the tetrahydro quinazoline that obtains new replacement of blocking group.

Flow process 5

Intermediate (V) commonly used is summarized in the flow process 6 to the conversion of the tetrahydro quinazoline of new replacement of the present invention (W-A ').

In inert solvent, have or alkali-free in the presence of, make described amine (V) and carboxylic acid (R ₁CO ₂H) and dehydrating condensation agent reaction, obtain new acid amides of the present invention (W).Described dehydrating condensation agent comprises dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCHCl), bromo-three-pyrrolidyl-phosphorus hexafluorophosphate (PyBroP), O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea hexafluorophosphate (HATU) or 1-cyclohexyl-3-methylated polystyrene-carbodiimide.Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine or triethylamine etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), nitrile solvent (preferred acetonitrile etc.) or amide solvent (preferred N, dinethylformamide etc.).Under the situation of needs, I-hydroxybenzotriazole (HOBT), HOBT-6-formamido-methylated polystyrene or 1-hydroxyl-7-azepine benzotriazole (HOAT) can be used as reagent.Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

Perhaps, in inert solvent,, use acyl chlorides (R by amidate action ₁COCl) and alkali, can obtain the new acid amides of the present invention (W).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles, poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), amide solvent (preferred N, dinethylformamide etc.) or aromatic solvent (preferred toluene or pyridine etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

In inert solvent, make new acid amides of the present invention (W) and reductive agent reaction, obtain new amine of the present invention (X).Described reductive agent comprises alkali metal aluminum hydride (preferred lithium aluminum hydride), alkali metal borohydride (preferred lithium borohydride), basic metal tri-alkoxy aluminum hydride (preferred three tert.-butoxy lithium aluminum hydrides), dialkyl group aluminum hydride (preferred two-hydrogenation aluminium isobutyl), borine, Dialkylborane (preferred two-isopentyl borine), basic metal trialkylboron hydride (preferred lithium triethylborohydride).Described inert solvent comprises ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Range of reaction temperature is being made an appointment with-78 ℃ to 200 ℃, preferred about 50 ℃-120 ℃.

Perhaps, in inert solvent, having in the presence of acid or the anacidity,, using aldehyde (R by the reductive amination reaction ₁CHO) and reductive agent, can obtain new amine of the present invention (X).Described reductive agent comprises sodium triacetoxy borohydride, sodium cyanoborohydride, sodium borohydride or borine-pyridine mixture, preferred sodium triacetoxy borohydride or sodium cyanoborohydride.Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol or ethanol etc.), rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Described acid comprises mineral acid (preferred hydrochloric acid or sulfuric acid) or organic acid (preferred acetate).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.This reaction also can be carried out under microwave condition.

In inert solvent, have or alkali-free in the presence of, by urea reaction, use isocyanic ester (R ₁NCO), can obtain new urea of the present invention (Y).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, make described amine (V) and lsothiocyanates (R ₁NCS) reaction obtains new thiocarbamide of the present invention (Z).Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred NN-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or amide solvent (preferred N, dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, by using R ₁OCOX (wherein X is a halogen, for example chloro base, bromo base or iodo base) carries out urethane reaction, can obtain new urethane of the present invention (A ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles or poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

Flow process 6

Formula (B ') compound can be as preparing as shown in the flow process 7.Make amine (M) (its can as synthetic as shown in the flow process 3) and tetrahydro quinazoline nuclear (T) (its can as synthetic as shown in the flow process 5) coupling, obtain 2, the dibasic amino tetrahydro quinazoline of 4-.The protection of going of Z-group can realize by hydrogen reduction, obtains formula (B ') compound.

Flow process 7

Formula (C ') compound can be as preparing as shown in the flow process 8.Make amine (O) (its can as synthetic as shown in the flow process 4) and tetrahydro quinazoline nuclear (T) (its can as synthetic as shown in the flow process 5) coupling, obtain 2, the dibasic amino tetrahydro quinazoline of 4-.The protection of going of Boc-group can realize by acid, obtains amine (C ').

Flow process 8

The intermediate commonly used of the pyrimidine of new replacement (H ') can be as preparing as shown in the flow process 9.Have or alkali-free in the presence of, by halogenating agent, can be with the uridylic of the replacement of commercially available acquisition (D '), wherein T and p are converted into 2 of replacement as defined above, 4-dihalo-pyrimidine (E '), wherein X be a halogen, for example chloro base, bromo base or iodo base).Described halogenating agent comprises phosphoryl chloride (POCl ₃), phosphoryl bromide (POBr ₃) or phosphorus pentachloride (PCl ₅).Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine etc.) or aromatic amine (preferred N, accelerine etc.).Range of reaction temperature is at about 100 ℃-200 ℃, preferred about 140 ℃-180 ℃.

In inert solvent, have or alkali-free exists down, can with replace 2, the halogen on the 4-position of 4-dihalo-pyrimidine (E ') is with primary amine or secondary amine (HNR _2aR _2b, R wherein _2aAnd R _2bOptionally replace as defined above), to obtain the amino adducts that corresponding 4-replaces (F ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.), or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane etc.), or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 0 ℃-200 ℃, preferred about 10 ℃-150 ℃.

Successively, in inert solvent, have or alkali-free exists down, it can be by the diamines (D) of one-protection (R wherein ₃, R ₄, A and B as defined above and P be blocking group) replace, obtaining 2, the dibasic aminopyrimidine of 4-(G ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.), or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-150 ℃.This reaction also can be carried out under microwave condition.

The going to protect of blocking group obtains the intermediate commonly used (H ') of the pyrimidine of described new replacement.

Flow process 9

Intermediate commonly used (H ') is summarized in the flow process 10 to the conversion of the pyrimidine of new replacement of the present invention (I '-M ').

In inert solvent, have or alkali-free in the presence of, make described amine (H ') and carboxylic acid (R ₁CO ₂H) and dehydrating condensation agent reaction, obtain new acid amides of the present invention (I ').Described dehydrating condensation agent comprises dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCHCl), bromo-three-pyrrolidino-phosphorus hexafluorophosphate (PyBroP), O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea hexafluorophosphate (HATU) or 1-cyclohexyl-3-methylated polystyrene-carbodiimide.Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine or triethylamine etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), nitrile solvent (preferred acetonitrile etc.), or amide solvent (preferred N, dinethylformamide etc.).Under the situation of needs, I-hydroxybenzotriazole (HOBT), HOBT-6-formamido-methylated polystyrene or 1-hydroxyl-7-azepine benzotriazole (HOAT) can be used as reagent.Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

Perhaps, in inert solvent,, use acyl chlorides (R by amidate action ₁COCl) and alkali, can obtain new acid amides of the present invention (I ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles, poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), amide solvent (preferred N, or aromatic solvent (preferred toluene or pyridine etc.) dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

In inert solvent, make new acid amides of the present invention (I ') and reductive agent reaction, obtain new amine of the present invention (J ').Described reductive agent comprises alkali metal aluminum hydride (preferred lithium aluminum hydride), alkali metal borohydride (preferred lithium borohydride), basic metal tri-alkoxy aluminum hydride (preferred lithium tri-t-butoxyaluminium hydride), dialkyl group aluminum hydride (preferred two-hydrogenation aluminium isobutyl), borine, Dialkylborane (preferred diisoamyl borine), basic metal trialkylboron hydride (preferred lithium triethylborohydride).Described inert solvent comprises ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Range of reaction temperature is being made an appointment with-78 ℃ to 200 ℃, preferred about 50 ℃-120 ℃.

Perhaps, in inert solvent, having in the presence of acid or the anacidity,, using aldehyde (R by the reductive amination reaction ₁CHO) and reductive agent, can obtain new amine of the present invention (J ').Described reductive agent comprises sodium triacetoxy borohydride, sodium cyanoborohydride, sodium borohydride or borine-pyridine mixture, preferred sodium triacetoxy borohydride or sodium cyanoborohydride.Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol or ethanol etc.), rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Described acid comprises mineral acid (preferred hydrochloric acid or sulfuric acid) or organic acid (preferred acetate).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.This reaction also can be carried out under microwave condition.

In inert solvent, have or alkali-free in the presence of, by urea reaction, use isocyanic ester (R ₁NCO), can obtain new urea of the present invention (K ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, make described amine (H ') and lsothiocyanates (R ₁NCS) reaction obtains new thiocarbamide of the present invention (L ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or amide solvent (preferred N, dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, by urethane reaction, use R ₁OCOCl, wherein X is a halogen, for example chloro base, bromo base or iodo base can obtain new urethane of the present invention (M ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles or poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

Flow process 10

Formula (N ') compound can prepare as shown in Scheme 11.Make amine (M) (its as shown in the flow process 3 synthetic) and pyrimidine nuclear (F ') (its as synthetic as shown in the flow process 9) coupling, obtain 2, the dibasic aminopyrimidine of 4-.The protection of going of Z-group can realize by hydrogen reduction, obtains formula (N ') compound.

Flow process 11

Formula (O ') compound can prepare as shown in Scheme 12.Make amine (O) (its as shown in the flow process 4 synthetic) and pyrimidine nuclear (F ') (its as synthetic as shown in the flow process 9) coupling, obtain 2, the dibasic aminopyrimidine of 4-.The protection of going of Boc-group can realize by acid, obtains amine (O ').

Flow process 12

The intermediate commonly used of the quinoline of new replacement (S ') can prepare as shown in Scheme 13.Have or alkali-free in the presence of, can make the 2-hydroxyl-quinoline (P ') of the replacement of commercially available acquisition by halogenating agent, wherein R ₂, T and p as defined above, be converted into 2-halo-quinoline (Q '), wherein X is a halogen, for example chloro base, bromo base or iodo base.Described halogenating agent comprises phosphoryl chloride (POCl ₃), phosphoryl bromide (POBr ₃) or phosphorus pentachloride (PCl ₅).Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine etc.) or aromatic amine (preferred N, accelerine etc.).Range of reaction temperature is at about 100 ℃-200 ℃, preferred about 140 ℃-180 ℃.

In inert solvent, have or alkali-free in the presence of, the diamines (D) of described halogenide (Q ') with one-protection replaced, wherein R ₃, R ₄, A and B as defined above and P be blocking group, obtain the quinolylamine that 2-replaces (R ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.), or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-150 ℃.This reaction also can be carried out under microwave condition.

The going to protect of blocking group obtains the intermediate commonly used (S ') of the quinoline of described new replacement.

Flow process 13

Intermediate commonly used (S ') is summarized in the flow process 14 to the conversion of the quinoline of new replacement of the present invention (T '-X ').

In inert solvent, have or alkali-free in the presence of, make described amine (S ') and carboxylic acid (R ₁CO ₂H) and dehydrating condensation agent reaction, obtain new acid amides of the present invention (T ').Described dehydrating condensation agent comprises dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCHCI), bromo-three-pyrrolidyl-phosphorus hexafluorophosphate (PyBroP), O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea hexafluorophosphate (HATU) or 1-cyclohexyl-3-methylated polystyrene-carbodiimide.Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine or triethylamine etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), nitrile solvent (preferred acetonitrile etc.), or amide solvent (preferred N, dinethylformamide etc.).Under the situation of needs, I-hydroxybenzotriazole (HOBT), HOBT-6-formamido-methylated polystyrene or 1-hydroxyl-7-azepine benzotriazole (HOAT) can be used as reagent.Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

Perhaps, in inert solvent,, use acyl chlorides (R by amidate action ₁COCl) and alkali, can obtain new acid amides of the present invention (T ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine, imidazoles, poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), amide solvent (preferred N, or aromatic solvent (preferred toluene or pyridine etc.) dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

In inert solvent, make new acid amides of the present invention (T ') and reductive agent reaction, obtain new amine of the present invention (U ').Described reductive agent comprises alkali metal aluminum hydride (preferred lithium aluminum hydride), alkali metal borohydride (preferred lithium borohydride), basic metal tri-alkoxy aluminum hydride (preferred lithium tri-t-butoxyaluminium hydride), dialkyl group aluminum hydride (preferred Di-Isobutyl aluminum hydride), borine, Dialkylborane (preferred diisoamyl borine), basic metal trialkyl borohydride (preferred lithium triethylborohydride).Described inert solvent comprises ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Range of reaction temperature is being made an appointment with-78 ℃ to 200 ℃, preferred about 50 ℃-120 ℃.

Perhaps, in inert solvent, having in the presence of acid or the anacidity, by using aldehyde (R ₁CHO) and reductive agent carry out reductive amination process, can obtain new amine of the present invention (U ').Described reductive agent comprises sodium triacetoxy borohydride, sodium cyanoborohydride, sodium borohydride or borine-pyridine mixture, preferred sodium triacetoxy borohydride or sodium cyanoborohydride.Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol or ethanol etc.), rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), or aromatic solvent (preferred toluene etc.).Described acid comprises mineral acid (preferred hydrochloric acid or sulfuric acid) or organic acid (preferred acetate).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.This reaction also can be carried out under microwave condition.

In inert solvent, have or alkali-free in the presence of, by using isocyanic ester (R ₁NCO) carry out urea reaction, can obtain new urea of the present invention (V ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.), or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, make described amine (S ') and lsothiocyanates (R ₁NCS) reaction obtains the new thiocarbamide of the present invention (W ').Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.), or amide solvent (preferred N, dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, by urethane reaction, use R ₁OCOCl can obtain new urethane of the present invention (X '), and wherein X is a halogen, for example chloro base, bromo base or iodo base.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.) or aromatic amine (preferred pyridine, imidazoles or poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.), or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

Flow process 14

Formula (Y ') compound can prepare as shown in Scheme 15.Make amine (M) (its as shown in the flow process 3 synthetic) and quinoline nuclei (Q ') (its as synthetic as shown in the flow process 13) coupling, obtain the quinolylamine that 2-replaces.The protection of going of Z-group can realize by hydrogen reduction, obtains formula (Y ') compound.

Flow process 15

Formula (Z ') compound can prepare as shown in Scheme 16.Make amine (O) (its as shown in the flow process 4 synthetic) and quinoline nuclei (Q ') (its as synthetic as shown in the flow process 13) coupling, obtain the quinolylamine that 2-replaces.The protection of going of Boc-group realizes by acid, obtains amine (Z ').

Flow process 16

The intermediate commonly used of the pyrimidine of new replacement (D ") can prepare as shown in Scheme 17.Have or alkali-free in the presence of, by halogenating agent, can be with the 2-hydroxyl-pyrimidine of the replacement of commercially available acquisition (A ") (R wherein ₂, T and p as defined above) be converted into 2-halo-pyrimidine (B ") (wherein X is a halogen, for example chloro base, bromo base or iodo base).Described halogenating agent comprises phosphoryl chloride (POCl ₃), phosphoryl bromide (POBr ₃) or phosphorus pentachloride (PCl ₅).Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine etc.) or aromatic amine (preferred N, accelerine etc.).Range of reaction temperature is at about 100 ℃-200 ℃, preferred about 140 ℃-180 ℃.

In inert solvent, have or alkali-free in the presence of, can be with the diamines (D) of halogenide (B ") by one-protection (R wherein ₃, R ₄, A and B as defined above, and P is a blocking group) replace, obtain the aminopyrimidine that 2-replaces (C ").Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.) or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-150 ℃.This reaction also can be carried out under microwave condition.

The going to protect of blocking group obtains the intermediate commonly used (D ") of the pyrimidine of described new replacement.

Flow process 17

Intermediate commonly used (D ") is summarized in the flow process 18 to the conversion of the pyrimidine of described new replacement of the present invention (E "-I ").

In inert solvent, have or alkali-free in the presence of, make described amine (D ") and carboxylic acid (R ₁CO ₂H) and dehydrating condensation agent reaction, obtain new acid amides of the present invention (E ").Described dehydrating condensation agent comprises dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCHCl), bromo-three-pyrrolidyl-phosphorus (phosnium) hexafluorophosphate (PyBroP), O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea hexafluorophosphate (HATU) or 1-cyclohexyl-3-methylated polystyrene-carbodiimide.Described alkali comprises tertiary amine (preferred N, N-diisopropylethylamine or triethylamine etc.).Described inert solvent comprises rudimentary halon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), nitrile solvent (preferred acetonitrile etc.), or amide solvent (preferred N, dinethylformamide etc.).Under the situation of needs, I-hydroxybenzotriazole (HOBT), HOBT-6-formamido-methylated polystyrene or 1-hydroxyl-7-azepine benzotriazole (HOAT) can be used as reagent.Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

Perhaps, in inert solvent,, use acyl chlorides (R by amidate action ₁COCl) and alkali, can obtain new acid amides of the present invention (E ").Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine, imidazoles, poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), amide solvent (preferred N, or aromatic solvent (preferred toluene or pyridine etc.) dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 50 ℃, preferred about 0 ℃-40 ℃.

In inert solvent, make new acid amides of the present invention (E ") and reductive agent reaction, obtain new amine of the present invention (F ").Described reductive agent comprises alkali metal aluminum hydride (preferred lithium aluminum hydride), alkali metal borohydride (preferred lithium borohydride), basic metal tri-alkoxy aluminum hydride (preferred three tert.-butoxy lithium aluminum hydrides), dialkyl group aluminum hydride (preferred Di-Isobutyl aluminum hydride), borine, Dialkylborane (preferred two-isopentyl borine), basic metal trialkylboron hydride (preferred lithium triethylborohydride).Described inert solvent comprises ether solvent (preferred tetrahydrofuran (THF) or dioxane) or aromatic solvent (preferred toluene etc.).Range of reaction temperature is being made an appointment with-78 ℃ to 200 ℃, preferred about 50 ℃-120 ℃.

Perhaps, in inert solvent, have acid or anacidity in the presence of, by with aldehyde (R ₁CHO) and reductive agent carry out reductive amination process, can obtain new amine of the present invention (F ").Described reductive agent comprises sodium triacetoxy borohydride, sodium cyanoborohydride, sodium borohydride, or borine-pyridine mixture, preferred sodium triacetoxy borohydride or sodium cyanoborohydride.Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol or ethanol etc.), rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), or aromatic solvent (preferred toluene etc.).Described acid comprises mineral acid (preferred hydrochloric acid or sulfuric acid) or organic acid (preferred acetate).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.This reaction also can be carried out under microwave condition.

In inert solvent, have or alkali-free in the presence of, by urea reaction, use isocyanic ester (R ₁NCO), can obtain the new urea of the present invention (G ").Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.), or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, make described amine (D ") and lsothiocyanates (R ₁NCS) reaction obtains new thiocarbamide of the present invention (H ").Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine or imidazoles etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.) or amide solvent (preferred N, dinethylformamide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

In inert solvent, have or alkali-free in the presence of, by urethane reaction, use R ₁OCOCl can obtain the new urethane of the present invention (I "), and wherein X is a halogen, for example chloro base, bromo base or iodo base.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali-metal supercarbonate (preferred sodium bicarbonate or saleratus etc.), alkali metal hydroxide (preferred sodium hydroxide or potassium hydroxide etc.), tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.), or aromatic amine (preferred pyridine, imidazoles or poly--(4-vinylpridine) etc.).Described inert solvent comprises rudimentary halocarbon solvent (preferred methylene dichloride, ethylene dichloride or chloroform etc.), ether solvent (preferred tetrahydrofuran (THF) or dioxane), aromatic solvent (preferred benzene or toluene etc.), or polar solvent (preferred N, dinethylformamide or methyl-sulphoxide etc.).Range of reaction temperature is being made an appointment with-20 ℃ to 120 ℃, preferred about 0 ℃-100 ℃.

Flow process 18

Formula (J ") compound can prepare as shown in Scheme 19.Make amine (M) (its as shown in the flow process 3 synthetic) and pyrimidine nuclear (B ") (its as synthetic as shown in the flow process 17) coupling, obtain the aminopyrimidine that 2-replaces.The protection of going of Z-group can realize by hydrogen reduction, obtains formula (J ") compound.

Flow process 19

Formula (K ") compound can prepare as shown in Scheme 20.Make amine (O) (its as shown in the flow process 4 synthetic) and pyrimidine nuclear (B ") (its as synthetic as shown in the flow process 17) coupling, obtain the aminopyrimidine that 2-replaces.The protection of going of Boc-group realizes by acid, obtains amine (K ").

Flow process 20

Perhaps, new quinoline of the present invention (M "), new tetrahydro quinazoline (N "), new pyrimidine (O "), new quinoline (P ") and new pyrimidine (Q ") can be as shown in the flow processs 21, directly synthesized by quinoline nuclei (C) (its as synthetic as shown in the flow process 1), tetrahydro quinazoline nuclear (T) (its as synthetic as shown in the flow process 5), pyrimidine nuclear (F ') (its as synthetic as shown in the flow process 9), quinoline nuclei (Q ') (its as synthetic as shown in the flow process 13) and pyrimidine nuclear (B ") (its as synthetic as shown in the flow process 17).Described coupling in inert solvent, have or alkali-free in the presence of carry out.Described alkali comprises alkaline carbonate (preferred yellow soda ash or salt of wormwood etc.), alkali metal hydroxide (preferred sodium hydroxide etc.), or tertiary amine (preferred N, N-diisopropylethylamine, triethylamine or N-methylmorpholine etc.).Described inert solvent comprises low alkyl group alcoholic solvent (particular methanol, ethanol, 2-propyl alcohol or butanols etc.) or amide solvent (preferred N, dinethylformamide or 1-methyl-pyrrolidin-2-one etc.).Range of reaction temperature is at about 50 ℃-200 ℃, preferred about 80 ℃-180 ℃.This reaction also can be carried out under microwave condition.

Flow process 21

For example, formula (T ") compound can prepare as shown in Scheme 22.By aldehyde (R ₁CHO), make described amine (O) (it is as synthesizing as shown in the flow process 4) experience reductive amination.The protection of going of Boc-group realizes by acid, obtains described amine.Make described amine and pyrimidine nuclear (F ') (its as synthetic as shown in the flow process 9) coupling, obtain new pyrimidine of the present invention (T ").

Flow process 22

Formula (W ") compound can prepare as shown in Scheme 23.Make described amine (O) (it is as synthesizing as shown in the flow process 4) by carboxylic acid (R ₁CO ₂H) or acyl chlorides (R ₁COCl) experience amidation.The protection of going of Boc-group realizes by acid, obtains described amine.Make amine and quinoline nuclei (Q ') (its as synthetic as shown in the flow process 13) coupling, obtain new quinoline of the present invention (W ").

Flow process 23

Formula (Z ") compound can prepare as shown in Scheme 24.Described amine (O) (it is as synthesizing as shown in the flow process 4) is by carboxylic acid (R ₁CO ₂H) or acyl chlorides (R ₁COCl) experience amidation.The protection of going of Boc-group realizes by acid, obtains described amine.Make amine and pyrimidine nuclear (B ") (its as synthetic as shown in the flow process 17) coupling, obtain new pyrimidine of the present invention (Z ").

Flow process 24

When compound of the present invention comprised optical isomer, steric isomer, regional isomer, rotational isomer, compound of the present invention comprised single material and their mixture.For example, when the chemical formula shown in is not represented stereochemical form, formula VI for example, then all possible steric isomer, optical isomer and composition thereof all are believed to comprise in the scope of this chemical formula.Therefore, formula VII specializes the cis relation between two amino groups on the cyclohexyl ring, thereby this chemical formula is also included by formula VI fully.

Other purposes disclosed by the invention will become apparent based on the field of the summary of patent document particularly.

Provide the following example with explanation the present invention, but and mean and contain all the elements by any way:

Embodiment

Compound of the present invention and the synthetic of them are further specified by following examples.Provide following examples to further describe the present invention, yet, do not limit the invention in these specific embodiments.Used " room temperature " means the temperature between 0 ℃-40 ℃ in following examples.Following compound is by Beilstein Auto Nom the 4.0th edition, CS Chem Draw Ultra the 6.0th edition, CS Chem Draw Ultra 6.0.2 version, CS Chem Draw Ultra 7.0.1 version or the 7.0th edition name of ACD Name (ACD name).

Abbreviation used among this specification sheets, particularly flow process and the embodiment is as follows:

¹H NMR: proton magnetic resonance (PMR) spectrum

AcOH: acetate

APCI: atmospheric pressure chemical ionization

(Boc) ₂O: two carbonic acid, two-tertiary butyl ester

BuLi: butyllithium

BuOH: butanols

Cbz: carbobenzoxy-(Cbz)

CDCl ₃: the deuterate chloroform

CH ₂Cl ₂: methylene dichloride

CHCl ₃: chloroform

CI: chemi-ionization

MCPBA: a chloro peroxybenzoic acid

DMA:N, the N-N,N-DIMETHYLACETAMIDE

DCM: methylene dichloride

DIEA: diisopropylethylamine

DMSO.: methyl-sulphoxide

Dppf: two-(diphenylphosphine acyl group) ferrocene

EI: electron ionization

ESI: electron spray ionisation

Et ₂O: ether

EtOAc: ethyl acetate

EtOH: ethanol

FAB: fast atom bombardment

HATU:O-(7-azepine benzo triazol-1-yl)-N, N, N ', N '-tetramethyl-urine-hexafluorophosphate

H ₂SO ₄: sulfuric acid

HCl: hydrogenchloride

IPA: Virahol

K ₂CO ₃: salt of wormwood

Me ₂NH: dimethylamine

MeNH ₂: methylamine

MeOH: methyl alcohol

MgSO ₄: sal epsom

MsOH: methylsulfonic acid

NaBH (OAc) ₃: sodium triacetoxy borohydride

NaBH ₃CN: sodium cyanoborohydride

NaBH ₄: sodium borohydride

NaHCO ₃: sodium bicarbonate

Pd/C: palladium on carbon

POCl ₃: phosphoryl chloride

PVP: poly-(4-vinylpridine)

SOCl ₂: thionyl chloride

TBME: t-butyl methyl ether

TFA: trifluoroacetic acid

THF: tetrahydrofuran (THF)

ZCI: benzyloxy carbonyl chloride

S: unimodal

D: bimodal

T: triplet

Q: quartet

Dd: two doublets

Dt: two triplets

Ddd: three doublets

Brs: wide unimodal

M: multiplet

J: coupling constant

Hz: hertz

Free: free.

Embodiment 1

N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride

Steps A: Synthetic 2,4-two chloro-quinoline.

With quinoline-2, (150g is 931mmol) at POCl for the 4-glycol ₃(975mL, 10.4mol) suspension returning in stirred 6 hours down, concentrated reaction mixture.With residue CHCl ₃(500mL) dilution is in this solution impouring frozen water.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (silica gel, the hexane solution of 20%EtOAc), obtains 2, and 4-two chloro-quinoline (177g, 96%) are the light brown solid.

EI?MS?m/e?197，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.50(s，1H)，7.65(ddd，J＝8.3，7.0，1.3Hz，1H)，7.79(ddd，J＝8.5，7.0，1.3Hz，1H)，8.00-8.06(m，1H)，8.16-8.21(m，1H).

Step B: synthetic (2-chloro-quinolyl-4)-methyl-amine.

To 2, (29.8g adds 40%MeNH in THF 150mmol) (300mL) solution to 4-two chloro-quinoline ₂Water (58.4g, 752mmol) solution.Under room temperature, stirred this mixture 12 days, concentrate then.Residue is suspended in CHCl ₃In water.Filter the collecting precipitation thing, use washing with acetone,, obtain (2-chloro-quinolyl-4)-methyl-amine (13.2g, 45%) in 50 ℃ of drying under reduced pressure, be colorless solid.

ESI?MS?m/e?215，M+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ2.91(d，J＝4.7Hz，3H)，6.35(s，1H)，7.47(ddd，J＝8.3，6.6，1.7Hz，1H)，7.62-7.75(m，3H)，8.16(d，J＝8.6Hz，1H).

Step C: synthetic (cis-4-benzyloxycarbonyl amino-cyclohexyl)-carboxylamine-benzyl ester.

To cis-hexanaphthene-I, the 4-dicarboxylic acid (25.0g, 145mmol) add in the suspension in benzene (125mL) phosphorazidic acid diphenyl (81.9g, 298mmol) and triethylamine (30.1g, 297mmol).This reaction mixture was stirred 2.5 hours under refluxing.(32.2g 298mmol), stirs this mixture 24 hours under refluxing to add benzyl alcohol.Concentrated reaction mixture is dissolved in EtOAc and the water residue.Separate organic layer, extract waterbearing stratum (twice) with EtOAc.With organic layer 1M aqueous potassium hydrogen sulfate, saturated sodium bicarbonate aqueous solution and the salt water washing that merges, through dried over mgso, filter, concentrate, through flash chromatography purifying (silica gel, the hexane solution of 33%EtOAc), obtain (cis-4-benzyloxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester (52.0g, 94%), be colorless oil.

ESI?MS?m/e?405，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.45-1.60(m，4H)，1.60-1.80(m，4H)，3.52-3.80(m，2H)，4.70-5.00(m，2H)，5.07(s，4H)，7.15-7.40(m，10H).

Step D: synthetic (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester.

(91.7g adds 5%Pd/C (9.17g) in MeOH 240mmol) (460mL) solution to (cis-4-benzyloxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester.Under room temperature, nitrogen atmosphere, stirred reaction mixture 2.5 days filters by Celite pad, concentrates and obtains diamines, is colorless oil.Be added dropwise to (Boc) with 4 hours in MeOH to described diamines (550mL) solution ₂O (6.59g, MeOH 30.2mmol) (80mL) solution.Stirred reaction mixture is 1.5 days under room temperature, concentrates then.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso, obtains (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (7.78g, 15%, crude product), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters and concentrates, and the diamines that obtains reclaiming (32.9g) is colorless oil.(32.9g was added dropwise to (Boc) in MeOH 288mmol) (660mL) solution to the diamines that reclaims with 5 hours ₂O (6.29g, MeOH 28.8mmol) (80mL) solution.Stirred reaction mixture is 10 hours under room temperature, concentrates then.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso, obtains (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (8.16g, 16%, crude product), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (23.1g) that obtains reclaiming, and is colorless oil.(23.1g was added dropwise to (Boc) in MeOH 202mmol) (462mL) solution to the diamines that reclaims with 4 hours ₂O (4.42g, MeOH 20.3mmol) (56mL) solution.Stirred reaction mixture is 3.5 days under room temperature, concentrates.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters also to concentrate, and obtains (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (5.01g, 10%, based on the starting raw material meter), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (16.0g) that obtains reclaiming, and is colorless oil.(16.0g was added dropwise to (Boc) in MeOH 140mmol) (320mL) solution to the diamines that reclaims with 4 hours ₂O (3.06g, MeOH 14.0mmol) (40mL) solution 4 hours.Stirred reaction mixture is 13 hours under room temperature, concentrates then.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso, obtains (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (3.53g, 7% based on the starting raw material meter), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (11.1g) that obtains reclaiming, and is colorless oil.

ESI?MS?m/e?215，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.20-1.80(m，8H)，1.44(s，9H)，2.78-2.95(m，1H)，3.50-3.80(m，1H)，4.30-4.82(m，1H).

Step e: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-quinoline-2, the 4-diamines.

In sealed tube, in 130 ℃, (2.00g, 10.4mmol) (2.45g, 11.4mmol) mixture in butanols (3mL) stirred 2 days with (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester with (2-chloro-quinolyl-4)-methyl-amine.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), obtains [cis-4-(4-methylamino-quinoline-2-base is amino)-cyclohexyl]-carboxylamine tertiary butyl ester (1.45g), be faint yellow oily thing.EtOAc (30mL) solution that in the EtOAc of above-mentioned substance (1.31g) (15mL) solution, adds 4M hydrogenchloride.Stirred reaction mixture is 5 hours under room temperature.Filter the collecting precipitation thing, it is dissolved in the saturated sodium bicarbonate aqueous solution.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso, obtains N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-quinoline-2,4-diamines (999mg, 40%) is faint yellow solid.

EI?MS?m/e?271M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.42-1.92(m，8H)，2.81(d，J＝4.7Hz，3H)，2.89-3.01(m，1H)，3.17(s，2H)，4.07(brs，1H)，5.77(s，1H)，6.32(d，J＝6.5Hz，1H)，6.69-6.80(m，1H)，6.94-7.06(m，1H)，7.34(d，J＝3.7Hz，2H)，7.85(d，J＝8.2Hz，1H).

Step F: synthetic 4-bromo-2-trifluoromethoxy-phenyl aldehyde.

With 4-bromo-1-iodo-2-trifluoromethoxy-benzene (1.00g, THF 2.72mmol) (15mL) solution is cooled to-78 ℃, be added dropwise to 2.66M BuLi hexane solution (2.05mL, 5.44mmol).In-78 ℃ of stirred reaction mixtures 1.5 hours, add the N-formyl morpholine (0.57mL, 5.63mmol).In-78 ℃ of stirred reaction mixtures 15 minutes, under room temperature, stirred 80 minutes.With 0.25M aqueous citric acid solution (10mL) quencher reactant, the mixture that obtains is extracted (3 times) with EtOAc.The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (silica gel, the hexane solution of 2%-5%EtOAc), obtains 4-bromo-2-trifluoromethoxy-phenyl aldehyde (560mg, 77%), is the light brown solid.

CI?MS?m/e?269，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.50-7.67(m，2H)，7.85(d，J＝8.1Hz，1H)，10.33(s，1H).

Step G: synthetic N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride.

To N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-quinoline-2, the 4-diamines (370mg, add in methyl alcohol 1.37mmol) (4mL) solution 4-bromo-2-trifluoromethoxy-phenyl aldehyde (368mg, 1.37mmol), acetate (82mg, 1.37mmol) and NaBH ₃CN (129mg, 2.05mmol).Stirred reaction mixture is 20 hours under room temperature.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through medium pressure liquid chromatography (NH-silica gel, the hexane solution of 20%EtOAc) and flash chromatography (silica gel, the CHCl of 5%MeOH ₃Solution) purifying obtains a kind of colorless oil.EtOAc (5mL) solution that in the EtOAc of above-mentioned oily matter solution (2mL), adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, concentrate then.Under room temperature with this residue at Et ₂Stirred 1 hour in the suspension of O (12mL).Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride (365mg, 45%) is white solid.

ESI?MS?m/e?523，M(free)+H ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.61-2.11(m，8H)，2.96(d，J＝4.4Hz，3H)，3.19-3.41(m，2H)，4.11-4.34(m，2H)，5.92(brs，1H)，7.40(t，J＝8.2Hz，1H)，7.63-7.79(m，3H)，7.93(d，J＝8.4Hz，1H)，8.22(d，J＝8.2Hz，1H)，8.30-8.48(m，2H)，9.59(brs，2H).

Embodiment 2

N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-quinoline 2,4-diamines dihydrochloride

Steps A: synthetic (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde.

(5.29g is 14.9mol) at Et to chlorination (methoxymethyl)-triphenyl phosphonium ₂The 30%Et that adds the 1.8M phenyl lithium in the suspension among the O (50mL) ₂The cyclohexane solution of O (8.58mL, 15.5mmol).Under room temperature, stirred this mixture 10 minutes.In reaction mixture, be added in the 4-bromo-2-trifluoromethoxy-phenyl aldehyde (4.00g, Et 14.9mmol) that obtain in the step F of embodiment 1 ₂O (18mL) solution.Under room temperature, stirred this mixture 4 hours, filter and concentrate.In above-mentioned residue, add 10% vitriolic AcOH (40mL) solution.Under room temperature, stirred this mixture 90 minutes.In this solution impouring water, with waterbearing stratum CHCl ₃Extract (3 times).With organic layer saturated sodium bicarbonate aqueous solution and the salt water washing that merges, through dried over mgso, filter, concentrate, through flash chromatography purifying (silica gel, the hexane solution of 9%EtOAc), obtain (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde (1.25g, 30%), is light brown oily thing.

ESI?MS?m/e?284，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ3.75(d，J＝1.5Hz，2H)，7.16(d，J＝8.4Hz，1H)，7.41-7.51(m，2H)，9.74(t，J＝1.5Hz，1H).

Step B: synthetic N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?537，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.62-2.06(m，8H)，2.96(d，J＝4.4Hz，3H)，3.04-3.39(m，5H)，4.17(brs，1H)，5.90(brs，1H)，7.40(t，J＝8.2Hz，1H)，7.52(d，J＝8.7Hz，1H)，7.57-7.85(m，3H)，8.20(d，J＝8.2Hz，1H)，8.26-8.47(m，2H)，9.23(brs，2H).

Embodiment 3

N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester.

(244g, 1.70mol) suspension in MeOH (2.45L) is cooled to-8 ℃ with cis-4-amino-hexahydrobenzoic acid.Be added dropwise to thionyl chloride (45.0mL, 617mmol).The solution that stirring generates under room temperature 4.5 hours concentrates and obtains white solid.To above-mentioned solid at CHCl ₃In the suspension (3.00L) order add triethylamine (261mL, 1.87mol) and (Boc) ₂O (409g, 1.87mol).Stirred reaction mixture is 5 hours under room temperature, then in the impouring water.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel, single CHCl through dried over mgso ₃CHCl to 10%MeOH ₃Solution), obtain colorless oil (531g).(78.3g is 2.06mol) at Et to the lithium aluminum hydride that is cooled to-4 ℃ ₂The Et that adds the above-mentioned oily matter (530.9g) below 0 ℃ in the suspension among the O (7.9L) ₂O (5.3L) solution.The suspension that stirring generates under room temperature 2 hours.This reaction mixture is cooled off on ice bath, use the cold water quencher, filter by Celite pad.Filtrate is filtered and is concentrated through dried over mgso.Throw out is suspended in the hexane (300mL), filters, use hexane wash, drying under reduced pressure obtains (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester (301g, 77%), is white solid.

ESI?MS?m/e?252，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.16-1.36(m，2H)，1.45(s，9H)，1.52-1.77(m，7H)，3.51(d，J＝6.2Hz，H)，3.75(brs，1H)，4.30-4.82(m，1H).

Step B: synthetic [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester.

To (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester (17.7g, in THF 77.2mmol) (245mL) solution order add triphenyl phosphine (20.2g, 77.0mmol) and phthalic imidine (11.4g, 77.5mmol).The suspension that generates is cooled off on ice bath, with the toluene (33.6mL, 74.1mmol) solution that added 40% azo-2-carboxylic acid's diethyl ester in 1 hour.Stirred reaction mixture is 2.5 days under room temperature, concentrates, through flash chromatography purifying (silica gel, the hexane solution of 33%EtOAc), obtains white solid.In the suspension of above-mentioned solid (27.5g) in EtOH (275mL), add hydrazine hydrate (5.76g, 115mmol).This mixture backflow was stirred 2.25 hours down, and cooling also concentrates.Residue is dissolved in 10% aqueous sodium hydroxide solution (350mL).With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.CHCl to above-mentioned residue ₃(275mL) add in the solution triethylamine (8.54g, 84.4mmol).The solution that generates is cooled to 0 ℃, add the ZCl that is lower than 5 ℃ (14.4g, 84.4mmol).Stirred reaction mixture is 16 hours under room temperature, in the impouring saturated sodium bicarbonate aqueous solution.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (silica gel, the CHCl of 2%MeOH ₃Solution), obtain [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester (25.3g, 91%), be colorless oil.

ESI?MS?m/e?385，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.13-1.31(m，2H)，1.44(s，9H)，1.48-1.75(m，7H)，3.10(t，J＝6.4Hz，2H)，3.72(brs，1H)，4.42-4.76(m，1H)，4.76-4.92(m，1H)，5.09(s，2H)，7.27-7.38(m，5H).

Step C: synthetic (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester.

To [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester (12.9g, EtOAc (129mL) solution of adding 4M hydrogenchloride in EtOAc 35.6mmol) (129mL) solution.Under room temperature stirred reaction mixture 3 hours, filtration, with the EtOAc washing, through drying under reduced pressure.This solid is dissolved in the saturated sodium bicarbonate aqueous solution.With water layer CHCl ₃Extract (5 times).The organic layer that merges filters, concentrates through dried over mgso, and drying under reduced pressure obtains (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (8.88g, 95%), is colorless oil.

ESI?MS?m/e?263，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.36-1.98(m，9H)，2.96-3.32(m，3H)，5.12(brs，3H)，7.36(s，5H).

Step D: synthetic [cis-4-(4-methylamino-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

In 130 ℃, in sealed tube, (2.00g, 10.4mmol) (3.27g, 12.5mmol) mixture in butanols (3mL) stirred 16 hours (the 2-chloro-quinolyl-4)-methyl-amine that obtains among the step B with embodiment 1 with (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel, the CHCl of 10%MeOH through dried over mgso ₃Solution), obtain [cis-4-(4-methylamino-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine-benzyl ester (2.16g, 49%), be white solid.

ESI?MS?m/e?419，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.42-1.99(m，9H)，3.05(d，J＝4.7Hz，3H)，3.08-3.16(m，2H)，3.81(brs，1H)，5.07(s，2H)，5.18-5.28(m，1H)，5.34(s，1H)，7.07-7.18(m，1H)，7.22-7.45(m，6H)，7.56-7.70(m，1H)，8.16(d，J＝8.4Hz，1H)，8.23(d，J＝7.6Hz，1H)，12.76(brs，1H).

Step e: synthetic N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride.

To [cis-4-(4-methylamino-quinoline-2-base is amino)-cyclohexyl methyl]-(2.02g adds 10%Pd/C (202mg) in MeOH 4.83mmol) (20mL) solution to carboxylamine-benzyl ester.Under 50 ℃, nitrogen atmosphere, this mixture was stirred 23.5 hours.Reaction mixture is filtered and concentrates by Celite pad.In methyl alcohol (5mL) solution of described residue (500mg), be added in 4-bromo-2-trifluoromethoxy-phenyl aldehyde of obtaining in the step F of embodiment 1 (497mg, 1.85mmol), acetate (111mg, 1.85mmol) and NaBH ₃CN (166mg, 2.64mmol).Stirred reaction mixture is 23 hours under room temperature.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through medium pressure liquid chromatography (NH-silica gel, the hexane solution of 50%EtOAc) and flash chromatography (silica gel, the CHCl of 2%-50%MeOH ₃Solution) purifying obtains a kind of colorless oil.EtOAc (5mL) solution that in the EtOAc of above-mentioned oily matter solution (2mL), adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Under room temperature, with this residue at Et ₂Suspension among the O (12mL) stirred 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-quinoline-2,4-diamines dihydrochloride (147mg, 14%) is white solid.

ESI?MS?m/e?537，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.34-2.15(m，9H)，2.63-3.08(m，5H)，3.41-3.88(m，1H)，4.28(s，2H)，7.00-7.62(m，6H)，7.65-8.38(m，3H)，10.01(brs，2H)，11.76(brs，1H).

Embodiment 4

N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-quinoline-2,4-diamines dihydrochloride.

The N that in embodiment 3 step e, obtains ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-quinoline-2, (250mg adds 10%Pd/C (75mg) in EtOH 0.465mmol) (2.5mL) solution to the 4-diamines.Under room temperature, nitrogen atmosphere, stirred this mixture 15 hours.Reaction mixture is filtered by Celite pad,, obtain a kind of colorless oil through flash chromatography purifying (NH-silica gel, the hexane solution of 50%EtOAc).EtOAc (5mL) solution that in the EtOAc of above-mentioned oily matter solution (2mL), adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Make described residue be suspended in Et ₂Among the O (10mL), under room temperature, stirred 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-quinoline-2,4-diamines dihydrochloride (114mg, 46%) is white solid.

ESI?MS?m/e?459，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.46-2.09(m，9H)，2.84(brs，3H)，2.92(brs，2H)，3.60-3.82(m，1H)，4.32(s，2H)，7.05-7.49(m，6H)，7.88(d，J＝7.8Hz，1H)，8.11-8.35(m，2H)，9.91(brs，2H)，11.83(s，1H).

Embodiment 5

N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic (2-chloro-quinolyl-4)-dimethyl-amine.

To 2,4-two chloro-quinoline (177g, the Me of adding 50% in THF 894mmol) (2.1L) solution ₂The NH aqueous solution (234mL, 2.23mol).Under room temperature, stirred this mixture 68 hours.In mixture, add 50%Me ₂(47mL 448mmol), stirred 3 hours under room temperature the aqueous solution of NH.This solution is poured in the saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 1%-3%EtOAc), obtain (2-chloro-quinolyl-4)-dimethyl-amine (75.9g for faint yellow oily thing, 41%) and be (the 4-chloro-quinoline-2-yl)-dimethyl-amine (28.0g, 15%) of faint yellow oily thing.

(2-chloro-quinolyl-4)-dimethyl-amine;

ESI MS m/e 207, M+H ^{+ 1}H NMR (300MHz, CDCl ₃) δ 3.06 (s, 6H), 6.71 (s, 1H), 7.45 (ddd, J=8.4,7.0,1.2Hz, 1H), 7.63 (ddd, J=8.4,6.9,1.5Hz, 1H), 7.91-7.93 (m, 1H), 7.97-8.03 (m, 1H). (4-chloro-quinoline-2-yl)-dimethyl-amine;

ESI?MS?m/e?229，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.18(s，6H)，6.97(brs，1H)，7.18-7.31(m，1H)，7.49-7.63(m，1H)，7.66-7.72(m，1H)，7.95-8.00(m，1H).

Step B: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines.

Adopt the method for the step e of embodiment 1, obtain title compound.

FAB?MS?m/e?285，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.12-2.00(m，9H)，2.81-2.98(m，1H)，2.93(s，6H)，4.09(brs，1H)，4.75(d，J＝7.9Hz，1H)，6.03(s，1H)，7.14(ddd，J＝8.2，6.7，1.3Hz，1H)，7.45(ddd，J＝8.4，6.8，1.5Hz，1H)，7.62(m，1H)，7.84(dd，J＝8.4，1.3Hz，1H).

Step C: synthetic N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴Diformazan yl-quinoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?537，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.73-2.36(m，10H)，3.05-3.31(m，2H)，3.20(s，6H)，4.32(s，2H)，7.30-7.62(m，5H)，7.86(d，J＝8.6Hz，1H)，8.21(d，J＝8.4Hz，1H)，8.53-8.64(m，1H)，13.04(brs，1H).

Embodiment 6

N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴Diformazan yl-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴Diformazan yl-quinoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?551，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.69-2.40(m，10H)，3.11-3.46(m，10H)，7.26-7.49(m，5H)，7.59(t，J＝7.3Hz，1H)，7.86(d，J＝7.5Hz，1H)，8.53-8.70(m，1H)，9.75-10.14(m，2H)，13.05(brs，1H).

Embodiment 7

N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

(the 2-chloro-quinolyl-4)-dimethyl-amine (23.6g that obtains in the steps A with embodiment 5,114mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester that obtains among the step C of embodiment 3 (36.0g, the 137mmol) stirring down 14 days that refluxes of the mixture in butanols (31mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 14%-66%EtOAc), obtain [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester (19.3g, 39%), is faint yellow solid.

ESI?MS?m/e?433，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.12-1.97(m，9H)，2.94(s，6H)，3.13(t，J＝6.4Hz，2H)，4.06-4.26(m，1H)，4.62-4.94(m，2H)，5.11(s，2H)，6.04(s，1H)，7.14(ddd，J＝8.4，7.0，1.3Hz，1H)，7.29-7.40(m，5H)，7.45(ddd，J＝8.4，6.8，1.5Hz，1H)，7.57-7.64(m，1H)，7.84(dd，J＝8.4，1.3Hz，1H).

Step B: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines.

To [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-(19.3g adds 5%Pd/C (1.93g) in MeOH 44.6mmol) (200mL) solution to the carboxylamine benzyl ester.Under room temperature, nitrogen atmosphere, stirred this mixture 6 days.Reaction mixture is filtered and concentrates by Celite pad.In methyl alcohol (200mL) solution of described residue, add 10%Pd/C (1.93g).Stirred this mixture 1 under room temperature, nitrogen atmosphere, reaction mixture filters by Celite pad, concentrates, through flash chromatography purifying (silica gel, the CHCl of 5%-14%7MNH3/MeOH ₃Solution), obtain N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines (12.7g, 95%) is faint yellow solid.

FAB?MS?m/e?299，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.08-1.99(m，11H)，2.60(d，J＝6.2Hz，2H)，2.94(s，6H)，4.04-4.22(m，1H)，4.77-4.93(m，1H)，6.06(s，1H)，7.14(ddd，J＝8.4，7.0，1.3Hz，1H)，7.45(ddd，J＝8.4，6.8，1.5Hz，1H)，7.61(m，1H)，7.84(dd，J＝8.4，1.3Hz，1H).

Step C: synthetic N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴, N ⁴Diformazan yl-quinoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?551，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.50-2.20(m，9H)，2.89(s，2H)，3.20(s，6H)，3.75-4.02(m，1H)，4.23(s，2H)，7.22-7.32(m，2H)，7.40-7.46(m，1H)，7.49-7.62(m，2H)，7.83(d，J＝8.7Hz，1H)，8.17(d，J＝8.4Hz，1H)，8.53-8.69(m，1H)，10.05(brs，2H)，13.00(brs，1H).

Embodiment 8

N ⁴, N ⁴Dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-quinoline-2,4-diamines dihydrochloride

Steps A: synthetic N ⁴, N ⁴-dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-quinoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?473，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.54-2.20(m，9H)，2.87(brs，2H)，3.19(s，6H)，3.70-4.03(m，1H)，4.28(brs，2H)，7.15-7.67(m，6H)，7.81(d，J＝8.4Hz，1H)，8.17(d，J＝7.3Hz，1H)，8.63(brs，1H)，9.92(brs，1H)，13.13(s，1H).

Embodiment 9

N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl) amino-cyclohexyl]-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthesize 5,6,7,8-tetrahydrochysene-quinazoline-2,4-glycol.

To 2-oxo-hexahydrobenzoic acid ethyl ester (61.5g, add in EtOH 361mmol) (61.5mL) solution urea (73.8g, 1.23mol).This mixture backflow was stirred 10.5 days down, under room temperature, stirred 30 minutes.Filtering-depositing is with washing with acetone and dry.The suspension of above-mentioned solid in water (100mL) was stirred on ice bath 1 hour.Filtering-depositing is used hexane wash, and drying under reduced pressure obtains 5,6,7,8-tetrahydrochysene-quinazoline-2, and 4-glycol (21.0g, 35%) is faint yellow solid.

CI?MS?m/e?167，M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.48-1，71(m，4H)，2.09-2.19(m，2H)，2.24-2.34(m，2H)，10.41-10.98(m，2H).

Step B: Synthetic 2,4-two chloro-5,6,7,8-tetrahydrochysene-quinazoline.

Adopt the method for the steps A of embodiment 1, obtain title compound.

ESI?MS?m/e?203，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.83-1.94(m，4H)，2.67-2.79(m，2H)，2.84-2.95(m，2H).

Step C: synthetic (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-methyl-amine.

Step C: synthetic (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-methyl-amine.

To 2,4-two chloro-5,6,7, (8.70g adds 40%MeNH in THF 42.8mmo1) (87mL) solution to 8-tetrahydrochysene-quinazoline ₂The aqueous solution (8.32g, 107mmol).Under room temperature, stirred this mixture 8 hours.In this solution impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso,, obtains (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-methyl-amine (7.04g, 83%) through flash chromatography purifying (NH-silica gel, the hexane solution of 50%EtOAc), is white solid.

ESI?MS?m/e?220，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.74-1.92(m，4H)，2.26(t，J＝5.5Hz，2H)，2.67(t，J＝5.6Hz，2H)，3.05(d，J＝5.0Hz，3H)，4.81(s，1H).

Step D: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines.

Adopt the method for the step e of embodiment 1, obtain title compound.

ESI?MS?m/e?276，M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.33-1.76(m，12H)，2.11-2.21(m，2H)，2.31-2.40(m，2H)，2.70-2.77(m，2H)，2.78(d，J＝4.5Hz，3H)，3.71-3.83(m，1H)，5.50-5.63(m，1H)，6.10-6.22(m，1H).

Step e: synthetic N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?528，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.24(m，12H)，2.41-2.56(m，4H)，3.00(d，J＝4.5Hz，3H)，3.04(brs，1H)，4.03(brs，1H)，4.30(brs，2H)，7.45-7.48(m，1H)，7.52(dd，J＝8.3，1.8Hz，1H)，7.61(d，J＝5.8Hz，1H)，7.74(brs，1H)，8.14(d，J＝8.2Hz，1H)，11.84(brs，1H).

Embodiment 10

N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?542，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.25(m，12H)，2.35-2.60(m，4H)，2.94-3.28(m，6H)，3.32-3.45(m，2H)，4.13(brs，1H)，7.30-7.51(m，4H)，7.72(d，J＝6.2Hz，1H)，9.86(brs，2H)11.90(s，1H).

Embodiment 11

N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-methylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

In 130 ℃, in sealed tube, (the 2-chloro-5 that obtains among the step C with embodiment 9,6,7,8-tetrahydrochysene-quinazoline-4-yl)-methyl-amine (2.00g, 10.1mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester that obtains among the step C of embodiment 3 (3.19g, 12.2mmol) mixture in butanols (3mL) stirred 16 hours.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel, the CHCl of 10%MeOH through dried over mgso ₃Solution), obtain [cis-4-(4-methylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester (1.38g, 32%), be faint yellow oily thing.

ESI?MS?m/e?424，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.31-2.02(m，13H)，2.22-2.34(m，2H)，2.52-2.64(m，2H)，3.05(d，J＝4.8Hz，3H)，3.11(t，J＝6.1Hz，2H)，5.05-5.23(m，1H)，5.08(s，2H)，6.34-6.47(m，1H)，7.23-7.42(m，5H)，7.99(d，J＝7.3Hz，1H)，12.34(brs，1H).

Step B: synthetic N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴-methyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Adopt the method for the step e of embodiment 3, obtain title compound.

ESI?MS?m/e?542，M(free)+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.50-2.19(m，13H)，2.58-2.61(m，2H)，2.72-2.91(m，2H)，2.83-2.97(m，2H)，3.24(s，6H)，4.15-4.20(m，1H)，4.22-4.38(m，2H)，7.43-7.50(m，1H)，7.56-7.61(m，1H)，8.18-8.29(m，2H)，10.06(brs，2H)，12.30(brs，1H).

Embodiment 12

N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic N ⁴-methyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?464，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.28-2.04(m，15H)，2.14-2.30(m，2H)，2.83-2.95(m，2H)，2.91(d，J＝4.5Hz，3H)，4.13(brs，1H)，4.22(brs，2H)，7.43-7.62(m，3H)，7.91(dd，J＝7.5，1.6Hz，1H)，8.09(d，J＝6.7Hz，2H)，9.37(brs，2H)，12.30-12.70(m，1H).

Embodiment 13

N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-dimethyl-amine.

To 2,4-two chloro-5,6,7, (7.00g adds 50%MeNH in THF 34.5mmol) (70mL) solution to 8-tetrahydrochysene-quinazoline ₂The aqueous solution (7.77g, 86.2mmol).Under room temperature, stirred this mixture 2.25 hours.In this solution impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso,, obtains (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-dimethyl-amine (6.08g, 83%) through flash chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), is white solid.

ESI?MS?m/e234，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-1.90(m，4H)，2.59(t，J＝6.0Hz，2H)，2.76(t，J＝6.6Hz，2H)，3.06(s，6H).

Step B: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines.

Adopt the method for the step e of embodiment 1, obtain title compound.

FAB?MS?m/e?290，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ0.95-1.94(m，14H)，2.49(t，J＝5.9Hz，2H)，2.61(t，J＝7.0Hz，2H)，2.72-2.94(m，1H)，2.94(s，6H)，3.89-4.11(m，1H)，4.73(d，J＝7.5Hz，1H).

Step C: synthetic N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines-dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?542，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.32(m，12H)，2.52-2.60(m，2H)，2.63-2.72(m，2H)，3.11-3.24(m，7H)，4.12-4.23(m，1H)，4.28(s，2H)，7.41(d，J＝10.4Hz，1H)，7.49(dd，J＝8.2，1.9Hz，1H)，8.19(d，J＝8.4Hz，1H)，8.25(d，J＝8.1Hz，1H)，10.02(brs，1H)，12.43(brs，1H).

Embodiment 14

N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl) ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines-dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?556，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.32(m，12H)，2.56(t，J＝5.8Hz，2H)，2.69(t，J＝6.2Hz，2H)，3.14-3.41(m，9H)，4.13-4.25(m，1H)，7.35-7.44(m，2H)，7.49-7.55(m，1H)，8.20(d，J＝7.8Hz，1H).

Embodiment 15

N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

Adopt the method for the steps A of embodiment 11, obtain title compound.

ESI?MS?m/e?438，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.18-1.39(m，2H)，1.48-1.94(m，11H)，2.49(t，J＝5.9Hz，2H)，2.60(t，J＝6.6Hz，2H)，2.94(s，6H)，3.09(t，J＝6.1Hz，2H)，4.01-4.13(m，1H)，4.70-4.91(m，2H)，5.09(s，2H)，7.27-7.39(m，5H).

Step B: synthetic N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Adopt the method for the step e of embodiment 3, obtain title compound.

ESI?MS?m/e?556，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.46-2.17(m，12H)，2.55(t，J＝5.8Hz，2H)，2.69(t，J＝6.1Hz，2H)，2.79-2.92(m，2H)，3.20(s，6H)，4.08-4.18(m，1H)，4.20-4.31(m，2H)，7.43-7.47(m，1H)，7.53(dd，J＝8.4，1.9Hz，1H)，8.16(d，J＝7.8Hz，1H)，8.22(d，J＝8.4Hz，1H)，10.02(brs，2H)，12.28(brs，1H).

Embodiment 16

N ⁴, N ⁴Dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride

Steps A: synthetic N ⁴, N ⁴-dimethyl-N ²-cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?478，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.48-2.15(m，13H)，2.55(t，J＝5.4Hz，2H)，2.71(t，J＝6，2Hz，2H)，2.77-2.89(m，2H)，3.19(s，6H)，4.10(brs，1H)，4.26-4.37(m，2H)，7.27-7.34(m，1H)，7.36-7.47(m，2H)，8.15-8.25(m，2H)，9.90(s，2H)，12.52(s，1H).

Embodiment 17

N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carboxylamine tertiary butyl ester.

(cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (6.72g, CHCl 31.4mmol) that in the step D of embodiment 1, obtain ₃(67mL) be added in the solution 4-bromo-2-trifluoromethoxy-phenyl aldehyde of obtaining in the step F of embodiment 1 (8.44g, 31.4mmol), acetate (1.88g, 31.3mmol) and NaBH (OAc) ₃(9.97g, 47.0mmol).Stirred reaction mixture is 4 hours under room temperature.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel through dried over mgso, the hexane solution of 33%EtOAc), obtain [cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carboxylamine tertiary butyl ester (10.28g, 70%), be faint yellow oily thing.

ESI?MS?m/e?467，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.16-1.78(m，17H)，2.57-2.70(m，1H)，3.62(brs，1H)，3.78(s，2H)，4.60(brs，1H)，7.34-7.54(m，3H).

Step B: synthetic (2-chloro-pyrimidine-4-yl)-dimethyl-amine.

To 2, (15.0g adds 50%MeNH in THF 10.15mmol) (150mL) solution to 4-two chloro-pyrimidines ₂The aqueous solution (22.7g, 25.2mmol).Under room temperature, stirred this mixture 2 hours.In this solution impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), obtain (2-chloro-pyrimidine-4-yl)-dimethyl-amine (8.66g for white solid, 55%) and be (the 4-chloro-pyrimidine-2-base)-dimethyl-amine (0.87g, 6%) of white solid.

(2-chloro-pyrimidine-4-yl)-dimethyl-amine;

CI?MS?m/e?158，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.12(s，6H)，6.32(d，J＝6.1Hz，1H)，8.00(d，J＝6.1Hz，1H).

(4-chloro-pyrimidine-2-base)-dimethyl-amine;

ESI?MS?m/e?157，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.21(s，6H)，6.50(d，J＝5.1Hz，1H)，8.18(d，J＝5.1Hz，1H).

Step C: synthetic N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines dihydrochloride.

To [cis-4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-carboxylamine tertiary butyl ester (3.00g, EtOAc (60mL) solution of adding 4M hydrogenchloride in EtOAc 6.42mmol) (30mL) solution.Stirred reaction mixture is 1 hour under room temperature, concentrates then.Described residue is alkalized with saturated sodium bicarbonate aqueous solution.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.In 130 ℃, in sealed tube, (466mg, 1.27mmol) (200mg 1.27mmol) stirred 13.5 hours in butanols (ImL) with (2-chloro-pyrimidine-4-yl)-dimethyl-amine with above-mentioned substance.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), obtains a kind of colorless oil.EtOAc (5mL) solution that in the EtOAc of above-mentioned oily matter solution (2mL), adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, concentrate then.With described residue at Et ₂Suspension among the O (12mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N ²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines dihydrochloride (180mg, 25%) is white solid.

ESI?MS?m/e?488，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.54-1.72(m，2H)，2.01-2.29(m，6H)，3.02(brs，1H)，3.16(s，3H)，3.24(s，3H)，4.13(brs，1H)，4.30(s，2H)，6.02(d，J＝7.5Hz，1H)，7.40-7.43(m，1H)，7.50(dd，J＝8.4，1.9Hz，1H)，7.99(d，J＝7.3Hz，1H)，8.26(d，J＝8.4Hz，1H)，8.57(d，J＝7.0Hz，1H)，10.25(s，2H).

Embodiment 18

N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

In 130 ℃, in sealed tube, (the 2-chloro-pyrimidine-4-yl)-dimethyl-amine (1.50g that obtains among the step B with embodiment 17,9.52mmol) and the step D of embodiment 1 in (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester of obtaining (2.24g, 10.5mmol) mixture in IPA (1.5mL) stirred 22 hours.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through medium pressure liquid chromatography purifying (NH-silica gel through dried over mgso, the hexane solution of 10%EtOAc), obtain [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (1.34g, 42%), be white solid.

ESI?MS?m/e?358，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.45(s，9H)，1.48(s，8H)，3.03(s，6H)，3.61(brs，1H)，3.89-4.04(m，1H)，4.47-4.63(m，1H)，4.77-4.89(m，1H)，5.80(d，J＝6.1Hz，1H)，7.84(d，J＝6.1Hz，1H).

Step B: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

To [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (1.26g, EtOAc (15mL) solution of adding 4M hydrogenchloride in EtOAc 3.76mmol) (15mL) solution.Under room temperature stirred reaction mixture l hour, concentrate then.Described residue is alkalized with the 1M NaOH aqueous solution.With waterbearing stratum CHCl ₃Extract (6 times).The organic layer that merges filters and concentrates through dried over mgso, obtains N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, (923mg quantitatively), is faint yellow oily thing to the 4-diamines.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.29-1.51(m，2H)，1.61-1.91(m，6H)，2.80-2.92(m，1H)，3.03(s，6H)，3.96-4.04(m，1H)，4.85-4.98(m，1H)，5.79(d，J＝6.1Hz，1H)，7.84(d，J＝6.1Hz，1H).

Step C: synthetic N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?502，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-1.82(m，2H)，1.97-2.44(m，6H)，3.16(s，3H)，3.14-3.31(m，1H)，3.25(s，3H)，3.34-3.46(m，2H)，4.18(brs，1H)，6.02(d，J＝6.8Hz，1H)，7.34-7.43(m，2H)，7.45-7.52(m，1H)，7.85-7.97(m，1H)，8.49-859(m，1H)，9.95(brs，2H)，12.42(brs，1H).

Embodiment 19

N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴, N ⁴Dimethyl-pyrimidine-2,4-diamines dihydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

In 130 ℃, in sealed tube, (the 2-chloro-pyrimidine-4-yl)-dimethyl-amine (1.50g that obtains among the step B with embodiment 17,9.52mmol) and cis-(4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (2.75g, 10.5mmol) mixture in IPA (1.5mL) stirred 22 hours.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 10%EtOAc-EtOAc), obtain [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl ester (816mg, 22%), is faint yellow oily thing.

ESI?MS?m/e?406，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.22-1.92(m，9H)，3.03(s，6H)，3.11(t，J＝6.2Hz，2H)，4.02-4.15(m，1H)，4.82-4.93(m，2H)，5.10(s，2H)，5.79(d，J＝6.1Hz，1H)，7.28-7.42(m，5H)，7.83(d，J＝6.1Hz，1H).

Step B: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Adopt the method for the step B of embodiment 7, obtain title compound.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.40-1.88(m，9H)，2.87(d，J＝5.9Hz，2H)，3.03(s，6H)，4.11(brs，1H)，5.63(brs，1H)，5.78(d，J＝6.2Hz，1H)，7.08(brs，2H)，7.82(d，J＝6.2Hz，1H).

Step C: synthetic N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl }-N ⁴, N ⁴Dimethyl-pyrimidine-2,4-diamines dihydrochloride.

Use the method for the step G of embodiment 1, obtain title compound.

ESI?MS?m/e?502，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.52-2.21(m，9H)，2.85(d，J＝5.8Hz，2H)，3.16(s，3H)，3.24(s，3H)，4.15-430(m，3H)，6.00(d，J＝7.6Hz，1H)，7.43-7.47(m，1H)，7.53(dd，J＝8.3，1.9Hz，1H)，7.66(d，J＝7.5Hz，1H)，8.20(d，J＝8.4Hz，1H)，8.53(d，J＝7.5Hz，1H)，10.07(brs，2H).

Embodiment 20-672

Under room temperature, in methylene dichloride (the 200 μ L) solution of poly-(4-vinylpridine) (75 μ L), add methylene dichloride (the 200 μ L) solution of amine as follows (30 μ mol) and methylene dichloride (the 200 μ L) solution of acyl chlorides (60 μ mol).After uniform temp stirs 19 hours down, filter reaction mixture, the drying nitrogen gas stream concentrates.In residue, add anhydrous methylene chloride (700 μ L) and PSA (300 μ L).After stirring 14 hours under the room temperature, reaction mixture obtains required product through silica gel column chromatography purifying (NH-silica gel, the hexane solution of 50%EtOAc is to single EtOAc).Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴Dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment 673-1084

Under room temperature, in methylene dichloride (the 400 μ L) solution of 1-cyclohexyl-3-methylated polystyrene-carbodiimide (150 μ L), add methylene dichloride (the 200 μ L) solution of amine (30 μ mol) as follows and methylene dichloride (the 200 μ L) solution of carboxylic acid (60 μ mol).Stirred 20 hours down in uniform temp, by NH-filtered through silica gel reaction mixture, the drying nitrogen gas stream concentrates, through silica gel column chromatography purifying (silica gel, 2%-7%2M NH ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment 1085-1446

-method A-

Under room temperature, in the MeOH of amine as follows (36 μ mol) (200 μ L) solution, add MeOH (200 μ L) and AcOH (the 90 μ mol) solution of aromatic aldehyde (30 μ mol).Stirred reaction mixture is 1 hour under identical temperature.In mixture, add NaBH ₃MeOH (the 200 μ L) solution of CN (120 μ mol).After uniform temp stirs 20 down, flow down concentrated reaction mixture in drying nitrogen.Make residue be allocated in CHCl ₃And between the 2M aqueous sodium hydroxide solution.With waterbearing stratum CHCl ₃Extract (500 μ L) and EtOAc (300 μ L).The organic layer that merges is through dried over mgso, and the drying nitrogen gas stream concentrates, through silica gel column chromatography purifying (silica gel, 2%-7%2M NH ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

-method B-

Under room temperature, in the MeOH of amine as follows (36 μ mol) (200 μ L) solution, add MeOH (200 μ L) solution, AcOH (90 μ mol) and the NaBH of aliphatic aldehyde (30 μ mol) ₃MeOH (the 200 μ L) solution of CN (120 μ mol).After uniform temp stirs 20 hours down, flow down concentrated reaction mixture in drying nitrogen.Make residue be allocated in CHCl ₃And between the 2M aqueous sodium hydroxide solution.With waterbearing stratum CHCl ₃(500 μ L) and EtOAc (300 μ L) extract.The organic layer that merges is through dried over mgso, and the drying nitrogen gas stream concentrates, through silica gel column chromatography purifying (silica gel, 2%-7%2M NH ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴Dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴Dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment 1457-1462,1478-1480,1491-1497 and 1510-1512

THF (300 μ l, the 300 μ mol) solution that in the THF of amide product (200 μ L) solution, adds 1M borine-THF mixture.Stirred these mixtures 1 hour in 80 ℃, the drying nitrogen gas stream concentrates.In residue, add the 1M HCl aqueous solution (300 μ l) and THF (200 μ l).Stirred these mixtures 1 hour in 80 ℃, the drying nitrogen gas stream concentrates.Make residue be allocated in CHCl ₃And between the 2M aqueous sodium hydroxide solution.With waterbearing stratum CHCl ₃(300 μ L, twice) and EtOAc (300 μ L) extract.The organic layer that merges is through dried over mgso, and the drying nitrogen gas stream concentrates, then through silica gel column chromatography purifying (silica gel, 2%-7%2M NH ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

Embodiment 1447-1456,1463-1477,1481-1490,1498-1509 and 1513-1538

Add alcohol (35 μ mol) solution in methylene dichloride (200 μ L) in methylene dichloride (the 200 μ L) suspension of Dess-Martin periodinane (63 μ mol), stirred reaction mixture is 18 hours under identical temperature.The MeOH (200 μ L) and AcOH (the 90 μ L) solution that in reaction mixture, add amine (36 μ mol) as follows.Under identical temperature, stirred the mixture 1 hour, and added NaBH then ₃MeOH (the 200 μ L) solution of CN (120 μ mol).Stirred 17 hours down in uniform temp, flow down concentrated reaction mixture in drying nitrogen.Make residue be allocated in CHCl ₃And between the 2M aqueous sodium hydroxide solution.With waterbearing stratum CHCl ₃(500mL) and EtOAc (300 μ L) extract.The organic layer that merges is through dried over mgso, and the drying nitrogen gas stream concentrates, through silica gel column chromatography purifying (silica gel, 2%-7%2M NH ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment 1539-1658

Under room temperature, in methylene dichloride (the 200 μ L) solution of poly-(4-vinylpridine) (75 μ L), add the methylene dichloride (200 μ L) of amine (30 μ mol) as follows and methylene dichloride (the 200 μ L) solution of chloro-formic ester (chloroformate) (60 μ mol).Stirred 17 hours down in uniform temp, filter reaction mixture, the drying nitrogen gas stream concentrates.In residue, add methylene dichloride (700 μ L) and PSA (300 μ L).After stirring 19 hours under the room temperature, filter reaction mixture, (NH-silica gel, the hexane solution of 20%EtOAc is to single EtOAc, and silica gel, 2%-7%2M NH through the silica gel column chromatography purifying ₃The CHCl of/MeOH ₃Solution), obtain required product.Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴Diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment 1659-2496

Under room temperature, in the DMSO of amine as follows (30 μ mol) (300 μ L) solution, add DMSO (the 200 μ L) solution of isocyanic ester or lsothiocyanates (60 μ mol).Under identical temperature, stirred the mixture 22 hours.Under room temperature, in reaction mixture, add 2MMeNH ₂THF (30 μ L, 60 μ mol) or DMSO (the 200 μ L) solution of D-glycosamine (gulcamine) (60 μ mol).Stirred 20 hours down in uniform temp, reaction mixture is filtered by SCX, the drying nitrogen gas stream concentrates, through silica gel column chromatography (silica gel, 2%-10%2MNH ₃The CHCl of/MeOH ₃Solution) and silica gel column chromatography (NH-silica gel, the hexane solution of 33%-50%EtOAc) purifying, obtain required product.Measure product by ESI-MS or APCI-MS.

Wherein said amine is selected from

The N that obtains among the step B of embodiment 5 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 7 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines, the N that obtains among the step B of embodiment 13 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains by the intermediate of the step B of embodiment 15 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines, the N that obtains among the step B of embodiment 18 ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines, or the N that obtains among the step B of embodiment 19 ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Embodiment number	The compound title	MS	Classification
				20	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-methoxy benzamide	419(M+H)	2
21	3-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	467(M+H)	1
				22	4-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	467(M+H)	2
23	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide	431(M+H)	1
				24	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	423(M+H)	1
25	4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	423(M+H)	1
				26	(2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-Phenyl Acrylamide	415(M+H)	3
27	4-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-nitrobenzamide	468(M+H)	1
				28	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	437(M+H)	3

29	3-cyano group-N-(cis [{ [4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	414(M+H)	2
				30	3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	457(M+H)	2
31	3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	457(M+H)	1
				32	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide	479(M+H)	2
33	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide	425(M+H)	1
				34	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide	425(M+H)	2
35	2-(2, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	463(M+H)	3
				36	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(ethylmercapto group) niacinamide	450(M+H)	3
37	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	407(M+H)	1
				38	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide	475(M+H)	2
39	2,4-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 5-fluoro benzamide	475(M+H)	3
				40	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) hexanamide	383(M+H)	3
41	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-phenyl-iodide methane amide	515(M+H)	3
				42	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(methylthio group) niacinamide	436(M+H)	3
43	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-methyl-3-nitro benzamide	448(M+H)	2
				44	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-nitrobenzamide	434(M+H)	1

45	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-phenyl-acetamides	403(M+H)	3
				46	(2R)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenyl cyclopropane carboxamide	429(M+H)	3
47	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide	433(M+H)	3
				48	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group butyramide	447(M+H)	1
49	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group propionic acid amide	433(M+H)	1
				50	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	403(M+H)	1
51	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	403(M+H)	3
				52	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	395(M+H)	3
53	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-thienyl) ethanamide	409(M+H)	3
				54	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide	473(M+H)	2
55	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) the carboxylamine benzyl ester	419(M+H)	3
				56	The 4-nitrobenzyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	464(M+H)	3
57	4-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	481(M+H)	1
				58	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-phenyl-iodide methane amide	515(M+H)	2
59	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-fluoro benzamide	441(M+H)	3
				60	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,3-two fluoro-4-methyl benzamides	439(M+H)	3

61	2-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	441(M+H)		3
					62	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	459(M+H)		2
63	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(thiophenyl) ethanamide	435(M+H)		3
					64	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-fluoro-3-(trifluoromethyl) benzamide	475(M+H)		3
65	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-fluoro-5-(trifluoromethyl) benzamide	475(M+H)		3
					66	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-phenylbutanamides	431(M+H)		3
67	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(3-p-methoxy-phenyl) ethanamide	433(M+H)		3
					68	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-fluoro phenyl) ethanamide	421(M+H)		3
69	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-p-methoxy-phenyl) ethanamide	433(M+H)		3
					70	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furoamide	461(M+H)		3
71	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,5-dimethyl-3-furoamide	407(M+H)		1
					72	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-ethoxy benzamide	433(M+H)		3
73	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	441(M+H)		1
					74	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide	421(M+H)		2
75	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	395(M+H)		3
					76	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide	449(M+H)		1

77	4-cyano group-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide		414(M+H)	3
					78	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide		525(M+H)	2
79	(2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(4-nitrophenyl) acrylamide		460(M+H)	3
					80	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide		481(M+H)	3
81	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide		421(M+H)	1
					82	The 2-[(difluoromethyl) sulfo-]-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide		471(M+H)	3
83	2, and 5-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-3-methane amide		463(M+H)	2
					84	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide		464(M+H)	3
85	1-benzyl-3-the tertiary butyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide		525(M+H)	3
					86	The 3-tertiary butyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-methyl isophthalic acid H-pyrazoles-5-methane amide		449(M+H)	3
87	(2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-methyl-3-Phenyl Acrylamide		429(M+H)	3
					88	5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) niacinamide		468(M+H)	3
89	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1-naphthyl) ethanamide		453(M+H)	3
					90	The 1-tertiary butyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl isophthalic acid H-pyrazole-3-formamide		449(M+H)	3
91	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-thionaphthene-3-methane amide		445(M+H)	3
					92	2-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino]-2-oxo-1-phenylethyl acetic ester		461(M+H)	3

93	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	389(M+H)		3
					94	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-thionaphthene-2-methane amide	445(M+H)		3
95	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	433(M+H)		3
					96	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	453(M+H)		1
97	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) cyclohexane carboxamide	395(M+H)		3
					98	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	504(M+H)		1
99	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) cyclopentane formamide	491(M+H)		2
					100	3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	522(M+H)		1
101	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl) thiophene-2-carboxamide derivatives	535(M+H)		3
					102	2-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-nitrobenzamide	468(M+H)		3
103	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1,3-dimethyl-1H-pyrazoles-5-methane amide	407(M+H)		3
					104	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,4-dimethoxy benzamide	449(M+H)		3
105	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-fluoro benzamide	407(M+H)		2
					106	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide	475(M+H)		1
107	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-2-phenyl-2H-I, 2,3-triazole-4-methane amide	470(M+H)		2
					108	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide	556(M+H)		1

109	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 1-naphthoamide	439(M+H)		3
					110	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-naphthoamide	439(M+H)		3
111	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitro-2-furoamide	424(M+H)		1
					112	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-phenoxy-acetamide	419(M+H)		1
113	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-nitro-phenoxy) ethanamide	464(M+H)		3
					114	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) quinoxaline-2-methane amide	441(M+H)		2
115	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide	479(M+H)		3
					116	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	457(M+H)		3
117	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	457(M+H)		3
					118	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(trifluoromethoxy) benzamide	473(M+H)		3
119	4, and 5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	524(M+H)		3
					120	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-phenoxy group butyramide	447(M+H)		3
121	2-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 5-methoxy benzamide	497(M+H)		3
					122	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(penta fluoro benzene oxygen base) ethanamide	509(M+H)		3
123	2-(3, the 4-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	463(M+H)		3
					124	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate	443(M+H)		3

125	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) cyclopentane formamide	381(M+H)		3
					126	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	425(M+H)		3
127	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-Phenylpropionamide	417(M+H)		3
					128	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,3,4, the 5-tetrafluoro is for benzamide	461(M+H)		3
129	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-oxyethyl group-1-naphthoamide	483(M+H)		3
					130	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,3,4,5,6-penta fluoro benzene methane amide	479(M+H)		3
131	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-[(trifluoromethyl) sulfydryl] benzamide	489(M+H)		3
					132	3,4, and 5-three chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	497(M+H)		3
133	2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	453(M+H)		1
					134	3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	538(M+H)		1
135	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenoxy group niacinamide	482(M+H)		1
					136	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(thiophenyl) niacinamide	498(M+H)		3
137	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methylphenoxy) niacinamide	496(M+H)		1
					138	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-[(dipropyl amino) alkylsulfonyl] benzamide	552(M+H)		3
139	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-methyl propanamide	481(M+H)		3
					140	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(trifluoromethyl)-3-furoamide	557(M+H)		3

141	2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1,3-thiazoles-4-methane amide	514(M+H)	3
				142	The 3-tertiary butyl-1-(2, the 4-dichloro benzyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide	593(M+H)	3
143	6-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2H-chromene-3-methane amide	477(M+H)	3
				144	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide	507(M+H)	3
145	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromene-8-yl) the oxygen base] ethanamide	501(M+H)	3
				146	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide	478(M+H)	1
147	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methoxy benzamide	433(M+H)	3
				148	3-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	481(M+H)	3
149	4-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	481(M+H)	3
				150	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,1,3-Ben Bing oxadiazole-5-methane amide	445(M+H)	3
151	3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	437(M+H)	3
				152	4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	437(M+H)	3
153	(2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-Phenyl Acrylamide	429(M+H)	3
				154	4-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	482(M+H)	3
155	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	451(M+H)	3
				156	3-cyano group-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	428(M+H)	3

157	3,5-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] benzamide	471(M+H)	3
				158	3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] benzamide	471(M+H)	3
159	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide	493(M+H)	2
				160	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide	439(M+H)	3
161	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 5-difluorobenzamide	439(M+H)	3
				162	2-(2, the 5-Dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	477(M+H)	3
163	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(ethylmercapto group) niacinamide	464(M+H)	3
				164	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	421(M+H)	3
165	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-3-fluoro-5-(trifluoromethyl) benzamide	489(M+H)	3
				166	2,4-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	489(M+H)	3
167	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] hexanamide	397(M+H)	3
				168	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-phenyl-iodide methane amide	529(M+H)	3
169	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(methylthio group) niacinamide	450(M+H)	3
				170	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-methyl-3-nitro benzamide	462(M+H)	3
171	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	448(M+H)	3
				172	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-phenyl-acetamides	417(M+H)	3

173	(2R)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenyl cyclopropane carboxamide		443(M+H)		3
						174	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-1,3-benzo dioxole-5-methane amide		447(M+H)		3
175	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group butyramide		461(M+H)		3
						176	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group propionic acid amide		447(M+H)		3
177	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide		417(M+H)		3
						178	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-methyl benzamide		417(M+H)		3
179	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives		409(M+H)		3
						180	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2-thienyl) ethanamide		423(M+H)		3
181	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide		487(M+H)		3
						182	[4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester		433(M+H)		3
183	[4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine 4-nitro-benzyl ester		478(M+H)		3
						184	4-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide		495(M+H)		3
185	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-phenyl-iodide methane amide		529(M+H)		3
						186	3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-fluoro benzamide		455(M+H)		3
187	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,3-two fluoro-4-methyl benzamides		453(M+H)		3
						188	2-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide		455(M+H)		3

189	3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2,4 difluorobenzene methane amide	473(M+H)	3
				190	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(thiophenyl) ethanamide	449(M+H)	3
191	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-2-fluoro-3-(trifluoromethyl) benzamide	489(M+H)	3
				192	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-2-fluoro-5-(trifluoromethyl) benzamide	489(M+H)	3
193	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-phenylbutanamides	445(M+H)	3
				194	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(3-p-methoxy-phenyl) ethanamide	447(M+H)	3
195	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(4-fluoro phenyl) ethanamide	435(M+H)	3
				196	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(4-p-methoxy-phenyl) ethanamide	447(M+H)	3
197	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furoamide	475(M+H)	3
				198	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,5-dimethyl-3-furoamide	421(M+H)	3
199	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-ethoxy benzamide	447(M+H)	3
				200	3-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	455(M+H)	3
201	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide	435(M+H)	3
				202	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	409(M+H)	3
203	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide	463(M+H)	3
				204	4-cyano group-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	428(M+H)	3

205	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide	539(M+H)	3
				206	(2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-(4-nitrophenyl) acrylamide	474(M+H)	2
207	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	495(M+H)	3
				208	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide	435(M+H)	3
209	The 2-[(difluoromethyl) sulfo-]-N-{ (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	485(M+H)	3
				210	2,5-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] thiophene-3-methane amide	477(M+H)	3
211	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(rosickyite base) niacinamide	478(M+H)	3
				212	1-benzyl-3-the tertiary butyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-1H-pyrazoles-5-methane amide	539(M+H)	3
213	The 3-tertiary butyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-1-methyl isophthalic acid H-pyrazoles-5-methane amide	463(M+H)	3
				214	(2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-methyl-3-Phenyl Acrylamide	443(M+H)	3
215	5-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] niacinamide	482(M+H)	3
				216	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(1-naphthyl) ethanamide	467(M+H)	3
217	The 1-tertiary butyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-methyl isophthalic acid H-pyrazole-3-formamide	463(M+H)	3
				218	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-1-thionaphthene-3-methane amide	459(M+H)	3
219	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] xenyl-4-methane amide	479(M+H)	3
				220	2-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	481(M+H)	3

221	2,6-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] benzamide	471(M+H)	2
				222	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-phenyl-iodide methane amide	529(M+H)	3
223	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-methyl benzamide	417(M+H)	3
				224	3-two chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] benzamide	471(M+H)	3
225	2-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	455(M+H)	3
				226	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-9-oxo-9H-fluorenes-4-methane amide	505(M+H)	3
227	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,3, the 6-benzamide trifluoroacetate	457(M+H)	3
				228	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2, the 3-difluorobenzamide	439(M+H)	3
229	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2, the 6-difluorobenzamide	439(M+H)	3
				230	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-2-fluoro-6-(trifluoromethyl) benzamide	489(M+H)	3
231	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide	445(M+H)	1
				232	2-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-the 6-fluoro benzamide	455(M+H)	3
233	2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) methyl] benzamide	505(M+H)	1
				234	(2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] acrylamide	463(M+H)	2
235	6-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-fluoro-3-methyl benzamide	469(M+H)	3
				236	2-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 6-difluorobenzamide	473(M+H)	3

237	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2, the 3-dimethyl benzamide	431(M+H)	3
				238	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-methoxy benzamide	370(M+H)	2
239	3-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	418(M+H)	1
				240	4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	418(M+H)	3
241	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide	382(M+H)	1
				242	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	374(M+H)	1
243	4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	374(M+H)	2
				244	(2E)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-Phenyl Acrylamide	366(M+H)	3
245	4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-nitrobenzamide	419(M+H)	1
				246	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) ethanamide	388(M+H)	3
247	3-cyano group-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	365(M+H)	3
				248	3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	408(M+H)	1
249	3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	408(M+H)	1
				250	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,2-phenylbenzene ethanamide	430(M+H)	2
251	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide	376(M+H)	1
				252	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 5-difluorobenzamide	376(M+H)	2

253	2-(2, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	414(M+H)	3
				254	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group) niacinamide	401(M+H)	3
255	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-fluoro benzamide	358(M+H)	3
				256	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide	426(M+H)	2
257	2,4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 5-fluoro benzamide	426(M+H)	3
				258	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) hexanamide	334(M+H)	3
259	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-phenyl-iodide methane amide	466(M+H)	3
				260	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(methylthio group) niacinamide	387(M+H)	3
261	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-methyl-3-nitro benzamide	399(M+H)	2
				262	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-nitrobenzamide	385(M+H)	1
263	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-phenyl-acetamides	354(M+H)	3
				264	(2R)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenyl cyclopropane carboxamide	380(M+H)	3
265	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide	384(M+H)	3
				266	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group butyramide	398(M+H)	2
267	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group propionic acid amide	384(M+H)	3
				268	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-methyl benzamide	354(M+H)	2

269	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-methyl benzamide		354(M+H)	3
					270	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiophene-2-carboxamide derivatives		346(M+H)	3
271	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl) ethanamide		360(M+H)	3
					272	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide		424(M+H)	1
273	[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine benzyl ester		370(M+H)	3
					274	[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine 4-nitro-benzyl ester		415(M+H)	3
275	4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-methyl benzamide		432(M+H)	1
					276	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenyl-iodide methane amide		466(M+H)	3
277	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-fluoro benzamide		392(M+H)	3
					278	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,3-two fluoro-4-methyl benzamides		390(M+H)	3
279	2-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-fluoro benzamide		392(M+H)	3
					280	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide		410(M+H)	3
281	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(thiophenyl) ethanamide		386(M+H)	3
					282	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-fluoro-3-(trifluoromethyl) benzamide		426(M+H)	3
283	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-fluoro-5-(trifluoromethyl) benzamide		426(M+H)	3
					284	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-phenylbutanamides		382(M+H)	3

285	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(3-p-methoxy-phenyl) ethanamide	384(M+H)	3
				286	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-fluoro phenyl) ethanamide	372(M+H)	3
287	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-p-methoxy-phenyl) ethanamide	384(M+H)	3
				288	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furoamide	412(M+H)	3
289	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,5-dimethyl-3-furoamide	358(M+H)	2
				290	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-ethoxy benzamide	384(M+H)	3
291	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-fluoro benzamide	392(M+H)	1
				292	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-fluoro-4-methyl benzamide	372(M+H)	3
293	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	346(M+H)	3
				294	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethoxy benzamide	400(M+H)	1
295	4-cyano group-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	365(M+H)	3
				296	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide	476(M+H)	1
297	(2E)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(4-nitrophenyl) acrylamide	411(M+H)	3
				298	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	432(M+H)	3
299	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-methyl benzamide	372(M+H)	1
				300	The 2-[(difluoromethyl) sulfydryl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	422(M+H)	3

301	2, and 5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiophene-3-methane amide	414(M+H)	2
				302	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(rosickyite base) niacinamide	415(M+H)	3
303	1-benzyl-3-the tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide	476(M+H)	2
				304	The 3-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl isophthalic acid H-pyrazoles-5-methane amide	400(M+H)	3
305	(2E)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl-3-Phenyl Acrylamide	380(M+H)	3
				306	5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) niacinamide	419(M+H)	3
307	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-naphthyl) ethanamide	404(M+H)	2
				308	The 1-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl isophthalic acid H-pyrazole-3-formamide	400(M+H)	3
309	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-thionaphthene-3-methane amide	396(M+H)	3
				310	Acetate 2-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino]-2-oxo-1-phenylethylester	412(M+H)	3
311	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	340(M+H)	3
				312	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-thionaphthene-2-methane amide	396(M+H)	3
313	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	384(M+H)	3
				314	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) ethanamide	404(M+H)	1
315	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) cyclohexane carboxamide	346(M+H)	3
				316	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	455(M+H)	3

317	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) cyclopentane formamide	442(M+H)	2
				318	3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	473(M+H)	2
319	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl) thiophene-2-carboxamide derivatives	486(M+H)	3
				320	2-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-nitrobenzamide	419(M+H)	3
321	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-dimethyl-1H-pyrazoles-5-methane amide	358(M+H)	3
				322	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,4-dimethoxy benzamide	400(M+H)	3
323	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-fluoro benzamide	358(M+H)	3
				324	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide	426(M+H)	1
325	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide	421(M+H)	1
				326	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide	507(M+H)	1
327	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 1-naphthoamide	390(M+H)	3
				328	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-naphthoamide	390(M+H)	3
329	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitro-2-furoamide	375(M+H)	3
				330	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-phenoxy-acetamide	370(M+H)	2
331	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-nitro-phenoxy) ethanamide	415(M+H)	3
				332	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) quinoxaline-2-methane amide	392(M+H)	1

333	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide	430(M+H)	3
				334	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	408(M+H)	2
335	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	408(M+H)	3
				336	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(trifluoromethoxy) benzamide	424(M+H)	3
337	4, and 5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carbamate	475(M+H)	3
				338	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-phenoxy group butyramide	398(M+H)	3
339	2-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 5-methoxy benzamide	448(M+H)	3
				340	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(penta fluoro benzene oxygen base) ethanamide	460(M+H)	2
341	2-(3, the 4-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	414(M+H)	3
				342	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate	394(M+H)	3
343	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) cyclopentane formamide	332(M+H)	3
				344	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	376(M+H)	3
345	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-Phenylpropionamide	368(M+H)	3
				346	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,3,4, the 5-tetrafluoro is for benzamide	412(M+H)	3
347	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-oxyethyl group-1-naphthoamide	434(M+H)	3
				348	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,3,4,5,6-penta fluoro benzene methane amide	430(M+H)	3

349	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-[(trifluoromethyl) sulfo-] benzamide	440(M+H)	3
				350	3,4, and 5-three chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiophene-2-carboxamide derivatives	448(M+H)	3
351	2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) ethanamide	404(M+H)	1
				352	3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	489(M+H)	1
353	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group niacinamide	433(M+H)	2
				354	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(thiophenyl) niacinamide	449(M+H)	3
355	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methylphenoxy) niacinamide	447(M+H)	1
				356	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-[(dipropyl amino) alkylsulfonyl] benzamide	503(M+H)	1
357	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-the 2-methyl propanamide	432(M+H)	2
				358	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-2-(trifluoromethyl)-3-furoamide	508(M+H)	3
359	2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-thiazoles-4-methane amide	465(M+H)	1
				360	The 3-tertiary butyl-1-(2, the 4-dichloro benzyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1H-pyrazoles-5-methane amide	544(M+H)	2
361	6-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2H-chromene-3-methane amide	428(M+H)	2
				362	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide	458(M+H)	3
363	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromene-8-yl) the oxygen base] ethanamide	452(M+H)	3
				364	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide	429(M+H)	1

365	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-methoxy benzamide	384(M+H)	3
				366	3-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	432(M+H)	3
367	4-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	432(M+H)	3
				368	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,1,3-Ben Bing oxadiazole-5-methane amide	396(M+H)	3
369	3-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	388(M+H)	3
				370	4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	388(M+H)	2
371	(2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-Phenyl Acrylamide	380(M+H)	2
				372	4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	433(M+H)	2
373	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] ethanamide	402(M+H)	2
				374	3-cyano group-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	379(M+H)	3
375	3,5-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] benzamide	422(M+H)	2
				376	3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] benzamide	422(M+H)	2
377	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide	444(M+H)	1
				378	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,4-phenyl-difluoride methane amide	390(M+H)	3
379	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3, the 5-difluorobenzamide	390(M+H)	3
				380	2-(2, the 5-Dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] ethanamide	428(M+H)	3

381	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(ethylmercapto group) niacinamide	415(M+H)	3
				382	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	372(M+H)	3
383	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-fluoro-5-(trifluoromethyl) benzamide	440(M+H)	3
				384	2,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	440(M+H)	2
385	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] hexanamide	348(M+H)	3
				386	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-4-phenyl-iodide methane amide	480(M+H)	3
387	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(methylthio group) niacinamide	401(M+H)	3
				388	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-4-methyl-3-nitro benzamide	413(M+H)	3
389	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	399(M+H)	3
				390	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenyl-acetamides	368(M+H)	3
391	(2R)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenyl cyclopropane carboxamide	394(M+H)	3
				392	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-1,3-benzo dioxole-5-methane amide	398(M+H)	3
393	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenoxy group butyramide	412(M+H)	2
				394	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenoxy group propionic acid amide	398(M+H)	3
395	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-methyl benzamide	368(M+H)	3
				396	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 4-methyl benzamide	368(M+H)	3

397	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives		360(M+H)	3
					398	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2-thienyl) ethanamide		374(M+H)	3
399	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2 base] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide		438(M+H)	3
					400	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] the carboxylamine benzyl ester		384(M+H)	3
401	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 4-nitrobenzyl ester		429(M+H)	3
					402	4-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 3-methyl benzamide		446(M+H)	3
403	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-phenyl-iodide methane amide		480(M+H)	3
					404	3-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-fluoro benzamide		406(M+H)	3
405	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,3-two fluoro-4-methyl benzamides		404(M+H)	3
					406	2-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 4-fluoro benzamide		406(M+H)	3
407	3-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2,4 difluorobenzene methane amide		424(M+H)	3
					408	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(thiophenyl) ethanamide		400(M+H)	3
409	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-2-fluoro-3-(trifluoromethyl) benzamide		440(M+H)	3
					410	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-2-fluoro-5-(trifluoromethyl) benzamide		440(M+H)	3
411	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenylbutanamides		396(M+H)	1
					412	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(3-p-methoxy-phenyl) ethanamide		398(M+H)	2

413	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(4-fluoro phenyl) ethanamide	386(M+H)		3
					414	N-[(cis-4-{[4-(dimethylamino } pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(4-p-methoxy-phenyl) ethanamide	398(M+H)		2
415	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furoamide	426(M+H)		3
					416	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,5-dimethyl-3-furoamide	372(M+H)		3
417	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-ethoxy benzamide	398(M+H)		3
					418	3-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	406(M+H)		3
419	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide	386(M+H)		3
					420	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] ethanamide	360(M+H)		3
421	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide	414(M+H)		3
					422	4-cyano group-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	379(M+H)		3
423	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide	490(M+H)		2
					424	(2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-(4-nitrophenyl) acrylamide	425(M+H)		1
425	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] ethanamide	446(M+H)		2
					426	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide	386(M+H)		3
427	The 2-[(difluoromethyl) sulfo-]-N-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	436(M+H)		3
					428	2,5-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] thiophene-3-methane amide	428(M+H)		3

429	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(rosickyite base) niacinamide	429(M+H)	2
				430	1-benzyl-3-the tertiary butyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl]-1H-pyrazoles-5-methane amide	490(M+H)	3
431	The 3-tertiary butyl-N-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl]-1-methyl isophthalic acid H-pyrazoles-5-methane amide	414(M+H)	3
				432	(2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-methyl }-the 3-Phenyl Acrylamide	394(M+H)	3
433	5-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] niacinamide	433(M+H)	3
				434	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(1-naphthyl) ethanamide	418(M+H)	1
435	The 1-tertiary butyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-5-methyl isophthalic acid H-pyrazole-3-formamide	414(M+H)	3
				436	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-1-thionaphthene-3-methane amide	410(M+H)	3
437	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] xenyl-4-methane amide	430(M+H)	3
				438	2-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide	432(M+H)	3
439	2,6-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] benzamide	422(M+H)	3
				440	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenyl-iodide methane amide	480(M+H)	3
441	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-methyl benzamide	368(M+H)	3
				442	2,3-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] benzamide	422(M+H)	3
443	2-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	406(M+H)	3
				444	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9-oxo-9H-fluorenes-4-methane amide	456(M+H)	2

445	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,3, the 6-benzamide trifluoroacetate	408(M+H)	3
				446	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2, the 3-difluorobenzamide	390(M+H)	3
447	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2, the 6-difluorobenzamide	390(M+H)	3
				448	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-fluoro-6-(trifluoromethyl) benzamide	440(M+H)	3
449	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide	396(M+H)	2
				450	2-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 6-fluoro benzamide	406(M+H)	3
451	2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) methyl] benzamide	456(M+H)	2
				452	(2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] acrylamide	414(M+H)	2
453	6-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-fluoro-3-methyl benzamide	420(M+H)	3
				454	2-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3, the 6-difluorobenzamide	424(M+H)	3
455	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2, the 3-dimethyl benzamide	382(M+H)	3
				456	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-methoxy benzamide	424(M+H)	1
457	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	472(M+H)	1
				458	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	472(M+H)	2
459	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide	436(M+H)	1
				460	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	428(M+H)	1

461	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	428(M+H)	1
				462	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-Phenyl Acrylamide	420(M+H)	3
463	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-nitrobenzamide	473(M+H)	1
				464	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	442(M+H)	1
465	3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinoline-2-yl] amino } cyclohexyl) benzamide	419(M+H)	1
				466	3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	462(M+H)	1
467	3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	462(M+H)	1
				468	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide	484(M+H)	1
469	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide	430(M+H)	1
				470	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide	430(M+H)	1
471	2-(2, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	468(M+H)	3
				472	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(ethylmercapto group) niacinamide	455(M+H)	3
473	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	412(M+H)	1
				474	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide	480(M+H)	1
475	2,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 5-fluoro benzamide	480(M+H)	3
				476	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) hexanamide	388(M+H)	2

477	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-phenyl-iodide methane amide	520(M+H)		3
					478	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(methylthio group) niacinamide	441(M+H)		3
479	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-methyl-3-nitro benzamide	453(M+H)		1
					480	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-nitrobenzamide	439(M+H)		1
481	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-phenyl-acetamides	408(M+H)		3
					482	(2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenyl cyclopropane carboxamide	434(M+H)		2
483	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide	438(M+H)		3
					484	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenoxy group butyramide	452(M+H)		1
485	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenoxy group propionic acid amide	438(M+H)		1
					486	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	408(M+H)		1
487	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	408(M+H)		2
					488	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	400(M+H)		3
489	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-thienyl) ethanamide	414(M+H)		3
					490	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide	478(M+H)		2
491	[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-carboxylamine benzyl ester	424(M+H)		3
					492	[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-carboxylamine 4-nitro-benzyl ester	469(M+H)		3

493	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino }-cyclohexyl)-the 3-methyl benzamide	486(M+H)		2
					494	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-3-phenyl-iodide methane amide	520(M+H)		1
495	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-fluoro benzamide	446(M+H)		3
					496	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,3-two fluoro-4-methyl benzamides	444(M+H)		3
497	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	446(M+H)		2
					498	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	464(M+H)		3
499	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(thiophenyl) ethanamide	440(M+H)		3
					500	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-fluoro-3-(trifluoromethyl) benzamide	480(M+H)		3
501	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-fluoro-5-(trifluoromethyl) benzamide	480(M+H)		3
					502	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-phenylbutanamides	436(M+H)		3
503	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(3-p-methoxy-phenyl) ethanamide	438(M+H)		2
					504	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-fluoro phenyl) ethanamide	426(M+H)		1
505	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-p-methoxy-phenyl) ethanamide	438(M+H)		2
					506	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furoamide	466(M+H)		2
507	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,5-dimethyl-3-furoamide	412(M+H)		1
					508	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-ethoxy benzamide	438(M+H)		3

509	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	446(M+H)	1
				510	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide	426(M+H)	2
511	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	400(M+H)	3
				512	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide	454(M+H)	1
513	4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	419(M+H)	3
				514	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide	530(M+H)	1
515	2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-(4-nitrophenyl) acrylamide	465(M+H)	3
				516	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	486(M+H)	3
517	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide	426(M+H)	1
				518	The 2-[(difluoromethyl) sulfo-]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	476(M+H)	3
519	2, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiophene-3-methane amide	468(M+H)	1
				520	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide	469(M+H)	2
521	1-benzyl-3-the tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide	530(M+H)	2
				522	The 3-tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1-methyl isophthalic acid H-pyrazoles-5-methane amide	454(M+H)	3
523	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-methyl-3-Phenyl Acrylamide	434(M+H)	3
				524	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline	473(M+H)	1

	-2-yl] amino } cyclohexyl) niacinamide
					525	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1-naphthyl) ethanamide	458(M+H)		3
526	The 1-tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl isophthalic acid H-pyrazole-3-formamide	454(M+H)		3
					527	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1-thionaphthene-3-methane amide	450(M+H)		3
528	2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino]-2-oxo-1-phenylethyl acetic ester	466(M+H)		1
					529	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	394(M+H)		2
530	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1-thionaphthene-2-methane amide	450(M+H)		3
					531	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	438(M+H)		2
532	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	458(M+H)		2
					533	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) cyclohexane carboxamide	400(M+H)		3
534	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	509(M+H)		2
					535	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-cyclopentane formamide	496(M+H)		2
536	3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide	527(M+H)		1
					537	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl) thiophene-2-carboxamide derivatives	540(M+H)		3
538	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-nitrobenzamide	473(M+H)		3
					539	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	412(M+H)		2

	Base] amino } cyclohexyl)-1,3-dimethyl-1H-pyrazoles-5-methane amide
					540	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,4-dimethoxy benzamide	454(M+H)		3
541	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-fluoro benzamide	412(M+H)		1
					542	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide	480(M+H)		1
543	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide	475(M+H)		2
					544	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide	561(M+H)		1
545	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 1-naphthoamide	444(M+H)		3
					546	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-naphthoamide	444(M+H)		3
547	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-nitro-2-furoamide	429(M+H)		1
					548	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-phenoxy-acetamide	424(M+H)		1
549	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-nitro-phenoxy) ethanamide	469(M+H)		3
					550	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) quinoxaline-2-methane amide	446(M+H)		1
551	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide	484(M+H)		3
					552	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	462(M+H)		1
553	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	462(M+H)		3
					554	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	478(M+H)		3

	Base] amino } cyclohexyl)-2-(trifluoromethoxy) benzamide
					555	4, and 5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carbamate	529(M+H)		3
556	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-phenoxy group butyramide	452(M+H)		3
					557	2-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 5-methoxy benzamide	502(M+H)		3
558	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(penta fluoro benzene oxygen base) ethanamide	514(M+H)		3
					559	2-(3, the 4-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	468(M+H)		3
560	N-(cis-4-{{4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate	448(M+H)		3
					561	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) cyclopentane formamide	386(M+H)		3
562	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	430(M+H)		3
					563	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-Phenylpropionamide	422(M+H)		3
564	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,3,4,5-tetra fluoro benzene methane amide	466(M+H)		3
					565	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-oxyethyl group-1-naphthoamide	488(M+H)		3
566	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2,3,4,5,6-penta fluoro benzene methane amide	484(M+H)		3
					567	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-[(trifluoromethyl) sulfo-] benzamide	494(M+H)		3
568	3,4, and 5-three chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	502(M+H)		3
					569	2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	458(M+H)		1
570	3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-	543(M+H)		1

	5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide
					571	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenoxy group niacinamide	487(M+H)		2
572	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(thiophenyl) niacinamide	503(M+H)		3
					573	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-methylphenoxy) niacinamide	501(M+H)		1
574	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-[(dipropyl amino) alkylsulfonyl] benzamide	557(M+H)		3
					575	2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-methyl propanamide	486(M+H)		3
576	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(trifluoromethyl)-3-furoamide	562(M+H)		3
					577	The 3-tertiary butyl-1-(2, the 4-dichloro benzyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1H-pyrazoles-5-methane amide	598(M+H)		3
578	6-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2H-chromene-3-methane amide	482(M+H)		3
					579	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy)-benzamide	512(M+H)		3
580	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromene-8-yl) the oxygen base] ethanamide	506(M+H)		3
					581	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide	483(M+H)		2
582	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-methoxy benzamide	438(M+H)		3
					583	3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	486(M+H)		2
584	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene quinoline azoles	486(M+H)		3

	Quinoline-2-yl] amino } cyclohexyl) methyl] benzamide
				585	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,1,3-Ben Bing oxadiazole-5-methane amide	450(M+H)	3
586	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8 tetrahydro quinazolines-2-yl] amino } cyclohexyl) methyl] benzamide	442(M+H)	3
				587	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	442(M+H)	3
588	(2E)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-Phenyl Acrylamide	434(M+H)	3
				589	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	487(M+H)	3
590	The 2-{4-chlorophenyl)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide	456(M+H)	3
				591	3-cyano group-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	433(M+H)	3
592	3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	476(M+H)	3
				593	3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	476(M+H)	3
594	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide	498(M+H)	3
				595	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide	444(M+H)	3
596	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3, the 5-difluorobenzamide	444(M+H)	3
				597	2-(2, the 5-Dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide	482(M+H)	3
598	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(ethylmercapto group) niacinamide	469(M+H)	1
				599	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	426(M+H)	3
600	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	494(M+H)	3

	Base] amino } cyclohexyl) methyl]-3-fluoro-5-(trifluoromethyl) benzamide
					601	2,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	494(M+H)		3
602	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] hexanamide	402(M+H)		3
					603	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-4-phenyl-iodide methane amide	534(M+H)		3
604	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(methylthio group) niacinamide	455(M+H)		3
					605	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-4-methyl-3-nitro benzamide	467(M+H)		3
606	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-nitrobenzamide	453(M+H)		3
					607	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-phenyl-acetamides	422(M+H)		3
608	(2R)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-benzyl ring propane-methane amide	448(M+H)		3
					609	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-1,3-benzo dioxole-5-methane amide	452(M+H)		3
610	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group butyramide	466(M+H)		3
					611	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-phenoxy group propionic acid amide	452(M+H)		3
612	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide	422(M+H)		3
					613	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 4-methyl benzamide	422(M+H)		3
614	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives	414(M+H)		3
					615	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(2-thienyl) ethanamide	428(M+H)		3

616	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide	492(M+H)	3
				617	Benzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carbamate	438(M+H)	3
618	The 4-nitrobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carbamate	483(M+H)	3
				619	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide	500(M+H)	3
620	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-phenyl-iodide methane amide	534(M+H)	3
				621	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-fluoro benzamide	460(M+H)	3
622	N-[(cis-4-{[4-(dimethylamino }-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,3-two fluoro-4-methyl benzamides	458(M+H)	3
				623	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	460(M+H)	3
624	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2,4 difluorobenzene methane amide	478(M+H)	3
				625	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(thiophenyl) ethanamide	454(M+H)	3
626	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-fluoro-3-(trifluoromethyl) benzamide	494(M+H)	3
				627	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-fluoro-5-(trifluoromethyl) benzamide	494(M+H)	3
628	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-phenylbutanamides	450(M+H)	3
				629	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(3-p-methoxy-phenyl) ethanamide	452(M+H)	3
630	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(4-fluoro phenyl) ethanamide	440(M+H)	3
				631	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(4-p-methoxy-phenyl) ethanamide	452(M+H)	1

632	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-5-methyl-2-(trifluoromethyl)-3-furoamide	480(M+H)		1
					633	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,5-dimethyl-3-furoamide	426(M+H)		3
634	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-ethoxy benzamide	452(M+H)		3
					635	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide	460(M+H)		3
636	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide	440(M+H)		3
					637	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide	414(M+H)		3
438	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide	468(M+H)		3
					639	4-cyano group-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	433(M+H)		3
640	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide	544(M+H)		3
					641	(2E)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-(4-nitrophenyl) acrylamide	479(M+H)		2
642	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide	500(M+H)		3
					643	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide	440(M+H)		2
644	The 2-[(difluoromethyl) sulfo-]-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	490(M+H)		3
					645	2,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] thiophene-3-methane amide	482(M+H)		3
646	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(rosickyite base) niacinamide	483(M+H)		1

647	1-benzyl-3-the tertiary butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-1H-pyrazoles-5-methane amide	544(M+H)	3
				648	The 3-tertiary butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-1-methyl isophthalic acid H-pyrazoles-5-methane amide	468(M+H)	3
649	(2E)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-methyl-3-Phenyl Acrylamide	448(M+H)	3
				650	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-methyl] niacinamide	487(M+H)	3
651	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(1-naphthyl) ethanamide	472(M+H)	3
				652	The 1-tertiary butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-5-methyl isophthalic acid H-pyrazoles-3-methane amide	468(M+H)	3
653	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-1-thionaphthene-3-methane amide	464(M+H)	3
				654	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] xenyl-4-methane amide	484(M+H)	3
655	2-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	486(M+H)	3
				656	2,6-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	476(M+H)	2
657	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-phenyl-iodide methane amide	534(M+H)	3
				658	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-methyl benzamide	422(M+H)	3
659	2,3-two chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	476(M+H)	3
				660	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl]-the 5-fluoro benzamide	460(M+H)	3
661	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	510(M+H)	3

	Base] amino } cyclohexyl) methyl]-9-oxo-9H-fluorenes-4-methane amide
				662	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,3, the 6-benzamide trifluoroacetate	462(M+H)	3
663	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2, the 3-difluorobenzamide	444(M+H)	3
				664	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2, the 6-difluorobenzamide	444(M+H)	3
665	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-fluoro-6-(trifluoromethyl)-benzamide	494(M+H)	3
				666	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide	450(M+H)	2
667	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl]-the 6-fluoro benzamide	460(M+H)	2
				668	2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide	510(M+H)
669	(2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] acrylamide	468(M+H)	3
				670	6-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl]-2-fluoro-3-methyl benzamide	474(M+H)	3
671	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl]-3, the 6-difluorobenzamide	478(M+H)	3
				672	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2, the 3-dimethyl benzamide	436(M+H)	3
673	5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	473(M+H)	2
				674	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2,3, the 6-trichlorophenyl) ethanamide	505(M+H)	3
675	2-(2-chloro-4-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	455(M+H)	3
				676	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-furoamide	534(M+H)	2

677	5-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	429(M+H)	2
				678	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2,3-diphenylprop acid amides	493(M+H)	3
679	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(2-hydroxy phenyl) propionic acid amide	433(M+H)	3
				680	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-iodo-2-furoamide	505(M+H)	1
681	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-iodine substituted phenyl) ethanamide	529(M+H)	2
				682	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide	486(M+H)	2
683	(2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(3-nitrophenyl) acrylamide	460(M+H)	2
				684	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-oxo indane-1-methane amide	443(M+H)	3
685	2-benzyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	479(M+H)	3
				686	2, and two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	547(M+H)	2
687	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide	514(M+H)	3
				688	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-2-methane amide	440(M+H)	1
689	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methyl-4-nitrobenzamide	448(M+H)	1
				690	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide	464(M+H)	1
691	1-benzyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1H-indoles-3-methane amide	518(M+H)	3
				692	3-ethanoyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	431(M+H)	3

693	(2R)-the 2-benzoyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) cyclohexane carboxamide	499(M+H)		3
					694	5-bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-furoamide	457(M+H)		1
695	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) propionic acid amide	423(M+H)		3
					696	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-[(4-methylpyrimidine-2-yl) sulfo-] ethanamide	451(M+H)		3
697	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-furoamide	489(M+H)		3
					698	3-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) propionic acid amide	485(M+H)		3
699	2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	471(M+H)		3
					700	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-hydroxyl-3,5-Dimethoxyphenyl) ethanamide	479(M+H)		3
701	4, and 5-two bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	551(M+H)		2
					702	2-(3, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	463(M+H)		3
703	2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	531(M+H)		3
					704	N～2～, N～6～-dibenzoyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) lysyl amine (lysinamide)	621(M+H)		3
705	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	432(M+H)		3
					706	4,5-two bromo-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-furoamide	535(M+H)		1
707	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(4-fluoro phenyl)-4-oxo butyramide	463(M+H)		3
					708	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide	511(M+H)		3

709	(1S)-and 1-[(1-benzyl-1H-imidazol-4 yl) methyl]-2-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino]-the 2-oxoethyl } the carboxylamine tertiary butyl ester	612(M+H)		3
					710	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl) phenyl] propionic acid amide	548(M+H)		3
711	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide	442(M+H)		1
					712	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazoles-4-yl) ethanamide	500(M+H)		3
713	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(6-methoxyl group-3-oxo-2,3-dihydro-1H-indenes-1-yl) ethanamide	487(M+H)		3
					714	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2{1-[(4-methoxy-benzyl) sulfydryl] cyclohexyl } ethanamide	561(M+H)		3
715	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(7-methoxyl group-2-oxo-2H-chromene-4-yl) ethanamide	501(M+H)		3
					716	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides	560(M+H)		2
717	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo butyramide	638(M+H)		3
					718	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy) phenyl] amino }-carbonyl) amino] benzamide	635(M+H)		3
719	3,5-two chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group) amino] benzamide	600(M+H)		3
					720	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxo butyramide	644(M+H)		3
721	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-oxo butyramide	630(M+H)		3
					722	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyryl	588(M+H)		3

	Amine
				723	N-(2,4 dichloro benzene base)-2-{2-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino]-the 2-oxoethyl } benzamide	590(M+H)	3
724	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide	595(M+H)	3
				725	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(4-nitrophenyl) butyramide	476(M+H)	3
726	(2E)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-(2-nitrophenyl) acrylamide	460(M+H)	3
				727	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(3-Phenoxyphenyl) ethanamide	495(M+H)	3
728	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-Phenoxyphenyl) ethanamide	495(M+H)	3
				729	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide	518(M+H)	2
730	N 2-benzoyl-N 5-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N1, N1-dipropyl glutamine	601(M+H)	3
				731	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 3-phenoxy benzamide	481(M+H)	3
732	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-phenylethyl) benzamide	493(M+H)	3
				733	The 3-benzoyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	493(M+H)	3
734	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide	539(M+H)	3
				735	The 2-[(2-cyano-phenyl) sulfo-]-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) benzamide	522(M+H)	3
736	2-[4-(benzyloxy)-3-p-methoxy-phenyl]-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	539(M+H)	3
				737	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[(1R)-and 1-(1-naphthyl) ethyl] phthalamide	586(M+H)	3

738	(2S)-and 2-(3-benzoyl phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) propionic acid amide	521(M+H)	3
				739	N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N, N-two [(1S)-and the 1-phenylethyl] phthalamide	640(M+H)	3
740	(2S)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2-fluoro phenyl-4-yl) propionic acid amide	511(M+H)	3
				741	2-[(4-benzyl chloride base) sulfo-]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-oxo butyramide	635(M+H)	3
742	2-[(4-benzyl chloride base) sulfo-]-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(4-aminomethyl phenyl)-4-oxo butyramide	615(M+H)	3
				743	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methyl sulfinyl) benzylidene]-1H-indenes-3-yl } ethanamide	623(M+H)	3
744	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide	527(M+H)	3
				745	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-oxo-4-(2-thienyl) butyramide	451(M+H)	3
746	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(2-thienyl) butyramide	437(M+H)	3
				747	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(2,4, the 6-Trichlorophenoxy) ethanamide	521(M+H)	2
748	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	548(M+H)	3
				749	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(1-naphthoyl) benzamide	543(M+H)	3
750	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-methoxy benzamide	525(M+H)	2
				751	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide	544(M+H)	3
752	1-{2-[(2-chloro-6-fluoro benzyl) sulfo-] ethyl }-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	670(M+H)	3

753	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) anthracene-9-methane amide	489(M+H)		3
					754	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 2-phenoxy benzamide	481(M+H)		2
755	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) xenyl-2-methane amide	465(M+H)		3
					756	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3,3-diphenylprop acid amides	493(M+H)		3
757	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-phenylquinoline-4-methane amide	516(M+H)		2
					758	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[(1S)-and the 1-phenylethyl] phthalamide	536(M+H)		3
759	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(4-methyl benzoyl) benzamide	507(M+H)		3
					760	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-2-(phenoxymethyl) benzamide	495(M+H)		3
761	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{ [4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) ethanamide	596(M+H)		3
					762	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 1-[(4-aminomethyl phenyl) alkylsulfonyl]-the 1H-pyrrole-3-carboxamide	532(M+H)		3
763	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide	500(M+H)		1
					764	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(methyl sulphonyl) thiophene-2-carboxamide derivatives	507(M+H)		3
765	3-chloro-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives	581(M+H)		3
					766	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-3-iodo-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives	673(M+H)		3
767	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-3-methane amide	440(M+H)		1
					768	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide	437(M+H)		1

785	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) quinoline-4-methane amide	440(M+H)		3
					786	2-(allyl group sulfenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) niacinamide	462(M+H)		3
787	3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-the 4-hydroxybenzamide	517(M+H)		3
					788	5-bromo-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives	487(M+H)		3
789	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide	519(M+H)		1
					790	2-(2-chloro-4-fluoro phenyl)-N-[(cis-4-{[4-(dimethylamino)-quinoline-2-yl] amino } cyclohexyl)-methyl] ethanamide	469(M+H)		3
791	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-quinoline-2-yl] amino } cyclohexyl) methyl]-the 2-furoamide	548(M+H)		3
					792	5-chloro-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives	443(M+H)		3
793	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2,3-diphenylprop acid amides	507(M+H)		3
					794	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-(2-hydroxy phenyl) propionic acid amide	447(M+H)		3
795	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-iodo-2-furoamide	519(M+H)		3
					796	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-2-(2-iodine substituted phenyl) ethanamide	543(M+H)		3
797	(2E)-and N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-(3-nitrophenyl) acrylamide	474(M+H)		2
					798	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide	457(M+H)		3
799	2-benzyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] benzamide	493(M+H)		3
					800	2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) quinoline of 2--2-yl] amino } cyclohexyl) methyl] ethanamide	561(M+H)		3

801	N-[(cis-4-{[4-(dimethylamino) 2 amino } cyclohexyl)-methyl]-5-(4-methyl-2-nitrophenyl)-2-furoamide	528(M+H)		3
					802	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-5-nitrothiophene-2-methane amide	454(M+H)		3
803	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide	462(M+H)		3
					804	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide	478(M+H)		3
805	1-benzyl-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-1H-indoles-3-methane amide	532(M+H)		3
					806	2-hexamethylene-1-alkene-1-base-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	421(M+H)		3
807	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-4-(4-ethoxyl phenenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1 h-pyrazole-4-yl)-4-oxo butyramide	675(M+H)		3
					808	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-2-[2-(trifluoromethoxy) phenyl] ethanamide	501(M+H)		3
809	4-(benzyl oxygen base)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-3, the 5-dimethyl benzamide	537(M+H)		3
					810	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide	507(M+H)		3
811	2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] ethanamide	473(M+H)		3
					812	5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiophene-2-carboxamide derivatives	424(M+H)		3
813	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2,3, the 6-trichlorophenyl) ethanamide	456(M+H)		3
					814	2-(2-chloro-4-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	406(M+H)		3
815	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-furoamide	485(M+H)		1
					816	5-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } ring	380(M+H)		3

	Hexyl) thiophene-2-carboxamide derivatives
				817	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,3-diphenylprop acid amides	444(M+H)	3
818	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(2-hydroxy phenyl) propionic acid amide	384(M+H)	3
				819	N-{ cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-iodo-2-furoamide	456(M+H)	2
820	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-iodine substituted phenyl) ethanamide	480(M+H)	3
				821	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide	437(M+H)	3
822	(2E)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(3-nitrophenyl) acrylamide	411(M+H)	3
				823	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-oxo indane-1-methane amide	394(M+H)	3
824	2-benzyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	430(M+H)	3
				825	2, and two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	498(M+H)	3
826	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide	465(M+H)	2
				827	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-2-methane amide	391(M+H)	2
828	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl-4-nitrobenzamide	399(M+H)	2
				829	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide	415(M+H)	1
830	1-benzyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1H-indoles-3-methane amide	469(M+H)	2
				831	3-ethanoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	382(M+H)	2
832	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-	450(M+H)	3

	Base] amino } cyclohexyl) cyclohexane carboxamide
					833	5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-furoamide	408(M+H)		1
834	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) propionic acid amide	374(M+H)		3
					835	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[(4-methylpyrimidine-2-yl) sulfo-] ethanamide	402(M+H)		3
836	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-the 2-furoamide	440(M+H)		1
					837	3-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) propionic acid amide	436(M+H)		3
838	2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) ethanamide	422(M+H)		3
					839	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-hydroxyl-3,5-Dimethoxyphenyl) ethanamide	430(M+H)		3
840	4, and 5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiophene-2-carboxamide derivatives	501(M+H)		2
					841	2-(3, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	414(M+H)		3
842	2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	482(M+H)		1
					843	N2, and N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) lysyl amine	572(M+H)		2
844	3-(dimethylamino }-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) benzamide	383(M+H)		2
					845	4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-furoamide	486(M+H)		1
846	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(4-fluoro phenyl)-4-oxo butyramide	414(M+H)		3
					847	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide	462(M+H)		3
848	1-benzyl-N-α-(tert-butoxycarbonyl)-N-(cis-4-{[4-(dimethyl	563(M+H)		3

	Amino) pyrimidine-2-base] amino } cyclohexyl)-L-histidyl-amine
					849	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindole-2-yl) phenyl] propionic acid amide	499(M+H)		3
850	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide	393(M+H)		2
					851	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazoles-4-yl) ethanamide	451(M+H)		2
852	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(6-methoxyl group-3-oxo-2,3-dihydro-1H-indenes-1-yl) ethanamide	438(M+H)		3
					853	N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-{1-[(4-methoxy-benzyl) sulfo-] cyclohexyl } ethanamide	512(M+H)		3
854	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(7-methoxyl group-2-oxo-2H-chromene-4-yl) ethanamide	452(M+H)		3
					855	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides	511(M+H)		1
856	4-(4-bromophenyl) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo butyramide	589(M+H)		2
					857	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy) phenyl] amino } carbonyl)-amino] benzamide	586(M+H)		3
858	3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group (prop-2-ynoyl) amino) benzamide	551(M+H)		2
					859	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrochysene-1H-indoles-1-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	655(M+H)		3
860	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxo butyramide	595(M+H)		3
					861	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-oxo butyramide	581(M+H)		3

862	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide	539(M+H)	1
				863	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide	546(M+H)	2
864	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(4-nitrophenyl) butyramide	427(M+H)	2
				865	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[(3-nitropyridine-2-yl) sulfo-] ethanamide	432(M+H)	-
866	(2E)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(2-nitrophenyl) acrylamide	411(M+H)	3
				867	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(3-Phenoxyphenyl) ethanamide	446(M+H)	3
868	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-Phenoxyphenyl) ethanamide	446(M+H)	3
				869	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide	469(M+H)	1
870	N2-benzoyl-N 5-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-N1, N1-dipropyl glutamine	552(M+H)	2
				871	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 3-phenoxy benzamide	432(M+H)	2
872	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenylethyl) benzamide	444(M+H)	3
				873	The 3-benzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	444(M+H)	2
874	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide	490(M+H)	1
				875	The 2-[(2-cyano-phenyl) sulfo-]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	473(M+H)	3
876	2-[4-(benzyloxy)-3-p-methoxy-phenyl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	490(M+H)	3

877	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(1R)-and 1-(1-naphthyl) ethyl] phthalamide	537(M+H)	2
				878	(2S)-and 2-(3-benzoyl phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) propionic acid amide	472(M+H)	2
879	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N, N-pair [(1S)-and the 1-phenylethyl] phthalamide	591(M+H)	1
				880	(2S)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide	462(M+H)	3
881	2-[(4-benzyl chloride base) sulfo-]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-oxo butyramide	586(M+H)	3
				882	2-[(4-benzyl chloride base) sulfo-]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-4-(4-aminomethyl phenyl)-4-oxo butyramide	566(M+H)	3
883	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl } ethanamide	574(M+H)	2
				884	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide	478(M+H)	2
885	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-oxo-4-(2-thienyl) butyramide	402(M+H)	3
				886	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(2-thienyl) butyramide	388(M+H)	3
887	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	499(M+H)	3
				888	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-naphthoyl) benzamide	494(M+H)	3
889	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 4-methoxy benzamide	476(M+H)	1
				890	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide	495(M+H)	1
891	1-{2-[(2-chloro-6-fluoro benzyl) sulfo-] ethyl }-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	621(M+H)

892	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) anthracene-9-methane amide	440(M+H)	3
				893	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 2-phenoxy benzamide	432(M+H)	2
894	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) xenyl-2-methane amide	416(M+H)	3
				895	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,3-diphenylprop acid amides	444(M+H)	3
896	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenylquinoline-4-methane amide	467(M+H)	2
				897	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(1S)-and the 1-phenylethyl] phthalamide	487(M+H)	3
898	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methyl benzoyl) benzamide	458(M+H)	3
				899	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(phenoxymethyl) benzamide	446(M+H)	3
900	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{ [4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	547(M+H)	1
				901	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-the 1-[(4-aminomethyl phenyl) alkylsulfonyl]-the 1H-pyrrole-3-carboxamide	483(M+H)	2
902	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide	451(M+H)	2
				903	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(methyl sulphonyl) thiophene-2-carboxamide derivatives	458(M+H)	3
904	3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives	532(M+H)	2
				905	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-iodo-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives	624(M+H)	2
906	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-3-methane amide	391(M+H)	1
				907	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide	388(M+H)

924	3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl)-the 4-hydroxybenzamide		468(M+H)		1
						925	5-bromo-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives		438(M+H)		3
926	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide		470(M+H)		1
						927	2-(2-chloro-4-fluoro phenyl)-N-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) methyl] ethanamide		420(M+H)		3
928	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino }-cyclohexyl) methyl]-the 2-furoamide		499(M+H)		3
						929	5-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives		394(M+H)		3
930	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,3-diphenylprop acid amides		458(M+H)		2
						931	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-(2-hydroxy phenyl) propionic acid amide		398(M+H)		3
932	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-5-iodo-2-furoamide		470(M+H)		2
						933	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide		451(M+H)		3
934	(2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-(3-nitrophenyl) acrylamide		425(M+H)		1
						935	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide		408(M+H)		1
936	2-benzyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] benzamide		444(M+H)		2
						937	2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases of 2-] amino } cyclohexyl) methyl] ethanamide		512(M+H)		1
938	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-5-(4-methyl-2-nitrophenyl)-2-furoamide		479(M+H)		3
						939	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-5-nitrothiophene-2-methane amide		405(M+H)		3

940	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide	413(M+H)	1
				941	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide	429(M+H)	1
942	1-benzyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-1H-indoles-3-methane amide	483(M+H)	3
				943	2-hexamethylene-1-alkene-1-base-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] ethanamide	372(M+H)	3
944	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-4-(4-ethoxyl phenenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1 h-pyrazole-4-yl)-4-oxo butyramide	626(M+H)	3
				945	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl]-ethanamide	452(M+H)	1
946	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3, the 5-dimethyl benzamide	488(M+H)	3
				947	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide	458(M+H)	1
948	2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] ethanamide	424(M+H)	1
				949	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-thiophene-2-carboxamide derivatives	478(M+H)	2
950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2,3, the 6-trichlorophenyl) ethanamide	510(M+H)	2
				951	2-(2-chloro-4-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	460(M+H)	1
952	5-(4-chloro-2-nitre phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-furoamide	539(M+H)	1
				953	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-thiophene-2-carboxamide derivatives	434(M+H)	1
954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinoline-2-yl] amino } cyclohexyl)-2,3-diphenylprop acid amides	498(M+H)	2
				955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	438(M+H)	2

	Base] amino } cyclohexyl)-3-(2-hydroxy phenyl) propionic acid amide
					956	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-iodo-2-furoamide	510(M+H)		1
957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-iodine substituted phenyl) ethanamide	534(M+H)		2
					958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(5-methoxyl group-2-Methyl-1H-indole-3-yl) ethanamide	491(M+H)		2
959	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinoline-2-yl] amino } cyclohexyl)-3-(3-nitrophenyl) acrylamide	465(M+H)		3
					960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-oxo indane-1-methane amide	448(M+H)		2
961	2-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	484(M+H)		2
					962	2, and two (4-the chlorophenyl)-N-of 2-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	552(M+H)		1
963	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide	519(M+H)		2
					964	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-5-nitrothiophene-2-methane amide	445(M+H)		1
965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-methyl-4-nitrobenzamide	453(M+H)		1
					966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide	469(M+H)		1
967	1-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-1H-indoles-3-methane amide	523(M+H)		3
					968	3-ethanoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	436(M+H)		1
969	(2R)-the 2-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-cyclohexane carboxamide	504(M+H)		3
					970	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline	462(M+H)		1

	-2-yl] amino } cyclohexyl)-the 2-furoamide
					971	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) propionic acid amide	428(M+H)		3
972	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-[(4-methylpyrimidine-2-yl) sulfo-] ethanamide	456(M+H)		2
					973	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-furoamide	494(M+H)		1
974	3-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) propionic acid amide	490(M+H)		3
					975	2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	476(M+H)		1
976	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-hydroxyl-3,5-Dimethoxyphenyl) ethanamide	484(M+H)		1
					977	4, and 5-two bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiophene-2-carboxamide derivatives	556(M+H)		2
978	2-(3, the 5-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	468(M+H)		3
					979	2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl) ethanamide	536(M+H)		3
980	N2, and N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) lysyl amine	626(M+H)		2
					981	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	437(M+H)		2
982	4,5-two bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-furoamide	540(M+H)		1
					983	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(4-fluoro phenyl)-4-oxo butyramide	468(M+H)		2
984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide	516(M+H)		2
					985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindole-	553(M+H)		2

	The 2-yl) phenyl] propionic acid amide
					986	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide		447(M+H)	1
987	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazoles-4-yl) ethanamide		505(M+H)	3
					988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(6-methoxyl group-3-oxo-2,3-dihydro-1H-indenes-1-yl) ethanamide		492(M+H)	3
989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-{1-[(4-methoxy-benzyl) sulfo-]-cyclohexyl } ethanamide		566(M+H)	3
					990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(7-methoxyl group-2-oxo-2H-chromene-4-yl) ethanamide		506(M+H)	1
991	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides		565(M+H)	2
					992	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo butyramide		643(M+H)	3
993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy) phenyl] amino } carbonyl) amino] benzamide		640(M+H)	1
					994	3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group) amino] benzamide		605(M+H)	1
995	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydrochysene-1H-indoles-1-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide		709(M+H)	3
					996	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(the 7-ethyl-		649(M+H)	1

	The 1H-indol-3-yl)-4-oxo butyramide
					997	4-(4-tert-butyl-phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-oxo butyramide	635(M+H)		3
998	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide	593(M+H)		2
					999	N-(2,4 dichloro benzene base)-2-{2-[(cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino]-the 2-oxoethyl } benzamide	595(M+H)		3
1000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide	600(M+H)		1
					1001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(4-nitrophenyl) butyramide	481(M+H)		1
1002	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3-(2-nitrophenyl) acrylamide	465(M+H)		3
					1003	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(3-Phenoxyphenyl) ethanamide	500(M+H)		2
1004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-Phenoxyphenyl) ethanamide	500(M+H)		2
					1005	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide	523(M+H)		1
1006	N2-benzoyl-N 5-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N1, N1-dipropyl glutamine (glutamamide)	606(M+H)		1
					1007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-phenoxy benzamide	486(M+H)		1
1008	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-phenylethyl) benzamide	498(M+H)		3
					1009	The 3-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	498(M+H)		3

1010	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide	544(M+H)		2
					1011	The 2-[(2-cyano-phenyl) sulfo-]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) benzamide	527(M+H)		3
1012	2-[4-(benzyl oxygen base)-3-p-methoxy-phenyl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	544(M+H)		3
					1013	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[(1R)-and 1-(1-naphthyl) ethyl] phthalamide	591(M+H)		3
1014	(2S)-and 2-(3-benzoyl phenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) propionic acid amide	526(M+H)		3
					1015	N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N, N-pair [(1S)-and the 1-phenylethyl] phthalamide	645(M+H)		1
1016	(2S)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2-fluorodiphenyl-4-yl) propionic acid amide	516(M+H)		2
					1017	2-[(4-benzyl chloride base) sulfo-]-4-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-oxo butyramide	640(M+H)		3
1018	2-[(4-benzyl chloride base) sulfo-]-N-(cis-4-{[4-(dimethylamino)-5, ó, 7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(4-aminomethyl phenyl)-4-oxo butyramide	620(M+H)		2
					1019	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl } ethanamide	628(M+H)		1
1020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide	532(M+H)		2
					1021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-oxo-4-(2-thienyl) butyramide	456(M+H)		3
1022	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-4-(2-thienyl) butyramide	442(M+H)		3

1023	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(2,4, the 6-Trichlorophenoxy) ethanamide	526(M+H)	3
				1024	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) ethanamide	553(M+H)	3
1025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(1-naphthoyl) benzamide	548(M+H)	3
				1026	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-methoxy benzamide	530(M+H)	1
1027	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide	549(M+H)	2
				1028	N-{2-[(2-chloro-6-fluoro benzyl) sulfo-] ethyl }-N-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide	675(M+H)	2
1029	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) anthracene-9-methane amide	494(M+H)	3
				1030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 2-phenoxy benzamide	486(M+H)	1
1031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) xenyl-2-methane amide	470(M+H)	3
				1032	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-3,3-diphenylprop acid amides	498(M+H)	3
1033	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-phenylquinoline-4-methane amide	521(M+H)	2
				1034	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[(1S)-and the 1-phenylethyl] phthalamide	541(M+H)	3
1035	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(4-methyl benzoyl) benzamide	512(M+H)	3
				1036	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-(phenoxymethyl) benzamide	500(M+H)	3
1037	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{ [4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } ring	601(M+H)	3

1052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-2-methoxyl group-2-phenyl-acetamides	438(M+H)		2
					1053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1,2,3,4-naphthane-2-methane amide	448(M+H)		3
1054	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-1,3-benzothiazole-6-methane amide	451(M+H)		3
					1055	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-the 2-hydroxybenzamide	444(M+H)		1
1056	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl)-5-(methylthio group)-benzamide	474(M+H)		3
					1057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-7-methoxyl group-1-benzofuran-2-carboxamides	464(M+H)		3
1058	2-amino-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	423(M+H)		3
					1059	2-(allyl group sulfenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) niacinamide	467(M+H)		3
1060	3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-the 4-hydroxybenzamide	522(M+H)		3
					1061	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives	492(M+H)		3
1062	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide	524(M+H)		2
					1063	2-(2-chloro-4-fluoro phenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-ethanamide	474(M+H)		3
1064	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-the 2-furoamide	553(M+H)		3
					1065	5-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) methyl] thiophene-2-carboxamide derivatives	448(M+H)		3
1066	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2,3-diphenylprop acid amides	512(M+H)		3
					1067	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	452(M+H)		3

	Base] amino } cyclohexyl) methyl]-3-(2-hydroxy phenyl) propionic acid amide
						1068	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-5-iodo-2-furoamide		524(M+H)		3
1069	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-(2-iodine substituted phenyl) ethanamide		548(M+H)		3
						1070	(2E)-and N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-(3-nitrophenyl) acrylamide		479(M+H)		2
1071	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide		462(M+H)		3
						1072	2-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] benzamide		498(M+H)		3
1073	2, two (4-the chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7 of 2-, 8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide		566(M+H)		3
						1074	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-5-(4-methyl-2-nitrophenyl)-2-furoamide		533(M+H)		3
1075	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-5-nitrothiophene-2-methane amide		459(M+H)		3
						1076	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide		467(M+H)		3
1077	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide		483(M+H)		3
						1078	1-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-1H-indoles-3-methane amide		537(M+H)		3
1079	2-hexamethylene-1-alkene-1-base-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide		426(M+H)		3
						1080	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-4-(4-ethoxyl phenenyl)-2-(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1 h-pyrazole-4-yl)-4-oxo butyramide		680(M+H)		3
1081	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl]-ethanamide		506(M+H)		3

1082	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-3, the 5-dimethyl benzamide	542(M+H)		3
					1083	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide	512(M+H)		3
1084	2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] ethanamide	478(M+H)		3
					1085	N2-{ cis-4-[(2, the 6-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	435(M+H)		3
1086	N2-{ cis-4-[(2-ethoxy benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	419(M+H)		3
					1087	N2-{ cis-4-[(1H-indol-3-yl methyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	414(M+H)		3
1088	N2-{ cis-4-[(2, the 5-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	435(M+H)		3
					1089	N2-(cis-4-{[(4-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	455(M+H)		3
1090	N2-(cis-4-{[(5-methoxyl group-1H-indol-3-yl) methyl] amino }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	444(M+H)		3
					1091	N2-(cis-4-{[(2-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	455(M+H)		3
1092	4-bromo-2-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-the 6-methoxyphenol	499(M+H)		3
					1093	N2-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	492(M+H)		3
1094	N2-{ cis-4-[(2, the 4-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	435(M+H)		3
					1095	N4, N4-dimethyl-N2-{ cis-4-[(2,3,4-trimethoxy benzyl) amino] cyclohexyl } quinoline-2, the 4-diamines	465(M+H)		3
1096	4-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-2, the 6-syringol	451(M+H)		3
					1097	N2-{ cis-4-[(3-oxyethyl group-4-p-methoxy-phenyl) amino] cyclohexyl }-N 4，N 4-dimethyl quinoline-2, the 4-diamines	449(M+H)		3

1098	N4, N4-dimethyl-N 2-cis-4-[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl) amino] cyclohexyl } quinoline-2, the 4-diamines	509(M+H)	3
				1099	N 4，N 4-diamino-N 2-{ cis-4-[(3,4,5-trimethoxy benzyl) amino] cyclohexyl } quinoline-2, the 4-diamines	465(M+H)	3
1100	N4, N4-dimethyl-N 2-cis-4-[(pentamethyl-benzyl) and amino] cyclohexyl } quinoline-2, the 4-diamines	445(M+H)	3
				1101	N 2-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	435(M+H)	3
1102	4-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-2-iodo-6-methoxyphenol	547(M+H)	3
				1103	4-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-2, the 6-xylenol	419(M+H)	3
1104	N2-{ cis-4-[(3-methoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	405(M+H)	3
				1105	N2-{ cis-4-[(3-bromo-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	471(M+H)	3
1106	N4, N4-dimethyl-N2-{ cis-4-[(3-phenyl butyl) amino] cyclohexyl } quinoline-2, the 4-diamines	417(M+H)	3
				1107	3-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-amino] methyl }-6-methyl-4H-chromene-4-ketone	457(M+H)	3
1108	3-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-amino] methyl }-6,8-dimethyl-4H-chromene-4-ketone	471(M+H)	3
				1109	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrroles-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	468(M+H)	3
1110	N4, N4-dimethyl-N 2-cis-4-[(2-phenyl propyl) and amino] cyclohexyl } quinoline-2, the 4-diamines	403(M+H)	3
				1111	N2-(cis-4-{[(2E)-2-benzylidene heptyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	471(M+H)	3
1112	N2-(cis-4-{[(2E)-3-(2-p-methoxy-phenyl) third-2-alkene-1-yl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	431(M+H)	3
				1113	6-chloro-3-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-4H-chromene-4-ketone	477(M+H)	3

1114	N2-[cis-4-({ [5-(4-fluoro phenyl) pyridin-3-yl] methyl } amino)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	470(M+H)	3
				1115	4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) quinoline-2-yls] amino } cyclohexyl) amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester	552(M-H)	1
1116	2-[(5-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl } imidazo [2,1-b] [1,3] thiazole-6-yl) sulfo-] benzoic acid methyl ester	587(M+H)	3
				1117	N2-[cis-4-({ [3-(4-fluoro phenyl)-1H-pyrazoles-4-yl] methyl } amino)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	459(M+H)	3
1118	N4, and N4-dimethyl-N2-(cis-4-{[4-(methylthio group) benzyl] amino } cyclohexyl) quinoline-2, the 4-diamines	421(M+H)	3
				1119	N4, N4-dimethyl-N2-{ cis-4-[(1-naphthyl methyl) amino] cyclohexyl } quinoline-2, the 4-diamines	425(M+H)	3
1120	4-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] methyl }-the 2-methoxyphenol	421(M+H)	3
				1121	N2-{ cis-4-[(3-chloro-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	427(M+H)	3
1122	N2-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)	2
				1123	N2-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	433(M+H)	2
1124	N2-(cis-4-{[(1H-indol-3-yl methyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	428(M+H)	3
				1125	N2-(cis-4-{[(2,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)	3
1126	N2-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	469(M+H)	2
				1127	N2-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	458(M+H)	3
1128	N2-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	469(M+H)	3
				1129	4-bromo-2-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }	513(M+H)	2

	Cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol
					1130	N2-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	506(M+H)		2
1131	N2-(cis-4-{[(2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)		3
					1132	N4, N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxy benzyl) amino] methyl } cyclohexyl)-quinoline-2, the 4-diamines	479(M+H)		3
1133	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2, the 6-syringol	465(M+H)		3
					1134	N2-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	463(M+H)		3
1135	N4, N4-dimethyl-N 2-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl) amino] methyl } cyclohexyl)-quinoline-2, the 4-diamines	523(M+H)		3
					1136	N4, N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxy benzyl) amino] methyl } cyclohexyl)-quinoline-2, the 4-diamines	479(M+H)		3
1137	N4, N4-dimethyl-N 2-(cis-4-{[(pentamethyl-benzyl) amino] methyl } cyclohexyl)-quinoline-2, the 4-diamines	459(M+H)		3
					1138	N2-(cis-4-{[(3,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)		3
1139	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2-iodo-6-methoxyphenol	561(M+H)		3
					1140	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol	433(M+H)		3
1141	N2-(cis-4-{[(4-methoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	419(M+H)		3
					1142	N2-(cis-4-{[(2,3-dihydro-1,4-benzo dioxin-6-ylmethyl) amino] methyl } cyclohexyl)-N 4，N 4-dimethyl quinoline-2, the 4-diamines	447(M+H)		3
1143	N2-(cis-4-{[(3-bromobenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	467(M+H)		3
					1144	N2-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N 4，N 4-dimethyl quinoline-2, the 4-diamines	527(M+H)		2

1145	N2-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	497(M+H)	3
				1146	3-chloro-4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenol	439(M+H)	3
1147	2-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) benzonitrile	414(M+H)	3
				1148	N2-(cis-4-{[(3-benzyl chloride base) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	423(M+H)	？
1149	N2-(cis-4-{[(4-chloro benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	423(M+H)	3
				1150	N 2-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	460(M+H)	3
1151	N2-[cis-4-({ [4-(dimethylamino) benzyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	432(M+H)	3
				1152	N2-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	506(M+H)	3
1153	N2-[cis-4-({ [2-fluoro-5-(trifluoromethyl) benzyl] amino } methyl)-cyclohexyl]-N 4，N 4-dimethyl quinoline-2, the 4-diamines	475(M+H)	3
				1154	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenol	405(M+H)	3
1155	[5-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 2-furyl] methyl alcohol	409(M+H)	3
				1156	N2-(cis-4-{[(4-isopropoxide benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	447(M+H)	3
1157	N2-[cis-4-({ [(5-ethyl-2-thienyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	423(M+H)	3
				1158	N2-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	491(M+H)	1
1159	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 2-thanatol	449(M+H)	3
				1160	N2-{ cis-4-[({[4-(dimethylamino)-1-naphthyl] methyl } amino)-methyl] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	482(M+H)	3

1161	N4, N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxy benzyl)-amino] methyl } cyclohexyl) quinoline-2, the 4-diamines	479(M+H)	2
				1162	2-bromo-4-chloro-6-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenol	517(M+H)	3
1163	3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) benzonitrile	414(M+H)	3
				1164	N2-(cis-4-{[(2-fluoro-5-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	437(M+H)	3
1165	N4, N4-dimethyl-N2-{ cis-4-[({2-[(trifluoromethyl) sulfo-] benzyl }-amino) methyl] cyclohexyl } quinoline-2, the 4-diamines	489(M+H)	3
				1166	N2-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	511(M+H)	3
1167	N2-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl }-cyclohexyl-N4, N4-dimethyl quinoline-2,4-diamines	463(M+H)	3
				1168	N4, N4-dimethyl-N 2-[cis-4-({ [2-(trifluoromethoxy) benzyl] amino } methyl) cyclohexyl]-quinoline-2, the 4-diamines	473(M+H)	3
1169	N2-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	477(M+H)	2
				1170	N2-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	477(M+H)	2
1171	N2-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	575(M+H)	2
				1172	N2-[cis-4-({ [2-(difluoro-methoxy) benzyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	455(M+H)	3
1173	N2-(cis-4-{[(5-fluoro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	437(M+H)	3
				1174	N4, N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl } cyclohexyl) quinoline-2, the 4-diamines	521(M+H)	2
1175	N4, N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl } cyclohexyl)-quinoline-2, the 4-diamines	479(M+H)	2
				1176	N2-(cis-4-{[(2,3-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)	3

	Base) methyl] amino } methyl) cyclohexyl] quinoline-2, the 4-diamines
					1193	N2-(cis-4-{[(3,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	449(M+H)		3
1194	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 2-methylphenol	419(M+H)		3
					1195	N2-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	447(M+H)		3
1196	2-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol	435(M+H)		3
					1197	N2-[cis-4-({ [3-chloro-2-fluoro-5-(trifluoromethyl) benzyl] amino } methyl) cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	509(M+H)		3
1198	N2-[cis-4-({ [3-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	475(M+H)		3
					1199	4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl] amino } methyl)-2-fluoro-6-methoxyphenol	453(M+H)		3
1200	N2-(cis-4-{[(2-fluoro-4,5-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	467(M+H)		3
					1201	N2-(cis-4-{[(2-Ethylbenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	417(M+H)		3
1202	3-[[4-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino }-cyclohexyl) methyl] amino } methyl) phenyl] (methyl) amino]-propionitrile	471(M+H)		3
					1203	N2-{ cis-4-[({4-[(4-bromobenzyl) oxygen base] benzyl } amino) methyl]-cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	573(M+H)		3
1204	N2-(cis-4-{[(3,5-two bromo-2-ethoxy benzyls) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	589(M+H)		3
					1205	N2-{ cis-4-[(2, the 6-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	386(M+H)		3
1206	N2-{ cis-4-[(2-ethoxy benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	370(M+H)		3
					1207	N2-{ cis-4-[(1H-indol-3-yl methyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	365(M+H)		3
1208	N2-{ cis-4-[(2, the 5-dimethoxy-benzyl) amino] cyclohexyl }-	386(M+H)		3

	N4, N4-dimethyl pyrimidine-2,4-diamines
				1209	N2-(cis-4-{[(4-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	406(M+H)	3
1210	N2-(cis-4-{[(5-methoxyl group-1H-indol-3-yl) methyl] amino }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	395(M+H)	3
				1211	N2-(cis-4-{[(2-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	406(M+H)	3
1212	4-bromo-2-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-the 6-methoxyphenol	450(M+H)	3
				1213	N2-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	443(M+H)	2
1214	N2-{ cis-4-[(2, the 4-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	386(M+H)	3
				1215	N4, N4-dimethyl-N2-{ cis-4-[(2,3,4-trimethoxy benzyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	416(M+H)	3
1216	4-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-2, the 6-syringol	402(M+H)	3
				1217	N2-{ cis-4-[(3-oxyethyl group-4-methoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)	3
1218	N4, N4-dimethyl-N2-{ cis-4-[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	460(M+H)	3
				1219	N4, N4-dimethyl-N2-{ cis-4-[(3,4,5-trimethoxy benzyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	416(M+H)	3
1220	N4, N4-dimethyl-N2-{ cis-4-[(pentamethyl-benzyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	396(M+H)	3
				1221	N2-{ cis-4-[(3, the 5-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	386(M+H)	3
1222	4-{[(cis-4-{[4-{ dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-2-iodo-6-methoxyphenol	498(M+H)	3
				1223	4-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-2, the 6-xylenol	370(M+H)	3
1224	N2-{ cis-4-[(3-methoxy-benzyl) amino] cyclohexyl }-N4, N4-two	356(M+H)	3

	Methylpyrimidine-2, the 4-diamines
					1225	N2-{ cis-4-[(3-bromo-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	422(M+H)		3
1226	N4, N4-dimethyl-N2-{ cis-4-[(3-phenyl butyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	368(M+H)		3
					1227	3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-amino] methyl }-6-methyl-4H-chromene-4-ketone	408(M+H)		3
1228	6-chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) amino] methyl }-7-methyl-4H-chromene-4-ketone	442(M+H)		3
					1229	3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-amino] methyl }-6,8-dimethyl-4H-chromene-4-ketone	422(M+H)		3
1230	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrroles-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	419(M+H)		3
					1231	N4, N4-dimethyl-N2-{ cis-4-[(2-phenyl propyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	354(M+H)		3
1232	N2-(cis-4-{[(2E)-2-benzylidene heptyl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	422(M+H)		3
					1233	N2-(cis-4-{[(2E)-3-(2-p-methoxy-phenyl) third-2-alkene-1-yl] amino } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	382(M+H)		3
1234	6-chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-4H-chromene-4-ketone	428(M+H)		3
					1235	N-[cis-4-({ [5-(4-fluoro phenyl) pyridin-3-yl] methyl }-amino) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	421(M+H)		2
1236	4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino } cyclohexyl) amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester	503(M-H)		1
					1237	2-[(5-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl } imidazo [2,1-b] [1,3] thiazole-6-yl) sulfo-] benzoic acid methyl ester	538(M+H)		3
1238	N2-[cis-4-({ [3-(4-fluoro phenyl)-1H-pyrazoles-4-yl] methyl }-amino) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	410(M+H)		3
					1239	N4, and N4-dimethyl-N2-(cis-4-{[4-(methylthio group) benzyl] amino } cyclohexyl) pyrimidine-2, the 4-diamines	372(M+H)		3

1240	N4, N4-dimethyl-N2-{ cis-4-[(1-naphthyl methyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	376(M+H)		3
					1241	4-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] methyl }-the 2-methoxyphenol	372(M+H)		3
1242	N2-{ cis-4-[(3-fluoro-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	378(M+H)		3
					1243	N2-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)		2
1244	N2-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	384(M+H)		2
					1245	N2-(cis-4-{[(1H-indol-3-yl methyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	379(M+H)		3
1246	N2-(cis-4-{[(2,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)		3
					1247	N2-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, the N4-dimethyl] pyrimidine-2, the 4-diamines	420(M+H)		1
1248	N2-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	407(M-H)		2
					1249	N2-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	420(M+H)		1
1250	4-bromo-2-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol	462(M-H)		1
					1251	N2-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	455(M-H)		1
1252	N2-(cis-4-{[(2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)		2
					1253	N4, N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxy benzyl)-amino] methyl } cyclohexyl)-pyrimidine-2, the 4-diamines	430(M+H)		1
1254	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-2, the 6-syringol	414(M-H)		3
					1255	N2-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	414(M-H)		1

1256	N4, N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl) amino] methyl } cyclohexyl)-pyrimidine-2, the 4-diamines	474(M+H)		1
					1257	N4, N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxy benzyl)-amino] methyl } cyclohexyl)-pyrimidine-2, the 4-diamines	430(M+H)		2
1258	N4, N4-dimethyl-N2-(cis-4-{[(pentamethyl-benzyl)-amino] methyl } cyclohexyl)-pyrimidine-2, the 4-diamines	410(M+H)		3
					1259	N2-(cis-4-{[(3,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)		3
1260	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-2-iodo-6-methoxyphenol	512(M+H)		1
					1261	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol	382(M+H)		1
1262	N2-(cis-4-{[(4-methoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	370(M+H)		3
					1263	N2-(cis-4-{[(2,3-dihydro-1,4-benzo dioxin-6-ylmethyl) amino]-methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	398(M+H)		3
1264	N2-(cis-4-{[(3-bromobenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	418(M+H)		3
					1265	N2-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	478(M+H)		1
1266	N2-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	448(M+H)		1
					1267	3-chloro-4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl) phenol	388(M-H)		3
1268	2-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl) benzonitrile	365(M+H)		3
					1269	N2-(cis-4-{[(3-benzyl chloride base) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	374M+H)		3
1270	N2-(cis-4-{[(4-benzyl chloride base) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	374(M+H)		3
					1271	N2-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) hexamethylene	411(M+H)		2

	Base]-N4, N4-dimethyl pyrimidine-2,4-diamines
				1272	N2-[cis-4-({ [4-(dimethylamino) benzyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	383(M+H)	3
1273	N2-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	457(M+H)	1
				1274	N2-[cis-4-({ [2-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	426(M+H)	3
1275	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl) phenol	354(M-H)	3
				1276	[5-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 2-furyl] methyl alcohol	360(M+H)	3
1277	N2-(cis-4-{[(4-isopropoxide benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	398(M+H)	2
				1278	N2-[cis-4-({ [(5-ethyl-2-thienyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	374(M+H)	3
1279	N2-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	442(M+H)	1
				1280	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 2-thanatol	400(M+H)	2
1281	N2-{ cis-4-[({[4-(dimethylamino)-1-naphthyl] methyl } amino)-methyl] cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	433(M+H)	2
				1282	N4, N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxy benzyl)-amino] methyl } cyclohexyl)-pyrimidine-2, the 4-diamines	430(M+H)	1
1283	2-bromo-4-chloro-6-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl) phenol	468(M+H)	3
				1284	3-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl) benzonitrile	365(M+H)	3
1285	N2-(cis-4-{[(2-fluoro-5-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	388(M+H)	3
				1286	N4, N4-dimethyl-N2-{ cis-4-[({2-[(trifluoromethyl) sulfo-] benzyl }-amino) methyl] cyclohexyl } pyrimidine-2, the 4-diamines	440(M+H)	3
1287	N2-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl }-hexamethylene	462(M+H)	1

	Base] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines
					1304	N4, N4-dimethyl-N2-(cis-4-{[(3-thienyl methyl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	346(M+H)		3
1305	N4, N4-dimethyl-N2-(cis-4-{[(3-methyl-benzyl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	354(M+H)		3
					1306	N4, N4-dimethyl-N2-(cis-4-{[(2-methyl-benzyl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	354(M+H)		3
1307	N4, N4-dimethyl-N2-(cis-4-{[(4-methyl-benzyl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	354(M+H)		3
					1308	N2-(cis-4-{[(3,5-dichloro benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	408(M+H)		3
1309	N2-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	414(M+H)		1
					1310	N2-(cis-4-{[(3-bromo-4,5-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	478(M+H)		1
1311	N2-(cis-4-{[(4-methoxyl group-3-methyl-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	384(M+H)		2
					1312	N2-(cis-4-{[(2-bromo-4,5-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	478(M+H)		2
1313	N4, N4-dimethyl-N2-[cis-4-({ [(2-methyl-5-phenyl-3-furyl) methyl] amino } methyl) cyclohexyl] pyrimidine-2, the 4-diamines	420(M+H)		3
					1314	N2-(cis-4-{[(3,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	400(M+H)		2
1315	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 2-methylphenol	368(M-H)		3
					1316	N2-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	398(M+H)		2
1317	2-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol	386(M+H)		3
					1318	N2-[cis-4-({ [3-chloro-2-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	460(M+H)		3

1319	N2-[cis-4-({ [3-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	426(M+H)	3
				1320	4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-2-fluoro-6-methoxyphenol	402(M-H)	3
1321	N2-(cis-4-{[(2-fluoro-4,5-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	418(M-H)	3
				1322	N2-(cis-4-{[(2-Ethylbenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	368(M+H)	3
1323	3-[[4-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-methyl] amino } methyl) phenyl] (methyl) amino]-propionitrile	422(M+H)	2
				1324	N2-{ cis-4-[({4-[(4-bromobenzyl) oxygen base] benzyl } amino) methyl]-cyclohexyl }-N4, N4-dimethyl pyrimidine-2,4-diamines	524(M+H)	2
1325	N2-(cis-4-{[(3,5-two bromo-2-ethoxy benzyls) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	540(M+H)	2
				1326	N2-{ cis-4-[(2, the 6-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	440(M+H)	3
1327	N2-{ cis-4-[(2-ethoxy benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	424(M+H)	3
				1328	N2-{ cis-4-[(1H-indol-3-yl methyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	419(M+H)	3
1329	N2-{ cis-4-[(2, the 5-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4 dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	440(M+H)	3
				1330	N2-(cis-4-{[(4-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	460(M+H)	3
1331	N2-(cis-4-{[(5-methoxyl group-1H-indol-3-yl) methyl] amino }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	449(M+H)	1
				1332	N2-(cis-4-{[(2-methoxyl group-1-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	460(M+H)	3
1333	4-bromo-2-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-the 6-methoxyphenol	504(M+H)	3
				1334	N2-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	497(M+H)	3

1335	N2-{ cis-4-[(2, the 4-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	440(M+H)	3
				1336	N4, N4-dimethyl-N2-{ cis-4-[(2,3,4-trimethoxy benzyl) amino]-cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	470(M+H)	3
1337	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-2, ó-syringol	456(M+H)	2
				1338	N2-{ cis-4-[(3-oxyethyl group-4-methoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	3
1339	N4, N4-dimethyl-N2-{ cis-4-[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl) amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	514(M+H)	3
				1340	N4, N4-dimethyl-N2-{ cis-4-[(3,4,5-trimethoxy benzyl) amino]-cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	470(M+H)	3
1341	N4, N4-dimethyl-N2-{ cis-4-[(pentamethyl-benzyl) amino]-cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	450(M+H)	2
				1342	N2-{ cis-4-[(3, the 5-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	440(M+H)	2
1343	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-2 iodos-6-methoxyphenol	552(M+H)	2
				1344	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-2, the 6-xylenol	424(M+H)	3
1345	N2-{ cis-4-[(3-methoxy-benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	410(M+H)	3
				1346	N2-{ cis-4-[(3-bromo-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	476(M+H)	3
1347	N4, N4-dimethyl-N2-{ cis-4-[(3-phenyl butyl) amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	422(M+H)	3
				1348	3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-6-methyl-4H-chromene-4-ketone	462(M+H)	3
1349	6-chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-7-methyl-4H-benzo pyrrole	496(M+H)	3

	Mutter-4-ketone
				1350	3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-6,8-dimethyl-4H-chromene-4-ketone	476(M+H)	2
1351	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrroles-3-yl) methyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	473(M+H)	3
				1352	N4, N4-dimethyl-N2-{ cis-4-[(2-phenyl propyl) amino] cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	408(M+H)	3
1353	N2-(cis-4-{[(2E)-2-benzylidene heptyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	476(M+H)	3
				1354	N2-(cis-4-{[(2E)-3-(2-p-methoxy-phenyl) third-2-alkene-1-yl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	436(M+H)	3
1355	6-chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-4H-chromene-4-ketone	482(M+H)	3
				1356	N2-[cis-4-({ [5-(4-fluoro phenyl) pyridin-3-yl] methyl }-amino) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	475(M+H)	3
1357	4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester	559(M+H)	1
				1358	2-[(5-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] methyl } imidazo-[2,1-b] [1,3] thiazole-6-yl) sulfo-] benzoic acid methyl ester	592(M+H)	3
1359	N2-[cis-4-({ [3-(4-fluoro phenyl)-1H-pyrazoles-4-yl] methyl } amino) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	464(M+H)	1
				1360	N4, N4-dimethyl-N2-(cis-4-{[4-(methylthio group) benzyl] amino }-cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines	426(M+H)	3
1361	N4, N4-dimethyl-N2-{ cis-4-[(1-naphthyl methyl) amino]-cyclohexyl }-5,6,7,8-tetrahydro quinazoline-2,4-diamines	430(M+H)	3
				1362	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	426(M+H)	3

	Base] amino } cyclohexyl) amino] methyl }-the 2-methoxyphenol
				1363	N2-{ cis-4-[(3-chloro-4-fluoro benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	432(M+H)	3
1364	N2-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	1
				1365	N2-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	438(M+H)	2
1366	N2-(cis-4-{[(1H-indol-3-yl methyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	433(M+H)	2
				1367	N2-(cis-4-{[(2,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	2
1368	N2-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	474(M+H)	2
				1369	N2-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	463(M+H)	1
1370	N2-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	474(M+H)	3
				1371	4-bromo-2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol	518(M+H)	2
1372	N2-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	511(M+H)	1
				1373	N2-(cis-4-{[(2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	3
1374	N4, N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxy benzyl)-amino] methyl } cyclohexyl)-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	484(M+H)	3
				1375	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-syringol	470(M+H)	3
1376	N2-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	468(M+H)	1
				1377	N4, N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-	528(M+H)	2

	1H-pyrazoles-4-yl } methyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines
					1378	N4, N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxy benzyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines		484(M+H)	2
1379	N4, N4-dimethyl-N2-(cis-4-{[(pentamethyl-benzyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines		464(M+H)	3
					1380	N2-(cis-4-{[(3,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		454(M+H)	2
1381	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-2-iodo-6-methoxyphenol		566(M+H)	1
					1382	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol		438(M+H)	2
1383	N2-(cis-4-{[(4-methoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		424(M+H)	3
					1384	N2-(cis-4-{[(2,3-dihydro-1,4-benzo dioxin-6-ylmethyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		452(M+H)	3
1385	N2-(cis-4-{[(3-bromobenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		472(M+H)	3
					1386	N2-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		532(M+H)	3
1387	N2-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		502(M+H)	3
					1388	3-chloro-4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino }-methyl) phenol		444(M+H)	2
1389	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) benzonitrile		419(M+H)	3
					1390	N2-(cis-4-{[(3-benzyl chloride base) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		428(M+H)	3
1391	N2-(cis-4-{[(4-benzyl chloride base) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines		428(M+H)	3

1392	N2-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	465(M+H)		2
					1393	N2-[cis-4-({ [4-(dimethylamino) benzyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	437(M+H)		3
1394	N2-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	511(M+H)		3
					1395	N2-[cis-4-({ [2-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	480(M+H)		3
1396	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenol	410(M+H)		3
					1397	[5-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 2-furyl] methyl alcohol	414(M+H)		3
1398	N2-(cis-4-{[(4-isopropoxide benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	452(M+H)		3
					1399	N2-[cis-4-({ [(5-ethyl-2-thienyl) methyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	428(M+H)		3
1400	N2-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	496(M+H)		1
					1401	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 2-thanatol	454(M+H)		2
1402	N2-{ cis-4-[({[4-(dimethylamino)-1-naphthyl] methyl } amino)-methyl] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	487(M+H)		2
					1403	N4, N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxy benzyl)-amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines	484(M+H)		1
1404	2-bromo-4-chloro-6-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-amino } methyl) phenol	522(M+H)		2
					1405	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) benzonitrile	419(M+H)		3
1406	N2-(cis-4-{[(2-fluoro-5-methoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	442(M+H)		3

1407	N4, N4-dimethyl-N2-{ cis-4-[({2-[(trifluoromethyl) sulfo-]-benzyl } amino) methyl] cyclohexyl }-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	494(M+H)	3
				1408	N2-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-four ammonia quinazolines-2,4-diamines	516(M+H)	3
1409	N2-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	468(M+H)	3
				1410	N4, N4-dimethyl-N2-[cis-4-({ [2-(trifluoromethoxy) benzyl] amino } methyl) cyclohexyl]-5,6,7,8-tetrahydro quinazoline-2,4-diamines	478(M+H)	3
1411	N2-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7, S-tetrahydro quinazoline-2,4-diamines	482(M+H)	1
				1412	N2-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	482(M+H)	1
1413	N2-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	580(M+H)	1
				1414	N2-[cis-4-({ [2-(difluoro-methoxy) benzyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	460(M+H)	3
1415	N2-(cis-4-{[(5-fluoro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	442(M+H)	3
				1416	N4, N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines	526(M+H)	1
1417	N4, N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines	484(M+H)	1
				1418	N2-(cis-4-{[(2,3-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	3
1419	N2-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	450(M+H)	3
				1420	N2-(cis-4-{[(1-thionaphthene-3-ylmethyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	450(M+H)	3
1421	N4, N4-dimethyl-N2-[cis-4-({ [(1-Methyl-1H-indole-3-yl) methyl] amino } methyl) cyclohexyl]-5,6,7,8-tetrahydro quinazoline-2,4-diamines	447(M+H)	3
				1422	N4, N4-dimethyl-N2-[cis-4-({ [(5-methyl-2-thienyl) methyl]	414(M+H)	3

1437	N2-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	452(M+H)	2
				1438	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol	440(M+H)	3
1439	N2-[cis-4-({ [3-chloro-2-fluoro-5-(trifluoromethyl) benzyl] amino } methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	514(M+H)	3
				1440	N2-[cis-4-({ [3-fluoro-5-(trifluoromethyl) benzyl] amino }-methyl) cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	480(M+H)	3
1441	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl)-2-fluoro-6-methoxyphenol	458(M+H)	2
				1442	N2-(cis-4-{[(2-fluoro-4,5-dimethoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	472(M+H)	3
1443	N2-(cis-4-{[(2-Ethylbenzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	422(M+H)	3
				1444	3-[[4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } methyl) phenyl] (methyl)-amino] propionitrile	476(M+H)	3
1445	N2-{ cis-4-[({4-[(4-bromobenzyl) oxygen base] benzyl } amino) methyl]-cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	578(M+H)	3
				1446	N2-(cis-4-{[(3,5-two bromo-2-ethoxy benzyls) amino] methyl }-cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	594(M+H)	3
1447	N2-(cis-4-{[2-(4-bromophenyl) ethyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	467(M+H)	3
				1448	N2-(cis-4-{[2-(3-chlorophenyl) ethyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	423(M+H)	-
1449	N2-(cis-4-{[2-(2-chloro phenoxy group) ethyl] amino } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	439(M+H)	3
				1450	N2-{ cis-4-[(2-methoxyl group-2-phenylethyl) amino] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	419(M+H)	3
1451	N4, N4-dimethyl-N2-[4-(pentamethylbenzene ylmethyl-amino)-hexamethylene	445(M+H)	3

	Cyclohexyl) quinoline-2, the 4-diamines
				1468	N2-[cis-4-({ [2-(4-tert-butyl-phenyl) ethyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	459(M+H)	3
1469	N4, N4-dimethyl-N2-(cis-4-{[(5-phenyl penta-4-alkynes-1-yl) amino] methyl } cyclohexyl) quinoline-2, the 4-diamines	441(M+H)	3
				1470	N2-[cis-4-({ [2-(2-p-methoxy-phenyl) ethyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	433(M+H)	3
1471	N4, N4-dimethyl-N2-(cis-4-{[(3-phenoxy propyl) amino] methyl } cyclohexyl) quinoline-2, the 4-diamines	433(M+H)	3
				1472	N4, N4-dimethyl-N2-(cis-4-{[(2,3,5, the 6-tetrafluoro is for benzyl)-amino] methyl } cyclohexyl) quinoline-2, the 4-diamines	461(M+H)	3
1473	N2-(cis-4-{[(2,5-dichloro benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	457(M+H)	3
				1474	N2-(cis-4-{[(5-chloro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	453(M+H)	3
1475	N2-(cis-4-{[(4-chloro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	453(M+H)	3
				1476	N2-(cis-4-{[(3-iodo-4-methyl-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl quinoline-2,4-diamines	529(M+H)	3
1477	N2-[cis-4-([(2S)-and 2-(dibenzyl amino) propyl group] amino } methyl)-cyclohexyl]-N4, N4-dimethyl quinoline-2,4-diamines	536(M+H)	3
				1478	N4, N4-dimethyl-N2-[cis-4-({ [(1-phenyl-5-propyl group-1H-pyrazoles-4-yl) methyl] amino } methyl) cyclohexyl] quinoline-2, the 4-diamines	497(M+H)	1
1479	N2-{ cis-4-[({[1-(4-chlorophenyl)-5-propyl group-1H-pyrazoles-4-yl] methyl } amino) methyl] cyclohexyl }-N4, N4-dimethyl quinoline-2,4-diamines	531(M+H)	1
				1480	N4, N4-dimethyl-N2-[cis-4-({ [4-(4-nitrophenyl) butyl] amino } methyl) cyclohexyl] quinoline-2, the 4-diamines	476(M+H)	3
1481	N2-(cis-4-{[2-(4-bromophenyl) ethyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	472(M+H)	3
				1482	N2-(cis-4-{[2-(3-chlorophenyl) ethyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	428(M+H)	3

1483	N2-{ cis-4-[(2-methoxyl group-2-phenylethyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	424(M+H)	3
				1484	N2-[4-(2-methoxyl group-2-phenyl-ethylamino)-cyclohexyl]-N4, N4-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	424(M+H)	3
1485	N4, N4-dimethyl-N2-[4-(pentamethylbenzene ylmethyl-amino)-cyclohexyl]-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines	450(M+H)	2
				1486	N2-{ cis-4-[(3-ethoxy benzyl) amino] cyclohexyl }-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	424(M+H)	3
1487	N2-(cis-4-{[(2S)-2, two (the benzyl oxygen base) propyl group of 3-] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	544(M+H)	3
				1488	N2-(cis-4-{[(3-methoxyl group-2-naphthyl) methyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	460(M+H)	3
1489	3-{[2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] ethyl } (3-aminomethyl phenyl)-amino] propionitrile	476(M+H)	2
				1490	3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] ethyl } (phenyl) amino]-propionitrile	462(M+H)	1
1491	N-{ (1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] ethyl }-the 4-methyl benzenesulfonamide	577(M+H)	1
				1492	(2-{[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl amino] methyl }-cyclohexyl)-phenyl-methyl alcohol	490(M+H)	3
1493	N2-(cis-4-{[2-(3, the 5-Dimethoxyphenyl) ethyl] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	454(M+H)	2
				1494	N4, and N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indoles-3-yl) ethyl] amino } cyclohexyl)-5,6,7,8-tetrahydro quinazoline-2,4-diamines	509(M+H)	3
1495	N2-(cis-4-{[2, two (4-chlorophenyl) ethyls of 2-] amino } cyclohexyl)-N4, N4-dimethyl-5,6,7,8-tetrahydro quinazoline-2,4-diamines	538(M+H)	3
				1496	(3-{ (1S)-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino]-the 1-methylethyl } phenyl) (phenyl) methyl alcohol	512(M+H)	3
1497	N2-[cis-4-({ [1-(diphenyl methyl) azetidine-3-yl] first	525(M+H)	1

1528	N4, N4-dimethyl-N2-(cis-4-{[(8-phenyl octyl group) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	438(M+H)		3
					1529	N2-[cis-4-({ [2-(4-tert-butyl-phenyl) ethyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	410(M+H)		3
1530	N4, N4-dimethyl-N2-(cis-4-{[(5-phenyl penta-4-alkynes-1-yl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	392(M+H)		3
					1531	N2-[cis-4-({ [2-(2-p-methoxy-phenyl) ethyl] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	384(M+H)		3
1532	N4, N4-dimethyl-N2-(cis-4-{[(3-phenoxy propyl) amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines	384(M+H)		3
					1533	N4, and N4-dimethyl-N2-(cis-4-{[(2,3,5, the 6-tetrafluoro is for benzyl) amino] methyl } cyclohexyl) and pyrimidine-2, the 4-diamines	412(M+H)		3
1534	N2-(cis-4-{[(2,5-dichloro benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	408(M+H)		3
					1535	N2-(cis-4-{[(5-chloro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	404(M+H)		3
1536	N2-(cis-4-{[(4-chloro-2-methoxy-benzyl) amino] methyl }-cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	404(M+H)		3
					1537	N2-(cis-4-{[(3-iodo-4-methyl-benzyl) amino] methyl } cyclohexyl)-N4, N4-dimethyl pyrimidine-2,4-diamines	480(M+H)		3
1538	N2-[cis-4-([(2S)-and 2-(dibenzyl amino) propyl group] amino } methyl)-cyclohexyl]-N4, N4-dimethyl pyrimidine-2,4-diamines	487(M+H)		3
					1539	2-(benzyloxy) ethyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	463(M+H)		3
1540	2, and the 2-dimethyl propyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	399(M+H)		3
					1541	" [4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-carboxylamine 4,5-dimethoxy-2-nitro-benzyl ester	524(M+H)		2
1542	3-(trifluoromethyl) phenyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	473(M+H)		3
					1543	The 4-bromophenyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	483(M+H)		3

1544	The 2-p-methoxy-phenyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	435(M+H)	3
				1545	The 2-methoxy ethyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	387(M+H)	3
1546	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine octyl group ester	441(M+H)	3
				1547	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine ethyl ester	357(M+H)	3
1548	[4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-carboxylamine 4-nitro-benzyl ester	464(M+H)	3
				1549	The 2-naphthyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	455(M+H)	3
1550	Allyl group (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	369(M+H)	3
				1551	[4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-carboxylamine benzyl ester	419(M+H)	3
1552	Phenyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	405(M+H)	3
				1553	(1R, 2S, 5R)-2-sec.-propyl-5-methylcyclohexyl (cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carbamate	467(M+H)	3
1554	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine 4-aminomethyl phenyl ester	419(M+H)	3
				1555	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) the carboxylamine methyl ester	343(M+H)	3
1556	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine 2-chloro benzyl ester	453(M+H)	3
				1557	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine 9H-fluorenes-9-ylmethyl ester	507(M+H)	3
1558	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) carboxylamine 2,2,2-three chloro-ethyl esters	459(M+H)	3
				1559	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-(benzyloxy) ethyl ester	477(M+H)	3

1560	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2,2-dimethyl propyl ester	413(M+H)		3
					1561	[(cis-4-{[4-(dimethylamino)-quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4,5-dimethoxy-2-nitrobenzyl ester	538(M+H)		3
1562	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 3-(trifluoromethyl) phenylester	487(M+H)		3
					1563	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4-bromophenyl ester	497(M+H)		3
1564	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-p-methoxy-phenyl ester	449(M+H)		3
					1565	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-methoxy ethyl ester	401(M+H)		3
1566	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine octyl group ester	455(M+H)		3
					1567	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine ethyl ester	371(M+H)		3
1568	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4-nitrobenzyl ester	478(M+H)		3
					1569	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-naphthyl ester	469(M+H)		3
1570	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine allyl ester	383(M+H)		3
					1571	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine benzyl ester	433(M+H)		3
1572	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine phenylester	419(M+H)		3
					1573	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-carboxylamine (1R, 2S, 5R)-2-sec.-propyl-5-methylcyclohexyl ester	481(M+H)		3
1574	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4-aminomethyl phenyl ester	433(M+H)		3
					1575	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine methyl ester	357(M+H)		3

1576	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-chlorine benzyl ester	467(M+H)		3
					1577	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 9H-fluorenes-9-ylmethyl ester	521(M+H)		3
1578	[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2,2,2-three chloro-ethyl esters	473(M+H)		3
					1579	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2-(benzyl oxygen base) ethyl ester	468(M+H)		3
1580	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2,2-dimethyl propyl ester	404(M+H)		3
					1581	[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-carboxylamine 4,5-dimethoxy-2-nitro-benzyl ester	529(M+H)		2
1582	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 3-(trifluoromethyl) phenylester	478(M+H)		3
					1583	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 4-bromophenyl ester	488(M+H)		3
1584	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2-p-methoxy-phenyl ester	440(M+H)		3
					1585	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2-methoxy ethyl ester	392(M+H)		3
1586	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine octyl group ester	446(M+H)		3
					1587	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine ethyl ester	362(M+H)		3
1588	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 4-nitrobenzyl ester	469(M+H)		3
					1589	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2-naphthyl ester	460(M+H)		3
1590	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) the carboxylamine allyl ester	374(M+H)		3
					1591	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) the carboxylamine benzyl ester	424(M+H)		3

1592	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) the carboxylamine phenylester	410(M+H)	3
				1593	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine (2S, 5R)-2-sec.-propyl-5-methylcyclohexyl ester	472(M+H)	3
1594	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 4-aminomethyl phenyl ester	424(M+H)	3
				1595	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) the carboxylamine methyl ester	348(M+H)	3
1596	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2-chlorine benzyl ester	458(M+H)	3
				1597	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 9H-fluorenes-9-ylmethyl ester	512(M+H)	3
1598	(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) carboxylamine 2,2,2-three chloro-ethyl esters	464(M+H)	3
				1599	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-(benzyloxy) ethyl ester	482(M+H)	3
1600	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2,2-dimethyl propyl ester	418(M+H)	3
				1601	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4,5-dimethoxy-2-nitrobenzyl ester	543(M+H)	3
1602	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 3-(trifluoromethyl) phenylester	492(M+H)	3
				1603	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } formic acid 4-bromophenyl ester	502(M+H)	3
1604	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-p-methoxy-phenyl ester	454(M+H)	3
				1605	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-methoxy ethyl ester	406(M+H)	3
1606	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine octyl group ester	460(M+H)	3

1607	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine ethyl ester	376(M+H)	3
				1608	[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-carboxylamine 4-nitro-benzyl ester	483(M+H)	3
1609	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-naphthyl ester	474(M+H)	3
				1610	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine allyl ester	388(M+H)	3
1611	[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester	438(M+H)	3
				1612	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine phenylester	424(M+H)	3
1613	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine (2S, 5R)-2-sec.-propyl-5-methylcyclohexyl ester	486(M+H)	3
				1614	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 4-aminomethyl phenyl ester	438(M+H)	3
1615	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] the carboxylamine methyl ester	362(M+H)	3
				1616	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2-chlorine benzyl ester	472(M+H)	3
1617	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 9H-fluorenes-9-ylmethyl ester	526(M+H)	3
				1618	[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] carboxylamine 2,2,2-three chloro-ethyl esters	478(M+H)	3
1619	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 2-(benzyloxy) ethyl ester	414(M+H)	3
				1620	2, and the 2-dimethyl propyl (cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carbamate	350(M+H)	3
1621	[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine 4,5-dimethoxy-2-nitro-benzyl ester	475(M+H)	3
				1622	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ammonia	424(M+H)	3

	Base formic acid 3-(trifluoromethyl) phenylester
					1623	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 4-bromophenyl ester	434(M+H)		3
1624	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 2-p-methoxy-phenyl ester	386(M+H)		3
					1625	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 2-methoxy ethyl ester	338(M+H)		3
1626	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine octyl group ester	392(M+H)		3
					1627	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine ethyl ester	308(M+H)		3
1628	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 4-nitrobenzyl ester	415(M+H)		3
					1629	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 2-naphthyl ester	406(M+H)		3
1630	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) the carboxylamine allyl ester	320(M+H)		3
					1631	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) the carboxylamine benzyl ester	370(M+H)		3
1632	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) the carboxylamine phenylester	356(M+H)		3
					1633	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine (2S, 5R)-2-sec.-propyl-5-methylcyclohexyl ester	418(M+H)		3
1634	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 4-aminomethyl phenyl ester	370(M+H)		3
					1635	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) the carboxylamine methyl ester	294(M+H)		3
1636	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 2-chlorine benzyl ester	404(M+H)		3
					1637	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) carboxylamine 9H-fluorenes-9-ylmethyl ester	458(M+H)		3
1638	(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ammonia	410(M+H)		3

	Base formic acid 2,2,2-three chloro-ethyl esters
					1639	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 2-(benzyloxy) ethyl ester	428(M+H)		3
1640	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 2,2-dimethyl propyl ester	364(M+H)		3
					1641	[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 4,5-dimethoxy-2-nitrobenzyl ester	489(M+H)		3
1642	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 3-(trifluoromethyl) phenylester	438(M+H)		3
					1643	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 4-bromophenyl ester	448(M+H)		3
1644	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 2-p-methoxy-phenyl ester	400(M+H)		3
					1645	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 2-methoxy ethyl ester	352(M+H)		3
1646	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine octyl group ester	406(M+H)		3
					1647	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine ethyl ester	322(M+H)		3
1648	[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine 4-nitro-benzyl ester	429(M+H)		3
					1649	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] carboxylamine 2-naphthyl ester	420(M+H)		3
1650	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] the carboxylamine allyl ester	334(M+H)		3
					1651	[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl ester	384(M+H)		3
1652	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] the carboxylamine phenylester	370(M+H)		3
					1653	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-carboxylamine (2S, 5R)-2-sec.-propyl-5-methylcyclohexyl ester	432(M+H)		3
1654	[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) first	384(M+H)		3

	Base] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl) urea
					1671	N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	583(M+H)		2
1672	N-(2,6-diethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	465(M+H)		1
					1673	N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	511(M+H)		3
1674	N-(2-chloro-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)		3
					1675	N-(2-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)		2
1676	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) urea	479(M+H)		2
					1677	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethylphenyl) urea	437(M+H)		2
1678	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-iodine substituted phenyl) urea	535(M+H)		3
					1679	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea	465(M+H)		2
1680	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-isopropyl phenyl) urea	451(M+H)		3
					1681	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-3-nitro phenyl) urea	468(M+H)		3
1682	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-propyl group phenyl) urea	451(M+H)		3
					1683	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	479(M+H)		2
1684	N-(2-tert-butyl-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	465(M+H)		3
					1685	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)		3
1686	N-(4-bromo-2,6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-	523(M+H)		3

	5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea
					1687	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	511(M+H)		3
1688	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	434(M+H)		3
					1689	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(diphenyl methyl) urea	499(M+H)		1
1690	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	515(M+H)		1
					1691	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea	490(M+H)		1
1692	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[5-methyl-2-(trifluoromethyl)-3-furyl]-urea	481(M+H)		3
					1693	N-(2-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	487(M+H)		3
1694	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	485(M+H)		3
					1695	N-butyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	389(M+H)		3
1696	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) urea	437(M+H)		3
					1697	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the phenylformic acid ethyl ester	481(M+H)		3
1698	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[1-(3-pseudoallyl phenyl)-1-methyl-ethyl]-urea	491(M+H)		3
					1699	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } the methylene-sulfonic acid methyl ester	479(M+H)		3
1700	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-1-naphthyl urea	459(M+H)		2
					1701	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	449(M+H)		3

	Base] amino } cyclohexyl)-N '-[(2S)-and the 2-phenycyclopropyl] urea
				1702	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-Phenoxyphenyl) urea	501(M+H)	3
1703	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-amyl group urea	403(M+H)	3
				1704	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl] urea	487(M+H)	1
1705	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl }-the phenylalanine methyl ester	495(M+H)	3
				1706	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(1-phenylethyl) urea	437(M+H)	3
1707	1-[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	437(M+H)	3
				1708	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,3,5,6-tetrachloro phenyl) urea	545(M+H)	3
1709	N-(2, the 4-dibromo phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	565(M+H)	2
				1710	N-(2, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	491(M+H)	2
1711	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	469(M+H)	2
				1712	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) urea	453(M+H)	2
1713	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro benzyl) urea	441(M+H)	2
				1714	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) urea	468(M+H)	3
1715	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-5-nitro phenyl) urea	468(M+H)	3
				1716	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-benzyl) urea	437(M+H)	3
1717	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-	454(M+H)	3

	Base] amino } cyclohexyl)-N '-(2-nitrophenyl) urea
					1718	N-1,3-benzo dioxole-5-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	453(M+H)		3
1719	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea	499(M+H)		1
					1720	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	469(M+H)		2
1721	N-(3-chloro-4-p-methoxy-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	473(M+H)		3
					1722	N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	555(M+H)		3
1723	N-(4-bromobenzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-quinazoline-2-yl] amino } cyclohexyl) urea	501(M+H)		3
					1724	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)		2
1725	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro benzyl) urea	441(M+H)		2
					1726	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) urea	453(M+H)		2
1727	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	503(M+H)		1
					1728	N-[1-(4-bromophenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	515(M+H)		2
1729	N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	501(M+H)		2
					1730	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl }-the phenylalanine ethyl ester	509(M+H)		3
1731	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-hydrogen-quinazoline-2-yl] amino } cyclohexyl) urea	467(M+H)		3
					1732	N ' (2,6-two bromo-4-isopropyl phenyls)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	607(M+H)		3
1733	N-[3-(cyclopentyloxy)-4-p-methoxy-phenyl]-N '-(cis-4-{[4-(diformazan	523(M+H)		3

	Base is amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea
					1734	N-(3,4-dihydro-2H-1,5-benzo two oxa-English in heptan-7-yls)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	481(M+H)		3
1735	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	479(M+H)		3
					1736	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) urea	490(M+H)		1
1737	N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	503(M+H)		3
					1738	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	450(M+H)		3
1739	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	493(M+H)		3
					1740	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	485(M+H)		1
1741	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 6-3,5-dimethylphenyl) thiocarbamide	453(M+H)		3
					1742	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) thiocarbamide	495(M+H)		3
1743	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-p-methoxy-phenyl) thiocarbamide	455(M+H)		3
					1744	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-1-naphthyl thiourea	475(M+H)		3
1745	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide	515(M+H)		3
					1746	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	485(M+H)		1
1747	N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	518(M+H)		2
					1748	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethylphenyl) thiocarbamide	453(M+H)		3

	5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide
				1765	N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	571(M+H)	1
1766	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	1
				1767	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(1-naphthyl methyl) thiocarbamide	489(M+H)	3
1768	N-(2, the 3-dimethoxy-benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	499(M+H)	3
				1769	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2) thiocarbamide	467(M+H)	3
1770	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	501(M+H)	3
				1771	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) thiocarbamide	482(M-H)	3
1772	N-(3-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	3
				1773	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-the phenylformic acid ethyl ester	497(M+H)	3
1774	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	527(M+H)	2
				1775	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro-2-aminomethyl phenyl) thiocarbamide	457(M+H)	2
1776	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) thiocarbamide	469(M+H)	2
				1777	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	519(M+H)	1
1778	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[(1R)-and the 1-phenylethyl] thiocarbamide	453(M+H)	2
				1779	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) thiocarbamide	453(M+H)	3

1780	N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	599(M+H)	2
				1781	N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	507(M+H)	1
1782	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) thiocarbamide	469(N+H)	2
				1783	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-2-sec.-propyl-6-aminomethyl phenyl) thiocarbamide	481(N+H)	3
1784	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	483(M+H)	3
				1785	N-1,3-benzodioxole-5-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	469(M+H)	3
1786	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	3
				1787	N-[4-bromo-2-(trifluoromethoxy) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino }-cyclohexyl)-thiocarbamide	587(M+H)	2
1788	N-(4-chloro-2,5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	519(M+H)	2
				1789	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl)-thiocarbamide	506(M+H)	3
1790	1-two ring [2.2.1] heptan-2-base-3-[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-thiocarbamide	443(M+H)	3
				1791	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-4-thiotolene-2-carboxylic acid methyl ester	503(M+H)	3
1792	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-thiophene-2-carboxylic acid methyl ester	489(M+H)	3
				1793	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	495(M+H)	3

1794	N-(3, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		3
					1795	N-(2, the 3-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		2
1796	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-aminomethyl phenyl) urea	423(M+H)		2
					1797	N-(2, the 6-diisopropyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	493(M+H)		2
1798	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,3-dimethyl-6-nitrophenyl) urea	482(M+H)		3
					1799	N-(2.6-two bromo-4-fluorophenyls)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	583(M+H)		3
1800	N-(2, the 6-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		3
					1801	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methoxyl group-5-aminomethyl phenyl) urea	453(M+H)		3
1802	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-6-nitrophenyl) urea	468(M+H)		3
					1803	N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	445(M+H)		3
1804	N-(3, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	445(M+H)		3
					1805	N-(3-chloro-4-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	461(M+H)		3
1806	N-(3-acetylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	451(M+H)		3
					1807	N-1-adamantyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	467(M+H)		3
1808	N-(4-acetylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	451(M+H)		3
					1809	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } benzamide	437(M+H)		3

1810	N-(tertiary butyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	389(M+H)		3
					1811	N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	545(M+H)		3
1812	N-benzyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	423(M+H)		3
					1813	N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	487(M+H)		3
1814	N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	443(M+H)		3
					1815	N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	443(M+H)		3
1816	N-cyclohexyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	415(M+H)		3
					1817	N-(3-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	434(M+H)		3
1818	N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		3
					1819	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		3
1820	N-(2, the 6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	445(M+H)		3
					1821	N-(2, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	477(M+H)		3
1822	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } the glycine ethyl ester	419(M+H)		3
					1823	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the phenylformic acid ethyl ester	481(M+H)		3
1824	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-ethylphenyl) urea	437(M+H)		3
					1825	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-ethyl carbamide	361(M+H)		3

1826	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro-3-nitrophenyl) urea	472(M+H)	3
				1827	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-fluoro phenyl) urea	427(M+H)	3
1828	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro phenyl) urea	427(M+H)	3
				1829	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-isopropyl phenyl) urea	451(M+H)	3
1830	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-sec.-propyl urea	375(M+H)	3
				1831	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-p-methoxy-phenyl urea	439(M+H)	3
1832	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methyl-2-nitrophenyl) urea	468(M+H)	3
				1833	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-p-methoxy-phenyl) urea	439(M+H)	3
1834	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea	439(M+H)	3
				1835	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxy-benzyl) urea	453(M+H)	3
1836	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-methyl-benzyl) urea	437(M+H)	3
				1837	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-propyl group urea	375(M+H)	3
1838	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-(trifluoromethyl) phenyl] urea	477(M+H)	3
				1839	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-(triethoxysilyl) propyl group] urea	537(M+H)	3
1840	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-aminomethyl phenyl) urea	423(M+H)	3
				1841	N-(3-chloro-4-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)	3

1842	1-[4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3-(1-naphthalene-1-base-ethyl)-urea	487(M+H)	3
				1843	N-[2-(difluoro-methoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	475(M+H)	3
1844	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-benzoic acid methyl ester	467(M+H)	3
				1845	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(methylthio group) phenyl] urea	455(M+H)	3
1846	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,4, the 5-trichlorophenyl) urea	511(M+H)	2
				1847	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 4-3,5-dimethylphenyl) urea	437(M+H)	3
1848	N-(2, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	445(M+H)	3
				1849	N-(2, the 5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	469(M+H)	2
1850	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 5-3,5-dimethylphenyl) urea	437(M+H)	3
				1851	N-(2-benzyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	499(M+H)	3
1852	N-(2-bromo-4,6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	523(M+H)	3
				1853	N-[2-chloro-4-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-urea	511(M+H)	3
1854	N-(2-chloro-4-nitrophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	488(M+H)	3
				1855	N-[2-chloro-5-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-urea	511(M+H)	3
1856	N-(2-chloro-5-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)	3
				1857	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the phenylformic acid ethyl ester	481(M+H)	3

1858	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-fluoro-3-(trifluoromethyl) phenyl]-urea	495(M+H)	3
				1859	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-fluoro-5-(trifluoromethyl) phenyl]-urea	495(M+H)	3
1860	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro-5-aminomethyl phenyl) urea	441(M+H)	3
				1861	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methoxyl group-4-nitrophenyl) urea	484(M+H)	3
1862	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methoxyl group-5-nitrophenyl) urea	484(M+H)	3
				1863	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-2-naphthyl urea	459(M+H)	3
1864	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-Phenoxyphenyl) urea	501(M+H)	3
				1865	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-(methylthio group) phenyl] urea	455(M+H)	3
1866	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-and the 3-[(trifluoromethyl) sulfo-] phenyl } urea	509(M+H)	3
				1867	N-(3, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	491(M+H)	3
1868	N-(3, the 5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	469(M+H)	3
				1869	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3, the 5-3,5-dimethylphenyl) urea	437(M+H)	3
1870	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-benzoic acid methyl ester	467(M+H)	3
				1871	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-ethylphenyl) urea	437(M+H)	3
1872	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-fluoro-5-(trifluoromethyl) phenyl]-urea	495(M+H)	3
				1873	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-fluoro benzyl) urea	441(M+H)	3

1874	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-nitrophenyl) urea	454(M+H)	3
				1875	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-Phenoxyphenyl) urea	501(M+H)	3
1876	N-[4-(difluoro-methoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	475(M+H)	3
				1877	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the phenylformic acid butyl ester	509(M+H)	3
1878	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(trifluoromethyl) phenyl] urea	477(M+H)	3
				1879	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-and the 4-[(trifluoromethyl) sulfo-] phenyl } urea	509(M+H)	3
1880	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4,5-dimethyl-2-nitrophenyl) urea	482(M+H)	3
				1881	N-[4-(benzyloxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	515(M+H)	3
1882	N-(4-benzyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	499(M+H)	3
				1883	N-(4-bromo-2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	521(M+H)	2
1884	N-(4-bromo-2-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	505(M+H)	3
				1885	N-(4-bromo-3-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	501(M+H)	3
1886	N-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	488(M+H)	3
				1887	N-[4-chloro-3-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	511(M+H)	3
1888	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-ethoxyl phenenyl) urea	453(M+H)	3
				1889	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro-2-nitrophenyl) urea	472(M+H)	3

1890	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-fluoro-3-(trifluoromethyl) phenyl]-urea	495(M+H)	3
				1891	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(heptyl oxygen base) phenyl] urea	523(M+H)	3
1892	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-iodine substituted phenyl) urea	535(M+H)	3
				1893	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-nitrophenyl) urea	484(M+H)	3
1894	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methyl-3-nitro phenyl) urea	468(M+H)	3
				1895	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methyl-benzyl) urea	437(M+H)	3
1896	N-(4-butoxy phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	481(M+H)	3
				1897	N-(4-butyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	465(M+H)	3
1898	N-biphenyl-4-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	485(M+H)	3
				1899	N-(5-chloro-2-p-methoxy-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	473(M+H)	3
1900	N-(5-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	457(M+H)	3
				1901	N-(5-chloro-2-nitrophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	488(M+H)	3
1902	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(5-fluoro-2-aminomethyl phenyl) urea	441(M+H)	3
				1903	N-(2,3-dihydro-1H-indenes-5-yl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	449(M+H)	3
1904	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-9H-fluorenes-2-base urea	497(M+H)	3
				1905	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-9H-fluorenes-9-base urea	497(M+H)	3

1906	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-phenylethyl) urea	437(M+H)		3
					1907	N-cyclopentyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	401(M+H)		3
1908	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-benzoic acid methyl ester	467(M+H)		3
					1909	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethoxy) phenyl] urea	493(M+H)		2
1910	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the phenylformic acid butyl ester	509(M+H)		3
					1911	5-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-the m-phthalic acid dimethyl esters	525(M+H)		3
1912	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(trifluoromethoxy) phenyl] urea	493(M+H)		3
					1913	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,2,4,4-tetrafluoro generation-4H-1,3-benzo dioxin-6-yl) urea	539(M+H)		3
1914	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(2-thienyl) ethyl] urea	443(M+H)		3
					1915	N-(2-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	434(M+H)		3
1916	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-2-thienyl urea	415(M+H)		3
					1917	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-3-thienyl urea	415(M+H)		3
1918	N-(4-tert-butyl-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	465(M+H)		3
					1919	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(5-phenyl-2-thienyl) urea	491(M+H)		3
1920	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(6-fluoro-4H-1,3-benzo dioxin-8-yl)	485(M+H)		3

	Urea
				1921	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino)-piperidines-1-carboxylic acid benzyl ester	550(M+H)	3
1922	N-[4-(dimethylamino) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	452(M+H)	3
				1923	N-(2,6-dichloropyridine-4-yl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) urea	478(M+H)	3
1924	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3,5-dimethyl isoxazole-4-yl) urea	428(M+H)	3
				1925	N-(3-acetylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	467(M+H)	3
1926	N-(4-acetylphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	465(M-H)	3
				1927	N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	561(M+H)	3
1928	N-benzyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	439(M+H)	3
				1929	N-(3-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	503(M+H)	3
1930	N-butyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	405(M+H)	3
				1931	N-cyclohexyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	431(M+H)	3
1932	N-cyclopentyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	417(M+H)	3
				1933	N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	459(M+H)	3
1934	N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	459(M+H)	3
				1935	N-(2, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	461(M+H)	3

1936	N-(2, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		493(M+H)	3
					1937	N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		493(M+H)	3
1938	N-(2, the 6-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		493(M+H)	3
					1939	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-ethoxyl phenenyl) thiocarbamide		469(M+H)	3
1940	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-furyl methyl) thiocarbamide		429(M+H)	3
					1941	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) thiocarbamide		443(M+H)	3
1942	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-hexyl thiocarbamide		433(M+H)	3
					1943	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(trans-4-propyl group cyclohexyl) phenyl]-thiocarbamide		549(M+H)	3
1944	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-isobutyl-thiocarbamide		405(M+H)	3
					1945	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl biphenyl base-3-yl) thiocarbamide		531(M+H)	3
1946	N-(1,3-benzodioxole-5-ylmethyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		483(M+H)	3
					1947	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-aminomethyl phenyl) thiocarbamide		439(M+H)	3
1948	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(methylthio group) phenyl] thiocarbamide		471(M+H)	3
					1949	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-p-methoxy-phenyl) thiocarbamide		453(M-H)	3
1950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-(2-methyl-prop-2-alkene-1-yl) thiocarbamide		403(M+H)	3

1951	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-methylthiourea	363(M+H)		3
					1952	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-(3-nitrophenyl) thiocarbamide	470(M+H)		3
1953	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-nitrophenyl) thiocarbamide	470(M+H)		3
					1954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(1,1,3, the 3-tetramethyl butyl) thiocarbamide	461(M+H)		3
1955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-phenylthiourea	425(M+H)		3
					195ó	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-propyl group thiocarbamide	391(M+H)		3
1957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-(trifluoromethyl) phenyl] thiocarbamide	493(M+H)		3
					1958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(tetrahydrofuran (THF)-2-ylmethyl) thiocarbamide	433(M+H)		3
1959	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-aminomethyl phenyl) thiocarbamide	439(M+H)		3
					1960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) thiocarbamide	439(M+H)		3
1961	N-(tertiary butyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	405(M+H)		3
					1962	N-1-adamantyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	483(M+H)		3
1963	N-(2-bromo phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	503(M+H)		3
					1964	N-(2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	459(M+H)		3
1965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-phenylethyl) thiocarbamide	453(M+H)		3
					1966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-ethylphenyl) thiocarbamide	453(M+H)		3

1967	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-[2-(methylthio group) phenyl] thiocarbamide	471(M+H)	3
				1968	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-[2-(trifluoromethoxy) phenyl] thiocarbamide	509(M+H)	3
1969	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethyl) phenyl] thiocarbamide	493(M+H)	3
				1970	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,3, the 4-trifluorophenyl) thiocarbamide	479(M+H)	3
1971	N-(2, the 3-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	493(M+H)	3
				1972	N-(2,4 difluorobenzene base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	461(M+H)	3
1973	N-(2, the 5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	485(M+H)	3
				1974	N-(2, the 6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	461(M+H)	3
1975	N-(2-chloro-4-nitrophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	504(M+H)	3
				1976	N-[2-(difluoro-methoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	491(M+H)	3
1977	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-fluoro-5-(trifluoromethyl) phenyl]-thiocarbamide	511(M+H)	3
				1978	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro phenyl) thiocarbamide	443(M+H)	3
1979	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-iodine substituted phenyl) thiocarbamide	551(M+H)	3
				1980	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-and the 3-[(trifluoromethyl) sulfo-] phenyl }-thiocarbamide	525(M+H)	3
1981	N-(3, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	493(M+H)	3
				1982	(3, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	461(M+H)	3

1983	N-(3-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	450(M+H)	3
				1984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-fluoro phenyl) thiocarbamide	443(M+H)	3
1985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-(3-iodine substituted phenyl) thiocarbamide	551(M+H)	3
				1986	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) thiocarbamide	455(M+H)	3
1987	N-[4-(difluoro-methoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	491(M+H)	3
				1988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(trifluoromethoxy) phenyl] thiocarbamide	509(M+H)	3
1989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(trifluoromethyl) phenyl] thiocarbamide	493(M+H)	3
				1990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-and the 4-[(trifluoromethyl) sulfo-] phenyl }-thiocarbamide	525(M+H)	3
1991	N-(4-bromo-2-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	520(M)	3
				1992	N-[4-chloro-3-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	527(M+H)	3
1993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-fluoro-3-(trifluoromethyl) phenyl]-thiocarbamide	511(M+H)	3
				1994	N-(5-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	3
1995	N-two ring [2.2.1] heptan-2-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	443(M+H)	3
				1996	[4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino) phenyl] the carboxylamine tertiary butyl ester	540(M+H)	3
1997	N-[2-(3, the 4-Dimethoxyphenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	513(M+H)	3
				1998	N-[2-(4-chlorophenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino	487(M+H)	3

	Base)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide
				1999	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,3,4,5-tetrachloro phenyl) thiocarbamide	561(M+H)	3
2000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,4, the 5-trichlorophenyl) thiocarbamide	527(M+H)	3
				2001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trifluorophenyl) thiocarbamide	479(M+H)	3
2002	N-(2, the 6-diisopropyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	509(M+H)	3
				2003	N-[2-chloro-5-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-thiocarbamide	527(M+H)	3
2004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[3-(methylthio group) phenyl] thiocarbamide	471(M+H)	3
				2005	N-(3, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	507(M+H)	3
2006	N-(3, the 5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	485(M+H)	3
				2007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3, the 5-3,5-dimethylphenyl) thiocarbamide	453(M+H)	3
2008	N-[3-(benzyloxy) phenyl }-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	531(M+H)	3
				2009	3-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino) phenylformic acid	469(M+H)	3
2010	N-(3-chloro-4-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	3
				2011	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-phenyl propyl) thiocarbamide	467(M+H)	3
2012	N-[4-(diethylamino) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	496(M+H)	3
				2013	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-the phenylformic acid ethyl ester	497(M+H)	3

2014	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[1-(4-fluoro phenyl) ethyl] thiocarbamide	471(M+H)	3
				2015	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N-(4-fluoro benzyl) thiocarbamide	457(M+H)	3
2016	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-isopropyl phenyl) thiocarbamide	466(M)	3
				2017	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-nitrophenyl) thiocarbamide	500(M+H)	3
2018	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methoxy-benzyl) thiocarbamide	469(M+H)	3
				2019	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-benzoic acid methyl ester	483(M+H)	3
2020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methyl-2-nitrophenyl) thiocarbamide	484(M+H)	3
				2021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-methyl-benzyl) thiocarbamide	453(M+H)	3
2022	N-(4-butyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	481(M+H)	3
				2023	N-(5-chloro-2-p-methoxy-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	489(M+H)	3
2024	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(1-phenylethyl) thiocarbamide	453(M+H)	3
				2025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(diphenyl methyl) thiocarbamide	515(M+H)	3
2026	N-cyclo-dodecyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	515(M+H)	3
				2027	N-(cyclohexyl methyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	445(M+H)	3
2028	N-ring octyl group-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	459(M+H)	3
				2029	N-cyclopropyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene	389(M+H)	3

	Quinazoline-2-yl] amino } cyclohexyl) thiocarbamide
					2030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 2-diphenyl-ethyl) thiocarbamide		529(M)	2
2031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2,3,5,6-tetrachlorobenzene base) thiocarbamide		561(M+H)	3
					2032	N-(2, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		507(M+H)	3
2033	N-(2, the 5-dibromo phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		581(M+H)	3
					2034	N-[2-(2, the 5-Dimethoxyphenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		513(M+H)	3
2035	N-(2-chloro-5-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		504(M+H)	3
					2036	N-(2-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		450(M+H)	3
2037	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro benzyl) thiocarbamide		457(M+H)	3
					2038	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl }-the 2-furoamide		443(M+H)	3
2039	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methoxyl group-5-nitrophenyl) thiocarbamide		500(M+H)	3
					2040	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-benzyl) thiocarbamide		453(M+H)	3
2041	N-(3, the 4-dimethoxy-benzyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide		499(M+H)	3
					2042	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-ethylphenyl) thiocarbamide		453(M+H)	3
2043	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-fluoro benzyl) thiocarbamide		457(M+H)	3
					2044	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-methoxy-benzyl) thiocarbamide		469(M+H)	3
2045	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-		453(M+H)	3

	Base] amino } cyclohexyl)-N '-(3-methyl-benzyl) thiocarbamide
				2046	N-(4-bromo-3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	537(M+H)	3
2047	N-(4-bromo-3-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	517(M+H)	3
				2048	N-(4-decyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	565(M+H)	3
2049	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(4-nitrophenoxy) phenyl] thiocarbamide	562(M+H)	3
				2050	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-and the 4-[(4-nitrophenyl) sulfo-] phenyl } thiocarbamide	578(M+H)	3
2051	4-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-benzsulfamide	502(M-H)	3
				2052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[2-(4-aminomethyl phenyl) ethyl] thiocarbamide	467(M+H)	3
2053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-Phenoxyphenyl) thiocarbamide	517(M+H)	3
				2054	N-(2,3-dihydro-1H-indenes-5-yl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	465(M+H)	3
2055	N-suberyl-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	445(M+H)	3
				2056	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-third-2-alkynes-1-base thiocarbamide	387(M+H)	3
2057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(piperidines-1-base alkylsulfonyl) phenyl]-thiocarbamide	572(M+H)	3
				2058	N-(2-hexamethylene-1-alkene-1-base ethyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	457(M+H)	3
2059	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2, the 5-3,5-dimethylphenyl) thiocarbamide	453(M+H)	3
				2060	N-(2-bromo-4-isopropyl phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	545(M+H)	3

2061	N-(2-bromo-5-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	521(M+H)	3
				2062	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-methoxy-benzyl) thiocarbamide	469(M+H)	3
2063	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3, the 4-3,5-dimethylphenyl) thiocarbamide	453(M+H)	3
				2064	N-(suitable-4-{14-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(4-phenyl butyl) thiocarbamide	481(M+H)	3
2065	N-(4-tert-butyl-phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	481(M+H)	3
				2066	N-(5-chloro-2-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	477(M+H)	3
2067	N-two ring [2.2.1] heptan-5-alkene-2-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	441(M+H)	3
				2068	N-(cyclopropyl methyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } the cyclohexyl thiocarbamide	403(M+H)	3
2069	2-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydrochysene-quinazoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-4,5,6,7-tetrahydrochysene-1-thionaphthene-3-carboxylic acid ethyl ester	557(M+H)	3
				2070	N-(2-bromo-4-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	521(M+H)	3
2071	N-(3-chloro-4-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	477(M+H)	3
				2072	N-[4-(dimethylamino) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	468(M+H)	3
2073	N-[3-(diethylamino) propyl group]-N '-(cis-4-{[4-(dimethyl base amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	462(M+H)	3
				2074	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-morpholine-4-base ethyl) thiocarbamide	462(M+H)	3
2075	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-quinazoline-2-yl] amino } cyclohexyl)-N '-(4-phenanthro-[9,10-d] [1,3] oxazole-2-base phenyl) thiocarbamide	642(M+H)	3

2076	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-pyridin-3-yl thiocarbamide	426(M+H)	3
				2077	N-(4-{ (E)-[4-(dimethylamino) phenyl] diazenyl } phenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	572(M+H)	3
2078	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3-morpholine-4-base propyl group) thiocarbamide	476(M+H)	3
				2079	N-(4-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	473(M+H)	3
2080	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-4-[(E)-the phenyl diazenyl] phenyl } thiocarbamide	529(M+H)	3
				2081	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(2-piperidines-1-base ethyl) thiocarbamide	460(M+H)	3
2082	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(1H-pyrazol-1-yl) phenyl] thiocarbamide	491(M+H)	3
				2083	N-2,1,3-diazosulfide-4-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	483(M+H)	3
2084	N-2,1,3-diazosulfide-5-base-N '-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) thiocarbamide	483(M+H)	3
				2085	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(3,5-dimethyl isoxazole-4-yl) thiocarbamide	444(M+H)	3
2086	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-[4-(1,3-oxazole-5-yl) phenyl] thiocarbamide	492(M+H)	3
				2087	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(6-morpholine-4-yl pyridines-3-yl) thiocarbamide	511(M+H)	3
2088	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-N '-(6-phenoxypyridines-3-yl) thiocarbamide	518(M+H)	3
				2089	N-(2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	438(M+H)	2
2090	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2, the 6-3,5-dimethylphenyl) urea	432(M+H)	3

2107	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethylphenyl) urea	432(M+H)		3
					2108	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-iodine substituted phenyl) urea	530(M+H)		3
2109	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea	460(M+H)		2
					2110	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-isopropyl phenyl) urea	446(M+H)		3
2111	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-3-nitro phenyl) urea	463(M+H)		3
					2112	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-propyl group phenyl) urea	446(M+H)		3
2113	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	474(M+H)		1
					2114	N-(2-tert-butyl-phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	460(M+H)		3
2115	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	452(M+H)		3
					2116	N-(4-bromo-2,6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	518(M+H)		3
2117	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	506(M+H)		3
					2118	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	429(M+H)		3
2119	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(diphenyl methyl) urea	494(M+H)		2
					2120	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	510(M+H)		1
2121	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea	485(M+H)		2
					2122	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[5-methyl-2-(trifluoromethyl)-3-furyl] urea	476(M+H)		3

2123	N-(2-bromophenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	482(M+H)		3
					2124	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	480(M+H)		3
2125	N-butyl-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	384(M+H)		3
					2126	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) urea	432(M+H)		3
2127	3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] carbonyl } amino) the phenylformic acid ethyl ester	476(M+H)		3
					2128	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[1-(3-pseudoallyl phenyl)-1-methylethyl] urea	486(M+H)		3
2129	N-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] carbonyl } the methylene-sulfonic acid methyl ester	474(M+H)		3
					2130	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-1-naphthyl urea	454(M+H)		1
2131	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[(2S)-and 2-benzyl ring hexyl] urea	444(M+H)		3
					2132	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(4-Phenoxyphenyl) urea	496(M+H)		3
2133	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-amyl group urea	398(M+H)		3
					2134	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl] urea	482(M+H)		1
2135	N-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] carbonyl } the phenylalanine methyl ester	490(M+H)		2
					2136	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(1-phenylethyl) urea	432(M+H)		3
2137	1-[4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	432(M+H)		3
					2138	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2,3,5,6-tetrachlorobenzene base) urea	540(M+H)		3

2139	N-(2, the 4-dibromo phenyl)-N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	560(M+H)	3
				2140	N-(2, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	486(M+H)	3
2141	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	464(M+H)	3
				2142	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) urea	448(M+H)	3
2143	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-fluoro benzyl) urea	436(M+H)	3
				2144	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) urea	463(M+H)	3
2145	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-5-nitro phenyl) urea	463(M+H)	3
				2146	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-benzyl) urea	432(M+H)	3
2147	(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-nitrophenyl) urea	449(M+H)	3
				2148	N-1,3-benzodioxole-5-base-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	448(M+H)	3
2149	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea	494(M+H)	1
				2150	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	464(M+H)	3
2151	N-(3-chloro-4-p-methoxy-phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	468(M+H)	3
				2152	N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	550(M+H)	3
2153	N-(4-bromobenzyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	496(M+H)	3
				2154	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea	452(M+H)	3

2155	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro benzyl) urea		436(M+H)		3
						2156	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) urea		448(M+H)		3
2157	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		498(M+H)		1
						2158	N-[1-(4-bromophenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		510(M+H)		3
2159	N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		496(M+H)		2
						2160	N-{[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] carbonyl } the phenylalanine ethyl ester		504(M+H)		3
2161	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		462(M+H)		3
						2162	N-(2,6-two bromo-4-isopropyl phenyls)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		602(M+H)		3
2163	N-[3-(cyclopentyloxy)-4-p-methoxy-phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		518(M+H)		3
						2164	N-(3,4-dihydro-2H-1,5-benzo two oxa-English in heptan-7-yls)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		476(M+H)		3
2165	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) urea		474(M+H)		3
						2166	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) urea		485(M+H)		3
2167	N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		498(M+H)		3
						2168	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		445(M+H)		3
2169	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		488(M+H)		3
						2170	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		480(M+H)		2

2171	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2, the 6-3,5-dimethylphenyl) thiocarbamide	448(M+H)	3
				2172	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) thiocarbamide	490(M+H)	3
2173	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-p-methoxy-phenyl) thiocarbamide	450(M+H)	3
				2174	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-1-naphthyl thiourea	470(M+H)	3
2175	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide	510(M+H)	1
				2176	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	480(M+H)	3
2177	N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	513(M+H)	2
				2178	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethylphenyl) thiocarbamide	448(M+H)	3
2179	N-(2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	389(M+H)	3
				2180	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2, the 6-3,5-dimethylphenyl) urea	383(M+H)	3
2181	N-(2,4 difluorobenzene base)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	391(M+H)	3
				2182	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-ethyl-6-aminomethyl phenyl) urea	397(M+H)	3
2183	N-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] carbonyl } leucinethylester	421(M+H)	3
				2184	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea	373(M+H)	3
2185	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[4-(methylthio group) phenyl] urea	401(M+H)	3
				2186	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[2-(trifluoromethyl) phenyl] urea	445(M+Na)	3

2203	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	425(M+H)		3
					2204	N-(2-tert-butyl-phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	411(M+H)		3
2205	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	403(M+H)		3
					2206	N-(4-bromo-2,6-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	469(M+H)		3
2207	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	457(M+H)		3
					2208	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	380(M+H)		3
2209	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(diphenyl methyl) urea	445(M+H)		1
					2210	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	461(M+H)		1
2211	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea	436(M+H)		3
					2212	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[5-methyl-2-(trifluoromethyl)-3-furyl] urea	427(M+H)		3
2213	N-(2-bromophenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	433(M+H)		3
					2214	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	431(M+H)		3
2215	N-butyl-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	335(M+H)		3
					2216	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) urea	383(M+H)		3
2217	3-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] carbonyl } amino) the phenylformic acid ethyl ester	427(M+H)		3
					2218	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[1-(3-pseudoallyl phenyl)-1-methylethyl] urea	437(M+H)		3

2219	N-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] carbonyl } the methylene-sulfonic acid methyl ester	425(M+H)		3
					2220	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-1-naphthyl urea	405(M+H)		3
2221	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(2S)-and the 2-phenycyclopropyl] urea	395(M+H)		3
					2222	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-Phenoxyphenyl) urea	447(M+H)		3
2223	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-amyl group urea	349(M+H)		3
					2224	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl] urea	433(M+H)		1
2225	N-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] carbonyl } the phenylalanine methyl ester	441(M+H)		3
					2226	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(1-phenylethyl) urea	383(M+H)		3
2227	1-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea	383(M+H)		3
					2228	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,3,5,6-tetrachlorobenzene base) urea	491(M+H)		3
2229	N-(2, the 4-dibromo phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	511(M+H)		3
					2230	N-(2, the 4-dichloro benzyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) urea	437(M+H)		3
2231	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	415(M+H)		3
					2232	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) urea	399(M+H)		3
2233	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-fluoro benzyl) urea	387(M+H)		3
					2234	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) urea	414(M+H)		3

2235	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-methyl-5-nitro phenyl) urea	414(M+H)		3
					2236	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-methyl-benzyl) urea	383(M+H)		3
2237	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-nitrophenyl) urea	400(M+H)		3
					2238	N-1,3-benzodioxole-5-base-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	399(M+H)		3
2239	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea	445(M+H)		1
					2240	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	415(M+H)		3
2241	N-(3-chloro-4-p-methoxy-phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	419(M+H)		3
					2242	N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	501(M+H)		3
2243	N-(4-bromobenzyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	447(M+H)		3
					2244	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	403(M+H)		2
2245	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-fluoro benzyl) urea	387(M+H)		3
					2246	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) urea	399(M+H)		3
2247	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	449(M+H)		1
					2248	N-[1-(4-bromophenyl) ethyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	461(M+H)		3
2249	N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	447(M+H)		2
					2250	N-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] carbonyl } the phenylalanine ethyl ester	455(M+H)		3

2251	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	413(M+H)		3
					2252	N-(2,6-two bromo-4-isopropyl phenyls)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	553(M+H)		2
2253	N-[3-(cyclopentyloxy)-4-p-methoxy-phenyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	469(M+H)		2
					2254	N-(3,4-dihydro-2H-1,5-benzo two oxa-English in heptan-7-yls)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	427(M+H)		3
2255	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea	425(M+H)		3
					2256	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) urea	436(M+H)		3
2257	N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	449(M+H)		3
					2258	N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) thiocarbamide	396(M+H)		2
2259	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) thiocarbamide	439(M+H)		3
					2260	N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	431(M+H)		2
2261	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2, the 6-3,5-dimethylphenyl) thiocarbamide	399(M+H)		3
					2262	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-ethyl-6-isopropyl phenyl) thiocarbamide	441(M+H)		3
2263	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-p-methoxy-phenyl) thiocarbamide	401(M+H)		3
					2264	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-1-naphthyl thiourea	421(M+H)		3
2265	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide	461(M+H)		1
					2266	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	431(M+H)		2

2283	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		526(M+H)		1
						2284	N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		512(M+H)		2
2285	N-[4-bromo-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		566(M+H)		2
						2286	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		468(M+H)		3
2287	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(1-naphthyl methyl) thiocarbamide		484(M+H)		3
						2288	N-(2, the 3-dimethoxy-benzyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		494(M+H)		3
2289	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2) thiocarbamide		462(M+H)		3
						2290	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		496(M+H)		3
2291	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) thiocarbamide		479(M+H)		3
						2292	N-(3-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		468(M+H)		3
2293	3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino) the phenylformic acid ethyl ester		492(M+H)		3
						2294	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		522(M+H)		3
2295	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(4-fluoro-2-aminomethyl phenyl) thiocarbamide		452(M+H)		3
						2296	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) thiocarbamide		464(M+H)		3
2297	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide		514(M+H)		1
						2298	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-[(1R)-and the 1-phenylethyl] thiocarbamide		448(M+H)		3

2299	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) thiocarbamide	448(M+H)		3
					2300	N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	594(M+H)		2
2301	N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	502(M+H)		1
					2302	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) thiocarbamide	464(M+H)		3
2303	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) thiocarbamide	476(M+H)		3
					2304	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	478(M+H)		3
2305	N-1,3-benzodioxole-5-base-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	464(M+H)		3
					2306	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	468(M+H)		3
2307	N-[4-bromo-2-(trifluoromethoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	582(M+H)		3
					2308	N-(4-chloro-2,5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	514(M+H)		3
2309	N-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) thiocarbamide	501(M+H)		3
					2310	N-two ring [22.1] heptan-2-base-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	438(M+H)		3
2311	3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino)-4-thiotolene-2-carboxylic acid methyl ester	498(M+H)		2
					2312	3-([(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) amino] thioformyl } amino) the thiophene-2-carboxylic acid methyl ester	484(M+H)		3
2313	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) thiocarbamide	490(M+H)		3
					2314	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-	446(M+H)		3

	Base) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide
						2331	N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		419(M+H)		3
2332	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(1-naphthyl methyl) thiocarbamide		435(M+H)		3
						2333	N-(2, the 3-dimethoxy-benzyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		443(M-H)		3
2334	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2) thiocarbamide		413(M+H)		3
						2335	N-xenyl-2-base-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) thiocarbamide		447(M+H)		3
2336	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-methyl-4-nitrophenyl) thiocarbamide		428(M-H)		3
						2337	N-(3-benzyl chloride base)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		419(M+H)		3
2338	3-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] thioformyl } amino) the phenylformic acid ethyl ester		441(M-H)		3
						2339	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		473(M+H)		3
2340	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-fluoro-2-aminomethyl phenyl) thiocarbamide		403(M+H)		3
						2341	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(4-methoxyl group-2-aminomethyl phenyl) thiocarbamide		415(M+H)		3
2342	N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		465(M+H)		1
						2343	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(1R)-and the 1-phenylethyl] thiocarbamide		397(M-H)		3
2344	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2, the 3-3,5-dimethylphenyl) thiocarbamide		399(M+H)		3
						2345	N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide		545(M+H)		2
2346	N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino		453(M+H)		2

	Base) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide
					2347	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) thiocarbamide	415(M+H)		3
2348	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2-sec.-propyl-6-aminomethyl phenyl) thiocarbamide	427(M+H)		3
					2349	N-(2,3-dihydro-1,4-benzo dioxin-6-yl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	429(M+H)		3
2350	N-1,3-benzodioxole-5-base-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	415(M+H)		3
					2351	N-(3-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	419(M+H)		3
2352	N-[4-bromo-2-(trifluoromethoxy) phenyl]-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	533(M+H)		3
					2353	N-(4-chloro-2,5-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	465(M+H)		3
2354	N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(5-methyl-3-phenyl-isoxazole azoles-4-yl) thiocarbamide	452(M+H)		3
					2355	N-two ring [2.2.1] heptan-2-base-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	387(M-H)		3
2356	3-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] thioformyl } amino)-4-thiotolene-2-carboxylic acid methyl ester	449(M+H)		3
					2357	3-([(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) amino] thioformyl } amino) the thiophene-2-carboxylic acid methyl ester	435(M+H)		3
2358	N-(4-butyl-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide	441(M+H)		3
					2359	N-(2-chlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea	452(M+H)		3
2360	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2, the 6-3,5-dimethylphenyl) urea	446(M+H)		3
					2361	N-(2,4 difluorobenzene base)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea	454(M+H)		3

2378	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-iodine substituted phenyl) urea		544(M+H)	3
					2379	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea		474(M+H)	2
2380	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-isopropyl phenyl) urea		460(M+H)	3
					2381	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea		477(M+H)	2
2382	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-propyl group phenyl) urea		460(M+H)	3
					2383	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		488(M+H)	1
2384	N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		474(M+H)	1
					2385	N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		466(M+H)	3
2386	N-(4-bromo-2,6-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		532(M+H)	3
					2387	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		520(M+H)	3
2388	N-(4-cyano-phenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		443(M+H)	3
					2389	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl]-N-(diphenyl methyl) urea		508(M+H)	2
2390	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		524(M+H)	1
					2391	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea		499(M+H)	3
2392	N-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl)-methyl]-N '-[5-methyl-2-(trifluoromethyl)-3-furyl] urea		490(M+H)	3
					2393	N-(3, the 5-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) quinoline-2-yl] amino } cyclohexyl) methyl] urea		486(M+H)	3

2426	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-isopropyl phenyl) urea		411(M+H)		3
						2427	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea		428(M+H)		1
2428	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-propyl group phenyl) urea		411(M+H)		2
						2429	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		439(M+H)		1
2430	N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		425(M+H)		1
						2431	N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		417(M+H)		1
2432	N-(4-bromo-2,6-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		483(M+H)		1
						2433	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		471(M+H)		2
2434	N-(4-cyano-phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] urea		394(M+H)		3
						2435	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(diphenyl methyl) urea		459(M+H)		1
2436	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		475(M+H)		1
						2437	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea		450(M+H)		1
2438	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-N '-[5-methyl-2-(trifluoromethyl)-3-furyl] urea		441(M+H)		3
						2439	N-(3, the 5-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] urea		437(M+H)		2
2440	N-(2, the 3-dichlorophenyl }-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		437(M+H)		1
						2441	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(4-aminomethyl phenyl) urea		383(M+H)		3

2442	N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		453(M+H)		1
						2443	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-N '-(2,3-dimethyl-6-nitrophenyl) urea		442(M+H)		1
2444	N-(2,6-two bromo-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		543(M+H)		1
						2445	N-(2, the 6-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] urea		437(M+H)		1
2446	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-N '-(2-methoxyl group-5-aminomethyl phenyl) urea		413(M+H)		2
						2447	N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-N '-(2-methyl-6-nitrophenyl) urea		428(M+H)		2
2448	N-(3, the 4-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] urea		405(M+H)		1
						2449	N-(3, the 5-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-yl] amino } cyclohexyl) methyl] urea		405(M+H)		1
2450	N-(3-chloro-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea		421(M+H)		1
						2451	N-(2-chlorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea		457(M+H)		3
2452	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2, the 6-3,5-dimethylphenyl) urea		451(M+H)		1
						2453	N-(2,4 difluorobenzene base)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea		459(M+H)		2
2454	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-aminomethyl phenyl) urea		465(M+H)		1
						2455	N-([(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] amino } carbonyl)-the leucine ethyl ester		489(M+H)		2
2456	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(4-fluoro phenyl) urea		441(M+H)		2
						2457	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-[4-(methylthio group) phenyl] urea		469(M+H)		3

	Base] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea
				2474	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-propyl group phenyl) urea	465(M+H)	3
2475	N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	493(M+H)	1
				2476	N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	479(M+H)	2
2477	N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	471(M+H)	2
				2478	N-(4-bromo-2,6-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	537(M+H)	3
2479	N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethyl-amino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl)-methyl] urea	525(M+H)	3
				2480	N-(4-cyano-phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	448(M+H)	3
2481	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(diphenyl methyl) urea	513(M+H)	3
				2482	N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	529(M+H)	1
2483	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea	504(M+H)	3
				2484	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-[5-methyl-2-(trifluoromethyl)-3-furyl] urea	495(M+H)	3
2485	N-(3, the 5-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	491(M+H)	3
				2486	N-(2, the 3-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	491(M+H)	3
2487	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(4-aminomethyl phenyl) urea	437(M+H)	3

2488	N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	507(M+H)	2
				2489	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2,3-dimethyl-6-nitrophenyl)-urea	496(M+H)	2
2490	N-(2,6-two bromo-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	597(M+H)	1
				2491	N-(2, the 6-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	491(M+H)	1
2492	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-methoxyl group-5-aminomethyl phenyl)-urea	467(M+H)	3
				2493	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl]-N '-(2-methyl-6-nitrophenyl) urea	482(M+H)	3
2494	N-(3, the 4-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	459(M+H)	3
				2495	N-(3, the 5-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	459(M+H)	3
2496	N-(3-chloro-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro quinazoline-2-yl] amino } cyclohexyl) methyl] urea	475(M+H)	3

Embodiment 2497

2,3,4-three fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-the benzamide trifluoroacetate

Steps A: synthesizing cis-(4-tert-butoxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester.

To cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (4g, add in 50mL dichloromethane solution 0.019mol) DIEA (4.9mL, 0.028mol).On ice bath the cooling this solution, slowly add CbzCl (2.9mL, 0.020mol).Remove this solution from ice bath, continue again to stir 1 hour.Evaporating solvent makes this material through chromatography (hexane solution of 0-40% ethyl acetate), obtains cis-(4-tert-butoxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester (6.2g, 0.018mol, 95%), is white solid.

ESI?MS?m/e?349.0M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.34-7.28(m，5H)，7.12(d，J＝5.6Hz，1H)，6.62(brs，1H)，4.98(s，2H)，3.39-3.37(m，2H)，1.60-1.45(m，8H)，1.37(s，9H).

Step B: synthesizing cis-(4-amino-cyclohexyl)-carboxylamine benzyl ester.

To cis-(4-tert-butoxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester (6.2g, add in 40mL dichloromethane solution 0.018mol) TFA (2.7mL, 0.36mol).Under room temperature, stirred this solution 4 hours.Evaporate excessive solvent, the oily matter of generation is dissolved in the 30mL methylene dichloride.Organic layer is extracted with the rare NaOH of 30mL (aq)/sodium bicarbonate (aq) solution.Return with methylene dichloride and to carry this waterbearing stratum twice, merge organic layer,, concentrate, obtain cis-(4-amino-cyclohexyl)-carboxylamine benzyl ester (4.3g, 97%), be colorless oil through dried over mgso.This oily matter need not be further purified and use.

ESI?MS?m/e?249.2?M+M ⁺。

Step C: synthesizing cis-[4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-carboxylamine benzyl ester.

To cis-(4-amino-cyclohexyl)-carboxylamine benzyl ester (0.5g, add in 1mL 2-propanol solution 0.0020mol) 2-chloro-4-methyl-quinoline (0.43g, 0.0024mol) and IEA (526uL, 0.0030mol).In 170 ℃, heated mixt is 5 hours in the microwave synthesizer.Repeat this reaction more than 7 times (material total amount 4g), reaction mixture.Evaporating solvent, this material is through chromatography (2-4%2M NH ₃The MeOH/ dichloromethane solution), obtain cis-[4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-carboxylamine benzyl ester (3.3g, 53%), be colorless oil.

ESI?MS?m/e?390.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.71(d，J＝8Hz，1H)，7.46-7.39(m，2H)，7.37-7.19(m，7H)，6.68(m，2H)，5.01(s，2H)，4.07(m，1H)，3.46(m，1H)，2.44(s，3H)，1.79-1.71(m，2H)，1.70-1.59(m，6H).

Step D: synthesizing cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines.

To cis-[4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-(3.3g adds 10%Pd/C (330mg) in 200mL EtOH solution 0.0085mol) to the carboxylamine benzyl ester.In room temperature, H ₂(g) under the atmosphere, stirred reaction mixture 3 hours.Remove H ₂(g) atmosphere makes this mixture by Celite pad, washs with ethyl acetate.Concentrated solvent makes this material through chromatography (2-4%2M NH ₃The MeOH/ dichloromethane solution), obtain cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1,4-diamines (2.0g, 92%) is the light brown solid.

ESI?MS?m/e?256.4M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.71(d，J＝8Hz，1H)，7.46-7.39(m，2H)，7.14-7.10(m，1H)，6.69-6.68(m，2H)，4.07-4.05(m，1H)，2.81-2.77(m，1H)，2.44(s，3H)，1.78-1.71(m，2H)，1.62-1.40(m，6H).

Step e: Synthetic 2,3,4-three fluoro-N-{ cis-4-[(4-toluquinoline-2-yl)-and amino] cyclohexyl }-the benzamide trifluoroacetate.

To cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines (23mg, add in 0.5mL DMF solution 0.090mmol) pyridine (12uL, 0.15mmol) and 2,3, the 4-trifluorobenzoyl chloride (12.8uL, 0.10mmol).Stirred reaction mixture spends the night, and then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain 2,3,4-three fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-benzamide trifluoroacetate (10.1mg, 21%), be white solid.

ESI?MS?m/e?414.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.44(brs，1H)，9.27(brs，1H)，8.45(d，J＝6.4Hz，1H)，7.98-7.93(m，2H)，7.80(t，J＝7.6Hz，1H)，7.53(t，J＝8.0Hz，1H)，7.43-7.37(m，2H)，7.01(s，1H)，4.05(m，1H)，3.97(m，1H)，2.69(s，3H)，1.86-1.74(m，8H).

Embodiment 2498

3,4-two fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: synthesize 3,4-two fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-the benzamide trifluoroacetate

Adopt the method for the step e of embodiment 2497, obtain title compound.

ESI?MS?m/e?396.18M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.40(brs，1H)，9.25(brs，1H)，8.33(d，J＝6.0Hz，1H)，7.98-7.90(m，3H)，7.80-7.76(m，2H)，7.58-7.50(m，2H)，7.02(brs，1H)，4.09(m，1H)，3.94(m，1H)，2.61(s，3H)，1.84-1.74(m，8H).

Embodiment 2499

4-cyano group-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: amino synthetic 4-cyano group-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the benzamide trifluoroacetate.

Adopt the method for the step e of embodiment 2497, obtain title compound.

ESI?MS?m/e?385.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.38(brs，1H)，9.27(brs，1H)，8.51(d，J＝6.0Hz，1H)，8.01-7.95(m，6H)，7.80(t，J＝7.2Hz，1H)，7.54(t，J＝8.0Hz，1H)，7.02(brs，1H)，4.09(m，1H)，3.96(m，1H)，2.66(s，3H)，1.85-1.75(m，8H).

Embodiment 2500

3-fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trichloroacetate

Steps A: synthetic 3-fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate.

Adopt the method for the step e of embodiment 2497, obtain title compound.

ESI?m/e?378M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.38(brs，1H)，9.25(brs，1H)，8.33(d，J＝6.0Hz，1H)，7.98-7.91(m，2H)，7.80(t，J＝7.6Hz，1H)，7.71-7.64(m，2H)，7.55-7.49(m，2H)，7.41-7.36(m，1H)，4.12(m，1H)，4.08(m，1H)，2.77(s，3H)，1.85-1.74(m，8H).

Embodiment 2501

3,5-two fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: synthesize 3,5-two fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-the benzamide trifluoroacetate.

Adopt the method for the step e of embodiment 2497, obtain title compound.

ESI?MS?m/e?396M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.40(brs，1H)，9.25(brs，1H)，8.40(d，J＝6.0Hz，1H)，7.98-7.96(m，2H)，7.80(t，J＝7.2Hz，1H)，7.59-7.44(m，4H)，7.02(brs，1H)，4.09(m，1H)，3.94(m，1H)，2.68(s，3H)，1.85-1.74(m，8H).

Embodiment 2502

N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-2-[4-(trifluoromethoxy) phenoxy group]-the ethanamide trifluoroacetate

Steps A: synthetic N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-2-[4-(trifluoromethoxy) phenoxy group]-the ethanamide trifluoroacetate.

To cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines (25.5mg, add in 0.5mL DMF solution 0.1mmol) 4-(trifluoromethoxy) phenylium (23.6mg, 0.1mmol), DIEA (0.026mL, 0.15mmol) and HATU (45.6mg, 0.12mmol).Stirred reaction mixture spends the night, and then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-2-[4-(trifluoromethoxy) phenoxy group]-ethanamide trifluoroacetate (22.3mg, 38%), be white solid.

ESI?MS?m/e?474.4M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.47(s，1H)，9.25(s，1H)，8.00-7.92(m，3H)，7.80(t，J＝7.2Hz，1H)，7.53(t，J＝8.0Hz，1H)，7.31(d，J＝8.8Hz，2H)，7.04-7.01(m，3H)，4.55(s，2H)，4.06(m，1H)，3.84(m，1H)，2.69(s，3H)，1.78-1.68(m，8H).

Embodiment 2503

2-(3, the 4-difluorophenyl)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the ethanamide trifluoroacetate

Steps A: amino Synthetic 2-(3, the 4-difluorophenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the ethanamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?410M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.42(brs，1H)，9.26(brs，1H)，8.09(d，J＝6.4Hz，1H)，7.98-7.92(m，2H)，7.80(t，J＝7.6Hz，1H)，7.54(t，J＝8.8Hz，1H)，7.38-7.27(m，2H)，7.10-7.07(m，1H)，7.01(brs，1H)，4.02(m，1H)，3.94(m，1H)，2.61(s，3H)，1.79-1.69(m，8H)。

Embodiment 2504

2-(2-bromo-4,5-Dimethoxyphenyl)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-the ethanamide trifluoroacetate

Steps A: amino Synthetic 2-(2-bromo-4,5-Dimethoxyphenyl)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the ethanamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?512.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.45(brs，1H)，9.25(brs，1H)，8.00-7.92(m，3H)，7.80(t，J＝7.6Hz，1H)，7.53(t，J＝7.6Hz，1H)，7.09(s，1H)，7.01(brs，1H)，6.95(s，1H)，4.10(m，1H)，3.78(m，1H)，3.74(s，3H)，3.72(s，3H)，3.53(s，2H)，2.69(s，3H)，1.78-1.67(m，8H).

Embodiment 2505

4-(benzyloxy)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: amino synthetic 4-(benzyloxy)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl }-the benzamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?466.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.39(brs，1H)，9.25(brs，1H)，8.06(d，J＝6.0Hz，1H)，7.98-7.96(m，2H)，7.84-7.76(m，3H)，7.54(t，J＝8.0Hz，1H)，7.46(d，J＝7.2Hz，2H)，7.41(t，J＝7.2Hz，2H)，7.35-7.31(m，1H)，7.08(d，J＝8.8Hz，2H)，7.02(brs，1H)，5.17(s，2H)，4.09(m，1H)，3.93(m，1H)，2.66(s，3H)，1.84-1.72(m，8H).

Embodiment 2506

2-(2-methoxyl group phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the ethanamide trifluoroacetate

Steps A: amino Synthetic 2-(2-methoxyl group phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the ethanamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?420.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.50(brs，1H)，9.25(brs，1H)，7.98-7.93(m，2H)，7.80-7.76(m，2H)，7.53(t，J＝5.6Hz，1H)，7.02-6.85(m，5H)，4.50(s，2H)，4.07(m，1H)，3.85(m，1H)，3.79(s，3H)，2.61(s，3H)，1.84-1.69(m，8H).

Embodiment 2507

2-(4-fluorinated phenoxy)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the niacinamide trifluoroacetate

Steps A: amino Synthetic 2-(4-fluorinated phenoxy)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the niacinamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?471.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.29(dd，J＝7.6，2.0Hz，1H)，8.19(dd，J＝4.8，2.0Hz，1H)，8.01(d，J＝8.0Hz，1H)，7.88(brs，1H)，7.80(t，J＝8.4Hz，1H)，7.57(t，J＝8.0Hz，1H)，7.25-7.15(m，5H)，6.90(brs，1H)，4.20(brs，1H)，4.07(brs，1H)，2.67(s，3H)，2.02-1.81(m，8H).

Embodiment 2508

2-(4-chloro phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the niacinamide trifluoroacetate

Steps A: amino Synthetic 2-(4-chloro phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl)] cyclohexyl } the niacinamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?487.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ13.0(brs，1H)，9.50(d，J＝6.8Hz，1H)，8.35(m，1H)，8.19(m，1H)，8.07(d，J＝6.8Hz，1H)，7.93(d，J＝7.6Hz，1H)，7.75(t，J＝7.2Hz，1H)，7.50(m，3H)，7.30(m，3H)，7.10(brs，1H)，4.38(brs，1H)，4.01(brs，1H)，2.57(s，3H)，1.83(m，8H).

Embodiment 2509

2,6-dimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the niacinamide trifluoroacetate

Steps A: Synthetic 2,6-dimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the niacinamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2502, obtain title compound.

ESI?MS?m/e?421.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ13.1(brs，1H)，9.74(d，J＝8.0Hz，1H)，8.30(d，J＝8.4Hz，1H)，8.17(d，J＝8.4Hz，1H)，7.98(m，2H)，7.60(m，1H)，7.50?(t，J＝7.6Hz，1H)，7.19(brs，1H)，4.43(brs，1H)，3.94(brs，7H)，2.58(s，3H)，1.90(m，8H).

Embodiment 2510

Cis-N-[4-bromo-2-(trifluoromethoxy) benzyl]-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate

Steps A: synthesizing cis-N-[4-bromo-2-(trifluoromethoxy) benzyl]-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate.

To cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines (25.5mg, and adding 4-bromo-2-trifluoro-methoxybenzaldehyde in 0.5mL MeOH solution 0.1mmol) (26.9mg, 0.1mmol).This reaction mixture is stirred half an hour, and (84.8mg 0.4mmol) joins in the reactant with sodium triacetoxy borohydride then.Stir this mixture overnight, add 0.5mLDMSO then.Make described compound through preparation type LCMS purifying then, obtain cis-N-[4-bromo-2-(trifluoromethoxy) benzyl]-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate (9.6mg, 13%), be white solid.

ESI?MS?m/e?508.0M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.04(d，J＝8.0Hz，1H)，7.84(brs，1H)，7.81(t，J＝7.2Hz，1H)，7.69-7.63(m，3H)，7.58(t，J＝8.0Hz，1H)，7.16(brs，1H)，4.36(s，2H)，4.26(m，1H)，3.32-3.30(m，1H)，2.71(s，2H)，2.66(s，3H)，2.16-1.93(m，8H).

Embodiment 2511

Cis-N-[(5-bromo-1H-indol-3-yl) methyl]-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate

Steps A: methyl synthesizing cis-N-[(5-bromo-1H-indol-3-yl)]-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate.

Adopt the method for the steps A of embodiment 2510, obtain title compound.

ESI?MS?m/e?463.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.03(d，J＝8.0Hz，1H)，7.92(s，1H)，7.87(brs，1H)，7.80-7.76(t，J＝7.2Hz，1H)，7.57-7.53(m，2H)，7.38(d，J＝8.8Hz，1H)，7.31(d，J＝8.4Hz，1H)，7.14(brs，1H)，4.47(s，2H)，4.23(m，1H)，3.37(m，1H)，2.71(brs，2H)，2.65(s，3H)，2.15-1.91(m，8H).

Embodiment 2512

Cis-N-(3, the 5-dimethoxy-benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate

Steps A: synthesizing cis-N-(3, the 5-dimethoxy-benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate.

Adopt the method for the steps A of embodiment 2510, obtain title compound.

ESI?MS?m/e?406.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.03(d，J＝8.0Hz，1H)，7.88(brs，1H)，7.80(t，J＝7.2Hz，1H)，7.57(t，J＝8.4Hz，1H)，7.17(brs，1H)，6.71(s，2H)，6.55(s，1H)，4.24(m，1H)，4.21(s，2H)，3.81(s，6H)，3.35(m，1H)，2.70(brs，2H)，2.66(s，3H)，2.14-1.90(m，8H).

Embodiment 2513

Cis-N-(3, the 5-dichloro benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate

Steps A: synthesizing cis-N-(3, the 5-dichloro benzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate.

Adopt the method for the steps A of embodiment 2510, obtain title compound.

ESI?MS?m/e?414.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.04(d，J＝8.4Hz，1H)，7.86(brs，1H)，7.81(t，J＝7.2Hz，1H)，7.58-7.54(m，4H)，7.16(brs，1H)，4.30(s，2H)，4.25(m，1H)，3.41(m，1H)，2.76(brs，2H)，2.66(s，3H)，2.12-1.92(m，8H).

Embodiment 2514

Cis-N-(3, the 4-difluorobenzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate

Steps A: synthesizing cis-N-(3, the 4-difluorobenzyl)-N '-(4-toluquinoline-2-yl) hexanaphthene-1, the 4-diamines is two-trifluoroacetate.

Adopt the method for the steps A of embodiment 2510, obtain title compound.

ESI?MS?m/e?382.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.03(d，J＝8.0Hz，1H)，7.86(brs，1H)，7.80(t，J＝7.2Hz，1H)，7.57-7.51(m，2H)，7.39-7.37(m，2H)，7.16(brs，1H)，4.29(s，2H)，4.25(m，1H)，3.37(m，1H)，2.71(brs，2H)，2.66(s，3H)，2.11-1.95(m，8H).

Embodiment 2515

N-(3, the 5-difluorophenyl)-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate

Steps A: synthetic N-(3, the 5-difluorophenyl)-N '-cis-4-[(4-toluquinoline-2-yl) and amino] cyclohexyl } the urea trifluoroacetate.

To cis-N-(4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines (20mg adds 3 in 0.5mL DMSO solution 0.078mmol), and the 5-difluorophenyl isocyanate (9.3uL, 0.078mmol).Stirred reaction mixture spends the night, and then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain N-(3, the 5-difluorophenyl)-N '-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } urea trifluoroacetate (12mg, 29%), be white solid.

ESI?MS?m/e?411.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.02(d，J＝8.0Hz，1H)，7.87(brs，1H)，7.80(t，J＝7.6Hz，1H)，7.56(t，J＝7.6Hz，1H)，7.07(s，1H)，7.03(s，1H)，6.97(brs，1H)，6.50(t，J＝9.2Hz，1H)，4.02(m，1H)，3.89(m，1H)，2.68(brs，3H)，2.66(s，3H)，1.99-1.78(m，8H).

Embodiment 2516

N-[3,5-two (trifluoromethyl) phenyl]-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate

Steps A: synthetic N-[3,5-two (trifluoromethyl) phenyl]-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate.

Adopt the method for the steps A of embodiment 2515, obtain title compound.

ESI?MS?m/e?511.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.02(s，2H)，8.00(s，1H)，7.87(brs，1H)，7.80(t，J＝7.2Hz，1H)，7.57(t，J＝8.0Hz，1H)，7.49(s，1H)，6.98(brs，1H)，4.04(m，1H)，3.91(m，1H)，2.69(brs，3H)，2.66(s，3H)，2.01-1.80(m，8H).

Embodiment 2517

N-(3-chlorophenyl)-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate

Steps A: synthetic N-(3-chlorophenyl)-N '-cis-4-[(4-toluquinoline-2-yl) and amino] cyclohexyl } the urea trifluoroacetate.

Adopt the method for the steps A of embodiment 2515, obtain title compound.

ESI?MS?m/e?409.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.00(d，J＝8.4Hz，1H)，7.87(brs，1H)，7.79(t，J＝7.6Hz，1H)，7.59(s，1H)，7.56(t，J＝7.6Hz，1H)，7.21-7.15(m，2H)，6.96(brs，1H)，6.93-6.91(m，1H)，4.01(m，1H)，3.89(t，1H)，2.66(brs，6H)，1.99-1.78(m，8H).

Embodiment 2518

N-(3, the 4-dichlorophenyl)-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate

Steps A: synthetic N-(3, the 4-dichlorophenyl)-N '-cis-4-[(4-toluquinoline-2-yl) and amino] cyclohexyl } the urea trifluoroacetate.

Adopt the method for the steps A of embodiment 2515, obtain title compound.

ESI?MS?m/e?443.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.00(d，J＝7.6Hz，1H)，7.87(brs，1H)，7.79-7.74(m，2H)，7.56(t，J＝7.6Hz，1H)，7.34(d，J＝8.4Hz，1H)，7.20(d，J＝8.4Hz，1H)，6.97(brs，1H)，4.02(m，1H)，3.88(m，1H)，2.66(brs，6H)，1.98-1.78(m，8H).

Embodiment 2519

N-(3-p-methoxy-phenyl)-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } the urea trifluoroacetate

Steps A: synthetic N-(3-p-methoxy-phenyl)-N '-cis-4-[(4-toluquinoline-2-yl) and amino] cyclohexyl } the urea trifluoroacetate.

Adopt the method for the steps A of embodiment 2515, obtain title compound.

ESI?MS?m/e?405.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.00(d，J＝8.0Hz，1H)，7.87(brs，1H)，7.79(t，J＝7.6Hz，1H)，7.56(t，J＝8.0Hz，1H)，7.14-7.10(m，2H)，6.96(brs，1H)，6.84(d，J＝8.0Hz，1H)，6.53(d，J＝8.4Hz，1H)，4.01(m，1H)，3.89(m，1H)，3.75(s，3H)，2.71(brs，6H)，1.99-1.78(m，8H).

Embodiment 2520

3-methoxyl group-N-[cis-4-(quinoline-2-base is amino) cyclohexyl] the benzamide trifluoroacetate

Steps A: synthesizing cis-[4-(3-methoxyl group-phenmethyl amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

Under in ice bath, stirring, to cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (2.8g, add in 40mL dichloromethane solution 0.013mol) DIEA (3.41mL, 0.020mol).This solution of cooling on ice bath, between slowly adding-the methyl-phenoxide muriate (1.84mL, 0.013mol).Remove this solution from ice bath, continue again to stir 1 hour.Evaporating solvent makes this material through chromatography (hexane solution of 0-40% ethyl acetate), obtains cis-[4-(3-methoxyl group-benzoyl-amido)-cyclohexyl]-carboxylamine tertiary butyl ester (4.3g, 94%), is white solid.

ESI?MS?m/e?349.0M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.03(d，J＝6.8Hz，1H)，7.42-7.32(m，3H)，7.07(dd，J＝8.4，2.4Hz，1H)，6.62(brs，1H)，3.79(s，3H)，3.77(m，1H)，3.41(m，1H)，1.71-1.70(m，4H)，1.52-1.46(m，4H)，1.38(s，9H).

Step B: synthesizing cis-N-(4-amino-cyclohexyl)-3-methoxyl group-benzamide.

To cis-[4-(3-methoxyl group-benzoyl-amido)-cyclohexyl]-carboxylamine tertiary butyl ester (4.3g, add in 50mL dichloromethane solution 0.012mol) TFA (1.84mL, 0.024mol).Stirred this solution 4 hours, evaporating solvent.The oily matter of generation is dissolved in the 50mL methylene dichloride again.Organic layer is extracted with the rare NaOH of 50mL (aq)/sodium bicarbonate (aq) solution.More than twice, merge organic layer with the dichloromethane extraction waterbearing stratum,, and concentrate through dried over mgso.Make the crystallization in ether and the hexane that is deposited in that obtains, obtain cis-N-(4-amino-cyclohexyl)-3-methoxyl group-benzamide (2.4g, 78%), be white solid.

ESI?MS?m/e?249.0M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.10(d，J＝7.2Hz，1H)，7.42-7.32(m，3H)，7.07(dd，J＝8.0，2.4Hz，1H)，3.79(brs，4H)，2.91(m，1H)，1.80-1.74(m，2H)，1.52-1.46(m，6H)，1.31(brs，2H).

Step C: synthetic 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino) cyclohexyl] the benzamide trifluoroacetate.

To cis-N-(4-amino-cyclohexyl)-3-methoxyl group-benzamide (28.4mg, add in 0.5mL 2-propanol solution 0.1mmol) the 2-chloroquinoline (32.7mg, 0.2mmol) and DIEA (34.8uL, 0.2mmol).In 170 ℃, this reaction mixture was heated 10 hours in the microwave synthesizer.Remove and desolvate, the oily matter of generation is dissolved among the 1mL DMSO.Make described compound through preparation type LCMS purifying then, obtain 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino) cyclohexyl] benzamide trifluoroacetate (26mg, 53%), be colorless oil.

ESI?MS?m/e?376.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.85(d，J＝9.2Hz，1H)，7.62(t，J＝8.8Hz，2H)，7.50(t，J＝7.2Hz，1H)，7.39-7.36(m，3H)，7.19(t，J＝7.2Hz，1H)，7.10-7.07(m，1H)，6.82(d，J＝9.2Hz，1H)，4.18(m，1H)，4.02(m，1H)，3.84(s，3H)，1.95-1.22(m，1H).

Embodiment 2521

3-methoxyl group-N-(cis-4-{[4-(trifluoromethyl) quinoline-2-yl] amino } cyclohexyl) the benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4-fluoroform yl-quinoline.

To 4-fluoroform yl-quinoline-2-alcohol (1.01g, 10mL POCl 0.0047mol) ₃Add N in the solution, and accelerine (661uL, 0.0052mol).This mixture heating up to refluxing (125 ℃) and stirring 4 hours, is dissolved fully until starting raw material, and this solution changes intense violet color into.Cool off this solution then, slow impouring is (30g on ice; Note highly heating), with the quencher reactant.Then the waterbearing stratum is extracted 3 times with methylene dichloride (25mL).Through the dried over mgso organic layer, concentrate, through chromatography purification (100% methylene dichloride), obtain 2-chloro-4-fluoroform yl-quinoline (823mg, 75%), be faint yellow solid.

ESI?MS?m/e?232.0M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.15-8.09(m，2H)，8.06(s，1H)，8.01-7.97(m，1H)，7.88-7.85(m，1H).

Step B: synthetic 3-methoxyl group-N-(cis-4-{[4-(trifluoromethyl) quinoline-2-yl] amino } cyclohexyl) the benzamide trifluoroacetate.

To cis-N-(4-amino-cyclohexyl)-3-methoxyl group-benzamide (50mg, add in 0.5mL 2-propanol solution 0.20mmol) 2-chloro-4-fluoroform yl-quinoline (56mg, 0.24mmol) and DIEA (52.6uL, 0.30mmol).In 170 ℃, this reaction mixture was heated 5 hours in the microwave synthesizer.Remove and desolvate, the oily matter of generation is dissolved among the 1mL DMSO.Make described compound through preparation type LCMS purifying then, obtain 3-methoxyl group-N-(cis-4-{[4-(trifluoromethyl) quinoline-2-yl] amino } cyclohexyl) benzamide trifluoroacetate (71.8mg, 64%), be white solid.

ESI?MS?m/e?444.4M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.22(d，J＝6.4Hz，1H)，7.79-7.77(m，2H)，7.69(m，1H)，7.50(s，1H)，7.44-7.34(m，4H)，7.09(dd，J＝8.0，2.4Hz?1H)，4.14(m，1H)，3.87(m，1H)，3.80(s，3H)，1.94-1.92(m，2H)，1.82-1.72(m，6H).

Embodiment 2522

3-methoxyl group-N-{ cis-4-[(quinoline-2-ylmethyl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: amino synthetic 3-methoxyl group-N-{ cis-4-[(quinoline-2-ylmethyl)] cyclohexyl } the benzamide trifluoroacetate.

Adopt the method for the steps A of embodiment 2510, obtain title compound.

ESI?MS?m/e?390.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.41(d，J＝8.8Hz，1H)，8.14(d，J＝8.4Hz，1H)，7.99(d，J＝8.0Hz，1H)，7.84(t，J＝7.2Hz，1H)，7.67(t，J＝7.2Hz，1H)，7.55(d，J＝8.4Hz，1H)，7.43-7.36(m，3H)，7.12-7.10(m，1H)，4.66(s，2H)，4.13(m，1H)，3.85(s，3H)，3.46(m，1H)，2.16-2.05(m，4H)，2.05-1.96(m，2H)，1.85-1.78(m，2H).

Embodiment 2523

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4-dimethylamino-5-methylpyrimidine.

In 0 ℃, make 2, (0.5g 3.07mmol) is dissolved in the 8mL tetrahydrofuran (THF) 4-two chloro-5-methylpyrimidines.In reaction mixture, be added dropwise to dimethyl amine (2M in methyl alcohol, 3.4mL, 6.8mmol).Stirred this reaction mixture 1.5 hours in 10 ℃: temperature of reaction does not raise.Concentrate this solution,, obtain 2-chloro-4-dimethylamino-5-methylpyrimidine (307mg, 58%), be white solid through flash chromatography purifying (silica gel, the hexane solution of 20% ethyl acetate and 5% methyl alcohol).

ESI?MS?m/e?172M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.8(s，1H)，3.18(s，6H)，2.23(s，3H).

Step B: synthesizing cis-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

To 2-chloro-4-dimethylamino-5-methylpyrimidine (250mg, 1.46mmol) add cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (340mg in the suspension in 2-propyl alcohol (2.5mL), 1.60mmol) and DIEA (507 μ L, 2.91mmol).In 175 ℃, in the Smith synthesizer, carry out this reaction 4.5 hours.Concentrate this solution,, obtain cis-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester (219mg, 43%), be faint yellow solid through flash chromatography purifying (silica gel, the dichloromethane solution of 1%MeOH).

ESI?MS?m/e?350.4M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.80(s，1H)，4.6(brs，1H)，3.94(brs，1H)，3.60(brs，1H)，3.02(s，6H)，2.18(s，3H)，1.85-1.70(m，8H)，1.41(s，9H).

Step C: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-4-amino-hexanaphthene.

To cis-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-(219mg 0.627mmol) adds trifluoroacetic acid (2mL) in the suspension in DCM (3mL) to the carboxylamine tertiary butyl ester.Reaction stirred is 2 hours under room temperature, concentrates then.After adding several sodium bicarbonates, then adding 1M NaOH, is alkalescence until this solution.Water and dichloromethane extraction product 3 times.Merge organic layer,, filter and concentrate, obtain cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-4-aminocyclohexane (115.9mg, 74%), be yellow oil through dried over mgso.

ESI?MS?m/e?250.2M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.60(s，1H)，4.95(brs，1H)，3.90(brs，1H)，2.98(s，6H)，2.80(brs，1H)，2.48(brs，2H)，2.04(s，3H)，1.78(m，2H)，1.62(m，4H)，1.4(m，2H).

Step D: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-4-methyl benzamide trifluoroacetate.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-4-aminocyclohexane (30mg, add in suspension 0.12mmol) 4-methyl-Benzoyl chloride (15.8 μ L, 0.12mmol) and DIEA (5).Under room temperature, argon atmospher, this reactant stirring is spent the night.Concentrate this solution,, obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide trifluoroacetate (29.1mg, 50.4%), be white solid product preparation HPLC purifying.

ESI?MS?m/e?368M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.70(s，1H)，7.68(d，J＝8.0Hz，2H)，7.24(d，J＝8.0Hz，2H)，6.72(s，1H)，4.25(s，1H)，3.23(s，6H)，2.71(s，1H)，2.34(s，3H)，2.27(s，3H)，1.7-1.88(m，8H).

Embodiment 2524

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-4-aminocyclohexane (70mg 0.28mmol) adds 3 in the suspension in DCM (5mL), the 4-difluoro benzoyl chloride (50mg, 0.28mmol) and DIEA (45 μ L, 0.28mmol).Reaction stirred is spent the night under room temperature, and product is through column chromatography purification (silica gel, DCM/MeOH=100: 0-90: 10).The product of purifying is dissolved among the DCM (3mL), adds the diethyl ether solution (0.3mL) of 2M-HCl.Stir after 20 minutes, remove volatile solvent, obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide hydrochloride (26mg, 23%) is white solid.

ESI?MS?m/e?390M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.8(brs，1H)，8.23(brs，1H)，7.80(m，2H)，7.63(m，1H)，7.51(s，1H)，7.40(d，J＝8.8Hz，1H)，3.74(brs，2H)，3.14(s，6H)，2.11(s，3H)，1.73-1.58(m，8H).

Embodiment 2525

3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 2524, obtain title compound.

ESI?MS?m/e?388M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.7(brs，1H)，8.22(brs，1H)，7.72(m，2H)，7.62(d，J＝8.0Hz，1H)，7.45(s，1H)，7.42(d，J＝8.0Hz，1H)，7.32(t，J＝7.6Hz，1H)，3.70(brs，2H)，3.10(s，6H)，2.06(s，3H)，1.68-1.54(m，8H).

Embodiment 2526

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4-dimethylamino-6-methylpyrimidine.

Under 0 ℃, in the 100mL tetrahydrofuran (THF), dissolve 2,4-two chloro-6-methylpyrimidines (10g, 61.3mmol).In reaction mixture, be added dropwise to dimethyl amine (2M in methyl alcohol, 67.4mL, 134.8mmol).Stirred this reaction mixture 2.5 hours in 10 ℃.Concentrate this solution,, obtain 2-chloro-4-dimethylamino-6-methylpyrimidine (4.18g, 40%), be faint yellow solid through flash chromatography purifying (silica gel, the hexane solution of 20% ethyl acetate and 5% methyl alcohol).

ESI?MS?m/e?172M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ6.25(s，1H)，3.2(s，6H)，2.64(s，3H).

Step B: synthesizing cis-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester.

To 2-chloro-4-dimethylamino-6-methylpyrimidine (15mg, 0.0874mmol) add cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (20.6mg in the suspension in 2-propyl alcohol (1.7mL), 0.096mmol) and DIEA (30.3 μ L, 0.175mmol).In 175 ℃, in the Smith synthesizer, carry out this reaction 4.5 hours.Concentrate this solution,, obtain cis-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester (18.9mg, 62%), be faint yellow solid through flash chromatography purifying (silica gel, the dichloromethane solution of 1%MeOH).

ESI?MS?m/e?350.4M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ5.65(s，1H)，4.75(brs，1H)，4.0(brs，1H)，3.60(brs，1H)，3.05(s，6H)，2.22(s，3H)，1.78(m，6H)，1.59(m，2H)，1.44(s，9H).

Step C: synthesizing cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-4-hexanaphthene.

To cis-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) cyclohexyl]-(617mg 1.77mmol) adds trifluoroacetic acid (2mL) in the suspension in DCM (3mL) to the carboxylamine tertiary butyl ester.Reaction stirred is 2 hours under room temperature, concentrates then.After adding several sodium bicarbonates, then adding 1M NaOH, is alkalescence until this solution.Water and dichloromethane extraction product 3 times.Merge organic layer,, filter and concentrate, obtain cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-4-aminocyclohexane (318mg, 72%), be yellow oil through dried over mgso.

ESI?MS?m/e?250M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ5.52(s，1H)，5.10(brs，1H)，3.88(brs，1H)，3.20(brs，2H)，2.88(s，6H)，2.75(s，1H)，2.04(s，3H)，1.70(m，2H)，1.58(m，4H)，1.38(m，2H).

Step D: synthetic N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide trifluoroacetate.

Adopt the method for the step D of embodiment 2523, obtain title compound.

ESI?MS?m/e?368.4M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)9.0(s，1H)，7.6(m，2H)，7.22(s，1H)，6.72(s，1H)，5.68(s，1H)，4.2(s，1H)，4.12(s，1H)，3.18(s，3H)，3.08(s，3H)，2.35(s，3H)，2.29(s，3H)，1.85-1.62(m，8H).

Embodiment 2527

Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl]-cyclohexane carboxamide

Steps A: synthesizing cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid ethyl ester.

To 2-chloro-4-dimethylamino-6-methylpyrimidine (250mg, 1.46mmol) add in the suspension in 2-propyl alcohol (1.5mL) cis-4-amino-hexahydrobenzoic acid ethyl ester hydrochloride (330mg, 1.59mmol) and DIEA (0.60mL, 3.44mmol).In 155 ℃, in the Smith synthesizer, carry out this reaction 1 hour.Concentrate this solution,, obtain cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid ethyl ester (378.9mg, 84.7%), be faint yellow solid through flash chromatography purifying (silica gel, the dichloromethane solution of 1%MeOH).

ESI?MS?m/e?307M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.62(brs，1H)，6.21(s，1H)，4.04(q，J＝6.4Hz，2H)，3.98(brs，1H)，3.15(s，6H)，2.20(s，3H)，1.58-1.80(m，8H)，1.20(t，J＝6.0Hz，3H).

Step B: synthesizing cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid.

To cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid ethyl ester (597.6mg, 1.95mmol) add in the suspension in water (10mL) and ethanol (0.3mL) KOH (547mg, 9.75mmol).In 70 ℃ of reaction stirred 2.5 hours, become even until reactant.On ice bath, cool off reactant, use the concentrated hydrochloric acid acidifying.Product with flash chromatography purifying (silica gel, the dichloromethane solution of 0-10%MeOH), is obtained cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid (302mg, 55%), be white solid.

ESI?MS?m/e?279.2M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.50(brs，1H)，5.79(s，1H)，4.02(brs，1H)，3.19(brs，6H)，2.49(brs，1H)，2.29(s，3H)，2.05(m，2H)，1.81(m，2H)，1.64(m，4H).

Step C: synthesizing cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl]-cyclohexane carboxamide.

To 3-trifluoromethyl benzyl amine (14 μ L, 0.0987mmol) and cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino) hexahydrobenzoic acid (25mg, 0.0898mmol) add in the suspension in DCM (5mL) HATU (37.5mg, 0.0987mmol).Under room temperature, argon atmospher, in 30 seconds of reaction stirred, add triethylamine (5).Reaction stirred is 16 hours under room temperature, argon atmospher.By diluting the quencher reactant,, wash 1 time with 1M HCl (5mL) washed twice and water (5mL) then with saturated sodium bicarbonate (5mL) washed twice with 5mL DCM.By the filtered through silica gel purified product, dichloromethane solution wash-out with 0-10%MeOH, obtain cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl]-cyclohexane carboxamide (17.6mg, 45%), be white solid.

ESI?MS?m/e?436M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.01(brs，1H)，7.59(brs，1H)，7.53(m，2H)，7.40(m，2H)，5.76(s，1H)，4.50(d，J＝6.4Hz，2H)，4.28(brs，1H)，3.19(s，6H)，2.39(m，1H)，2.30(s，3H)，2.0(m，2H)，1.87(m，4H)，1.60(m，2H).

Embodiment 2528

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[3-(propionyl amino) benzyl]-cyclohexane carboxamide

Steps A: synthesizing cis-[4-(3-nitrobenzyl formamyl)-cyclohexyl]-carboxylamine tertiary butyl ester.

HATU (3.5g, 9.02mmol) and Et ₃Under the existence of N (4mL), (2.0g is 8.2mmol) with 3-nitrobenzyl amine hydrochlorate (1.54g, 8.2mmol) reaction in DCM (30mL) to make cis-4-(tert-butoxycarbonyl amino)-hexahydrobenzoic acid.With DCM diluting reaction thing,,, and concentrate through dried over mgso with 1N-HCl and water washing.From column chromatography for separation (silica gel, DCM/MeOH=100: 0-95: 5) 2.7g (90%) cis-[4-(3-nitrobenzyl formamyl)-cyclohexyl]-carboxylamine tertiary butyl ester.

ESI?MS?m/e?378M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.11(brs，1H)，8.09(s，1H)，7.60(d，J＝8.0Hz，1H)，7.48(t，J＝7.6Hz，1H)，6.17(brs，1H)，4.72(brs，1H)，4.53(d，J＝6.0Hz，2H)，3.74(brs，1H)，2.27(m，1H)，1.80-1.71(m，6H)，1.65-1.59(m，2H)，1.45(s，9H).

Step B: synthesizing cis-4-amino-hexahydrobenzoic acid 3-nitro-benzamide hydrochloride salt.

Under room temperature, (2.5g, 6.6mmol) (1: reaction is 2 hours 2=23mL) at TFA/DCM to make cis-[4-(3-nitrobenzyl formamyl)-cyclohexyl]-carboxylamine tertiary butyl ester.Except that after desolvating, residue is dissolved among the DCM (15mL), add ether (2 equivalent) solution of 2M-HCl.After stirring 20 minutes under the room temperature, remove volatile solvent, obtain cis-4-amino-hexahydrobenzoic acid 3-nitro-benzamide hydrochloride salt (2.0g, 95%), be white-yellowish solid.

ESI?MS?m/e?278M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.53(t，J＝60Hz，1H)，8.07(d，J＝7.6Hz，1H)，8.06(s，1H)，7.84(brs，2H)，7.68(d，J＝7.6Hz，1H)，7.59(t，J＝7.6Hz，1H)，4.37(d，J＝6.4Hz，2H)，3.13(m，1H)，2.40(m，1H)，1.89(m，2H)，1.68(m，4H)，1.57(m，2H).

Step C: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) hexahydrobenzoic acid 3-nitro-benzyl acid amides.

In the Smith synthesizer, make 2-chloro-4-dimethylamino-5-methylpyrimidine (0.31g, 1.8mmol) and cis-4-amino-hexahydrobenzoic acid 3-nitro-benzyl amide hydrochloride (0.52g, 1 equivalent) in IPA (2.5mL) and DIEA (0.7mL), react.With DCM diluting reaction thing,,, and concentrate through dried over mgso with 1N-HCl and water washing.Crude compound is through column chromatography purification (silica gel, DCM/MeOH=100: 0-90: 10), obtain 0.23g (31%) cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid 3-nitro-benzyl acid amides.

ESI?MS?m/e?413M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.11(brs，1H)，8.03(d，J＝8.0Hz，1H)，7.95(brs，1H)，7.62(d，J＝8.0Hz，1H)，7.43(t，J＝7.6Hz，1H)，7.28(s，1H)，4.51(d，J＝5.6Hz，2H)，4.33(m，1H)，3.23(s，6H)，2.39(m，1H)，2.22(s，3H)，2.02(m，2H)，186(m，4H)，1.60(m，2H).

Step D: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid 3-amino-benzyl acid amides.

Under room temperature, nitrogen atmosphere, with cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid 3-amino-benzyl acid amides (0.21g, 0.5mmol) and EtOH (10mL) solution stirring of 10%Pd/C (50mg) spend the night.By Celite pad filtering reaction thing.After removing volatile solvent, residue is through purifying (DCM/MeOH=100: 0-80: 20) from short silicagel column, obtain 0.18g (95%) cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid 3-amino-benzyl acid amides, be required product.

ESI?MS?m/e?383M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.29(s，1H)，7.03(t，J＝7.6Hz，1H)，6.64(m，2H)，6.51(d，J＝8.0Hz，1H)，4.33(d，J＝5.6Hz，2H)，4.25(brs，1H)，319(s，6H)，2.32(m，1H)，2.19(s，3H)，1.97-1.78(m，6H)，1.62(m，2H).

Step e: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[3-(propionyl amino) benzyl] cyclohexane carboxamide.

Et at catalytic amount ₃N (7) exists down, make cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid 3-amino-benzyl acid amides (30mg, 0.075mmol) and propionyl chloride (7mg 0.075mmol) reacts.Product through column chromatography purification (silica gel, DCM/MeOH=100: 0-90: 10), obtain cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[3-(propionyl amino) benzyl] cyclohexane carboxamide (11mg, 32%).

ESI?MS?m/e?439M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.63(brs，1H)，7.92(brs，1H)，7.35(s，1H)，7.28(s，1H)，7.21(t，J＝7.6Hz，1H)，6.92(d，J＝7.6Hz，1H)，6.46(brs，1H)，4.42(d，J＝6.0Hz，2H)，4.23(m，1H)，3.22(s，6H)，2.47(d，J＝7.6Hz，2H)，2.33(m，1H)，2.22(s，3H)，1.95-1.90(m，6H)，1.63(m，2H)，1.22(t，J＝7.6Hz，3H).

Embodiment 2529

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[3-(isobutyryl amino) benzyl]-cyclohexane carboxamide

Steps A: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[3-(isobutyryl amino) benzyl] cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?453M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.80(brs，1H)，8.10(brs，1H)，7.93(brs，1H)，7.39(s，1H)，7.23(s，1H)，7.18(t，J＝7.6Hz，1H)，6.91(d，J＝7.6Hz，1H)，6.69(brs，1H)，4.40(d，J＝5.6Hz，2H)，4.22(m，1H)，3.23(s，6H)，2.74(m，1H)，2.33(m，1H)，2.20(s，3H)，1.96-1.87(m，6H)，1.60(m，2H)，1.22(d，J＝6.4Hz，6H).

Embodiment 2530

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{3-[(3-methylbutyryl base) amino]-benzyl } cyclohexane carboxamide.

Steps A: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{3-[(3-methylbutyryl base) amino] benzyl } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?467M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.62(brs，1H)，8.04(brs，1H)，7.91(d，J＝7.2Hz，1H)，7.35(s，1H)，7.26(s，1H)，7.20(t，J＝7.6Hz，1H)，6.93(d，J＝7.6Hz，1H)，6.59(brs，1H)，4.42(d，J＝5.2Hz，2H)，4.22(m，1H)，3.23(s，6H)，2.33(m，1H)，2.31(d，J＝7.2Hz，2H)，2.23(m，1H)，2.21(s，3H)，1.96-1.87(m，6H)，1.62(m，2H)，1.00(d，J＝6.0Hz，6H).

Embodiment 2531

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{3-[(2,2-dimethyl-propionyl) amino] benzyl } cyclohexane carboxamide

Steps A: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{3-[(2,2-dimethyl propylene acyl group) amino] benzyl } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?467M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.84(brs，1H)，7.78(d，J＝7.6Hz，1H)，7.40(s，1H)，7.25(s，1H)，7.22(t，J＝7.6Hz，1H)，7.00(d，J＝7.6Hz，1H)，6.85(brs，1H)，4.41(d，J＝5.6Hz，2H)，4.23(m，1H)，3.23(s，6H)，2.34(m，1H)，2.22(s，3H)，1.99-1.84(m，6H)，1.60(m，2H)，1.33(s，9H).

Embodiment 2532

Cis-N-{3-[(cyclobutyl carbonyl) amino] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide

Steps A: amino synthesizing cis-N-{3-[(cyclobutyl carbonyl)] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?465M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.50(brs，1H)，8.23(brs，1H)，7.93(d，J＝6.4Hz，1H)，7.33(s，1H)，7.24(s，1H)，7.20(t，J＝8.0Hz，1H)，6.92(d，J＝8.0Hz，1H)，6.76(brs，1H)，4.41(d，J＝5.6Hz，2H)，4.23(m，1H)，3.33(m，1H)，3.24(s，6H)，2.35(m，4H)，2.21(s，3H)，2.18(m，1H)，2.00-1.87(m，8H)，1.60(m，2H).

Embodiment 2533

Cis-N-{3-[(cyclopentylcarbonyl) amino] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide

Steps A: amino synthesizing cis-N-{3-[(cyclopentylcarbonyl)] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?479M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.47(brs，1H)，8.10(brs，1H)，7.91(d，J＝6.4Hz，1H)，7.35(s，1H)，7.26(s，1H)，7.20(t，J＝8.0Hz，1H)，6.93(d，J＝7.6Hz，1H)，6.61(brs，1H)，4.42(d，J＝5.6Hz，2H)，4.22(m，1H)，3.22(s，6H)，2.85(m，1H)，2.33(m，1H)，2.21(s，3H)，2.00-1.88(m，10H)，1.75(m，2H)，1.60(m，4H).

Embodiment 2534

Cis-N-{3-[(cyclohexyl-carbonyl) amino] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide.

Steps A: amino synthesizing cis-N-{3-[(cyclohexyl-carbonyl)] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?493M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.30(brs，1H)，8.01(brs，1H)，7.86(d，J＝7.6Hz，1H)，7.36(s，1H)，7.26(s，1H)，7.20(t，J＝8.0Hz，1H)，6.94(d，J＝7.6Hz，1H)，6.65(brs，1H)，4.41(d，J＝5.2Hz，2H)，4.22(m，1H)，3.22(s，6H)，2.35(m，2H)，2.21(s，3H)，196-1.28(m，18H).

Embodiment 2535

Cis-N-{3-[(cyclopropyl carbonyl) amino] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide

Steps A: amino synthesizing cis-N-{3-[(cyclopropyl carbonyl)] benzyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide.

Adopt the method for the step e of embodiment 2528, obtain title compound.

ESI?MS?m/e?451M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.10(brs，1H)，7.93(m，1H)，7.36(s，1H)，7.25(s，1H)，7.19(t，J＝8.0Hz，1H)，6.90(d，J＝7.2Hz，1H)，6.50(brs，1H)，4.43(d，J＝6.0Hz，2H)，4.23(m，1H)，3.23(s，6H)，2.33(m，1H)，2.21(s，3H)，1.96-1.88(m，7H)，1.63(m，2H)，1.03(m，2H)，0.79(m，2H).

Embodiment 2536

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-[(3-methylbutyryl base) amino] benzamide.

Steps A: synthetic cis-4-[(3-nitro-benzoyl-amido)-methyl]-cyclohexyl }-the carboxylamine tertiary butyl ester.

Under room temperature, (1.55g, 6.8mmol) (1.25g, mixture 6.8mmol) stir and spend the night, and with the DCM dilution, with 1N-HCl and water washing, concentrate then with the 3-nitrobenzoyl chloride with cis-(4-amino methyl-cyclohexyl)-carboxylamine tertiary butyl ester.Crude product is through short silicagel column preliminary purification, with DCM/MeOH (100: 0-90: 10) wash-out, obtain 1.5g (75%) cis-4-[(3-nitro-benzoyl-amido)-methyl]-cyclohexyl-the carboxylamine tertiary butyl ester.

ESI?MS?m/e?378M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.54(t，J＝2.0Hz，1H)，8.33(d，J＝8.0Hz，1H)，8.14(d，J＝8.0Hz，1H)，7.63(t，J＝7.6Hz，1H)，6.31(brs，1H)，4.62(brs，1H)，3.73(brs，1H)，3.41(t，J＝6.4Hz，2H)，1.72-1.57(m，7H)，1.44(s，9H)，1.32(m，2H).

Step B: synthesizing cis-N-(4-amino-cyclohexyl methyl)-3-nitro-benzamide hydrochloride salt.

Under room temperature, will cis-4-[(3-nitro-benzoyl-amido)-methyl]-cyclohexyl }-(1.4g is 3.7mmol) at DCM/TFA (1: stirred 2 hours 1=13mL) for the carboxylamine tertiary butyl ester.After removing volatile solvent, residue is dissolved among the DCM (10mL), adds ether (4mL) solution of 2M-HCl.After stirring 20 minutes under the room temperature, remove volatile solvent, obtain 1.2g (82%) cis-N-(4-amino-cyclohexyl methyl)-3-nitro-benzamide hydrochloride salt, be required product.

ESI?MS?m/e?278M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.91(t，J＝5.6Hz，1H)，8.65(m，1H)，8.36(d，J＝2.0Hz，1H)，8.29(d，J＝8.0Hz，1H)，7.97(brs，2H)，7.74(t，J＝8.0Hz，1H)，3.25(t，J＝6.8Hz，2H)，3.13(brs，1H)，1.77(m，1H)，1.65-1.61(m，4H)，1.51(m，4H).

Step C: synthesizing cis-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-3-nitro-benzamide.

In 155 ℃, in the Smith synthesizer, with 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25g, 1.46mmol) and cis-N-(4-amino-cyclohexyl methyl)-3-nitro-benzamide hydrochloride salt (0.46g) in IPA (2mL) and DIEA (0.46mL) solution, reacted 1 hour 10 minutes.With DCM diluting reaction thing,,, and concentrate through dried over mgso with 1N-HCl and water washing.Crude compound through column chromatography purification (silica gel, DCM/MeOH=100: 0-90: 10), obtain 0.23g (38%) cis-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-3-nitro-benzamide.

ESI?MS?m/e?413.2M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.73(t，J＝2.0Hz，1H)，8.34(d，J＝7.6Hz，1H)，8.28(d，J＝8.0Hz，，1H)，8.20(brs，1H)，7.60(t，J＝7.6Hz，1H)，7.35(brs，1H)，7.25(s，1H)，4.18(m，1H)，3.48(t，J＝4.8Hz，2H)，3.24(s，6H)，2.21(s，3H)，1.89-1.57(m，9H).

Step D: synthetic N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) methyl]-3-[(3-methylbutyryl base) amino] benzamide.

Under room temperature, nitrogen atmosphere, with cis-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-3-nitro-benzamide (0.22g, 0.53mmol) and EtOH (15mL) solution stirring of 10%Pd/C (30mg) spend the night.By Celite pad filtering reaction thing.After removing volatile solvent, residue is through purifying (DCM/MeOH=100: 0-80: 20), obtain 0.19g (95%), be yellow oil from short silicagel column.Use the method for the step e of embodiment 2528; make this oily matter and the isoveryl chloride (5mg of 17mg (0.04mmol); 0.04mmol) reaction; obtain N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-[(3-methylbutyryl base) amino] benzamide (9mg, 47%).

ESI?MS?m/e?467.6M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.11(brs，1H)，8.22(d，J＝7.2Hz，1H)，8.04(s，1H)，7.55(d，J＝7.6Hz，1H)，7.34(t，J＝7.6Hz，1H)，7.30(s，1H)，6.42(m，1H)，4.14(m，1H)，3.43(t，J＝4.8Hz，2H)，3.19(s，6H)，2.33(d，J＝6.8Hz，2H)，2.25(m，1H)，2.20(s，3H)，1.94(m，2H)，1.72～1.59(m，7H)，1.02(d，J＝6.4Hz，6H).

Embodiment 2537

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(propionyl amino) benzamide

Steps A: synthetic N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) methyl]-3-(propionyl amino) benzamide.

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?439M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.10(brs，1H)，8.23(d，J＝7.2Hz，1H)，8.02(s，1H)，7.55(d，J＝8.0Hz，1H)，7.35(t，J＝7.6Hz，1H)，7.29(s，1H)，6.36(m，1H)，4.16(brs，1H)，3.47(m，2H)，3.21(s，6H)，2.50(q，J＝7.6Hz，2H)，2.21(s，3H)，1.95(m，2H)，1.72-1.61(m，7H)，1.25(t，J＝7.2Hz，3H).

Embodiment 2538

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(isobutyryl amino) benzamide

Steps A: synthetic N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) methyl]-3-(isobutyryl amino) benzamide

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?453M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.09(brs，1H)，8.23(d，J＝6.8Hz，1H)，8.07(s，1H)，7.55(d，J＝7.6Hz，1H)，7.34(t，J＝7.6Hz，1H)，7.29(s，1H)，6.38(m，1H)，4.16(brs，1H)，3.45(m，2H)，3.21(s，6H)，2.73(m，1H)，2.20(s，3H)，1.95(m，2H)，1.72-1.61(m，7H)，1.26(d，J＝6.8Hz，6H).

Embodiment 2539

The 3-[(cyclopropyl carbonyl) amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide

Steps A: amino synthetic 3-[(cyclopropyl carbonyl)]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?451M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.60(brs，1H)，8.22(d，J＝6.8Hz，1H)，8.03(s，1H)，7.56(brs，1H)，7.55(d，J＝7.6Hz，1H)，7.32(t，J＝7.6Hz，1H)，7.28(s，1H)，6.41(m，1H)，4.15(brs，1H)，3.45(m，2H)，3.21(s，6H)，2.20(s，3H)，1.95(m，2H)，1.89(m，1H)，1.72～1.61(m，7H)，1.05(m，2H)，0.82(m，2H).

Embodiment 2540

The 3-[(cyclobutyl carbonyl) amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide

Steps A: amino synthetic 3-[(cyclobutyl carbonyl)]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide.

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?465M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.90(brs，1H)，8.21(d，J＝6.8Hz，1H)，8.04(s，1H)，7.54(d，J＝8.0Hz，1H)，7.34(t，J＝7.6Hz，1H)，7.31(s，1H)，6.41(m，1H)，4.14(brs，1H)，3.43(t，J＝5.2Hz，2H)，3.34(m，1H)，3.19(s，6H)，2.41(m，2H)，2.23(m，1H)，2.20(s，3H)，2.02-1.88(m，4H)，1.72-1.55(m，8H).

Embodiment 2541

The 3-[(cyclopentylcarbonyl) amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide.

Steps A: synthetic 3-[(cyclopentylcarbonyl) amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide.

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?479M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.14(brs，1H)，8.22(d，J＝7.2Hz，1H)，8.07(s，1H)，7.54(d，J＝8.0Hz，1H)，7.33(t，J＝8.0Hz，1H)，7.29(s，1H)，6.43(m，1H)，4.14(brs，1H)，3.44(t，J＝5.2Hz，2H)，3.19(s，6H)，2.91(m，1H)，2.20(s，3H)，1.98-1.59(m，17H).

Embodiment 2542

The 3-[(cyclohexyl-carbonyl) amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide

Steps A: amino synthetic 3-[(cyclohexyl-carbonyl)]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide.

Adopt the method for the step D of embodiment 2536, obtain title compound.

ESI?MS?m/e?479M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.94(brs，1H)，8.17(d，J＝7.2Hz，1H)，8.05(s，1H)，7.54(d，J＝8.0Hz，1H)，7.33(t，J＝8.0Hz，1H)，7.30(s，1H)，6.44(m，1H)，4.13(brs，1H)，3.42(t，J＝5.2Hz，2H)，3.19(s，6H)，2.42(m，1H)，2.20(s，3H)，1.98-1.52(m，15H)，1.29(m，4H).

Embodiment 2543-2553

With the similar approach described in embodiment 2497, use suitable acyl chlorides and the amine intermediate that derives from step D, preparation compound 2543-2553.

Embodiment 2554-2557

With the similar approach described in embodiment 2502, use suitable carboxylic acid and the amine intermediate that derives from embodiment 2497 step D, preparation compound 2554-2557.

Embodiment 2558-2561

With the similar approach described in embodiment 2515, use suitable isocyanic ester and the amine intermediate that derives from embodiment 2497 step D, preparation compound 2558-2561.

Embodiment 2562 and 2563

With the similar approach described in embodiment 2523, use suitable acyl chlorides and the amine intermediate that derives from step C, preparation compound 2562 and 2563.

Embodiment 2564-2570

With the similar approach described in embodiment 2526, use suitable acyl chlorides and the amine intermediate that derives from step C, preparation compound 2564-2570.

Embodiment 2571-2587

With the similar approach described in embodiment 2527, use suitable benzyl amine and the carboxylic acid intermediate that derives from step B, preparation compound 2571-2587.

Embodiment number	The compound title	MS	Classification
				2543	3-methyl-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	374.2(M+H)	1
2544	4-methyl-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	374.2(M+H)	1
				2545	4-fluoro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	378.2(M+H)	1
2546	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-3-(trifluoromethyl) benzamide	428(M+H)	3
				2547	3-chloro-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzene	394.2(M+H)	1

	Methane amide
					2548	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide	496.2(M+H)		1
2549	3-methoxyl group-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	390.4(M+H)		1
					2550	3-cyano group-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	385.2(M+H)		1
2551	2-(4-chloro phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } ethanamide	424.2(M+H)		1
					2552	3,4,5-trimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	450.4(M+H)		1
2553	3,5-dimethoxy-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } benzamide	420.2(M+H)		1
					2554	2-(3-methoxyl group phenoxy group)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } ethanamide	420.2(M+H)		1
2555	(2R)-2-(3-chlorophenyl)-2-hydroxy-n-cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } ethanamide	424.2(M+H)		1
					2556	2-(3-methylphenoxy)-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } ethanamide	404.2(M+H)		1
2557	5-bromo-N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-the 2-furoamide	428(M+H)		1
					2558	N-[4-(benzyloxy) phenyl]-N '-and cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl } urea	481.2(M+H)		2
2559	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-N '-(4-Phenoxyphenyl) urea	467.4(M+H)		1
					2560	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-N '-(3-Phenoxyphenyl) urea	467.4(M+H)		2
2561	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-N '-(2-Phenoxyphenyl) urea	467.4(M+H)		1
					2562	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	368.2(M+H)		1
2563	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }	384.2(M+H)		1

	Cyclohexyl)-the 3-methoxy benzamide
				2564	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methoxy benzamide	384.2(M+H)	1
2565	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	368.2(M+H)	1
				2566	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388.2(M+H)	1
2567	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388.4(M+H)	1
				2568	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide	390.2(M+H)	1
2569	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide	438.2(M+H)	3
				2570	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	372.2(M+H)	1
2571	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide) cyclohexane carboxamide	494.2(M+H)	1
				2572	Cis-N-(2, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436.2(M+H)	1
2573	Cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436.2(M+H)	1
				2574	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl) cyclohexane carboxamide	382.2(M+H)	1
2575	Cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436.2(M+H)	1
				2576	Cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	428.2(M+H)	1
2577	Cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	402.2(M+H)	1
				2578	Cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	504.2(M+H)	1
2579	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-	398.2(M+H)	1

	(3-methoxy-benzyl) cyclohexane carboxamide
				2580	Cis-N-(4-chloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	402.2(M+H)	1
2581	Cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436.2(M+H)	1
				2582	Cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404.2(M+H)	1
2583	Cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404.2(M+H)	1
				2584	Cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404.2(M+H)	1
2585	Cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	464.2(M+H)	1
				2586	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl) cyclohexane carboxamide	382.4(M+H)	1
2587	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl] cyclohexane carboxamide	452.2(M+H)	1

Embodiment 2588

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate.

Under room temperature, nitrogen atmosphere, (2.18g slowly adds 3 in dry-out benzene 10mmol) (25mL) solution, and 5-two (trifluoromethyl) Benzoyl chloride (2.8g, 1 equivalent) then adds Et to cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester ₃N (about 3mL): the formation of solid salt makes stirs difficulty.This reactant of vigorous stirring is other 2 hours under room temperature; with saturated sodium bicarbonate (3x) and water (1x) washing; through dried over mgso; concentrate; obtain [cis-4-[(3; 5-two (trifluoromethyl)-benzoyl-amido)-cyclohexyl]-carboxylamine tertiary butyl ester (4.5g, 99%), it need not be further purified and be used for next step reaction.

ESI?MS?m/e?455(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.16(s，2H)，7.98(s，1H)，6.12(bs，1H)，4.58(bs，1H)，4.11(m，1H)，3.69(bs，1H)，1.95～1.65(m，8H)，1.44(s，9H).

Make [cis-4-[(3,5-two (trifluoromethyl)-benzoyl-amido)-cyclohexyl]-(4.5g 10mmol) is dissolved among the DCM (20mL) the carboxylamine tertiary butyl ester, and TFA (10mL) is joined in the reactant.After stirring 1.5 hours under the room temperature, remove volatile solvent, obtain crude product N-(cis-4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate is thickness oily matter.With water (～50mL) join in the crude product product, vibrated the precipitation that obtains forming 5-10 minute.Filtering-depositing washes with water and drying.Isolate 3.98 (82%) N-(cis-4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate is white powder.

ESIMS?m/e?355(M+H) ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.62(bd，1H，J＝4.8Hz)，8.47(s，2H)，8.29(s，1H)，7.84(bs，3H)，3.91(bs，1H)，3.16(bs，1H)，1.94(m，2H)，1.75～1,66(m，6H).

Step B: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

In 180 ℃, in Smith microwave synthesizer, make the 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25g in the sealed tube of packing into, 1.45mmol), N-(cis-4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate (0.68g, 1 equivalent), DIEA (0.5mL, 2 equivalents) and uncle-BuOH (2.5mL) reaction is 2 hours: observe by LC-MS and surpass 95% transformation efficiency.With DCM diluting reaction thing,, dry and concentrated with rare HCl and water washing.Through column chromatography (silica gel; DCM: MeOH=100: 0-95: 5) isolate 0.35g (48%) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two (trifluoromethyl)-benzamide.

Dioxane (0.4mL, the 2 equivalents) solution that in the DCM of this neutral compound (10mL) solution, adds 4M-HCl.After stirring 30 minutes under the room temperature, remove volatile solvent, obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt is white powder.

ESI?MS?m/e?490(M+H) ⁺； ¹HNMR(400MHz，DMSO-d ₆)δ12.1(bs，1H)，8.78(bd，1H，J＝5.6Hz)，8.48(s，2H)，8.28(s，1H)，8.05(bd，1H，J＝6.4Hz)，7.62(s，1H)，3.91(bs，2H)，3.26(s，6H)，2.23(s，3H)，1.87(m，2H)，1.73(bs，6H).

Embodiment 2589

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate.

Under room temperature, nitrogen, (1.1g adds 3 in dry-out benzene 4.8mmol) (15mL) solution, and 5-two (trifluoromethyl) Benzoyl chloride (1.33g, 1 equivalent) then adds Et to cis-(4-amino methyl-cyclohexyl)-carboxylamine tertiary butyl ester ₃N (2mL).The restir reactant is 2 hours under room temperature, with saturated sodium bicarbonate (3x) and water (1x) washing, through dried over mgso, and concentrates.Crude product cis-4-[(3,5-two (trifluoromethyl)-benzoyl-amido)-methyl]-cyclohexyl }-the carboxylamine tertiary butyl ester need not be further purified and be used for next step reaction.

Under room temperature, to cis-4-[(3,5-two (trifluoromethyl)-benzoyl-amido)-methyl]-cyclohexyl }-(2.1g adds TFA (5mL) in DCM 4.5mmol) (10mL) solution to the carboxylamine tertiary butyl ester.After stirring 1.5 hours under the room temperature, remove volatile solvent, obtain crude product N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate is thickness oily matter.(about 40mL) joins crude product with water, vibrates the precipitation that obtains forming 5-10 minute.Filtering-depositing (ppts) washes with water and drying.Isolate 1.40 (61%) N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate is white powder.

ESI?MS?m/e?369(M+H) ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.97(bs，1H)，8.47(s，2H)，8.29(s，1H)，7.78(bs，3H)，3.29(t，2H，J＝6.8Hz)，3.15(bs，1H)，1.78(bs，1H)，1.66(m，4H)，1.52(m，4H).

Step B: synthetic N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

In 185 ℃, in Smith microwave synthesizer, make the 2-chloro-4-dimethylamino-5-methylpyrimidine (0.21g in the sealed tube of packing into, 1.2mmol), N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate (0.6g, 1 equivalent), DIEA (0.45mL, 2 equivalents) and uncle-BuOH (2.5mL) reaction is 1.6 hours.With DCM diluting reaction thing,, dry and concentrated with rare HCl and water washing.Crude product is through column chromatography purification (silica gel; DCM: MeOH=100: 0-95: 5).Isolate 0.3g (50%) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-3,5-two (trifluoromethyl)-benzamide.

Dioxane (0.3mL, the 2 equivalents) solution that in the DCM of neutral compound (10mL) solution, adds 4M-HCl.After stirring 30 minutes under the room temperature, remove volatile solvent, obtain N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt is white powder.

ESI?MS?m/e?504(M+H) ⁺； ¹HNMR(400MHz，CDCl ₃)δ12.5(bs，1H)，8.79(d，1H，J＝8.0Hz)，8.43(s，2H)，7.93(s，1H)，7.50(bs，1H)，7.15(d，1H，J＝4.4Hz)，4.23(bs，1H)，3.51(bs，2H)，3.27(s，6H)，2.23(s，3H)，1.89～1.82(m，5H)，1.66～1.60(m，4H).

Embodiment 2590

N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethoxy) benzamide trifluoroacetate

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the carboxylamine benzyl ester.

In 185 ℃, with 6 sealed tubes, each sealed tube fills 2-chloro-4-dimethylamino-5-methylpyrimidine (0.4g, 2.3mmol), cis-(4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (0.61g, 1 equivalent), DIEA (0.8mL, 2 equivalents) and t-BuOH (2.5mL), place Smith microwave synthesizer reaction 6500 seconds.Finish through LC-MS confirmation reaction.The reactant that merges is diluted with DCM, with 1N-HCl (2x) and water (1x) washing, through anhydrous magnesium sulfate drying.Concentrate organism, through column chromatography purification (silica gel; Hexane: DCM: MeOH=1: 5: 0-0: 95: 5).Remove and desolvate, obtain 3.2g (58%) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the carboxylamine benzyl ester.

ESI MS m/z 398 (M+H) ^{+ 1}H NMR (400MHz, CDCl ₃) δ 8.00 (bs, 1H), 7.36 (m, 6H), 5.10 (NH-is overlapping for s, 3H), 4.12 (bs, 1H), 3.24 (s, 6H), 3.14 (t, 2H, J=6.4Hz), 2.22 (s, 3H), 1.88-1.50 (m, 9H).

Step B: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl] amine.

Under room temperature, nitrogen atmosphere, with N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the carboxylamine benzyl ester (3.0g, 7.5mmol) and the out-phase mixture of 10%Pd/C (0.12g) in EtOH (20mL) stir and to spend the night.The Cbz that separates all starting raw materials, this can confirm through ESI MS.By Celite pad filtering reaction thing, concentrate organism, through column chromatography purification (silica gel, DCM: MeOH=100: 0-80: 20).Isolate 1.5g (75%) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl] amine, be pale yellow powder.

ESI?MS?m/z?264(M+H) ⁺； ¹H?NMR(400MHz，DMSO-d6)(7.70(bs，2H)，7.60(s，1H)，6.05(d，1H，J＝6.4Hz)，3.89(bs，1H)，2.96(s，6H)，2.71(d，2H，J＝6.8Hz)，2.08(s，3H)，1.70～1.45(m，9H).

Step C: synthetic N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethoxy) benzamide trifluoroacetate.

To N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl] (25mg adds 4-trifluoromethoxy Benzoyl chloride (21mg, 1 equivalent) to amine in DCM 0.01mmol) (1.0mL) solution, then add Et ₃N (30 (L).Reaction stirred is 4 hours under room temperature, concentrates, through the preparation HPLC purifying.Isolate 20mg (38%) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethoxy) benzamide trifluoroacetate, be white powder.

ESI?MS?m/z?452(M+H)+；1H?NMR(400MHz，CDCl3)(13.9(bs，1H)，8.36(bd，1H，J＝6.4Hz)，7.88(d，2H，J＝8.4Hz)，7.27(s，1H)，7.23(d，2H，J＝8.4Hz)，7.08(bs，1H)，4.17(bs，1H)，3.42(t，2H，J＝5.6Hz)，3.28(s，6H)，2.23(s，3H)，1.91～1.78(m，3H)，1.65～1.55(m，6H).

Embodiment 2591

3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-methyl) cyclohexyl] the benzamide trifluoroacetate

Steps A: synthetic N-cis-4-[(4-dimethylamino-5-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine.

In 185 ℃, with 6 sealed tubes, each sealed tube fills 2-chloro-4-dimethylamino-5-methylpyrimidine (0.4g, 2.3mmol), cis-(4-amino methyl-cyclohexyl)-carboxylamine tertiary butyl ester (0.53g, 1 equivalent), DIEA (0.7mL, 2 equivalents) and t-BuOH (2mL), place 7000 seconds of Smith microwave synthesizer reaction.ESI MS confirms that all starting raw materials are consumed.Merge reactant, with the DCM dilution, with 1N-HCl (2x) and water (1x) washing.Concentrate organism, need not be further purified and be used for next step.

With crude product N-{ cis-4-[(4-dimethylamino-5-methyl-pyrimidine-2--amino)-methyl]-cyclohexyl }-the carboxylamine tertiary butyl ester is dissolved among the DCM (15mL), adds TFA (10mL).Stir after 1.5 hours, remove volatile solvent, obtain N-cis-4-[(4-dimethylamino-5-methyl-pyrimidine-2--amino)-methyl]-the cyclo-hexylamine trifluoroacetate, be thickness oily matter.Handle this thickness oily matter with saturated NaOH (15mL), extract alkaline aqueous layer with DCM (2x), to remove nonpolar organic impurity, concentrated aqueous liquid obtains solid residue then.Solid residue is extracted for several times with DCM/MeOH (3/1), removes and desolvate, obtain neutral N-cis-4-[(4-dimethylamino-5-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine (1.5g, 41%), be pale yellow powder.

ESI MS m/z 264 (M+H) ^{+ 1}H NMR (400MHz, CDCl ₃) δ 7.60 (s, 1H), 5.05 (bs, 1H), 3.29 (t, 2H, J=6.4Hz), 3.03 (s, 7H, CH-NH ₂Overlapping), 2.54 (bs, 2H), 2.13 (s, 3H), 1.72 (bm, 1H), 1.59-1.45 (m, 8H).

Step B: synthesize 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] the benzamide trifluoroacetate.

To N-cis-4-[(4-dimethylamino-5-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine (28mg, and benzene/DCM 0.01mmol) (2/1,1.5mL) add 3 in the solution, 5-dichlorobenzoyl chloride (22mg, 1 equivalent) then adds Et ₃N (30 μ L).Reaction stirred is 3 hours under room temperature, concentrates, through the preparation HPLC purifying.Isolate 30mg (51%) 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] the benzamide trifluoroacetate, white powder.

ESI?MS?m/e?436(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.7(bs，1H)，8.71(bs，1H)，7.61(d，2H，J＝1.6Hz)，7.44(t，1H，J＝1.6Hz)，7.29(s，1H)，6.59(d，1H，J＝6.4Hz)，4.23(bm，1H)，3.36(t，2H，J＝6.0Hz)，3.29(s，6H)，2.24(s，3H)，1.81(m，3H)，1.68(m，4H)，1.45(m，2H).

Embodiment 2592

N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide trifluoroacetate

Steps A: synthetic N-cis-4-[(4-dimethylamino-6-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine.

In 185 ℃, with 6 sealed tubes, each sealed tube fills 2-chloro-4-dimethylamino-6-methylpyrimidine (0.4g, 2.3mmol), cis-(4-amino methyl-cyclohexyl)-carboxylamine tertiary butyl ester (0.53g, 1 equivalent), DIEA (0.7mL, 2 equivalents) and t-BuOH (2mL), place 6500 seconds of Smith microwave synthesizer reaction.Through the LC-MS monitoring reaction.The reactant that merges is diluted with DCM, with 1N-HCl (2x) and water (1x) washing.Concentrate organism, need not be further purified and go protection.

To N-{ cis-4-[(4-dimethylamino-6-methyl-pyrimidine-2--amino)-methyl]-cyclohexyl }-add TFA (10mL) in DCM (15mL) solution of carboxylamine tertiary butyl ester.Reaction stirred is 1.5 hours under room temperature, removes volatile solvent, obtains N-cis-4-[(4-dimethylamino-6-methyl-pyrimidine-2--amino)-methyl]-the cyclo-hexylamine trifluoroacetate, be thickness oily matter.Handle this thickness oily matter with saturated NaOH (15mL), extract alkaline aqueous layer with DCM (2x), concentrated aqueous liquid obtains solid residue.Solid residue is extracted for several times with DCM/MeOH (3/1), removes and desolvate, obtain neutral N-cis-4-[(4-dimethylamino-6-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine (2.1g, 57%), be pale yellow powder.

ESI?MS?m/e?264(M+H) ⁺； ¹H?NMR(400MHz，CDCll ₃)δ5.91(bs，1H)，5.65(s，1H)，3.33(t，2H，J＝6.4Hz)，3.06(s，6H)，2.97(m，1H)，2.27(bs，2H)，2.11(s，3H)，1.70(m，1H)，1.59～1.45(m，8H).

Step B: synthetic N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide trifluoroacetate.

To N-cis-4-[(4-dimethylamino-6-methyl-pyrimidine-2--amino)-methyl]-cyclo-hexylamine (20mg, and benzene/DCM 0.008mmol) (2/1,1.5mL) add 3 in the solution, 5-two (trifluoromethyl) Benzoyl chloride (21mg, 1 equivalent) then adds Et ₃N (30 μ L).Reaction stirred is 3 hours under room temperature, concentrates, through the preparation HPLC purifying.Isolate 25mg (53%) N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide trifluoroacetate is white powder.

ESI?MS?m/e?504(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.9(bs，1H)，8.86(bs，1H)，8.25(s，2H)，7.96(s，1H)，7.30(d，1H，J＝6.4Hz)，5.74(s，1H)，4.40(bm，1H)，3.42(t，2H，J＝6.0Hz)，3.26(s，3H)，3.13(s，3H)，2.33(s，3H)，1.91～1.60(m，9H).

Embodiment 2593

4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] the benzamide trifluoroacetate

Steps A: synthetic N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl salt.

In 180 ℃, with 6 sealed tubes, each sealed tube fills 2-chloro-4-dimethylamino-6-methylpyrimidine (0.4g, 2.3mmol), cis-(4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (0.61g, 1 equivalent), DIEA (0.8mL, 2 equivalents) and t-BuOH (2.5mL), place 6500 seconds of Smith microwave synthesizer reaction.The reactant that merges is diluted with DCM,,, and concentrate through dried over mgso with 1N-HCl (2x) and water (1x) washing.Through column chromatography purification (silica gel; Hexane: DCM: MeOH=1: 5: 0-0: 95: 5), obtain 4.8g (86%) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the carboxylamine benzyl ester.

ESI MS m/z 398 (M+H) ^{+ 1}H NMR (400MHz, CDCl ₃) δ 8.40 (bs, 1H), 7.38 (m, 5H), 5.70 (s, 1H), 5.10 (NH-is overlapping for s, 3H), 4.17 (bs, 1H), 3.14 (bs, 6H), 3.12 (t, 2H, J=6.0Hz), 2.32 (s, 3H), 1.90-1.50 (m, 9H).

Step B: synthetic N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl] amine.

Under room temperature, hydrogen, with N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-(4.5g's carboxylamine benzyl ester 11.3mmol) spends the night with the non-even solution stirring mutually of the EtOH (25mL) of 10%Pd/C (0.20g).By Celite pad filtering reaction thing, concentrate organism, through column chromatography purification (silica gel, DCM: MeOH=100: 0-80: 20).Isolate 2.2g (76%) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl] amine, be pale yellow powder.

ESI?MS?m/e?264(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.82(bs，1H)，5.72(s，1H)，4.40(bs，2H)，4.15(bm，1H)，3.16(s，6H)，2.84(d，2H，J＝6.8Hz)，2.32(s，3H)，1.80(m，2H)，1.70～1.45(m，7H).

Step C: synthetic 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] the benzamide trifluoroacetate.

To N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl methyl] amine (25mg, and DCM/ benzene 0.01mmol) (3/1,1.0mL) add 4-chlorinated benzene formyl chloride (17mg, 1 equivalent) in the solution, then add Et ₃N (30 μ L).Reaction stirred is 4 hours under room temperature, concentrates, through the preparation HPLC purifying.Isolate 25mg (51%) 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] the benzamide trifluoroacetate, be white powder.

ESI?MS?m/e?402(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.8(bs，1H)，8.60(bd，1H，J＝6.4Hz)，7.78(d，2H，J＝8.4Hz)，7.35(d，2H，J＝8.4Hz)，7.03(bm，1H)，5.71(s，1H)，4.20(bs，1H)，3.42(t，2H，J＝6.0Hz)，3.22(s，3H)，3.10(s，3H)，2.31(s，3H)，1.91～1.78(m，3H)，1.65～1.55(m，6H).

Embodiment 2594

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-methyl-phenyl) ethyl] the cyclohexane carboxamide hydrochloride

Steps A: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid ethyl ester.

In 155 ℃, to fill 2-chloro-4-dimethylamino-5-methylpyrimidine (0.28g, 1.6mmol), cis-4-amino-hexahydrobenzoic acid ethyl ester hydrochloride (0.33g, 1 equivalent), the sealed tube of the suspension of DIEA (0.65mL, 2 equivalents) in IPA (2mL) places Smith microwave synthesizer reaction 1 hour.This solution is diluted with DCM,, concentrate with 1N-HCl and water washing, through flash chromatography purifying (silica gel, the dichloromethane solution of 1%MeOH), obtain cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) hexahydrobenzoic acid ethyl ester (0.3g, 60%), is faint yellow solid.

ESI?MS?m/e?307(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.66(s，1H)，4.72(bd，1H，J＝6.8Hz)，4.13(q，2H，J＝6.8Hz)，3.96(bs，1H)，3.01(s，6H)，2.44(m，1H)，2.13(s，3H)，1.89(m，2H)，1.72(m，6H)，1.25(t，3H，J＝6.8Hz).

Step B: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid.

In 85 ℃, (0.25g, 0.8mmol) suspension in 4N-HCl (10mL) stirred 4 hours with cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) hexahydrobenzoic acid ethyl ester.Progress through the LC-MS monitoring reaction.Make reactant be cooled to room temperature, under vacuum, remove volatile matter fully, obtain cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) hexahydrobenzoic acid (0.2g, 90%), be white powder.

ESI MS m/e 279 (M+H) ^{+ 1}H NMR (400MHz, CDCl ₃) (bs, 1H), 7.43 (s, 1H), 3.94 (bs, 1H), 3.28 (bs, 6H), 2.49 (bs, 1H), 2.25 (s, 3H), 2.04 (m, 2H), 1.82 (m, 2H), 1.73 (m, 4H), COOH is not observed δ 7.95.

Step C: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] the cyclohexane carboxamide hydrochloride.

(24mg 0.09mmol) adds HATU (36mg, 1.1 equivalents) in the suspension in DCM (2mL) to (S)-1-(4-aminomethyl phenyl)-ethamine (12mg, 1 equivalent) and cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) hexahydrobenzoic acid.Under room temperature, argon gas, this reactant was stirred for 30 seconds, add triethylamine (5).Reaction stirred is spent the night under room temperature.With DCM diluting reaction thing,, and concentrate with saturated sodium bicarbonate (2x) and water (1x) washing.Through column chromatography purification (silica gel; DCM: MeOH=100: 0-94: 6), obtain cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid (S)-(1-p-methylphenyl-ethyl)-acid amides (15mg, 43%).The dioxane (50 μ l) that in the DCM of described acid amides (1mL) solution, adds 4M-HCl.Reaction stirred is 30 minutes under room temperature, removes volatile solvent, obtains cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] the cyclohexane carboxamide hydrochloride, be white powder.

ESI?MS?m/e?396(M+H) ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.0(bs，1H)，8.14(d，1H，J＝8.4Hz)，7.68(bs，1H)，7.54(s，1H)，7.14(d，2H，J＝8.0Hz)，7.07(d，2H，J＝8.0Hz)，4.84(m，1H)，4.01(bs，1H)，3.24(s，6H)，2.27(m，1H)，2.25(s，3H)，2.22(s，3H)，1.80～1.54(m，8H)，1.29(d，3H，J＝6.8Hz).

Embodiment 2595

2, and 2-two fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate

Steps A: Synthetic 2,2-two fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate.

In glassiness agglomerating synthetic flask, with 2-(3,5-dimethoxy-4 '-formyl radical) phenoxy group ethyl polystyrene resin (1.0 grams; 0.94mmol/ the gram) and methylamine (0.0122mol) be suspended in the 15mL methylene dichloride.In this suspension, add NaBH (OAc) ₃Methylene dichloride (0.0122mol) (15mL) solution.This mixture overnight of vibration removes by filter this solution in the rotation electromagnetic shaker.The N-methylamine of the resin-bonded that generates is washed in proper order with methylene dichloride, DMF and MeOH.Repeated washing order 4 times.The N-methylamine of vacuum-drying resin-bonded 20 minutes.

The N methylamine of described resin-bonded is suspended among the DMF (10mL).In this resin suspension, add 2,4-two chloro-5-methyl-pyrimidines (1.41mmol), then add triethylamine (0.393mL, 2.82mmol).In 40 ℃ of these mixture overnight of vibrations.Remove by filter this solution, wash this resin in proper order with DMF, methylene dichloride and MeOH.Repeated washing order 4 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

The intermediate of resin-bonded is divided into 3 parts, every part is moved in the 5ml Smith synthesizer reaction vessel.Described resin (0.282mmol) is suspended in respectively in 1: 1 IPA/ water (3mL) solution.In each suspension, add cis-1,4-diamino-hexanaphthene (0.85mmol) and DIEA (0.295ml; 1.69mmol).In 180 ℃, this reactant was heated 4.5 hours in the microwave synthesizer.Described resin is combined; Remove by filter solution.Wash this resin in proper order with IPA, water, MeOH, methylene dichloride and MeOH.Repeated washing order 3 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

The intermediate of resin-bonded is suspended among the DMF (10ml).Add 2 in this resin suspension, 2-two fluoro-benzo [1,3] dioxole 5-carbonyl chlorides (carbonylchloride) (0.94mmol) and triethylamine (0.256mL; 1.88mol).In in impeller, jolting reactant under the room temperature 45 minutes.Remove by filter this solution, order DMF, methylene dichloride, MeOH washing resin.Repeated washing order 3 times.

Drying is after 20 minutes, with described resin 15mL TFA solution (TFA/ methylene dichloride/water 20: 20: 1v/v) handle under vacuum.This reactant is jolted 2 hours, filter the back and collect TFA solution.Remove TFA through rotary evaporation, described compound is through the preparation HPLC purifying, obtain 2,2-two fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate (8.6mg, 5%), is white solid.

ESI?MS?m/e?420.5M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.21(d，J＝4Hz，1H)，7.75-7.67(m，2H)，7.41(s，1H)，7.28(d，J＝8Hz，1H)，3.99(m，2H)，3.05(s，3H)，1.99(s，3H)，1.95-1.71(m，8H).

Embodiment 2596

5-bromo-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide trifluoroacetate

Steps A: synthetic 5-bromo-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?408.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.41(s，1H)，7.10(s，1H)，6.60(s，1H)，4.08-3.97(m，2H)，3.05(s，3H)，1.99(s，3H)，1.95-1.71(m，8H).

Embodiment 2597

3,5-two bromo-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-the benzamide trifluoroacetate

Steps A: synthesize 3,5-two bromo-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) the benzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?496.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.37(m，J＝4Hz，1H)，8.02-7.91(m，3H)7.41(s，1H)，4.12-3.97(m，2H)，3.05(s，3H)，1.99(s，3H)，1.95-1.71(m，8H).

Embodiment 2598

3-fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(trifluoromethyl) benzamide trifluoroacetate

Steps A: synthetic 3-fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(trifluoromethyl) benzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?426.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.02(m，1H)，7.98(d，J＝4Hz，1H)7.68(d，J＝4Hz?1H)，7.43-7.41(s，1H)4.31-3.81(m，2H)，3.05(s，3H)，1.87(s，3H)，1.87-1.73(m，8H).

Embodiment 2599

N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide trifluoroacetate

Steps A: synthetic N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?424.3M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.34(d，J＝4Hz，1H)，7.85(d，J＝8Hz，1H)7.72-7.55(s，1H)，7.47-7.31(m，3H)，4.31-3.82(m，2H)，3.05(s，3H)，1.98(s，3H)，1.96-1.72(m，8H).

Embodiment 2600

N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To (2-chloro-5-methyl-pyrimidine-4 base)-methyl-amine (200mg 1.27mmol) adds cis-N-(4-amino-cyclohexyl)-3 in 1mL 2-propanol solution, 5-di-trifluoromethyl-benzamide (676mg, 1.91mmol) and DIEA (2.54mmol).In 180 ℃, in the microwave synthesizer with this mixture heating up 2 hours.Evaporating solvent, this material is through chromatography (70-95% ethyl acetate/hexane).The compound of merging that will be in methylene dichloride add 2M HCl diethyl ether solution (1.5ml, 0.38mmol) in.Solvent removed in vacuo obtains N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-3, and 5-two (trifluoromethyl) benzamide hydrochloride salt (385.5mg, 0.75mmol, 59%) is white solid.

ESI?MS?476.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d6)δ11.7(s，1H)，8.64(s，1H)，8.35(s，2H)，8.14(s，1H)，8.09(bs，1H)，8.00(bs，1H)，7.45(s，1H)，3.83(bs，1H)，3.75(bs，1H)，3.20(s，3H)，2.77-2.76(d，J＝4Hz，3H)，1.76(m，2H)，1.58(m，6H).

Embodiment 2601

N-(cis-4-{[4-(ethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(ethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?390.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.22(d，J＝4Hz，1H)，7.78(m，1H)，7.68(m，1H)，7.42(s，1H)，7.38(m，1H)，4.22-3.99(m，2H)，3.63-3.56(quartet，J＝4Hz，2H)，1.99(s，3H)，1.93-1.81(m，8H)，1.29-1.19(t，J＝8Hz，3H).

Embodiment 2602

3,4-two fluoro-N-(cis-4-{[4-(sec.-propyl amino)-5-methylpyrimidine-2 base] amino } cyclohexyl)-the benzamide trifluoroacetate

Steps A: synthesize 3,4-two fluoro-N-(cis-4-{[4-(sec.-propyl amino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the benzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?404.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.10(m，1H)，7.80-7.75(m，1H)，7.68(m，1H)，7.42(s，1H)，7.39-7.34(m，1H)，4.28-4.07(m，3H)，2.03(s，3H)，1.99-1.79(m，8H)，1.31-1.26(d，J＝12Hz，6H).

Embodiment 2603

N-(cis-4-{[4-(cyclopropyl amino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(cyclopropyl amino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?402.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.78-7.73(m，1H)，7.69-7.66(m，1H)，7.42(s，1H)，7.40-7.33(m，1H)，4.26-3.88(m，2H)，3.02-2.96(m，1H)，1.97-1.81(m，11H)，0.90-0.85(m，2H)，0.72-0.68(m，2H).

Embodiment 2604

3,4-two fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-the benzamide trifluoroacetate

Steps A: synthesize 3,4-two fluoro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) the benzamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?376.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.80-7.75(m，1H)，7.68(m，1H)，7.43-7.35(m，2H)，4.31-4.06(m，2H)，3.05(s，3H)，2.04(s，3H)，1.99-1.75(m，8H).

Embodiment 2605

2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) the ethanamide trifluoroacetate

Steps A: Synthetic 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)-pyrimidine-2-base] amino } cyclohexyl) the ethanamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?438.3M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.45-7.40(m，2H)，7.20(s，1H)，6.97-6.94(m，1H)，4.55(s，2H)，3.92-3.34(s，2H)3.04(s，3H)，1.98(s，3H)，1.53-1.71(m，8H).

Embodiment 2606

2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) the ethanamide trifluoroacetate

Steps A: Synthetic 2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)-pyrimidine-2-base] amino } cyclohexyl) the ethanamide trifluoroacetate.

Adopt the method for embodiment 2595, obtain title compound.

ESI?MS?m/e?438.3M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.42(s，1H)，7.31-6.92(m，3H)，4.65(s，2H)，4.07-3.95(m，2H)，3.05(s，3H)，1.98(s，3H)，1.93-1.69(m，8H).

Embodiment 2607

N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) the benzamide trifluoroacetate

Steps A: Synthetic 2,4-two chloro-5,6-dimethyl-pyrimidine.

To 2,4-dihydroxyl-5, (6.2g is 0.044mol) at POCl for the 6-dimethyl pyrimidine ₃Slowly add N in the suspension (25mL), and accelerine (6.18mL, 0.049mol).In 125 ℃, this mixture was refluxed 3 hours then.At this moment, starting raw material dissolves fully, represents that this reaction finishes.Reaction mixture is during slowly impouring is iced then, with quencher POCl ₃(careful heat release! ).Filter the precipitation that forms, with ice-cooled water washing.With this throw out dried overnight under high vacuum, obtain 2,4-two chloro-5,6-dimethyl-pyrimidine (7.2g, 0.041mol, 92%) is yellow solid.

¹H?NMR(400MHz，CDCl ₃)δ2.56(s，3H)，2.36(s，3H)。

Step B: synthetic (2-chloro-5,6-dimethyl-pyrimidine-4-yl)-dimethyl-amine.

To 2,4-two chloro-5,6-dimethyl-pyrimidine (0.2g, add in 1mL 2-propanol solution 0.0011mol) DIEA (268uL, 0.0017mol) and dimethyl amine (514uL, 0.0010mol).Then in 170 ℃, with this mixture heating up 10 minutes.Reaction mixture concentrates, and the oily matter of generation obtains (2-chloro-5,6-dimethyl-pyrimidine-4-yl)-dimethyl-amine (75mg, 0.40mmol, 40%) through column purification (hexane solution of 0-50% ethyl acetate), is white solid.

ESI?MS?186.0M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ3.03(s，6H)，2.37(s，3H)，2.15(s，3H).

Step C: synthesizing cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

To (2-chloro-5,6-dimethyl-pyrimidine-4-yl)-dimethyl-amine (0.5g, 0.0027mol) 2mL 2-propanol solution in add DIEA (514uL, 0.0040mol) and cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (635mg, 0.0030mol).Then in 170 ℃, with this mixture heating up 1 hour.Reaction mixture, concentrate, the oily matter that generates is through column purification (hexane solution of 0-100% ethyl acetate), obtain cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (875mg, 2.4mmol, 89%), be white solid.

ESI?MS?364.6M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ3.97(m，1H)，3.53(m，1H)，2.95(s，6H)，2.23(s，3H)，2.09(s，3H)，1.78-1.55(m，8H)，1.48(s，9H).

Step D: synthesizing cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-1-aminocyclohexane.

To cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (3.4g, add in 40mL dichloromethane solution 0.0094mol) TFA (1.4mL, 0.019mol).Under room temperature, stirred this solution 4 hours (perhaps finishing) until judging to react through TLC.Evaporate excessive solvent, the oily matter of generation is dissolved in the 30mL methylene dichloride.Organic layer is extracted (during milking, confirming that with pH test paper indicator the waterbearing stratum keeps alkalescence) with the rare NaOH of 30mL (aq)/sodium bicarbonate (aq) solution.The waterbearing stratum returned with methylene dichloride carry twice, merge organic layer,, concentrate, obtain cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-1-aminocyclohexane (2.2g, 0.0084mol, 90%), be white solid through dried over mgso.

ESI?MS?264.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ3.99(m，1H)，2.95(s，6H)，2.80(m，1H)，2.23(s，3H)，2.09(s，3H)，1.84-1.67(m，6H)，1.52-1.49(m，2H).

Step e: synthetic N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl) the benzamide trifluoroacetate.

To cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-1-aminocyclohexane (30mg, add in 0.5mL DMF solution 0.11mmol) pyridine (13.8uL, 0.17mmol) and Benzoyl chloride (12.6uL, 0.11mmol).Stirred reaction mixture spends the night, and then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide trifluoroacetate (27mg, 0.056mmol, 52%), be the white solid tfa salt.

ESI?MS?m/e?368.2M+H ⁺； ¹H?NMR(400MHz，CD3OD)δ7.85-7.83(m，2H)，7.58-7.54(m，1H)，7.51-7.47(m，2H)，4.15(m，1H)，4.03(m，1H)，3.28(s，6H)，2.34(s，3H)，2.19(s，3H)，2.00-1.80(m，8H).

Embodiment 2608

N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl)-3-(trifluoromethyl) benzamide trifluoroacetate.

Adopt the method for embodiment 2607, obtain title compound, be the white solid tfa salt.

ESI?MS?m/e?436.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.16(s，1H)，8.12(d，1H，J＝7.6Hz)，7.89(d，1H，J＝8.0Hz)，7.71(t，1H，J＝8.0Hz)，4.16(m，1H)，4.05(m，1H)，3.28(s，6H)，2.34(s，3H)，2.20(s，3H)，2.00-1.82(m，8H).

Embodiment 2609

N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-hydroxy nicotinoyl amine trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl)-2-hydroxy nicotinoyl amine trifluoroacetate.

To cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-the 1-aminocyclohexane (30mg, add in 0.5mL DMF solution 0.11mmol) the 2-hydroxy niacin (15mg, 0.11mmol), DIEA (29.8uL, 0.17mmol) and HATU (52mg, 0.14mmol).Stirred reaction mixture spends the night, and then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-hydroxy nicotinoyl amine trifluoroacetate (17mg, 0.034mmol, 31%), be white solid.

ESI?MS?m/e?385.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.53(dd，1H，J ₁＝7.2Hz，J ₂＝2.0Hz)，7.70(dd，1H，J ₁＝6.4Hz，J ₂＝2.0Hz)，6.61(t，1H，J＝6.8Hz)，4.17(m，1H)，4.01(m，1H)，3.28(s，6H)，2.33(s，3H)，2.19(s，3H)，1.98-1.72(m，8H).

Embodiment 2610

5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide trifluoroacetate

Steps A: synthetic 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide trifluoroacetate.

Adopt the similar method of embodiment 2609, obtain title compound, be the white solid tfa salt.

ESI?MS?m/e?436.2M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.15(d，1H，J＝3.6Hz)，6.63(d，1H，J＝3.2Hz)，4.16(m，1H)，3.99(m，1H)，3.27(s，6H)，2.34(s，3H)，2.19(s，3H)，1.98-1.95(m，2H)，1.89-1.76(m，6H).

Embodiment 2611

N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2, the 4-diamines is two-trifluoroacetate

Steps A: synthetic N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2, the 4-diamines is two-trifluoroacetate.

To cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-1-aminocyclohexane (26.3mg adds 3 in 0.5mL MeOH solution 0.1mmol), the 5-dimethoxy benzaldehyde (15.0mg, 0.09mmol).Under room temperature, stir this mixture half an hour, add then sodium triacetoxy borohydride (84.8mg, 0.4mmol).Under room temperature, stir this mixture overnight, then 0.5mL DMSO is joined in this mixture.Make described compound through preparation type LCMS purifying then, obtain N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2, the 4-diamines is two-trifluoro-acetate (24mg, 0.037mmol, 42%), be the white solid tfa salt.

ESI?MS?m/e?414.6M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ6.71(d，2H，J＝2.0Hz)，6.59(t，1H，J＝2.0Hz)，4.28(m，1H)，4.21(s，2H)，3.84(s，6H)，3.28(m，1H)，3.27(s，6H)，2.34(s，3H)，2.19(s，3H)，2.10-2.08(m，4H)，1.85-1.83(m，4H).

Embodiment 2612

N ²-cis-4-[(3-bromobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2, the 4-diamines is two-trifluoroacetate

Steps A: synthetic N ²-cis-4-[(3-bromobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2, the 4-diamines is two-trifluoroacetate.

Adopt the method for embodiment 2611, obtain title compound, be the white solid tfa salt.

ESI?MS?m/e?432.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.78(s，1H)，7.68(d，1H，J＝8.0Hz)，7.54(d，1H，J＝7.6Hz)，7.45(t，1H，J＝4Hz)，4.29(m，3H)，3.28(m，1H)，3.27(s，6H)，2.34(s，3H)，2.20(s，3H)，2.11-2.09(m，4H)，1.87-1.82(m，4H).

Embodiment 2613

N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl)-N '-(3-p-methoxy-phenyl) urea trifluoroacetate.

To cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidine-2--amino)-1-aminocyclohexane (26.3mg, add in 0.5mL DMSO solution 0.1mmol) 3-anisole based isocyanate (13.1uL, 0.1mmol).Under room temperature, stir this mixture overnight, then 0.5mLDMSO is joined in this mixture.Described then compound is through preparation type LC MS purifying, obtain N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea trifluoroacetate (28mg, 0.053mmol, 53%), is white solid.

ESI?MS?m/e?413.6M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.18(m，2H)，6.86(dd，1H，J ₁＝8.0Hz，J ₂＝2.0Hz)，6.58(dd，1H，J ₁＝8.4Hz，J ₂＝2.4Hz)，4.03(m，1H)，3.82(m，1H)，3.79(s，3H)，3.27(s，6H)，2.33(s，3H)，2.19(s，3H)，1.92-1.73(m，8H).

Embodiment 2614

N-(3, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) the urea trifluoro-acetate

Steps A: synthetic N-(3, the 5-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) the urea trifluoroacetate.

Adopt the method for embodiment 2613, obtain title compound, be the white solid tfa salt.

ESI?MS?m/e?419.3M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ7.08-7.03(m，2H)，6.55-6.49(m，1H)，4.04(m，1H)，3.81(m，1H)，3.28(s，6H)，2.33(s，3H)，2.20(s，3H)，1.93-1.73(m，8H).

Embodiment 2615

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide trifluoroacetate

Steps A: synthetic 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide trifluoroacetate.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane (35mg, 0.14mmol), 1-(4-chlorophenyl)-cyclobutane-carboxylic acid (30mg, 1 equivalent) adds HATU (58mg, 1.1 equivalents) in DCM (2mL) solution, then add Et ₃N (40 μ L, 2 equivalents).Reaction stirred is 4 hours under room temperature, confirms to react through LCMS and finishes.After removing volatile solvent, described residue is through the preparation HPLC purifying, obtain 32mg (41%) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide trifluoroacetate, be white solid.

ESI?MS?m/e?442M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.6(bs，1H)，8.38(d，1H，J＝7.2Hz)，7.32-7.22(m，5H)，5.76(d，1H，J＝8.8Hz)，4.09(bs，1H)，3.81(m，1H)，3.26(s，6H)，2.77(m，2H)，2.44(m，2H)，2.22(s，3H)，2.02(m，1H)，1.86(m，1H)，1.65～1.50(m，8H).

Embodiment 2616

2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate

Steps A: Synthetic 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate.

Adopt the method for embodiment 2615, obtain title compound.

ESI?MS?m/e?430M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.3(bs，1H)，8.21(d，1H，J＝7.6Hz)，7.28(bs，4H)，7.22(m，1H)，5.67(d，1H，J＝8.4Hz)，4.09(bs，1H)，3.85(m，1H)，3.26(s，6H)，2.22(s，3H)，1.71～1.61(m，6H)，1.54(s，6H)，1.50(m，2H).

Embodiment 2617

2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate

Steps A: Synthetic 2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate.

Adopt the method for embodiment 2615, obtain title compound.

ESI?MS?m/e?532M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.9(bs，1H)，8.68(d，1H，J＝7.6Hz)，7.78(s，2H)，7.72(s，1H)，7.21(d，1H，J＝4.4Hz)，6.14(d，1H，J＝8.4Hz)，4.20(bs，1H)，3.93(m，1H)，3.26(s，6H)，2.22(s，3H)，1.77～1.56(m，8H)，1.61(s，6H).

Embodiment 2618

2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the ethanamide trifluoroacetate

Steps A: Synthetic 2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the ethanamide trifluoroacetate.

Adopt the method for embodiment 2615, obtain title compound.

ESI?MS?m/e?504M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.8(bs，1H)，8.51(d，1H，J＝7.8Hz)，7.78(s，2H)，7.73(s，1H)，7.22(m，1H)，5.87(d，1H，J＝8.0Hz)，4.15(bs，1H)，3.96(m，1H)，3.62(s，2H)，3.28(s，6H)，2.24(s，3H)，1.80～1.65(m，8H).

Embodiment 2619

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate

Steps A: synthetic 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate.

To cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-1-aminocyclohexane (36mg, 0.14mmol), 1-(4-chlorophenyl)-cyclopropane-carboxylic acid (31mg, 1 equivalent) adds HATU (60mg, 1.1 equivalents) in DCM (2mL) solution, then add Et ₃N (40 μ L, 2 equivalents).Reaction stirred is 4 hours under room temperature, confirms to react through ESI MS and finishes.After removing volatile solvent, described residue is through the preparation HPLC purifying, obtain 45mg (72%) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide trifluoroacetate, be white solid.

ESI?MS?m/e?428M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.4(bs，1H)，8.61(d，1H，J＝7.2Hz)，7.32(m，4H)，5.70(s，1H)，5.46(d，1H，J＝8.0Hz)，4.04(bs，1H)，3.79(m，1H)，3.21(s，3H)，3.10(s，3H)，2.31(s，3H)，1.68～1.47(m，9H)，1.22(m，1H)，1.00(m，2H).

Embodiment 2620

1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide trifluoroacetate

Steps A: synthetic 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide trifluoroacetate.

Adopt the method for embodiment 2619, obtain title compound.

ESI?MS?m/e?442M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.1(bs，1H)，8.41(d，1H，J＝7.6Hz)，7.28(s，4H)，5.95(d，1H，J＝8.8Hz)，5.72(s，1H)，4.14(bs，1H)，3.82(m，1H)，3.21(s，3H)，3.11(s，3H)，2.77(m，2H)，2.44(m，2H)，2.31(s，3H)，2.01(m，1H)，1.83(m，1H)，1.70～1.50(m，8H).

Embodiment 2621

1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate

Steps A: synthetic 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate.

Adopt the method for embodiment 2619, obtain title compound.

ESI?MS?m/e?462M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.4(bs，1H)，8.54(bs，1H)，7.43(s，1H)，7.28(d，1H，J＝8.4Hz)，7.26(d，1H，J＝8.0Hz)，5.70(s，1H)，5.39(d，1H，J＝8.0Hz)，4.06(bs，1H)，3.84(m，1H)，3.20(s，3H)，3.10(s，3H)，2.30(s，3H)，1.69～1.62(m，8H)，1.50(m，2H)，1.01(m，2H).

Embodiment 2622

2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate

Steps A: Synthetic 2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide trifluoroacetate.

Adopt the method for embodiment 2619, obtain title compound.

ESI?MS?m/e?532M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.8(bs，1H)，8.80(d，1H，J＝8.4Hz)，7.79(s，2H)，7.72(s，1H)，6.20(d，1H，J＝8.4Hz)，5.70(s，1H)，4.24(bs，1H)，3.94(bm，1H)，3.22(s，3H)，3.10(s，3H)，2.30(s，3H)，1.79～1.60(m，8H)，1.61(s，6H).

Embodiment 2623

2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-glycoloyl amine hydrochlorate

Steps A: 2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-glycoloyl amine hydrochlorate.

(43mg 0.17mmol), 3, adds HATU (68mg, 1.1 equivalents) in DCM (2mL) solution of 4-difluoro amygdalic acid (34mg, 1 equivalent), then add Et to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane ₃N (50 μ L, 2 equivalents).Reaction stirred is 4 hours under room temperature, quencher then.After removing volatile solvent, described residue is through column chromatography purification (DCM: MeOH=100: 0-94: 6).Separate 28mg (39%) product, be translated into HCl salt.

ESI?MS?m/e?420M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.48(d，1H，J＝8.0Hz)，7.39～7.20(m，3H)，7.04(m，1H)，5.05(s，1H)，4.08(bs，1H)，3.89(bs，1H)，3.26(s，6H)，2.22(s，3H)，1.78～1.60(m，8H)，

Two tradable protons (NH-and-OH) do not detect.

Embodiment 2624

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide.

Adopt the method for embodiment 2623, obtain title compound.

ESI?MS?m/e?452M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.83(bs，1H)，7.22(s，1H)，7.65(d，1H，J＝8.0Hz)，7.51(d，1H，J＝8.0Hz)，7.42(t，1H，J＝8.0Hz)，7.22(s，1H)，7.00(d，1H，J＝8.0Hz)，5.10(s，1H)，4.04(bs，1H)，3.89(bs，1H)，3.20(s，6H)，2.18(s，3H)，1.78～1.64(m，8H)，

A tradable proton (OH) does not detect.

Embodiment 2625

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide.

Adopt the method for embodiment 2623, obtain title compound.

ESI?MS?m/e?414M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.72(d，1H，J＝6.8Hz)，7.31(d，2H，J＝8.4Hz)，7.22(s，1H)，6.83(d，2H，J＝8.4Hz)，6.78(d，1H，J＝7.6Hz)，4.98(s，1H)，4.06(bs，1H)，3.90(bs，1H)，3.76(s，3H)，3.25(s，6H)，2.20(s，3H)，1.78～1.64(m，8H.

Embodiment 2626

2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide

Steps A: Synthetic 2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide.

Adopt the method for embodiment 2623, obtain title compound.

ESI?MS?m/e?418M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.63(bs，1H)，7.44(s，1H)，7.33(m，1H)，7.21(m，2H)，7.12(bs，1H)，5.03(s，1H)，4.08(bs，1H)，3.88(bs，1H)，3.24(s，6H)，2.19(s，3H)，1.78～1.63(m，8H).

Embodiment 2627

2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide

Steps A: Synthetic 2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide.

Adopt the method for embodiment 2623, obtain title compound.

ESI?MS?m/e?420M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.26(s，1H)，7.14(m，1H)，7.06(m，2H)，6.73(d，1H，J＝8.0Hz)，5.32(s，1H)，406(bs，1H)，3.93(bs，1H)，3.22(s，6H)，2.20(s，3H)，1.78～1.64(m，8H).

Embodiment 2628

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(trifluoromethyl) benzsulfamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-(trifluoromethyl) benzsulfamide hydrochloride.

(45mg adds 2-trifluoromethyl benzene sulfonyl chloride (44mg, 1 equivalent) in IPA 0.18mmol) (2mL) solution, then add DIEA (50 μ L, 2 equivalents) to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane.Reaction stirred is 1.5 hours under room temperature, inert atmosphere, through the progress of ESI MS monitoring reaction.With DCM (7mL) diluting reaction thing,, and concentrate with saturated sodium bicarbonate (1x5mL) and water (1x5mL) washing.Crude product is through column chromatography purification (DCM: MeOH=100: 0-95: 5).Isolate 31mg (38%) product, be translated into HCl salt.

ESI?MS?m/e?458M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(bs，1H)，8.13(m，2H)，8.06(d，1H，J＝6.0Hz)，7.93(d，1H，J＝8.0Hz)，7.87(t，1H，J＝7.6Hz)，7.79(t，1H，J＝7.6Hz)，7.62(bs，1H)，3.78(bs，1H)，3.22(s，6H)，3.21(bs，1H)，2.20(s，3H)，1.78～1.54(m，8H).

Embodiment 2629

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the benzsulfamide hydrochloride

Steps A: synthetic 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the benzsulfamide hydrochloride.

Adopt the method for embodiment 2628, obtain title compound.

ESI MS m/e 424M+H ^{+ 1}H NMR (400MHz, DMSO-d ₆) δ 11.9 (bs, 1H), 7.92 (bs, 1H), 7.83 (s, 1H, bimodal overlapping with 7.81ppm), 7.81 (d, 2H, J=8.4Hz), 7.64 (d, 2H, J=8.4Hz), 7.58 (bs, 1H), 3.74 (bs, 1H), 3.21 (s, 6H), 3.08 (bs, 1H), 2.20 (s, 3H), 1.70-1.44 (m, 8H).

Embodiment 2630

2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the benzsulfamide hydrochloride

Steps A: Synthetic 2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the benzsulfamide hydrochloride.

Adopt the method for embodiment 2628, obtain title compound.

ESI?MS?m/e?468M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.9(bs，1H)，8.00(d，1H，J＝7.2Hz)，7.92(bs，1H)，7.82(d，2H，J＝7.6Hz)，7.59～7.48(m，3H)，3.73(bs，1H)，3.21(s，6H)，3.20(bs，1H)，2.20(s，3H)，1.72(m，2H)，1.58(m，6H).

Embodiment 2631

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) thiophene-2-sulfonamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) thiophene-2-sulfonamide hydrochloride.

Adopt the method for embodiment 2628, obtain title compound.

ESI?MS?m/e?396M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.1(bs，1H)，7.99(bs，1H)，7.92(bs，1H)，7.88(d，1H，J＝4.8Hz)，7.60(bs，1H)，7.57(d，1H，J＝2.8Hz)，7.14(t，1H，J＝4.8Hz)，3.75(bs，1H)，3.22(s，6H)，3.17(bs，1H)，2.20(s，3H)，1.70～1.51(m，8H).

Embodiment 2632

N, N ⁴, 5-trimethylammonium-N ²-(cis-4-{[3-(trifluoromethyl) benzyl] amino } cyclohexyl) pyrimidine-2, the two trifluoroacetates of 4-diamines

Steps A: synthetic N ⁴, N ⁴, 5-trimethylammonium-N ²-(cis-4-{[3-(trifluoromethyl) benzyl] amino }-cyclohexyl) pyrimidine-2, the two trifluoroacetates of 4-diamines.

(31mg, 0.12mmol) MeOH (1.5mL) solution with 3-trifluoromethylated benzaldehyde (22mg, 1 equivalent) stirred under room temperature 4 hours with cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane.With NaBH (OAc) ₃(85mg, about 4 equivalents) join in this reactant, this reactant is stirred spend the night.Water quencher reactant extracts with DCM, concentrates, through the preparation HPLC purifying.Isolate 35mg (54%) N ⁴, N ⁴, 5-trimethylammonium-N ²-(cis-4-{[3-(trifluoromethyl) benzyl] amino } cyclohexyl) pyrimidine-2, the two trifluoroacetates of 4-diamines are white powder.

ESI?MS?m/e?408M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.7(bs，1H)，9.70(bs，2H)，8.60(d，1H，J＝8.8Hz)，7.70(m，2H)，7.59(d，1H，J＝8.0Hz)，7.48(t，1H，J＝8.4Hz)，4.31(m，1H)，4.23(s，2H)，3.30(m，1H)，3.29(s，6H)，2.25(s，3H)，2.05(m，2H)，1.93(m，4H)，1.64(m，2H)

Embodiment 2633

N ²-(cis-4-{[4-(difluoro-methoxy) benzyl] amino } cyclohexyl)-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2, the two trifluoroacetates of 4-diamines

Steps A: synthetic N ²-(cis-4-{[4-(difluoro-methoxy) benzyl] amino } cyclohexyl)-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2, the two trifluoroacetates of 4-diamines.

Adopt the method for embodiment 2632, obtain title compound;

ESI?MS?m/e?406M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.8(bs，1H)，9.60(bs，1H)，8.60(d，1H，J＝8.8Hz)，7.46(d，2H，J＝8.8Hz)，7.24(s，1H)，7.07(d，2H，J＝8.8Hz)，6.48(t，1H，J _F-H＝73.6Hz)，4.31(m，1H)，4.15(s，2H)，3.40(bs，1H)，3.29(s，6H)，2.24(s，3H)，2.05(m，2H)，1.90(m，4H)，1.63(m，2H).

Embodiment 2634

N ²-(cis-4-[(3-bromo-4-methoxy-benzyl) amino] cyclohexyl }-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2, the two trifluoroacetates of 4-diamines

Steps A: synthetic N ²-cis-4-[(3-bromo-4-methoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2, the two trifluoroacetates of 4-diamines.

Adopt the method for embodiment 2632, obtain title compound.

ESI?MS?m/e?448M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.8(bs，1H)，9.44(bs，1H)，8.57(d，1H，J＝8.0Hz)，7.58(d，1H，J＝2.4Hz)，7.41(dd，1H，J＝8.8and?2.0Hz)，7.24(s，1H)，6.86(d，1H，J＝8.0Hz)，4.29(m，1H)，4.07(s，2H)，3.86(s，3H)，3.28(s，6H)，3.25(bs，1H)，2.24(s，3H)，2.05～1.85(m，6H)，1.64(m，2H).

Embodiment 2635

N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²The two trifluoroacetates of-methyl G-NH2

Steps A: Synthetic 2-bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide.

Make that cis-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-(3.5g 14.0mmol) is dissolved in the 20mL methylene dichloride carboxylamine tertiary butyl ester, is cooled to 0 ℃ on ice bath.(1.26mL 14.0mmol) is added drop-wise in the solution that stirs in ice bath with the bromo-acetyl bromide.Stirred reaction mixture is 10 minutes under room temperature.Methylene dichloride is removed in evaporation, obtains 2-bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide, be pinkish rough solid (6.1g, 95%).

ESI?MS?m/z?370.1(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ12.20(s，1H)，8.21(d，J＝7.2Hz，1H)，6.85(d，J＝6.8Hz，1H)，4.15(s，1H)，3.97-3.89(m，3H)，3.31(s，6H)，2.27(s，3H)，1.93-1.72(m，8H).

Step B: synthetic N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²The two trifluoroacetates of-methyl G-NH2.

With 2-bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-(50mg is 0.135mmol) with (3,4-two chloro-phenyl)-(48mg 0.270mmol) is dissolved among the 0.8mL DMF methyl-amine ethanamide.In the Smith synthesizer, under 180 ℃, with reaction mixture heating 50 minutes.Crude product obtains N through the HPLC purifying ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²The two trifluoroacetates of-methyl G-NH2 are white solid (12.8mg, 18%).

ESI?MS?m/z?465.3(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ8.75(d，J＝6.0Hz，1H)，6.80(d，J＝2.8Hz，1H)，6.67-6.65(m，1H)，6.57(dd，J＝9.0，3.0Hz，1H)，4.13(s，1H)，3.98(s，1H)，3.86(s，2H)，3.29(s，6H)，3.06(s，3H)，2.25(s，3H)，1.73-1.62(m，8H).

Embodiment 2636

N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(4-fluorinated phenoxy) niacinamide trifluoroacetate

Steps A: synthetic (3-{[(2-chloro-pyridine-3-carbonyl)-amino] methyl }-cyclopentyl)-the carboxylamine tertiary butyl ester.

Under room temperature, with (3-amino methyl-cyclopentyl)-carboxylamine tertiary butyl ester (0.050g, 0.23mmol), 2-chloro nicotinoyl chlorine (0.041g, 0.23mmol) and diisopropylethylamine (0.061mL, 0.34mmol) mixed and stirred 18 hours in methylene dichloride (2.00mL).Concentrate this mixture,, obtain (3-{[(2-chloro-pyridine-3-carbonyl)-amino through quick silica gel column chromatography purifying (ethyl acetate solution of 5% methyl alcohol)] methyl }-cyclopentyl)-carboxylamine tertiary butyl ester (0.035g, 43%), be solid.

ESI?MS?m/e?354，M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.47(dd，Jaa＝1.5Hz，Jab＝4.7Hz，1H)，8.11(dd，Jaa＝1.5Hz，Jab＝7.6Hz，1H)，7.35(dq，Jaa＝1.2Hz，Jab＝4.8Hz，Jac＝7.6Hz，1H)，6.56(bs，1H)，4.59(bs，1H)，3.97(m，1H)，3.48(m，2H)，2.27(m，2H)，1.94(m，2H)，1.49(m，1H)，1.44(s，9H)，1.25(m，2H).

Step B: synthetic N-(3-amino-cyclopentyl-methyl)-2-(4-fluoro-phenoxy group)-niacinamide.

Use Smith synthesizer microwave device.With (3-{[(2-chloro-pyridine-3-carbonyl)-amino] methyl }-cyclopentyl)-carboxylamine tertiary butyl ester (0.23mmol), 4-fluorophenol (0.026g, 0.23mmol), cesium carbonate (0.152g, 0.46mmol) and dioxane (2.00mL) mixed and be heated to 180 ℃ 1 hour.Add trifluoroacetic acid (3.00mL), this mixture was stirred 18 hours.Concentrate it then,, use dichloromethane extraction, concentrate, obtain N-(3-amino-cyclopentyl-methyl)-2-(4-fluoro-phenoxy group)-niacinamide, be crude product with the saturated sodium bicarbonate aqueous solution neutralization.

ESI?MS?m/e?330，M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.52(dd，Jaa＝1.0Hz，Jab＝7.6Hz，1H)，8.19(dd，Jaa＝1.9Hz，Jab＝3.9Hz，1H)，8.06(t，J＝5.8Hz，1Hz)，6.91(t，J＝8.2Hz，1H)，6.77(dd，Jaa＝3.6Hz，Jab＝3.2Hz，1H)，3.62(m，2H)，2.26(m，2H)，2.05(m，1H)，1.81(m，2H)，1.62(m，1H)，1.48(m，2H).

Step C: synthetic N-[((1R, 3S)-and 3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(4-fluorinated phenoxy) niacinamide trifluoroacetate.

Use Smith synthesizer microwave device, with 5-methyl-4-dimethylamino-2-chloropyrimide (0.040g, 0.23mmol), N-(3-amino-cyclopentyl-methyl)-2-(4-fluoro-phenoxy group)-niacinamide (0.23mmol), di-isopropyl-ethamine (0.061mL, 0.34mmol) and Virahol (2.00mL) mixed and be heated to 180 ℃ 2 hours.Mixture is through preparation type LCMS purifying (gradient: 15-95% acetonitrile-the contain water of 0.05%TFA) then, obtain N-[((1R, 3S)-and 3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(4-fluorinated phenoxy) niacinamide trifluoroacetate, be white solid (0.018g, 13.5% liang of step).

ESI?MS?m/e?465，M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.63(bs，1H)，8.44(t，J＝5.7Hz，1H)，8.16(dd，Jaa＝1.9Hz，Jab＝4.8Hz，1H)，8.04(dd，Jaa＝1.8Hz，Jab＝7.4Hz，1H)，7.98(bs，1H)，7.53(s，1H)，7.25-7.19(m，2H)，4.08(bs，1H)，3.22(s，6H)，2.53(s，3H)，2.19(m，2H)，1.95(m，1H)，1.71(m，1H)，1.54(m，2H)，1.46(m，2H)，1.22(m，2H).

Embodiment 2637

N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(2-methoxyl group phenoxy group) niacinamide trifluoroacetate

Steps A: synthetic (3-{[(6-chloro-pyridine-3-carbonyl)-amino]-methyl }-cyclopentyl)-the carboxylamine tertiary butyl ester.

Under room temperature, with (3-amino methyl-cyclopentyl)-carboxylamine tertiary butyl ester (0.050g, 0.23mmol), 6-chloro nicotinoyl chlorine (0.041g, 0.23mmol) and diisopropylethylamine (0.061mL, 0.34mmol) mixed and stirred 18 hours in methylene dichloride (2.00mL).Concentrate this mixture,, obtain orange gel through quick silica gel column chromatography purifying (ethyl acetate solution of 5% methyl alcohol).

ESI?MS?m/e?354，M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.75(d，J＝2.1Hz，1H)，8.09(dd，Jaa＝1.8Hz，Jab＝8.3Hz，1H)，7.41(d，J＝8.3Hz，1H)，6.48(bs，1H)，4.65(d，J＝8Hz，1H)，3.92(m，1H)，3.46(m，2H)，2.25(m，2H)，1.98(m，2H)，1.81(m，1H)，1.47(s，9H)，1.18(m，2H).

Step B: synthetic N-[((1R, 3S)-and 3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(2-methoxyl group phenoxy group) niacinamide trifluoroacetate.

Use Smith synthesizer microwave device.With (3-{[(6-chloro-pyridine-3-carbonyl)-amino] methyl }-cyclopentyl)-carboxylamine tertiary butyl ester (0.23mmol), 2-methoxyphenol (0.029g, 0.23mmol), cesium carbonate (0.152g, 0.46mmol) and dioxane (2.00mL) mixed and be heated to 180 ℃ 1 hour.Add trifluoroacetic acid (3.00mL), this mixture was stirred 18 hours.Concentrate it then,, use dichloromethane extraction, concentrate and obtain the foam thing with the saturated sodium bicarbonate aqueous solution neutralization.Add 5-methyl-4-dimethylamino-2-chloropyrimide (0.040g, 0.23mmol), diisopropylethylamine (0.061mL, 0.34mmol) and Virahol (2.00mL), use Smith synthesizer microwave device, with the mixture heating up to 180 that merges ℃ 2 hours, make this mixture through preparation type LCMS purifying (gradient: 15-95% acetonitrile-the contain water of 0.05%TFA) then, obtain N-[((1R, 3S)-and 3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(2-methoxyl group phenoxy group) niacinamide trifluoroacetate, be white solid (0.011g, 8.1% 4 step).

ESI?MS?m/e?477，M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ9.05(bs，1H)，8.63(s，1H)，8.16(dd，Jaa＝2.2Hz，Jab＝8.6Hz，1H)，7.58(bs，1H)，7.23(s，1H)，7.19(d，J＝6.2Hz，1H)，7.16(dd，Jaa＝1.5Hz，Jab＝7.7Hz，1H)，7.00(t，J＝8.8Hz，1H)，6.91(d，J＝12Hz，1H)，4.25(bs，1H)，3.75(s，3H)，3.66(m，1H)，3.29(s，6H)，3.11(m，2H)，2.52(m，2H)，2.23(s，3H)，2.10(m，2H)，1.78(m，1H)，1.62(m，2H).

Embodiment 2638

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-bromoacetamide.

Under 0 ℃, inert atmosphere, (150mg is added dropwise to bromoacetyl bromide (120mg, 1 equivalent) in DCM 0.6mmol) (10mL) solution to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane.Stir after 5 minutes, DIEA (0.1mL, 1 equivalent) is joined in this reactant.In the temperature that is lower than 15 ℃, other 3 hours of reaction stirred, quencher is through column chromatography purification.

Isolate 0.12g (55%) product.

Step B: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide.

In 180 °, will fill N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-bromoacetamide (30mg, 0.08mmol), 3-fluorophenol (27mg, 3 equivalents) and Cs ₂CO ₃The sealed tube of the non-even phase solution of dioxane (about 0.7mL) of (30mg, 1.1 equivalents) places Smith microwave synthesizer to react for 3000 seconds.With DCM diluting reaction thing, with saturated sodium bicarbonate (2x) and water (1x) washing, concentrate, through column chromatography purification, obtain 11mg (34%) product.

ESI?MS?m/e?402M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.58(s，1H)，7.26(m，1H)，6.74～6.63(m，3H)，6.51(d，1H，J＝8.0Hz)，5.15(bs，1H)，4.45(s，2H)，4.01(m，1H)，3.97(bs，1H)，3.05(s，6H)，2.15(s，3H)，1.82～1.61(m，8H).

Embodiment 2639

2-[(5-chloropyridine-3-yl) oxygen base]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide

Steps A: Synthetic 2-[(5-chloropyridine-3-yl) oxygen base]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide.

Adopt the method for embodiment 2638, obtain title compound.

ESI?MS?m/e?419M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.25(m，2H)，7.53(s，1H)，7.27(t，1H，J＝2.4Hz)，6.56(d，1H，J＝7.6Hz)，5.57(bs，1H)，4.50(s，2H)，4.01(bs，2H)，3.08(s，6H)，2.16(s，3H)，1.83～1.64(m，8H).

Embodiment 2640

N-(cis-4-{[4-(dimethylamino)-5-ethyl-pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide

Steps A: Synthetic 2,4-two chloro-5-ethyl-pyrimidines.

(1g is 7.1mmol) at POCl to the 5-ethyl uracil ₃Slowly add N, accelerine (1mL) in the suspension (4.5mL).With this reactant reflux (about 120 ℃) 5 hours, dissolve fully until starting raw material, whole solution transfers purple to.Make mixture cooling, extremely lentamente impouring (about 40g) on ice.Filter the precipitation that generates, wash with frozen water.With minimum DCM dissolution precipitation, in the short silicagel column of impouring, obtain product (1.2g, about 100%) through the DCM column chromatography.

¹H?NMR(400MHz，CDCl ₃)δ8.42(s，1H)，2.75(q，2H，J＝7.6Hz)，1.29(t，3H，J＝7.6Hz).

Step B: synthetic N-(cis-4-{[4-(dimethylamino)-5-ethyl-pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide.

In ice bath, with 2, (1.2g, THF 6.8mmol) (15mL) solution is cooled to 5 ℃ to 4-two chloro-5-ethyl-pyrimidines, slowly adds 2M-dimethyl amine (7mL, 2 equivalents).Under about 10 ℃, reaction stirred 2 hours is removed volatile solvent.Described residue is through column chromatography purification (hexane: DCM=50: 50-10: 90), obtain 0.89g (70%) 2-chloro-4-dimethylamino-5-ethyl-pyrimidine: ESI MS m/e=186M+H ⁺

In 180, to fill 2-chloro-4-dimethylamino-5-ethyl-pyrimidine (35mg, 0.019mmol), cis-(4-amino-cyclohexyl)-3,4-two fluoro-benzamide (48mg, 1 equivalent), the sealed tube of DIEA (50mg, 2 equivalents) and IPA (1mL) places Smith microwave synthesizer reaction 2 hours.With DCM diluting reaction thing,, concentrate, through column chromatography purification (DCM: MeOH=100: 0-95: 5), obtain 11mg (14%) product with 1-N HCl and water washing.

ESI?MS?m/e?404M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.68(s，1H)，7.61(m，1H)，7.48(m，1H)，7.19(m，1H)，5.99(d，1H，J＝7.2Hz)，4.38(d，1H，J＝6.0Hz)，4.20(m，1H)，4.12(m，1H)，3.10(s，6H)，2.29(q，2H，J＝7.2Hz)，1.96～1.64(m，8H)，1.18(t，3H，J＝7.6Hz).

Embodiment 2641

N-[cis-4-(4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3,4-difluorobenzamide hydrochloride

Steps A: synthetic N-[cis-4-(4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3,4-difluorobenzamide hydrochloride.

In＜10 ℃, with 2,4-two chloro-5-methylpyrimidines (2.6g, 16mmol) and THF (20mL) solution stirring of ethylmethylamine (2.7mL, 2 equivalents) 4 hours.After removing volatile solvent, described residue is through column chromatography purification.Isolate 1.3g (45%) of2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine.

ESI?MS?m/e?186M+H ⁺。

In 180 °, to fill 2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine (80mg, 0.019mmol), cis-(4-amino-cyclohexyl)-3,4-two fluoro-benzamide (100mg, 1 equivalent), the sealed tube of DIEA (0.14mL, 2 equivalents) and IPA (1mL) places Smith microwave synthesizer reaction 2 hours.With DCM diluting reaction thing, with 1-N HCl and water washing, concentrate, (DCM: MeOH=100: 0-95: 5), obtain 35mg (20%) product, it can be converted into HCl salt through column chromatography purification.

ESI?MS?m/e?404M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.0(bs，1H)，8.36(bs，1H)，7.97(d，1H，J＝6.0Hz)，7.90(m，1H)，7.73(m，1H)，7.63(s，1H)，7.51(m，1H)，3.85(bm，2H)，3.65(q，2H，J＝7.2Hz)，3.25(s，3H)，2.22(s，3H)，1.84(m，2H)，1.69(m，6H)，1.18(t，3H，J＝7.2Hz).

Embodiment 2642

N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4-dimethylamino-5-trifluoromethyl pyrimidine.

In 0 ℃, to 2, (1g adds 2M-dimethyl amine (4.6mL, 2 equivalents) to 4-two chloro-5-trifluoromethyl pyrimidines in THF 4.6mmol) (15mL) solution.In＜5 ℃, reactant was stirred other 1.5 hours, concentrate, through column chromatography purification (DCM: hexane: MeOH=90: 10: 0-95: 0: 5).Isolate 0.49g (47%) 2-chloro-4-dimethylamino-5-trifluoromethyl pyrimidine.

ESI?MS?m/e?226M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.36(s，1H)，3.21(s，6H).

Step B: synthesizing cis-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

In 175 °, to fill 2-chloro-4-dimethylamino-5-trifluoromethyl pyrimidine (0.49g, 2.0mmol), cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (0.47g, 1 equivalent), the sealed tube of IPA (2.5mL) solution of DIEA (0.7mL, 2 equivalents) places Smith microwave synthesizer reaction 2 hours.Concentrate this solution, through column chromatography purification (DCM: MeOH=100: 0-96: 4).Isolate 0.57g (65%) cis-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

ESI?MS?m/e?404M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.15(s，1H)，5.10(bs，1H)，4.53(bs，1H)，3.94(bs，1H)，3.61(bs，1H)，3.09(s，6H)，1.78～1.49(m，8H)，1.44(s，9H).

Step C: synthesizing cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2-base)-hexanaphthene-1, the 4-diamines.

To cis-(0.55g adds TFA (7mL) in DCM 1.3mmol) (10mL) solution to [4-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.Under room temperature, reaction stirred 2 hours also concentrates.Described residue is neutralized with saturated NaOH, the waterbearing stratum is extracted with DCM (3x).The organic layer that merges washes with water, and drying concentrates, and obtains 0.25g (65%) cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2-base)-hexanaphthene-1, the 4-diamines.

ESI?MS?m/e?304M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.16(s，1H)，5.42(bs，1H)，3.98(bs，1H)，3.09(s，6H)，2.87(bs，1H)，1.81(m，2H)，1.73～1.65(m，4H)，1.43(m，4H).

Step D: synthetic N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate.

To cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidine-2-base)-hexanaphthene-1, (30mg adds 3 in dry-out benzene 0.01mmol) (2mL) solution to the 4-diamines, and 5-two (trifluoromethyl) Benzoyl chloride (27mg, 1 equivalent) then adds Et ₃N (20 μ L, 2.5 equivalents).This reactant stirring is spent the night, concentrate, through the preparation HPLC purifying.Isolate 32mg (49%) N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate is white powder.

ESI?MS?m/e?544M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.35(d，1H，J＝8.0Hz)，8.47(s，1H)，8.32(s，2H)，8.07(s，1H)，7.61(d，1H，J＝8.4Hz)，4.31(bs，1H)，4.20(bs，1H)，3.33(s，6H)，1.93～1.79(m，8H.

Embodiment 2643

N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide trifluoroacetate

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide trifluoroacetate.

Adopt the method for embodiment 2642, obtain title compound.

ESI?MS?m/e?492M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ9.45(d，1H，J＝8.0Hz)，8.05(s，1H)，7.88(d，2H，J＝8.8Hz)，7.24(m，2H，overlapped?with?solvent)，7.04(d，1H，J＝8.4Hz)，4.27(bs，1H)，4.18(bs，1H)，3，31(s，6H)，1.89～1.77(m，8H).

Embodiment 2644

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] sulfinyl } acetamide hydrochloride

Steps A: synthetic (3-trifluoromethyl-phenyl sulfane base)-acetate ethyl ester.

In 62 ℃, with the monobromo-acetic acid ethyl ester (0.65g, 3.2mmol), 3-trifluoromethyl thiophenol (0.88g, 1.5 equivalents) and Et ₃THF (15mL) solution stirring of N (1.5mL) 2 hours.Dilute this mixture with DCM,,, and concentrate through dried over mgso with saturated sodium bicarbonate (3x) and water washing.Crude product (0.73g, 85%) need not be further purified and be used for next step reaction.

¹H?NMR(400MHz，CDCl ₃)δ7.62(s，1H)，7.55(d，1H，J＝8.0Hz)，7.46～7.37(m，2H)，4.16(q，2H，J＝7.2Hz)，3.66(s，2H)，1.22(t，3H，J＝7.2Hz).

Step B: synthetic (3-trifluoromethyl-phenyl sulfinyl)-acetate ethyl ester.

Under 0 ℃, argon atmospher, (0.5g adds 77%-MCPBA (0.42g, 1 equivalent) in DCM 1.9mmol) (10mL) solution to (3-trifluoromethyl-phenyl sulfane base)-acetate ethyl ester.With this reactant restir 3 hours,,, and concentrate with saturated sodium bicarbonate and water washing with the DCM dilution.Through column chromatography (hexane: EtOAc=95: 5-80: 20) separate (3-trifluoromethyl-phenyl sulfinyl)-acetate ethyl ester (0.34g, 64%) and (3-trifluoromethyl-phenyl sulfonyl)-acetate ethyl ester (0.15g, 27%).

(3-trifluoromethyl-phenyl sulfinyl)-acetate ethyl ester:

¹H?NMR(400MHz，CDCl ₃)δ7.95(s，1H)，7.87(d，1H，J＝8.0Hz)，7.78(d，1H，J＝8.0Hz)，7.67(t，1H，J＝8.0Hz)，4.15(q，2H，J＝7.2Hz)，3.86(d，1H，J＝14.0Hz)，3.70(d，1H，J＝14.0Hz)，1.22(t，3H，J＝7.2Hz).

(3-trifluoromethyl-phenyl sulfonyl)-acetate ethyl ester:

¹H?NMR(400MHz，CDCl ₃)δ8.20(s，1H)，8.14(d，1H，J＝7.6Hz)，7.94(d，1H，J＝7.6Hz)，7.74(t，1H，J＝7.6Hz)，4.15(s，2H)，4.14(q，2H，J＝7.6Hz)，1.20(t，3H，J＝7.2Hz).

Step C: synthetic (3-trifluoromethyl-phenyl sulfinyl)-acetate.

(0.2g 0.7mmol) adds KOH (120mg, 3 equivalents) in the out-phase solution of water (5mL)/EtOH (0.5mL) to (3-trifluoromethyl-phenyl sulfinyl)-acetate ethyl ester.In 85 ℃, reactant was stirred 2 hours, be concentrated into the reactant volume pact half, in ice bath with dense HCl acidifying.Filter out (3-trifluoromethyl-phenyl sulfinyl)-acetate (100mg, 56%) and dry.

¹H?NMR(400MHz，DMSO-d ₆)δ8.05(s，1H)，8.01(d，1H，J＝8.0Hz)，7.92(d，1H，J＝8.0Hz)，7.81(t，1H，J＝8.0Hz)，4.16(d，1H，J＝14.4Hz)，3.87(d，1H，J＝14.4Hz).

Step D: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] sulfinyl } acetamide hydrochloride.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane (60mg; 0.024mmol) DCM (5mL) solution in add (3-trifluoromethyl-phenyl sulfinyl)-acetate (60mg; 1 equivalent), then add HATU (85mg, 1.1 equivalents) and Et ₃N (30 μ l).Reaction stirred 16 hours and concentrated under room temperature.Described residue is through column chromatography purification; obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] sulfinyl } ethanamide (52mg; 45%), is used in the 4M-HCl in the dioxane, can be translated into HCl salt.

ESI?MS?m/e?484M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.7(bs，1H)，8.08(d，1H，J＝6.4Hz)，7.99(m，2H)，7.92(d，1H，J＝8.0Hz)，7.90(bs，1H)，7.82(t，1H，J＝8.0Hz)，7.59(s，1H)，3.94(d，1H，J＝12.8Hz)，3.86(d，1H，J＝12.8Hz)，3.80(bs，1H)，3.68(bs，1H)，3.25(s，6H)，2.23(s，3H)，1.70～1.50(m，8H).

Embodiment 2645

2-[(3, the 4-dichlorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) acetamide hydrochloride

Steps A: Synthetic 2-[(3, the 4-dichlorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) acetamide hydrochloride.

Adopt the method for embodiment 2644, obtain title compound.

ESI?MS?m/e?484M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.9(bs，1H)，8.13(d，1H，J＝6.8Hz)，7.98(bs，1H)，7.87(s，1H)，7.86(d，1H，J＝8.8Hz)，7.65(d，1H，J＝8.8Hz)，7.61(bs，1H)，3.93(d，1H，J＝12.8Hz)，3.87(d，1H，J＝12.8Hz)，3.81(bs，1H)，3.64(bs，1H)，3.25(s，6H)，2.23(s，3H)，1.70～1.50(m，8H).

Embodiment 2646

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl } acetamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl } acetamide hydrochloride.

Obtain (3-trifluoromethyl-phenyl sulfonyl)-acetate ethyl ester by the step B among the embodiment 2644.Adopt the method for step C among the embodiment 2644, this ester is hydrolyzed to (3-trifluoromethyl-phenyl sulfonyl)-acetate.

¹H?NMR(400MHz，DMSO-d ₆)δ8.22(d，1H，J＝8.0Hz)，8.21(s，1H)，8.14(d，1H，J＝8.0Hz)，7.90(t，1H，J＝8.0Hz)，4.69(s，2H).

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane (56mg; 0.023mmol) DCM (5mL) solution in add (3-trifluoromethyl-phenyl sulfonyl)-acetate (60mg; 1 equivalent), then add HATU (85mg, 1.1 equivalents) and Et ₃N (30 μ l).Under room temperature, should react and stir 16 hours and concentrated.Described residue is through column chromatography purification; obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl } ethanamide (50mg; 45%), is used in the 4M HCl in the dioxane, is translated into hydrochloride.

ESI?MS?m/e?500M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.6(bs，1H)，8.22(d，1H，J＝6.4Hz)，8.17～8.12(m，3H)，7.90(t，1H，J＝7.6Hz)，7.87(bs，1H)，7.57(s，1H)，4.45(s，2H)，3.79(bs.1H)，3.61(bs，1H)，3.25(s，6H)，2.23(s，3H)，1.70～1.47(m，8H).

Embodiment 2647

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide hydrochloride

Steps A: Synthetic 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide.

(0.6g adds 2-chloronicotinoyl chloride (0.44g, 1.01 equivalents) in DCM 2.4mmol) (20mL) solution, then add DIEA (0.4mL, about 1.1 equivalents) to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane.Reactant stirred under room temperature spend the night, with saturated sodium bicarbonate (2x) and water (1x) washing,, concentrated through dried over mgso.Rough residue obtains 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl through column chromatography purification]-niacinamide (0.57g, 65%).

ESI?MS?m/e?389M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.72(bs，1H)，8.47(d，1H，J＝5.0Hz)，7.98(d，1H，J＝7.0Hz)，7.32(dd，1H，J＝8.0and?5.0Hz)，7.28(s，1H)，6.88(d，1H，J＝8.0Hz)，4.18(m，2H)，3.27(s，6H)，2.23(s，3H)，1.90～1.80(m，8H).

Step B: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide hydrochloride.

In 180 ℃, will fill 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (0.35g, 0.9mmol), 4-fluorophenol (0.25g, 2.5 equivalents), Cs ₂CO ₃The sealed tube of (0.33g, 1.1 equivalents) and dioxane (3mL) places Smith microwave synthesizer reaction 1 hour.With DCM diluting reaction thing,, dry and concentrated with saturated sodium bicarbonate (3x) and water (1x) washing.Described residue through column chromatography purification (DCM: MeOH=100: 0-95: 5), obtain N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide (0.33g, 80%).Neutral compound is dissolved among the DCM (5mL), adds the dioxane solution of 4M-HCl (0.45mL, 2.5 equivalents).Stir after 20 minutes, remove volatile solvent, obtain N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide hydrochloride.

ESI?MS?m/e?465M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.1(bs，1H)，8.34(d，1H，J＝7.2Hz)，8.15(dd，1H，J＝5.2and?2.0Hz)，8.06(d，1H，J＝6.8Hz)，8.01(d，1H，J＝7.6Hz)，7.63(s，1H)，7.26～7.18(m，5H)，3.94(bs，1H)，3.88(bs，1H)，3.25(s，6H)，2.21(s，3H)，1.72(bs，8H).

Embodiment 2648

2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride

Steps A: Synthetic 2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Adopt the method for embodiment 2647, obtain title compound.

ESI?MS?m/e?525M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.8(bs，1H)，8.20(d，1H，J＝7.6Hz)，8.16～8.11(m，2H)，7.96(bs，1H)，7.70(dd，1H，J＝8.0and?1.6Hz)，7.60(s，1H)，7.47～7.38(m，2H)，7.25～7.19(m，2H)，3.97(bs，1H)，3.89(bs，1H)，3.24(s，6H)，2.22(s，3H)，1.74(bs，8H).

Embodiment 2649

2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride

Steps A: Synthetic 2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Adopt the method for embodiment 2647, obtain title compound.

ESI?MS?m/e?525M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.9(bs，1H)，8.28(d，1H，J＝7.0Hz)，8.12(dd，1H，J＝4.4and?1.6Hz)，7.97(d，1H，J＝7.6Hz)，7.91(bs，1H)，7.56(bs，1H)，7.54(d，2H，J＝8.8Hz)，7.17(m，1H)，7.14(d，2H，J＝8.8Hz)，3.87(bs，1H)，3.81(bs，1H)，3.19(s，6H)，2.16(s，3H)，1.65(bs，8H).

Embodiment 2650

2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride

Steps A: Synthetic 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Adopt the method for embodiment 2647, obtain title compound.

ESI?MS?m/e?481M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.8(bs，1H)，8.27(d，1H，J＝6.6Hz)，8.12(dd，1H，J＝4.8and?1.6Hz)，7.97(dd，1H，J＝7.0and?1.6Hz)，7.86(bs，1H)，7.55(s，1H)，7.41(d，2H，J＝8.8Hz)，7.20(d，2H，J＝8.8Hz)，7.17(m，1H)，3.88(bs，1H)，3.81(bs，1H)，3.19(s，6H)，2.16(s，3H)，1.65(bs，8H).

Embodiment 2651

2-[(5-chloropyridine-3-yl) oxygen base]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride

Steps A: Synthetic 2-[(5-chloropyridine-3-yl) oxygen base]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Adopt the method for embodiment 2647, obtain title compound.

ESI?MS?m/e?482M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.6(bs，1H)，8.46(s，1H)，8.31(d，1H，J＝1.6Hz)，8.01(bm，1H)，7.83(t，1H，J＝2.0Hz)，7.56(d，1H，J＝5.2Hz)，7.49(bm，1H)，7.25(bs，1H)，6.07(bs，1H)，5.74(s，1H)，4.51(bs，1H)，4.00(bs，1H)，3.23(s，6H)，2.19(s，3H)，1.90(m，2H)，1.75(m，4H)，1.39(m，2H).

Embodiment 2652

2-(uncle's butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) the niacinamide hydrochloride

Steps A: Synthetic 2-(uncle's butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

In 180 °, will fill 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (70mg, 0.018mmol), 2-methyl-2-propylmercaptan (80mg, 5 equivalents), Cs ₂CO ₃The sealed tube of dioxane (0.8mL) solution of (60mg, 1.1 equivalents) places Smith microwave synthesizer reaction 1.5 hours.With DCM diluting reaction thing,, dry and concentrated with saturated sodium bicarbonate (3x) and water (1x) washing.Described residue is through column chromatography purification (DCM: MeOH=100: 0-95: 5), obtain 2-(uncle's butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide (50mg, 62%), is translated into HCl salt.

ESI?MS?m/e?443M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(bs，1H)，8.47(dd，1H，J＝4.8and?1.6Hz)，8.40(d，1H，J＝6.0Hz)，8.00(bm，1H)，7.62(s，1H)，7.56(dd，1H，J＝7.6and?1.6Hz)，7.15(m，1H)，3.90(bs，2H)，3.25(s，6H)，2.21(s，3H)，1.80～1.65(m，8H)，1.49(s，9H).

Embodiment 2653

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide hydrochloride.

Adopt the method for embodiment 2652, obtain title compound.

ESI?MS?m/e?429M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.4(bs，1H)，8.44(m，2H)，8.04(d，1H，J＝6.8Hz)，7.63(d，2H，J＝6.4Hz)，7.12(m，1H)，3.85(bs，2H)，3.24(s，6H)，3.06(t，2H，J＝6.8Hz)，2.21(s，3H)，1.83～1.65(m，8H)，1.62(m，2H)，0.95(t，3H，J＝7.2Hz).

Embodiment 2654

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(iprotiazem base) niacinamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-2-(iprotiazem base) niacinamide hydrochloride.

Adopt the method for embodiment 2652, obtain title compound.

ESI?MS?m/e?429M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(bs，1H)，8.46(dd，1H，J＝4.8and?1.6Hz)，8.42(bs，1H)，8.02(d，1H，J＝6.4Hz)，7.62(m，2H)，7.12(m，1H)，3.95(sept，1H，J＝6.4Hz)，3.83(bs，2H)，3.25(s，6H)，2.21(s，3H)，1.82～1.65(m，8H)，1.30(d，6H，J＝6.8Hz).

Embodiment 2655

2-(tertiary butyl sulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide

Steps A: Synthetic 2-(tertiary butyl sulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide.

In 0 ℃, to N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-(30mg adds MCPBA (16mg, 1.1 equivalents) to 2-tertiary butyl sulfane base-niacinamide in DCM 0.07mmol) (5mL) solution.In＜10 ℃, with this reactant restir 2 hours, simultaneously through the carrying out of ESI MS monitoring reaction.With DCM diluting reaction thing, with saturated sodium bicarbonate (2x) and water (1x) washing, drying concentrates, through column chromatography purification (DCM: MeOH=100: 0-94: 6).Isolate 26mg (85%) 2-(tertiary butyl sulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide.

ESI?MS?m/e?459M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.71(dd，1H，J＝4.8and?1.6Hz)，8.54(d，1H，J＝6.8Hz)，8.20(d，1H，J＝8.0Hz)，7.61(s，1H)，7.43(dd，1H，J＝8.0and?4.0Hz)，5.03(d，1H，J＝6.0Hz)，4.12(bs，1H)，3.98(bs，1H)，2.99(s，6H)，2.12(s，3H)，1.87～1.75(m，8H)，1.23(s，9H).

Embodiment 2656

2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(3, the 4-difluorophenyl)-sulfane base-niacinamide.

In 180 ℃, will fill 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (100mg, 0.025mmol), 3,4-difluoro thiophenol (90mg, 2.5 equivalents), Cs ₂CO ₃The sealed tube of (150mg, 2 equivalents) and dioxane (2mL) places Smith microwave synthesizer reaction 1.0 hours.With DCM diluting reaction thing,, dry and concentrated with saturated sodium bicarbonate (3x) and water (1x) washing.Described residue through column chromatography purification (DCM: MeOH=100: 0-95: 5), obtain N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(3, the 4-difluorophenyl)-sulfane base-niacinamide (70mg, 55%).

ESI?MS?m/e?499M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.34(dd，1H，J＝4.8and?1.6Hz)，7.79(dd，1H，J＝7.2and?2.0Hz)，7.62(s，1H)，7.35(m，1H)，7.25(m，1H)，7.16(m，1H)，7.08(dd，1H，J＝7.6and?4.8Hz)，6.28(d，1H，J＝7.2Hz)，4.71(d，1H，J＝7.2Hz)，418(m，1H)，3.97(m，1H)，3.02(s，6H)，2.13(s，3H)，1.92～1.85(m，4H)，1.80～1.74(m，4H)

Step B: Synthetic 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Under 0 ℃, argon atmospher, to N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-(45mg adds MCPBA (77% in DCM 0.09mmol) (6mL) solution to 2-(3, the 4-difluorophenyl)-sulfane base-niacinamide, 31mg, 2 equivalents).This reactant stirring is spent the night,, concentrate, through column chromatography purification (DCM: MeOH=100: 0-94: 6) with saturated sodium bicarbonate (2x) and water washing.Isolate 25mg (53%) 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide, and be translated into its hydrochloride.

ESI?MS?m/e?531M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.8(bs，1H)，8.70(m，2H)，8.04(m，1H)，7.95(dd，1H，J＝7.6and?1.6Hz)，7.89(m，1H)，7.78～7.70(m，2H)，7.60(s，1H)，3.95(bs，1H)，3.87(bs，1H)，3.25(s，6H)，2.22(s，3H)，1.76(bs，8H).

Embodiment 2657

N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea trifluoroacetate

Steps A: synthesize 3,4-difluorophenyl carboxylamine ethyl ester.

Make 3, (2.8mL, 28mmol) and N, (5.4mL 31mmol) is dissolved among the anhydrous THF of 10mL N '-diisopropylethylamine the 4-difluoroaniline, is cooled to 0 ℃ in ice bath.(5.4mL 31mmol) slowly joins in the solution that stirs on ice bath with Vinyl chloroformate.Make this solution be warmed to room temperature, stirred 30 minutes.Through solvent removed in vacuo, the crude product solid with ethyl acetate and hexanes mixtures (3: 97) wash-out, obtains 3 through column chromatography purification, and 4-difluorophenyl carboxylamine ethyl ester is pale solid (5.59g, 99%).

ESI?MS?m/z?202.1(M+H ⁺)； ¹H?NMR(400MHz，DMSO-d ₆)δ9.79(s，1H)，7.55-7.50(m，1H)，7.29-7.22(m，1H)，7.16-7.15(m，1H)，4.10(q，J＝7.2Hz，2H)，1.22(t，J＝7.2Hz，3H).

Step B: synthetic (3,4-two fluoro-phenyl)-methyl-amine.

(2.2g 56mmol) places the 500mL round-bottomed flask with lithium aluminum hydride.Under argon gas, THF (100mL) is injected in this flask.In ice bath, this solution is cooled to 0 ℃.In the flask that fills this ice-cooled solution, slowly add 3, and 4-difluorophenyl carbamate (5.59g, 28mmol).This solution was refluxed 3 hours.After this reaction mixture is cooled to 0 ℃, add entry (3mL), 1N NaOH (3mL), add more water (15mL) quencher then.Remove by filter precipitation, from filtrate, evaporate THF.Rough thing is dissolved in the 150mL ethyl acetate, washes with water, through dried over sodium sulfate.Remove organic solvent through vacuum, obtain (3,4-two fluoro-phenyl)-methyl-amine, be light brown oily thing (2.86g, 71%).

ESI?MS?m/z?144.2(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ7.04-6.97(m，1H)，6.45-6.39(m，1H)，6.32-6.28(m，1H)，3.69(b，1H)，2.86(s，3H).

Step C: synthetic N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methyl-pyrimidine-2-base] amino } cyclohexyl)-N-methyl urea trifluoroacetate.

(100mg, 0.402mmol) with 1, (78.1mg 0.482mmol) is dissolved in the 1mL methylene dichloride 1 '-carbonyl dimidazoles, stirs under room temperature and spends the night to make cis-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester.Adding (3,4-two fluoro-phenyl)-methyl-amine in bottle (88mg, 0.603mmol).By the Smith synthesizer this solution was heated 15 minutes in 130 ℃.Evaporating solvent joins 1mL methyl alcohol in this crude product.This crude product is through the HPLC purifying, obtains N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea trifluoroacetate, is white solid (47.8mg, 22%).

ESI?MS?m/z?419.3(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ14.0(s，1H)，8.62(d，J＝64Hz，1H)，7.29-7.21(m，2H)，7.13-7.01(m，2H)，4.61(bs，1H)，4.10(m，1H)，3.78(m，1H)，3.46-3.29(b，3H)，3.24(s，6H)，2.24(s，3H)，1.77-1.56(m，8H).

Embodiment 2658

N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate.

Under room temperature, nitrogen, (1.1g adds 3 in dry-out benzene 4.8mmol) (15mL) solution, and 5-two (trifluoromethyl) Benzoyl chloride (1.33g, 1 equivalent) then adds Et to cis-(4-amino methyl-cyclohexyl)-carboxylamine tertiary butyl ester ₃N (about 2mL).Under room temperature, restir reactant 2 hours with saturated sodium bicarbonate (3x) and water (1x) washing, through dried over mgso, and concentrates.Crude product cis-4-[(3,5-di-trifluoromethyl-benzoyl-amido)-methyl]-cyclohexyl }-purity of carboxylamine tertiary butyl ester need not be further purified and be used for next step and go to protect step.

Make cis-4-[(3,5-di-trifluoromethyl-benzoyl-amido)-methyl]-cyclohexyl }-(2.1g 4.5mmol) is dissolved among the DCM (10mL) the carboxylamine tertiary butyl ester, and TFA (5mL) is joined in the reactant.After stirring 1.5 hours under the room temperature, remove volatile solvent, obtain crude product N-(4-amino-cyclohexyl methyl)-3,5-di-trifluoromethyl-benzamide trifluoroacetate is thickness oily matter.(about 40mL) joins in the crude product with water, fully jolts 5-10 minute, the precipitation that obtains forming, and filtering-depositing washes with water, drying; Isolate 1.40 (61%) N-(4-amino-cyclohexyl methyl)-3,5-di-trifluoromethyl-benzamide trifluoroacetate is white powder.

ESI?MS?m/e?369M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.97(bs，1H)，8.47(s，2H)，8.29(s，1H)，7.78(bs，3H)，3.29(t，2H，J＝6.8Hz)，3.15(bs，1H)，1.78(bs，1H)，1.66(m，4H)，1.52(m，4H).

Step B: synthetic N-[(cis-{ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

In 185 ℃, to fill 2-chloro-4-dimethylamino-6-methylpyrimidine (021g, 1.2mmol), N-(cis-4-amino-cyclohexyl methyl)-3,5-two (trifluoromethyl)-benzamide trifluoroacetate (0.6g, 1 equivalent), the sealed tube of DIEA (0.45mL, 2 equivalents) and uncle-BuOH (2.5mL) places Smith microwave synthesizer reaction 1.6 hours.With DCM diluting reaction thing,, dry and concentrated with rare HCl and water washing.Crude product is through column chromatography purification (silica gel; DCM: MeOH=100: 0-95: 5).Isolate 0.3g (50%) N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide, and be translated into hydrochloride.

ESI?MS?m/e?504M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.8(bs，1H)，8.72(d，1H，J＝8.0Hz)，8.39(s，2H)，7.93(s，1H)，7.43(bs，1H)，5.70(s，1H)，4.24(bm，1H)，3.49(t，2H，J＝4.4Hz)，3.22(s，3H)，3.11(s，3H)，2.31(s，3H)，1.91～1.79(m，5H)，1.64～1.56(m，4H).

Embodiment 2659

N ²-[cis-4-({ 6-[(3,4-difluorophenyl } sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines

Steps A: synthesizing cis-[1-(6-chloro pyrazine-2-base is amino)-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)]-hexanaphthene.

In 170 ℃, to fill cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane hydrochloride (0.2g, 0.7mmol), 2,6-dichloropyrazine (0.1g, 1 equivalent), the sealed tube of DIEA (0.3mL, 2 equivalents) and IPA (2mL) places Smith microwave synthesizer reaction 1.5 hours.With DCM diluting reaction thing,, concentrate, through column chromatography purification (DCM: MeOH=100: 0-96: 4) with 1N-HCl and water washing.Isolate 0.15g (61%) cis-[1-(6-chloro-pyrazine-2-base is amino)-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)]-hexanaphthene.

ESI?MS?m/e?362M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.70(bs，1H)，7.76(s，1H)，771(s，1H)，7.29(s，1H)，5.32(bs，1H)，4.11(bs，1H)，4.00(bs，1H)，3.27(s，6H)，2.23(s，3H)，1.80(m，8H).

Step B: synthesizing cis-1-[6-(3,4-two fluoro-phenyl sulfane bases)-pyrazine-2-base is amino]-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) }-hexanaphthene.

In 180 ℃, will fill cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-(6-chloro-pyrazine-2-base amino)-hexanaphthene (0.1g, 0.27mmol), 3,4-difluoro thiophenol (0.1g, 2.5 equivalents), Cs ₂CO ₃The sealed tube of (0.15g, 2 equivalents) and dioxane (2mL) places Smith microwave synthesizer reaction 1 hour.With DCM diluting reaction thing, with saturated sodium bicarbonate (3x) and water washing, concentrate, through column chromatography purification, obtain 85mg (65%) cis-{ 1-[6-(3,4-two fluoro-phenyl sulfane bases)-pyrazine-2-base is amino]-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) }-hexanaphthene.

ESI?MS?m/e?472M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.60(s，1H)，7.48(s，1H)，7.42(m，2H)，7.29(m，1H)，7.15(m，1H)，6.70(bs，1H)，5.15(d，1H，J＝7.6Hz)，4.03(bs，1H)，3.67(bm，1H)，3.16(s，6H)，2.19(s，3H)，1.81～1.61(m，8H).

Step C: synthetic N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino)-cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines.

Under room temperature, argon atmospher, to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-[6-(3,4-two fluoro-phenyl sulfane bases)-pyrazine-2-base is amino]-(35mg adds MCPBA (33mg, 2 equivalents) to hexanaphthene in DCM 0.07mmol) (5mL) solution.This reactant stirring is spent the night,, concentrate, through column chromatography purification (DCM: MeOH=100: 0-95: 5) with saturated sodium bicarbonate (2x) and water washing.Isolate 12mg (33%) N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines.

ESI?MS?m/e?488M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.25(s，1H)，7.87(s，1H)，7.63(m，1H)，7.57(s，1H)，7.53(m，1H)，7.26(m，1H)，5.36(bs，1H)，5.14(d，1H，J＝6.8Hz)，4.01(bs，1H)，3.82(bm，1H)，3.06(s，6H)，2.15(s，3H)，1.87～1.60(m，8H).

Embodiment 2660

Cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide hydrochloride

Steps A: synthesizing cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide hydrochloride.

Cis-the 4-that in the step B of embodiment 2594, obtains (4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid (24mg, 0.08mmol) DCM (3mL) solution in add 1-(4-bromophenyl)-ethamine (18mg, 1 equivalent), then add HATU (36mg, 1.1 equivalents) and Et ₃N (20 μ L).This reactant stirring is spent the night, concentrate, through column chromatography purification (DCM: MeOH=100: 0-95: 5).Isolate 16mg (41%) cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide, and be translated into hydrochloride.

ESI?MS?m/e?460M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.0(bs，1H)，8.20(d，1H，J＝7.6Hz)，7.66(bs，1H)，7.50(s，1H)，7.43(d，2H，J＝8.4Hz)，7.18(d，2H，J＝8.4Hz)，4.79(m，1H)，3.95(bs，1H)，3.19(s，6H)，2.23(bs，1H)，2.16(s，3H)，1.70～1.50(m，8H)，1.24(d，3H，J＝7.2Hz).

Embodiment 2661

N-[(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic (2-chloro-5-methyl-pyrimidine-4-yl)-methyl-amine.

In 0 ℃, to 2,4-two chloro-5-methylpyrimidines (3.8g, methylol (14.05ml, 28.1mmol) solution of adding 2.0M methylamine in 20ml dichloromethane solution 23.4mmol).This reaction mixture stirring is spent the night, evaporate excessive solvent then, this material obtains (2-chloro-5-methyl-pyrimidine-4-yl)-methyl-amine (968.7mg, 6.17mmol, 26%) through chromatography (ethyl acetate solution of 50% hexane), is white solid.

ESI?MS?158.0M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.86(s，1H)，7.39(s，1H)，2.93-2.92(d，J＝4Hz，3H)，2.04(s，3H).

Step B: synthetic N-[(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To (2-chloro-5-methyl-pyrimidine-4-yl)-methyl-amine (200mg, 1.27mmol) 1mL 2-propanol solution in add cis-N-(4-amino-cyclohexyl methyl)-3, the tfa salt of 5-di-trifluoromethyl-benzamide (736mg, 1.52mmol) and DIEA (2.54mmol).In 180 ℃, this mixture was heated 2 hours in the microwave synthesizer.Evaporating solvent, this material is through chromatography (70-95% ethyl acetate/hexane).The compound of merging is dissolved in the methylene dichloride, ether solution (the 5.6ml that adds 2M HCl, 1.42mmol) in, obtain N-[(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide hydrochloride salt (443mg, 0.84mmol, 66%), be white solid.

ESI?MS?490.4M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.5(s，1H)，8.86-8.83(t，J＝4Hz，8Hz，1H)，8.32(s，2H)，8.11(s，1H)，8.03(bs，1H)，7.97(bs，1H)，7.40(s，1H)，3.90(bs，1H)，3.24(s，3H)，3.06-3.04(d，J＝8Hz，2H)，2.72-2.71(d，J＝4Hz，3H)，1.54(bs，4H)，1.42(m，4H)，1.20(2H).

Embodiment 2662

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] the cyclohexane carboxamide hydrochloride

Steps A: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] the cyclohexane carboxamide hydrochloride.

Adopt the method for embodiment 2660, obtain title compound.

ESI?MS?m/e?412M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ10.9(bs，1H)，7.98(d，1H，J＝8.0Hz)，7.53(bs，1H)，6.98(t，1H，J＝8.0Hz)，6.63(d，1H，J＝7.4Hz)，6.62(s，1H)，6.54(d，2H，J＝8.0Hz)，4.64(m，1H)，3.79(bs，1H)，3.50(s，3H)，3.03(s，6H)，2.08(bs，1H)，1.97(s，3H)，1.60～1.30(m，8H)，1.10(d，3H，J＝6.8Hz).

Embodiment 2663

Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(1-naphthyl) ethyl] the cyclohexane carboxamide hydrochloride

Steps A: synthesizing cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(1-naphthyl) ethyl] the cyclohexane carboxamide hydrochloride.

Adopt the method for embodiment 2660, obtain title compound.

ESI?MS?m/e?432M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.1(bs，1H)，8.39(d，1H，J＝8.0Hz)，8.09(d，1H，J＝8.0Hz)，7.94(m，1H)，7.82(d，1H，J＝8.0Hz)，7.73(bs，1H)，7.56～7.49(m，5H)，5.69(m，1H)，4.01(bs，1H)，3.25(s，6H)，2.33(bs，1H)，2.23(s，3H)，1.85～1.55(m，8H)，1.49(d，3H，J＝6.8Hz).

Embodiment 2664

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-toluyl amine hydrochlorate

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-3-toluyl amine hydrochlorate.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?368M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(bs，1H)，8.28(bs，1H)，7.98(bd，1H，J＝6.0Hz)，7.64(m，3H)，7.31(s，1H)，7.30(s，1H)，3.91(bs，1H)，3.85(bs，1H)，3.25(s，6H)，2.35(s，3H)，2.22(s，3H)，1.85(bs，2H)，1.70(bs，6H).

Embodiment 2665

N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthesizing cis-N-(4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide.

To cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (3.2g, add in methylene dichloride 0.015mol) (50mL) solution DIEA (3.9mL, 0.022mol).This mixture of cooling slowly adds 3 on ice bath, and 5-two (trifluoromethyl) Benzoyl chloride (2.9mL, 0.015mol).Make this mixture rise to room temperature and stirred 1 hour.At this moment, vacuum evaporating solvent and excessive DIEA.The oily matter of generation is dissolved in the methylene dichloride (30mL) again, water (30mL), 1MNaOH (30mL) and salt solution (30mL) washing.Return with methylene dichloride and to carry brine layer twice, merge organic layer,, and concentrate through dried over mgso.The precipitation of generation is dissolved in the methylene dichloride (50mL) once more, and adding TFA (4.6mL, 0.060mol).Under room temperature, stirred this solution 4 hours (perhaps finishing) until judging to react through TLC.Evaporate excessive solvent, the oily matter of generation is dissolved in the 30mL methylene dichloride.Organic layer is extracted (during milking, confirming that with pH test paper indicator the waterbearing stratum still is an alkalescence) with the rare NaOH of 30mL (aq)/sodium bicarbonate (aq) solution.The waterbearing stratum returned with methylene dichloride carry twice, merge organic layer,, and concentrate through dried over mgso.Form precipitation, filter then, the hexane solution washing with 50% cold ether obtains cis-N-(4-amino-cyclohexyl)-3 again, and 5-two (trifluoromethyl)-benzamide (4.0g, 0.011mol, 77%) is white solid.

ESI?MS?355.0M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.44(s，2H)，8.18(s，1H)，4.04(m，1H)，3.00(m，1H)，1.89-1.84(m，2H)，1.79-1.74(m，4H)，1.74-1.64(m，2H).

Step B synthesizes N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To 2-chloro-4-methyl-quinoline (326mg, add in 2mL t-BuOH solution 1.84mmol) DIEA (369uL, 2.12mmol) and cis-N-(4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide (500mg, 1.41mmol).With microwave this mixture was heated 12 hours in 180 ℃ then.Reaction mixture concentrates, and the oily matter of generation is through column purification (dichloromethane solution of＜5%MeOH).The evaporation organic solvent is dissolved in the 4mL methylene dichloride oily matter of generation once more, and adding HCl (1.4mL, 2.82mol).This reactant was stirred 30 minutes, remove and desolvate.Hexane solution with 50% cold ether washs the precipitation that forms then, filters and obtains N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt (620mg, 1.17mmol, 83%).

ESI?MS?496.4M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ8.47(s，2H)，8.21(s，1H)，8.05(d，1H，J＝8.0Hz)，7.93(bs，1H)，7.82(t，1H，J＝7.8Hz)，7.59(t，1H，J＝8.2Hz)，7.09(bs，1H)，4.17(m，1H)，4.15(m，1H)，2.73(s，3H)，2.08-1.95(m，8H).

Embodiment 2666

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?438M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.9(bs，1H)，8.59(bd，1H，J＝6.8Hz)，7.69(s，1H)，7.68(d，1H，J＝8.4Hz)，7.43(t，1H，J＝8.0Hz)，7.30(d，1H，J＝7.6Hz)，7.20(d，1H，J＝5.2Hz)，6.55(d，1H，J＝8.0Hz)，4.17(bs，1H)，4.10(bs，1H)，3.29(s，6H)，2.24(s，3H)，1.98～1.83(m，6H)，1.73(m，2H).

Embodiment 2667

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?438M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.3(bs，1H)，8.54(bd，1H，J＝6.8Hz)，7.86(d，2H，J＝8.8Hz)，7.22(d，2H，J＝8.8Hz)，7.21(s，1H)，6.68(d，1H，J＝8.0Hz)，4.17(bs，1H)，4.10(bs，1H)，3.28(s，6H)，2.24(s，3H)，1.95～1.85(m，6H)，1.72(m，2H).

Embodiment 2668

3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?472M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.5(bs，1H)，8.37(bd，1H，J＝7.2Hz)，8.06(s，1H)，7.86(d，1H，J＝8.4Hz)，7.51(d，1H，J＝8.4Hz)，7.30(d，1H，J＝8.0Hz)，7.24(s，1H)，4.17(bs，1H)，4.08(bm，1H)，3.28(s，6H)，2.23(s，3H)，1.92～1.85(m，6H)，1.71(m，2H).

Embodiment 2669

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?456M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.8(bs，1H)，8.58(bd，1H，J＝6.8Hz)，8.19(s，1H)，7.90(d，1H，J＝8.4Hz)，7.54(d，1H，J＝8.4Hz)，7.19(bd，1H，J＝5.2Hz)，6.76(d，1H，J＝8.4Hz)，4.19(bs，1H)，4.10(bm，1H)，3.29(s，6H)，2.24(s，3H)，1.94～1.83(m，6H)，1.72(m，2H).

Embodiment 2670

3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt

Steps A: synthesize 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?422M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.1(bs，1H)，8.50(bs，1H)，8.02(bd，1H，J＝5.2Hz)，7.86(d，2H，J＝1.6Hz)，7.77(t，1H，J＝1.6Hz)，7.63(s，1H)，3.90(bs，1H)，3.85(bs，1H)，3.25(s，6H)，2.22(s，3H)，1.85(bs，2H)，1.70(bs，6H).

Embodiment 2671

3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide hydrochloride salt

Steps A: synthesize 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?422M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(bs，1H)，8.47(bs，1H)，8.09(d，1H，J＝2.0Hz)，8.05(d，1H，J＝6.4Hz)，7.82(dd，1H，J＝8.0and?1.6Hz)，7.71(d，1H，J＝8.4Hz)，7.63(s，1H)，3.90(bs，1H)，3.85(bs，1H)，3.25(s，6H)，2.22(s，3H)，1.85(bs，2H)，1.70(bs，6H).

Embodiment 2672

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-furoamide

Steps A: synthetic 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-furoamide.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?422M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.64(s，1H)，7.02(d，1H，J＝3.6Hz)，6.41(d，1H，J＝3.6Hz)，6.23(bs，1H)，4.77(bs，1H)，4.08(bs，1H)，3.96(bs，1H)，3.02(s，6H)，2.14(s，3H)，1.88～1.60(m，8H).

Embodiment 2673

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(methyl sulphonyl) benzamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(methyl sulphonyl) benzamide.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?432M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.02(d，1H，J＝7.6Hz)，7.69(t，1H，J＝8.0Hz)，7.59(t，2H，J＝7.6Hz)，6.39(d，1H，J＝8.0Hz)，6.34(bs，1H)，4.10(bs，2H)，3.33(s，3H)，3.25(s，6H)，2.25(s，3H)，1.93～1.71(m，8H).

Embodiment 2674

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(methyl sulphonyl) benzamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(methyl sulphonyl) benzamide.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?432M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.40(s，1H)，8.18(d，1H，J＝7.6Hz)，8.08(d，1H，J＝7.6Hz)，7.67(t，1H，J＝7.6Hz)，7.34(s，1H)，6.99(d，1H，J＝8.0Hz)，6.57(bd，1H，J＝6.4Hz)，4.17(bm，2H)，3.32(s，6H)，3.16(s，3H)，2.27(s，3H)，1.90～1.71(m，8H).

Embodiment 2675

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(methyl sulphonyl) benzamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-4-(methyl sulphonyl) benzamide.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?432M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.04(d，2H，J＝8.4Hz)，7.98(d，2H，J＝8.4Hz)，7.28(s，1H)，6.86(d，1H，J＝8.4Hz)，6.41(d，1H，J＝7.6Hz)，4.14(bm，2H)，3.32(s，6H)，3.07(s，3H)，2.27(s，3H)，1.90～1.71(m，8H).

Embodiment 2676

2-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-amino] carbonyl } benzoic acid methyl ester

Steps A: Synthetic 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] carbonyl } benzoic acid methyl ester.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?428?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.10(bs，1H)，7.87(d，1H，J＝7.6Hz)，7.52(t，1H，J＝7.6Hz)，7.46(m，2H)，7.30(s，1H)，6.56(d，1H，J＝8.0Hz)，4.13(bm，2H)，3.87(s，3H)，3.24(s，6H)，2.22(s，3H)，1.93～1.75(m，8H).

Embodiment 2677

3-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-amino] carbonyl } benzoic acid methyl ester

Steps A: synthetic 3-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] carbonyl } benzoic acid methyl ester.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?428?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.48(s，1H)，8.17(bs，1H)，8.14(d，1H，J＝7.6Hz)，8.08(d，1H，J＝7.6Hz)，7.51(t，1H，J＝8.0Hz)，7.31(s，1H)，7.16(d，1H，J＝7.6Hz)，4.14(bm，2H)，3.94(s，3H)，3.26(s，6H)，2.23(s，3H)，1.93～1.73(m，8H).

Embodiment 2678

2-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-amino] carbonyl } the benzoate hydrochlorate

Steps A: Synthetic 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] carbonyl } the benzoate hydrochlorate.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?398?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.5(bs，2H)，8.32(bs，1H)，8.04(d，1H，J＝6.4Hz)，7.80(d，1H，J＝7.6Hz)，7.68(s，1H)，7.58(m，1H)，7.51(t，1H，J＝7.6Hz)，7.39(d，1H，J＝7.6Hz)，3.89(bs，2H)，3.28(s，6H)，2.25(s，3H)，1.85～1.70(m，8H).

Embodiment 2679

3-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-amino] carbonyl } the benzoate hydrochlorate

Steps A: synthetic 3-{[(cis-4-{[(4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] carbonyl } the benzoate hydrochlorate.

Adopt the method for embodiment 2523, obtain title compound.

ESI?MS?m/e?398?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ13.2(bs，1H)，12.3(bs，1H)，8.59(bs，1H)，8.47(m，1H)，8.16～8.11(m，3H)，7.72(s，1H)，7.64(t，1H，J＝8.0Hz)，3.95(bs，2H)，3.32(s，6H)，2.29(s，3H)，1.93(bs，2H)，1.78(bs，6H).

Embodiment 2680

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4-difluorobenzamide hydrochloride

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?390?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.7(bs，1H)，8.37(bs，1H)，7.93～7.88(m，2H)，7.73(m，1H)，7.51(dd，1H，J＝18.8?and?8.4Hz)，6.26(s，1H)，3.96(bs，1H)，3.84(bs，1H)，3.17(s，3H)，3.13(s，3H)，2.25(s，3H)，1.85(bm，2H)，1.70(bs，6H).

Embodiment 2681

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To (2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine (242mg, 1.41mmol) 2mLt-BuOH solution in add DIEA (369uL, 2.12mmol) and cis-N-(4-amino-cyclohexyl)-3, and 5-two (trifluoromethyl)-benzamide (500mg, 1.41mmol).With microwave this mixture was heated 1.7 hours in 180 ℃ then.Reaction mixture concentrates, and the oily matter of generation is through column purification (dichloromethane solution of＜5%MeOH).The evaporation organic solvent is dissolved in the 4mL methylene dichloride oily matter of generation once more, and adding HCl (1.4mL, 2.82mol).This reactant was stirred 30 minutes, remove and desolvate.Filter the precipitation that forms, then with the washing of the hexane solution of 50% cold ether, obtain N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt (653mg, 1.24mmol, 88%).

ESI?MS?490.4?M+H ⁺； ¹H?NMR(400MHz，CD3OD)δ12.58(bs，1H)，8.81(d，1H，J＝6.4Hz)，8.50(s，2H)，8.30(s，1H)，7.89(bs，1H)，6.28(s，1H)，4.00(m，1H)，3.90(m，1H)，3.18(s，3H)，3.12(s，3H)，2.25(s，3H)，1.87-1.71(m，8H).

Embodiment 2682

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?438?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.0(bs，1H)，8.52(bd，1H，J＝7.6Hz)，7.87(d，2H，J＝8.8Hz)，7.23(d，2H，J＝8.8Hz)，6.84(d，1H，J＝8.0Hz)，5.72(s，1H)，4.22(bm，1H)，4.11(bm，1H)，3.24(s，3H)，3.12(s，3H)，2.34(s，3H)，1.95～1.85(m，6H)，1.72(m，2H).

Embodiment 2683

3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?472?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ12.9(bs，1H)，8.52(d，1H，J＝7.6Hz)，7.96(d，1H，J＝2.4Hz)，7.73(dd，1H，J＝8.8?and?2.0Hz)，7.34(d，1H，J＝8.4Hz)，6.59(d，1H，J＝8.0Hz)，5.72(s，1H)，4.22(bm，1H)，4.10(bm，1H)，3.24(s，3H)，3.12(s，3H)，2.34(s，3H)，1.95～1.83(m，6H)，1.72(m，2H).

Embodiment 2684

4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?388?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.1(bs，1H)，8.57(bd，1H，J＝8.0Hz)，7.73(d，2H，J＝8.4Hz)，7.37(d，2H，J＝8.4Hz)，6.46(d，1H，J＝6.0Hz)，5.71(s，1H)，4.20(bs，1H)，4.10(bs，1H)，3.24(s，3H)，3.12(s，3H)，2.34(s，3H)，1.94～1.82(m，6H)，1.73(m，2H).

Embodiment 2685

3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide hydrochloride salt

Steps A: synthesize 3,4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?422?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.0(bs，1H)，8.51(d，1H，J＝7.6Hz)，7.94(d，1H，J＝2.0Hz)，7.64(dd，1H，J＝8.4?and?2.0Hz)，7.47(d，1H，J＝8.4Hz)，6.88(d，1H，J＝8.8Hz)，5.72(s，1H)，4.22(bm，1H)，4.09(bm，1H)，3.24(s，3H)，3.13(s，3H)，2.34(s，3H)，1.94～1.82(m，6H)，1.72(m，2H).

Embodiment 2686

N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexyl)-3,5-dimethoxy benzamide.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?m/e?414?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ6.88(d，2H，J＝2.0Hz)，6.57(t，1H，J＝2.0Hz)，6.15(d，1H，J＝7.6Hz)，5.69(s，1H)，5.10(bs，1H)，4.06(bm，2H)，3.82(s，6H)，3.04(s，6H)，2.21(s，3H)，1.90～1.81(m，6H)，1.67(m，2H).

Embodiment 2687

5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the niacinamide hydrochloride

Steps A: synthetic 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide hydrochloride.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?433.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.2(s，1H)，8.85(d，J＝4Hz，1H)，8.73(d，J＝4Hz，1H)，8.51(bs，1H)，8.34-8.33(m，1H)，7.55(bs，1H)，3.76(bs，2H)，3.14(bs，6H)，2.10(s，3H)，1.74-1.59(m，8H).

Embodiment 2688

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-[2,2,2-three fluoro-1-hydroxyl-1-(trifluoromethyl) ethyls] benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-4-[2,2,2-three fluoro-1-hydroxyl-1-(trifluoromethyl) ethyls] benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?520.4?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.0(s，1H)，8.84(s，1H)，8.36(bs，1H)，7.91(bs，1H)，7.88(d，J＝8Hz，2H)，7.73-7.71(d，J＝8Hz?2H)，7.60(s，1H)，3.85(bs，2H)，3,23(s，6H)，2.20(s，3H)，1.82(m，2H)，1.68(m，6H).

Embodiment 2689

3-bromo-4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt

Steps A: synthetic 3-bromo-4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide hydrochloride salt.

Adopt the method for embodiment 2526, obtain title compound.

ESI?MS?466.0?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ12.0(s，1H)，8.32-8.31(d，J＝4Hz，1H)，8.08-8.07(d，J＝2Hz，1H)，7.88-7.86(d，J＝8Hz，1H)，7.73-7.70(dd，J ₁＝4Hz，J ₂＝4Hz，1H)，7.57-7.55(d，J＝8Hz，1H)，7.49(s，1H)，3.76-3.69(m，2H)，3.16(s，6H)，2.07(s，3H)，1.70(bs，2H)，1.55(bs，6H).

Embodiment 2690-2711

With similar method described in embodiment 2590, use suitable acyl chlorides and the amine intermediate that derives from step B, preparation compound 2690-2711.

Embodiment 2712-2731

With similar method described in embodiment 2591, use suitable acyl chlorides and the amine intermediate that derives from steps A, preparation compound 2712-2731.

Embodiment 2732-2750

With similar method described in embodiment 2592, use suitable acyl chlorides and the amine intermediate that derives from steps A, preparation compound 2732-2750.

Embodiment 2751-2770

With similar method described in embodiment 2593, use suitable acyl chlorides and the amine intermediate that derives from step B, preparation compound 2751-2770.

Embodiment 2771-2794

With similar method described in embodiment 2594, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 2771-2794.

Embodiment 2795-2823

With the similar approach described in embodiment 2527, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 2795-2823.

Embodiment 2824-2864

With similar method described in embodiment 2607, use suitable acyl chlorides and the amine intermediate that derives from step D, preparation compound 2824-2864.

Embodiment 2865-2866

With similar method described in embodiment 2611, use suitable phenyl aldehyde and the amine that derives from steps A, preparation compound 2865 and 2866.

Embodiment 2867-2869

With similar method described in embodiment 2613, use suitable isocyanic ester and the amine that derives from steps A, preparation compound 2867-2869.

Embodiment 2870-2875

With similar method described in embodiment 2615, use suitable carboxylic acid and the amine that derives from steps A, preparation compound 2870-2875.

Embodiment 2876

With similar method described in embodiment 2623, use suitable 4-chloro mandelic acid and the amine that derives from steps A, preparation compound 2876.

Embodiment 2877-2879

With similar method described in embodiment 2638, use suitable phenol and the bromoacetamide intermediate that derives from step B, preparation compound 2877-2879.

Embodiment 2880-2884

With similar method described in embodiment 2644, use suitable thiophenol, preparation compound 2880-2884.

Embodiment 2885-2895

With similar method described in embodiment 2647, use suitable phenol and the chloro-pyridine base intermediate that derives from steps A, preparation compound 2885-2895.

Embodiment 2896-2940

With the similar approach described in embodiment 2523, use suitable acyl chlorides and the amine that derives from step C, preparation compound 2896-2940.

Embodiment 2941-2948

With similar method described in embodiment 2635, use suitable methylphenylamine and the bromo acetamide intermediate that derives from steps A, preparation compound 2941-2948.

Embodiment 2949-2950

With similar method described in embodiment 2619, use suitable carboxylic acid and the amine that derives from steps A, preparation compound 2949 and 2950.

Embodiment 2951-2994

With the similar approach described in embodiment 2526, use suitable acyl chlorides and the amine that derives from step C, preparation compound 2951-2994.

Embodiment 2995

With similar method described in embodiment 2628, use benzene sulfonyl chloride and the amine that derives from steps A, preparation compound 2995.

Embodiment 2996-3004

With similar method described in embodiment 2632, use suitable phenyl aldehyde and the amine that derives from steps A, preparation compound 2996-3004.

Embodiment 3005

With similar method described in embodiment 2632, use 3-trifluoro-methoxybenzaldehyde and the amine that derives from embodiment 2526 step C, preparation compound 3005.

Embodiment 3006

With similar method described in embodiment 2642, it is suitable 3 to use, and 4-difluoro benzoyl chloride and derive from the amine of step C prepares compound 3006.

Embodiment 3007-3011

With similar method described in embodiment 2637, use suitable phenol and the chloro-pyridine base intermediate that derives from steps A, preparation compound 3007-3011.

Embodiment 3012-3020

With similar method described in embodiment 2636, use suitable phenol and the chloro-pyridine base intermediate that derives from steps A, preparation compound 3012-3020.

Embodiment 3021-3029

With similar method described in embodiment 2657, use the intermediate for preparing among suitable methylphenylamine and the step C, preparation compound 3021-3029.

Embodiment 3030

With similar method described in embodiment 2595, use 3, the amine in 4-dichlorobenzoyl chloride and the steps A, preparation compound 3030.

As the embodiment of the invention and the table as shown in concrete compound can be with one or two-salt, for example, trifluoroacetate, hydrochloride wait to be represented; Or represent as its free alkali.Should be appreciated that the compound of these concrete expressions also limits the scope of the present invention to its salt or free alkali separately never in any form.For example, the alkaline purification by with capacity can easily be converted into corresponding unhindered amina with trifluoroacetate, and if desired, can be converted into another kind of salt, for example, and pharmacy acceptable salt as described herein.

Should be appreciated that the compound that the present invention includes is included compound as disclosed herein, as the compound of free alkali, inorganic salt and organic salt; And solvate and hydrate.

Compound in the following table is listed with free alkali form especially, and can be as separated with salt form such as trifluoroacetate, hydrochloride especially described in the concrete synthetic method.

Embodiment number	The compound title	MS	Classification
				2690	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide	368(M+H)	3
2691	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-methyl benzamide	382(M+H)	3
				2692	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide	404(M+H)	2
2693	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-methoxy benzamide	398(M+H)	3
				2694	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide	428(M+H)	1
2695	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide	400(M+H)	2
				2696	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide	400(M+H)	2
2697	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide	436(M+H)	1
				2698	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethyl) benzamide	436(M+H)	3
2699	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide	452(M+H)	2
				2700	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }	452(M+H)	2

	Cyclohexyl) methyl]-4-(trifluoromethoxy) benzamide
					2701	4-cyano group-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		393(M+H)	2
2702	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		446(M+H)	1
					2703	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide		460(M+H)	1
2704	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide		420(M+H)	1
					2705	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-(trifluoromethyl) benzamide		454(M+H)	2
2706	3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		436(M+H)	1
					2707	3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		436(M+H)	1
2708	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-2,2-two fluoro-1,3-benzo dioxole-5-methane amide		448(M+H)	2
					2709	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] xenyl-4-methane amide		444(M+H)	3
2710	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		402(M+H)	2
					2711	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide		428(M+H)	2
2712	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide		368(M+H)	3
					2713	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-methyl benzamide		382(M+H)	3
2714	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3, the 4-difluorobenzamide		404(M+H)	3
					2715	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-methoxy benzamide		398(M+H)	3

2716	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-dimethoxy benzamide	428(M+H)	2
				2717	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-fluoro-4-methyl benzamide	400(M+H)	3
2718	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-fluoro-3-methyl benzamide	400(M+H)	2
				2719	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-(trifluoromethyl) benzamide	436(M+H)	3
2720	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-(trifluoromethyl) benzamide	436(M+H)	3
				2721	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-(trifluoromethoxy) benzamide	452(M+H)	3
2722	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-(trifluoromethoxy) benzamide	452(M+H)	3
				2723	4-cyano group-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	393(M+H)	3
2724	4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	446(M+H)	3
				2725	4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 3-methyl benzamide	460(M+H)	2
2726	3-chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-fluoro benzamide	420(M+H)	2
				2727	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-fluoro-4-(trifluoromethyl)-benzamide	454(M+H)	3
2728	3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	436(M+H)	2
				2729	3,4-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	436(M+H)	3
2730	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-2,2-two fluoro-1,3-benzo dioxole-5-methane amide	448(M+H)	3
				2731	N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }	504(M+H)	2

	Methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide
				2732	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	368(M+H)	3
2733	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-methyl benzamide	382(M+H)	3
				2734	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3, the 4-difluorobenzamide	404(M+H)	3
2735	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-methoxy benzamide	398(M+H)	3
				2736	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-dimethoxy benzamide	428(M+H)	3
2737	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-fluoro-4-methyl benzamide	400(M+H)	3
				2738	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-fluoro-3-methyl benzamide	400(M+H)	3
2739	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-(trifluoromethyl) benzamide	436(M+H)	3
				2740	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-(trifluoromethyl) benzamide	436(M+H)	3
2741	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3-(trifluoromethoxy) benzamide	452(M+H)	3
				2742	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-4-(trifluoromethoxy) benzamide	452(M+H)	3
2743	4-cyano group-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	393(M+H)	3
				2744	4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide	446(M+H)	2
2745	4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 3-methyl benzamide	460(M+H)	2
				2746	3-chloro-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 4-fluoro benzamide	420(M+H)	3
2747	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }	454(M+H)	3

	Methyl) cyclohexyl]-3-fluoro-4-(trifluoromethyl)-benzamide
						2748	3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide		436(M+H)		2
2749	3,4-two chloro-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide		436(M+H)		2
						2750	N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-2,2-two fluoro-1,3-benzo dioxole-5-methane amide		448(M+H)		3
2751	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		368(M+H)		3
						2752	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-methyl benzamide		382(M+H)		3
2753	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide		404(M+H)		3
						2754	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-methoxy benzamide		398(M+H)		3
2755	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide		400(M+H)		2
						2756	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-fluoro-3-methyl benzamide		400(M+H)		3
2757	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide		436(M+H)		3
						2758	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethyl) benzamide		436(M+H)		2
2759	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide		452(M+H)		3
						2760	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-4-(trifluoromethoxy) benzamide		452(M+H)		3
2761	4-cyano group-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		393(M+H)		3
						2762	4-bromo-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		446(M+H)		1

2763	4-bromo-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 3-methyl benzamide		460(M+H)	1
					2764	3-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-the 4-fluoro benzamide		420(M+H)	1
2765	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-(trifluoromethyl)-benzamide		454(M+H)	2
					2766	3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		436(M+H)	2
2767	3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		436(M+H)	2
					2768	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-2,2-two fluoro-1,3-benzo dioxole-5-methane amide		448(M+H)
2769	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] xenyl-4-methane amide		444(M+H)
					2770	4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide		402(M+H)	2
2771	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and the 1-phenylethyl] cyclohexane carboxamide		382(M+H)	2
					2772	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide		396(M+H)	1
2773	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide		400(M+H)	1
					2774	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide		400(M+H)	2
2775	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide		412(M+H)	1
					2776	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide		412(M+H)	1
2777	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide		412(M+H)	1
					2778	Cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino		416(M+H)	1

	Base)-and 5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide
				2779	Cis-N-[1-(4-bromo phenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	460(M+H)	1
2780	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide	427(M+H)	1
				2781	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide	427(M+H)	2
2782	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(1-naphthyl) ethyl] cyclohexane carboxamide	432(M+H)	1
				2783	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(1-naphthyl) ethyl] cyclohexane carboxamide	432(M+H)	1
2784	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-fluoro phenyl) cyclohexane carboxamide	372(M+H)	2
				2785	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(4-propyl group phenyl) cyclohexane carboxamide	396(M+H)	2
2786	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(4-p-methoxy-phenyl) cyclohexane carboxamide	384(M+H)	3
				2787	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-p-methoxy-phenyl) cyclohexane carboxamide	384(M+H)	1
2788	Cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	388(M+H)	1
				2789	Cis-N-(2-bromophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	432(M+H)	3
2790	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S, 2R)-the 2-phenycyclopropyl] cyclohexane carboxamide	394(M+H)	1
				2791	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[4-(trifluoromethyl) phenyl] cyclohexane carboxamide	422(M+H)	1
2792	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[2-(methylthio group) phenyl] cyclohexane carboxamide	400(M+H)	2
				2793	N2-[cis-4-(3,4-dihydro-isoquinoline-2 (1H)-Ji carbonyl) cyclohexyl]-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	394(M+H)	3
2794	Cis-N-(4-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine	402(M+H)

	-2-yl] amino }-N-methylcyclohexane methane amide
				2795	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide	396(M+H)	1
2796	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide	412(M+H)	2
				2797	Cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	416(M+H)	1
2798	Cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	368(M+H)	2
				2799	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-fluoro benzyl) cyclohexane carboxamide	386(M+H)	2
2800	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(2-fluoro benzyl) cyclohexane carboxamide	386(M+H)	2
				2801	Cis-N-(3, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404(M+H)	1
2802	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide	412(M+H)	1
				2803	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide	412(M+H)	1
2804	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide	400(M+H)	2
				2805	Cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	416(M+H)	1
2806	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide) cyclohexane carboxamide	494(M+H)	1
				2807	Cis-N-(2, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436(M+H)	1
2808	Cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436(M+H)	1
				2809	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl) cyclohexane carboxamide	382(M+H)	1
2810	Cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methyl is phonetic	436(M+H)	1

	Pyridine-2-yl] amino } cyclohexane carboxamide
				2811	Cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	428(M+H)	1
2812	Cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	402(M+H)	1
				2813	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl] cyclohexane carboxamide	436(M+H)	2
2814	Cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	504(M+H)	1
				2815	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methoxy-benzyl) cyclohexane carboxamide	398(M+H)	1
2816	Cis-N-(4-benzyl chloride base)-4-[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	402(M+H)	1
				2817	Cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	436(M+H)	1
2818	Cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404(M+H)	1
				2819	Cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404(M+H)	1
2820	Cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	404(M+H)	1
				2821	Cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	464(M+H)	1
2822	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl) cyclohexane carboxamide	382(M+H)	1
				2823	Cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl] cyclohexane carboxamide	452(M+H)	1
2824	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 3-methoxy benzamide	398(M+H)	1
				2825	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2, the 6-citrazinic amide	401(M+H)	3
2826	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] ammonia	370(M+H)	3

	Base } cyclohexyl) pyrazine-2-methane amide
						2827	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 6-hydroxy nicotinoyl amine		385(M+H)		3
2828	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-3-methane amide		373(M+H)		2
						2829	2-(3, the 5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide		434(M+H)		2
2830	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 2-methyl isophthalic acid, 3-oxazole-4-methane amide		373(M+H)		2
						2831	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 2-methylnicotinamide		383(M+H)		3
2832	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2,6-dimethoxy niacinamide		429(M+H)		1
						2833	3-amino-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) pyrazine-2-methane amide		385(M+H)		2
2834	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-oxyethyl group niacinamide		413(M+H)		3
						2835	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) pyridine-2-carboxamide		369(M+H)		3
2836	3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide		393(M+H)		1
						2837	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide		382(M+H)		1
2838	8-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide		402(M+H)		1
						2839	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide		446(M+H)		1
2840	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide		428(M+H)		1
						2841	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide		504(M+H)		1
2842	3, (cis-4-{[4-(dimethylamino)-5, the 6-dimethyl is phonetic for 4-two chloro-N-		436(M+H		1

	Pyridine-2-yl] amino } cyclohexyl) benzamide
				2843	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide	452(M+H)	2
2844	4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide	393(M+H)	1
				2845	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	382(M+H)	1
2846	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	386(M+H)	1
				2847	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide	402(M+H)	1
2848	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 2-methoxy benzamide	398(M+H)	2
				2849	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide	446(M+H)	1
2850	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	436(M+H)	1
				2851	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 4-ethoxy benzamide	412(M+H)	3
2852	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	460(M+H)	1
				2853	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide	400(M+H)	1
2854	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide	400(M+H)	1
				2855	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 3-ethyl benzamide	396(M+H)	2
2856	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide	452(M+H)	1
				2857	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) niacinamide	447(M+H)	1
2858	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] ammonia	388(M+H)	1

	Base } cyclohexyl)-5-thiotolene-2-methane amide
				2859	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-6-(trifluoromethyl) niacinamide	437(M+H)	2
2860	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide	456(M+H)	1
				2861	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-the 3-ethoxy benzamide	412(M+H)	1
2862	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide	426(M+H)	1
				2863	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-6-pyridone-2-methane amide	385(M+H)	3
2864	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide	404(M+H)	1
				2865	N4, N4,5,6-tetramethyl--N2-(cis-4-{[3-(trifluoromethoxy) benzyl] amino } cyclohexyl) pyrimidine-2, the 4-diamines	438(M+H)	3
2866	N2-{ cis-4-[(3, the 4-difluorobenzyl) amino] cyclohexyl }-N4, N4,5,6-tetramethyl-pyrimidine-2,4-diamines	390(M+H)	2
				2867	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea	433(M+H)	1
2868	N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-N '-(2-ethoxyl phenenyl) urea	427(M+H)	1
				2869	N-[4-(benzyloxy) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea	489(M+H)	3
2870	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	428(M+H)	1
				2871	1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	462(M+H)	1
2872	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	402(M+H)	1
				2873	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-aminomethyl phenyl)-cyclopropane carboxamide	408(M+H)	1
2874	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methyl	416(M+H)	1

	Pyrimidine-2-base] amino } cyclohexyl) propionic acid amide
				2875	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-p-methoxy-phenyl)-cyclopropane carboxamide	424(M+H)	1
2876	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-hydroxyl acetamide	418(M+H)	1
				2877	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) ethanamide	414(M+H)	1
2878	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] ethanamide	452(M+H)	1
				2879	2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	418(M+H)	1
2880	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[2-(trifluoromethyl) phenyl]-sulfinyl } ethanamide	484(M+H)	1
				2881	The 2-[(2-chlorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	450(M+H)	1
2882	The 2-[(3-bromophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	494(M+H)	1
				2883	2-[(3, the 4-difluorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	452(M+H)	2
2884	2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	468(M+H)
				2885	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methylphenoxy) niacinamide	461(M+H)	1
2886	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) niacinamide	465(M+H)	1
				2887	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) niacinamide	477(M+H)	1
2888	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group) niacinamide	477(M+H)	1
				2889	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-iodo phenoxy group) niacinamide	573(M+H)	1
2890	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }	477(M+H)	1

	Cyclohexyl)-2-(2-methoxyl group phenoxy group) niacinamide
				2891	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-fluorinated phenoxy) niacinamide	465(M+H)	1
2892	2-(2-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	481(M+H)	1
				2893	2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	481(M+H)	1
2894	2-(3-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	525(M+H)	1
				2895	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group]-niacinamide	515(M+H)	1
2896	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	422(M+H)	1
				2897	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-fluoro benzamide	372(M+H)	1
2898	3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	432(M+H)	1
				2899	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	372(M+H)	1
2900	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide	414(M+H)	1
				2901	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2,4 difluorobenzene methane amide	390(M+H)	1
2902	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2, the 5-difluorobenzamide	390(M+H)	1
				2903	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate	408(M+H)	1
2904	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	354(M+H)	2
				2905	The 4-tertiary butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	410(M+H)	1
2906	4-butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-	410(M+H)

	Base] amino } cyclohexyl) benzamide
				2907	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388(M+H)	1
2908	3-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	379(M+H)	1
				2909	4-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	379(M+H)	1
2910	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-methoxy benzamide	384(M+H)	3
				2911	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	432(M+H)	1
2912	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	422(M+H)	1
				2913	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-methoxy benzamide	384(M+H)	3
2914	2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	432(M+H)	3
				2915	2-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388(M+H)	3
2916	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-fluoro benzamide	372(M+H)	3
				2917	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-methyl benzamide	368(M+H)	3
2918	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(trifluoromethyl) benzamide	422(M+H)	3
				2919	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide	440(M+H)	1
2920	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	446(M+H)	1
				2921	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-ethoxy benzamide	398(M+H)	2
2922	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5-methyl	397(M+H)

	Pyrimidine-2-base] amino } cyclohexyl) benzamide
				2923	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide	386(M+H)	1
2924	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide	386(M+H)	1
				2925	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2 base] amino } cyclohexyl)-the 3-ethyl benzamide	382(M+H)	1
2926	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-two fluoro-1,3-benzo dioxole-5-methane amide	434(M+H)	1
				2927	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-ethoxy benzamide	398(M+H)	2
2928	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide	412(M+H)	2
				2929	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide	442(M+H)	1
2930	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide	440(M+H)	1
				2931	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide	440(M+H)	3
2932	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	406(M+H)	3
				2933	3, and 5-two bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	510(M+H)	1
2934	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-dimethyl benzamide	382(M+H)	1
				2935	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	402(M+H)	1
2936	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide	452(M+H)	1
				2937	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	368(M+H)	1
2938	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }	384(M+H)	1

	Cyclohexyl)-the 3-methoxy benzamide
				2939	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	368(M+H)	1
2940	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388(M+H)	1
				2941	N-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-methyl G-NH2	431(M+H)	1
2942	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-methyl-N2-(3-aminomethyl phenyl)-G-NH2	411(M+H)	1
				2943	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-(3-fluoro phenyl)-N2-methyl G-NH2	415(M+H)	1
2944	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-(4-fluoro phenyl)-N2-methyl G-NH2	415(M+H)	1
				2945	N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-methyl G-NH2	431(M+H)	1
2946	N2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-methyl G-NH2	433(M+H)	1
				2947	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-(3-p-methoxy-phenyl)-N2-methyl G-NH2	427(M+H)	1
2948	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N2-(4-p-methoxy-phenyl)-N2-methyl G-NH2	427(M+H)	2
				2949	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-methyl propanamide	430(M+H)	1
2950	2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide	504(M+H)	2
				2951	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	354(M+H)	3
2952	4-butyl-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	410(M+H)	3
				2953	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-fluoro benzamide	372(M+H)	2
2954	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }	422(M+H)	1

	Cyclohexyl)-3-(trifluoromethyl) benzamide
					2955	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-methoxy benzamide		384(M+H)	3
2956	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-methoxy benzamide		384(M+H)	3
					2957	3-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide		379(M+H)	1
2958	4-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide		379(M+H)	1
					2959	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide		414(M+H)	1
2960	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide		440(M+H)	2
					2961	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide		440(M+H)	1
2962	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide		440(M+H)	1
					2963	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide		406(M+H)	1
2964	N-cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide		386(M+H)	1
					2965	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide		386(M+H)	1
2966	3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide		422(M+H)	1
					2967	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide		438(M+H)	1
2968	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide		390(M+H)	1
					2969	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide		446(M+H)	1
2970	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }		382(M+H)	3

	Cyclohexyl)-the 3-ethyl benzamide
					2971	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-ethoxy benzamide	398(M+H)		3
2972	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide	422(M+H)		2
					2973	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	432(M+H)		1
2974	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-ethyl benzamide	382(M+H)		2
					2975	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide	442(M+H)		1
2976	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-ethoxy benzamide	398(M+H)		2
					2977	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide	412(M+H)		1
2978	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	433(M+H)		1
					2979	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-furoamide	422(M+H)		1
2980	5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-furoamide	378(M+H)		1
					2981	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide	452(M+H)		2
2982	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	456(M+H)		1
					2983	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methyl benzamide	368(M+H)		1
2984	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-methoxy benzamide	384(M+H)		1
					2985	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-methyl benzamide	368(M+H)		1
2986	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl]	388(M+H)		1

	Amino } cyclohexyl) benzamide
				2987	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	388(M+H)	1
2988	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide	390(M+H)	1
				2989	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide	438(M+H)	3
2990	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 4-fluoro benzamide	372(M+H)	1
				2991	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide	444(M+H)	1
2992	N-(4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 3-nitrobenzamide	399(M+H)	1
				2993	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide	444(M+H)	1
2994	3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide	422(M+H)	1
				2995	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzsulfamide	390(M+H)	3
2996	N4, N4,5-trimethylammonium-N2-{ cis-4-[(4-methyl-benzyl) amino] cyclohexyl } pyrimidine-2, the 4-diamines	354(M+H)	3
				2997	N2-{ cis-4-[(3, the 4-difluorobenzyl) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	376(M+H)	3
2998	N2-{ cis-4-[(3-benzyl chloride base) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	374(M+H)	3
				2999	N2-{ cis-4-[(3-bromobenzyl) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	418(M+H)	3
3000	N2-{ cis-4-[(3, the 5-dimethoxy-benzyl) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	400(M+H)	2
				3001	N2-{ cis-4-[(3, the 5-dichloro benzyl) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	408(M+H)	3
3002	N2-{ cis-4-[(3, the 4-dichloro benzyl) amino] cyclohexyl }-N4, N4,5-	408(M+H)	3

	Trimethylammonium pyrimidine-2, the 4-diamines
				3003	N2-{ cis-4-[(4-methoxyl group-3-methyl-benzyl) amino] cyclohexyl }-N4, N4,5-trimethylammonium pyrimidine-2,4-diamines	384(M+H)	3
3004	N4, N4,5-trimethylammonium-N2-(cis-4-{[3-(trifluoromethoxy) benzyl] amino } cyclohexyl) pyrimidine-2, the 4-diamines	424(M+H)	3
				3005	N4, N4,6-trimethylammonium-N2-(cis-4-{[3-(trifluoromethoxy) benzyl] amino } cyclohexyl) pyrimidine-2, the 4-diamines	424(M+H)	3
3006	N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide	444(M+H)	3
				3007	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(3-fluorinated phenoxy) niacinamide	465(M+H)
3008	6-(3-chloro phenoxy group)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl] niacinamide	481(M+H)
				3009	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(3-methoxyl group phenoxy group)-niacinamide	477(M+H)
3010	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(2-methoxyl group phenoxy group)-niacinamide	477(M+H)
				3011	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-6-(2-fluorinated phenoxy) niacinamide	465(M+H)
3012	2-(4-bromine phenoxy group)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] niacinamide	525(M+H)	2
				3013	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(2-methoxyl group phenoxy group)-niacinamide	477(M+H)	1
3014	2-(2-bromine phenoxy group)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl] niacinamide	525(M+H)	3
				3015	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(2-fluorinated phenoxy) niacinamide	465(M+H)	1
3016	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(4-methoxyl group phenoxy group)-niacinamide	477(M+H)
				3017	N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-2-(3-fluorinated phenoxy) niacinamide	465(M+H)	3
3018	2-(3-chloro phenoxy group)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-	481(M+H)	3

	Methylpyrimidine-2-yl] amino } cyclopentyl) methyl] niacinamide
				3019	2-(3-chloro-4-fluorinated phenoxy)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-niacinamide	499(M+H)	2
3020	2-(4-chloro-3-fluorinated phenoxy)-N-[((1R, 3S)-3-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl) methyl]-niacinamide	499(M+H)	3
				3021	N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	417(M+H)	1
3022	N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclopentyl)-N-methyl urea	451(M+H)	1
				3023	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(3-aminomethyl phenyl) urea	397(M+H)	1
3024	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(4-aminomethyl phenyl) urea	397(M+H)	1
				3025	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-fluoro phenyl)-N-methyl urea	401(M+H)	1
3026	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-fluoro phenyl)-N-methyl urea	401(M+H)	1
				3027	N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	417(M+H)	1
3028	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-p-methoxy-phenyl)-N-methyl urea	413(M+H)	1
				3029	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-p-methoxy-phenyl)-N-methyl urea	413(M+H)	1
3030	3, and 4-two chloro-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) benzamide	408(M+H)	3

Embodiment 3031

3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic (cis-4-benzyl oxygen base carbonylamino-cyclohexyl)-carboxylamine benzyl ester.

To cis-hexanaphthene-1, the 4-dicarboxylic acid (25.0g, 145mmol) add in the suspension in benzene (125mL) phosphorazidic acid diphenyl (81.9g, 298mmol) and triethylamine (30.1g, 297mmol).This reaction mixture was stirred 2.5 hours under refluxing.(32.2g 298mmol), stirs this mixture 24 hours under refluxing to add benzyl alcohol.Concentrated reaction mixture is dissolved in EtOAc and the water residue.Separate organic layer, extract waterbearing stratum (twice) with EtOAc.With organic layer 1M aqueous potassium hydrogen sulfate, saturated sodium bicarbonate aqueous solution and the salt water washing that merges, through dried over mgso, filter, concentrate, through flash chromatography purifying (silica gel, the hexane solution of 33%EtOAc), obtain (cis-4-benzyloxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester (52.0g, 94%), is colorless oil.

ESI?MS?m/e?405，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.15-7.40(m，10H)，5.07(s，4H)，4.70-5.00(m，2H)，3.52-3.80(m，2H)，1.60-1.80(m，4H)，1.45-1.60(m，4H).

Step B: synthetic (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester.

(91.7g adds 5%Pd/C (9.17g) in MeOH 240mmol) (460mL) solution to (cis-4-benzyloxycarbonyl amino-cyclohexyl)-carboxylamine benzyl ester.Under room temperature, nitrogen atmosphere, stirred reaction mixture 2.5 days filters by Celite pad, concentrates and obtains diamines, is colorless oil.With 4 hours, in the MeOH of described diamines (550mL) solution, be added dropwise to (Boc) ₂O (6.59g, MeOH 30.2mmol) (80mL) solution.Under room temperature, stirred reaction mixture 1.5 days also concentrates.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, obtains cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (7.78g, 15%, crude product), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (32.9g) that obtains reclaiming, and is colorless oil.With 5 hours, (32.9g was added dropwise to (Boc) in MeOH 288mmol) (660mL) solution to the diamines that reclaims ₂O (6.29g, MeOH 28.8mmol) (80mL) solution.Under room temperature, stirred reaction mixture 10 hours also concentrates.After washing with water, with water layer CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, obtains cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (8.16g, 16%, crude product), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (23.1g) that obtains reclaiming, and is colorless oil.(23.1g was added dropwise to (Boc) in MeOH 202mmol) (462mL) solution to the diamines that reclaims with 4 hours ₂O (4.42g, MeOH 20.3mmol) (56mL) solution.Stirred reaction mixture 3.5 days and concentrated under room temperature.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, obtains cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (5.01g, 10% based on the starting raw material meter), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (16.0g) that obtains reclaiming, and is colorless oil.With 4 hours, (16.0g was added dropwise to (Boc) in MeOH 140mmol) (320mL) solution to the diamines that reclaims ₂O (3.06g, MeOH 14.0mmol) (40mL) solution.Stirred reaction mixture 13 hours and concentrated under room temperature.After water dissolution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, obtains cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (3.53g, 7%, based on the starting raw material meter), is colorless oil.Concentrated aqueous layer is dissolved among the MeOH residue, through dried over mgso, filters, concentrates the diamines (11.1g) that obtains reclaiming, and is colorless oil.

ESI?MS?m/e?215，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ4.30-4.82(m，1H)，3.50-3.80(m，1H)，2.78-2.95(m，1H)，1.44(s，9H)，1.20-1.80(m，8H).

Step C: synthetic (cis-4-{[1-(3,4-two fluoro-phenyl)-formyl radical (methanoyl)] amino }-cyclohexyl)-the carboxylamine tertiary butyl ester.

To 3, (4.10g, 25.9mmol) (5.05g adds Et in DMF 23.6mmol) (50mL) solution to 4-two fluoro-phenylformic acid with (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester ₃N (90mL, 56.7mmol), HOBt-water (5.41g, 35.3mmol) and EDC-HCl (4.97g, 25.9mmol).Stirred reaction mixture is 17 hours under room temperature.In reaction mixture, add entry (200mL), under room temperature, stirred this suspension 10 minutes.Filter collecting precipitation, water and EtOH washing, in 80 ℃ of drying under reduced pressure, obtain (cis-4-{[1-(3,4-two fluoro-phenyl)-formyl radical] amino }-cyclohexyl)-carboxylamine tertiary butyl ester (5.20g, 62.3%), be white solid.

ESI?MS?m/e?377，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.45(s，9H)，1.53-1.95(m，8H)，3.60-3.74(m，1H)，4.00-4.16(m，1H)，4.50-4.68(m，1H)，5.95-6.09(m，1H)，7.15-7.28(m，1H)，7.43-7.68(m，2H).

Step D: synthetic N-(cis-4-amino-cyclohexyl)-3,4-two fluoro-benzamide.

Will (cis-4-{[1-(3,4-two fluoro-phenyl)-methanoyl] amino }-cyclohexyl)-(5.20g, EtOAc 14.7mmol) (52mL) solution cool off on ice bath the carboxylamine tertiary butyl ester, add EtOAc (104mL) solution of 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is dissolved in the 1M NaOH aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, in 60 ℃ of drying under reduced pressure, obtains N-(cis-4-amino-cyclohexyl)-3, and 4-two fluoro-benzamide (3.00g, 80%) are white solid.

ESI?MS?m/e?255，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.15-1.52(m，3H)，1.59-1.89(m，5H)，2.94-3.06(m，1H)，4.06-4.20(m，1H)，6.01-6.18(m，1H)，7.13-7.26(m，1H)，7.43-7.50(m，1H)，7.57-7.67(m，1H).

Step e: synthesize 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

In sealed tube, (200mg, 1.22mmol) and N-(cis-4-amino-cyclohexyl)-3, (342mg, 1.34mmol) mixture in butanols (1mL) stirred 60 hours in 130 ℃ 4-two fluoro-benzamide with 2-chloro-quinoline.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).The EtOAc solution (10mL) that in the EtOAc of above-mentioned substance solution (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filtering-depositing is used Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (189mg, 37%), be white solid.

ESI?MS?m/e?382，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.09(m，8H)，3.96-4.24(m，2H)，6.90-7.03(m，2H)，7.14-7.25(m，1H)，7.41-7.48(m，1H)，7.57-7.64(m，1H)，7.69-7.79(m，4H)，8.18(d，J＝9.6Hz，1H)，9.73-9.76(m，1H).

Embodiment 3032

2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: synthetic N-(cis-4-amino-cyclohexyl)-2-phenoxy group-niacinamide.

To (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (6.00g, CHCl 27.8mmol) that in embodiment 3031 step B, obtain ₃(60mL) add i-Pr in the solution ₂NEt (9.67mL, 55.6mmol).This mixture of cooling on ice bath, and adding 2-phenoxy group-nicotinoyl chlorine (6.50g, 27.8mmol).Under room temperature, stirred this mixture 17 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.To EtOAc of above-mentioned substance (100mL) and CHCl ₃(40mL) the EtOAc solution (100mL) of adding 4M hydrogenchloride in the solution.Stir this mixture under room temperature also concentrated in 1 hour.Residue is dissolved in the 1M NaOH aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 0.2%-1%MeOH ₃Solution), obtain N-(cis-4-amino-cyclohexyl)-2-phenoxy group-niacinamide (3.51g, 41%), be faint yellow oily thing.

ESI?MS?m/e?312，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.12-1.39(m，3H)，1.65-1.94(m，5H)，2.80-2.91(m，1H)，4.18-4.30(m，1H)，7.13-7.22(m，3H)，7.25-7.33(m，1H)，7.41-7.51(m，2H)，8.04-8.14(m，1H)，8.22(dd，J＝4.7，2.1Hz，1H)，8.62(dd，J＝7.6，2.0Hz，1H).

Step B: Synthetic 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

In sealed tube, with 2-chloro-quinoline (200mg, 1.22mmol) and cis-N-(4-amino-cyclohexyl)-2-phenoxy group-niacinamide (418mg, 1.34mmol) mixture in butanols (1mL) stirred 6 days in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 10%-16%EtOAc).The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, and concentrate.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide hydrochloride (138mg, 37%), be white solid.

ESI?MS?m/e?461，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.87-2.10(m，8H)，3.83-3.97(m，1H)4.12-4.24(m，1H)，6.90(d，J＝9.5Hz，1H)，7.12(dd，J＝7.6，4.5Hz，1H)，7.20-7.32(m，3H)，7.37-7.50(m，3H)，7.66-7.80(m，3H)，7.95(d，J＝7.0Hz，1H)8.13(d，J＝9.6Hz，1H)，8.21(dd，J＝4.6，2.2Hz，1H)，8.53(dd，J＝7.6，1.9Hz，1H)，9.77-9.92(m，1H).

Embodiment 3033

3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesizing cis-N-quinoline-2-base-hexanaphthene-1,4-diamines.

With 2-chloro-quinoline (16.0g, 97.8mol) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester that in embodiment 3031 step B, obtains (23.0g, 107.5mol) mixture in butanols (16mL) stirred 3 days in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 10%EtOAc).Obtain faint yellow oily thing.The EtOAc solution (80mL) that in the EtOAc of above-mentioned substance (160mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 12 hours.Residue is dissolved in the 1M NaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, through in press liquid chromatography purification (NH-silica gel, the CHCl of 2%-5%MeOH ₃Solution), obtain cis-N-quinoline-2-base-hexanaphthene-1,4-diamines (6.30g, 27%) is faint yellow solid.

ESI?MS?m/e?242，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.12-1.53(m，4H)，1.65-1.93(m，6H)，2.84-2.98(m，1H)，4.04-4.16(m，1H)，4.78-4.91(m，1H)，6.61(d，J＝9.0Hz，1H)，7.17(ddd，J＝8.0，6.9，1.2Hz，1H)，7.46-7.58(m，2H)，7.61-7.66(m，1H)，7.79(d，J＝8.9Hz.1H).

Step B: synthetic 3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

To cis-N-quinoline-2-base-hexanaphthene-1,4-diamines (300mg, CHCl 1.24mmol) ₃(2mL) add i-Pr in the solution ₂(0.45mL is 2.60mmol) with 3-methyl-Benzoyl chloride (210mg, CHCl 1.36mmol) for NEt ₃(1mL) solution.Under room temperature, stirred this mixture 17 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc), obtain colorless oil.

The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (294mg, 60%), be white solid.

ESI?MS?m/e?382，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.82-2.07(m，8H)，2.40(s，3H)，3.93-4.04(m，1H)，4.08-4.26(m，1H)，6.49-6.58(m，1H)，6.94(d，J＝9.5Hz，1H)，7.25-7.32(m，2H)，7.40-7.48(m，1H)，7.56-7.66(m，2H)，7.67-7.81(m，3H)8.17(d，J＝9.5Hz，1H)，9.74-9.87(m，1H).

Embodiment 3034

3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?398，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.09(m，8H)，3.86(s，3H)，3.94-4.06(m，1H)，4.08-4.25(m，1H)，6.63(d，J＝8.6Hz，1H)，6.91-7.05(m，2H)，7.28-7.48(m，4H)，7.68-7.80(m，3H)，8.17(d，J＝9.3Hz，1H)，9.75-9.84(m，1H).

Embodiment 3035

3-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?402，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.82-2.10(m，8H)，3.96-4.07(m，1H)，4.09-4.26(m，1H)，6.75(d，J＝7.8Hz，1H)，6.96(d，J＝9.3Hz，1H)，7.33-7.49(m，3H)，7.66-7.79(m，4H)，7.83-7.88(m，1H)，8.19(d，J＝9.3Hz，1H)，9.80(d，J＝8.5Hz，1H).

Embodiment 3036

5-nitro-thiophene-3-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

(516mg, 2.98mmol) and the cis-N-quinoline-2-base-hexanaphthene-1 that obtains in the steps A of embodiment 3033, (600mg adds Et in DMF 2.48mmol) (6mL) solution to the 4-diamines to 5-nitro-thiophene-3-carboxylic acid ₃N (0.83mL, 5.95mmol), HOBt-H ₂O (570mg, 3.72mmol) and EDC-HCl (571g, 2.98mmol).Stirred reaction mixture is 12 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 33%-50%EtOAc and silica gel, the CHCl of 2%-5%MeOH in the warp ₃Solution), obtain faint yellow oily thing.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride (329mg, 60%), is yellow solid.

ESI?MS?m/e?419，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.18(m，8H)，3.96-4.25(m，2H)，6.97(d，J＝9.3Hz，1H)，7.39-7.53(m，2H)，7.67-7.80(m，3H)，8.20(d，J＝9.4Hz，1H)，8.26-8.30(m，1H)，8.39-8.42(m，1H)，9.59(d，J＝8,6Hz，1H).

Embodiment 3037

2-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?403，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.84-2.17(m，8H)，3.93-4.05(m，1H)，4.13-4.30(m，1H)，6.89-7.02(m，2H)，7.30-7.50(m，2H)，7.67-7.81(m，3H)，7.96(d，J＝7.5Hz，1H)，8.19(d，J＝9.6Hz，1H)，8.44-8.50(m，1H)，9.73-9.87(m，1H).

Embodiment 3038

3-chloro-4-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-4-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?420，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.08(m，8H)，3.95-4.06(m，1H)，4.07-4.23(m，1H)，6.68-6.78(m，1H)，6.95(d，J＝9.6Hz，1H)，7.18(t，J＝8.6Hz，1H)，7.41-7.48(m，1H)，7.68-7.79(m，4H)，7.95(dd，J＝7.0，2.2Hz，1H)，8.18(d，J＝9.6Hz，1H)，9.79(d，J＝8.4Hz，1H).

Embodiment 3039

3,5-dimethoxy-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,5-dimethoxy-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?428，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.14(m，8H)，3.85(s，6H)，3.95-4.26(m，2H)，6.53-6.66(m，2H)，6.89-7.01(m，3H)，7.40-7.51(m，1H)，7.68-7.82(m，3H)，8.18(d，J＝9.6Hz，1H)，9.76-9.85(m，1H).

Embodiment 3040

3,4-two chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two chloro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?436，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.15(m，8H)，3.98-4.25(m，2H)，6.87-7.00(m，2H)，7.42-7.52(m，2H)，7.65-7.80(m，4H)，7.98(d，J＝2.0Hz，1H)，8.19(d，J＝9.5Hz，1H)，9.87(d，J＝8.6Hz，1H).

Embodiment 3041

Benzo [2,1,3] oxadiazole-5-carboxylic acids-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic benzo [2,1,3] oxadiazole-5-carboxylic acids-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the step B of embodiment 3033, obtain title compound.

ESI?MS?m/e?388，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.23(m，8H)，3.98-4.31(m，2H)，6.97(d，J＝9.5Hz，1H)，7.38-7.50(m，2H)，7.70-7.78(m，3H)，7.88(ddd，J＝14.3，9.3，1.2Hz，2H)，8.20(d，J＝9.5Hz，1H)，8.41(t，J＝1.2Hz，1H)，9.75(d，J＝8.1Hz，1H).

Embodiment 3042

1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?394，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.14(m，8H)，3.91-4.15(m，5H)，6.96(d，J＝9.4Hz，1H)，7.09(d，J＝9.0Hz，1H)，7.28-7.31(m，1H)，7.41-7.54(m，2H)，7.67-7.79(m，3H)，8.19(d，J＝9.6Hz，1H)，9.66(m，1H).

Embodiment 3043

9H-xanthene-9-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride steps A: synthetic 9H-xanthene-9-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?472，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-1.89(m，8H)，3.76-3.94(m，2H)，5.99-6.09(m，1H)，6.87(d，J＝10.1Hz，1H)，7.05-7.18(m，4H)，7.24-7.47(m，5H)，7.65-7.79(m，3H)8.13(d，J＝9.6Hz，1H)，9.62(d，J＝7.6Hz，1H).

Embodiment 3044

5-(4-chloro-phenyl)-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-(4-chloro-phenyl)-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?468，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.13(m，8H)，3.93-4.07(m，1H)，4.10-4.28(m，1H)，6.65-7.03(m，3H)，7.12-7.23(m，1H)，7.32-7.52(m，3H)，7.63-7.85(m，5H)，8.12-8.26(m，1H)，9.74-9.94(m，1H).

Embodiment 3045

3-nitro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-nitro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?413，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.83-2.30(m，8H)，3.99-4.10(m，1H)，4.13-4.31(m，1H)，6.97(d，J＝9.5Hz，1H)，7.24-7.33(m，1H)，7.42-7.51(m，1H)，7.63(t，J＝7.9Hz，1H)，7.70-7.79(m，3H)，8.17-8.24(m，2H)，8.30-8.35(m，1H)，8.75-8.77(m，1H)，9.76(d，J＝7.3Hz，1H).

Embodiment 3046

4-fluoro-3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-fluoro-3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

The cis that in the steps A of embodiment 3033, obtains-N-quinoline-2-base-hexanaphthene-1,4-diamines (250mg, CHCl 1.04mmol) ₃(5mL) add Et in the solution ₃N (0.3mL, 2.15mmol) and 4-fluoro-3-methyl-Benzoyl chloride (197mg, 1.14mmol).Under room temperature, stirred this mixture 12 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc) in the warp through dried over mgso.The EtOAc solution (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 2 hours.Residue is suspended in Et ₂O (20mL) stirs this suspension 6 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 4-fluoro-3-methyl-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (363mg, 85%), be white solid.

ESI?MS?m/e?400，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.82-2.10(m，8H)，2.32(d，J＝1.9Hz，3H)，3.96-4.07(m，1H)，4.09-4.27(m，1H)，6.62-6.72(m，1H)，6.96(d，J＝9.5Hz，1H)，7.04(t，J＝8.9Hz，1H)，7.40-7.51(m，1H)，7.61-7.83(m，5H)?8.19(d，J＝9.6Hz，1H)，9.71-9.85(m，1H).

Embodiment 3047

3-bromo-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-bromo-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?446，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.13(m，8H)，3.96-4.08(m，1H)，4.09-4.27(m，1H)，6.84(d，J＝7.8Hz，1H)，6.96(d，J＝9.6Hz，1H)，7.30(t，J＝7.9Hz，1H)，7.41-7.50(m，1H)，7.57-7.64(m，1H)，7.69-7.80(m，4H)，8.01(t，J＝1.6Hz，1H)，8.19(d，J＝9.3Hz，1H)，9.71(m，1H).

Embodiment 3048

2-(2-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(2-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

To 2-bromo-phenol (453mg, add in DMA 2.62mmol) (4mL) solution 60%NaH oil suspension (210mg, 5.24mmol).Under room temperature, stirred this mixture 1 hour.In mixture, be added in 2-chloro-N-[cis-4-(quinoline-2-base the is amino)-cyclohexyl that obtains in the steps A of embodiment 3037]-niacinamide (1.00g, DMA 2.62mmol) (2mL) solution.This mixture was stirred 3 hours water quencher reactant in 120 ℃.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc, silica gel, the CHCl of 1%-2%MeOH ₃Solution), obtain a kind of colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 2-(2-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-niacinamide hydrochloride (262mg, 18%), be white solid.

ESI?MS?m/e?517，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.89-2.17(m，8H)，3.81-3.98(m，1H)，4.14-4.30(m，1H)，6.92(d，J＝9.5Hz，1H)，7.11-7.20(m，2H)，7.34-7.47(m，3H)，7.63-7.80(m，4H)，7.92-8.00(m，1H)，8.10-8.20(m，2H)，8.54(dd，J＝7.5，2.0Hz，1H)，9.71-9.88(m，1H).

Embodiment 3049

3-cyano group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-cyano group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?393，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.17(m，8H)，3.98-4.30(m，2H)，6.97(d，J＝9.3Hz，1H)，7.07-7.18(m，1H)，7.42-7.50(m，1H)7.56(t，J＝7.8Hz，1H)，7.70-7.80(m，4H)，8.08(d，J＝7.9Hz，1H)，8.17-8.25(m，2H)，9.69-9.84(m，1H).

Embodiment 3050

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?436，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.13(m，8H)，3.97-4.09(m，1H)，4.12-4.33(m，1H)，6.92-7.05(m，2H)，7.41-7.50(m，1H)，7.57(t，J＝7.7Hz，1H)，7.69-7.79(m，4H)，8.02(d，J＝8.1Hz，1H)，8.13-8.26(m，2H)，9.72-9.85(m，1H).

Embodiment 3051

N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-acetamide hydrochloride

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-2-between-tolyloxy-acetamide hydrochloride.

To-(189mg, 1.14mmol) and the cis that obtains in the steps A of embodiment 3036-N-quinoline-2-base-hexanaphthene-1, (250mg adds Et in DMF 1.04mmol) (15mL) solution to the 4-diamines to tolyloxy-acetate ₃N (0.35mL, 2.50mmol), HOBt-H ₂O (238mg, 1.56mmol) and EDC-HCl (219g, 1.14mmol).Stirred reaction mixture is 13 hours under room temperature.In reaction mixture, add entry (30mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain colorless oil.

The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-2-between-tolyloxy-acetamide hydrochloride (140mg, 32%), be white solid.

ESI?MS?m/e?412，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.06(m，8H)，2.33(s，3H)，3.88-4.12(m，2H)，4.44(s，2H)，6.72-6.96(m，5H)，7.18(t，J＝8.0Hz，1H)，7.39-7.47(m，1H)，7.68-7.81(m，3H)，8.17(d，J＝9.3Hz，1H)，9.72-9.89(m，1H).

Embodiment 3052

2,2-phenylbenzene-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2,2-phenylbenzene-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?458，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.71-1.97(m，8H)，3.84-4.10(m，2H)，4.87(s，1H)，6.16-6.25(m，1H)，6.90(d，J＝9.5Hz，1H)，7.20-7.36(m，10H)，7.39-7.48(m，1H)，7.67-7.79(m，3H)，8.15(d，J＝9.2Hz，1H)，9.63-9.77(m，1H).

Embodiment 3053

5-bromo-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-bromo-furans-2-carboxylic acid [cis-4-(quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?436，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.84-2.09(m，8H)，3.92-4.18(m，2H)，6.42(d，J＝3.5Hz，1H)，6.61(d，J＝8.6Hz，1H)，6.95(d，J＝8.2Hz，1H)，7.05(d，J＝3.5Hz，1H)，7.42-7.48(m，1H)，7.69-7.83(m，3H)，8.19(d，J＝9.5Hz，1H)，9.85(d，J＝8.6Hz，1H).

Embodiment 3054

2-(4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: 2-(4-fluoro-phenoxy group)-nicotinic acid ethyl ester.

To 2-fluoro-phenol (3.02g, add in DMA 26.9mmol) (20mL) solution 60%NaH oil suspension (1.08mg, 26.9mmol).Under room temperature, stirred this mixture 1.5 hours.In mixture, add 2-chloro-nicotinic acid ethyl ester (5.00g, DMA 26.9mmol) (5mL) solution.In 120 ℃ this mixture was stirred 2 hours, with saturated sodium bicarbonate aqueous solution quencher reactant.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.Residue is suspended in 10%Et ₂The hexane solution of O (50mL) stirred this suspension 1 hour under room temperature.Filter the collecting precipitation thing, use hexane wash,, obtain 2-(4-fluoro-phenoxy group)-nicotinic acid ethyl ester (3.08g, 44%), be white solid in 70 ℃ of drying under reduced pressure.

ESI?MS?m/e?284，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.40(td，J＝7.1，1.6Hz，3H)，4.41(qd，J＝7.1，1.6Hz，2H)，6.99-7.21(m，5H)，8.23-8.29(m，2H).

Step B: Synthetic 2-(4-fluoro-phenoxy group)-nicotinic acid.

(3.00g adds the 2M NaOH aqueous solution (6mL) in EtOH 11.5mmol) (90mL) solution to 2-(4-fluoro-phenoxy group)-nicotinic acid ethyl ester.Under room temperature, stirred this mixture 4 hours.In mixture, add the 1M HCl aqueous solution (pH=3) and concentrated.Make residue soluble in water, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.Residue is suspended in 10%Et ₂In the hexane solution of O (80mL), under room temperature, stirred this suspension 1 hour.Filter the collecting precipitation thing, use hexane wash,, obtain 2-(4-fluoro-phenoxy group)-nicotinic acid (2.39g, 89%), be white solid in 70 ℃ of drying under reduced pressure.

ESI?MS?m/e?233，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.05-7.25(m，5H)，8.32(dd，J＝4.8，2.0Hz，1H)，8.49(dd，J＝7.6，2.0Hz，1H).

Step C: Synthetic 2-(4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?479，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.83-2.14(m，8H)，3.88-4.01(m，1H)，4.13-4.30(m，1H)，6.93(d，J＝9.3Hz，1H)，7.11-7.20(m，3H)，7.25-7.31(m，2H)，7.43(t，J＝7.9Hz，1H)，7.67-7.81(m，3H)，7.93(d，J＝7.2Hz，1H)，8.16(d，J＝9.2Hz，1H)，8.21(dd，J＝4.8，2.0Hz，1H)，8.54(dd，J＝7.6，2.0Hz，1H)，9.81-9.94(m，1H).

Embodiment 3055

2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(3,4-two fluoro-phenoxy groups)-nicotinic acid.

To 3,4-two fluoro-phenol (3.77g, and the oil suspension of adding 60%NaH in DMA 28.9mmol) (20mL) solution (1.16mg, 28.9mmol).Under room temperature, stirred this mixture 1 hour.In mixture, add 2-chloro-nicotinic acid ethyl ester (5.36g, DMA 28.9mmol) (5mL) solution.In 120 ℃ this mixture was stirred 2.5 hours, with saturated sodium bicarbonate aqueous solution quencher reactant.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.Residue is suspended in 10%Et ₂In the hexane solution of O (150mL), under room temperature, stirred this suspension 1 hour.Filtering-depositing is used hexane wash, in 70 ℃ of drying under reduced pressure, obtains white solid.In the EtOH of above-mentioned substance (150mL) solution, add the 2MNaOH aqueous solution (15.2mL).Under room temperature, stirred this mixture 12 hours.(46mL pH=3) also concentrates to add the 1M HCl aqueous solution in mixture.Make residue soluble in water, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.Residue is suspended in 10%Et ₂In the hexane solution of O (150mL), under room temperature, stirred this suspension 30 minutes.Filter the collecting precipitation thing, use hexane wash,, obtain 2-(3,4-two fluoro-phenoxy groups)-nicotinic acid (4.85g, 67), be white solid in 70 ℃ of drying under reduced pressure.

ESI?MS?m/e?251，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ6.90-7.30(m，4H)，8.30-8.35(m，1H)，8.46-8.52(m，1H).

Step B: Synthetic 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?475，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.85-2.13(m，8H)，3.91-4.03(m，1H)，4.13-4.29(m，1H)，6.94(d，J＝9.6Hz，1H)，7.11-7.34(m，4H)，7.40-7.47(m，1H)，7.67-7.85(m，4H)，8.17(d，J＝9.5Hz，1H)，8.22(dd，J＝4.8，2.0Hz，1H)，8.53(dd，J＝7.6，2.0Hz，1H)，9.84-9.98(m，1H).

Embodiment 3056

N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide hydrochloride

Steps A: Synthetic 2-right-tolyloxy-nicotinic acid.

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?229，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.40(s，3H)7.05-7.31(m，5H)，8.30-8.35(m，1H)，8.52-8.57(m，1H).

Step B: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?475，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.86-2.13(m，8H)，2.36(s，3H)，3.86-3.98(m，1H)，4.11-4.29(m，1H)，6.86-7.00(m，1H)，7.07-7.31(m，5H)，7.43(t，J＝7.6Hz，1H)，7.64-7.82(m，3H)，7.92-8.28(m，3H)，8.53(d，J＝7.0Hz，1H)，9.74-9.87(m，1H).

Embodiment 3057

2-(4-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-chloro-phenoxy group)-nicotinic acid.

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.10-7.21(m，3H)，7.36-7.45(m，2H)，8.30-8.36(m，1H)，8.45-8.51(m，1H).

Step B: Synthetic 2-(4-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?473，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.83-2.13(m，8H)，3.87-4.04(m，1H)，4.10-4.33(m，1H)，6.87-7.01(m，1H)，7.10-7.35(m，3H)，7.38-7.50(m，3H)，7.65-7.93(m，4H)，8.10-8.26(m，2H)，8.53(d，J＝6.4Hz，1H)，9.78-9.97(m，1H).

Embodiment 3058

2-(4-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: 2-(4-bromo-phenoxy group)-nicotinic acid

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?294，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.05-7.12(m，2H)，7.18(dd，J＝7.6，4.8Hz，1H)，7.52-7.62(m，2H)，8.31-8.35(m，1H)，8.48(dd，J＝7.6，2.0Hz，1H).

Step B: Synthetic 2-(4-bromo-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?517，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.11(m，8H)，3.87-4.02(m，1H)，4.12-4.30(m，1H)，6.86-7.01(m，1H)，7.09-7.29(m，3H)，7.38-7.48(m，1H)，7.51-7.62(m，2H)，7.64-7.93(m，4H)，8.11-8.25(m，2H)，8.53(d，J＝7.6Hz，1H)，9.78-9.96(m，1H).

Embodiment 3059

2-(4-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-methoxyl group-phenoxy group)-nicotinic acid.

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?245，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ6.94-7.01(m，2H)，7.09-7.20(m，3H)，8.31-8.35(m，1H)，8.50-8.55(m，1H).

Step B: Synthetic 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?491，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.85-2.12(m，8H)，3.81(brs，3H)，3.86-3.99(m，1H)，4.12-4.30(m，1H)，6.84-7.29(m，6H)，7.37-7.49(m，1H)，7.64-7.82(m，3H)，7.96-8.28(m，3H)，8.48-8.60(m，1H)，9.71-9.86(m，1H).

Embodiment 3060

2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(3-chloro-4-fluoro-phenoxy group)-nicotinic acid.

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?268，M+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ7.03-7.32(m，4H)，8.29-8.37(m，1H)，8.44-8.53(m，1H).

Step B: Synthetic 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?491，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.83-2.10(m，8H)，3.88-4.04(m，1H)，4.11-4.27(m，1H)，6.92(d，J＝9.6Hz，1H)7.16(dd，J＝7.6，4.8Hz，1H)，7.21-7.46(m，4H)，7.67-7.81(m，4H)，8.15(d，J＝9.5Hz，1H)，8.20(dd，J＝4.8，2.0Hz，1H)，8.52(dd，J＝7.6，2.0Hz，1H)，9.83-9.95(m，1H).

Embodiment 3061

N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide hydrochloride

Steps A: Synthetic 2--tolyloxy-nicotinic acid

Adopt the method for the steps A of embodiment 3055, obtain title compound.

ESI?MS?m/e?229，M ⁺； ¹H?NMR(200MHz，CDCl ₃)δ2.40(s，3H)，6.95-7.41(m，5H)，8.33(dd，J＝4.8，1.8Hz，1H)，8.54(dd，J＝7.7，1.9Hz，1H).

Step B: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-2-between-tolyloxy-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?475，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.87-2.07(m，8H)，2.40(s，3H)，3.85-3.98(m，1H)，4.10-4.25(m，1H)，6.88-6.99(m，1H)，7.01-7.18(m，4H)，7.33(t，J＝7.8Hz，1H)，7.42(t，J＝7.5Hz，1H)，7.66-7.81(m，3H)，7.93-8.03(m，1H)，8.12-8.20(m，1H)，8.23(dd，J＝4.7，1.9Hz，1H)，8.52(dd，J＝7.5，1.9Hz，1H)，9.71-9.83(m，1H).

Embodiment 3062

2-(3-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: synthetic (3-methoxyl group-phenoxy group)-acetate ethyl ester.

To 3-methoxyl group-phenol (3.54g, add in DMA 28.5mmol) (20mL) solution 60%NaH oil suspension (1.14g, 28.5mmol).Under room temperature, stirred this mixture 1.5 hours.In this mixture, add bromo-acetate ethyl ester (4.53g, DMA 28.5mmol) (10mL) solution.Under room temperature, stirred this mixture 1.5 hours, with saturated sodium bicarbonate aqueous solution quencher reactant.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (silica gel, the hexane solution of 20%EtOAc).Obtain (3-methoxyl group-phenoxy group)-acetate ethyl ester (5.19g, 91%), be colorless oil.

ESI?MS?m/e?233，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.30(t，J＝7.1Hz，3H)，3.79(s，3H)，4.27(q，J＝7.1Hz，2H)，4.60(s，2H)，6.44-6.61(m，3H)，7.15-7.23(m，1H).

Step B: synthetic (3-methoxyl group-phenoxy group)-acetate.

(5.06g adds the 1MNaOH aqueous solution (25.3mL) in EtOH 24.1mmol) (100mL) solution to (3-methoxyl group-phenoxy group)-acetate ethyl ester.Under room temperature, stirred this mixture 1 hour.In this mixture, add the 1M HCl aqueous solution (pH=3) and concentrated.Make residue soluble in water, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, obtains (3-methoxyl group-phenoxy group)-acetate (4.05g, 92%), is white solid.

ESI?MS?m/e?182，M ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ3.73(s，3H)，4.65(s，2H)，6.45-6.57(m，3H)，7.13-7.23(m，1H)，12.97(brs，1H).

Step C: Synthetic 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.79-2.05(m，8H)，3.82(s，3H)，3.90-4.11(m，2H)，4.46(s，2H)，6.52-6.61(m，3H)，6.80-6.87(m，1H)，6.93(d，J＝9.5Hz，1H)，7.16-7.24(m，1H)，7.41-7.48(m，1H)，7.69-7.82(m，3H)，8.17(d，J＝9.5Hz，1H)9.78-9.88(m，1H).

Embodiment 3063

2-(3-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: synthetic (3-chloro-phenoxy group)-acetate ethyl ester.

Adopt the method for the steps A of embodiment 3062, obtain title compound.

ESI?MS?m/e?237，M+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.30(t，J＝7.2Hz，3H)，4.28(q，J＝7.2Hz，2H)，4.60(s，2H)，6.73-7.02(m，3H)，7.14-7.30(m，1H).

Step B: synthetic (3-chloro-phenoxy group)-acetate.

Adopt the method for the step B of embodiment 3062, obtain title compound.

ESI?MS?m/e?187，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ4.73(d，J＝1.2Hz，2H)，6.87-6.94(m，1H)，6.98-7.05(m，2H)，7.27-7.35(m，1H)，13.07(s，1H).

Step C: Synthetic 2-(3-chloro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?410，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.07(m，8H)，3.90-4.14(m，2H)，4.45(s，2H)6.74-6.84(m，1H)，6.86-7.03(m，4H)，7.20-7.29(m，1H)，7.40-7.49(m，1H)，7.69-7.82(m，3H)，8.18(d，J＝9.3Hz，1H)，9.79-9.93(m，1H).

Embodiment 3064

2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: synthetic (3-chloro-4-fluoro-phenoxy group)-acetate ethyl ester.

Adopt the method for the steps A of embodiment 3062, obtain title compound.

ESI?MS?m/e?233，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.30(t，J＝7.1Hz，3H)，4.28(q，J＝7.1Hz，2H)，4.58(s，2H)，6.75-6.82(m，1H)，6.95(dd，J＝5.9，3.1Hz，1H)，7.01-7.11(m，1H).

Step B: synthetic (3-chloro-4-fluoro-phenoxy group)-acetate.

Adopt the method for the step B of embodiment 3062, obtain title compound.

ESI?MS?m/e?205，M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ4.72(s，2H)，6.92-6.97(m，1H)，7.17(dd，J＝6.1，3.1Hz，1H)，7.34(t，J＝9.1Hz，1H)，13.08(brs，1H).

Step C: Synthetic 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?450，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.76-2.08(m，8H)，3.91-4.13(m，2H)，4.42(s，2H)，6.73-6.97(m，3H)，7.00-7.14(m，2H)，7.41-7.49(m，1H)，7.70-7.80(m，3H)，8.18(d，J＝9.5Hz，1H)，9.79-9.90(m，1H).

Embodiment 3065

2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: synthetic (3,4-two chloro-phenoxy groups)-acetate ethyl ester.

Adopt the method for the steps A of embodiment 3062, obtain title compound.

CI?MS?m/e?249，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.30(t，J＝7.1Hz，3H)，4.28(q，J＝7.1Hz，2H)，4.59(s，2H)，6.78(dd，J＝9.0，2.9Hz，1H)，7.01(d，J＝2.8Hz，1H)，7.34(d，J＝9.1Hz，1H).

Step B: synthetic (3,4-two chloro-phenoxy groups)-acetate.

Adopt the method for the step B of embodiment 3062, obtain title compound.

ESI?MS?m/e?221，M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ4.76(s，2H)，6.96(dd，J＝8.9，2.9Hz，1H)，7.24(d，J＝2.9Hz，1H)，7.53(d，J＝8.9Hz，1H)，13.12(brs，1H).

Step C: Synthetic 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?466，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.75-2.07(m，8H)，3.92-4.13(m，2H)，4.44(s，2H)，6.78(d，J＝8.1Hz，1H)，6.86-6.97(m，2H)，7.10(d，J＝2.9Hz，1H)，7.37(d，J＝8.9Hz，1H)，7.41-7.49(m，1H)，7.67-7.82(m，3H)，8.18(d，J＝9.5Hz，1H)，9.80-9.90(m，1H).

Embodiment 3066

C-(methyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic (methyl-phenyl-amino)-acetate ethyl ester.

(5.00g adds i-Pr in IPA 29.9mmol) (10mL) solution to bromo-acetate ethyl ester ₂NEt (4.06g, 31.4mmol) and methyl-phenyl-amine (3.37g, 31.4mmol).This mixture backflow was stirred 2.5 hours down, with saturated sodium bicarbonate aqueous solution quencher reactant.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (silica gel, the hexane solution of 20%EtOAc), obtain (methyl-phenyl-amino)-acetate ethyl ester (5.61g, 97%), be yellow oil.

ESI?MS?m/e?216，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.24(t，J＝7.1Hz，3H)，3.07(s，3H)，4.05(s，2H)，4.17(q，J＝7.1Hz，2H)，6.63-6.79(m，3H)，7.18-7.29(m，2H).

Step B: synthetic (methyl-phenyl-amino)-acetate.

(5.48g adds the 1M NaOH aqueous solution (29.8mL) in EtOH 28.4mmol) (100mL) solution to (methyl-phenyl-amino)-acetate ethyl ester.Under room temperature, stirred this mixture 1.5 hours.In mixture, add the 1M HCl aqueous solution (pH=3) and concentrated.Make residue soluble in water, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (silica gel, the hexane solution of 20%EtOAc), obtain (methyl-phenyl-amino)-acetate (1.73g, 37%), be yellow oil.

ESI?MS?m/e?165，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.05(s，3H)，4.07(s，2H)，6.65-6.85(m，3H)，7.18-7.30(m，2H)，8.62(brs，1H).

Step C: synthetic C-(methyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?411，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.73-1.99(m，8H)，3.05-3.16(m，3H)，3.79-4.02(m，4H)，6.82-7.00(m，4H)，7.06-7.49(m，5H)，7.65-7.80(m，3H)，8.15(d，J＝9.9Hz，1H)，9.57-9.68(m，1H).

Embodiment 3067

2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic (3,4-two chloro-phenyl aminos)-acetate ethyl ester.

Adopt the method for the steps A of embodiment 3066, obtain title compound.

CI?MS?m/e?248，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.31(t，J＝7.1Hz，3H)，3.85(d，J＝5.4Hz，2H)，4.26(q，J＝7.1Hz，2H)，4.33-4.42(m，1H)，6.45(dd，J＝8.7，2.8Hz，1H)，6.66(d，J＝2.8Hz，1H)，7.21(d，J＝8.7Hz，1H).

Step B: synthetic (3,4-two chloro-phenyl aminos)-acetate.

Adopt the method for the step B of embodiment 3054, obtain title compound.

ESI?MS?m/e?220，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.84(s，2H)，6.37(brs，1H)，6.57(dd，J＝8.8，2.7Hz，1H)，6.76(d，J＝2.6Hz，1H)，7.26(d，J＝8.8Hz，1H)，12.67(brs，1H).

Step C: Synthetic 2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?465，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.72-2.05(m，8H)，3.80(s，2H)，3.87-4.10(m，2H)，6.48-6.57(m，1H)，6.73(brs，1H)，6.86-7.05(m，2H)，7.18(d，J＝8.7Hz，1H)，7.39-7.50(m，1H)，7.66-7.80(m，3H)，8.11-8.24(m，1H)，9.55-9.68(m，1H).

Embodiment 3068

3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt

Steps A: synthetic (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester.

(244g, 1.70mol) suspension in MeOH (2.45L) is cooled to-8 ℃ with cis-4-amino-hexahydrobenzoic acid.Be added dropwise to thionyl chloride (45.0mL, 617mmol).The solution that stirring generates under room temperature 4.5 hours concentrates and obtains white solid.To above-mentioned solid at CHCl ₃In the suspension (3.00L) order add triethylamine (261mL, 1.37mol) and (Boc) ₂O (409g, 1.87mol).Stirred reaction mixture is 5 hours under room temperature, then in the impouring water.With water layer CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (silica gel, simple CHCl ₃CHCl to 10%MeOH ₃Solution), obtain colorless oil (531g).(78.3g is 2.06mol) at Et to the lithium aluminum hydride that is cooled to-4 ℃ ₂The Et that adds the above-mentioned oily matter (530.9g) that is lower than 0 ℃ in the suspension among the O (7.9L) ₂The solution of O (5.3L).The suspension that stirring generates under room temperature 2 hours.This reaction mixture is cooled off on ice bath, use the cold water quencher, filter by Celite pad.Filtrate is filtered and is concentrated through dried over mgso.Throw out is suspended in hexane (300mL), filters, use hexane wash, drying under reduced pressure obtains (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester (301g, 77%), is white solid.

ESI?MS?m/e?252，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.16-1.36(m，2H)，1.45(s，9H)，1.52-1.77(m，7H)，3.51(d，J＝6.2Hz，2H)，3.75(brs，1H)，4.30-4.82(m，1H).

Step B: synthetic [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester.

To (cis-4-hydroxymethyl-cyclohexyl)-carboxylamine tertiary butyl ester (17.7g, in THF 77.2mmol) (245mL) solution order add triphenyl phosphine (20.2g, 77.0mmol) and phthalic imidine (11.4g, 77.5mmol).The suspension that generates is cooled off on ice bath, with the toluene (33.6mL, 74.1mmol) solution that added 40% azo-2-carboxylic acid's diethyl ester (DEAD) in 1 hour.Stirred reaction mixture is 2.5 days under room temperature, concentrates, through flash chromatography purifying (silica gel, the hexane solution of 33%EtOAc).Obtain white solid.In the suspension of above-mentioned solid (27.5g) in EtOH (275mL), add hydrazine hydrate (5.76g, 115mmol).This mixture backflow was stirred 2.25 hours down, and cooling also concentrates.Make residue be dissolved in 10% aqueous sodium hydroxide solution (350mL).With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters and concentrates through dried over mgso.CHCl to above-mentioned residue ₃(275mL) add in the solution triethylamine (8.54g, 84.4mmol).The solution that generates is cooled to 0 ℃, add the ZCl that is lower than 5 ℃ (14.4g, 84.4mmol).Stirred reaction mixture is 16 hours under room temperature, in the impouring saturated sodium bicarbonate aqueous solution.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel, the CHCl of 2%MeOH through dried over mgso ₃Solution), obtain [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester (25.3g, 91%), be colorless oil.

ESI?MS?m/e?385，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.13-1.31(m，2H)，1.44(s，9H)，1.48-1.75(m，7H)，3.10(t，J＝6.4Hz，2H)，3.72(brs，1H)，4.42-4.76(m，1H)，4.76-4.92(m，1H)，5.09(s，2H)，7.27-7.38(m，5H).

Step C: synthetic (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester.

To [cis-4-(benzyloxycarbonyl amino-methyl)-cyclohexyl]-carboxylamine tertiary butyl ester (12.9g, the EtOAc solution (129mL) of adding 4M hydrogenchloride in EtOAc 35.6mmol) (129mL) solution.Stirred reaction mixture is 3 hours under room temperature, filters, with the EtOAc washing, through drying under reduced pressure.This solid is dissolved in the saturated sodium bicarbonate aqueous solution.With waterbearing stratum CHCl ₃Extract (5 times).The organic layer that merges filters, concentrates through dried over mgso, and drying under reduced pressure obtains (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (8.88g, 95%), is colorless oil.

ESI?MS?m/e?263，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.36-1.98(m，9H)，2.96-3.32(m，3H)，5.12(brs，3H)，7.36(s，5H).

Step D: synthetic (cis-4-amino methyl-cyclohexyl)-quinoline-2-base-amine.

(10.0g, 61.1mmol) (17.6g stirred 2 days under 67.2mmol) mixture in butanols (10mL) refluxes with (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester with 2-chloro-quinoline.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (NH-silica gel, the hexane solution of 33%-50%EtOAc), obtains faint yellow oily thing.In the MeOH of above-mentioned oily matter (100mL) solution, add 10%Pd/C (1.00g).Under room temperature, nitrogen atmosphere, stirred this mixture 1.5 days.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 2%MeOH ₃Solution), obtain (cis-4-amino methyl-cyclohexyl)-quinoline-2-base-amine (6.20g, 40%), be faint yellow solid.

ESI?MS?m/e?256，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.12-1.51(m，4H)，1.59-1.93(m，5H)，2.60(d，J＝6.2Hz，2H)，4.08-4.20(m，1H)，4.94(d，J＝7.4Hz，1H)，6.65(d，J＝9.0Hz，1H)，7.18(ddd，J＝7.9，6.8，1.1Hz，1H)7.47-7.59(m，2H)，7.61-7.67(m，1H)7.81(d，J＝8.9Hz，1H).

Step e: synthesize 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt.

(300mg, 1.17mmol) with 3, (223mg adds Et in DMF 1.41mmol) (3mL) solution to 4-two fluoro-phenylformic acid to cis-(4-amino methyl-cyclohexyl)-quinoline-2-base-amine ₃N (0.40mL, 2.87mmol), HOBt-water (270mg, 1.76mmol) and EDC-HCl (270mg, 1.41mmol).Stirred reaction mixture is 16 hours under room temperature.In reaction mixture, add entry (20mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).The EtOAc (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stir this mixture 2 hours, filter, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 3,4-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt (390mg, 77%), be white solid.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.08(m，9H)，3.48-3.56(m，2H)，3.98-4.09(m，1H)，6.92-7.07(m，2H)，7.18-7.29(m，1H)，7.39-7.47(m，1H)，7.67-7.76(m，3H)，7.81-7.93(m，2H)，8.15(d，J＝9.6Hz，1H)，9.86-9.95(m，1H).

Embodiment 3069

2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-phenoxy group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl methyl]-the niacinamide hydrochloride.

Adopt the method for the step e of embodiment 3068, obtain title compound.

ESI?MS?m/e?475，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.54-2.02(m，9H)，3.42-3.52(m，2H)，3.91-4.05(m，1H)，6.91(d，J＝9.5Hz，1H)，7.10-7.20(m，3H)，7.23-7.31(m，1H)，7.38-7.50(m，3H)，7.65-7.82(m，3H)，8.06-8.17(m，2H)，8.20(dd，J＝4.7，2.0Hz，1H)8.60(dd，J＝7.7，1.9Hz，1H)，9.65-9.78(m，1H).

Embodiment 3070

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride steps A: synthetic N-(cis-4-methyl-quinoline-2-yl)-hexanaphthene-1,4-diamines.

With 2-chloro-4-methyl-quinoline (10.0g, 56.3mmol) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester that in embodiment 3031 step B, obtains (13.3g, the 62.1mmol) stirring down 7 days that refluxes of the mixture in IPA (10mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc), obtain faint yellow oily thing.The EtOAc (150mL) that in the EtOAc of above-mentioned substance (150mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is dissolved in the 1M NaOH aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, through in press liquid chromatography purification (NH-silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain N-(cis-4-methyl-quinoline-2-yl)-hexanaphthene-1,4-diamines (3.41g, 24%) is faint yellow solid.

ESI?MS?m/e?256，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.19-1.55(m，4H)，1.67-1.94(m，4H)，2.56(s，3H)，2.85-2.98(m，1H)，4.03-4.15(m，1H)，4.77(d，J＝6.8Hz，1H)，6.49(s，1H)，7.17-7.25(m，1H)，7.47-7.55(m，1H)，7.62-7.68(m，1H)，7.72-7.77(m，1H).

Step B: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

To N-(cis-4-methyl-quinoline-2-yl)-hexanaphthene-1,4-diamines (300mg, CHCl 1.17mmol) ₃(2mL) add Et in the solution ₃(0.45mL is 2.60mmol) with 2-phenoxy group-nicotinoyl chlorine (411mg, CHCl 1.76mmol) for N ₃(1mL) solution.Under room temperature, stirred this mixture 14 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc), obtain a kind of colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (85mg, 15%), be white solid.

ESI?MS?m/e?453，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.85-2.12(m，8H)，2.70(s，3H)，3.83-4.00(m，1H)，4.11-4.28(m，1H)，6.74(s，1H)，7.08-7.18(m，1H)，7.19-7.34(m，3H)，7.38-7.53(m，3H)，7.63-7.85(m，3H)，7.91-7.99(m，1H)，8.20-8.24(m，1H)，8.54(d，J＝7.4Hz，1H).

Embodiment 3071

3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

To 3, (222mg, 1.40mmol) and the N-that obtains in the steps A of embodiment 3070 (cis-4-methyl-quinoline-2-yl)-hexanaphthene-1, (300mg adds Et in DMF 117mmol) (3mL) solution to the 4-diamines to 4-two fluoro-phenylformic acid ₃N (0.39mL, 2.80mmol), HOBt-water (268mg, 1.76mmol) and EDC-HCl (268g, 1.40mmol).Stirred reaction mixture is 12 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc and silica gel, the CHCl of 2%-5%MeOH in the warp ₃Solution), obtain yellow oil.The EtOAc solution (0.5mL) that in the EtOAc of above-mentioned substance (8mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (377mg, 75%), be white solid.

ESI?MS?m/e?396，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.75-2.17(m，8H)，2.73(s，3H)，3.95-4.26(m，2H)，6.71(d，J＝7.1Hz，1H)，6.79(s，1H)，7.14-7.28(m，1H)，7.41-7.51(m，1H)，7.54-7.64(m，1H)，7.66-7.79(m，3H)，7.85(d，J＝8.2Hz，1H)，9.57-9.67(m，1H).

Embodiment 3072

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the urea hydrochloride.

To the N-that in the steps A of embodiment 3070, obtains (cis-4-methyl-quinoline-2-yl)-hexanaphthene-1, the 4-diamines (300mg adds 1 in DMSO 1.17mmol) (3mL) solution, and 2-two chloro-3-isocyanato-benzene (242mg, 1.29mmol).Under room temperature, stirred this mixture 5 hours, in the impouring water (20mL).Filter the collecting precipitation thing, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-33%EtOAc) and flash chromatography purifying (silica gel, the CHCl of 2%MeOH in the warp ₃Solution), obtain faint yellow oily thing.EtOAc (0.2mL) solution that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Just described residue is at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-urea hydrochloride (421mg, 68%), be white solid.

ESI?MS?m/e?465，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.76-2.17(m，8H)，2.70(s，3H)，3.69-4.08(m，2H)，6.65-6.83(m，2H)，6.95-7.17(m，2H)，7.41(t，J＝8.1Hz，1H)，7.54-7.89(m，4H)，8.05-8.17(m，1H)，9.13-9.27(m，1H).

Embodiment 3073

3-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

To the N-that in the steps A of embodiment 3070, obtains (cis-4-methyl-quinoline-2-yl)-hexanaphthene-1,4-diamines (300mg, CHCl 1.17mmol) ₃(3mL) add Et in the solution ₃N (0.35mL, 2.51mmol) and 3-chloro-Benzoyl chloride (226mg, 1.29mmol).Under room temperature, stirred this mixture 1.5 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).The EtOAc solution (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, concentrate.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 3-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (441mg, 87%), be white solid.

ESI?MS?m/e?416，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.11(m，8H)，2.72(s，3H)，3.92-4.29(m，2H)，6.78(s，1H)，6.94(d，J＝9.0Hz，1H)，7.33-7.50(m，3H)，7.68-7.76(m，3H)，7.83-7.88(m，2H)，9.58(d，J＝9.0Hz，1H).

Embodiment 3074

5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?411，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.14(m，8H)，2.73(s，3H)，3.97-4.26(m，2H)，6.79(s，1H)，7.41-7.57(m，2H)，7.68-7.76(m，2H)，7.85(d，J＝8.2Hz，1H)，8.26(d，J＝1.4Hz，1H)，8.38(d，J＝1.4Hz，1H)，9.41(d，J＝9.0Hz，1H).

Embodiment 3075

3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?374，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.10(m，8H)，2.41(s，3H)，2.72(d，J＝0.8Hz，3H)，3.94-4.05(m，1H)，4.08-4.25(m，1H)，6.62(d，J＝8.1Hz，1H)，6.78(s，1H)，7.28-7.36(m，2H)，7.42-7.49(m，1H)，7.58-7.66(m，2H)，7.67-7.79(m，2H)，7.84(d，J＝8.1Hz，1H)，9.62(d，J＝8.1Hz，1H).

Embodiment 3076

3-methoxyl group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-methoxyl group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?390，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.10(m，8H)，2.72(s，3H)，3.87(s，3H)，3.94-4.26(m，2H)，6.69-6.81(m，2H)，6.99-7.07(m，1H)，7.28-7.51(m，4H)，7.66-7.79(m，2H)，7.84(d，J＝7.9Hz，1H)，9.55-9.68(m，1H).

Embodiment 3077

4-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?385，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.79-2.16(m，8H)，2.73(d，J＝0.9Hz，3H)，3.99-4.29(m，2H)，6.79(s，1H)，7.20-7.28(m，1H)，7.42-7.51(m，1H)，7.69-7.76(m，4H)，7.86(d，J＝8.2Hz，1H)，7.95-8.02(m，2H)，9.54(d，J＝8.9Hz，1H).

Embodiment 3078

3,4-two chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?428，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.14(m，8H)，2.73(d，J＝0.6Hz，3H)，3.95-4.24(m，2H)，6.75-6.87(m，2H)，7.42-7.52(m，2H)，7.64-7.76(m，3H)，7.85(d，J＝8.2Hz，1H)，7.98(d，J＝1.9Hz，1H)，9.60(d，J＝7.9Hz，1H).

Embodiment 3079

3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?412，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.79-2.14(m，8H)，2.73(d，J＝0.8Hz，3H)，3.96-4.26(m，2H)，6.70-6.82(m，2H)，7.18(t，J＝8.6Hz，1H)，7.42-7.51(m，1H)，7.68-7.78(m，3H)，7.85(d，J＝8.2Hz，1H)，7.96(dd，J＝7.0，2.2Hz，1H)，9.61(d，J＝8.4Hz，1H).

Embodiment 3080

4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?414，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.73-2.10(m，8H)，2.33(d，J＝1.9Hz，3H)，2.72(s，3H)，3.95-4.25(m，2H)，6.45-6.54(m，1H)，6.78(s，1H)，7.00-7.08(m，1H)，7.42-7.50(m，1H)，7.60-7.80(m，4H)，7.84(d，J＝8.6Hz，1H)，9.58-9.70(m，1H).

Embodiment 3081

1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?408，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.11(m，8H)，2.72(s，3H)，3.94-4.14(m，5H)，6.77(s，1H)，7.09-7.16(m，1H)，7.26-7.29(m，1H)，7.41-7.55(m，2H)，7.67-7.78(m，2H)，7.84(d，J＝8.2Hz，1H)，9.51-9.63(m，1H).

Embodiment 3082

9H-xanthene-9-carboxylic acid-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?486，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.63-1.91(m，8H)，2.68(s，3H)，3.75-3.97(m，2H)，4.88(s，1H)，6.14-6.27(m，1H)，6.69(brs，1H)，7.03-7.18(m，4H)，7.23-7.49(m，5H)，7.62-7.86(m，3H)，9.34-9.47(m，1H).

Embodiment 3083

5-bromo-furans-2-carboxylic acid-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-bromo-furans-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?428，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-2.08(m，8H)，2.72(s，3H)，3.90-4.19(m，2H)，6.42(d，J＝3.6Hz，1H)，6.67-6.80(m，2H)，7.05(d，J＝3.6Hz，1H)，7.41-7.51(m，1H)，7.67-7.81(m，2H)，7.85(d，J＝8.4Hz，1H)，9.59-9.72(m，1H).

Embodiment 3084

N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-acetamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-between-tolyloxy-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?426，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.75-2.07(m，8H)，2.34(s，3H)，2.72(s，3H)，3.86-4.14(m，2H)，4.46(s，2H)，6.70-6.95(m，5H)，7.15-7.24(m，1H)，7.41-7.50(m，1H)，7.67-7.88(m，3H)，9.58-9.69(m，1H).

Embodiment 3085

Benzo [2,1,3] oxadiazole-5-carboxylic acids-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic benzo [2,1,3] oxadiazole-5-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3073, obtain title compound.

ESI?MS?m/e?402，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.79-2.28(m，8H)，2.73(s，3H)，3.98-4.11(m，1H)，4.12-4.32(m，1H)，6.79(s，1H)，7.37-7.50(m，2H)，7.71(s，1H)，7.72(s，1H)，7.81-7.96(m，3H)，8.40(s，1H)，9.56(d，J＝8.7Hz，1H).

Embodiment 3086

3-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3073, obtain title compound.

ESI?MS?m/e?438，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.13(m，8H)，2.72(s，3H)，3.96-4.06(m，1H)，4.08-4.26(m，1H)，6.75-6.85(m，2H)，7.26-7.34(m，1H)，7.42-7.50(m，1H)，7.57-7.64(m，1H)，7.66-7.79(m，3H)，7.85(d，J＝8.2Hz，1H)，8.01(s，1H)，9.55-9.66(m，1H).

Embodiment 3087

3-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-cyano group-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3073, obtain title compound.

ESI?MS?m/e?385，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.18(m，8H)，2.73(s，3H)，3.98-4.29(m，2H)，6.80(s，1H)，7.13-7.22(m，1H)，7.43-7.60(m，2H)，7.68-7.79(m，3H)，7.85(d，J＝8.1Hz，1H)，8.08(d，J＝7.2Hz，1H)，8.22(s，1H)，9.49-9.62(m，1H).

Embodiment 3088

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3073, obtain title compound.

ESI?MS?m/e?428，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.14(m，8H)，2.73(s，3H)，3.95-4.09(m，1H)，4.12-4.31(m，1H)，6.79(s，1H)，6.85-6.99(m，1H)，7.43-7.50(m，1H)，7.57(t，J＝7.8Hz，1H)，7.64-7.79(m，3H)，7.85(d，J＝8.2Hz，1H)，8.01(d，J＝7.8Hz，1H)，8.15(s，1H)，9.56-9.68(m，1H).

Embodiment 3089

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2,2-phenylbenzene-acetamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2,2-phenylbenzene-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3073, obtain title compound.

ESI?MS?m/e?472，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.56-2.10(m，8H)，2.51-2.87(m，3H)，3.81-4.16(m，2H)，4.94(s，1H)，6.40-6.88(m，2H)，7.17-7.51(m，11H)，7.63-7.89(m，3H)，9.44(brs，1H).

Embodiment 3090

2-(4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?493，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.85-2.12(m，8H)，2.71(s，3H)，3.87-4.00(m，1H)，4.11-4.30(m，1H)，6.76(brs，1H)，7.09-7.21(m，3H)，7.24-7.35(m，2H)，7.44(t，J＝7.1Hz，1H)，7.65-7.99(m，4H)，8.19-8.25(m，1H)，8.54(d，J＝6.2Hz，1H)，9.60-9.73(m，1H).

Embodiment 3091

2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(3,4-two fluoro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?511，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.13(m，8H)，2.71(s，3H)，3.90-4.03(m，1H)，4.13-4.30(m，1H)，6.76(s，1H)，7.10-7.51(m，5H)，7.65-7.88(m，4H)，8.18-8.27(m，1H)，8.50-8.58(m，1H)，9.67-9.81(m，1H).

Embodiment 3092

N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-is right-tolyloxy-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?489，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.83-2.15(m，8H)，2.36(s，3H)，2.71(s，3H)，3.78-4.03(m，1H)，4.10-4.32(m，1H)，6.67-6.84(m，1H)，7.06-7.51(m，6H)，7.62-7.90(m，3H)，7.95-8.08(m，1H)，8.19-8.30(m，1H)，8.48-8.61(m，1H)，9.62(brs，1H).

Embodiment 3093

2-(4-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?487，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.58-2.13(m，8H)，2.71(s，3H)，3.87-4.02(m，1H)，4.10-4.31(m，1H)，6.75(brs，1H)，7.15(dd，J＝7.5，4.8Hz，1H)，7.22-7.33(m，2H)，7.37-7.49(m，3H)，7.64-7.92(m，4H)，8.21(dd，J＝4.8，2.0Hz，1H)，8.53(dd，J＝7.6，2.0Hz，1H)，9.63-9.78(m，1H).

Embodiment 3094

2-(4-bromo-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-bromo-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?531，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.20(m，8H)，2.72(s，3H)，3.83-4.31(m，2H)，6.66-6.85(m，1H)，7.03-7.93(m，10H)，8.16-8.28(m，1H)，8.46-8.61(m，1H)，9.55-9.61(m，1H).

Embodiment 3095

2-(4-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(4-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?483，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.84-2.19(m，8H)，2.71(s，3H)，3.74-4.00(m，4H)，4.12-4.28(m，1H)，6.68-6.82(m，1H)，6.91-7.30(m，5H)，7.38-7.50(m，1H)，7.63-7.88(m，3H)，7.96-8.09(m，1H)，8.17-8.33(m，1H)，8.48-8.61(m，1H)，9.50-9.70(m，1H).

Embodiment 3096

2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?505，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.13(m，8H)，2.71(s，3H)，3.89-4.02(m，1H)，4.13-4.29(m，1H)，6.76(brs，1H)，7.17(dd，J＝7.6，4.8Hz，1H)，7.22-7.49(m，4H)，7.65-7.87(m，4H)，8.21(dd，J＝4.8，2.0Hz，1H)，8.52(dd，J＝7.6，2.0Hz，1H)，9.65-9.77(m，1H).

Embodiment 3097

N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-2-between-tolyloxy-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-2-between-tolyloxy-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?467，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.85-2.10(m，8H)，2.40(s，3H)，2.70(s，3H)，3.84-3.98(m，1H)，4.10-4.24(m，1H)，6.76(brs，1H)，7.00-7.21(m，4H)，7.28-7.48(m，2H)，7.62-7.87(m，3H)，7.94-8.06(m，1H)，8.21-8.29(m，1H)，8.53(d，J＝6.4Hz，1H)，9.51-9.64(m，1H).

Embodiment 3098

2-(3-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3-methoxyl group-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?442，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.71-2.06(m，8H)，2.72(s，3H)，3.82(s，3H)，3.89-4.11(m，2H)，4.46(s，3H)，6.52-6.61(m，3H)，6.75(s，1H)6.84-6.92(m，1H)，7.16-7.24(m，1H)，7.41-7.49(m，1H)，7.67-7.80(m，1H)，7.84(d，J＝8.2Hz，1H)，9.57-9.70(m，1H).

Embodiment 3099

2-(3-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3-chloro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?446，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.06(m，8H)，2.72(s，3H)，3.91-4.13(m，2H)，4.45(s，2H)，6.73-7.03(m，5H)，7.19-7.28(m，1H)，7.41-7.50(m，1H)，7.67-7.87(m，3H)，9.58-9.72(m，1H).

Embodiment 3100

2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3-chloro-4-fluoro-phenoxy group)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?464，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.70-2.07(m，8H)，2.72(s，3H)，3.91-4.14(m，2H)，4.42(s，2H)，6.76(s，1H)，6.83-6.95(m，2H)，6.99-7.16(m，2H)，7.42-7.50(m，1H)，7.67-7.80(m，2H)，7.84(d，J＝7.9Hz，1H)，9.59-9.70(m，1H).

Embodiment 3101

2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?480，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.13(m，8H)，2.72(s，3H)，3.91-4.14(m，2H)，4.44(s，2H)，6.76(brs，1H)，6.84-6.93(m，2H)，7.09(d，J＝2.8Hz，1H)，7.37(d，J＝8.9Hz，1H)，7.42-7.49(m，1H)，7.67-7.80(m，2H)，7.84(d，J＝8.1Hz，1H)，9.54-9.72(m，1H).

Embodiment 3102

C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?403，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-1.99(m，8H)，2.70(s，3H)，3.11(s，3H)，3.76-4.06(m，4H)，6.63-7.01(m，4H)，7.08-7.50(m，4H)，7.60-7.92(m，3H)，9.34-9.51(m，1H).

Embodiment 3103

2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: Synthetic 2-(3,4-two chloro-phenyl aminos)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?479，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.75-2.02(m，8H)，2.71(s，3H)，3.74-4.08(m，4H)，6.45-6.56(m，1H)，6.67-6.78(m，2H)，7.04-7.19(m，2H)，7.39-7.50(m，1H)，7.62-7.87(m，3H)，9.31-9.46(m，1H).

Embodiment 3104

3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt

Steps A: synthetic (cis-4-amino methyl-cyclohexyl)-(4-methyl-quinoline-2-yl)-amine.

With 2-chloro-4-methyl-quinoline (10.0g, 56.3mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester that in the step C of embodiment 3068, obtains (17.7g, the 67.6mmol) stirring down 5 days that refluxes of the mixture in butanols (10mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 10%-20%EtOAc and silica gel, the CHCl of 2%-10%MeOH ₃Solution), obtain faint yellow oily thing.In the MeOH of above-mentioned oily matter (140mL) solution, add 10%Pd/C (1.40g).Under room temperature, nitrogen atmosphere, stirred this mixture 6 days.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 2%-10%MeOH ₃Solution), obtain (cis-4-amino methyl-cyclohexyl)-(4-methyl-quinoline-2-yl)-amine (5.74g, 38%), be faint yellow solid.

ESI?MS?m/e?470，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.14-1.51(m，4H)，1.60-1.94(m，5H)，2.56(s，3H)，2.60(d，J＝6.4Hz，2H)，4.08-4.22(m，1H)，4.82-4.92(m，1H)，6.52(s，1H)，7.17-7.24(m，1H)，7.47-7.54(m，1H)，7.62-7.67(m，1H)，7.72-7.77(m，1H).

Step B: synthesize 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt.

To (cis-4-amino methyl-cyclohexyl)-(4-methyl-quinoline-2-yl)-amine (300mg, CHCl 0.90mmol) ₃(2mL) add i-Pr in the solution ₂NEt (0.33mL, 1.89mmol) with 3,4-two fluoro-Benzoyl chlorides (175mg, CHCl 0.99mmol) ₃(1mL) solution.Under room temperature, stirred this mixture 6 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-25%EtOAc).Obtain a kind of colorless oil.The EtOAc (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-benzamide hydrochloride salt (289mg, 72%), be white solid.

ESI?MS?m/e?432，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.56-2.05(m，9H)，2.70(s，3H)，3.49-3.54(m，2H)，3.97-4.09(m，1H)，6.75(s，1H)，6.89-6.98(m，1H)，7.19-7.30(m，1H)，7.40-7.47(m，1H)，7.66-7.75(m，2H)，7.79-7.93(m，3H)，9.72-9.85(m，1H).

Embodiment 3105

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the step C of embodiment 3104, obtain title compound.

ESI?MS?m/e?467，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-2.14(m，9H)，2.69(s，3H)，3.42-3.50(m，2H)，3.92-4.04(m，1H)，6.73(brs，1H)，7.10-7.32(m，4H)，7.38-7.49(m，3H)，7.64-7.84(m，3H)，8.06-8.15(m，1H)，8.19-8.24(m，1H)，8.57-8.63(m，1H)，9.49-9.62(m，1H).

Embodiment 3106

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride.

To (cis-4-amino methyl-cyclohexyl) that in the step B of embodiment 3014, obtain-(4-methyl-quinoline-2-yl)-amine (300mg adds 1 in DMSO 1.11mmol) (3mL) solution, 2-two chloro-3-isocyanato-benzene (230mg, 1.22mmol).Under room temperature, stirred this mixture 21 hours, in the impouring water (20mL).Filter the collecting precipitation thing, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc) in the warp obtains faint yellow oily thing.The EtOAc (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl methyl]-urea hydrochloride (247mg, 45%), be white solid.

ESI?MS?m/e?479，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.51-2.18(m，9H)，2.71(d，J＝0.8Hz，3H)，3.37-3.44(m，2H)，4.04-4.14(m，1H)，6.78(s，1H)，6.89-7.13(m，3H)，7.42-7.50(m，1H)，7.70-7.76(m，2H)，7.84(d，J＝8.1Hz，1H)，8.13-8.22(m，2H)，9.38(d，J＝9.2Hz，1H)，13.95(brs，1H).

Embodiment 3107

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthesize 5,6,7,8-tetrahydrochysene-quinazoline-2,4-glycol.

To 2-oxo-hexahydrobenzoic acid ethyl ester (61.5g, add in EtOH 361mmol) (61.5mL) solution urea (73.8g, 1.23mol).This mixture backflow was stirred 10.5 days down, under room temperature, stirred 30 minutes.Filtering-depositing is with washing with acetone and dry.The suspension of above-mentioned solid in water (100mL) was stirred on ice bath 1 hour.Filtering-depositing is used hexane wash, and drying under reduced pressure obtains 5,6,7,8-tetrahydrochysene-quinazoline-2, and 4-glycol (21.0g, 35%) is faint yellow solid.

CI?MS?m/e?167，M+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.48-1.71(m，4H)，2.09-2.19(m，2H)，2.24-2.34(m，2H)，10.41-10.98(m，2H).

Step B: synthetic (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-dimethyl-amine.

With 5,6,7,8-tetrahydrochysene-quinazoline-2, (20.9g is 100mmol) at POCl for the 4-glycol ₃Suspension (105mL) stirred 2 hours under refluxing, concentrated reaction mixture.In residue impouring frozen water.(3 times) are extracted with EtOAc in the waterbearing stratum.The organic layer that merges filters and concentrates through dried over mgso.In the THF of residue (7.00g) (70mL) solution, add 50%Me ₂(7.77g 86.2mmol), stirred this mixture 2 hours to the aqueous solution of NH under room temperature.In reactant, add saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (silica gel, the hexane solution of 20%EtOAc), obtains (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-dimethyl-amine (6.08g, 64%), is white solid.

ESI?MS?m/e?234，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-1.90(m，4H)，2.59(t，J＝6.0Hz，2H)，2.76(t，J＝6.6Hz，2H)，3.06(s，6H).

Step C: synthetic (cis-4-amino-cyclohexyl)-carboxylamine benzyl ester.

To (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (75.0g, CHCl 350mmol) that in embodiment 3031 step B, obtain ₃(750mL) add Et in the solution ₃N (53.7mL, 385mmol) and benzyl chloroformate (55mL, 385mmol).Under room temperature, stirred this mixture 20 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (silica gel, the CHCl of 0.4%-5%MeOH ₃Solution), obtain faint yellow oily thing.EtOAc (200mL) solution that in the EtOAc of described residue (200mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 2 hours.Residue is dissolved in the 1MNaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (silica gel, the hexane solution of 25%-50%EtOAc).Obtain (cis-4-amino-cyclohexyl)-carboxylamine benzyl ester (37.6g, 43%), be light brown oily thing.

ESI?MS?m/e?249，M ⁺+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.13-1.83(m，8H)，2.77-2.97(m，1H)，3.63-3.83(m，1H)，4.92-5.20(m，3H)，7.25-7.47(m，5H).

Step D: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines.

(16.0g, 75.7mmol) (18.8g, 75.7mmol) mixture in butanols (21mL) stirred 6 days under refluxing with (cis-4-amino-cyclohexyl)-carboxylamine benzyl ester with (2-chloro-5,6,7,8-tetrahydrochysene-quinazoline-4-yl)-dimethyl-amine.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (NH-silica gel, the hexane solution of 33%-50%EtOAc) through dried over mgso.Obtain faint yellow oily thing.In the MeOH of above-mentioned oily matter (270mL) solution, add 10%Pd/C (2.70g).Under room temperature, nitrogen atmosphere, stirred this mixture 1.5 days.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines (15.8g, 72%) is faint yellow solid.

FAB?MS?m/e?290，M ⁺+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.00-1.90(m，14H)，2.49(t，J＝5.9Hz，2H)，2.61(t，J＝6.6Hz，2H)，2.71-3.00(m，7H)，3.93-4.07(m，1H)，4.67-4.80(m，1H).

Step e: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

To N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines (300mg, CHCl 1.04mmol) ₃(3mL) add Et in the solution ₃N (0.31mL, 2.22mmol) and 2-phenoxy group-nicotinoyl chlorine (266mg, 1.14mmol).Under room temperature, stirred this mixture 3 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc).The EtOAc (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (159mg, 29%), be white solid.

ESI?MS?m/e?487，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-1.98(m，12H)，2.54(t，J＝5.9Hz，2H)，2.74(t，J＝6.5Hz，2H)，3.20(s，6H)，4.02-4.20(m，2H)，7.12(dd，J＝7.5，4.8Hz，1H)，7.21-7.30(m，3H)，7.42-7.50(m，2H)，7.87-7.93(m，1H)，8.21(dd，J＝4.8，2.2Hz，1H)，8.25-8.32(m，1H)，8.52(dd，J＝7.6，2.0Hz，1H)，13.18(s，1H).

Embodiment 3108

3-chloro-N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the step e of embodiment 3107, obtain title compound.

ESI?MS?m/e?468，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-2.00(m，12H)，2.51-2.61(m，2H)，2.68-2.81(m，2H)，3.23(s，6H)，4.02-4.26(m，2H)，6.73-6.90(m，1H)，7.13-7.23(m，1H)，7.65-7.82(m，1H)，7.96(d，J＝6.8Hz，1H)，8.22-8.44(m，1H)，12.63-12.89(m，1H).

Embodiment 3109

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride salt.

Adopt the method for the step e of embodiment 3107, obtain title compound.

ESI?MS?m/e?448，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.60-2.04(m，12H)，2.27-2.36(m，3H)，2.50-2.61(m，2H)，2.65-2.84(m，2H)，3.23(s，6H)，4.03-4.27(m，2H)，6.42-6.58(m，1H)，6.96-7.11(m，1H)，7.56-7.75(m，2H)，8.25-8.47(m，1H).

Embodiment 3110

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride salt.

Adopt the method for the step e of embodiment 3107, obtain title compound.

ESI?MS?m/e?476，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.63-2.04(m，12H)，2.51-2.62(m，2H)，2.66-2.86(m，2H)，3.23(s，6H)，3.85(s，6H)，4.04-4.27(m，2H)，6.50-6.70(m，2H)，6.95(brs，2H)，8.19-8.47(m，1H).

Embodiment 3111

Benzo [2,1,3] oxadiazole-5-carboxylic acids-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic benzo [2,1,3] oxadiazole-5-carboxylic acids-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the step e of embodiment 3107, obtain title compound.

ESI?MS?m/e?458，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-2.01(m，12H)，2.56(t，J＝5.8Hz，2H)，2.71(t，J＝6.5Hz，2H)，3.23(s，6H)，4.04-4.27(m，2H)，7.71(d，J＝8.2Hz，1H)，7.85(dd，J＝9.5，1.1Hz，1H)，7.91-7.96(m，1H)，8.27(d，J＝8.1Hz，1H)，8.42(t，J＝1.2Hz，1H).

Embodiment 3112

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3-nitro-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3-nitro-benzamide hydrochloride salt.

Adopt the method for the step e of embodiment 3107, obtain title compound.

ESI?MS?m/e?461，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.04(m，12H)，2.50-2.85(m，4H)，3.24(s，6H)，4.11-4.29(m，2H)，7.04-7.20(m，1H)，7.56-7.68(m，1H)，8.13-8.38(m，3H)，8.72-8.79(m，1H).

Embodiment 3113

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines.

(cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester (3.10g that will in the step C of embodiment 3068, obtain, 11.8mmol) and (the 2-chloro-5 that in the step B of embodiment 3107, obtains, 6,7,8-tetrahydrochysene-quinazoline-4-yl)-(2.00g, 9.44mmol) mixture in butanols (3mL) stirred 19 hours under refluxing dimethyl-amine.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (NH-silica gel, the hexane solution of 33%-50%EtOAc), obtains faint yellow oily thing.In the MeOH of above-mentioned oily matter (2.48g) (25mL) solution, add 10%Pd/C (248mg).Under 50 ℃, nitrogen atmosphere, this mixture was stirred 8 hours.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2,4-diamines (1.70g, 59%) is faint yellow solid.

FAB MS m/e 304, M (dissociating)+H ⁺

Step B: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI MS m/e 501, M (dissociating)+H ⁺

Embodiment 3114

N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: Synthetic 2,4-two chloro-quinoline.

With quinoline-2, (150g is 931mmol) at POCl for the 4-glycol ₃(975mL, 10.4mol) suspension in stirred 6 hours under refluxing, concentrated reaction mixture.With residue CHCl ₃(500mL) dilution is in this solution impouring frozen water.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates, through flash chromatography purifying (silica gel, the hexane solution of 20%EtOAc) through dried over mgso.Obtain 2,4-two chloro-quinoline (177g, 96%) are the light brown solid.

EI?MS?m/e?197，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ7.50(s，1H)，7.65(ddd，J＝8.3，7.0，1.3Hz，1H)，7.79(ddd，J＝8.5，7.0，1.3Hz，1H)，8.00-8.06(m，1H)，8.16-8.21(m，1H).

Step B: synthetic (2-chloro-quinolyl-4)-dimethyl-amine.

To 2, (177g adds 50%Me in THF 894mmol) (2.1L) solution to 4-two chloro-quinoline ₂The aqueous solution of NH (234mL, 2.23mol).Under room temperature, stirred this mixture 68 hours.In this mixture, add 50%Me ₂(47mL 448mmol), stirred 3 hours under room temperature the aqueous solution of NH.In this solution impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 1%-3%EtOAc), obtain (2-chloro-quinolyl-4)-dimethyl-amine (75.9g for faint yellow oily thing, 41%) and be (the 4-chloro-quinoline-2-yl)-dimethyl-amine (28.0g, 15%) of faint yellow oily thing.

(2-chloro-quinolyl-4)-dimethyl-amine;

ESI?MS?m/e?207，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.06(s，6H)，6.71(s，1H)，7.45(ddd，J＝8.4，7.0，1.2Hz，1H)，7.63(ddd，J＝8.4，6.9，1.5Hz，1H)，7.91-7.93(m，1H)，7.97-8.03(m，1H).

(4-chloro-quinoline-2-yl)-dimethyl-amine;

ESI?MS?m/e?207，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.18(s，6H)，6.97(brs，1H)，7.18-7.31(m，1H)，7.49-7.63(m，1H)，7.66-7.72(m，1H)，7.95-8.00(m，1H).

Step C: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines.

With (2-chloro-quinolyl-4)-dimethyl-amine (15.6g, 75.7mmol) and (cis-4-amino-cyclohexyl)-carboxylamine benzyl ester of in the step C of embodiment 3107, obtaining (18.8g, the 75.7mmol) stirring down 6 days that refluxes of the mixture in butanols (20mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (NH-silica gel, the hexane solution of 33%-50%EtOAc), obtains faint yellow oily thing.In the MeOH of above-mentioned oily matter (170mL) solution, add 10%Pd/C (1.70g).Under room temperature, nitrogen atmosphere, stirred this mixture 1.5 days.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain N ²-(cis-4-amino-cyclohexyl-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines (11.7g, 55%) is faint yellow solid.

FAB?MS?m/e?285，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.19-1.96(m，10H)，2.81-3.03(m，7H)，4.02-4.17(m，1H)，4.66-4.83(m，1H)，6.03(s，1H)，7.06-7.21(m，1H)，7.39-7.52(m，1H)，7.55-7.67(m，1H)，7.80-7.90(m，1H).

Step D: synthetic N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

To N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines (300mg, CHCl 1.05mmol) ₃(3mL) add Et in the solution ₃N (0.31mL, 2.22mmol) and 2-phenoxy group-nicotinoyl chlorine (271mg, 1.16mmol).Under room temperature, stirred this mixture 3 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc).The EtOAc (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (160mg, 29%), be white solid.

ESI?MS?m/e?482，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.15(m，8H)，3.21(s，6H)，3.73-3.88(m，1H)，4.06-4.27(m，1H)，5.79(s，1H)，7.12(dd，J＝7.6，4.8Hz，1H)，7.19-7.33(m，4H)，7.41-7.71(m，4H)，7.81-7.97(m，2H)，8.21(dd，J＝4.8，2.0Hz，1H)，8.52(dd，J＝7.6，2.0Hz，1H)，8.94-9.08(m，1H)，13.81(brs，1H).

Embodiment 3115

N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

In sealed tube, to in the steps A of embodiment 3114, obtain 2,4-two chloro-quinoline (1.5g, 7.57mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy group-niacinamide of in the steps A of embodiment 2, obtaining (2.3g, 7.57mmol) mixture in butanols (2mL) stirred 3 days in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc), obtain colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing, in 60 ℃ of drying under reduced pressure, obtain N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (295mg, 8%), be white solid, and N-[cis-4-(2-chloro-quinolyl-4 amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (283mg, 7%), be white solid.

N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride;

ESI?MS?m/e?495，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.86-2.10(m，8H)，3.82-3.96(m，1H)，4.13-4.28(m，1H)，7.04(s，1H)，7.10-7.34(m，4H)，7.41-7.55(m，3H)，7.71-7.84(m，2H)，7.92-8.11(m，2H)，8.20-8.26(m，1H)，8.50-8.59(m，1H)，9.83(brs，1H).

N-[cis-4-(2-chloro-quinolyl-4 amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride;

ESI?MS?m/e?495，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.72-2.37(m，8H)，3.64-3.84(m，1H)，4.36(brs，1H)，6.33(brs，1H)，7.05-7.60(m，8H)，8.06-8.66(m，6H).

Embodiment 3116

3,4-two fluoro-N-[cis-4-(4-methoxy yl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2-chloro-quinoline-4-alcohol.

To in the steps A of embodiment 3114, obtain 2,4-two chloro-quinoline (3.00g, 15.1mmol) and MeOH (485mg, 15.1mmol) mixture in butanols (3mL) stirred 3 hours under refluxing.Make reaction mixture be suspended in CHCl ₃(15mL), under room temperature, stirred 30 minutes.Filter the collecting precipitation thing, use CHCl ₃Washing in 50 ℃ of drying under reduced pressure, obtains 2-chloro-quinoline-4-alcohol (1.47g, 54%), is faint yellow solid.

ESI?MS?m/e?179，M ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ6.83(s，1H)，7.27-7.43(m，2H)，7.60-7.67(m，1H)，7.86(d，J＝7.9Hz，1H)，12.05(brs，1H).

Step B: Synthetic 2-chloro-4-methoxy yl-quinoline.

To 2-chloro-quinoline-4-alcohol (500mg, add in DMF 2.78mmol) (5mL) solution salt of wormwood (462mg, 3.37mmol) and MeI (210 μ L, 3.37mmol).Stirred this mixture 3 hours in 50 ℃.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 10%EtOAc), obtain 2-chloro-4-methoxy yl-quinoline (440mg, 82%), be white solid.

ESI?MS?m/e?194，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.71(s，3H)，6.89(s，1H)，7.27-7.43(m，2H)，7.60-7.69(m，1H)，8.01(d，J＝8.1Hz，1H).

Step C: synthesize 3,4-two fluoro-N-[cis-4-(4-methoxy yl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

In 130 ℃, with 2-chlorine 4-methoxy yl-quinoline (250mg, 1.29mmol) and the N-(cis-4-amino-cyclohexyl)-3 that in the step D of embodiment 3031, obtains, (361mg, 1.42mmol) mixture in butanols (1mL) stirred in sealed tube 5 days 4-two fluoro-benzamide.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).The EtOAc (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filtering-depositing is used Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains cis-3,4-two fluoro-N-[4-(4-methoxy yl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (79mg, 14%), be white solid.

ESI?MS?m/e434，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.58-2.09(m，8H)，3.55-3.72(m，4H)，3.88-4.06(m，1H)，5.93(s，1H)，7.03-8.09(m，7H)，8.25-8.45(m，2H).

Embodiment 3117

N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3115, obtain title compound.

N-[cis-4-(4-chloro-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts;

ESI?MS?m/e?416，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.82-2.22(m，8H)，3.93-4.28(m，2H)，6.65-6.77(m，1H)，7.08(s，1H)，7.14-7.29(m，1H)，7.48-7.64(m，2H)，7.68-7.88(m，3H)，8.09(d，J＝8.1Hz，1H)，9.82-9.90(m，1H).

N-[cis-4-(2-chloro-quinolyl-4 amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts;

ESI?MS?m/e?438，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.72-2.37(m，8H)，3.76-3.95(m，1H)，4.49-4.65(m，1H)，6.37(brs，1H)，6.94-7.12(m，1H)，7.18-7.33(m，1H)，7.39-7.55(m，1H)，7.60-7.76(m，1H)，7.85-7.95(m，1H)，8.06-8.20(m，2H)，8.46-8.58(m，1H)，8.70-8.87(m，1H).

Embodiment 3118

N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

(2-chloro-quinolyl-4)-dimethyl-amine (23.6g that will in the step B of embodiment 3114, obtain, 114mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester that in the step C of embodiment 3068, obtains (36.0g, the 137mmol) stirring down 14 days that refluxes of the mixture in butanols (31mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 14%-66%EtOAc), obtain [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-carboxylamine benzyl ester (19.3g, 39%), is faint yellow solid.

ESI?MS?m/e?433，M(free)+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.12-1.97(m，9H)，2.94(s，6H)，3.13(t，J＝6.4Hz，2H)，4.06-4.26(m，1H)，4.62-4.94(m，2H)，5.11(s，2H)，6.04(s，1H)，7.14(ddd，J＝8.4，7.0，1.3Hz，1H)，7.29-7.40(m，5H)，7.45(ddd，J＝8.4，6.8，1.5H2，1H)，7.57-7.64(m，1H)，7.84(dd，J＝8.4，1.3Hz，1H).

Step B: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2, the 4-diamines.

To [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-(19.3g adds 5%Pd/C (1.93g) in MeOH 44.6mmol) (200mL) solution to the carboxylamine benzyl ester.Under room temperature, nitrogen atmosphere, stirred this mixture 6 days.Reaction mixture is filtered and concentrates by Celite pad.In methyl alcohol (200mL) solution of described residue, add 10%Pd/C (1.93g).Under room temperature, nitrogen atmosphere, stirred this mixture 1.This reaction mixture is filtered by Celite pad, concentrate, through flash chromatography purifying (silica gel, 5%-14% 7M NH ₃The CHCl of/MeOH ₃Solution), obtain N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2,4-diamines (12.7g, 95%) is faint yellow solid.

FAB?MS?m/e?299，M ⁺+H ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.08-1.99(m，11H)，2.60(d，J＝6.2Hz，2H)，2.94(s，6H)，4.04-4.22(m，1H)，4.77-4.93(m，1H)，6.06(s，1H)，7.14(ddd，J＝8.4，7.0，1.3Hz，1H)，7.45(ddd，J＝8.4，6.8，1.5Hz，1H)，7.61(s，1H)，7.84(dd，J＝8.4，1.3Hz，1H).

Step C: synthetic N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride.

To 2-phenoxy group-nicotinic acid (190mg, 1.20mmol) and N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2, (300mg adds Et in DMF 1.00mmol) (3mL) solution to the 4-diamines ₃N (0.33mL, 2.40mmol), HOBt-water (230mg, 1.50mmol) and EDC-HCl (230g, 1.20mmol).Under room temperature, stirred reaction mixture 20 hours.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc) in the warp obtains faint yellow oily thing.The EtOAc (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride (164mg, 31%), be white solid.

ESI MS m/e 496, M (dissociating)+H ⁺

Embodiment 3119

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: Synthetic 2-chloro-4-dimethylamino-5-methylpyrimidine.

To 2, (20.0g adds 50%Me in THF 123mmol) (200mL) solution to 4-two chloro-5-methylpyrimidines ₂(13.3g 143mol), stirred this mixture 5 days to the aqueous solution of NH under room temperature.In reactant, add saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 2%EtOAc), obtain 2-chloro-4-dimethylamino-5-methylpyrimidine (19.9g for white solid, 94%) and be the 4-chloro-2-dimethylamino-5-methylpyrimidine (1.53g, 7%) of white solid.

2-chloro-4-dimethylamino-5-methylpyrimidine;

ESI?MS?m/e?172，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.27(s，3H)，3.15(s，6H)，7.82(s，1H)。

4-chloro-2-dimethylamino-5-methylpyrimidine;

ESI?MS?m/e?194，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.14(s，3H)，3.15(s，6H)，8.06(s，1H)。

Step B: synthetic [cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

With 2-chloro-4-dimethylamino-5-methylpyrimidine (7.00g, 40.8mmol) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester of in embodiment 3031 step B, obtaining (9.61g, 44.8mmol) mixture in butanols (7mL) stirred 26 hours in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 3%-50%EtOAc), obtain [cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester (5.90g, 42%), is colorless oil.

ESI?MS?m/e?350，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.40-1.84(m，17H)，2.14(d，J＝0.8Hz，3H)，3.02(s，6H)，3.53-3.71(m，1H)，3.85-3.99(m，1H)，4.51-4.64(m，1H)，4.68-4.78(m，1H)，7.66(s，1H).

Step C: synthetic N ²-(cis-4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, the 4-diamines.

(5.71g, EtOAc 16.3mmol) (60mL) solution cools off on ice bath, adds the EtOAc solution (120mL) of 4M hydrogenchloride with [cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino) cyclohexyl]-carboxylamine tertiary butyl ester.Stir this mixture under room temperature also concentrated in 1.5 hours.Residue is dissolved in the 1M NaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, and filtration, concentrated, drying under reduced pressure obtain N ²-(cis-4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2,4-diamines (3.99g, 98%) is faint yellow oily thing.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.39-1.91(m，8H)，2.12(s，3H)，2.79-2.97(m，1H)，3.00(s，6H)，3.86-4.05(m，1H)，4.71-4.92(m，1H)，7.66(s，1H).

Step D: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

To N ²-(cis-4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2,4-diamines (200mg, CHCl 0.80mmol) ₃(4mL) add Et in the solution ₃N (0.25mL, 1.79mmol) with 1,3-two fluoro-Benzoyl chlorides (156mg, 0.88mmol).Under room temperature, stirred this mixture 22 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc and silica gel, the CHCl of 3%MeOH ₃Solution).The EtOAc (10mL) that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, and concentrate.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts (56mg, 16%) are white solid.

ESI?MS?m/e?412，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-1.99(m，8H)，2.26(s，3H)，3.30(s，6H)，4.02-4.25(m，2H)，6.65-6.74(m，1H)，7.13-7.26(m，2H)，7.53-7.62(m，1H)，7.67-7.79(m，1H)，8.55-8.65(m，1H).

Embodiment 3120

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Obtain among the step D of employing embodiment 3119, obtain title compound.

ESI?MS?m/e?447，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-1.97(m，8H)，2.23(s，3H)，3.28(s，6H)，4.01-4.21(m，2H)，7.13(dd，J＝7.6，4.8Hz，1H)，7.19-7.32(m，4H)，7.42-7.52(m，2H)，7.86-7.95(m，1H)，8.21(dd，J＝4.8，2.0Hz，1H)，8.39-8.48(m，1H)，8.53(dd，J＝7.6，2.0Hz，1H).

Embodiment 3121

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-methyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-methyl-benzamide hydrochloride salt.

Obtain among the step D of employing embodiment 3119, obtain title compound.

ESI?MS?m/e?390，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.01(m，8H)，2.25(s，3H)，2.41(s，3H)，3.30(s，6H)，4.04-4.22(m，2H)，6.41-6.52(m，1H)，7.19-7.34(m，3H)，7.56-7.66(m，2H)，8.53-8.63(m，1H)，13.04(s，1H).

Embodiment 3122

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-methoxyl group-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-methoxyl group-benzamide hydrochloride salt.

Obtain among the step D of employing embodiment 3119, obtain title compound.

ESI?MS?m/e?406，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-1.99(m，8H)，2.25(s，3H)，3.30(s，6H)，3.86(s，3H)，4.06-4.23(m，2H)，6.72-6.81(m，1H)，6.98-7.05(m，1H)，7.20-7.43(m，4H)，8.47-8.57(m，1H).

Embodiment 3123

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide hydrochloride.

To 4-fluoro-phenol (317mg, add in DMA 2.83mmol) (4mL) solution 60%NaH oil suspension (226mg, 5.56mmol).Under room temperature, stirred this mixture 1 hour.In this mixture, add 2-chloro-N-[cis-4-(dimethylamino-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (1.10g, DMA 2.83mmol) (3mL) solution.In 120 ℃, this mixture was stirred 2 hours water (60mL) quencher reactant.With waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 33%-50%EtOAc), obtain a kind of colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide hydrochloride (154mg, 11%), be white solid.

ESI?MS?m/e?487，M(free)+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.61-2.02(m，8H)，2.24(s，3H)，3.28(s，6H)，4.03-4.25(m，2H)，7.06-7.33(m，6H)，7.79-7.91(m，1H)，8.16-8.23(m，1H)，8.46-8.59(m，2H).

Embodiment 3124

2-(2-bromo-phenoxy group)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-(2-bromo-phenoxy group)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3123, obtain title compound.

ESI?MS?m/e?547，M(free)+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.72-2.02(m，8H)，2.23(s，3H)，3.28(s，6H)，3.97-4.27(m，2H)，7.09-7.48(m，5H)，7.66(dd，J＝7.9，1.3Hz，1H)，7.84-7.95(m，1H)，8.13-8.19(m，1H)，8.31-8.43(m，1H)，8.53(dd，J＝7.4，2.2Hz，1H)，13.32(s，1H).

Embodiment 3125

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the urea hydrochloride

Steps A: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, the 4-diamines.

The 2-chloro-4-dimethylamino-5-methylpyrimidine (3.00g that will in the steps A of embodiment 3119, obtain, 17.4mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester of in the step C of embodiment 3068, obtaining (5.48g, the 20.9mmol) stirring down 70 hours that refluxes of the mixture in butanols (3mL).In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges filters, concentrates through dried over mgso, through flash chromatography purifying (NH-silica gel, the hexane solution of 33%-50%EtOAc), obtains a kind of faint yellow oily thing.In the MeOH of above-mentioned oily matter (30mL) solution, add 10%Pd/C (600mg).Under room temperature, nitrogen atmosphere, stirred this mixture 1.5 days.Reaction mixture is filtered by Celite pad, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 2%MeOH ₃Solution), obtain N ²-(cis-4-amino methyl-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2,4-diamines (1.03g, 22%) is faint yellow solid.

ESI?MS?m/e?264，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.15-1.89(m，11H)，2.13(s，3H)，2.59(d，J＝6.4Hz，2H)，3.02(s，6H)，4.03-4.13(m，1H)，4.77-4.85(m，1H)，7.67(s，1H)

Step B: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-the urea hydrochloride.

To N ²-(cis-4-amino methyl-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, the 4-diamines (300mg adds 1 in DMSO 1.14mmol) (3mL) solution, and 2-two chloro-3-isocyanato-benzene (236mg, 1.25mmol).Under room temperature, stirred this mixture 16 hours, in the impouring water (20mL).Filter the collecting precipitation thing, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc and silica gel, the CHCl of 3%MeOH in the warp ₃Solution), obtain a kind of faint yellow oily thing.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Under room temperature, with described residue at Et ₂Suspension among the O (20mL) stirred 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-urea hydrochloride (326mg, 59%), be white solid.

ESI?MS?m/e?473，M(free)+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.45-1.99(m，9H)，2.24(s，3H)，3.30(s，6H)，3.32-3.43(m，2H)，4.22-4.38(m，2H)，6.85-7.15(m，3H)，7.22(brs，1H)，8.14-8.26(m，2H)，8.49-8.62(m，1H)，12.14(s，1H).

Embodiment 3126

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic (2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine.

To 2, (20.0g adds 50%Me in THF 123mmol) (200mL) solution to 4-two chloro-6-methylpyrimidines ₂(13.3g 147mmol), stirred this mixture 24 hours to the aqueous solution of NH under room temperature.In reactant, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 5%-16%EtOAc), obtain (2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine (14.4g for faint yellow solid, 68%) and be (the 4-chloro-6-methyl-pyrimidine-2-base)-dimethyl-amine (6.57g, 31%) of faint yellow solid.

(2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine;

ESI?MS?m/e?194，M ⁺+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.34(s，3H)，3.10(s，6H)，6.16(s，1H)。

(4-chloro-6-methyl-pyrimidine-2-base)-dimethyl-amine;

CI?MS?m/e?172，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.29(s，3H)，3.16(s，6H)，6.34(s，1H)。

Step B: synthetic N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl }-2-phenoxy group-niacinamide hydrochloride.

In 130 ℃, with (2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine (300mg, 1.75mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy group-niacinamide of in the steps A of embodiment 3032, obtaining (598mg, 1.92mmol) mixture in butanols (1mL) stirred in sealed tube 40 hours.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filtering-depositing is used Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (549mg, 65%), be white solid.

ESI?MS?m/e?447，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.05(m，8H)，2.34(s，3H)，3.12(s，3H)，3.23(s，3H)，4.03-4.22(m，2H)，5.71(s，1H)，7.13(dd，J＝7.5，4.8Hz，1H)，7.21-7.32(m，3H)，7.41-7.51(m，2H)，7.84-7.95(m，1H)，8.21(dd，J＝4.7，2.1Hz，1H)，8.45-8.57(m，2H)，13.43(brs，1H).

Embodiment 3127

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N ²-(cis-4-amino-cyclohexyl)-6, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, the 4-diamines.

In 130 ℃, with (2-chloro-6-methyl-pyrimidine-4-yl)-dimethyl-amine (6.00g, 35.0mmol) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester of in embodiment 3031 step B, obtaining (8.30g, 38.5mmol) mixture in butanols (6mL) stirred 48 hours.In reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 16%-50%EtOAc).The EtOAc solution (60mL) that in the EtOAc of above-mentioned substance (60mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 2 hours.Make residue be dissolved in the 1M NaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the CHCl of 2%-10%MeOH ₃Solution), obtain N ²-(cis-4-amino-cyclohexyl)-6, N ⁴, N ⁴-trimethylammonium-pyrimidine-2,4-diamines (2.29g, 26%) is faint yellow oily thing.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.18-1.50(m，4H)，1.58-1.93(m，6H)，2.19(s，3H)，2.76-2.87(m，1H)，3.03(s，6H)，3.96-4.06(m，1H)，4.78-4.89(m，1H)，5.67(s，1H).

Step B: synthetic N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

To N ²-(cis-4-amino-cyclohexyl)-6, N ⁴, N ⁴-trimethylammonium-pyrimidine-2,4-diamines (300mg, CHCl 1.20mmol) ₃(2mL) add i-Pr in the solution ₂NEt (0.44mL, 2.52mmol) with 3,4-two fluoro-Benzoyl chlorides (233mg, CHCl 1.32mmol) ₃(1mL) solution.Under room temperature, stirred this mixture 15 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc), obtain a kind of colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts (359mg, 70%) are white solid.

ESI?MS?m/e?390，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.00(m，8H)，2.35(d，J＝0.6Hz，3H)，3.14(s，3H)，3.26(s，3H)，4.03-4.29(m，2H)，5.74(d，J＝0.7Hz，1H)，6.61-6.72(m，1H)，7.14-7.26(m，1H)，7.53-7.62(m，1H)，7.67-7.78(m，1H)，8.59(d，J＝7.8Hz，1H).

Embodiment 3128

3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3127, obtain title compound.

ESI?MS?m/e?410，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.00(m，8H)，2.35(s，3H)，3.13(s，3H)，3.25(s，3H)，4.04-4.26(m，2H)，5.75(s，1H)，6.53(d，J＝8.6Hz，1H)，7.32-7.48(m，2H)，7.64-7.70(m，1H)，7.83(t，J＝1.9Hz，1H)，8.60(d，J＝7.9Hz，1H)，13.11(brs，1H).

Embodiment 3129

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic (2-chloro-pyrimidine-4-yl)-dimethyl-amine.

To 2, (15.0g adds 50%MeNH in THF 10.15mmol) (150mL) solution to 4-two chloro-pyrimidines ₂The aqueous solution (22.7g, 25.2mmol).Under room temperature, stirred this mixture 2 hours.In this solution impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), obtain (2-chloro-pyrimidine-4-yl)-dimethyl-amine (8.66g for white solid, 55%) and be (the 4-chloro-pyrimidine-2-base)-dimethyl-amine (0.87g, 6%) of white solid.

(2-chloro-pyrimidine-4-yl)-dimethyl-amine;

CI?MS?m/e?158，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.12(s，6H)，6.32(d，J＝6.1Hz，1H)，8.00(d，J＝6.1Hz，1H).

(4-chloro-pyrimidine-2-base)-dimethyl-amine;

ESI?MS?m/e?157，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.21(s，6H)，6.50(d，J＝5.1Hz，1H)，8.18(d，J＝5.1Hz，1H).

Step B: synthetic [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

In 130 ℃, in sealed tube, with (2-chloro-pyrimidine-4-yl)-dimethyl-amine (1.50g, 9.52mmol) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester of in embodiment 3031 step B, obtaining (2.24g, 10.5mmol) mixture in IPA (1.5mL) stirred 22 hours.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 10%EtOAc), obtain [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (1.34g, 42%), is white solid.

ESI?MS?m/e?358，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.45(s，9H)，1.48(s，8H)，3.03(s，6H)，3.61(brs，1H)，3.89-4.04(m，1H)，4.47-4.63(m，1H)，4.77-4.89(m，1H)，5.80(d，J＝6.1Hz，1H)，7.84(d，J＝6.1Hz，1H).

Step C: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

To [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (1.26g, the EtOAc solution (15mL) of adding 4M hydrogenchloride in EtOAc 3.76mmol) (15mL) solution.Stirred reaction mixture 1 hour and concentrated under room temperature.Described residue is alkalized with the 1M NaOH aqueous solution.With waterbearing stratum CHCl ₃Extract (6 times).The organic layer that merges filters and concentrates through dried over mgso, obtains N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴Methyl-pyrimidine-2, the 4-diamines (923mg, quantitatively .), be faint yellow oily thing.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.29-1.51(m，2H)，1.61-1.91(m，6H)，2.80-2.92(m，1H)，3.03(s，6H)，3.96-4.04(m，1H)，4.85-4.98(m，1H)，5.79(d，J＝6.1Hz，1H)，7.84(d，J＝6.1Hz，1H).

Step D: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

To N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines (300mg, CHCl 1.20mmol) ₃(3mL) add Et in the solution ₃N (0.35mL, 2.51mmol) and 2-phenoxy group-nicotinoyl chlorine (309mg, 1.32mmol).Under room temperature, stirred this mixture 22 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc and silica gel, the CHCl of 3%MeOH ₃Solution).EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride (150mg, 26%), be white solid.

ESI MS m/e 433, M (dissociating)+H ⁺

Embodiment 3130

3,4-two fluoro-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base) amino-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base) amino-cyclohexyl]-benzamide hydrochloride salt.

In sealed tube, with 2-chloro-4-three fluoro methyl-pyrimidine (200mg, 1.09mmol) and the N-(cis-4-amino-cyclohexyl)-3 that in the step D of embodiment 3031, obtains, (306mg, 1.20mmol) mixture in butanols (1mL) stirred 12 hours in 130 ℃ 4-two fluoro-benzamide.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.

Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂O (20mL) stirred this suspension 2 hours under room temperature.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 3,4-two fluoro-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base) amino-cyclohexyl]-benzamide hydrochloride salt (123mg, 26%), be white solid.

ESI MS m/e 423, M ⁺(dissociating)+Na ⁺

Embodiment 3131

3,4-two fluoro-N-[cis-4-(4-methoxyl group-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(4-methoxyl group-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 385, M (dissociating)+Na ⁺

Embodiment 3132

N-[cis-4-(4,6-dimethoxy-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4,6-dimethoxy-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 415, M (dissociating)+Na ⁺

Embodiment 3133

2-phenoxy group-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base)-amino-cyclohexyl]-the niacinamide hydrochloride

Steps A: Synthetic 2-phenoxy group-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base)-amino-cyclohexyl]-the niacinamide hydrochloride.

In sealed tube, with 2-chloro-4-trifluoromethyl-pyrimidine (200mg, 1.10mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy group-niacinamide of in the steps A of embodiment 3032, obtaining (375mg, 1.20mmol) mixture in butanols (1mL) stirred 3 days in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-33%EtOAc), obtain a kind of faint yellow oily thing.EtOAc (0.2mL) solution that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains 2-phenoxy group-N-[cis-4-(4-trifluoromethyl-pyrimidine-2-base)-amino-cyclohexyl]-niacinamide hydrochloride (111mg, 21%), be white solid.

ESI MS m/e 480, M (dissociating)+Na ⁺

Embodiment 3134

N-[cis-4-(4-methoxyl group-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methoxyl group-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 442, M (dissociating)+Na ⁺

Embodiment 3135

N-[cis-4-(4,6-dimethoxy-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4,6-dimethoxy-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 472, M (dissociating)+Na ⁺

Embodiment 3136

N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidine-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic (5-bromo-2-chloro-pyrimidine-4-yl)-dimethyl-amine.

Adopt the method for the steps A of embodiment 3129, obtain title compound.

ESI?MS?m/e?236，M+H ⁺

Step B: synthetic (2-chloro-5-phenyl-pyrimidine-4-yl)-dimethyl-amine.

To (5-bromo-2-chloro-pyrimidine-4-yl)-dimethyl-amine (2.00g, add in toluene 8.46mmol) (30mL) solution 2M wet chemical (15mL), phenyl-boron dihydroxide (1.03g, 8.45mmol) and four-(triphenyl phosphine)-palladium (977mg, 0.845mmol).This reaction mixture was stirred 8 hours under refluxing.In this mixture impouring water, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (NH-silica gel, the hexane solution of 3%EtOAc), obtains (2-chloro-5-phenyl-pyrimidine-4-yl)-dimethyl-amine (1.44g, 73%).

ESI?MS?m/e?256，M+Na ⁺

Step C: synthetic N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidine-2-base is amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 531, M (dissociating)+Na ⁺

Embodiment 3137

N-[cis-4-(5-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic (2,5-two chloro-pyrimidine-4-yl)-dimethyl-amine.

Adopt the method for the steps A of embodiment 3129, obtain title compound.

ESI?MS?m/e?191，M ⁺

Step B: synthetic N-[cis-4-(5-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 467, M (dissociating)+H ⁺

Embodiment 3138

N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidine-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidine-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 474, M (dissociating)+Na ⁺

Embodiment 3139

N-[cis-4-(5-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(5-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 432, M (dissociating)+Na ⁺

Embodiment 3140

N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic (2-chloro-5-fluoro-pyrimidine-4-yl)-dimethyl-amine.

Adopt the method for the steps A of embodiment 3129, obtain title compound.

ESI?MS?m/e?176，M+H ⁺

Step B: synthetic N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 451, M (dissociating)+H ⁺

Embodiment 3141

1-[cis-4-(5-bromo-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(5-bromo-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 533, M (dissociating)+Na ⁺

Embodiment 3142

N-[cis-4-(4,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 383, M (dissociating)+Na ⁺

Embodiment 3143

N-[cis-4-(4,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4,6-dimethyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3133, obtain title compound.

ESI MS m/e 440, M (dissociating)+Na ⁺

Embodiment 3144

3,4-two fluoro-N-[cis-4-(pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3130, obtain title compound.

ESI MS m/e 355, M (dissociating)+Na ⁺

Embodiment 3145

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl ester.

In sealed tube, (2-chloro-pyrimidine-4-yl)-dimethyl-amine (1.50g that will in the steps A of embodiment 3129, obtain, 9.52mmol) and (cis-4-amino-cyclohexyl methyl)-carboxylamine benzyl ester of in the step C of embodiment 3068, obtaining (2.75g, 10.5mmol) mixture in IPA (1.5mL) stirred 22 hours in 130 ℃.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through medium pressure liquid chromatography purifying (NH-silica gel, the hexane solution of 10%EtOAc is to EtOAc), obtain [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-carboxylamine benzyl ester (816mg, 22%), is faint yellow oily thing.

ESI?MS?m/e?406，M+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.22-1.92(m，9H)，3.03(s，6H)，3.11(t，J＝6.2Hz，2H)，4.02-4.15(m，1H)，4.82-4.93(m，2H)，5.10(s，2H)，5.79(d，J＝6.1Hz，1H)，7.28-7.42(m，5H)，7.83(d，J＝6.1Hz，1H).

Step B: synthetic N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines.

Adopt the method for the step B of embodiment 3118, obtain title compound.

ESI?MS?m/e?250，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.40-1.88(m，9H)，2.87(d，J＝5.9Hz，2H)，3.03(s，6H)，4.11(brs，1H)，5.63(brs，1H)，5.78(d，J＝6.2Hz，1H)，7.08(brs，2H)，7.82(d，J＝6.2Hz，1H).

Step C: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride.

To N ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2,4-diamines (400mg, CHCl 1.60mmol) ₃(2mL) add i-Pr in the solution ₂(0.56mL is 3.36mmol) with 2-phenoxy group-nicotinoyl chlorine (523mg, CHCl 2.24mmol) for NEt ₃(2mL) solution.Under room temperature, stirred this mixture 5 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).Obtain a kind of colorless oil.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 60 ℃ of drying under reduced pressure, obtains N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-2-phenoxy group-niacinamide hydrochloride (199mg, 26%), be white solid.

ESI MS m/e 469, M (dissociating)+Na ⁺

Embodiment 3146

3-hydroxy-n-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-hydroxy-n-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?362，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.60-2.09(m，8H)，3.83-4.02(m，1H)，4.22-4.49(m，1H)，6.79-7.02(m，1H)，7.12-7.59(m，5H)，7.67-8.45(m，5H)，9.40-9.78(m，2H)，12.91-13.17(m，1H).

Embodiment 3147

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?404，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.54-2.12(m，8H)，3.89-4.31(m，5H)，6.89-7.05(m，2H)，7.41-7.58(m，2H)，7.68-7.82(m，3H)，8.00-8.22(m，3H)，8.46-8.51(m，1H)，9.66-9.85(m，1H).

Embodiment 3148

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3,5-di-trifluoromethyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3,5-di-trifluoromethyl-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?482，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.75-2.27(m，8H)，4.00-4.32(m，2H)，6.97(d，J＝9.4Hz，1H)，7.42-7.65(m，2H)，7.69-7.80(m，3H)，7.96-8.02(m，1H)，8.20(d，J＝9.3Hz，1H)，8.35-8.42(m，2H)，9.69-9.79(m，1H).

Embodiment 3149

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride salt steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?430，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.33(m，8H)，3.96-4.29(m，2H)，6.88-7.03(m，2H)，7.29-7.51(m，3H)，7.69-7.82(m，5H)，8.19(d，J＝9.5Hz，1H)，9.73-9.86(m，1H).

Embodiment 3150

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the isophthalamic acid methyl ester.

The cis that obtains in the steps A of m-phthalic acid monomethyl ester (435mg) and embodiment 3033-N-quinoline-2-base-hexanaphthene-1 adds Et in DMF (5mL) solution of 4-diamines (500mg) ₃N (0.96mL), HOBt-water (476mg) and EDC-HCl (437mg).Stirred reaction mixture is 18 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 25%EtOAc) in the warp obtains N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid methyl ester (740mg), be white solid.

ESI?MS?m/e?404，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.71-2.05(m，8H)，3.96(s，3H)，4.10-4.28(m，2H)，4.80-4.90(m，1H)，6.16-6.26(m，1H)，6.66(d，J＝8.8Hz，1H)，7.18-7.20(m，1H)，7.49-7.68(m，4H)，7.84(d，J＝8.3Hz，1H)，8.03-8.10(m，1H)，8.15-8.22(m，1H)，8.35-8.38(m，1H).

Step B: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid.

To N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-add the 2M NaOH aqueous solution (0.52mL) in EtOH (12mL) solution of isophthalamic acid methyl ester (400mg).Stirred reaction mixture is 11 hours under room temperature.In this reaction mixture, add the 1M HCl aqueous solution (0.6mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain white solid.With above-mentioned solid at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour, filtered to obtain N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid (183mg), be white solid.

ESI?MS?m/e?412，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.63-2.09(m，8H)，3.84-4.18(m，2H)，6.83-6.91(m，2H)，7.07-7.17(m，1H)，7.39-7.64(m，4H)，7.83(d，J＝9.0Hz，1H)，8.03-8.13(m，2H)，8.39-8.53(m，2H).

Embodiment 3151

C-(ethyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-(ethyl-phenyl-amino)-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?403，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.18-1.36(m，3H)，1.54-2.15(m，8H)，3.39-3.65(m，3H)，3.68-4.11(m，3H)，6.80-7.20(m，3H)，7.29-7.86(m，8H)，8.07-8.23(m，1H)，9.48-9.68(m，1H).

Embodiment 3152

3,5-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,5-two fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3046, obtain title compound.

ESI?MS?m/e?404，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.71-2.02(m，8H)，3.87-4.13(m，1H)，4.24-4.53(m，1H)，7.21-8.01(m，7H)，8.18-8.60(m，3H)，9.48-9.81(m，1H)，13.09-13.28(m，1H).

Embodiment 3153

4-chloro-3-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide-hydrochloride

Steps A: synthetic 4-chloro-3-fluoro-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?398，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.10(m，8H)，3.97-4.27(m，2H)，6.88-7.03(m，2H)，7.39-7.50(m，2H)，7.54-7.62(m，1H)，7.66-7.83(m，4H)，8.19(d，J＝9.4Hz，1H)，9.65-9.82(m，1H).

Embodiment 3154

C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3036, obtain title compound.

ESI?MS?m/e?459，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ0.99-1.19(m，3H)，1.42-1.96(m，8H)，3.30-3.55(m，2H)，3.71-3.87(m，1H)，3.94(s，2H)，4.29-4.51(m，1H)，6.57-6.77(m，2H)，7.02-7.58(m，4H)，7.65-8.04(m，3H)，8.15-8.44(m，2H)，9.61-9.85(m，1H)，13.17-13.42(m，1H).

Embodiment 3155

N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride

Steps A: synthetic N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride.

To the N-[cis-4-that in the step B of embodiment 3150, obtains (quinoline-2-base amino)-cyclohexyl]-add 28%NH in DMF (2mL) solution of isophthalamic acid (160mg) ₃The aqueous solution (30mg), Et ₃N (0.14mL), HOBt-water (94mg) and EDC-HCl (95mg).Stirred reaction mixture is 16 hours under room temperature.In reaction mixture, add entry (20mL), with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).EtOH (3mL) solution of above-mentioned purifying substance is added in the EtOAc solution (0.3mL) of 4M hydrogenchloride.Stirred this mixture 2 hours under room temperature, filtration, drying under reduced pressure obtain N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride (9mg), be white solid.

ESI?MS?m/e?411，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.70-2.06(m，8H)，3.89-4.08(m，1H)，4.19-4.39(m，1H)，7.17-7.60(m，4H)，7.71-8.46(m，8H)，12.84-12.97(m，1H).

Embodiment 3156

3,4-two fluoro-N-{ cis-4-[(quinoline-2-ylmethyl)-amino]-cyclohexyl }-benzamide dihydrochloride

Steps A: synthesize 3,4-two fluoro-N-{ cis-4-[(quinoline-2-ylmethyl)-amino]-cyclohexyl }-benzamide dihydrochloride.

To the N-that in the step D of embodiment 3031, obtains (cis-4-amino-cyclohexyl)-3, the CHCl of 4-two fluoro-benzamide (250mg) ₃(5mL) add quinoline-2-formaldehyde (185mg), acetate (71mg) and NaBH (OAc) in the solution ₃(316mg).Stirred reaction mixture is 16 hours under room temperature.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc and silica gel, the CHCl of 2%-5%MeOH ₃Solution), obtain a kind of colorless oil.The EtOAc solution (O.2mL) that in the EtOAc of above-mentioned oily matter solution (10mL), adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (12mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 3,4-two fluoro-N-{ cis-4-[(quinoline-2-ylmethyl)-amino]-cyclohexyl }-benzamide dihydrochloride (100mg), be white solid.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.50-1.68(m，2H)，1.90-2.15(m，6H)，3.20-3.37(m，1H)，3.91-4.01(m，1H)，4.53-4.66(m，2H)，7.46-8.29(m，9H)，8.52(d，J＝8.5Hz，1H)，9.44-9.62(m，2H).

Embodiment 3157

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3,5-di-trifluoromethyl-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3,5-di-trifluoromethyl-benzamide hydrochloride salt

Adopt the method for embodiment 3070 step B, obtain title compound.

ESI?MS?m/e?496，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.19(m，8H)，2.74(s，3H)，3.98-4.31(m，2H)，6.78-6.81(m，1H)，7.40-7.52(m，1H)，7.58-7.78(m，3H)，7.85(d，J＝9.2Hz，1H)，7.96-8.01(m，1H)，8.36-8.41(m，2H)，9.49-9.64(m，1H).

Embodiment 3158

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?444，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.68-2.20(m，8H)，2.71-2.75(m，3H)，3.96-4.30(m，2H)，6.76-6.87(m，2H)，7.30-7.39(m，1H)，7.42-7.52(m，2H)，7.67-7.89(m，5H)，9.50-9.72(m，1H).

Embodiment 3159

C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?417，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.10-1.38(m，3H)，1.59-2.05(m，8H)，2.45-2.84(m，3H)，3.35-4.15(m，6H)，6.57-6.81(m，1H)，6.85-7.52(m，7H)，7.57-7.89(m，4H)，9.20-9.50(m，1H).

Embodiment 3160

3-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?398，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.67-2.02(m，8H)，2.53-2.70(m，3H)，3.86-3.99(m，1H)，4.24-4.40(m，1H)，6.88-6.96(m，1H)，7.06-7.31(m，4H)，7.46-7.57(m，1H)，7.73-7.83(m，1H)，7.92-8.28(m，3H)，9.66(s，1H)，12.83-12.94(m，1H).

Embodiment 3161

2-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride

Steps A: Synthetic 2-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?376，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.63-2.06(m，8H)，2.53-2.70(m，3H)，3.87-4.04(m，1H)，4.36-4.59(m，1H)，6.92-7.06(m，1H)，7.15-7.27(m，1H)，7.45-7.58(m，1H)，7.69-7.84(m，1H)，7.89-8.01(m，1H)，8.14-8.58(m，4H)，8.69-8.86(m，1H)，9.54-9.72(m，1H).

Embodiment 3162

2,3-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2,3-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.56-2.17(m，8H)，2.72(s，3H)，3.88-4.04(m，1H)，4.09-4.30(m，1H)，6.67-6.92(m，2H)，7.10-7.35(m，2H)，7.41-7.52(m，1H)，7.60-7.93(m，4H)，9.53-9.75(m，1H).

Embodiment 3163

2,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.22(m，8H)，2.73(s，3H)，3.87-4.06(m，1H)，4.11-4.31(m，1H)，6.69-7.06(m，4H)，7.40-7.56(m，1H)，7.65-7.88(m，3H)，7.98-8.14(m，1H)，9.51-9.83(m，1H).

Embodiment 3164

2,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.46-2.14(m，8H)，2.72(s，3H)，3.84-4.04(m，1H)，4.09-4.32(m，1H)，6.77(s，1H)，6.82-7.21(m，3H)，7.37-7.54(m，1H)，7.63-7.89(m，4H)，9.54-9.72(m，1H).

Embodiment 3165

2,6-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2,6-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.72-2.08(m，8H)，2.72(s，3H)，3.91-4.03(m，1H)，4.13-4.33(m，1H)，6.42-6.54(m，1H)，6.77(s，1H)，6.88-6.99(m，2H)，7.27-7.50(m，2H)，7.66-7.78(m，2H)，7.84(d，J＝8.2Hz，1H)，9.53-9.70(m，1H).

Embodiment 3166

3,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,5-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?418，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.16(m，8H)，2.72(s，3H)，3.96-4.26(m，2H)，6.78(s，1H)，6.86-7.02(m，2H)，7.33-7.52(m，3H)，7.67-7.78(m，2H)，7.85(d，J＝8.2Hz，1H)，9.48-9.71(m，1H).

Embodiment 3167

C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?451，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.14-1.26(m，3H)，1.69-2.00(m，8H)，2.60(s，3H)，3.39-3.61(m，2H)，3.75-4.03(m，4H)，6.63-7.06(m，4H)，7.14-7.32(m，2H)，7.39-7.51(m，1H)，7.64-7.89(m，3H)，9.44-9.59(m，1H).

Embodiment 3168

4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?412，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.13(m，8H)，2.70-2.76(m，3H)，3.95-4.28(m，2H)，6.65-6.81(m，2H)，7.41-7.50(m，2H)，7.53-7.59(m，1H)，7.65-7.77(m，3H)，7.82-7.88(m，1H)，9.57-9.71(m，1H).

Embodiment 3169

4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?378，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.81-2.10(m，8H)，2.72(s，3H)，3.95-4.29(m，2H)，6.65-6.81(m，2H)，7.10(t，J＝8.6Hz，2H)，7.42-7.51(m，1H)，7.67-7.91(m，5H)，9.55-9.67(m，1H).

Embodiment 3170

3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?378，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.77-2.09(m，8H)，2.71-2.76(m，3H)，3.94-4.25(m，2H)，6.54-6.65(m，1H)，6.76-6.81(m，1H)，7.13-7.23(m，1H)，7.35-7.61(m，4H)，7.67-7.88(m，3H)，9.58-9.73(m，1H).

Embodiment 3171

2-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: Synthetic 2-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?378，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.84-2.15(m，8H)，2.72(s，3H)，3.87-4.01(m，1H)，4.13-4.29(m，1H)，6.73-6.89(m，2H)，7.07-7.28(m，2H)，7.40-7.51(m，2H)，7.66-7.87(m，3H)，7.96-8.05(m，1H)，9.62-9.72(m，1H).

Embodiment 3172

4-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3070, obtain title compound.

ESI?MS?m/e?394，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.64-2.04(m，8H)，2.55-2.70(m，3H)，3.87-4.04(m，1H)，4.27-4.52(m，1H)，7.07-7.18(m，1H)，7.46-7.58(m，3H)，7.73-8.02(m，4H)，8.23-8.38(m，2H)，9.39-9.52(m，1H)，12.96-13.10(m，1H).

Embodiment 3173

2-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide hydrochloride

Steps A: Synthetic 2-hydroxy-n-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?399，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.46-1.99(m，8H)，2.53-2.72(m，3H)，4.02-4.15(m，1H)，4.20-4.45(m，1H)，6.46-6.56(m，1H)，6.95-7.08(m，1H)，7.45-7.57(m，1H)，7.69-7.83(m，2H)，7.90-8.47(m，3H)，10.08-10.27(m，1H)，12.48-12.63(m，1H).

Embodiment 3174

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid-methyl ester hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?440，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.78-2.21(m，8H)，2.73(d，J＝1.1Hz，3H)，3.92-4.07(m，4H)，4.13-4.29(m，1H)，6.78(s，1H)，6.99-7.10(m，1H)，7.40-7.57(m，2H)，7.67-7.79(m，2H)，7.82-7.89(m，1H)，8.02-8.19(m，2H)，8.46-8.52(m，1H)，9.46-9.65(m，1H).

Embodiment 3175

6-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: synthetic 6-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?417，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.67-2.03(m，8H)，2.54-2.72(m，3H)，3.91-4.06(m，1H)，4.26-4.42(m，1H)，7.05-7.18(m，1H)，7.45-7.57(m，1H)，7.63-7.69(m，1H)，7.73-7.83(m，1H)，7.91-8.04(m，1H)，8.17-8.31(m，2H)，8.51-8.62(m，1H)，8.83-8.89(m，1H)，9.33-9.51(m，1H)，12.86-13.03(m，1H).

Embodiment 3176

6-dimethylamino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride

Steps A: synthetic 6-dimethylamino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride.

To the 6-chloro-N-[cis-4-that in the steps A of embodiment 3175, obtains (4-methyl-quinoline-2-base amino)-cyclohexyl]-add 50% Me in IPA (1mL) solution of niacinamide (250mg) ₂The NH aqueous solution (63mg) and iPr ₂NEt (172mg).This mixture backflow was stirred 5 hours down, add 50%Me ₂The aqueous solution of NH (120mg) stirred 5 hours under refluxing.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in the press liquid chromatography purification (NH-silica gel, EtOAc).The EtOAc solution (0.47mL) that in above-mentioned substance EtOH (3mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (3mL) stirred under room temperature 4 hours.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 6-dimethylamino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide dihydrochloride (200mg), be white solid.

ESI?MS?m/e?426，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.73-2.13(m，8H)，2.63-2.80(m，3H)，3.34-3.61(m，6H)，3.91-4.28(m，2H)，6.70-7.07(m，2H)，7.35-8.10(m，5H)，8.29-8.46(m，1H)，8.82-8.98(m，1H)，9.36-9.51(m，1H).

Embodiment 3177

3-hydroxymethyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-hydroxymethyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

To LiAlH (18mg) at Et ₂Be added in N-[cis-4-of obtaining in the steps A of embodiment 3174 (4-methyl-quinoline-2-base is amino)-cyclohexyl in the suspension among the O (5mL)]-Et of isophthalamic acid methyl ester (200mg) ₂O (2mL) solution.Under room temperature, stirred this mixture 3 hours.Water quencher reactant is with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (silica gel, the CHCl of 3%-10%MeOH ₃Solution).The EtOAc solution (0.24mL) that in the EtOH of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 2 hours and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (3mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing in 70 ℃ of drying under reduced pressure, obtains 3-hydroxymethyl-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt (93mg), be white solid.

ESI?MS?m/e?390，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.66-2.02(m，8H)，2.61(s，3H)，3.87(brs，1H)，4.22-4.42(m，1H)，4.55(s，2H)，7.03-7.17(m，1H)，7.35-7.59(m，3H)，7.67-7.87(m，3H)，7.91-8.04(m，1H)，8.11-8.31(m，2H)，12.75-12.96(m，1H).

Embodiment 3178

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the isophthalamic acid methyl ester.

To m-phthalic acid monomethyl ester (400mg) and N-(cis-4-methyl-quinoline-2-yl)-hexanaphthene-1 of in the steps A of embodiment 3070, obtaining, add Et in DMF (4mL) solution of 4-diamines (400mg) ₃N (0.52mL), HOBt-water (358mg) and EDC-HCl (330mg).Stirred reaction mixture is 12 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (silica gel, the CHCl of 9%MeOH in the warp ₃Solution), obtain N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-isophthalamic acid methyl ester (740mg), be white solid.

ESI?MS?m/e?440，M+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.59-2.09(m，8H)，2.58(s，3H)，3.96(s，3H)，4.02-4.29(m，2H)，4.72-4.87(m，1H)，6.12-6.27(m，1H)，6.48-6.59(m，1H)，7.17-7.30(m，1H)，7.45-7.82(m，4H)，8.00-8.22(m，2H)，8.32-8.39(m，1H).

Step B: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride.

To N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-add the 2M NaOH aqueous solution (0.27mL) in EtOH (4.5mL) solution of isophthalamic acid methyl ester (150mg).Stirred reaction mixture is 13 hours under room temperature.In reaction mixture, add the 1M HCl aqueous solution (03mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (silica gel, the CHCl of 1%-5%MeOH ₃Solution), obtain white solid.In above-mentioned solid DMF (2mL) solution, add the 28%NH3 aqueous solution (21mg), Et ₃N (0.1mL), HOBt-water (67mg) and EDC-HCl (67mg).Stirred reaction mixture is 12 hours under room temperature.In reaction mixture, add entry (20mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the CHCl of 3%-9%MeOH ₃Solution).EtOAc (10mL) solution of above-mentioned substance is joined in EtOAc (0.2mL) solution of 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour, and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (12mL) stirred under room temperature 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing, concentrating under reduced pressure obtains N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-different benzene diamide hydrochloride.

ESI?MS?m/e?403，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.69-2.04(m，8H)，2.56-2.63(m，3H)，3.92-4.06(m，1H)，4.28-4.48(m，1H)，7.06-7.17(m，1H)，7.41-7.58(m，3H)，7.70-8.04(m，3H)，8.06-8.43(m，3H)，9.35-9.54(m，1H)，12.87-13.07(m，1H).

Embodiment 3179

3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?412，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.79-2.12(m，8H)，2.73(d，J＝0.9Hz，3H)，3.96-4.22(m，2H)，6.75-6.90(m，2H)，7.17-7.25(m，1H)，7.42-7.51(m，2H)，7.59-7.89(m，4H)，9.51-9.72(m，1H).

Embodiment 3180

3,4,5-three fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4,5-three fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?414，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.76-2.16(m，8H)，2.73(d，J＝1.1Hz，3H)，3.97-4.24(m，2H)，6.78(s，1H)，6.92-7.04(m，1H)，7.41-7.60(m，3H)，7.68-7.77(m，2H)，7.82-7.89(m，1H)，9.50-9.64(m，1H).

Embodiment 3181

Pyridine-2-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: pyridine synthesis-2-carboxylic acid [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?383，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.63-2.07(m，8H)，2.54-2.71(m，3H)，4.00-4.13(m，1H)，4.49-4.62(m，1H)，7.10-7.20(m，1H)，7.46-7.56(m，1H)，7.61-8.12(m，5H)，8.33-8.42(m，2H)，8.65-8.72(m，1H)，9.46-9.60(m，1H)，13.23-13.38(m，1H).

Embodiment 3182

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?383，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.76-2.05(m，8H)，2.54-2.73(m，3H)，3.93-4.07(m，1H)，4.29-4.48(m，1H)，7.10-7.19(m，1H)，7.47-7.57(m，1H)，7.72-7.85(m，2H)，7.92-8.04(m，1H)，8.21-8.33(m，1H)，8.48-8.57(m，1H)，8.65-8.73(m，1H)，8.82-8.89(m，1H)，9.14-9.20(m，1H)，9.42-9.58(m，1H)，12.93-13.08(m，1H).

Embodiment 3183

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the Isonicotinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the Isonicotinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?383，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.68-2.08(m，8H)，2.53-2.71(m，3H)，3.92-4.08(m，1H)，4.33-4.54(m，1H)，7.11-7.22(m，1H)，7.43-7.60(m，1H)，7.69-7.86(m，1H)，7.89-8.41(m，4H)，8.81-9.07(m，3H)，9.48-9.67(m，1H)，13.03-13.24(m，1H).

Embodiment 3184

4-chloro-pyridine-2-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 4-chloro-pyridine-2-carboxylic acids [cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?417，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.62-2.05(m，8H)，2.53-2.72(m，3H)，3.99-4.51(m，2H)，7.04-7.15(m，1H)，7.46-7.57(m，1H)，7.72-7.85(m，2H)，7.92-8.10(m，2H)，8.16-8.29(m，1H)，8.39(d，J＝8.1Hz，1H)，8.66(d，J＝5.3Hz，1H)，9.32-9.51(m，1H)，12.93-13.08(m，1H).

Embodiment 3185

5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride

Steps A: synthetic 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?439，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.71-2.02(m，8H)，2.54-2.71(m，3H)，3.88-4.08(m，1H)，4.25-4.50(m，1H)，7.06-7.18(m，1H)，7.47-7.56(m，1H)，7.70-7.83(m，1H)，7.91-8.04(m，1H)，8.19-8.33(m，1H)，8.43-8.64(m，2H)，8.86-8.88(m，1H)，8.97-8.99(m，1H)，9.35-9.50(m，1H)，12.89-13.08(m，1H).

Embodiment 3186

N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-6-trifluoromethyl-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-6-trifluoromethyl-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3071, obtain title compound.

ESI?MS?m/e?451，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.58-2.04(m，8H)，2.53-2.75(m，3H)，3.91-4.09(m，1H)，4.22-4.44(m，1H)，7.03-7.22(m，1H)，7.45-7.59(m，1H)，7.71-7.85(m，1H)，7.91-8.10(m，2H)，8.15-8.30(m，1H)，8.42-8.54(m，1H)，8.64-8.81(m，1H)，9.12-9.21(m，1H)，9.33-9.54(m，1H)，12.88-13.00(m，1H).

Embodiment 3187

6-imidazoles-1-base-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride

Steps A: synthetic 6-imidazoles-1-base-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the niacinamide dihydrochloride.

To the 6-chloro-N-[cis-4-that in the steps A of embodiment 3175, obtains (4-methyl-quinoline-2-base amino)-cyclohexyl]-add imidazoles (47mg) and iPr in BuOH (1mL) solution of niacinamide (250mg) ₂NEt (172mg).In the microwave synthesizer, this mixture in 220 ℃ of heating 10 minutes, was heated 20 minutes in 230 ℃.In this mixture, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 50%EtOAc).EtOAc (0.2mL) solution that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (12mL) stirred under room temperature 4 hours.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 6-imidazoles-1-base-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide dihydrochloride (83mg), be white solid.

ESI?MS?m/e?427，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.35-2.39(m，8H)，2.60-2.81(m，3H)，3.92-4.28(m，2H)，6.63-6.92(m，1H)，7.09-8.23(m，8H)，8.53-8.82(m，1H)，8.95-9.41(m，2H)，9.96-10.17(m，1H)，13.97-14.19(m，1H).

Embodiment 3188

N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

To in the step e of embodiment 1, obtain 3,4-two fluoro-phenylformic acid (199mg) and N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-quinoline-2 adds Et in DMF (3mL) solution of 4-diamines (300mg) ₃N (0.35mL), HOBt-water (241mg) and EDC-HCl (242mg).Stirred reaction mixture is 15 hours under room temperature.In mixture, add entry (4.8mL), with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc).The EtOAc solution (0.5mL) that in the EtOAc of above-mentioned substance (4mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour.Filter the collecting precipitation thing,, obtain N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl with EtOAc washing, drying under reduced pressure]-3,4-two fluoro-benzamide hydrochloride salts (263mg) are white solid.

ESI?MS?m/e?425，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.69-2.20(m，8H)，3.24(s，6H)，3.81-4.30(m，2H)，5.82(s，1H)，6.74-6.88(m，1H)，7.10-7.40(m，2H)，7.51-7.98(m，5H)，8.86-8.99(m，1H)，13.44-13.63(m，1H).

Embodiment 3189

5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3188, obtain title compound.

ESI?MS?m/e?462，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.17(m，8H)，3.25(s，6H)，3.82-4.00(m，1H)，4.00-4.23(m，1H)，5.82(s，1H)，7.25-7.40(m，1H)，7.58-7.97(m，4H)8.28-8.42(m，2H)，8.56-8.73(m，1H)，13.02-13.30(m，1H).

Embodiment 3190

N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts.

To the N that in the step B of embodiment 7, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴Methyl-quinoline-2, the CHCl of 4-diamines (300mg) ₃(3mL) add iPr in the solution ₂NEt (0.36mL) and 3,4-two fluoro-Benzoyl chlorides (194mg).Under room temperature, stirred this mixture 6 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 9%-20%EtOAc and the CHCl of 2%-9%MeOH ₃Solution), obtain N-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts (272mg) are white solid.

ESI?MS?m/e?439，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.53-2.08(m，9H)，3.21(s，6H)，3.47-3.56(m，2H)，3.86-3.98(m，1H)，5.81(s，1H)，6.95-7.09(m，1H)，7.16-7.34(m，2H)，7.53-7.68(m，2H)，7.80-7.95(m，3H)，9.08-9.22(m，1H)，13.40-13.51(m，1H).

Embodiment 3191

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride.

To the N that in the step B of embodiment 7, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-diformazan yl-quinoline-2 adds 1 in DMSO (3mL) solution of 4-diamines (300mg), 2-two chloro-4-isocyanato-benzene (207mg).Under room temperature, stirred this mixture 12 hours, then in the impouring water.Filtering-depositing washes with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 25%-50%EtOAc) in the warp.EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino yl-quinoline-2-base is amino)-cyclohexyl methyl]-urea hydrochloride (170mg), be white solid.

ESI?MS?m/e?486，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.51-2.18(m，9H)，3.23(s，6H)，3.36-3.44(m，2H)，3.91-4.02(m，1H)，5.78-5.88(m，1H)，6.97-7.12(m，3H)，7.26-7.35(m，1H)，7.58-7.66(m，1H)，7.86(m，J＝9.0Hz，2H)，8.16(dd，J＝8.2，1.7Hz，1H)，8.20-8.31(m，1H)，8.65-8.76(m，1H)，12.98-13.21(m，1H).

Embodiment 3192

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

To in the step D of embodiment 3107, obtain 3,4-two fluoro-phenylformic acid (199mg) and N ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2 adds Et in DMF (4mL) solution of 4-diamines (304mg) ₃N (0.35mL), HOBt-water (241mg) and EDC-HCl (242mg).Stirred reaction mixture is 7 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 1 hour.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc) in the warp.EtOAc (0.2mL) solution that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour.Filter the collecting precipitation thing,, obtain N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl with EtOAc washing, drying under reduced pressure]-3,4-two fluoro-benzamide hydrochloride salts (252mg) are white solid.

ESI?MS?m/e?430，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.56-2.22(m，12H)，2.48-2.84(m，4H)，3.23(s，6H)，3.92-4.33(m，2H)，6.51-6.77(m，1H)，7.01-7.30(m，1H)，7.43-7.86(m，2H)，8.28-8.57(m，1H)，12.56(m，1H).

Embodiment 3193

5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3192, obtain title compound.

ESI?MS?m/e?467，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.51-2.24(m，12H)，2.51-2.62(m，2H)，2.67-2.81(m，2H)，3.23(s，6H)，3.98-4.29(m，2H)，7.42-7.48(m，1H)，8.22-8.29(m，2H)，8.37(s，1H).

Embodiment 3194

1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 1-methyl-4-nitro-1H-pyrroles-2-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl]-amide hydrochloride

Adopt the method for the steps A of embodiment 3192, obtain title compound.

ESI?MS?m/e?442，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-2.13(m，12H)，2.49-2.61(m，2H)，2.68-2.81(m，2H)，3.22(s，6H)，3.93-4.04(m，4H)，4.14-4.24(m，1H)，7.04-7.12(m，1H)，7.23-7.27(m，1H)，7.49-7.54(m，1H)，8.30-8.41(m，1H)，12.66-12.92(m，1H).

Embodiment 3195

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts.

To the N that in the steps A of embodiment 3113, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2, the CHCl of 4-diamines (300mg) ₃(3mL) add iPr in the solution ₂NEt (0.36mL) and 3,4-two fluoro-Benzoyl chlorides (194mg).Under room temperature, stirred this mixture 17 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 33%EtOAc).EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts (263mg) are white solid.

ESI?MS?m/e?466，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.50-1.96(m，13H)，2.49-2.59(m，2H)，2.66-2.77(m，2H)，3.21(s，6H)，3.42-3.51(m，2H)，4.16-4.28(m，1H)，6.91-7.01(m，1H)，7.17-7.26(m，1H)，7.80-7.92(m，2H)，8.55(d，J＝8.2Hz，1H)，12.61-12.77(m，1H).

Embodiment 3196

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-the urea hydrochloride.

To the N that in the steps A of embodiment 3113, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-5,6,7,8-tetrahydrochysene-quinazoline-2 adds 1 in DMSO (3mL) solution of 4-diamines (300mg), 2-two chloro-4-isocyanato-benzene (207mg).Under room temperature, stirred this mixture 12 hours, then in the impouring water.Filtering-depositing washes with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 25%-50%EtOAc) in the warp.EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydrochysene-quinazoline-2-base is amino)-cyclohexyl methyl]-urea hydrochloride (113mg), be white solid.

ESI?MS?m/e?491，M ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.42-2.04(m，13H)，2.46-2.80(m，4H)，3.21(s，6H)，3.29-3.44(m，2H)，4.18-4.38(m，1H)，6.80-7.22(m，3H)，8.06-8.45(m，3H)，12.04-12.29(m，1H).

Embodiment 3197

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step D of embodiment 3129, obtain title compound.

ESI?MS?m/e?376，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-2.01(m，8H)，3.17(s，3H)，3.28(s，3H)，3.98-4.32(m，2H)，5.98(d，J＝7.3Hz，1H)，6.45-6.63(m，1H)，7.11-7.30(m，1H)，7.41-7.79(m，3H)，8.67-8.94(m，1H)，12.89-13.06(m，1H).

Embodiment 3198

5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride.

Cis-N in the step C of 5-nitro-thiophene-3-carboxylic acid (265mg) and embodiment 3129 ²-(4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2 adds Et in DMF (3mL) solution of 4-diamines (300mg) ₃N (0.43mL), HOBt-H ₂O (293mg) and EDC-HCl (293mg).Stirred reaction mixture is 12 hours under room temperature.In reaction mixture, add entry (20mL), under room temperature, this suspension was stirred 1 hour.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc) in the warp.The EtOAc (2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour.Filter the collecting precipitation thing, with the EtOAc washing, drying under reduced pressure obtains 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride (71mg), is white solid.

ESI?MS?m/e?413，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-2.02(m，8H)，3.18(s，3H)，3.27(s，3H)，3.99-4.29(m，2H)5.99(d，J＝7.5Hz，1H)，7.48-7.64(m，2H)，8.34(d，J＝1.8Hz，1H)，8.48(d，J＝1.8Hz，1H)，8.50-8.67(m，1H)，12.58-12.76(m，1H).

Embodiment 3199

5-(4-chloro-phenyl)-furans-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 5-(4-chloro-phenyl)-furans-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?462，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.07(m，8H)，3.17(s，3H)，3.28(s，3H)，4.01-4.27(m，2H)，5.97(d，J＝6.9Hz，1H)，6.71(d，J＝3.5Hz，1H)，6.76-6.87(m，1H)，7.17(d，J＝3.5Hz，1H)，7.36-7.55(m，3H)，7.69-7.79(m，2H)，8.65-8.86(m，1H)，13.08-13.30(m，1H).

Embodiment 3200

4 '-fluoro-xenyl-4-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 4 '-fluoro-xenyl-4-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?456，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.06(m，8H)，3.17(s，3H)，3.28(s，3H)，4.06-4.32(m，2H)，5.97(d，J＝7.3Hz，1H)，6.50-6.60(m，1H)，7.09-7.20(m，2H)，7.43-7.64(m，5H)，7.85-7.91(m，2H)，8.74-8.86(m，1H)，12.98-13.23(m，1H).

Embodiment 3201

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?473，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-2.05(m，8H)，3.16(s，3H)，3.26(s，3H)，4.07-4.24(m，2H)，5.94(d，J＝7.3Hz，1H)，7.09-7.20(m，3H)，7.23-7.32(m，2H)，7.42-7.52(m，1H)，7.81-7.94(m，1H)，8.20(dd，J＝4.8，2.0Hz，1H)，8.54(dd，J＝7.5，2.1Hz，1H)，8.70-8.80(m，1H)，13.23-13.38(m，1H).

Embodiment 3202

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide dihydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?419，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.14-1.35(m，3H)，1.55-1.92(m，8H)，3.15(s，3H)，3.24(s，3H)，3.45-3.64(m，2H)，3.75-4.06(m，4H)，5.91-6.03(m，1H)，7.00-7.64(m，7H)，8.32-8.48(m，1H)，13.12-13.34(m，1H).

Embodiment 3203

C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the ethanamide dihydrochloride

Steps A: synthetic C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?431，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.12-1.24(m，3H)，1.51-1.96(m，8H)，3.15(s，3H)，3.25(s，3H)，3.43-3.55(m，2H)，3.74-3.98(m，3H)，4.01-4.18(m，1H)，5.88-6.02(m，1H)，6.68-6.87(m，3H)，7.15-7.24(m，2H)，7.43-7.52(m，1H)，8.49-8.62(m，1H)，13.11-13.28(m，1H).

Embodiment 3204

2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?390，M(free)+H ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.46-1.87(m，8H)，3.15(s，3H)，3.18(s，3H)，3.46(s，2H)，3.58-3.75(m，1H)，3.86-4.04(m，1H)，6.36(d，J＝7.4Hz，1H)，7.05-7.13(m，1H)，7.27-7.40(m，2H)，7.84-7.94(m，1H)，8.10-8.19(m，1H)，8.27-8.38(m，1H)，12.14-12.23(m，1H).

Embodiment 3205

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step D of embodiment 3129, obtain title compound.

ESI?MS?m/e?376，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.64-2.02(m，8H)，3.17(s，3H)，3.28(s，3H)，4.01-4.31(m，2H)，5.97(d，J＝7.4Hz，1H)，6.46-6.57(m，1H)，6.87-6.98(m，1H)，7.30-7.40(m，2H)，7.49(d，J＝7.4Hz，1H)，8.77-8.93(m，1H).

Embodiment 3206

3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?392，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.00(m，8H)，3.17(s，3H)，3.28(s，3H)，4.03-4.30(m，2H)，5.97(d，J＝7.5Hz，1H)，6.43-6.53(m，1H)，7.19(t，J＝8.5Hz，1H)，7.43-7.54(m，1H)，7.65-7.75(m，1H)，7.90-7.97(m，1H)，8.76-8.94(m，1H)，12.95-13.14(m，1H).

Embodiment 3207

4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?392，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.56-1.98(m，8H)，3.05-3.27(m，6H)，3.76-4.10(m，2H)，6.37(d，J＝7.6Hz，1H)，7.65-7.80(m，2H)，7.84-7.97(m，2H)，8.21-8.34(m，1H)，8.39-8.56(m，1H)，12.09-12.27(m，1H).

Embodiment 3208

Pyridine-2-carboxylic acids [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride

Steps A: pyridine synthesis-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?341，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.72-2.07(m，8H)，3.17(s，3H)，3.27(s，3H)，4.02-4.22(m，2H)，5.97(d，J＝7.4Hz，1H)，7.36-7.55(m，2H)，7.76-7.88(m，1H)，8.10-8.29(m，2H)，8.52-8.70(m，2H).

Embodiment 3209

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the niacinamide dihydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the niacinamide dihydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?341，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.62-2.03(m，8H)，3.15(s，3H)，3.20(s，3H)，3.83-4.08(m，2H)，6.37(d，J＝7.4Hz，1H)，7.81-7.98(m，2H)，8.34-8.48(m，1H)，8.58-8.66(m，1H)，8.76-8.93(m，2H)，9.17-9.23(m，1H)，12.30-12.48(m，1H).

Embodiment 3210

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the Isonicotinamide dihydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the Isonicotinamide dihydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?341，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.67-1.99(m，8H)，3.16(s，3H)，3.20(s，3H)，3.84-4.07(m，2H)，6.37(d，J＝7.4Hz，1H)，7.86-8.02(m，1H)，8.25(d，J＝6.5Hz，2H)，8.48-8.57(m，1H)，8.95-9.13(m，3H)，12.53-12.69(m，1H).

Embodiment 3211

5-bromo-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the niacinamide hydrochloride

Steps A: synthetic 5-bromo-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?419，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.07(m，8H)，3.18(s，3H)，3.28(s，3H)，4.04-4.31(m，2H)，5.95-6.04(m，1H)，7.37-7.65(m，2H)，8.42(brs，1H)，8.63-8.74(m，1H)，8.79(brs，1H)，9.12(brs，1H)，12.72-12.97(m，1H).

Embodiment 3212

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-6-trifluoromethyl-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-6-trifluoromethyl-niacinamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?409，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.63-2.06(m，8H)，3.18(s，3H)，3.27(s，3H)，4.07-4.34(m，2H)，5.98(d，J＝7.4Hz，1H)，7.47-7.62(m，2H)，7.72(d，J＝8.0Hz，1H)，8.35-8.45(m，1H)，8.57-8.74(m，1H)，9.24-9.31(m，1H).

Embodiment 3213

4-chloro-pyridine-2-carboxylic acids [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride

Steps A: synthetic 4-chloro-pyridine-2-carboxylic acids [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-amide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?375，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.71-2.09(m，8H)，3.18(s，3H)，3.28(s，3H)，4.01-4.24(m，2H)，5.88-6.08(m，1H)，7.39-7.59(m，2H)，8.05-8.35(m，2H)，8.43-8.72(m，2H)，13.20-13.45(m，1H).

Embodiment 3214

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the step D of embodiment 3129, obtain title compound.

ESI?MS?m/e?380，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.63-2.24(m，8H)，3.17(s，3H)，3.27(s，3H)，4.01-4.32(m，2H)，5.97(d，J＝7.3Hz，1H)，6.38-6.57(m，1H)，7.01-7.17(m，2H)，7.41-7.54(m，1H)，7.77-7.91(m，2H)，8.76-8.84(m，1H)，12.86-13.14(m，1H).

Embodiment 3215

3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?414，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.03(m，8H)，3.17(s，3H)，3.28(s，3H)，4.02-4.31(m，2H)，5.97(d，J＝7.4Hz，1H)，6.53-6.67(m，1H)，7.16-7.23(m，1H)，7.41-7.51(m，2H)，7.58-7.64(m，1H)，8.76-8.91(m，1H).

Embodiment 3216

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?416，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.03(m，8H)，3.18(s，3H)，3.28(s，3H)，4.01-4.34(m，2H)，5.98(d，J＝7.4Hz，1H)，6.70-6.79(m，1H)，7.42-7.63(m，3H)，8.73-8.86(m，1H).

Embodiment 3217

3,5-two-tertiary butyl-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-dihydroxyl-benzamide hydrochloride salt

Steps A: synthesize 3,5-two-tertiary butyl-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-hydroxyl-benzamide hydrochloride salt.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?490，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.47(s，18H)，1.63-2.13(m，8H)，3.17(s，3H)，3.28(s，3H)，4.05-4.27(m，2H)，5.52(s，1H)，5.90-6.02(m，1H)，6.57-6.73(m，1H)，7.41-7.55(m，1H)，7.63(s，2H)，8.60-8.77(m，1H)，13.00-13.24(m，1H).

Embodiment 3218

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-the urea hydrochloride.

To the N that in the step C of embodiment 3129, obtains ²-(cis-4-amino-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2 adds 1 in DMSO (3mL) solution of 4-diamines (300mg), 2-two chloro-3-isocyanato-benzene (264mg).Under room temperature, stirred this mixture 12 hours, then in the impouring water.Filtering-depositing washes with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 25%-50%EtOAc) in the warp.EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-urea hydrochloride (421mg), be white solid.

ESI?MS?m/e?445，M(free)+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.63-2.19(m，8H)，3.15(s，3H)，3.25(s，3H)，3.80-4.22(m，2H)，5.94(d，J＝7.4Hz，1H)，7.00-7.19(m，2H)，7.43-7.64(m，2H)，8.16(dd，J＝8.3，1.7Hz，1H)，8.37-8.52(m，1H)，12.70-13.00(m，1H).

Embodiment 3219

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts.

To the N that in embodiment 3145 step B, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴-dimethyl-pyrimidine-2, the CHCl of 4-diamines (300mg) ₃(3mL) add iPr in the solution ₂NEt (0.59mL) and 3,4-two fluoro-Benzoyl chlorides (233mg).Under room temperature, stirred this mixture 17 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 33%EtOAc).EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide hydrochloride salts (155mg) are white solid.

ESI?MS?m/e?412，M(free)+Na ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.26-2.03(m，9H)，3.16(s，3H)，3.26(s，3H)，3.37-3.61(m，2H)，4.18-4.35(m，1H)，5.94(d，J＝7.4Hz，1H)，6.82-7.33(m，2H)，7.46(d，J＝7.4Hz，1H)，7.74-8.07(m，2H)，8.83-9.12(m，1H).

Embodiment 3220

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-2-(2,3,6-three chloro-phenyl)-acetamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-2-(2,3,6-three chloro-phenyl)-acetamide hydrochloride.

Adopt the method for the step C of embodiment 3118, obtain title compound.

ESI?MS?m/e?492，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-1.98(m，9H)，3.16(s，3H)，3.21-3.33(m，4H)，4.16(s，2H)，4.20-4.34(m，1H)，5.95-5.99(m，1H)，6.51-6.64(m，1H)，7.23-7.51(m，3H)，8.75-8.83(m，1H)，12.80-12.95(m，1H).

Embodiment 3221

9H-xanthene-9-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-amide hydrochloride

Steps A: synthetic 9H-xanthene-9-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-amide hydrochloride.

Adopt the method for the step C of embodiment 3118, obtain title compound.

ESI?MS?m/e?480，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.27-1.94(m，9H)，3.05-3.19(m，5H)，3.24(s，3H)，4.14-4.28(m，1H)，5.10(s，1H)，5.91(d，J＝7.4Hz，1H)，6.19-6.33(m，1H)，6.98-7.18(m，3H)，7.20-7.31(m，2H)，7.37-7.54(m，3H)，8.62-8.82(m，1H)12.88-13.08(m，1H)

Embodiment 3222

1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-the urea hydrochloride

Steps A: synthetic 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-the urea hydrochloride.

To the N that in embodiment 3145 step B, obtains ²-(cis-4-amino methyl-cyclohexyl)-N ⁴, N ⁴Methyl-pyrimidine-2 adds 1 in DMSO (3mL) solution of 4-diamines (300mg), 2-two chloro-3-isocyanato-benzene (249mg).Under room temperature, stirred this mixture 15 hours, in the impouring water (20mL).Filtering-depositing washes with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 25%-50%EtOAc) in the warp.EtOAc (10mL) solution that in the EtOAc of above-mentioned substance (2mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With described residue at Et ₂Suspension among the O (20mL) stirred under room temperature 1 hour.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-urea hydrochloride (260mg), be white solid.

ESI?MS?m/e?437，M ⁺； ¹H?NMR(200MHz，CDCl ₃)δ1.35-2.10(m，9H)，3.16(s，3H)，3.26(s，3H)，3.32-3.47(m，2H)，4.27-4.47(m，1H)，5.96(d，J＝7.5Hz，1H)，6.80-7.20(m，3H)，7.47(d，J＝7.5Hz，1H)，8.08-8.37(m，2H)，8.63-8.93(m，1H).

Embodiment 3223

3,4-two fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide-hydrochloride

Steps A: synthetic (2-chloro-pyrimidine-4-yl)-methyl-amine.

To 2, add 40% MeNH in THF (150mL) solution of 4-two chloro-pyrimidines (15.0g) ₂The aqueous solution (19.5g).Under room temperature, stirred this mixture 1.5 hours.In this solution impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc), obtain to (the 2-chloro-pyrimidine-4-yl)-methyl-amine (10.0g) of white solid and be (the 4-chloro-pyrimidine-2-base)-methyl-amine of white solid (0.87g, 6%).

(2-chloro-pyrimidine-4-yl)-methyl-amine;

ESI?MS?m/e?143，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.01(d，J＝5.0Hz，3H)，5.58-5.96(m，1H)，6.55(d，J＝5.1Hz，1H)，8.09-8.23(m，1H).

(4-chloro-pyrimidine-2-base)-methyl-amine;

ESI?MS?m/e?143，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.98(d，J＝5.0Hz，3H)，6.27(d，J＝6.1Hz，1H)，7.93-8.20(m，1H).

Step B: synthetic [cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester.

The stirring down 24 hours that refluxes of the mixture in BuOH (2.50mL) with (2-chloro-pyrimidine-4-yl)-methyl-amine (2.50g) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (4.10g) of in the step B of embodiment 1, obtaining.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 25%-66%EtOAc).Obtain [cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (2.63g), be white solid.

ESI?MS?m/e?344，M+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.36-1.88(m，17H)，2.89(d，J＝5.1Hz，3H)，3.53-3.69(m，1H)，3.84-4.04(m，1H)，4.44-4.70(m，2H)，4.76-4.86(m，1H)，5.69-5.72(m，＝1H)，7.80-7.91(m，1H).

Step C: synthetic N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-pyrimidine-2, the 4-diamines.

EtOAc (48mL) solution of [cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-carboxylamine tertiary butyl ester (4.76g) is cooled off on ice bath, add the EtOAc solution (24mL) of 4M hydrogenchloride.Under room temperature, stirred this mixture 4 hours and concentrating under reduced pressure.Residue is dissolved in the 1M NaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (5 times).The organic layer that merges is through dried over mgso, filters, concentrating under reduced pressure, and drying under reduced pressure obtains N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-pyrimidine-2,4-diamines (3.00g, 80%) is white solid.

ESI?MS?m/e?222，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ0.95-1.92(m，10H)，2.78-2.99(m，4H)，3.92-4.08(m，1H)，4.56-4.75(m，1H)，4.84-4.97(m，1H)，5.68(d，J＝5.9Hz，1H)，7.85(d，J＝5.7Hz，1H).

Step D: synthesize 3,4-two fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

To 3,4-two fluoro-phenylformic acid (196mg) and N ²-(cis-4-amino-cyclohexyl)-N ⁴-methyl-pyrimidine-2 adds Et in DMF (4mL) solution of 4-diamines (250mg) ₃N (0.38mL), HOBt-water (259mg) and EDC-HCl (238mg).Stirred reaction mixture is 12 hours under room temperature.In mixture, add entry (20mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 33%-75%EtOAc).The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour.Filter the collecting precipitation thing, with the EtOAc washing, drying under reduced pressure obtains 3,4-two fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt (317mg), be white solid.

ESI?MS?m/e?362，M(free)+H ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.59-1.90(m，8H)，2.89(d，J＝4.6Hz，3H)，3.80-4.11(m，2H)，6.03-6.13(m，1H)，7.47-8.03(m，4H)，8.27-8.49(m，2H)，8.82-9.06(m，1H)，11.92-12.11(m，1H).

Embodiment 3224

3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step C of embodiment 3223, obtain title compound.

ESI?MS?m/e?378，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.59-1.90(m，8H)，2.89(d，J＝4.6Hz，3H)，3.77-4.10(m，2H)，6.00-6.12(m，1H)，7.49-7.60(m，1H)，7.67-7.76(m，1H)，7.85-7.94(m，1H)，8.11(dd，J＝7.1，2.2Hz，1H)，8.24-8.51(m，2H)，8.82-8.94(m，1H)，11.80-11.98(m，1H).

Embodiment 3225

N-[cis-4-(4-ethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic (2-chloro-pyrimidine-4-yl)-ethyl-amine.

To 2, add 70%EtNH in THF (50mL) solution of 4-two chloro-pyrimidines (5.00g) ₂The aqueous solution (5.40g).Under room temperature, stirred this mixture 1 hour.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (2 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, through flash chromatography purifying (silica gel, the hexane solution of 17%-50%EtOAc), obtain to (the 2-chloro-pyrimidine-4-yl)-ethyl-amine (3.69g) of white solid and be (the 4-chloro-pyrimidine-2-base)-ethyl-amine (1.28g) of white solid.

(2-chloro-pyrimidine-4-yl)-ethyl-amine;

ESI?MS?m/e?157，M ⁺； ¹H?NMR(500MHz，CDCl ₃)δ1.26(t，J＝7.3Hz，3H)，3.16-3.62(m，2H)，4.80-5.95(m，1H)，6.23(d，J＝5.8Hz，1H)，8.02-8.22(m，1H).

(4-chloro-pyrimidine-2-base)-ethyl-amine;

CI?MS?m/e?158，M+H ⁺； ¹H?NMR(500MHz，CDCl ₃)δ1.23(t，J＝7.5Hz，3H)，3.42-3.49(m，2H)，5.30-5.62(m，1H)，6.54(d，J＝5.2Hz，1H)，8.02-8.22(m，1H).

Step B: synthetic N-[cis-4-(4-ethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

To the N-that in the step D of embodiment 3031, obtains (cis-4-amino-cyclohexyl)-3, add (2-chloro-pyrimidine-4-yl)-ethyl-amine (532mg) in BuOH (1mL) solution of 4-two fluoro-benzamide (300mg).In the microwave synthesizer, this mixture was heated 30 minutes in 200 ℃.Add saturated sodium bicarbonate aqueous solution to mixture, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc).The EtOAc solution (5.00mL) that in the EtOAc of above-mentioned substance (10.0mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (20mL) stirred under room temperature 4 hours.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains N-[cis-4-(4-ethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts (398mg) are white solid.

ESI?MS?m/e?398，M(free)+Na ⁺； ¹H?NMR(500MHz，CDCl ₃)δ1.19-1.42(m，3H)，1.61-2.05(m，8H)，3.46-3.65(m，2H)，4.00-4.34(m，2H)，5.85-6.00(m，1H)，6.42-6.72(m，2H)，7.11-7.37(m，2H)，7.52-7.82(m，2H)，8.68-8.90(m，1H).

Embodiment 3226

N-{ cis-4-[4-(ethyl-methyl-amino)-pyrimidine-2--amino]-cyclohexyl }-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic (2-chloro-pyrimidine-4-yl)-ethyl-methyl-amine.

To 2, add ethyl-methyl-amine (2.08g) in THF (50mL) solution of 4-two chloro-pyrimidines (5.00g).Under room temperature, stirred this mixture 1 hour.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (2 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, through flash chromatography purifying (silica gel, the hexane solution of 17%-50%EtOAc), obtain (2-chloro-pyrimidine-4-yl)-ethyl-methyl-amine (4.49g), be white solid, and (4-chloro-pyrimidine-2-base)-ethyl-methyl-amine (0.91g), be colorless oil.

(2-chloro-pyrimidine-4-yl)-ethyl-methyl-amine;

CI?MS?m/e?172，M(free)+H ⁺； ¹H?NMR(500MHz，CDCl ₃)δ1.18(t，J＝3.0Hz，3H)，3.06(brs，3H)，3.35-3.70(m，2H)，6.29(d，J＝4.8Hz，1H)，7.99(d，J＝6.1Hz，1H).

(4-chloro-pyrimidine-2-base)-ethyl-methyl-amine;

CI?MS?m/e?172，M+H ⁺； ¹H?NMR(500MHz，CDCl ₃)δ1.17(t，J＝3.0Hz，3H)，3.10(s，3H)，3.66(q，J＝7.0Hz，2H)，6.45(d，J＝5.0Hz，1H)，8.14(d，J＝5.0Hz，1H).

Step B: synthetic N-{ cis-4-[4-(ethyl-methyl-amino)-pyrimidine-2--amino]-cyclohexyl }-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?412，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.18-1.33(m，3H)，1.64-2.03(m，8H)，3.13-3.32(m，3H)，3.44-3.56(m，1H)，3.67-3.82(m，1H)，4.04-4.31(m，2H)，5.90-6.00(m，1H)，6.59-6.72(m，1H)，7.14-7.27(m，1H)，7.43-7.62(m，2H)，7.68-7.79(m，1H)，8.71-8.83(m，1H).

Embodiment 3227

3,4-two fluoro-N-(cis-4-{4-[(2-hydroxyl-ethyl)-methyl-amino]-pyrimidine-2--amino }-cyclohexyl)-benzamide hydrochloride salt

Steps A: synthetic [(2-chloro-pyrimidine-4-yl)-methyl-amino]-ethanol.

To 2, add 2-methylamino-ethanol (2.65g) in THF (50mL) solution of 4-two chloro-pyrimidines (5.00g).Under room temperature, stirred this mixture 1 hour.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (2 times).The organic layer that merges is through dried over mgso, and filtration, concentrating under reduced pressure are through flash chromatography purifying (silica gel, the hexane solution of 17%-50%EtOAc).Obtain to [(2-chloro-pyrimidine-4-yl)-methyl-amino]-ethanol (3.50g) of white solid and be [(4-chloro-pyrimidine-2-base)-methyl-amino]-ethanol (827mg) of white solid.

[(2-chloro-pyrimidine-4-yl)-methyl-amino]-ethanol;

ESI?MS?m/e?188，M(free)+H ⁺； ¹H?NMR(500MHz，CDCl ₃)δ2.91(brs，3H)，3.13(s，3H)，3.64-3.92(m，4H)，6.46-6.49(m，1H)，7.99(d，J＝6.1Hz，1H).

[(4-chloro-pyrimidine-2-base)-methyl-amino]-ethanol;

ESI?MS?m/e?210，M+Na ⁺； ¹HNMR(500MHz，CDCl ₃)δ3.23(s，3H)，3.76-3.92(m，4H)，6.52(d，J＝5.2Hz，1H)，8.12(d，J＝4.6Hz，1H).

Step B: synthesize 3,4-two fluoro-N-(cis-4-{4-[(2-hydroxyl-ethyl)-methyl-amino]-pyrimidine-2--amino }-cyclohexyl)-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?428，M(free)+Na ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.61-1.98(m，8H)，3.13-3.25(m，3H)，3.54-4.31(m，5H)，4.76-5.02(m，1H)，6.26-6.52(m，1H)，7.48-7.62(m，1H)，7.68-8.17(m，4H)，8.28-8.47(m，1H)，11.74-11.95(m，1H).

Embodiment 3228

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide.

In DMF (300mL) solution of 3-chloro-4-fluoro-phenylformic acid (26.9g) and (cis-4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (30.0g), add Et ₃N (46.8mL), HOBt-water (32.2g) and EDC-HCl (29.5g).Stirred reaction mixture is 20 hours under room temperature.In mixture, add entry (1.20L), with water layer CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrating under reduced pressure.EtOAc (650mL) solution of above-mentioned substance is cooled off on ice bath, add the EtOAc solution (325mL) of 4M hydrogenchloride.Under room temperature, stirred this mixture 16 hours and concentrating under reduced pressure.Residue is dissolved in the 1M NaOH aqueous solution (300mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrating under reduced pressure, and drying under reduced pressure obtains N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide (44.4g), is brown solid.

ESI?MS?m/e?271，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.37-1.92(m，8H)，2.94-3.08(m，1H)，4.06-4.22(m，1H)，6.13-6.31(m，1H)，7.19(t，J＝8.5Hz，1H)，7.61-7.70(m，1H)，7.79-7.87(m，1H).

Step B: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

In BuOH (1mL) solution of N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide (432mg), be added in the 2-chloro-4-dimethylamino-5-methylpyrimidine (250mg) that obtains in the steps A of embodiment 3119.In the microwave synthesizer, this mixture was heated 10 minutes in 200 ℃.Add saturated sodium bicarbonate aqueous solution to mixture, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc), obtain faint yellow oily thing.The EtOAc solution (0.2mL) that in the EtOAc of above-mentioned substance (10mL) solution, adds 4M hydrogenchloride.Under room temperature, stirred this mixture 1 hour and concentrating under reduced pressure.With above-mentioned substance at Et ₂Suspension among the O (20mL) stirred under room temperature 4 hours.Filter the collecting precipitation thing, use Et ₂The O washing, drying under reduced pressure obtains 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt (174mg), be white solid.

ESI?MS?m/e406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-2.02(m，8H)，2.25(s，3H)，3.30(s，6H)，4.02-4.26(m，2H)，6.81-6.93(m，1H)，7.13-7.27(m，2H)，7.70-7.78(m，1H)，7.93-8.00(m，1H)，8.50-8.63(m，1H)，12.68-12.85(m，1H).

Embodiment 3229

3-chloro-N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3228, obtain title compound.

ESI?MS?m/e?410，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.03(m，8H)，3.36(s，6H)，4.00-4.23(m，2H)，6.73-6.84(m，1H)，7.18(t，J＝8.6Hz，1H)，7.45(d，J＝7.6Hz，1H)，7.67-7.76(m，1H)，7.95(dd，J＝7.0，2.2Hz，1H)，8.64-8.78(m，1H).

Embodiment 3230

3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3228, obtain title compound.

ESI?MS?m/e?406，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.62-2.04(m，8H)，2.36(s，3H)，3.15(s，3H)，3.27(s，3H)，4.01-4.31(m，2H)，5.76(s，1H)，6.73-6.84(m，1H)，7.19(t，J＝8.6Hz，1H)，7.68-7.79(m，1H)，7.97(dd，J＝6.9，2.2Hz，1H)，8.50-8.63(m，1H)，12.94-13.16(m，1H).

Embodiment 3231

N-[cis-4-(4-dimethylamino-6-ethyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic (2,6-two chloro-pyrimidine-4-yl)-dimethyl-amine.

To 2,4, add 50%Me in THF (50mL) solution of 6-three chloro-pyrimidines (10.0g) ₂The NH aqueous solution (4.92g) and iPr ₂NEt (8.46g).Under room temperature, stirred this mixture 1.5 hours and concentrating under reduced pressure.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, and filtration, concentrating under reduced pressure, obtain (2,6-two chloro-pyrimidine-4-yl)-dimethyl-amine (6.03g) through flash chromatography purifying (NH-silica gel, the hexane solution of 3%EtOAc), are white solid.

ESI?MS?m/e?192，M ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.77-3.46(m，6H)，6.34(s，1H)。

Step B: synthetic (2-chloro-6-ethyl-pyrimidine-4-yl)-dimethyl-amine.

With ZnBr ₂THF (3.87g) (60mL) solution is cooled to-60 ℃, adds THF (17.2mL) solution of 1MEtMgBr.Under-60 ℃, stirred this mixture 1 hour, be warmed to room temperature then.In this mixture, add THF (60mL) solution of (2,6-two chloro-pyrimidine-4-yl)-dimethyl-amine, under refluxing, stirred 5 days.In mixture, add saturated aqueous ammonium chloride, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, press liquid chromatography purification (silica gel in the warp, the hexane solution of 17%-33%EtOAc), obtain to (the 2-chloro-6-ethyl-pyrimidine-4-yl)-dimethyl-amine (352mg) of faint yellow solid and be (the 6-chloro-2-ethyl-pyrimidine-4-yl)-dimethyl-amine (622mg) of faint yellow solid.

(2-chloro-6-ethyl-pyrimidine-4-yl)-dimethyl-amine;

ESI?MS?m/e?208，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.25(t，J＝7.6Hz，3H)，2.54-2.66(m，2H)，3.11(s，6H)，6.15(s，1H).

(6-chloro-2-ethyl-pyrimidine-4-yl)-dimethyl-amine;

ESI?MS?m/e186，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.29(t，J＝7.6Hz，3H)，2.74(q，J＝7.7Hz，2H)，3.10(s，6H)，6.24(s，1H).

Step C: synthetic N-[cis-4-(4-dimethylamino-6-ethyl-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?426，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.29-1.44(m，3H)，1.58-2.19(m，8H)，2.54-2.77(m，2H)，3.15(s，3H)，3.26(s，3H)，3.98-4.34(m，2H)，5.74(s，1H)，6.41-6.63(m，1H)，7.08-7.32(m，1H)，7.46-7.81(m，2H)，8.58-8.81(m，1H)，12.83-13.09(m，1H).

Embodiment 3232

N-[cis-4-(4,6-two-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: Synthetic 2-chloro-N, N, N ', N '-tetramethyl--pyrimidine-4,6-diamines.

In THF (2mL) solution of (2, the 6-two chloro-pyrimidine-4-yl)-dimethyl-amine (1.60g) that in the steps A of embodiment 3231, obtains, add 50%Me ₂The NH aqueous solution (789mg).In sealed tube, this mixture backflow was stirred 3.5 hours down, in residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (silica gel, the hexane solution of 20%EtOAc).Obtain being light brown solid 2-chloro-N, N, N ', N '-tetramethyl--pyrimidine-4,6-diamines (203mg) and be the 6-chloro-N of faint yellow solid, N, N ', N '-tetramethyl--pyrimidine-2,4-diamines (1.43g).

2-chloro-N, N, N ', N '-tetramethyl--pyrimidine-4,6-diamines;

ESI MS m/e 201, M (dissociating)+H ^{+ 1}H NMR (300MHz, CDCl ₃) δ 3.05 (s, 12H), 5.15 (s, 1H).

6-chloro-N, N, N ', N '-tetramethyl--pyrimidine-2,4-diamines;

ESI?MS?m/e?201，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ3.04(s，6H)，3.13(s，6H)，5.76(s，1H)。

Step B: synthetic N-[cis-4-(4,6-two-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?441，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.61-2.09(m，8H)，2.96-3.38(m，12H)，4.00-4.31(m，2H)，4.73(s，1H)，6.65-6.82(m，1H)，7.13-7.25(m，1H)，7.55-7.63(m，1H)，7.68-7.78(m，1H)，8.70-8.82(m，1H)，11.79-11.99(m，1H).

Embodiment 3233

N-[cis-4-(6-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride

Steps A: synthetic N-[cis-4-(6-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide hydrochloride.

Adopt the method for the step B of embodiment 3032, obtain title compound.

ESI?MS?m/e?489，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.52-2.10(m，8H)，2.96-3.38(m，6H)，4.02-4.29(m，2H)，5.82-6.03(m，1H)，7.04-7.55(m，6H)，7.80-8.01(m，1H)，8.15-8.28(m，1H)，8.47-8.61(m，1H).

Embodiment 3234

N-[cis-4-(6-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(6-chloro-4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?432，M(free)+Na ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.63-2.05(m，8H)，3.04-3.37(m，6H)，4.02-4.37(m，2H)，5.88-6.03(m，1H)，6.56-6.86(m，1H)，7.14-7.27(m，1H)，7.51-7.63(m，1H)，7.66-7.82(m，1H)，8.85-9.02(m，1H).

Embodiment 3235

N-[cis-4-(4-amino-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts

Steps A: Synthetic 2-chloro-quinolyl-4 amine.

To in the steps A of embodiment 1, obtain 2, add 28%NH in IPA (40mL) solution of 4-two chloro-quinoline (4.00g) ₃Water (40.0mL).In sealed tube, this mixture backflow was stirred 10 days down.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, through in press liquid chromatography purification (silica gel, the hexane solution of 9%-17%EtOAc), obtain to the 2-chloro-quinolyl-4 amine (1.39g) of white solid and be the basic amine (1.17g) of the 4-chloro-quinoline of white solid-2-.

2-chloro-quinolyl-4 amine;

ESI?MS?m/e?178，M ⁺； ¹HNMR(200MHz，CDCl ₃)δ4.69-4.97(m，2H)，6.61(s，1H)，7.37-7.78(m，3H)，7.84-8.02(m，1H).

4-chloro-quinoline-2-base amine

ESI?MS?m/e?178，M ⁺； ¹HNMR(300MHz，CDCl ₃)δ4.58-4.96(m，2H)，6.85(s，1H)，7.23-7.41(m，1H)，7.53-7.72(m，2H)，7.98-8.09(m，1H).

Step B: synthetic N-[cis-4-(4-amino-quinoline-2-base is amino)-cyclohexyl]-3,4-two fluoro-benzamide hydrochloride salts.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?397，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.29-2.15(m，8H)，3.75-3.90(m，1H)4.05，4.26(m，1H)，5.44-5.59(m，2H)，5.89(s，1H)，6.99-7.43(m，3H)，7.55-7.84(m，5H)，8.81-8.98(m，1H).

Embodiment 3236

2-(cis-4-{[1-(3,4-two fluoro-phenyl)-formyl radical] amino }-cyclohexyl amino)-Cinchonic Acid's acid amides

Steps A: Synthetic 2-chloro-Cinchonic Acid acid amides.

In 2-chloro-Cinchonic Acid's (3.00g) DMF (30mL) solution, add 28%NH ₃The aqueous solution (1.05g), Et ₃N (5.04mL), HOBt-water (3.32g) and EDC-HCl (3.32g).Stirred reaction mixture is 16 hours under room temperature.In reaction mixture, add entry (20mL), with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc), obtain 2-chloro-Cinchonic Acid acid amides (1.77g), be white solid.

ESI?MS?m/e?207，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ7.65(s，1H)，7.68-7.77(m，1H)，7.83-7.93(m，1H)，7.98-8.09(m，2H)，8.18-8.25(m，1H)，8.30-8.40(m，1H).

Step B: Synthetic 2-(cis-4-{[1-(3,4-two fluoro-phenyl)-formyl radical] amino }-cyclohexyl amino)-Cinchonic Acid's acid amides.

With 2-chloro-Cinchonic Acid acid amides (300mg) and the N-(cis-4-amino-cyclohexyl)-3 that obtains in the steps A of embodiment 3031, the mixture of 4-two fluoro-benzamide (406mg) in butanols (1mL) and DMSO (1mL) stirred 24 hours under refluxing.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in the press liquid chromatography purification (NH-silica gel, EtOAc), concentrating under reduced pressure, washing above-mentioned substance, drying under reduced pressure.Obtain 2-(cis-4-{[1-(3,4-two fluoro-phenyl)-formyl radical] amino }-cyclohexyl amino)-Cinchonic Acid's acid amides (136mg), be white solid.

ESI?MS?m/e?447，M(free)+Na ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.61-2.03(m，8H)，3.78-3.93(m，1H)，4.05-4.20(m，1H)，6.89(s，1H)，6.99-7.07(m，1H)，7.11-7.21(m，1H)，7.42-7.61(m，3H)，7.65-7.82(m，3H)，7.88-7.99(m，1H)，8.02-8.10(m，1H)，8.28-8.36(m，1H).

Embodiment 3237

3,4-two fluoro-N-[cis-4-(4-fluoroform yl-quinoline-2-yl)-amino-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(4-fluoroform yl-quinoline-2-yl)-amino-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3225, obtain title compound.

ESI?MS?m/e?472，M(free)+Na ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.80-2.10(m，8H)，3.99-4.28(m，2H)，6.46-6.63(m，1H)，7.12-7.34(m，2H)，7.48-7.63(m，2H)，7.66-7.90(m，3H)，7.94-8.05(m，1H)，10.14-10.35(m，1H).

Embodiment 3238

3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid

Steps A: synthesize 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid.

To the N-that in the steps A of embodiment 3070, obtains (cis-4-methyl-quinoline-2-yl)-hexanaphthene-1, the CHCl of 4-diamines (3.00g) ₃(30mL) add Et in the solution ₃N (3.40mL) and 3,4-two fluoro-Benzoyl chlorides (2.28g).Under room temperature, stirred this mixture 6 hours.In this mixture, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-33%EtOAc and silica gel, the CHCl of 2%-5%MeOH ₃Solution), obtain 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide (3.52g), be colorless solid.To 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-add MsOH (179mg) in EtOH (7mL) solution of benzamide (700mg).Under room temperature, stirred this mixture 3 hours.Filter the collecting precipitation thing,,, obtain 3,4-two fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl in 70 ℃ of drying under reduced pressure with the EtOH washing]-benzamide methylsulfonic acid (769mg), be white solid.

ESI?MS?m/e?396，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.69-2.01(m，8H)，2.42(s，3H)，2.62(brs，3H)，3.90-4.21(m，2H)，7.02-7.13(m，1H)，7.47-7.61(m，2H)，7.75-8.04(m，5H)，8.35，(d，J＝6.4Hz，1H)，9.15-9.42(m，1H)，12.27-12.51(m，1H).

Embodiment 3239

3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid

Steps A: synthetic 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid.

To 3-chloro-4-fluoro-phenylformic acid (2.26g) and N-(cis-4-methyl-quinoline-2-yl)-hexanaphthene-1 of in the steps A of embodiment 3070, obtaining, add Et in DMF (30mL) solution of 4-diamines (3.00g) ₃N (3.93mL), HOBt-water (2.70g) and EDC-HCl (2.47g).Stirred reaction mixture is 6 hours under room temperature.In reaction mixture, add entry (200mL), under room temperature, this suspension was stirred 30 minutes.Filter collecting precipitation, wash with water, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-33%EtOAc) in the warp.Obtain 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-benzamide (4.40g), be colorless solid.To 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-add MsOH (196mg) in EtOH (8mL) solution of benzamide (800mg).Under room temperature, stirred this mixture 4 hours.Filter the collecting precipitation thing,,, obtain 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl in 80 ℃ of drying under reduced pressure with the EtOH washing]-benzamide methylsulfonic acid (845mg), be white solid.

ESI?MS?m/e?434，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.66-1.99(m，8H)，2.38(s，3H)，2.56-2.73(m，3H)，3.87-4.21(m，2H)，6.99-7.14(m，1H)7.48-7.58(m，2H)，7.74-7.84(m，1H)，7.87-8.05(m，3H)，8.12(dd，J＝7.2，2.2Hz，1H)，8.36-8.41(m，1H)，9.14-9.39(m，1H)，12.28-12.55(m，1H).

Embodiment 3240

3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid

Steps A: synthetic 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-the benzamide methylsulfonic acid.

The cis that in the steps A of embodiment 3033, obtains-N-quinoline-2-base-hexanaphthene-1, the CHCl of 4-diamines (4.00g) ₃(40mL) add Et in the solution ₃N (4.85mL) and 3-methoxyl group-Benzoyl chloride (3.10g).Under room temperature, stirred this mixture 6 hours.With saturated sodium bicarbonate aqueous solution quencher reactant, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%EtOAc).Obtain 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl]-benzamide (5.42g), be colorless solid.To 3-methoxyl group-N-[cis-4-(quinoline-2-base amino)-cyclohexyl]-add MsOH (188mg) in EtOH (7mL) solution of benzamide (700mg).Under room temperature, stirred this mixture 24 hours.Filter the collecting precipitation thing,,, obtain 3-methoxyl group-N-[cis-4-(quinoline-2-base is amino)-cyclohexyl in 80 ℃ of drying under reduced pressure with the EtOH washing]-benzamide methylsulfonic acid (741mg), be white solid.

ESI?MS?m/e?398，M(free)+Na ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.70-1.99(m，8H)，2.35(s，3H)，3.81(s，3H)3.90-4.04(m，1H)，4.08-4.22(m，1H)，7.06-7.26(m，2H)，7.32-7.56(m，4H)，7.73-8.02(m，3H)，8.17-8.38(m，2H)，12.41-12.58(m，1H).

Embodiment 3241

N-{ cis-4-[(4-amino-5-methylpyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: Synthetic 2-chloro-5-methyl-pyrimidine-4-base amine.

Make 2, (4.1g 0.025mol) is dissolved among the THF (30mL) 4-two chloro-5-methyl-pyrimidine solution, cools off on ice bath.In mixture, add 7N NH ₃MeOH (14.4mL, 0.10mol) solution continue to stir spend the night (wherein ice-out and reactant are warmed to the required time of room temperature).Vacuum is removed excessive solvent, and throw out is suspended in the methylene dichloride (20mL).Organic layer is extracted with sodium bicarbonate aqueous solution (20mL), filter two-layer extract, collect the infusible precipitate that generates.With cold water washing throw out and dry, obtain 2-chloro-5-methyl-pyrimidine-4-base amine (1.0g, 0.0070mol, 27%), be white solid.

ESI-MS?m/e?144.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.80(s，1H)，7.22(bs，2H)，1.93(s，3H).

Step B: synthetic N-{ cis-4-[(4-amino-5-methylpyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To 2-chloro-5-methyl-pyrimidine-4-base amine (292mg, add in 2mL 2-propanol solution 2.03mmol) DIEA (531uL, 3.05mmol) and cis-N-(4-amino-cyclohexyl)-3,5-two (trifluoromethyl)-benzamide (720mg, 2.03mmol).Then in 170 ℃, with this mixture heating up 1 hour.Reaction mixture concentrates, and the oily matter of generation is through column purification (dichloromethane solution of 0-5%MeOH).The evaporation organic solvent is dissolved in the 4mL methylene dichloride oily matter of generation once more, adds the Et of 2M HCl ₂O solution (2.0mL, 4.0mmol).This reactant was stirred 30 minutes, remove and desolvate.With the sedimentation and filtration that forms, then, with the hexane solution washing of 50% cold ether, obtain N-{ cis-4-[(4-amino-5-methylpyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide hydrochloride salt (500mg, 1.00mmol, 49%), is hydrochloride.

ESI-MS?m/e?462.2?M+H ⁺； ¹HNMR(400MHz，DMSO-d ₆)δ11.86(s，1H)，8.79(s，1H)，8.51(s，1H)，8.39(s，1H)，8.31(s，1H)，8.01(s，1H)，7.85(s，1H)，7.66(s，1H)，3.90(bs，2H)，1.90(s，3H)，1.89-1.61(m，8H).

Embodiment 3242

2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino]-1-[4-(trifluoromethoxy) phenyl] the ethyl ketone trifluoroacetate

Steps A: Synthetic 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino]-1-[4-(trifluoromethoxy) phenyl] the ethyl ketone trifluoroacetate.

(37mg, 0.14mmol) (42mg adds DIEA (20 μ L) in THF 0.14mmol) (2mL) solution with 4-trifluoro-methoxyl bromobenzene ethyl ketone to cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-cyclo-hexylamine.In 65 ℃, this reactant was stirred 2 hours, concentrate, make and be dissolved among the DMSO (1mL), through preparation type-HPLC purifying, obtain 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino]-1-[4-(trifluoromethoxy) phenyl] ethyl ketone trifluoroacetate 24mg (30%), be white powder.

ESI-MS?m/e?452(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.28(bs，2H)，8.09(d，2H，J＝8.8Hz)，7.29(m，2H)，7.20(m，1H)，4.13(bs，1H)，3.45(bs，1H)，3.33(s，6H)，3.27(bm，2H)，2.28(s，3H)，2.02-1.71(m，8H).

Embodiment 3243

N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the urea trifluoroacetate

Steps A: synthetic N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the urea trifluoroacetate.

To 2-(3,5-two (trifluoromethyl)-phenyl)-2 Methylpropionic acid (0.4g, 1.3mmol) and Et ₃N (0.17mL, add in dry-out benzene 1.3mmol) (4mL) solution diphenyl phosphoryl azide (0.36g, 1.3mmol)., form during about 3 hours in back flow reaction as 3 of reaction intermediate, 5-two (trifluoromethyl)-4-(isocyanato-1-methyl-ethyl)-benzene, it is directly used in the preparation urea derivatives.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane (40mg, 0.16mmol) EtOH (1mL) solution in add and to derive from 3 of above-mentioned reaction, 5-two (trifluoromethyl)-4-(isocyanato-1-methyl-ethyl)-benzene (48mg, 0.16mmol).This reaction mixture in 60 ℃ of stirrings 1 hour, is observed the starting raw material completely consumed through LC-MS.After removing volatile solvent, residue is dissolved among the DMSO (1.5mL), through preparation type-HPLC purifying, obtain 35mg (35%) N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the urea trifluoro-acetate.

ESI-MS?m/e?547(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ13.4(bs，1H)，8.37(bd，1H，J＝6.4Hz)，7.84(s，3H)，7.71(s，1H)，5,56(bs，1H)，4.01(bs，1H)，3.75(m，1H)，3.29(s，6H)，2.25(s，3H)，1.75-1.60(m，14H).

Embodiment 3244

N-{1-[3,5-two-(trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea trifluoroacetate

Steps A: synthetic N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea trifluoroacetate.

Under inert atmosphere, with 3,5-two (trifluoromethyl)-4-(isocyanato-1-methyl-ethyl)-benzene (36mg, 0.12mmol) join cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-1-aminocyclohexane (30mg, 0.12mmol) and CH ₃(0.17g is in dry-out benzene 1.2mmol) (1mL) solution for I.This reaction mixture in 50 ℃ of stirrings 2 hours, is observed formation through LC-MS and methylated and protonated product.After removing volatile solvent, residue is dissolved among the DMSO (1.5mL), through preparation type-HPLC purifying.Isolate 20mg (25%) N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea trifluoro-acetate, be white powder.

ESI-MS?m/e?561(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ14.5(bs，1H)，9.19(bd，1H，J＝6.0Hz)，7.84(s，2H)，7.79(s，1H)，7.70(s，1H)，4.87(s，1H)，4.23(bs，1H)，4.14(m，1H)，3.26(s，6H)，2.98(s，3H)，2.23(s，3H)，1.75-1.65(m，14H).

Embodiment 3245

Cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide trifluoroacetate

Steps A: synthetic 1-(3,5-two (trifluoromethyl)-phenyl)-1-methyl-ethamine.

Handle 3 with 8-N HCl (4mL), and 5-two (trifluoromethyl)-4-(isocyanato-1-methyl-ethyl)-benzene (0.1g, 0.33mmol).In 60 ℃ this acidic aqueous solution was heated 1 hour.After the reactant cooling, add the NaOH particle, make above mixture aqueous solution be alkalescence.Filter solid precipitation, this alkaline aqueous solution is extracted (2x) with DCM.The organism that merges is washed with water, and drying concentrates, and (3,5-two (trifluoromethyl)-phenyl)-1-methyl-ethamine is seemingly unsettled on pure state to obtain 1-(3,5-two (trifluoromethyl)-phenyl)-1-methyl-ethamine: 1-.Product is remained in the DCM solution.

ESI-MS?m/e?272(M+H) ⁺

Step B: synthesizing cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide trifluoroacetate.

To cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid (15mg, 0.05mmol) and 1-(3,5-two (trifluoromethyl)-phenyl)-1-methyl-ethamine (15mg, 0.05mmol) DCM (1.5mL) solution in add HATU (25mg, 0.06mmol), then add Et ₃N (10mg, 0.1mmol).After stirring 4 hours under the room temperature, the concentration response thing, make and be dissolved among the DMSO (1.5mL), through preparation type-HPLC purifying, obtain 11mg (30%) cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide trifluoroacetate.

ESI-MS?m/e?532(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ14.6(bs，1H)，8.64(bd，1H，J＝6.0Hz)，7.78(s，2H)，7.69(s，1H)，7.30(d，1H，J＝7.2Hz)，7.16(s，1H)，4.40(bs，1H)，3.30(s，6H)，2.26(s，3H)，2.18(m，1H)，2.07-1.80(m，8H)，1.70(s，6H).

Embodiment 3246

3,4-two fluoro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4-methoxyl group-5-methylpyrimidine.

Make 2, (0.8g 5mmol) is dissolved among the MeOH (10mL), with 0.5M-NaOCH 4-two chloro-5-methylpyrimidines ₃MeOH (10mL, 5mmol) solution slowly joins in this solution.Under room temperature this reactant was stirred 40 minutes, dilute with water extracts (3x) with DCM.With organism water (2x) and salt solution (1x) washing that merges, dry and concentrated.Isolate 2-chloro-4-methoxyl group-5-methylpyrimidine of 0.8g (99%), it need not be further purified and be directly used in next step reaction.

¹H?NMR(400MHz，CDCl ₃)δ8.10(s，1H)，4.03(s，3H)，2.12(s，3H)。

Step B: synthetic N-[cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-cyclohexyl] the carboxylamine tertiary butyl ester.

In 175 ℃, to fill 2-chloro-4-methoxyl group-5-methylpyrimidine (0.35g, 2.2mmol), cis-(4-amino-cyclohexyl)-carboxylamine tertiary butyl ester (0.56g, 2.4mmol), DIEA (0.8mL, 4.5mmol) and the sealed tube of IPA (2mL) place 4000 seconds of Personal microwave synthesizer reaction.With DCM diluting reaction thing,, dry and concentrated with 1N-HCl and water washing.Crude product is through column chromatography purification [silica gel, DCM: MeOH (100: 0-97: 3)].Isolate 0.25g (34%) N-[cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-cyclohexyl] the carboxylamine tertiary butyl ester.

ESI-MS?m/e?337(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.80(s，1H)，4.86(bd，1H，J＝6.0Hz)，4.55(bs，1H)，3.93(bm，1H)，3.89(s，3H)，3.62(bs，1H)，1.97(s，3H)，1.83-1.55(m，8H)，1.45(s，9H).

Step C: synthesizing cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-aminocyclohexane.

To N-[cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-cyclohexyl] (0.24g adds TFA (5mL) in DCM 0.7mmol) (10mL) solution to the carboxylamine butyl ester.Reaction stirred is 1.5 hours under room temperature.After removing volatile solvent, described residue is handled with 4N-NaOH (3mL).Extract (3x) alkaline aqueous solution with DCM, organism water (2x) and salt solution (1x) washing with merging concentrate.Isolate 0.13g (82%) cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-aminocyclohexane, be faint yellow solid.

ESI-MS?m/e?237(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.79(s，1H)，5.05(bd，1H，J＝6.4Hz)，3.99(bs，1H)，3.89(s，3H)，2.92(bm，1H)，2.45(bs，2H)，1.96(s，3H)，1.83-1.45(m，8H).

Step D: synthesize 3,4-two fluoro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate.

(20mg adds 3 in DCM 0.08mmol) (1mL) solution, and (14mg 0.08mmol), then adds Et to the 4-difluoro benzoyl chloride to cis-4-(4-methoxyl group-5-methyl-pyrimidine-2--amino)-aminocyclohexane ₃N (25 μ L).This reactant was stirred under room temperature 2 hours, add MeOH (0.2mL) with the quencher reactant.After removing volatile solvent, residue is dissolved among the DMSO (1.5mL),, obtains 3 of 12mg (40%) through preparation type-HPLC purifying, 4-two fluoro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } the benzamide trifluoroacetate, be white powder.

ESI-MS?m/e?377(M+H) ⁺； ¹H?NMR(400MHz，CDCl ₃)δ15.7(bs，1H)，9.55(d，1H，J＝7.2Hz)，7.73(m，1H)，7.59(m，1H)，7.57(s，1H)，7.20(m，1H)，6.80(d，1H，J＝8.0Hz)，4.37(bs，1H)，4.18(bm，1H)，4.09(s，3H)，2.04(s，3H)，1.89-1.75(m，8H).

Embodiment 3247

N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt

Steps A: synthetic (2-chloro-6-methyl-pyrimidine-4-yl)-methyl-amine.

In 0 ℃, will be in the 50mL methylene dichloride 2,4-two chloro-6-methylpyrimidines (10g, 61.34mmol) join in the methylol solution of 2M methylamine (46.01ml, 92.02mmol).The reaction mixture stirring is spent the night, evaporate excessive solvent then, this material obtains (2-chloro-6-methyl-pyrimidine-4 base)-methyl-amine (5.835g, 37.17mmol, 60.59%) through chromatography (ethyl acetate solution of 50% hexane), is white solid.

ESI-MS?158.0?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.62(s，1H)，6.18(s，1H)，2.70(bs，3H)，2.10(bs，3H).

Step B: synthetic N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt.

To (2-chloro-6-methyl-pyrimidine-4 base)-methyl-amine (500mg, 3.18mmol) 3mL 2-propanol solution in add cis-N-(4-amino-cyclohexyl)-4-trifluoromethoxy-benzamide (1.25g, 4.14mmol) and DIEA (1.108mL, 6.36mmol).In 180 ℃, in the microwave synthesizer with this mixture heating up 2 hours.Evaporating solvent, the compound of acquisition is dissolved in the methylene dichloride, ether (6.2mL) solution that adds 2M HCl, obtain N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide hydrochloride salt (1.3014g, 2.83mmol, 89%), is faint yellow solid.

ESI-MS?424.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.72(s，1H)，8.44(s，1H)，7.99-7.96(d，J＝8Hz，2H)，7.86(s，1H)，7.47-7.45(d，J＝8Hz，2H，4.03(s，1H)，3.87(s，1H)，2.89-2.88(d，J＝4Hz，3H)，2.20(s，3H)，1.85(bs，2H)，1.72(bs，6H).

Embodiment 3248

N-(cis-4-[(4-amino-5-methylpyrimidine-2-yl) and amino] cyclohexyl } methyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt

Steps A: synthetic N-(cis-4-[(4-amino-5-methylpyrimidine-2-yl) and amino] cyclohexyl } methyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt.

To 2-chloro-5-methyl-pyrimidine-4-base amine (269mg, 1.87mmol) 1mL 2-propanol solution in add cis-N-(4-amino-cyclohexyl methyl)-3,5-di-trifluoromethyl-benzamide (689.8mg, 1.87mmol) and DIEA (489.5.4 μ l, 2.81mmol).In 180 ℃, in the microwave synthesizer with this mixture heating up 2 hours.Evaporating solvent, this material is through chromatography (1-2% methyl alcohol/CH ₂Cl ₂).The compound of acquisition is dissolved in the methylene dichloride, the diethyl ether solution (2.2mL) that adds 2M HCl, obtain N-({ cis .4-[(4-amino-5-methylpyrimidine-2-yl) amino] cyclohexyl } methyl)-3,5-two (trifluoromethyl) benzamide hydrochloride salt (667.1mg, 1.30mmol, 70%), is white solid.

ESI-MS?476.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ9.16-9.13(t，J＝4Hz，J＝8Hz，1H)，8.55(s，2H)，8.36-8.31(bs，2H)，7.86(bs，1H)，7.71(bs，1H)，4.07(bs，1H)，3.27-3.24(t，J＝8Hz，J＝4Hz，2H)，1.91(bs，3H)，1.73-1.42(m，8H).

Embodiment 3249

The 2-[(2-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide trifluoroacetate

Steps A: synthesizing cis-2-chloro-N-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide

With cis-N ²-(4-amino-cyclohexyl)-6, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, the 4-diamines (2.86g, add in 20mL dichloromethane solution 11.5mmol) the 2-chloronicotinoyl chloride (2.02g, 11.5mmol) and DIEA (3.9mL, 23mmol).This reaction mixture was stirred 1 hour.Solvent evaporated makes described compound crystal (diethyl ether solution of 2% hexane), obtains cis-2-chloro-N-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (4.2g, 10.8mmol, 94%).

ESI-MS?389.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ13.1(bs，1H)，8.72-8.70(d，J＝8Hz，1H)，8.49-8.46(dt，J＝8Hz，J＝4Hz，1H)，8.04(s，1H)，7.89-7.87(dd，J＝4Hz，J＝4Hz，1H)，7.52-7.47(q，J＝8Hz，J＝4Hz，1H)，6.27(s，1H)，3.95(bs，2H)，3.27(bs，6H)，2.31(s，3H)，1.82-1.74(m，8H).

Step B: Synthetic 2-[(2-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) the niacinamide trifluoroacetate.

To cis-2-chloro-N-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (50mg, 0.128mmol) the 1mL dioxane solution in add 2-chlorinated benzene mercaptan (chlorobenzenethiol) (37.1mg, 0.256mmol) and Cs ₂CO ₃(83.4mg, 0.256mmol).In 180 ℃, in the microwave synthesizer with this mixture heating up 1 hour.Behind the evaporating solvent, make described compound through the preparation HPLC purifying then, obtain cis-2-(2-chloro-phenyl sulfane base)-N-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide trifluoroacetate (23.2mg, 30%), be white solid.

ESI-MS?m/e?497.4?M+H ⁺；

To cis-2-(2-chloro-phenyl sulfane base)-N-[4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-(23.2mg adds 3-chloroperoxybenzoic acid (31.5mg 0.14mmol) to the niacinamide trifluoroacetate in 1mL dichloromethane solution 0.038mmol).This reaction mixture was stirred 15 hours, use the sodium bicarbonate quencher.Evaporating solvent.Make described compound through the preparation HPLC purifying then; obtain the 2-[(2-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide trifluoroacetate (8.9mg; 0.014mmol, 36%), be white solid.

ESI-MS?m/e?529.2M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ11.98(s，1H)，8.61-8.59(m，2H)，8.24-8.21(dd，J＝4Hz，4Hz，1H)，8.08-8.06(d，J＝8Hz，1H)，7.79-7.74(m，2H)，7.71-7.69(t，J＝4Hz，1H)，7.64-7.62(d，J＝8Hz，1H)，7.58(bs，1H)，6.32(s，1H)，3.94(bs，2H)，3.21(s，3H)，3.15(s，3H)，2.28(s，3H)，1.84-1.78(m，8H).

Embodiment 3250

N-(cis-4-{[(4-toluquinoline-2-yl) methyl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate

Steps A: synthetic 4-methyl-2-ethene yl-quinoline.

In the 150mL round-bottomed flask that fills 50mL toluene, add 2-chlorine p-methyl quinoline (1g, 63mmol), four (triphenyl phosphine) palladium (0) (65mg, 0.63mmol), triphenyl phosphine (0.495g, 1.89mmol) and the vinyl tributyl tin (2.2g, 6.76mmol).Under 116 ℃, nitrogen, this mixture 2 hours refluxes.Concentrated reaction mixture through silica gel purification, is used the 0-10%EtOAc/ hexane wash, obtains 4-methyl-2-ethene yl-quinoline (720mg, 4.26mmol, 76%).

ESI?MS?m/e：170.0?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.96(d，J＝8Hz，1H)，7.85(d，J＝8Hz，1H)，7.58(dd，J ₁＝J ₂＝8Hz，1H)，7.43(dd，J ₁＝J ₂＝8Hz，1H)，(7.15(s，1H)，6.89(dd，J ₁＝16Hz，J ₂＝12Hz，1H)，6.15(d，J＝16Hz，1H)，5.54(d，J＝8Hz，1H)，2.60(s，3H)

Step B: synthetic 4-methyl-quinoline-2-formaldehyde.

Under nitrogen, to 40mL 90%THF/H is housed ₂Add in the 500mL round-bottomed flask of O 4-methyl-2-ethene yl-quinoline (1.2g, 7.1mmol), NMO (1.29g, 10.65mmol) and OsO ₄(1.3mL, 0.21mmol).Under room temperature, nitrogen, stir this mixture overnight.Use saturated Na ₂S ₂O ₃Solution quencher reactant uses EtOAc (100mL * 4) to extract organic phase then.Merge organic layer, use the salt water washing, and concentrate.Crude product 1-(4-methyl-quinoline-2-yl)-ethane-1,2-glycol (1.5g) need not be further purified and is directly used in next step.

To 60mL 90%THF/H ₂Add 1.5g crude product 1-(4-methyl-quinoline-2-yl)-ethane-1,2-two pure and mild NaIO among the O ₄(1.4g, 8.86mmol).Under room temperature, nitrogen, stirred this mixture 6 hours.Organic phase is extracted (100mL * 4) with EtOAc, merge, through anhydrous magnesium sulfate drying.It is concentrated,, use 0-5%EtOAc/ hexane wash-out, obtain 4-methyl-quinoline-2-formaldehyde (600mg, 3.5mL, 49.4%) through the silicagel column purifying.

ESI?MS?m/e：1720?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ10.2(s，1H)，8.25(d，J＝8Hz，1H)，8.07(d，J＝8Hz，1H)，7.88(s，1H)，7.82(dd，J ₁＝J ₂＝8Hz，1H)，7.71(dd，J ₁＝J ₂＝8Hz，1H)，2.79(s，3H).

Step C: synthetic resins bonded cis-(4-aminocyclohexyl) carboxylamine fluorenyl methyl ester.

In the manual synthesising container of a 30mL, make 2-(3,5-dimethoxy-4 '-formyl radical) phenoxy group ethyl polystyrene resin (0.5 gram; 0.90mmol/ restrain) and cis-(453mg 1.35mmol) is suspended among the 4mL DMF (4-aminocyclohexyl) carboxylamine fluorenyl methyl ester 2.In this suspension, add NaBH (OAc) ₃(299mg, 1% acetate 1.35mmol)/DMF solution (4mL).This mixture overnight of vibration removes by filter solution in the rotation electromagnetic shaker, with DMF, 10%DIEA/DMF, DMF, DCM and MeOH order washing resin.Repeat this washing sequence 4 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

Step D: synthetic resins bonded-cis-[4-(4-methyl-quinoline-2-methyl-amino)-cyclohexyl]-carboxylamine fluorenyl methyl ester.

In the intermediate (0.315mmol) of resin-bonded, add 4-methyl-quinoline-2-formaldehyde (96mg, N,N-DIMETHYLACETAMIDE 0.564mmol) (5mL) and 1% acetate (.050mL).Under room temperature, resin suspension is mixed 1 hour in the rotation electromagnetic shaker.(195mg 3.15mmol) joins in this resin suspension, spends the night this reactant is mixed under room temperature with sodium cyanoborohydride.When reaction is finished, filter this solution, with this resin DMF, 10%DIEA/DMF, DMF, DCM and MeOH wash successively.Repeat this washing sequence 4 times.With the intermediate 5 of the resin-bonded that generates under vacuum dry 20 minutes.

Step e: synthetic N-(cis-4-{[(4-toluquinoline-2-yl) methyl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate.

Under room temperature, with the intermediate (0.171mmol) of resin-bonded with DMF (3mL) solution-treated of 20% piperidines 30 minutes.After 30 minutes, filter this solution, this resin is washed in proper order with DMF, DCM and MeOH.Repeat this washing sequence 4 times.

The intermediate of de-protected resin-bonded is suspended among the DMF (1.0mL).With 3,5-is two-trifluoromethyl benzoyl chloride (47mg 0.171mmol) joins in this resin suspension, then add triethylamine (0.0519mL, 0.513mmol).Mixed reactant is 30 minutes under room temperature.Filter this solution then, this resin is washed in proper order with DMF, DCM and MeOH.Repeated washing order 4 times.

Drying is after 20 minutes, with the intermediate of this resin-bonded 5mL TFA solution (TFA/ methylene dichloride/water 20: 20: 1v/v) handle under vacuum.This reactant is jolted 2 hours, filter the back and collect TFA solution.Remove TFA through rotary evaporation, described compound obtains N-(cis-4-{[(4-toluquinoline-2-yl) methyl through the preparation HPLC purifying] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide trifluoroacetate (3.8mg; 8%), is white solid.

ESI?MS?m/e?510.2?M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ(ppm)：8.56(m，1H)，8.42(s，2H)，8.19(m，3H)，7.82(m，1H)，7.69(m，1H)，7.39(s，1H)，4.6(s，2H)，4.14(m，1H)，3.40(m，1H)，2.78(s，3H)，2.22-1.81(m，8H).

Embodiment 3251

Cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide trifluoroacetate

Steps A: synthesizing cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid.

Under room temperature, nitrogen, (28.9g, 0.186mol) (20g, 0.140mol) mixture in 100mL toluene stirred 5 minutes, to form soup compound with 4-amino-hexahydrobenzoic acid with (2-chloro-5-methyl-pyrimidine-4-yl)-dimethyl-amine.In this soup compound, add Pd (OAc) ₂(0.34g, 1.5 * 10 ^-3Mol), 2-(two-tertiary butyl phosphine) biphenyl (0.24,0.8mmol) and NaOtBu (33.64g, 0.35mol).This mixture is heated under 118 ℃, nitrogen and refluxed 2 hours.Concentrated reaction mixture obtains brown solid.Make top brown solid be dissolved in 100mLMeOH and 5mL H ₂Among the O, neutralize with acetate.Filtering precipitate with cold water (5mL * 2) and toluene (100mL * 2) washing, obtains cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid (36.7g, 0.132mol, 94%), is white solid.

ESI?MS?m/e?279?M+H ⁺， ¹H?NMR(400MHz，CDCl ₃)δ7.46(s，1H)，4.20(s，1H)，3.3(s，6H)，3.2(s，1H)，2.48(m，1H)，2.27(s，3H)，2.15-1.63(m，8H).

Step B: synthesizing cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } the cyclohexane carboxamide trifluoroacetate.

To (S)-1-(4-chloro-phenyl)-ethamine (61.5mg, 0.395mmol) 10mL DCM solution in add cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-hexahydrobenzoic acid (100mg, 0.395mmol), HATU (150mg, 0.395mmol) and 5 Et ₃N.Under room temperature, nitrogen, this reaction mixture stirring is spent the night.Evaporating solvent, this material is through preparation HPLC, obtains cis-N-[(1S)-1-(4-chloro-phenyl-) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide trifluoroacetate (20mg, 0.048mmol, 13.4%), is white solid.

ESI?MS?m/e?416.3?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ8.24-8.12(d，1H)，7.55(s，1H)，7.32-7.10(m，4H)，4.87(m，1H)，2.47(s，6H)，2.28(bs，1H)，2.18(s，3H)，1.81-1.39(m，8H)，1.31(d，3H).

Embodiment 3252

Cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] the cyclohexane carboxamide trifluoroacetate

Steps A: synthesizing cis-4-(4-toluquinoline-2-base is amino) hexahydrobenzoic acid.

(6.67,0.0375mol) (4.48g, mixture 0.0312mol) are dissolved in the 100mL toluene, stir 5 minutes down in room temperature, nitrogen, to form soup compound with 4-amino-hexahydrobenzoic acid with 2-chloro-4-methyl-quinoline.In this soup compound, add Pd (OAc) ₂(0.077g, 3.43 * 10 ^-4Mol), 2-(two-tertiary butyl phosphine) biphenyl (0.093,3.12 * 10 ^-4Mol) and NaOtBu (7.5g, 0.078mol).Under 118 ℃, nitrogen, with the above-mentioned substance heating and refluxed 2 hours.The concentrating under reduced pressure reaction mixture obtains brown solid.Make above brown solid be dissolved in 100mL MeOH and 5mL H ₂Among the O, neutralize with acetate.Filtering precipitate with cold water (5mL * 2) and toluene (100mL * 2) washing, obtains cis-4-(4-toluquinoline-2-base is amino) hexahydrobenzoic acid (7.45g, 0.026mol, 84%), is white solid.

ESI?MS?m/e?285.1?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ7.78(d，1H)，7.49(m，1H)，7.21(m，1H)，6.85(d，1H)，6.72(s，1H)，4.19(s，1H)，2,54-2.53(m，2H)，2.46(s，3H).

Step B: synthesizing cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] the cyclohexane carboxamide trifluoroacetate.

To (R)-1-(4-bromo-phenyl)-ethamine (77.4mg, add in 10mL DCM solution 0.39mmol) cis-4-(4-toluquinoline-2-base amino) hexahydrobenzoic acid (100mg, 0.35mmol), HATU (148mg, 0.39mmol) and 5 Et ₃N.Under room temperature, nitrogen, this reaction mixture stirring is spent the night.Evaporating solvent, this material be through preparation HPLC, obtains cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide trifluoroacetate (24mg, 0.052mmol, 14.7%), be white solid.

ESI?MS?m/e?468.2?M+H ⁺； ¹H?NMR(400MHz，DMSO-d ₆)δ9.18-9.07(s，1H)，7.94-7.84(t，1H)，7.74-7.68(t，1H)，7.46-7.42(m，2H)，7.22-7.17(m，2H)，7.00-6.94(s，1H)，4.86(m，1H)，4.11(s，1H)，2.58(s，3H)，2.40-2.23(m，2H)，1.88-1.49(m，8H)，1.33-1.19(d，3H).

Embodiment 3253

Trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate

Steps A: synthesis of trans-3-(4-chlorophenyl)-N-methoxyl group-N methacrylamide.

Under room temperature, (3g, 21.34mmol) (8.5g, dichloromethane solution 23.47mmol) stirred 16 hours ethanamide with N-methoxyl group-N-methyl-2-(the inferior phosphoranyl (phosphoranylidene) of triphenyl) with 4-chlorinated benzene formaldehyde.Vacuum evaporating solvent, crude product obtain trans-3-(4-chlorophenyl)-N-methoxyl group-N methacrylamide (4.78g, 99%) through purification by silica gel column chromatography (0-20%EtOAc/Hex), are colourless crystallization.

ESI?MS?m/e?226.1?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.66(d，J＝5.6Hz，1H)，7.45(d，J＝8.4Hz，2H)，7.33(d，J＝8.4Hz，2H)，6.99d，J＝5.6Hz，1H)，3.75(s，3H)，3.29(s，3H)

Step B: synthetic N-methoxyl group-N-methyl-trans-2-(4-chlorophenyl) cyclopropane carboxamide.

Under room temperature, to trimethylammonium sulfoxonium iodide (9.3g, add in DMSO 42.4mmol) (40mL) solution in batches sodium hydride (1.7g, 42.4mmol).After 1 hour, under room temperature, add trans-3-(4-chlorophenyl)-N-methoxyl group-N methacrylamide (4.78g, DMSO 21.2mmol) (20mL) solution by conduit.With this mixture restir 6 hours, then it is used saturated NH ₄Dichloromethane extraction is used in the quencher of the Cl aqueous solution, uses the salt water washing, through anhydrous magnesium sulfate drying.Crude product obtains N-methoxyl group-N-methyl-trans-2-(4-chlorophenyl) cyclopropane carboxamide through column chromatography purification (0-50%EtOAc/Hex), is colorless oil (4.76g, 88.5%).

ESI?MS?m/e?239.9?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ7.24(d，J＝8Hz，2H)，7.06(d，J＝8Hz，2H)，3.69(s，3H)，3.23(s，3H)，2.47(m，1H)，2.37(bs，1H)，1.63(m，1H)，1.27(m，1H)

Step C: synthesis of trans-2-(4-chloro-phenyl) cyclopropane-carboxylic acid.

Under room temperature, with N-methoxyl group-N-methyl-trans-2-(4-chlorophenyl) cyclopropane carboxamide (4.76g, 18.76mmol) and potassium tert.-butoxide (4.76g, 18.76mmol) (0.68mL, 37.5mmol) suspension in stirred 16 hours at TBME (130mL) and water.By slow adding concentrated hydrochloric acid acidifying mixture, with aqueous mixture dichloromethane extraction (3 * 60mL).With the organic layer salt water washing that merges, through anhydrous magnesium sulfate drying.Solvent removed in vacuo obtains product, is white solid (3.447g, 93.5%).

ESI?MS?m/e?197.0?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ11.4(bs，1H)，7.28(d，J＝8.4Hz，2H)，7.06(d，J＝8.4Hz，2H)，2.60(ddd，J ₁＝9.5Hz，J ₂＝6.6Hz，J ₃＝4.1Hz，1H)，1.89(ddd，J ₁＝9.5Hz，J ₂＝5.2Hz，J ₃＝4.2Hz，1H)，1.69(dt，J ₁＝9.5Hz，J ₂＝5.1Hz，1H)，1.40(ddd，J ₁＝8.4Hz，J ₂＝5.2Hz，J ₃＝4.3Hz，1H)

Step D: synthesis of trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the cyclopropane carboxamide trifluoroacetate.

Under room temperature, to trans-2-(4-chloro-phenyl) cyclopropane-carboxylic acid (22.1mg, 0.112mmol) and 2-chloro-4-dimethylamino-5-methylpyrimidine (28mg, add in methylene dichloride 0.112mmol) (5mL) mixture HATU (42.6mg, 0.112mmol).Be added dropwise to Et after 30 seconds ₃N (5).Stir this mixture overnight.Obtain trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide trifluoroacetate (20mg, 37%) by preparation type-HPLC.

ESI?MS?m/e：428.4?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.49(bs，1H)，7.23(d，J＝8Hz，2H)，7.02(d，J＝8Hz，2H)，6.28(d，J＝8Hz，1H)，4.11(m，1H)，3.99(m，1H)，3.29(s，6H)，2.45(ddd，J ₁＝12Hz，J ₂＝8Hz，J ₃＝4Hz，1H)，2.25(s，3H)，1.85-1.65(m，11H)，1.58(dt，J ₁＝8Hz，J ₂＝4Hz，1H)，1.18(dt，J ₁＝8Hz，J ₂＝4Hz，1H)

Embodiment 3254

N-{ cis-4-[(4,5-dimethyl pyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide trifluoroacetate

Steps A: Synthetic 2-chloro-4,5-dimethyl pyrimidine.

In 150 ℃ microwave synthesizer, with 2,4-two chloro-5-methylpyrimidines (0.3g, 1.84mmol), AlMe ₃(0.3mL, 2.0M) and Pd (PPh ₃) ₄(85mg, 4%mol) mixture heating up in anhydrous THF (5mL) is 20 minutes.Solvent removed in vacuo, crude product obtains 2-chloro-4 through chromatography (0-40%EtOAC/Hex) purifying, and 5-dimethyl pyrimidine (0.13g, 50%) is yellow solid.

ESI?MS?m/e：143.1?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.24(s，1H)，2.45(s，3H)，2.22(s，3H)

Step B: synthetic N-{ cis-4-[(4,5-dimethyl pyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide trifluoroacetate.

In 150 ℃ microwave synthesizer, with 2-chloro-4, the 5-dimethyl pyrimidine (30mg, 0.21mmol), N-(cis-4-aminocyclohexyl)-3,5-two (trifluoromethyl) benzamide (74.6mg, 0.21mmol), Pd (OAc) ₂(0.47mg, 0.01 equivalent), dppf (1.16mg, 0.01equiv.) and KOtBu (59mg, 0.53mmol) mixture heating up in toluene (3mL) is 20 minutes.Solvent removed in vacuo, crude product obtain N-{ cis-4-[(4 through the HPLC purifying, 5-dimethyl pyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide trifluoroacetate (25mg, 21%) is yellow solid.

ESI?MS?m/e?461.2?M+H ⁺； ¹H?NMR(400MHz，CDCl ₃)δ8.36(s，3H)，7.99(s，1H)，4.47(d，1H)，4.23(bs，1H)，2.52(s，3H)，2.13(s，3H)，1.95-1.65(m，8H)

Embodiment 3255

N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the urea trifluoroacetate

Steps A: synthetic N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) the urea trifluoroacetate.

Make cis-N ²-(4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, (30mg 0.12mmol) is dissolved among the 1mL DMSO 4-diamines.With 1,2-two fluoro-4-isocyanato-benzene join in this solution, and this solution stirring is spent the night.Crude product is through the HPLC purifying, obtains N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea trifluoroacetate, is white solid (32.2mg, 54.0%).

ESI?MS?m/e?405.3(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ13.45(s，1H)，8.35(d，J＝8.0Hz，1H)，7.67(s，1H)，7.52-7.47(m，1H)，7.28-7.26(m，1H)，7.07-6.99(m，2H)，4.00(m，1H)，3.96(m，1H)，3.32(s，6H)，2.27(s，3H)，1.78-1.67(m，8H).

Embodiment 3256

2-[(3, the 4-difluorophenyl) amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide

Steps A: Synthetic 2-[(3, the 4-difluorophenyl) amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide.

Make 3, (20.6uL 0.204mmol) is dissolved among the 1.0mL DMF 4-two fluoro-aniline.(8.2mg 0.204mmol) joins in this solution, stirs 10 minutes with NaH.Add 2-chloro-N-[4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-niacinamide (40mg, 0.102mmol), with this mixture restir 5 minutes.In 200 ℃, reactant was heated 1 hour by the Smith synthesizer.Crude product is through purification by silica gel column chromatography.Mixture and this post of 100mL washed with methanol with 200mL methyl alcohol and methylene dichloride (1: 9), obtain 2-[(3, the 4-difluorophenyl) amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide, be white solid (30.0mg, 61.2%).

ESI-MS?m/z?482.5(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ8.32(dd，J＝4.8，1.6Hz，1H)，7.92-7.86(m，1H)，7.71(dd，J＝7.6，J＝1.6Hz，1H)，7.64(s，1H)，7.19-7.03(m，2H)，6.76-6.73(m，1H)，6.34(d，J＝6.8Hz，1H)，4.95(s，1H)，4.11-4.03(m，2H)，2.96(s，6H)，2.15(s，3H)，1.90-1.68(m，8H).

Embodiment 3257

N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl carbamide trifluoroacetate

Steps A: synthetic N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl carbamide trifluoroacetate.

In Smith synthesizer bottle, make cis-N ²-(4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2, (75mg, 0.30mmol) with 1, (58mg 0.36mmol) is dissolved in the 1mL methylene dichloride 1 '-carbonyl dimidazoles the 4-diamines, stirs under room temperature and spends the night.Adding (4-chloro-phenyl)-ethyl-amine in this bottle (94mg, 0.60mmol).In 130 ℃, this solution was heated 30 minutes by the Smith synthesizer.Evaporating solvent joins 1mL methyl alcohol in the crude product, with its dissolving.Crude product is through the HPLC purifying then, obtains N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl carbamide trifluoroacetate, is white solid (25.0mg, 15%).

ESI?MS?m/e?431.3(M+H ⁺)； ¹H?NMR(400MHz，CDCl ₃)δ14.0(s，1H)，8.65(d，J＝6.4Hz，1H)，7.53(dd，J＝9.2，J＝2.4Hz，2H)，7.43(b，1H)，7.28(dd，J＝9.2，J＝2.4Hz，2H)，4.48(bs，1H)，4.16(bs，1H)，3.99(m，2H)，3.39(s，6H)，2.34(s，3H)，1.84-1.60(m，8H)，1.21(t，J＝7.0Hz，3H).

Embodiment 3258

N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{[2-(trifluoromethyl) pyrimidine-4-yl] the oxygen base } the ethanamide trifluoroacetate

Steps A: synthetic resins bonded N-methylamine.

With 2-(3,5-dimethoxy-4 '-formyl radical) phenoxy group ethyl polystyrene resin (1.0 grams; 0.90mmol/ the gram) and the methanol solution of methylamine 2M (5.85mL 11.7mmol) is suspended in the 15mL methylene dichloride in vitreous synthetic flask.In this suspension, add NaBH (OAc) ₃Methylene dichloride (.0117mol) (15mL) solution.This mixture overnight of vibration removes by filter solution in the rotation electromagnetic shaker.The N-methylamine of the resin-bonded that generates is washed in proper order with methylene dichloride, DMF and MeOH.Repeated washing order 4 times.With the N-methylamine vacuum-drying of this resin-bonded 20 minutes.

Step B: synthetic resins bonded-4-(N-methyl-5-methyl-2-chlorine)-pyrimidine.

Make the N-methylamine of resin-bonded be suspended in DMF (10mL).In this resin suspension, add 2,4-two chloro-5-methyl-pyrimidines (1.35mmol), then add triethylamine (0.273mL, 2.70mmol).Under room temperature, reaction mixture jolted spend the night.Remove by filter solution, wash this resin in proper order with DMF, methylene dichloride and MeOH.Repeated washing order 4 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes..

Step C: synthetic resins bonded cis-N-(4-N-methyl-5 methyl-pyrimidine-2 base) hexanaphthene-1,4-diamines.

The intermediate of resin-bonded is divided into 3 parts, every part is moved in the 5mL Smith synthesizer reaction vessel.Described resin (0.272mmol) is suspended in the anhydrous dioxane (3mL) separately.In each suspension, add cis-1,4-diamino-cyclohexane (0.405mmol), three (dibenzalacetones), two palladiums (O) (0.027mol), 2, two (diphenylphosphine)-1 of 2-, 1-dinaphthalene (BINAP) (0.081mmol) and sodium tert-butoxide (1.35mmol).In 140 ℃ microwave synthesizer, with this reactant heating 20 minutes.When reaction is finished, this resin suspension is transferred in the 8mL glassiness pipe.Remove by filter solution.With described resin MeOH, H ₂O, MeOH, methylene dichloride and MeOH wash in proper order.Repeated washing order 3 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

Step D: synthesizing cis-N-[4-(4-N-methyl-5-methyl-pyrimidine-2-base-amino)-cyclohexyl]-bromoacetamide.

The intermediate (0.27mmol) of resin-bonded is suspended among the DCM (3mL).In this resin suspension, add bromoacetyl bromide (0.27mmol) and DIEA (.094mL; 0.54mmol).Under room temperature, this reactant is mixed 45 minutes in the rotation electromagnetic shaker.When reaction is finished, remove by filter this solution.Resin is washed in proper order with DCM, DMF, DCM and MeOH.Repeated washing order 3 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

Step e: synthetic N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{[2-(trifluoromethyl) pyrimidine-4-yl] the oxygen base } the ethanamide trifluoroacetate.

The intermediate (0.27mmol) that derives from the resin-bonded of step D is transferred in the 5mL microwave synthesizer bottle.This resin is suspended in the dry DMF (2mL).In this resin suspension, add 4-hydroxyl-2-trifluoromethyl pyrimidine (0.54mmol) and salt of wormwood (0.54mmol).In microwave oven, reactant was heated 30 minutes in 140 ℃.When reaction is finished, this resin suspension is transferred in the 8mL glassiness bottle.Remove by filter this solution, resin is washed in proper order with DMF, DCM, MeOH.Repeated washing order 3 times.

Drying is after 20 minutes, with the intermediate of resin-bonded 5mL TFA solution (TFA/ methylene dichloride/water 20: 20: 1v/v) handle under vacuum.This reactant is jolted 2 hours, filter the back and collect TFA solution.Remove TFA through rotary evaporation, described compound is through the preparation HPLC purifying, obtain N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{[2-(trifluoromethyl) pyrimidine-4-yl] the oxygen base } ethanamide trifluoroacetate (2.1mg, 5%), be white solid.

ESI?MS?m/e?440.3?M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ(ppm)：8.69(m，1H)，7.45(m，1H)，7.21-7.17(m，1H)，4.95(m，2H)，4.03(bs，1H)，3.82(bs，1H)，3.04(s，3H)，1.98(s，3H)，1.93-1.61(m，8H).

Embodiment 3259

2, and 2-two fluoro-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate

Steps A: synthetic resins bonded N-methylamine.

Will be at the 2-in the 15mL methylene dichloride (3,5-dimethoxy-4 '-formyl radical) phenoxy group ethyl polystyrene resin (1.0 grams; 0.94mmol/ gram) and methylamine (0.0122mol) be suspended in the glassiness and synthesize in the flask.In this suspension, add NaBH (OAc) ₃Methylene dichloride (0.0122mol) (15mL) solution.This mixture overnight of vibration removes by filter this solution in the rotation electromagnetic shaker.The N-methylamine of the resin-bonded that generates is washed in proper order with methylene dichloride, DMF and MeOH.Repeated washing order 4 times.With the N-methylamine vacuum-drying of resin-bonded 20 minutes.

Step B: synthetic resins bonded-4-(N-methyl-6 methyl-2-chlorine)-pyrimidine.

The N-methylamine of resin-bonded is suspended among the DMF (10mL).In this resin suspension, add 2,4 two chloro-6-methyl-pyrimidines (1.41mmol), then add triethylamine (0.393mL, 2.82mmol).In 40 ℃ of these mixture overnight of vibrations.Remove by filter this solution, wash this resin in proper order with DMF, methylene dichloride and MeOH.Repeated washing order 4 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

Step C: synthetic resins bonded cis-N-(4-N-methyl-6 methyl-pyrimidine-2 base) hexanaphthene-1,4-diamines.

The intermediate of resin-bonded is divided into 3 parts, every part is moved in the 5mL Smith synthesizer reaction vessel.Described resin (0.282mmol) is suspended in respectively in 1: 1 IPA/ water (3mL) solution.In each suspension, add cis-1,4-diamino-cyclohexane (0.85mmol) and DIEA (0.295ml; 1.69mmol).In 180 ℃, this reactant was heated 4.5 hours in the microwave synthesizer.Described resin is combined; Remove by filter solution.With described resin IPA, H ₂O, MeOH, methylene dichloride and MeOH wash in proper order.Repeated washing order 3 times.With the intermediate of the resin-bonded that generates under vacuum dry 20 minutes.

Step D: Synthetic 2,2-two fluoro-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate.

The intermediate of resin-bonded is suspended among the DMF (8mL).In this resin suspension, add 2,2-two fluoro-1,3-benzo dioxole 5-carbonyl chloride (0.846mmol) and triethylamine (0.256mL; 1.69mmol).In in impeller, jolting reactant under the room temperature 45 minutes.Remove by filter this solution, order DMF, methylene dichloride, MeOH washing resin.Repeated washing order 3 times.

Under vacuum, after dry 20 minutes, the intermediate of described resin-bonded is handled with 15mL TFA solution (20: 20: 1 v/v of TFA/ methylene dichloride/water).This reactant is jolted 2 hours, filter the back and collect TFA solution.Remove TFA through rotary evaporation, described compound is through the preparation HPLC purifying, obtain 2,2-two fluoro-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide trifluoroacetate (2.0mg, 2%), is white solid.

ESI?MS?m/e?420.5?M+H ⁺； ¹H?NMR(400MHz，CD ₃OD)δ(ppm)：8.24(m，1H)，7.72-7.68(m，2H)，7.31-7.29(m，1H)，5.86(s，1H)，4.18-3.99(m，2H)，2.99(s，3H)，2.25(s，3H)，1.93-1.80(m，8H).

Embodiment 3260-3262

With as in similar method described in the embodiment 3242, use suitable bromoacetophenone and the amine intermediate that derives from steps A, preparation compound 3260-3262.

Embodiment 3263-3267

With as in similar method described in the embodiment 3243, uses suitable acid and derives from the amine intermediate of steps A, prepare compound 3263-3267.

Embodiment 3268-3272

With as in similar method described in the embodiment 3244, use suitable isocyanic ester and the amine intermediate that derives from steps A, preparation compound 3268-3272.

Embodiment 3273-3275

With as in similar method described in the embodiment 3245, use suitable amine and carboxylic acid (carboxylic) intermediate that derives from steps A, preparation compound 3723-3275.

Embodiment 3276-3280

With as in similar method described in the embodiment 3246, use suitable acyl chlorides and the amine intermediate that derives from step D, preparation compound 3276-3280.

Embodiment 3281-3291

With as in similar method described in the embodiment 2656, uses suitable thio derivative (thioderivative) and derives from the amine intermediate of steps A, prepare compound 3281-3291.

Embodiment 3292-3303

With as in similar method described in the embodiment 3251, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 3292-3303.

Embodiment 3304-3307

With as in similar method described in the embodiment 3252, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 3304-3307.

Embodiment 3308

With as in similar method described in the embodiment 3251, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 3308.

Embodiment 3309-3315

With as in similar method described in the embodiment 3252, use suitable amine and the carboxylic acid intermediate that derives from step B, preparation compound 3309-3315.

Embodiment 3316-3320

With as in similar method described in the embodiment 3253, use suitable aldehyde and the amine intermediate that derives from step D, preparation compound 3316-3320.

Embodiment 3321-3345

With as in similar method described in the embodiment 3255, uses suitable isocyanic ester (isocyate) and derives from the amine intermediate of steps A, prepare compound 3321-3345.

Embodiment 3346-3355

With as in similar method described in the embodiment 3257, use suitable aniline and the amine intermediate that derives from steps A, preparation compound 3346-3355.

Embodiment 3356-3357

Use suitable hydroxyaryl derivative and the bromide intermediate that derives from step B, with similar method described in embodiment 2638, preparation compound 3356-3357.

Embodiment 3358-3359

With similar method described in embodiment 3259, use suitable acyl chlorides and the amine intermediate that derives from step D, preparation compound 3358-3359.

Embodiment 3360-3365

With similar method described in embodiment 3259, use suitable hydroxyaryl derivative and derive from step e bromide intermediate, preparation compound 3360-3365.

Embodiment 3366-3367

With similar method described in embodiment 3250, use suitable chloride derivative and the amine intermediate that derives from step e, preparation compound 3366-3367.

Embodiment 3368-3381

With similar method described in embodiment 3249, use suitable thiophenol and the niacinamide intermediate that derives from steps A, preparation compound 3368-3381.

Embodiment 3382

With the similar approach described in embodiment 2497, use 4-trifluoromethoxy-Benzoyl chloride and the amine intermediate that derives from step e, preparation compound 3382.

Embodiment number	The compound title	MS		Classification
					3260	1-(4-chlorophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] ethyl ketone	402.4(M+H)		2
3261	1-(3, the 4-difluorophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] ethyl ketone	404.4(M+H)		3
					3262	1-(4-bromophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) amino] ethyl ketone	446.3(M+H)		3
3263	N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-the cyclohexyl urea	547.6(M+H)		2
					3264	N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	445.3(M+H)		1
3265	N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea	445.2(M+H)		2
					3266	N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	443.3(M+H)		1
3267	N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea	443.4(M+H)		1
					3268	N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	561.4(M+H)		3
3269	N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	459.6(M+H)		1
					3270	N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	459.5(M+H)		2
3271	N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	457.5(M+H)		2
					3272	N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	457.2(M+H)		3

3273	Cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	430.3(M+H)	2
				3274	Cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	430.4(M+H)	3
3275	Cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	532.3(M+H)	3
				3276	4-chloro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } benzamide	375.1(M+H)	3
3277	N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl }-4-(trifluoromethoxy) benzamide	425.1(M+H)	3
				3278	3,4-two chloro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } benzamide	408.9(M+H)	2
3279	3,5-two chloro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl } benzamide	409.1(M+H)	3
				3280	N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl }-3,5-two (trifluoromethyl) benzamide	477.2(M+H)	3
3281	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[(4-fluoro phenyl) alkylsulfonyl] niacinamide	513.4(M+H)	1
				3282	The 2-[(4-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	529.4(M+H)	1
3283	The 2-[(3-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	529.4(M+H)	2
				3284	The 2-[(2-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	529.3(M+H)	2
3285	The 2-[(3-bromophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-niacinamide	573.6(M+H)	2
				3286	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(4-p-methoxy-phenyl) alkylsulfonyl]-niacinamide	525.4(M+H)	3
3287	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl }-niacinamide	563.5(M+H)	2
				3288	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2 base] amino }	509.6(M+H)	2

	Cyclohexyl)-and the 2-[(4-aminomethyl phenyl) alkylsulfonyl] niacinamide
				3289	The 2-[(4-bromophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide	573.5(M+H)	2
3290	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[(2-methyl-3-furyl) alkylsulfonyl] niacinamide	499.4(M+H)	3
				3291	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[4-(trifluoromethyl) phenyl] alkylsulfonyl }-niacinamide	563.5(M+H)	2
3292	Cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	416.3(M+H)	2
				3293	Cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	518.4(M+H)	3
3294	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide	400.3(M+H)	3
				3295	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino)-N-[(1S)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide	400.3(M+H)	3
3296	Cis-N-[(1S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	460.3(M+H)	1
				3297	Cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	460.3(M+H)	2
3298	4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1S)-and 1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	450.2(M+H)	1
				3299	4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1R)-and 1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	450.3(M+H)	1
3300	4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1S)-and 1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	450.4(M+H)	1
				3301	4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1R)-and 1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	450(M+H)	3
3302	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1S)-and 1-[4-(trifluoromethoxy) phenyl] ethyl }-cyclohexane carboxamide	466.4(M+H)	1
				3303	Cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(1R)-and 1-[4-(trifluoromethoxy) phenyl] ethyl }-cyclohexane carboxamide	466.4(M+H)	2
3304	Cis-N-[(1S)-1-(4-bromophenyl) ethyl]-4-[(4-toluquinoline-2-	466.4(M+H)	3

	Base) amino] cyclohexane carboxamide
				3305	Cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide	422.3(M+H)	2
3306	Cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide	422.4(M+H)	2
				3307	Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1R)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	456.3(M+H)	1
3308	Cis-N-[(1S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide	460(M+H)	1
				3309	Cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide	524.2(M+H)	2
3310	Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1R)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide	472.4(M+H)	3
				3311	Cis-N-[(1R)-1-(2-fluoro phenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide	406.2(M+H)	3
3312	Cis-N-[(1S)-1-(2-fluoro phenyl) ethyl]-4-[(4-toluquinoline-2-yl) amino] cyclohexane carboxamide	406.3(M+H)	1
				3313	Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1R)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	456.2(M+H)	2
3314	Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	456.3(M+H)	1
				3315	Cis-4-[(4-toluquinoline-2-yl) amino]-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide	456(M+H)	1
3316	Trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	428.4(M+H)	1
				3317	Trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	428(M+H)	1
3318	Trans-2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	430.2(M+H)	1
				3319	Trans-2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide	462.3(M+H)	1
3320	Trans-2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(diformazan	530.2(M+H)	1

	Base is amino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-cyclopropane carboxamide
					3321	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-p-methoxy-phenyl) urea	399.3(M+H)		2
3322	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea	399.3(M+H)		3
					3323	N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	429.4(M+H)		1
3324	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-fluoro phenyl) urea	387.5(M+H)		2
					3325	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(3-fluoro phenyl) urea	387.4(M+H)		2
3326	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea	387.4(M+H)		1
					3327	N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	405.3(M+H)		2
3328	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[3-(trifluoromethyl) phenyl] urea	437.3(M+H)
					3329	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[4-(trifluoromethyl) phenyl] urea	437.2(M+H)
3330	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethoxy) phenyl] urea	453.1(M+H)		1
					3331	N-(3-chloro-4-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	421.1(M+H)		2
3332	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[4-fluoro-3-(trifluoromethyl) phenyl] urea	455.3(M+H)
					3333	N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	403.2(M+H)		2
3334	N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	505.3(M+H)		2
					3335	N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	447.1(M+H)		1

3336	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) urea	383.2(M+H)	2
				3337	N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	437.3(M+H)	2
3338	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	437.3(M+H)	2
				3339	N-(3, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	437.3(M+H)	2
3340	N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	403.4(M+H)
				3341	N-benzyl-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	383.5(M+H)	2
3342	N-(2, the 5-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	437.3(M+H)	2
				3343	N-(2, the 3-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	437.3(M+H)	3
3344	N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea	471.3(M+H)	3
				3345	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea	471.3(M+H)	1
3346	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(2-fluoro phenyl)-N-methyl urea	401.2(M+H)	3
				3347	N-(2-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	417.1(M+H)	2
3348	N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea	451.2(M+H)	1
				3349	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy)-phenyl] urea	481.3(M+H)	2
3350	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-phenylurea	397.1(M+H)	1
				3351	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-[4-(trifluoromethoxy) phenyl] urea	481.1(M+H)	1

3352	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy) phenyl] urea	467.2(M+H)	1
				3353	N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide	431.3(M+H)	1
3354	N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide	533.1(M+H)	1
				3355	N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-(3-aminomethyl phenyl) urea	411.3(M+H)	1
3356	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide	456.4(M+H)	1
				3357	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[6-(trifluoromethyl) pyrimidine-4-yl] the oxygen base } ethanamide	454.2(M+H)	3
3358	2, and 2-two fluoro-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-yl] amino } cyclohexyl)-1,3-benzo dioxole-5-methane amide	420.5(M+H)
				3359	4-chloro-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethyl) benzamide	442.1(M+H)
3360	2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide	438.3(M+H)	1
				3361	N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-{[2-(trifluoromethyl) pyrimidine-4-yl] the oxygen base }-ethanamide	440.3(M+H)
3362	N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide	442.5(M+H)	3
				3363	N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-{[6-(trifluoromethyl) pyrimidine-4-yl] the oxygen base } ethanamide	440.3(M+H)	3
3364	N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-{[1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-yl] the oxygen base } ethanamide	442.4(M+H)	3
				3365	N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-{[3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base }-acetyl	428.2(M+H)

	Amine
					3366	3,4-two fluoro-N-(cis-4-{[(4-toluquinoline-2-yl) methyl] amino } cyclohexyl) benzamide		410.3(M+H)	3
3367	3-chloro-N-(cis-4-{[(4-toluquinoline-2-yl) methyl] amino } cyclohexyl) benzamide		408.3(M+H)
					3368	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[(4-fluoro phenyl) alkylsulfonyl] niacinamide		513.5(M+H)	2
3369	The 2-[(2-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		513.5(M+H)	2
					3370	The 3-[(3-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		529.1(M+H)	2
3371	The 2-[(4-chlorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		529.1(M+H)	3
					3372	The 2-[(2-bromophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		573.3(M+H)	3
3373	The 2-[(3-bromophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		575.4(M+H)	2
					3374	The 2-[(4-bromophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide		573.2(M+H)	3
3375	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(2-aminomethyl phenyl) alkylsulfonyl] niacinamide		509.5(M+H)	2
					3376	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(3-aminomethyl phenyl) alkylsulfonyl] niacinamide		509.5(M+H)	3
3377	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(4-aminomethyl phenyl) alkylsulfonyl] niacinamide		509.5(M+H)	2
					3378	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(2-p-methoxy-phenyl) alkylsulfonyl]-niacinamide		525.3(M+H)	3
3379	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(3-p-methoxy-phenyl) alkylsulfonyl]-niacinamide		525.3(M+H)	3
					3380	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-the 2-[(4-p-methoxy-phenyl) alkylsulfonyl]-niacinamide		525.3(M+H)	3
3381	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }		563.4(M+H)	3

	Cyclohexyl)-2-{[2-(trifluoromethyl) phenyl]-alkylsulfonyl } niacinamide
				3382	N-{ cis-4-[(4-toluquinoline-2-yl) amino] cyclohexyl }-4-(trifluoromethoxy) benzamide	444.4(M+H)	?1

Embodiment 3383

4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt.

To the N that in the steps A of embodiment 3127, obtains ²-(cis-4-amino-cyclohexyl)-6, N ⁴, N ⁴-trimethylammonium-pyrimidine-2 adds 4-chloro-3-fluoro-phenylformic acid (252mg), Et in DMF (3mL) solution of 4-diamines (300mg) ₃N (0.42mL), HOBt-H ₂O (276mg) and EDC-HCl (277mg).Stirred reaction mixture is 1 day under room temperature.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 15%-60%EtOAc).EtOAc (5mL) solution of the material of above-mentioned purifying is added in EtOAc (10mL) solution of 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (20mL), under room temperature, stirred this suspension 2 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt (335mg), be white solid.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.01(m，8H)，2.35(s，3H)，3.14(s，3H)，3.26(s，3H)，4.02-4.31(m，2H)，5.74(s，1H)，6.84-6.96(m，1H)，7.40-7.49(m，1H)，7.53-7.60(m，1H)，7.69(dd，J＝9.7，1.9Hz，1H)，8.48-8.65(m，1H)，12.93-13.08(m，1H).

Embodiment 3384

3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt.

Adopt the method for embodiment 3383 steps A, obtain title compound.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.05(m，8H)，2.36(s，3H)，3.15(s，3H)，3.26(s，3H)，4.01-4.30(m，2H)，5.75(s，1H)，6.45-6.54(m，1H)，7.17-7.23(m，1H)，7.40-7.47(m，1H)，7.57-7.61(m，1H)，8.60-8.71(m，1H)，13.07-13.19(m，1H).

Embodiment 3385

N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts.

Adopt the method for embodiment 3383 steps A, obtain title compound.

ESI?MS?m/e408，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.62-2.01(m，8H)，2.36(s，3H)，3.14(s，3H)，3.26(s，3H)，4.00-4.32(m，2H)，5.75(s，1H)，6.70-6.81(m，1H)，7.47-7.59(m，2H)，8.54-8.66(m，1H)，12.92-13.08(m，1H).

Embodiment 3386

3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt

Steps A: synthetic (2-chloro-5-methyl-pyrimidine-4-yl)-methyl-amine.

To 2, add iPr in THF (50mL) solution of 4-two chloro-5-methylpyrimidines (5.00g) ₂NEt (6.4mL) and 40%MeNH ₂The aqueous solution (4.78mL).Under room temperature, stirred this mixture 12 hours and concentrating under reduced pressure.In residue, add saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification NH-silica gel, the hexane solution of 9%-20%EtOAc), obtain (2-chloro-5-methyl-pyrimidine-4-yl)-methyl-amine (3.55g), be white solid.

ESI?MS?m/e?408，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ2.01(d，J＝0.8Hz，3H)，3.07(d，J＝5.0Hz，3H)，4.89-5.06(m，1H)，7.79(s，1H).

Step B: synthetic 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3228, obtain title compound.

ESI?MS?m/e?392，M(free)+H ⁺； ¹HNMR(300MHz，DMSO-d ₆)δ1.64-1.98(m，11H)，2.94(d，J＝4.5Hz，3H)，3.80-4.08(m，2H)，7.48-7.67(m，2H)，7.87-7.95(m，1H)，8.08-8.51(m，4H)，11.95-12.03(m，1H).

Embodiment 3387

4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt

Steps A: synthetic 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt.

To the N that in the step C of embodiment 3119, obtains ²-(cis-4-amino-cyclohexyl)-5, N ⁴, N ⁴-trimethylammonium-pyrimidine-2 adds 4-chloro-3-fluoro-phenylformic acid (209mg), Et in DMF (4mL) solution of 4-diamines (250mg) ₃N (0.36mL), HOBt-water (230mg) and EDC-HCl (230mg).Stirred reaction mixture is 16 hours under room temperature.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-40%EtOAc).EtOAc (10mL) solution of the material of above-mentioned purifying is added in the EtOAc solution (0.5mL) of 4M hydrogenchloride.Stir this mixture under room temperature also concentrated in 1 hour.Residue is suspended in Et ₂Among the O (10mL), under room temperature, this suspension was stirred 4 hours.Filter the collecting precipitation thing, use Et ₂The O washing in 80 ℃ of drying under reduced pressure, obtains 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide hydrochloride salt (208mg), be white solid.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.00(m，8H)，2.26(s，3H)，3.31(s，6H)，3.98-4.27(m，2H)，6.53-6.72(m，1H)，7.20-7.27(m，1H)，7.41-7.59(m，2H)，7.64-7.73(m，1H)，8.53-8.73(m，1H)，12.76-12.95(m，1H).

Embodiment 3388

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide hydrochloride salt.

Adopt the method for embodiment 3387 steps A, obtain title compound.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.64-2.01(m，8H)，2.26(s，3H)，3.30(s，6H)，4.02-4.25(m，2H)，7.02-7.28(m，3H)，7.46-7.53(m，1H)，7.63-7.68(m，1H)，8.48-8.60(m，1H)，12.70-12.84(m，1H).

Embodiment 3389

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide hydrochloride salts.

Adopt the method for embodiment 3387 steps A, obtain title compound.

ESI?MS?m/e?408，M(free)+H ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.60-2.02(m，8H)，2.26(s，3H)，3.31(s，6H)，4.01-4.26(m，2H)，6.65-6.76(m，1H)，7.21-7.29(m，1H)，7.48-7.60(m，2H)，8.57-8.69(m，1H)，12.73-12.91(m，1H).

Embodiment 3390

N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide hydrochloride salts

Steps A: synthetic N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide hydrochloride salts.

Method among the step D of employing embodiment 3119 obtains title compound.

ESI?MS?m/e?390，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.61-2.06(m，8H)，2.26(s，3H)，3.31(s，6H)，4.01-4.29(m，2H)，6.55-6.70(m，1H)，6.84-7.01(m，1H)，7.18-7.43(m，3H)，8.54-8.71(m，1H)，12.77-12.97(m，1H).

Embodiment 3391

2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for embodiment 3387 steps A, obtain title compound.

ESI?MS?m/e?404，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.57-1.94(m，8H)，2.24(s，3H)，3.29(s，6H)，3.47(s，2H)，3.80-3.97(m，1H)，4.05-4.18(m，1H)，6.01-6.15(m，1H)，6.95-7.28(m，4H)，8.46-8.86(m，1H)，12.81-13.01(m，1H).

Embodiment 3392

N-[cis-4-(4-amino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-chloro-4-fluoro-benzamide hydrochloride salt

Steps A: Synthetic 2-chloro-5-methyl-pyrimidine-4-base amine.

To 2, add 28%NH in IPA (2mL) solution of 4-two chloro-5-methylpyrimidines (1.00g) ₃The aqueous solution (2mL).In 120 ℃, in the microwave synthesizer, with this mixture heating up 20 minutes.Add saturated sodium bicarbonate aqueous solution to this mixture, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrate, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-50%EtOAc), obtain 2-chloro-5-methyl-pyrimidine-4-base amine (151mg), be white solid.

ESI?MS?m/e?143，M ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.94(s，3H)，7.81(s，1H)。

Step B: synthetic N-[cis-4-(4-amino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-chloro-4-fluoro-benzamide hydrochloride salt.

Adopt the method for the step B of embodiment 3228, obtain title compound.

ESI?MS?m/e?378，M(free)+H ⁺； ¹H?NMR(300MHz，DMSO-d ₆)δ1.63-1.94(m，8H)，1.91(s，3H)，3.79-4.00(m，2H)，7.52(t，J＝8.9Hz，1H)，7.63-7.70(m，1H)，7.78-7.99(m，2H)，8.07-8.13(m，1H)，8.28-8.48(m，1H)，11.86-11.96(m，1H).

Embodiment 3393

2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride

Steps A: Synthetic 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?438，M(free) ⁺； ¹HNMR(300MHz，CDCl ₃)δ1.59-2.03(m，8H)，3.17(s，3H)，3.27(s，3H)，3.88-4.08(m，1H)，4.11-4.25(m，1H)，4.43(s，2H)，5.96(d，J＝7.5Hz，1H)，6.66-6.79(m，1H)，6.88(dd，J＝8.9，3.0Hz，1H)，7.10(d，J＝3.0Hz，1H)，7.37(d，J＝8.9Hz，1H)，7.43-7.53(m，1H)，8.69-8.83(m，1H)，13.21(brs，1H).

Embodiment 3394

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-acetamide hydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-acetamide hydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?400，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.63-2.03(m，8H)，3.16(s，3H)，3.27(s，3H)，3.82(s，3H)，3.92-4.08(m，1H)，4.09-4.23(m，1H)，4.45(s，2H)，5.96(d，J＝7.3Hz，1H)，6.47-6.64(m，3H)，6.75-6.90(m，1H)，7.14-7.25(m，1H)，7.40-7.56(m，1H)，8.62-8.79(m，1H)，13.29(brs，1H).

Embodiment 3395

N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide dihydrochloride

Steps A: synthetic N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide dihydrochloride.

Adopt the method for the steps A of embodiment 3198, obtain title compound.

ESI?MS?m/e?397，M(free)+H ⁺； ¹HNMR(300MHz，DMSO-d6)δ1.09(t，J＝7.0Hz，3H)，1.41-1.87(m，8H)，3.14(s，3H)，3.18(s，3H)，3.43(q，J＝7.0Hz，2H)，3.60-3.80(m，1H)，3.82-4.01(m，3H)，6.36(d，J＝7.5Hz，1H)，6.57-6.80(m，3H)，7.06-7.28(m，2H)，7.72-8.05(m，2H)，8.20-8.42(m，1H)，12.19(brs，1H).

Embodiment 3396

5-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide

Steps A: synthetic 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide.

To the N-that in the steps A of embodiment 3070, obtains (cis-4-methyl-quinoline-2-yl)-hexanaphthene-1, add 5-bromo-nicotinic acid (4.74g), Et in DMF (50mL) solution of 4-diamines (5.00g) ₃N (6.55mL), HOBt-water (4.50g) and EDC-HCl (4.51g).Stirred reaction mixture is 16 hours under room temperature.In this reaction mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, press liquid chromatography purification (NH-silica gel, the hexane solution of 20%-40%EtOAc) in the warp, obtain 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide (9.81g), be white solid.

ESI?MS?m/e?439，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.84(m，8H)，2.58(s，3H)，4.07-4.24(m，2H)，4.72-4.83(m，1H)，6.11-6.20(m，1H)，6.52(s，1H)，7.20-7.28(m，1H)，7.49-7.81(m，3H)，8.23-8.29(m，1H)，8.79(d，J＝2.3Hz，1H)，8.86(d，J＝1.9Hz，1H).

Step B: synthetic 5-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide.

To 5-bromo-N-[cis-4-(4-methyl-quinoline-2-base amino)-cyclohexyl]-add copper (2.17g), cuprous chloride (3.37g) and 28%NH in EtOH (40mL) solution of niacinamide (6.00g) ₃The aqueous solution (40.0mL).In 180 ℃, in sealed tube, stirred this mixture 4 hours.Mixture is filtered by Celite pad, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filtration, concentrating under reduced pressure, press liquid chromatography purification (silica gel, the hexane solution of 25%-50%EtOAc) in the warp, obtain 5-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide (3.92g), be white solid.

ESI?MS?m/e?376，M+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.66-2.04(m，8H)，2.58(s，3H)，3.88-4.24(m，4H)，4.75-4.90(m，1H)，6.18-6.31(m，1H)，6.52(s，1H)，7.19-7.29(m，1H)，7.39-7.44(m，1H)，7.48-7.58(m，1H)，7.62-7.70(m，1H)，7.73-7.80(m，1H)，8.19(d，J＝2.8Hz，1H)，8.29(d，J＝1.6Hz，1H).

Step C: synthetic 5-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide.

In 70 ℃, with concentrated hydrochloric acid (1.33mL) and NaNO ₂Mixture (137.8mg) stirred 10 minutes, was cooled to room temperature.In reaction mixture, add 5-amino-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-AcOH (45mL) solution of niacinamide (500mg), under room temperature, stirred this mixture 30 minutes.Concentrated hydrochloric acid (3.0mL) solution that adds CuCl (460.8mg) in reaction mixture stirred this mixture 6 hours in 80 ℃.Reaction mixture is made alkalize with the 1MNaOH aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filters, concentrates, through flash chromatography purifying (NH-silica gel, the hexane solution of 20%EtOAc and silica gel, the CHCl of 2%MeOH ₃Solution), obtain 5-chloro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide (52.3mg), be yellow solid.

ESI?MS?m/e?395，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.65-2.03(m，8H)，2.57(s，3H)，4.03-4.29(m，2H)，5.05(brs，1H)，6.33-6.44(m，1H)，6.53(s，1H)，7.19-7.28(m，1H)，7.48-7.56(m，1H)，7.61-7.67(m，1H)，7.73-7.79(m，1H)，8.08-8.13(m，1H)，8.66(d，J＝2.3Hz，1H)，8.83(d，J＝1.9Hz，1H).

Embodiment 3397

5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide

Steps A: synthetic 5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide.

Under room temperature, to the 5-amino-N-[cis-4-that in the step B of embodiment 3396, obtains (4-methyl-quinoline-2-base amino)-cyclohexyl]-48% HBF of niacinamide (500mg) ₄Add CuF in the aqueous solution (3.95mL) and EtOH (4.00mL) solution ₂(132.0mg).In reaction mixture, add NaNO ₂Water (183.5mg) (3.95mL) solution stirred this mixture 1 hour under room temperature.Stirred these mixtures 2 hours in 50 ℃ then, stirred 2 hours in 80 ℃.Reaction mixture is made alkalize with the 1M NaOH aqueous solution, (3 times) are extracted with EtOAc in the waterbearing stratum.The organic layer that merges is through dried over mgso, filter, concentrate, through flash chromatography purifying (NH-silica gel, the hexane solution of 50%EtOAc), obtain 5-fluoro-N-[cis-4-(4-methyl-quinoline-2-base is amino)-cyclohexyl]-niacinamide (20.9mg), be yellow amorphous substance.

ESI?MS?m/e?379，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.67-2.05(m，8H)，2.57(s，3H)，4.08-4.25(m，2H)，4.72(brs，1H)，6.17-6.29(m，1H)，6.52(s，1H)，7.19-7.28(m，1H)，7.48-7.57(m，1H)，7.62-7.69(m，1H)，7.73-7.80(m，1H)，7.82-7.91(m，1H)，8.60(d，J＝2.8Hz，1H)，8.76(t，J＝1.5Hz，1H).

Embodiment 3398

3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide methylsulfonic acid

Steps A: synthetic 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide methylsulfonic acid.

In BuOH (2.5mL) solution of the N-that in the steps A of embodiment 3228, obtains (cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide (1.76g), be added in the 2-chloro-4-dimethylamino-5-methylpyrimidine (1.00g) that obtains in the steps A of embodiment 3119.In the microwave synthesizer, this mixture was heated 15 minutes in 200 ℃.Reaction repeated merges reaction mixture more than 3 times.With this mixture impouring saturated sodium bicarbonate aqueous solution, with waterbearing stratum CHCl ₃Extract (3 times).The organic layer that merges is through dried over mgso, filter, concentrating under reduced pressure, through in press liquid chromatography purification (NH-silica gel, the hexane solution of 15%-80%EtOAc), obtain a kind of colorless solid.In the EtOH of above-mentioned solid (1.85g) (18mL) solution, add MsOH (460mg).Under room temperature, stirred this mixture 30 minutes, on ice bath, stirred 4 hours.Filter the collecting precipitation thing,,, obtain 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl in 80 ℃ of drying under reduced pressure with the EtOH washing]-4-fluoro-benzamide methylsulfonic acid (1.41g), be white solid.

ESI?MS?m/e?406，M(free)+H ⁺； ¹H?NMR(300MHz，CDCl ₃)δ1.60-2.03(m，8H)，2.25(s，3H)，2.89(s，3H)，3.30(s，6H)，4.07-4.30(m，2H)，7.13-7.29(m，2H)，7.38-7.49(m，1H)，7.81-7.89(m，1H)，7.96-8.05(m，1H)，8.07(dd，J＝7.1，2.3Hz，1H)，12.07-12.23(m，1H).

The analytical test program

Embodiment 3399

The active assay determination of the formation of GPCRs

A. IP in the cell ₃The assay determination of accumulating

At the 1st day, can be generally 1 * 10 transfected cell is planted on 24 orifice plates ⁵Cells/well (though this number can be optimized).At the 2nd day, can be by mixing and transfectional cell at 0.25 μ g DNA in the 50 μ l serum-free DMEM/ holes (for example pCMV carrier or comprise the pCMV carrier of the acceptor of polynucleotide encoding) and 2 μ l fat transfection amine in 50 μ l serum-free DMEM/ holes earlier.This solution is mixed carefully and at room temperature hatched 15-30 minute.With 0.5ml PBS washed cell, then 400 μ l serum-free media are mixed with transfection medium, add in the cell again.Then with cell at 37 ℃/5%CO ₂Under hatched 3-4 hour, remove transfection medium again and replace with the conventional growth medium in 1ml/ hole.At the 3rd day, with ³H-myo-inositol labeled cell.In brief, remove medium and with 0.5ml PBS washed cell.In every hole, add 0.5ml then and do not have inositol/serum-free medium (GIBCO BRL) and 0.25 μ Ci ³The H-myo-inositol, and with cell at 37 ℃/5%CO ₂Under hatch 16-18 hour o/n.At the 4th day,, add 0.45ml then and comprise the analytical test medium of no inositol/serum-free medium, 10 μ M Pargylines, 10mM lithium chloride or 0.4ml and analyze medium and 50 μ l 10x ketanserins (ket) to final concentration 10 μ M with 0.5ml PBS washed cell.Then cell was hatched under 37 ℃ 30 minutes.Then with 0.5ml PBS washed cell, and in every hole, add 200 μ l fresh/ice-cold stop bath (1M potassium hydroxide; The 18mM Sodium Tetraborate; 3.8mM EDTA).This solution preserved on ice 5-10 minute or until cytolysis, then with 200 μ l fresh/ice-cold neutralization solution (7.5%HCL) neutralization.Lysate is transferred in the 1.5ml eppendoff pipe then, and in every pipe, adds 1ml chloroform/methanol (1: 2).With 15 seconds of solution vortex, the upper strata is added to Biorad AGI-X8 ^TMOn the anionite-exchange resin (100-200 mesh).At first, press 1 with water: the 1.25W/V washing resin, in the post of being packed into mutually in the 0.9ml upper strata then.With the 5mM inositol of 10ml and the 5mM Sodium Tetraborate of 10ml/60mM sodium formiate washing column.The InsP3 wash-out is gone into to comprise in the scintillation vial of 10ml liquid scintillation cocktail (scintillation cocktail) and 2ml 0.1M formic acid/1M ammonium formiate.Make this column regeneration by 0.1M formic acid/3M ammonium formiate washing, with water flushing 2 times, under 4 ℃, be stored in the water then again with 10ml.

Embodiment 3400

High throughput functional screening: FLIPR ^TM

Subsequently, use a analytical test and confirm this leading triggering (leadhits), i.e. FLIPR based on function ^TM(fluoroscopic image is read the plate device) and FDSS6000 ^TM(function medicament screening system) test macro.This analytical test use described MCH acceptor a kind of non-endogenous, constitute active form.

FLIPR and FDSS analytical test can be measured intracellular intracellular fluid Ca ²⁺Concentration can be utilized the activation of this assessment acceptor and confirm whether a kind of candidate compound is for example a kind of antagonist, inverse agonist or agonist of Gq-coupled receptor.Free Ca in the cytoplasm of any cell ²⁺Concentration be extremely low, and its concentration is very high in extracellular fluid and endoplasmic reticulum (ER).Like this, exist a big gradient to make Ca ²⁺Enter in the cytoplasm by endochylema film and endoplasmic reticulum.People design FLIPR ^TMAnd FDSS6000 ^TMSystem (MolecularDevices Corporation, HAMAMATSU Photonics K.K.) carries out the analytical test based on cell function, as measures intracellular calcium to carry out the high throughput screening.This fluorescence measurement discharges relevant with the calcium that the activation of Gq-coupled receptor causes.Gi or Go coupled receptor are difficult for passing through FLIPR ^TMAnd FDSS6000 ^TMSystem monitors, reason be these G albumen not with the coupling of calcium signalling channel.

Fluoroscopic image is read plate device system is used to carry out fluorescence in the cell in 96 hole microplates (or 384 hole microplates) quick, dynamic measurement.FLIPR by hypersensitivity and accuracy ^TMOr FDSS ^TMSystem, p.s. to the fluorescence in porose measure in real time.For the analytical test of measuring based on cell function, as the intracellular calcium current quantitative changeization that takes place in the monitoring Gq coupled receptor activation back several seconds, these systems are ideal.

In brief, with cell with 5.5 * 10 ⁴Cells/well is inoculated in 96 orifice plates that perfect medium (contain Dulbeceo ' s improvement Eagle substratum, 2mM L-L-glutamic acid, 1mM Sodium.alpha.-ketopropionate and the 0.5mg/ml G418 of 10% foetal calf serum, pH 7.4) are arranged, in order to analyzing next day.In analytical test day, remove medium, with cell with 100 μ l loading buffer liquid (4 μ MFluo4-AM in the perfect medium that comprises 2.5mM probenecid, 0.5mg/ml and 0.2% bovine serum albumin) at 5%CO ₂Under 37 ℃, hatched 1 hour in the insulation can.Remove loading buffer liquid, with lavation buffer solution (comprise the Hank ' s balanced salt solution of 2.5mM probenecid, 20mM HEPES, 0.5mg/ml and 0.2% bovine serum albumin, pH 7.4) washed cell.The 150 μ l lavation buffer solutions that will comprise the testing compound of different concns join in the cell, at 5%CO ₂In the incubator, under 37 ℃, cell was hatched 30 minutes.The 50 μ l lavation buffer solutions that will comprise the MCH of different concns join in every hole, in 96 orifice plates, use FLIPR or FDSS, measure for 290 seconds in Ex.488nm and Em.530nm, to monitor [the Ca that MCH brings out ²⁺] the of short duration change of i.When the antagonistic activity of test compounds, use the MCH of 50nM.

Can use FLIPR according to manufacturer's working instructions ^TMAnd FDSS6000 ^TM(Molecular Device Corporation and HAMAMATSU Photonics K.K.).

Representational embodiment is as follows:

Compound number	IC 50(nM)
		Embodiment 7	11
Embodiment 15	19
		Embodiment 19	2.1
Embodiment 2524	2.1
		Embodiment 2526	7.6

In the table of embodiment part with the result shown in the table of nextpage with consistent with undefined classification.

The 1st class: 10 ^-7The M down percent value of control is less than 40% or IC ₅₀Value is less than 50nM.

The 2nd class: 10 ^-7M down the percent value of control between 40% to 60% or IC ₅₀Value is between between the 50nM to 200nM.

The 3rd class: 10 ^-7The percent value of M control is greater than 60% or IC ₅₀Value is greater than 200nM.

Tested the compound of embodiment 2497 to 2542,2588 to 2689 and 3241 to 3259, they all show the IC that is less than about 50 μ M ₅₀Active.

3031	1	3077	1	3123	1	3169	1	3215	2
										3032	1	3078	1	3124	1	3170	1	3216	1
3033	1	3079	1	3125	1	3171	2	3217	1
										3034	1	3080	1	3126	1	3172	1	3218	3
3035	1	3081	1	3127	1	3173	3	3219	2
										3036	1	3082	1	3128	1	3174	1	3220	1
3037	3	3083	1	3129	2	3175	1	3221	1
										3038	1	3084	1	3130	3	3176	2	3222	1
3039	1	3085	1	3131	3	3177	2	3223	3
										3040	1	3086	1	3132	3	3178	2	3224	2
3041	1	3087	1	3133	3	3179	1	3225	3
										3042	1	3088	1	3134	3	3180	1	3226	3
3043	1	3089	1	3135	3	3181	2	3227	3
										3044	2	3090	1	3136	3	3182	3	3228	1
3045	1	3091	1	3137	2	3183	3	3229	1
										3046	1	3092	1	3138	2	3184	2	3230	1
3047	1	3093	1	3139	2	3185	1	3231	2
										3048	1	3094	1	3140	2	3186	2	3232	2
3049	1	3095	1	3141	2	3187	3	3233	3
										3050	1	3096	1	3142	3	3188	1	3234	3
3051	1	3097	1	3143	3	3189	1	3235	1
										3052	1	3098	1	3144	3	3190	2	3236	3
3053	1	3099	1	3145	3	3191	2	3237	3
										3054	1	3100	1	3146	1	3192	1	3238	1
3055	1	3101	1	3147	2	3193	1	3239	1
										3056	1	3102	1	3148	3	3194	1	3240	1
3057	1	3103	2	3149	2	3195	2	3383	1

Embodiment 3401

Receptor binding assay

Except method described here, another method of assessing a kind of testing compound is to be undertaken by measuring its binding affinity for the MCH acceptor.This alanysis needs a kind of radiolabeled part of MCH acceptor usually.Except part and the radio-labeled beyond the region of objective existence thereof of using known MCH acceptor, can be with formula (I) compound with a kind of labelled with radioisotope and be used for assessing a kind of analytical test for the treatment of the avidity of side compound and MCH acceptor.

The screening experiment that a kind of radiolabeled formula (I) MCH compound can be used for a kind of discriminating/assessment compound.In general, can assess a kind of new synthetic or new compounds identified (being testing compound) by its minimizing " radiolabeled formula (I) compound " and the bonded ability of MCH acceptor.Correspondingly, directly relevant with " radiolabeled formula (I) compound " or radiolabeled MCH part competitiveness with the avidity of testing compound and MCH acceptor in conjunction with the ability of MCH acceptor.

Measure the experimental design scheme of receptors bind MCH:

The preparation of A.MCH acceptor

With 293 cell (human kidneys, ATCC) momently with 10 μ g people MCH acceptors and 60 μ l fat transfection amine transfections (every 15-centimetre ware), in ware with a kind of substratum grow 24 hours (75% merge), this substratum changes with the Hepes-EDTA damping fluid (20mMHepes+10mM EDTA, pH 7.4) of 10ml/ ware and removes.Then with cell in the BeckmanCoulter whizzer with 17, centrifugal 20 minutes of 000rpm (JA-25.50 rotor).Subsequently, at 20mM Hepes+1mM EDTA, resuspending among the pH 7.4 is used 50-ml Dounce homogenizer mixing and recentrifuge then with pellet.After removing supernatant liquor, pellet can be stored in-80 ℃ up to being used in conjunction with experiment.When being applied to this experiment, film placed on ice it was melted in 20 minutes, add 10ml incubation buffer (20mM Hepes, 1mM MgCl then ₂, 100mM NaCl, pH 7.4).Then with the film vortex with heavy suspendible this rough membrane-like throw out, again with Brinkmann PT-3100 Polytron homogenizer, setting 6 place's mixings 15 minutes.Use BRL Bradford protein analyzer and measure membranin concentration.

B. binding analysis

Fully in conjunction with the time, with total amount 50 μ l suitably the dilution film (to comprise 50mM TrisHCl (pH 7.4), 10mM MgCl ₂With 1mM EDTA; The proteic analysis buffer dilution of 5-50 μ g) joins in the 96 hole polypropylene microwell plates, add 100 μ l analysis buffer and the radiolabeled MCH part of 50 μ l again.During non-specific binding, add 50 μ l but not 100 μ l analysis buffer, and before adding the radiolabeled MCH part of 50 μ l, add the cold MCH of 10 μ M of 50 μ l in addition.Then plate was placed incubated at room 60-120 minute.Filter test panel by a Microplate Devices GF/C Unifilter screen plate that Brandell 96 orifice plate harvesting devices are arranged and stop described association reaction, subsequently with the cold 50mM Tris HCI that comprises 0.9%NaCl, pH 7.4 washings.Then,, 50 μ lOptiphase Supermix are joined in every hole,, each plate is counted with a TriluxMicroBeta scintillometer with each plate top seal with the screen plate closed bottom.During research compound competitive, the testing compound that 100 μ l are suitably diluted but not 100 μ l analysis buffer add in each suitable hole, add the radiolabeled MCH part of 50 μ l subsequently.

C. calculate

Testing compound being carried out initial analysis in 1 and 0.1 μ M, analyze in a selected concentration range then, (is IC so that median doses can cause the inhibition of radiolabeled MCH part bonded about 50% ₅₀).Specificity during no testing compound is total combination (B in conjunction with (Bo) _T) deduct the difference of non-specific binding (NSB), and specificity is to replace in conjunction with (B (B) in conjunction with (when testing compound is arranged) similarly _D) deduct the difference of non-specific binding (NSB).By an inhibited reaction curve, promptly the logarithmic curve of B/Bo% and testing compound concentration (logit-log plot) is measured IC ₅₀Value.

Transform (Cheng and Prustoff transformation) calculating K by Cheng and PrustoffShi _iValue:

K _i＝IC ₅₀/(1+[L]/K _D)

Wherein [L] is the concentration that is used for the radiolabeled MCH part of this analysis test, K _DBe in same dissociation constant in conjunction with the independent radiolabeled MCH part of measuring under the condition.

The all kinds of patents, application, printed publication and other the disclosed file that this invention is intended to the application mentioned or relate to all are attached to herein by reference.

It should be appreciated by those skilled in the art, can carry out various changes and modification the preferred embodiments of the invention, and such change and modify and can carry out not deviating under the spirit of the present invention.Therefore, the expectation appending claims covers all these and falls into the interior equivalent variations of real spiritual scope of the present invention.

Claims (42)

1. formula (1) compound or its pharmacy acceptable salt, hydrate or solvate:

R wherein ₁Be selected from:

(i) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● hydroxyl,

● C _1-5Alkyl,

● C _1-5Alkoxyl group,

● by independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

● ● halogen,

● ● isocyclic aryl and

● ● by the isocyclic aryl of halogen replacement,

● C _2-5Alkenyl oxy,

● one-C _1-5Alkylamino,

● two-C _1-5Alkylamino,

● by one-C of cyano group replacement _1-5Alkylamino and

● by two-C of cyano group replacement _1-5Alkylamino,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● C _1-5Alkyl,

● C _1-5Alkoxyl group,

● C _1-5Alkoxy carbonyl,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl;

R ₂Be methylamino or dimethylamino;

B be singly-bound or-CH ₂-;

Y be singly-bound or-CH ₂-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 9H-carbazyl, benzo [1,3] dioxolyl, pyrazolyl or pyridyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

2. according to the compound of claim 1, R wherein ₁Be selected from:

(i) C _2-5Alkenyl and

C by the isocyclic aryl replacement _2-5Alkenyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● hydroxyl,

● C _1-5Alkyl

● C _1-5Alkoxyl group,

● by the C of halogen replacement _1-5Alkoxyl group,

● C _2-5Alkenyl oxy,

(iii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● C _1-5Alkyl,

● C _1-5Alkoxyl group,

● C _1-5Alkoxy carbonyl,

● isocyclic aryl,

● by C _1-5The isocyclic aryl that alkyl replaces and

● by halogenated C _1-5The isocyclic aryl that alkyl replaces;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 1H-indyl, 9H-carbazyl, benzo [1,3] dioxolyl or pyrazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base; Or its pharmacy acceptable salt, hydrate or solvate.

3. according to the compound of claim 1, it is selected from:

1) N ²-(cis-4-{[(5-bromo-1H-indol-3-yl) methyl] amino } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

2) N ²-[cis-4-({ [5-(4-fluoro phenyl) pyridin-3-yl] methyl } amino) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

3) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl)-amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

4) N ²-(cis-4-{[(2,6-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

5) N ²-(cis-4-{[(2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

6) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

7) N ²-[cis-4-({ [(5-methoxyl group-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

8) N ²-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

9) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol;

10) N ²-[cis-4-({ [(5-bromo-1H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

11) N ²-(cis-4-{[(2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

12) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,3,4-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

13) N ²-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

14) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl)-amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines;

15) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(3,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

16) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] amino } methyl)-2-iodo-6-methoxyphenol;

17) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol;

18) N ²-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

19) N ²-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

20) N ²-[cis-4-({ [4-(diethylamino) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

21) N ²-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

22) N ²-(cis-4-{[(4-isopropoxide benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

23) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

24) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-the 2-thanatol;

25) N ²-cis-4-[({[4-(dimethylamino)-1-naphthyl] and methyl } amino) methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

26) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

27) N ²-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

28) N ²-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

29) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

30) N ²-(cis-4-{[(2,4-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

31) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

32) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

33) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

34) N ²-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

35) N ⁴, N ⁴-dimethyl-N ²-[cis-4-({ [(1-Methyl-1H-indole-3-yl) methyl] amino }-methyl) cyclohexyl] pyrimidine-2, the 4-diamines;

36) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

37) N ²-(cis-4-{[(3-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

38) N ²-(cis-4-{[(4-methoxyl group-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

39) N ²-(cis-4-{[(2-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

40) N ²-(cis-4-{[(3,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

41) N ²-(cis-4-{[(4-methoxyl group-2,5-dimethyl benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

42) 3-[[4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] amino } methyl) phenyl] (methyl) amino] propionitrile;

43) N ²-cis-4-[({4-[(4-bromobenzyl) and the oxygen base] benzyl } amino) methyl] cyclohexyl }-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

44) N ²-(cis-4-{[(3,5-two bromo-2-ethoxy benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

45) N ²-[4-(4-bromo-2-trifluoromethoxy-benzyl) amino-cyclohexyl]-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

46) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines; With

47) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

4. according to the compound of claim 1, it is selected from:

1) 4,6-two chloro-3-{[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl)-amino] methyl }-1H-Indoline-2-carboxylic acid ethyl ester;

2) N ²-[cis-4-({ [(4-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

3) N ²-[cis-4-({ [(2-methoxyl group-1-naphthyl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

4) 4-bromo-2-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) methyl] amino } methyl)-the 6-methoxyphenol;

5) N ²-[cis-4-({ [(5-bromo-1 H-indol-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

6) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,3,4-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

7) N ²-(cis-4-{[(3-oxyethyl group-4-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

8) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[({3-[4-(trifluoromethyl) phenyl]-1H-pyrazoles-4-yl } methyl)-amino] methyl } cyclohexyl) pyrimidine-2, the 4-diamines;

9) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2-iodo-6-methoxyphenol;

10) 4-({ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] amino } methyl)-2, the 6-xylenol;

11) N ²-(cis-4-{[(5-bromo-2,4-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

12) N ²-(cis-4-{[(5-bromo-2-methoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

13) N ²-[cis-4-({ [(9-ethyl-9H-carbazole-3-yl) methyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

14) N ²-(cis-4-{[(3,3-diphenylprop-2-alkene-1-yl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

15) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,6-trimethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

16) N ²-(cis-4-{[(5-bromo-2-ethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

17) N ²-(cis-4-{[(2,4-dimethoxy-3-methyl-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

18) N ²-(cis-4-{[(2,5-diethoxy benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

19) N ²-(cis-4-{[(3,5-two bromo-2-methoxy-benzyls) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

20) N ⁴, N ⁴-dimethyl-N ²-(cis-4-{[(2,4,5-triethoxy benzyl) amino] methyl }-cyclohexyl) pyrimidine-2, the 4-diamines;

21) N ²-[cis-4-({ [2-(allyloxy) benzyl] amino } methyl) cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

22) N ²-[cis-4-({ [(7-methoxyl group-1,3-benzodioxole-5-yl) methyl] amino } methyl)-cyclohexyl]-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

23) N ²-(cis-4-{[(3-bromo-4,5-dimethoxy-benzyl) amino] methyl } cyclohexyl)-N ⁴, N ⁴-dimethyl pyrimidine-2, the 4-diamines;

24) N ²-cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines; With

25) N ²-cis-4-[(4-bromo-2-trifluoromethoxy-benzyl) amino-methyl]-cyclohexyl }-N ⁴, N ⁴-dimethyl-pyrimidine-2, the 4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

5. formula (1) compound or its pharmacy acceptable salt, hydrate or solvate:

R wherein ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

● oxo,

● isocyclic aryl oxygen base,

● by the isocyclic aryl oxygen base of halogen replacement,

● by C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

● one-C _1-5Alkyl amino-carbonyl,

● two-C _1-5Alkyl amino-carbonyl,

● one-C _1-5Alkylamino,

● two-C _1-5Alkylamino,

● one-isocyclic aryl amino,

● two-isocyclic aryl amino,

● by one-isocyclic aryl amino of halogen replacement,

● by two-isocyclic aryl amino of halogen replacement,

● the isocyclic aryl carbonylamino,

● C _1-5Alkylthio,

● C _3-6Cycloalkyl,

● carbocylic radical,

● by independently being selected from the carbocylic radical that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl,

● ● C _2-5Alkenyl and

● ● by independently being selected from the C that following substituting group replaces _2-5Alkenyl:

● ● ● isocyclic aryl and

● ● ● by C _1-5The isocyclic aryl that alkyl sulphinyl replaces,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● hydroxyl,

● ● nitro,

● ● C _1-5Alkyl,

● ● by independently being selected from the C that following substituting group replaces _1-5Alkyl:

● ● ● oxo,

● ● ● isocyclic aryl and

● ● ● heterocyclic radical

● ● C _1-5Alkoxyl group,

● ● by the C of halogen replacement _1-5Alkoxyl group,

● heterocyclic radical and

● by independently being selected from the heterocyclic radical that following substituting group replaces:

● ● C _1-5Alkyl,

● ● isocyclic aryl and

● ● by the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen and

● ● nitro,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● hydroxyl,

● nitro,

● C _1-5Alkyl,

● by independently being selected from the C that following substituting group replaces _1-5Alkyl:

● ● halogen,

● ● oxo and

● ● isocyclic aryl,

● C _1-5Alkoxyl group,

● by independently being selected from the C that following substituting group replaces _1-5Alkoxyl group:

● ● halogen and

● ● isocyclic aryl,

● isocyclic aryl oxygen base,

● by C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

● one-C _1-5Alkyl amino-carbonyl,

● two-C _1-5Alkyl amino-carbonyl,

● by one-C of isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

● by two-C of isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

● one-C _1-5Alkylamino,

● two-C _1-5Alkylamino,

● C _2-5The alkynyl carbonylamino,

● by the C of isocyclic aryl replacement _2-5The alkynyl carbonylamino,

● one-C _1-5Alkyl amino sulfonyl and

● two-C _1-5Alkyl amino sulfonyl,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● nitro,

● C _1-5Alkyl,

● by independently being selected from the C that following substituting group replaces _1-5Alkyl:

● ● C _1-5Alkylthio,

● ● by the C of isocyclic aryl replacement _1-5Alkylthio,

● ● by the C of halogenated isocyclic aryl replacement _1-5Alkylthio,

● ● isocyclic aryl,

● ● the isocyclic aryl that replaces by halogen and

● ● heterocyclic radical,

● isocyclic aryl oxygen base,

● by the isocyclic aryl oxygen base of halogen replacement,

● by C _1-5The isocyclic aryl oxygen base that alkyl replaces,

● C _1-5Alkylthio,

● C _1-5Alkyl sulphonyl,

● the isocyclic aryl alkylsulfonyl,

● by C _1-5The isocyclic aryl alkylsulfonyl that alkyl replaces,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● nitro and

● ● C _1-5Alkyl,

● heterocyclic radical;

R ₂Be methylamino, dimethylamino, ethylamino, ethylmethylamino or hydroxyethyl methylamino;

B be singly-bound or-CH ₂-;

Y is-C (O)-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is 1-oxo-indanyl, 9-oxo-9H-fluorenyl or indenyl;

Heterocyclic radical is 1,2,3-triazolyl, 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 9H-xanthenyl, benzo [2,1,3] oxadiazole base, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, quinolyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

6. according to the compound of claim 5, R wherein ₁Be selected from:

(i) C _1-5Alkyl and

By independently being selected from the C that following substituting group replaces _1-5Alkyl:

● oxo,

● isocyclic aryl oxygen base,

● by the isocyclic aryl oxygen base of halogen replacement,

● by C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

● one-C _1-5Alkylamino,

● two-C _1-5Alkylamino,

● one-isocyclic aryl amino,

● two-isocyclic aryl amino,

● by one-isocyclic aryl amino of halogen replacement,

● by two-isocyclic aryl amino of halogen replacement,

● C _1-5Alkylthio,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● hydroxyl,

● ● C _1-5Alkyl,

● ● C _1-5Alkoxyl group and

● ● by the C of halogen replacement _1-5Alkoxyl group,

● heterocyclic radical and

● by independently being selected from the heterocyclic radical that following substituting group replaces:

● ● C _1-5Alkyl,

● ● isocyclic aryl and

● ● by the isocyclic aryl of halogen replacement,

(ii) C _2-5Alkenyl and

By independently being selected from the C that following substituting group replaces _2-5Alkenyl:

● isocyclic aryl,

● by the isocyclic aryl of nitro replacement,

(iii) carbocylic radical,

(iv) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● hydroxyl,

● nitro,

● C _1-5Alkyl,

● by the C of halogen replacement _1-5Alkyl,

● C _1-5Alkoxyl group,

● by the C of halogen replacement _1-5Alkoxyl group,

● by the C of isocyclic aryl replacement _1-5Alkoxyl group,

● isocyclic aryl oxygen base,

● by C _1-5The isocyclic aryl oxygen base that alkoxyl group replaces,

● one-C _1-5Alkyl amino-carbonyl,

● two-C _1-5Alkyl amino-carbonyl,

● by one-C of isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

● by two-C of isocyclic aryl replacement _1-5Alkyl amino-carbonyl,

● one-C _1-5Alkyl amino sulfonyl and

● two-C _1-5Alkyl amino sulfonyl,

(v) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● nitro,

● C _1-5Alkyl,

● by independently being selected from the C that following substituting group replaces _1-5Alkyl:

● ● C _1-5Alkylthio,

● ● by the C of isocyclic aryl replacement _1-5Alkylthio and

● ● by the C of halogenated isocyclic aryl replacement _1-5Alkylthio,

● isocyclic aryl oxygen base,

● by the isocyclic aryl oxygen base of halogen replacement,

● by C _1-5The isocyclic aryl oxygen base that alkyl replaces,

● isocyclic aryl,

● by the isocyclic aryl of halogen replacement,

● the isocyclic aryl that replaces by nitro and

● heterocyclic radical;

Wherein isocyclic aryl is a phenyl or naphthyl;

Carbocylic radical is 1-oxo-indanyl;

Heterocyclic radical is 1,2,3-triazolyl, 1H-indyl, 1H-pyrryl, 2,3-dihydro-benzofuryl, 9H-xanthenyl, benzo [2,1,3] oxadiazole bases, benzo [1,2,5] oxadiazole bases, benzo [b] thienyl, furyl, isoxazolyl, pyridyl, quinoxalinyl, thiazolyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

Or its pharmacy acceptable salt, hydrate or solvate.

7. according to the compound of claim 5, it is selected from:

1) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxy benzamide;

2) 3-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

3) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

4) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

5) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

6) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

7) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

8) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

9) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

10) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide;

11) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 5-difluorobenzamide;

12) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

13) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-methyl-3-nitro benzamide;

14) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

15) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group butyramide;

16) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

17) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethoxy)-benzamide;

18) 4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

19) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenyl-iodide methane amide;

20) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,5-dimethyl-3-furoamide;

21) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro benzamide;

22) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethoxy benzamide;

23) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

24) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

25) 2,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiophene-3-methane amide;

26) the 1-benzyl-3-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-1H-pyrazoles-5-methane amide;

27) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-naphthyl) ethanamide;

28) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

29) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) cyclopentane formamide;

30) 3-(2-chloro-6-fluoro phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

31) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

32) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

33) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

34) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy-acetamide;

35) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-quinoxaline-2-methane amide;

36) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

37) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(penta fluoro benzene oxygen base) ethanamide;

38) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-ethanamide;

39) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

40) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy group niacinamide;

41) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methylphenoxy) niacinamide;

42) alkylsulfonyl N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-[(dipropyl amino)] benzamide;

43) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl propanamide;

44) 2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-thiazoles-4-methane amide;

45) the 3-tertiary butyl-1-(2, the 4-dichloro benzyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1H-pyrazoles-5-methane amide;

46) 6-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2H-chromene-3-methane amide;

47) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

48) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

49) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-iodo-2-furoamide;

50) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furoamide;

51) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-2-methane amide;

52) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl-4-nitrobenzamide;

53) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

54) 1-benzyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1H-indoles-3-methane amide;

55) 3-ethanoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

56) 5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

57) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

58) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiophene-2-carboxamide derivatives;

59) 2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) ethanamide;

60) N ², N ⁶-dibenzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) lysyl amine;

61) 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

62) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

63) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl) ethanamide;

64) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazoles-4-yl) ethanamide;

65) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

66) 4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-(1H-indol-3-yl)-4-oxo butyramide;

67) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-2-[(3-phenyl third-2-alkynes acyl group) amino] benzamide;

68) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

69) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid-(3-morpholine-4-base propyl group)-5-phenyl-1H-pyrrole-3-carboxamide;

70) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(4-nitrophenyl)-butyramide;

71) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

72) N ²-benzoyl-N ⁵-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-N ¹, N ¹-dipropyl glutamine;

73) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenoxy benzamide;

74) the 3-benzoyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

75) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide;

76) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[(1R)-1-(1-naphthyl) ethyl] phthalamide;

77) (2S)-2-(3-benzoyl phenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-propionic acid amide;

78) N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N, N-two [(1S)-and the 1-phenylethyl] phthalamide;

79) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-{ (1E)-5-fluoro-2-methyl isophthalic acid-[4-(methylsulfinyl) benzylidene]-1H-indenes-3-yl } ethanamide;

80) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-[4-(2-thienyl carbonyl) phenyl] propionic acid amide;

81) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-methoxy benzamide;

82) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide;

83) sulfo-1-{2-[(2-chloro-6-fluoro benzyl)] ethyl }-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

84) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenoxy benzamide;

85) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-phenylquinoline-4-methane amide;

86) 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

87) alkylsulfonyl N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-[(4-aminomethyl phenyl)]-the 1H-pyrrole-3-carboxamide;

88) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-(3-nitrophenyl)-2-furoamide,

89) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives;

90) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-iodo-4-(sec.-propyl alkylsulfonyl)-5-(methylthio group) thiophene-2-carboxamide derivatives;

91) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

92) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

93) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-nitrobenzamide;

94) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethyl-4-nitrobenzamide;

95) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-

Base-2-oxo ethanamide;

96) 3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-hydroxybenzamide;

97) 4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] benzamide;

98) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-the 3-Phenyl Acrylamide;

99) 4-chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-the 3-nitrobenzamide;

100) 2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-methyl] ethanamide;

101) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl] benzamide;

102) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-benzamide;

103) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide;

104) 2,4-two chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl]-the 5-fluoro benzamide;

105) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-phenoxy group butyramide;

106) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenylbutanamides;

107) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(3-p-methoxy-phenyl) ethanamide;

108) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(4-p-methoxy-phenyl) ethanamide;

109) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

110) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

111) 2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-methyl] ethanamide;

112) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(rosickyite base) niacinamide;

113) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(1-naphthyl) ethanamide;

114) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9-oxo-9H-fluorenes-4-methane amide;

115) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,4,6-Three methyl Benzene methane amide;

116) 2,4,6-three chloro-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases] amino }-cyclohexyl) methyl] benzamide;

117) (2E)-and 3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] acrylamide;

118) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

119) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,3-diphenylprop acid amides;

120) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-5-iodo-2-furoamide;

121) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide;

122) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide;

123) 2-benzyl-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-benzamide;

124) 2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases of 2-] amino } cyclohexyl)-methyl] ethanamide;

125) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

126) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

127) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl] ethanamide;

128) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide;

129) 2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] ethanamide;

130) N-[(cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide;

131) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

132) C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

133) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

134) 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

135) 5-bromo-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-niacinamide;

136) 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

137) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

138) 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

139) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

140) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl methyl]-3,4-two fluoro-benzamide;

141) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

142) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-ethanamide; With

143) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

8. according to the compound of claim 5, it is selected from:

1) 3-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

2) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2,1,3-Ben Bing oxadiazole-5-methane amide;

3) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-benzamide;

4) 4-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

5) 3,5-two chloro-N-(cis-4-[[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide,

6) 3,4-two chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) benzamide;

7) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3, the 4-difluorobenzamide;

8) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-nitrobenzamide;

9) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

10) 4-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methyl benzamide;

11) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-phenyl-iodide methane amide;

12) 3-chloro-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro benzamide;

13) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-dimethoxy benzamide;

14) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3,5-two (trifluoromethyl)-benzamide;

15) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

16) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

17) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-fluoro-3-(trifluoromethyl) benzamide;

18) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-methane amide;

19) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group)-5-nitrobenzamide;

20) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-quinoxaline-2-methane amide;

21) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) ethanamide;

22) 3-(2, the 6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-methyl-isoxazole-4-methane amide;

22) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(4-methylphenoxy)-niacinamide;

24) alkylsulfonyl N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-4-[(dipropyl amino)] benzamide;

25) 2-(2,3-dihydro-1-cumarone-5-yl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1,3-thiazoles-4-methane amide;

26) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-thienyl)-1,3-thiazoles-4-methane amide;

27) 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

28) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-3-methoxyl group-4-nitrobenzamide;

29) 5-bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-furoamide;

30) 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

31) 2-(3,5-two-tert-butyl-hydroxy phenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) ethanamide;

32) 4,5-two bromo-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 2-furoamide;

33) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamides;

34) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(1-Methyl-1H-indole-3-yl)-4-(4-aminomethyl phenyl)-4-oxo butyramide;

35) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(2-phenyl-1H-indol-3-yl) ethanamide;

36) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-(ethylmercapto group)-2,2-phenylbenzene ethanamide;

37) N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N, N-two [(1S)-and the 1-phenylethyl] phthalamide;

38) 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-methoxy benzamide;

39) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-2-methyl isophthalic acid, 5-phenylbenzene-1H-pyrrole-3-carboxamide;

40) sulfo-1-{2-[(2-chloro-6-fluoro benzyl)] ethyl }-N-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;

41) 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazoles-5-yl]-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

42) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-5-nitrothiophene-3-methane amide;

43) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-1-methyl-4-nitro-1H-pyrroles-2-methane amide;

44) 3,5-two-tertiary butyl-N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl)-the 4-hydroxybenzamide;

45) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2,2-phenylbenzene ethanamide;

46) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-the 2-phenylbutanamides;

47) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(4-nitrophenyl) acrylamide;

48) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(1-naphthyl) ethanamide;

49) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-(2,3, the 6-trichlorophenyl) ethanamide;

50) (2E)-and N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl]-3-(3-nitrophenyl) acrylamide;

51) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-oxo indane-1-methane amide;

52) 2, two (4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-bases of 2-] amino } cyclohexyl)-methyl] ethanamide;

53) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methyl-4-nitrobenzamide;

54) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-3-methoxyl group-4-nitrobenzamide;

55) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-2-[2-(trifluoromethoxy) phenyl] ethanamide;

56) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-9H-xanthene-9-methane amide;

57) 2-(1-thionaphthene-3-yl)-N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] ethanamide;

58) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(4-fluoro-phenoxy group)-niacinamide;

59) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

60) C-[(cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

61) 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

62) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

63) 2-(3,4-two chloro-phenoxy groups)-N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

64) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-2-(3-methoxyl group-phenoxy group)-ethanamide; With

65) N-[cis-4-(4-dimethylamino-pyrimidine-2--amino)-cyclohexyl]-C-(ethyl-phenyl-amino)-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

9. formula (I) compound or its pharmacy acceptable salt, hydrate or solvate:

R wherein ₁Be selected from

(i) C _1-5Alkyl and

C by the isocyclic aryl replacement _1-5Alkyl,

(ii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● nitro,

● C _1-5Alkyl,

● by the C of halogen replacement _1-5Alkyl,

● C _1-5Alkoxyl group and

● C _3-6Cycloalkyloxy,

(iii) heterocyclic radical and

By C _1-5The heterocyclic radical that alkyl replaces and

Heterocyclic radical by the isocyclic aryl replacement;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is an isoxazolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base;

R ₂Be methylamino or dimethylamino;

B be singly-bound or-CH ₂-;

Y is-C (O) NH-.

10. according to the compound of claim 9, it is selected from:

1) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '- The base urea;

2) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

3) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl)-urea;

4) N-(2,4-bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea;

5) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(diphenyl methyl) urea;

6) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea;

7) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-[1-(1-naphthyl) ethyl]-urea;

8) N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) urea;

9) N-(4-chloro-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea;

10) N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) urea;

11) N-(4-bromo-2-aminomethyl phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) urea;

12) N-(2,6-two bromo-4-isopropyl phenyls)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) urea;

13) N-[3-(cyclopentyloxy)-4-p-methoxy-phenyl]-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) urea;

14) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2, the 6-3,5-dimethylphenyl) urea;

15) N-(2,4 difluorobenzene base)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

16) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-aminomethyl phenyl) urea;

17) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(4-fluoro phenyl) urea;

18) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-

The base urea;

19) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,4, the 6-trichlorophenyl) urea;

20) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,4,6-tribromo phenyl) urea;

21) N-(2,4-two bromo-6-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

22) N-(2,6-diethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

23) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

24) N-(2-chloro-6-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

25) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-ethyl-6-isopropyl phenyl) urea;

26) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-sec.-propyl-6-aminomethyl phenyl) urea;

27) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methyl-3-nitro phenyl) urea;

28) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-propyl group phenyl) urea;

29) methyl N-(the 2-tertiary butyl-6-aminomethyl phenyl)-N '-{ [(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)] urea;

30) N-(2-tert-butyl-phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

31) N-(3-chloro-2-aminomethyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

32) N-(4-bromo-2,6-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

33) N-[4-chloro-2-(trifluoromethyl) phenyl]-N '-[(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

34) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(diphenyl methyl) urea;

35) N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

36) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(3-methyl-5-phenyl-isoxazole azoles-4-yl) urea;

37) N-(3, the 5-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

38) N-(2, the 3-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

39) N-(2, the 6-diisopropyl phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

40) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2,3-dimethyl-6-nitrophenyl) urea;

41) N-(2,6-two bromo-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

42) N-(2, the 6-dichlorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

43) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methoxyl group-5-aminomethyl phenyl) urea;

44) N-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl]-N '-(2-methyl-6-nitrophenyl) urea;

45) N-(3, the 4-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea;

46) N-(3, the 5-difluorophenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-methyl] urea; With

47) N-(3-chloro-4-fluoro phenyl)-N '-[(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) methyl] urea;

Or its pharmacy acceptable salt, hydrate or solvate.

11. formula (I) compound or its pharmacy acceptable salt, hydrate or solvate:

R wherein ₁Be selected from:

Isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● cyano group,

● C _1-5Alkyl,

● C _1-5Alkoxyl group,

● one-C _1-5Alkylamino and

● two-C _1-5Alkylamino;

R ₂Be methylamino or dimethylamino;

B be singly-bound or-CH ₂-;

Y is-C (S) NH-;

Wherein isocyclic aryl is a phenyl or naphthyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

12. according to the compound of claim 11, it is selected from

N-(4-cyano-phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino }-cyclohexyl) thiocarbamide;

N-(2, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(3,4, the 5-trimethoxyphenyl) thiocarbamide;

N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

N-[4-(dimethylamino)-1-naphthyl]-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '-(2,4,6-tribromo phenyl) thiocarbamide;

N-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl)-N '- The base thiocarbamide;

N-(4-bromo-2,6-3,5-dimethylphenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

N-(5-chloro-2,4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

N-(2,4-two bromo-6-fluoro phenyl)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide; With

N-(2,4-two chloro-6-aminomethyl phenyls)-N '-(cis-4-{[4-(dimethylamino) pyrimidine-2-base] amino } cyclohexyl) thiocarbamide;

Or its pharmacy acceptable salt, hydrate or solvate.

13. formula (2) compound or its pharmacy acceptable salt, hydrate or solvate,

R wherein ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen and

● ● C _1-5Alkoxyl group,

(ii) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● the isocyclic aryl sulfinyl and

● by the isocyclic aryl sulfinyl of halogen replacement,

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Each T independently is C separately _1-5Alkyl, halogen, phenyl or dimethylamino;

P is 1 or 2;

B be singly-bound or-CH ₂-;

R ₄Be hydrogen or C _1-5Alkyl;

Y be singly-bound or-CH ₂-

Isocyclic aryl is a phenyl;

Heterocyclic radical is a pyrazinyl; With

Halogen is fluoro base or bromo base.

14. according to the compound of claim 13, wherein R ₁Be selected from:

Heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● the isocyclic aryl sulfinyl and

● by the isocyclic aryl sulfinyl of halogen replacement,

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Isocyclic aryl is a phenyl;

Heterocyclic radical is a pyrazinyl; With

Halogen is the fluoro base;

Or its pharmacy acceptable salt, hydrate or solvate.

15. according to the compound of claim 13 or 14, wherein p is 1 and R ₄Be hydrogen; B is a singly-bound;

Or its pharmacy acceptable salt, hydrate or solvate.

16. according to the compound of claim 13, it is selected from:

N ²-cis-4-[(3,5-dimethoxy-benzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

N ²-cis-4-[(3-bromobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2,4-diamines;

N ²-cis-4-[(3,4-difluorobenzyl) and amino] cyclohexyl }-N ⁴, N ⁴, 5,6-tetramethyl-pyrimidine-2,4-diamines; With

N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

17. according to the compound of claim 13, described compound is:

N ²-[cis-4-(6-[(3,4-difluorophenyl) and sulfinyl] pyrazine-2-yl } amino) cyclohexyl]-N ⁴, N ⁴, 5-trimethylammonium pyrimidine-2,4-diamines;

Or its pharmacy acceptable salt, hydrate or solvate.

18. formula (2) compound or its pharmacy acceptable salt, hydrate or solvate,

R wherein ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

● hydroxyl,

● isocyclic aryl oxygen base,

● by independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl,

● ● by the C of halogen replacement _1-5Alkyl and

● ● C _1-5Alkoxyl group,

● the heterocyclyloxy base,

● by the heterocyclyloxy base of halogen replacement,

● one-isocyclic aryl amino,

● by independently being selected from one-isocyclic aryl amino that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkoxyl group and

● ● C _1-5Alkyl,

● the isocyclic aryl sulfinyl,

● by independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

● the isocyclic aryl alkylsulfonyl,

● by independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

● isocyclic aryl and

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● C _1-5Alkoxyl group,

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● cyano group,

● nitro,

● C _1-10Alkyl,

● by independently being selected from the C that following substituting group replaces _1-10Alkyl:

● ● halogen and

● ● hydroxyl,

● C _1-9Alkoxyl group,

● by the C of halogen replacement _1-9Alkoxyl group,

● carboxyl,

● C _1-5Alkoxy carbonyl and

● C _1-5Alkyl sulphonyl,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● C _1-5Alkyl,

● by the C of halogen replacement _1-5Alkyl,

● C _1-5Alkoxyl group,

● isocyclic aryl oxygen base,

● by independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl,

● ● by the C of halogen replacement _1-5Alkyl and

● ● C _1-5Alkoxyl group,

● the heterocyclyloxy base,

● by the heterocyclyloxy base of halogen replacement,

● the heterocyclic radical alkylsulfonyl,

● by C _1-5The heterocyclic radical alkylsulfonyl that alkyl replaces,

● one-isocyclic aryl amino,

● by one-isocyclic aryl amino of halogen replacement,

● C _1-5Alkylthio,

● the isocyclic aryl alkylsulfonyl,

● by independently being selected from the isocyclic aryl alkylsulfonyl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Each T independently is C separately _1-5Alkyl, halogen, phenyl or dimethylamino;

P is 1 or 2;

B be singly-bound or-CH ₂-;

R ₄Be hydrogen or C _1-5Alkyl;

Y is-C (O)-;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is benzo [1,3] dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

19. compound or its pharmacy acceptable salt, hydrate or solvate, wherein R according to claim 18 ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

● hydroxyl,

● isocyclic aryl oxygen base,

● by independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl,

● ● by the C of halogen replacement _1-5Alkyl and

● ● C _1-5Alkoxyl group,

● the heterocyclyloxy base,

● by independently being selected from the heterocyclyloxy base that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

● one-isocyclic aryl amino,

● by independently being selected from one-isocyclic aryl amino that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkoxyl group and

● ● C _1-5Alkyl,

● the isocyclic aryl sulfinyl,

● by independently being selected from the isocyclic aryl sulfinyl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

● isocyclic aryl and

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● C _1-5Alkoxyl group,

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● cyano group,

● nitro,

● C _1-10Alkyl

● by the C of halogen replacement _1-10Alkyl,

● C _1-9Alkoxyl group and

● by the C of halogen replacement _1-9Alkoxyl group,

(iv) heterocyclic radical and

By independently being selected from the heterocyclic radical that following substituting group replaces:

● halogen,

● C _1-5Alkyl,

● by the C of halogen replacement _1-5Alkyl,

● C _1-5Alkoxyl group,

● isocyclic aryl oxygen base,

● by independently being selected from the isocyclic aryl oxygen base that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl,

● ● by the C of halogen replacement _1-5Alkyl and

● ● C _1-5Alkoxyl group,

● C _1-5Alkylthio,

● the isocyclic aryl alkylsulfonyl,

● by the isocyclic aryl alkylsulfonyl of halogen replacement,

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Wherein isocyclic aryl is a phenyl;

Heterocyclic radical is benzo [1,3] dioxolyl, furyl, pyrazolyl, pyridyl or thienyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

20. according to the compound of claim 18 or 19, wherein p is 1 and R ₄Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

21. according to the compound of claim 18, it is selected from:

1) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

2) N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

3) N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

4) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) methyl] benzamide;

5) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3, the 4-difluorobenzamide;

6) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

7) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-methyl benzamide;

8) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;

9) N-[(cis-4-{ (4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethoxy) benzamide;

10) 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

11) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-fluoro-4-(trifluoromethyl) benzamide;

12) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

13) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

14) 4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

15) 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

16) N-[(formula-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-dimethoxy benzamide;

17) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide;

18) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 3-methyl benzamide;

19) 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide;

20) 3,4-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide;

21) N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3,5-two (trifluoromethyl) benzamide;

22) N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-3, the 4-difluorobenzamide;

23) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide;

24) 4-bromo-N-[cis-4-({ [4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } methyl) cyclohexyl]-the 3-methyl benzamide;

25) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-fluorinated phenoxy) niacinamide;

26) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide;

27) N-(4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

28) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

29) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

30) 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

31) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

32) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

33) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

34) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

35) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

36) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

37) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

38) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

39) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

40) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

41) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methylphenoxy) niacinamide;

42) 2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

43) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

44) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide;

45) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) niacinamide;

46) 2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

47) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) niacinamide;

48) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group) niacinamide;

49) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-iodo phenoxy group) niacinamide;

50) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

51) 2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-(methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

52) 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

53) N-(cis-4-{[4-(dimethylamino)-5-ethyl-pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

54) N-[cis-4-({ 4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3, the 4-difluorobenzamide;

55) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

56) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-methoxyl group phenoxy group) niacinamide;

57) 2-(2-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

58) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

59) 2-(3-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

60) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] niacinamide;

61) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide;

62) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) ethanamide;

63) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] ethanamide;

64) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

65) oxygen base 2-[(5-chloropyridine-3-yl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

66) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

67) 2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl acetamide;

68) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide;

69) 2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

70) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide;

71) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[2-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

72) sulfinyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

73) sulfinyl 2-[(3-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

74) 2-[(3, the 4-difluorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

75) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

76) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

77) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

78) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

79) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

80) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

81) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

82) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

83) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,4 difluorobenzene methane amide;

84) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2, the 5-difluorobenzamide;

85) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate;

86) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

87) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

88) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

89) 2-[(3, the 4-dichlorophenyl) sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

90) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

91) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[3-(trifluoromethyl) phenyl] alkylsulfonyl } ethanamide;

92) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(iprotiazem base) niacinamide;

93) 2-(uncle's butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

94) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide;

95) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(methyl sulphonyl) benzamide;

96) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

97) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

98) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

99) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

100) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

101) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

102) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

103) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

104) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

105) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

106) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

107) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

108) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

109) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

110) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

111) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

112) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

113) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

114) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-methoxy benzamide;

115) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

116) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

117) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

118) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

119) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-methyl-isoxazole-3-methane amide;

120) 2-(3, the 5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino }-cyclohexyl)-the 2-hydroxyl acetamide;

121) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-methyl isophthalic acid, 3-oxazole-4-methane amide;

122) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2,6-dimethoxy niacinamide;

123) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

124) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

125) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

126) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

127) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

128) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

129) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

130) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) niacinamide;

131) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-thiotolene-2-methane amide;

132) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-6-(trifluoromethyl) niacinamide;

133) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

134) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

135) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

136) 3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

137) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

138) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethoxy benzamide;

139) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

140) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

141) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

142) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

143) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

144) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

145) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

146) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

147) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

148) 3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

149) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

150) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide;

151) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

152) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

153) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

154) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

155) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethyl benzamide;

156) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

157) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

158) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

159) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

160) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

161) 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

162) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

163) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-two fluoro-1,3-benzo dioxole-5-methane amide;

164) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

165) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

166) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

167) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

168) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

169) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

170) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

171) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

172) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

173) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

174) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide;

175) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

176) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide;

177) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

178) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide;

179) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

180) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide;

181) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

182) 2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

183) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-[2,2,2-three fluoro-1-hydroxyl-1-(trifluoromethyl) ethyls] benzamide;

184) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

185) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-aminomethyl phenyl) cyclopropane carboxamide;

186) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) propionic acid amide;

187) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl acetamide;

188) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-p-methoxy-phenyl) cyclopropane carboxamide;

189) N ²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

190) N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl)-N ²-methyl G-NH2;

191) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl-N ²-(3-aminomethyl phenyl) G-NH2;

192) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-fluoro phenyl)-N ²-methyl G-NH2;

193) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-fluoro phenyl)-N ²-methyl G-NH2;

194) N ²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

195) N ²-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

196) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-p-methoxy-phenyl)-N ²-methyl G-NH2;

197) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-p-methoxy-phenyl)-N ²-methyl G-NH2;

198) 2-[(3, the 4-difluorophenyl) amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

199) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

200) trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

201) trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

202) trans-2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

203) trans-2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

204) trans-2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

205) alkylsulfonyl 2-[(4-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

206) alkylsulfonyl 2-[(3-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

207) alkylsulfonyl 2-[(4-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

208) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[4-(trifluoromethyl) phenyl] alkylsulfonyl } niacinamide;

209) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide;

210) alkylsulfonyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

211) alkylsulfonyl 2-[(3-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

212) 3,4-two chloro-N-{ cis-4-[(4-methoxyl group-5-methylpyrimidine-2-yl) amino] cyclohexyl }-benzamide;

213) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

214) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

215) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

216) 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

217) 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

218) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

219) 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

220) 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

221) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

222) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

223) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide; With

224) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

Or its pharmacy acceptable salt hydrate or solvate.

22. according to the compound of claim 18, it is selected from:

1) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-two (trifluoromethyl) benzamide;

2) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3,5-dimethoxy benzamide;

3) N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) methyl]-3-(trifluoromethyl) benzamide;

4) 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl]-the 3-methyl benzamide;

5) 3,5-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

6) 3,4-two chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-methyl] benzamide;

7) 3,5-two chloro-N-[cis-4-({ [4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } methyl) cyclohexyl] benzamide;

8) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-fluorinated phenoxy) niacinamide;

9) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,4, the 5-trimethoxy-benzamide;

10) N-(4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-nitrobenzamide;

11) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-phenylbenzene ethanamide;

12) 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

13) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

14) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

15) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

16) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

17) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

20) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

21) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

22) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

23) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methylphenoxy) niacinamide;

24) 2-(4-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

25) 2-(4-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

26) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-fluorinated phenoxy) niacinamide;

27) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) niacinamide;

28) 2-(2-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

29) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) niacinamide;

30) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-methoxyl group phenoxy group) niacinamide;

31) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(4-iodo phenoxy group) niacinamide;

32) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

33) 2-(2, the 3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

34) 2-[(3, the 4-difluorophenyl) alkylsulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

35) N-[cis-4-({ 4-[ethyl (methyl) amino]-5-methylpyrimidine-2-yl } amino) cyclohexyl]-3, the 4-difluorobenzamide;

36) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

37) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(2-methoxyl group phenoxy group) niacinamide;

38) 2-(2-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

39) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

40) 2-(3-bromine phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) niacinamide;

41) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] niacinamide;

42) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-fluorinated phenoxy) ethanamide;

43) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(3-methoxyl group phenoxy group) ethanamide;

44) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-[3-(trifluoromethyl) phenoxy group] ethanamide;

45) 2-(3-chloro phenoxy group)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-cyclohexyl) ethanamide;

46) oxygen base 2-[(5-chloropyridine-3-yl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

47) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3, the 4-difluorobenzamide;

48) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-(4-p-methoxy-phenyl) ethanamide;

49) 2-(2, the 3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl acetamide;

50) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl-2-[3-(trifluoromethyl) phenyl] ethanamide;

51) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[2-(trifluoromethyl) phenyl] sulfinyl } ethanamide;

52) sulfinyl 2-[(2-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

53) sulfinyl 2-[(3-bromophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

54) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

55) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro benzamide;

56) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

57) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

58) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

59) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

60) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

61) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

62) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,4 difluorobenzene methane amide;

63) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2, the 5-difluorobenzamide;

64) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,3, the 4-benzamide trifluoroacetate;

65) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

66) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

67) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

68N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(iprotiazem base) niacinamide;

69) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-(rosickyite base) niacinamide;

70) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

71) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

72) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

73) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

74) 3-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

750) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

76) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

77) 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-benzamide;

78) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-dimethoxy benzamide;

79) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

80) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

81) 4-cyano group-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

82) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-methyl benzamide;

83) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

84) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

85) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

86) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

87) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methoxy benzamide;

88) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

89) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-2,6-dimethoxy niacinamide;

90) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) benzamide;

91) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethyl) benzamide;

92) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

93) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

94) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

95) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

96) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) niacinamide;

97) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-5-thiotolene-2-methane amide;

98) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

99) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

100) N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

101) 3, and 5-two chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

102) 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

103) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

104) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

105) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

106) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-two (trifluoromethyl) benzamide;

107) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-(trifluoromethyl) benzamide;

108) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

109) 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro benzamide;

110) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-fluoro-3-methyl benzamide;

111) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-4-methyl benzamide;

112) 3,5-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-benzamide;

113) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethoxy) benzamide;

114) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3, the 5-difluorobenzamide;

115) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-methyl benzamide;

116) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethyl benzamide;

117) 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

118) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-ethyl benzamide;

119) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

120) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

121) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-3-isopropoxy benzamide;

122) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

123) 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

124) 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

125) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-fluoro-5-(trifluoromethyl) benzamide;

126) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2,2-two fluoro-1,3-benzo dioxole-5-methane amide;

127) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-ethoxy benzamide;

128) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-furoamide;

129) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3,5-diethoxy benzamide;

130) 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-3-(trifluoromethyl) benzamide;

131) 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

132) 3, and 4-two chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) benzamide;

133) 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-(trifluoromethoxy) benzamide;

134) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

135) N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-4-methoxyl group-3-(trifluoromethyl) benzamide;

136) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide

137) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

138) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide;

139) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

140) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-2-methyl propanamide;

141) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

142) 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) tetramethylene methane amide;

143) 1-(2,4 dichloro benzene base)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

144) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) ethanamide;

145) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-aminomethyl phenyl) cyclopropane carboxamide;

146) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) propionic acid amide;

147) 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-hydroxyl acetamide;

148) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-1-(4-p-methoxy-phenyl) cyclopropane carboxamide;

149) N ²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

150) N ²-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

151) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl-N ²-(3-aminomethyl phenyl) G-NH2;

152) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-fluoro phenyl)-N ²-methyl G-NH2;

153) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(4-fluoro phenyl)-N ²-methyl G-NH2;

154) N ²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

155) N ²-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-methyl G-NH2;

156) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N ²-(3-p-methoxy-phenyl)-N ²-methyl G-NH2;

157) 2-(3, the 4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino) pyrimidine-2-base] amino } cyclohexyl) ethanamide;

158) trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

159) trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

160) trans-2-(3, the 4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

161) trans-2-(3, the 4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

162) trans-2-[3,5-two (trifluoromethyl) phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) cyclopropane carboxamide;

163) alkylsulfonyl 2-[(4-chlorophenyl)]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) niacinamide;

164) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazoles-5-yl] the oxygen base } ethanamide;

165) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

166) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-2-phenoxy group-niacinamide;

167) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-4-fluoro-benzamide;

168) 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

169) 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

170) N-[cis-4-(4-dimethylamino-6-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

171) 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidine-2--amino)-cyclohexyl]-benzamide;

172) 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3-fluoro-benzamide;

173) 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-5-fluoro-benzamide;

174) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,4,5-three fluoro-benzamide;

175) N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-3,5-two fluoro-benzamide; With

176) 2-(3,4-two fluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl]-ethanamide;

Or its pharmacy acceptable salt, hydrate or solvate.

23. formula (3) compound or its pharmacy acceptable salt, hydrate or solvate,

R wherein ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● nitro,

● ● C _1-5Alkyl,

● ● by the C of halogen replacement _1-5Alkyl,

● ● C _1-5Alkoxyl group and

● ● by the C of halogen replacement _1-5Alkoxyl group,

(ii) C _3-12Cycloalkyl and

C by the isocyclic aryl replacement _3-12Cycloalkyl,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● C _1-10Alkyl,

● by the C of halogen replacement _1-10Alkyl and

● C _1-9Alkoxyl group,

R ₂Be selected from:

-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Each T independently is C separately _1-5Alkyl, halogen, phenyl or dimethylamino;

P is 1 or 2;

B be singly-bound or-CH ₂-;

Y is-C (O) NR ₅-;

R ₅Be hydrogen or C _1-5Alkyl, or R ₅And R ₁Form heterocyclic radical with nitrogen with its bonding;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is 3,4-dihydro-1H-isoquinolyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

24. according to the compound of claim 23, wherein p is 1; R ₄Be hydrogen; And B is a singly-bound; R ₅Be hydrogen; Or its pharmacy acceptable salt, hydrate or solvate.

25. according to the compound of claim 23, it is selected from:

1) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide) cyclohexane carboxamide;

2) cis-N-(2, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

3) cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

4) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl) cyclohexane carboxamide;

5) cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

6) cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

7) cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

8) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[3-(trifluoromethyl) benzyl] cyclohexane carboxamide;

9) cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

10) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methoxy-benzyl) cyclohexane carboxamide;

11) cis-N-(4-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

12) cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

13) cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

14) cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

15) cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

16) cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

17) cis-4-{ (dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl) cyclohexane carboxamide;

18) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl] cyclohexane carboxamide;

19) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and the 1-phenylethyl] cyclohexane carboxamide;

20) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide;

21) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

22) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

23) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

24) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

25) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

26) cis-N-[(R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

27) cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

28) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide;

29) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide;

30) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-fluoro phenyl) cyclohexane carboxamide;

31) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-p-methoxy-phenyl) cyclohexane carboxamide;

32) cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

33) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S, 2R)-the 2-phenycyclopropyl] cyclohexane carboxamide;

34) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[4-(trifluoromethyl) phenyl] cyclohexane carboxamide;

35) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

36) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

37) cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

38) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-fluoro benzyl)-cyclohexane carboxamide;

39) cis-N-(3, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-cyclohexane carboxamide;

40) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

41) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

42) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

43) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

44) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-1-(1-naphthyl) ethyl]-cyclohexane carboxamide;

45) cis-N-[(1R)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

46) cis-N-[(1S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

47) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

48) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide;

49) cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

50) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

51) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

52) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1R)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

53) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

54) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

55) cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide; With

56) cis-N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

26. according to the compound of claim 23, it is selected from:

1) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-benzyl iodide) cyclohexane carboxamide;

2) cis-N-(2,4-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

3) cis-N-(2, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

4) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(4-methyl-benzyl) cyclohexane carboxamide;

5) cis-N-(3, the 5-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

6) cis-N-(3, the 5-dimethoxy-benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

7) cis-N-(3-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

8) cis-N-[3,5-two (trifluoromethyl) benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

9) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methoxy-benzyl) cyclohexane carboxamide;

10) cis-N-(4-benzyl chloride base)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

11) cis-N-(3, the 4-dichloro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

12) cis-N-(2, the 5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

13) cis-N-(2, the 3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

14) cis-N-(4-bromo-2-fluoro benzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

15) cis-N-(2, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

16) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-(3-methyl-benzyl)-cyclohexane carboxamide;

17) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[2-(trifluoromethoxy) benzyl] cyclohexane carboxamide;

18) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-aminomethyl phenyl) ethyl] cyclohexane carboxamide;

19) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-fluoro phenyl) ethyl] cyclohexane carboxamide;

20) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

21) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

22) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

23) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

24) cis-N-[1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

25) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(4-nitrophenyl) ethyl] cyclohexane carboxamide;

26) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-(3-p-methoxy-phenyl) cyclohexane carboxamide;

27) cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

28) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S, 2R)-the 2-phenycyclopropyl] cyclohexane carboxamide;

29) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[4-(trifluoromethyl) phenyl] cyclohexane carboxamide;

30) cis-N-[(1S)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

31) cis-N-(3, the 4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

32) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(4-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

33) cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(3-p-methoxy-phenyl) ethyl] cyclohexane carboxamide;

34) cis-N-[(1R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

35) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1S)-and 1-(1-naphthyl) ethyl] cyclohexane carboxamide;

36) cis-N-[(S)-1-(4-bromophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

37) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[4-(trifluoromethoxy) phenyl] ethyl } cyclohexane carboxamide;

38) cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-[(1R)-and 1-(2-fluoro phenyl) ethyl] cyclohexane carboxamide;

39) cis-N-{ (1S)-1-[3,5-two (trifluoromethyl) phenyl] ethyl }-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

40) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[3-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide;

41) 4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino }-N-{ (1S)-1-[2-(trifluoromethyl) phenyl] ethyl } cyclohexane carboxamide; With

42) cis-N-[(R)-1-(4-chlorophenyl) ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexane carboxamide;

Or its pharmacy acceptable salt, hydrate or solvate.

27. formula (2) compound or its pharmacy acceptable salt, hydrate or solvate,

R wherein ₁Be selected from:

(i) C _1-8Alkyl and

By independently being selected from the C that following substituting group replaces _1-8Alkyl:

● isocyclic aryl,

● by independently being selected from the isocyclic aryl that following substituting group replaces:

● ● halogen,

● ● C _1-5Alkyl and

● ● by the C of halogen replacement _1-5Alkyl,

(ii) C _3-12Cycloalkyl and

By independently being selected from the C that following substituting group replaces _3-12Cycloalkyl:

● isocyclic aryl and

● by the isocyclic aryl of halogen replacement,

(iii) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● C _1-10Alkyl,

● by the C of halogen replacement _1-10Alkyl,

● C _1-9Alkoxyl group,

● by independently being selected from the C that following substituting group replaces _1-9Alkoxyl group:

● ● halogen and

● ● isocyclic aryl,

D is-NR ₄-;

Y is-C (O) NR ₅-;

R ₂For-N (R _2a) (R _2b), R wherein _2aBe hydrogen or C _1-5Alkyl and R _2bBe C _1-5Alkyl;

Each T independently is C separately _1-5Alkyl;

P is 1 or 2;

B is a singly-bound;

R ₄Be hydrogen or C _1-5Alkyl;

Y is-C (O) NH-;

Wherein isocyclic aryl is a phenyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

28. according to the compound of claim 27, it is selected from:

1) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea;

2) N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

3) N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

4) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(3-aminomethyl phenyl) urea;

5) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(4-aminomethyl phenyl) urea;

6) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-fluoro phenyl)-N-methyl urea;

7) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-fluoro phenyl)-N-methyl urea;

8) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

9) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

10) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-p-methoxy-phenyl)-N-methyl urea;

11) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-p-methoxy-phenyl)-N-methyl urea;

12) N-{1-[3,5-two (trifluoromethyl) phenyl]-the 1-methylethyl }-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

13) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

14) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

15) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

16) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

17) N-[1-(4-chlorophenyl) cyclopropyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino cyclohexyl]-N '-(2-p-methoxy-phenyl) urea;

19) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(3-p-methoxy-phenyl) urea;

20) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

21) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea;

22) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

23) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino cyclohexyl]-N '-[2-(trifluoromethoxy) phenyl] urea;

24) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

25) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

26) N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

27) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) urea;

28) N-benzyl-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

29) N-[2-chloro-6-(trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

30) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

31) N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

32) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy) phenyl] urea;

33) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl carbamide;

34) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide;

35) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(2-fluoro phenyl)-N-methyl urea;

36) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy) phenyl] urea;

37) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-phenylurea;

38) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-(3-aminomethyl phenyl) urea; With

39) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

29. according to the compound of claim 27, it is selected from:

1) N-(3, the 4-Dimethoxyphenyl)-N '-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidine-2-yl] amino } cyclohexyl) urea;

2) N-(3-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

3) N-(3, the 4-dichlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

4) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(3-aminomethyl phenyl) urea;

5) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-(4-aminomethyl phenyl) urea;

6) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-fluoro phenyl)-N-methyl urea;

7) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-fluoro phenyl)-N-methyl urea;

8) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

9) N-(3, the 4-difluorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

10) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(3-p-methoxy-phenyl)-N-methyl urea;

11) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-(4-p-methoxy-phenyl)-N-methyl urea;

12) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

13) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-6-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

14) N-[1-(4-chlorophenyl)-1-methylethyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

15) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(4-fluoro phenyl) urea;

16) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-[2-(trifluoromethoxy) phenyl] urea;

17) N-(4-bromophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) urea;

18) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2-aminomethyl phenyl) urea;

19) N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N '-(2,4, the 6-trichlorophenyl) urea;

20) N-(2,4 dichloro benzene base)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl urea;

21) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy) phenyl] urea;

22) N-(4-chlorophenyl)-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl carbamide;

23) N-[3,5-two (trifluoromethyl) phenyl]-N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-the N-ethyl carbamide;

24) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-phenylurea;

25) N '-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl)-N-ethyl-N-(3-aminomethyl phenyl) urea; With

26) 1-(2,3-two chloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidine-2--amino)-cyclohexyl methyl]-urea;

Or its pharmacy acceptable salt, hydrate or solvate.

30. formula (2) compound or its pharmacy acceptable salt, hydrate or solvate,

R wherein ₁Be selected from:

(i) isocyclic aryl and

By independently being selected from the isocyclic aryl that following substituting group replaces:

● halogen,

● C _1-10Alkyl and

● by the C of halogen replacement _1-10Alkyl,

(ii) heterocyclic radical,

D is-NR ₄-;

Y is-S (O) ₂-;

R ₂For-N (R _2a) (R _2b), R wherein _2aBe C _1-5Alkyl and R _2bBe C _1-5Alkyl;

T is C _1-5Alkyl;

P is 1;

B is a singly-bound;

R ₄Be hydrogen;

Y is-S (O) ₂-;

Wherein isocyclic aryl is a phenyl or naphthyl;

Heterocyclic radical is a furyl; With

Halogen is fluoro base, chloro base, bromo base or iodo base.

31. according to the compound of claim 30, it is:

4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidine-2-yl] amino } cyclohexyl) benzsulfamide;

Or its pharmacy acceptable salt, hydrate or solvate.

32. a medicinal compositions, it comprise significant quantity on the therapeutics according to each compound and pharmaceutically acceptable carrier among the claim 1-31.

33. according to each compound among the claim 1-31 in preparation prevention or treat following disease: improve the purposes in the medicine of memory function, sleep, emotional handicap, epileptic seizures, obesity, diabetes, appetite and eating disorder, cardiovascular disorder, psychological disorders, dyskinesia or addiction.

34. according to the purposes of claim 33, wherein disease is excitement, anxiety disorder, dysthymia disorders.

35. according to the purposes of claim 33, wherein disease is hypertension, hyperlipemia or myocardial infarction.

36. according to the purposes of claim 33, wherein disease is mad food disease or anorexia.

37. according to the purposes of claim 33, wherein disease is a Bulimia nerovsa.

38. according to the purposes of claim 33, wherein disease is manic depression of sex, schizophrenia, psychiatric disorder, dementia, stress, cognitive disorder, attention deficit syndrome, substance abuse disease out of control.

39. according to the purposes of claim 33, wherein disease is Parkinson's disease, epilepsy.

40. according to each the purposes of compound in the medicine of preparation prevention or treatment eating disorder, obesity or the disease relevant among the claim 1-31 with obesity.

41. according to each the purposes of compound in the medicine of preparation prevention or treatment anxiety disorder, dysthymia disorders, schizophrenia, addiction or epilepsy among the claim 1-31.

42. a method for preparing medicinal compositions, it comprises and will mix with pharmaceutically acceptable carrier according to each compound among the claim 1-31.